<SEC-DOCUMENT>0001193125-21-217965.txt : 20210719
<SEC-HEADER>0001193125-21-217965.hdr.sgml : 20210719
<ACCEPTANCE-DATETIME>20210719060729
ACCESSION NUMBER:		0001193125-21-217965
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		41
FILED AS OF DATE:		20210719
DATE AS OF CHANGE:		20210719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytek BioSciences, Inc.
		CENTRAL INDEX KEY:			0001831915
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				472547526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257663
		FILM NUMBER:		211096763

	BUSINESS ADDRESS:	
		STREET 1:		46107 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		(877) 922-9835

	MAIL ADDRESS:	
		STREET 1:		46107 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d80783ds1a.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 2 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the U.S. Securities and Exchange Commission on July 19, 2021. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-257663</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 2 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>3826</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-2547526</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>46107 Landing Pkwy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, California 94538 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(877) <FONT STYLE="white-space:nowrap">922-9835</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Wenbin Jiang, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>46107 Landing Pkwy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, California 94538 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(877) <FONT STYLE="white-space:nowrap">922-9835</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Gordon K. Ho</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>J. Patrick Loofbourrow</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>John T. McKenna</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cooley
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>3175 Hanover Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto,&nbsp;California&nbsp;94304</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(650)&nbsp;843-5000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Valerie Barnett</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cytek
Biosciences, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>46107 Landing Pkwy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, California 94538</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(877) <FONT STYLE="white-space:nowrap">922-9835</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ilir Mujalovic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Shearman&nbsp;&amp; Sterling LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>599 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10022</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">848-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this Registration Statement
is declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Smaller&nbsp;reporting&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class of<BR>Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount to be<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Offering Price<BR>Per&nbsp;Share(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed&nbsp;Maximum<BR>Aggregate&nbsp;Offering<BR>Price(1)(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>Registration&nbsp;Fee(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">16,749,330</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$18.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$301,487,940</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$32,892.33</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Includes the aggregate offering price of additional shares of common stock that the underwriters have the
option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The Registrant previously paid a registration fee of $10,910 in connection with the initial filing of this
Registration Statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and
may be changed. We and the selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and
we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>  <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#cc062a"><I>PRELIMINARY PROSPECTUS </I></FONT></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT
 COLOR="#cc062a"><I>Subject To Completion, Dated July&nbsp;19, 2021 </I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>14,564,635 Shares </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g62v59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>COMMON STOCK </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>We are
offering 11,764,706 shares of our common stock and the selling stockholders identified in this prospectus are offering additional 2,799,929 shares of our common stock. We will not receive any proceeds from the sale of shares by the selling
stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>This is our initial public offering, and no public market currently exists for our common stock. We expect the
initial public offering price to be between $16.00 and $18.00 per share. We have applied to have our common stock listed on the Nasdaq Global Select Market under the symbol &#147;CTKB.&#148; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>Upon the closing of this offering, our executive officers, directors and current beneficial owners of five percent or more of our common stock
will, in the aggregate, beneficially own approximately 46.1% of our common stock. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company&#148; as defined under the U.S. federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so in
future filings. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Investing in our common stock involves risks. Please read &#147;<A HREF="#toc80783_2">Risk&nbsp;Factors</A>&#148; beginning on page 16
of this prospectus. </I></B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities that may be
offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Per&nbsp;Share</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Total</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Initial public offering price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Underwriting discount and commissions
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to us</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to the selling stockholders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE>  <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(1)&nbsp;&nbsp;&nbsp;&nbsp; See &#147;Underwriting&#148; for additional information regarding
underwriting compensation. </I></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>At our request, the underwriters have reserved five percent of the shares of common stock to be issued
by the company and offered by this prospectus for sale, at the initial public offering price, to certain individuals through a directed share program. See &#147;Underwriting&#151;Directed Share Program.&#148; </I></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to an additional
2,184,695 shares of common stock. </I></P>  <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The underwriters expect to deliver the shares of common stock against payment in New York,
New York on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </I></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>GOLDMAN&nbsp;SACHS&nbsp;&amp;&nbsp;CO.&nbsp;LLC</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>PIPER&nbsp;SANDLER</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>COWEN</I></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_4">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_9">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_15">Principal and Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_18">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80783_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We<I>, </I>the selling stockholders and the underwriters have not authorized anyone to provide you with any information or to
make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We<I>, </I>the selling stockholders and the underwriters take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. We, the selling stockholders and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted.
The information contained in this prospectus or in any applicable free writing prospectus is accurate only as of the date of this prospectus or any such free writing prospectus, as applicable, regardless of its time of delivery or of any sale of our
common stock. Our business, financial condition, results of operations and future growth prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside the United States: Neither we, the selling stockholders nor any of the underwriters have done anything
that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights selected information included elsewhere in this prospectus. This summary does not contain all of
the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.
Unless the context otherwise requires, all references in this prospectus to &#147;Cytek Biosciences,&#148; &#147;Cytek,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and &#147;the company&#148; refer to Cytek Biosciences, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific
advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell
analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). Our novel approach harnesses the power of information
within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Our patented FSP technology optimizes sensitivity and accuracy through its novel optical and electronic designs that utilize an
innovative method of light detection and distribution. Our FSP platform includes instruments, reagents, software and services to provide a comprehensive and integrated suite of solutions for our customers. Since our first U.S. commercial launch in <FONT
STYLE="white-space:nowrap">mid-2017</FONT> through March&nbsp;31, 2021, we have sold and deployed over 750 instruments&#151;primarily comprised of our Aurora and Northern Lights systems&#151;to over 620 customers around the world, including the
largest pharmaceutical companies, over 125 biopharma companies, leading academic research centers, and clinical research organizations (&#147;CROs&#148;). In June 2021, we began shipping the Aurora cell sorter (&#147;Aurora CS&#148;), which uses our
FSP technology to further broaden our potential applications across cell analysis. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Biological systems are highly
complex, and the multitude of questions that remain unanswered sets many challenges for scientists. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological
question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell
function. There is growing demand for deep content through high-dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and
isolate rare events or unique populations down to the single cell through highly resolvable multi-dimensional cell analysis. While flow cytometry is a widely used tool for single-cell analysis, conventional flow cytometry, mass cytometry and early
approaches to spectral flow cytometry technologies have historically been challenged due to limited dimensionality, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> resolution, low throughput, high cost for performance and/or significant
technical expertise required to operate systems. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our FSP platform addresses the inherent limitations of other
technologies by providing a higher density of information with greater sensitivity, more flexibility and increased efficiency, all at a lower cost for performance. Our patented FSP technology is designed to optimize sensitivity and accuracy through
its novel optical and electronic designs that utilize an innovative method of light detection and distribution to a specifically selected number of detectors of a particular type. This patented optics design enables researchers to effectively
collect the full range of light emissions in an extremely compact space, resulting in higher resolution. Our platform also provides higher content by enabling development of highly complex assays with 40 different colors (individual fluorochromes)
and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers, all accessible within just a single tube. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our solutions have enabled researchers to make significant scientific
advances in key areas of medical discovery (such as oncology, immunology and infectious diseases) and empowered improved downstream cell analysis with complementary cell analysis technologies (such as next-generation sequencing (&#147;NGS&#148;)).
We believe that our innovative FSP and targeted cell isolation technology has the potential to accelerate scientific discovery and to have a profound impact on the understanding of cell biology, immunotherapy, and targeted therapeutic approaches
(personalized medicine). Further, the rate of publications generated, showcasing our technology across a wide range of applications including oncology, infectious diseases, immunology, immunotherapy and immuno-oncology, has meaningfully accelerated.
Over 210 peer-reviewed articles have been published over three years, including many articles that appear in prominent journals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our FSP platform was purpose-built to advance the next generation of cell analysis by delivering deep insights, high
throughputs and ease of use. Our FSP platform is designed to offer the following key benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ultra-sensitive:</I></B> resolve the most challenging cell populations (such as cells with high
autofluorescence or low levels of expression of key biomarkers) by providing high-resolution data at the single-cell level with an optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Deep, high-integrity content:</I></B> allow development of highly complex assays through access to 40
different colors and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers in a single tube without sacrificing precision and throughput to gain a deeper understanding of biological systems and arrive at faster and more
accurate diagnoses in clinical settings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Flexible and compatible:</I></B> enable a single configuration across a wide range of reagents and
applications, full backwards compatibility across panels, and greater leverage for downstream analysis with complementary technologies, including NGS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Efficient and compact:</I></B> improve costs and save time while maintaining industry-leading
performance and efficient workflows that limit consumables usage and reduce labor costs&#151;all within a highly compact footprint minimizing space requirements for laboratories. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Integrated and intuitive:</I></B> provide fully-integrated workflows through a suite of solutions that
include instruments, reagents and kits, software and services. Our proprietary tools and the intuitive functionality of our proprietary SpectroFlo software, coupled with a user-friendly interface, allow for enhanced <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ease-of-use</FONT></FONT> and minimal operator training. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our core
instruments, the Aurora and Northern Lights systems, are full spectrum flow cytometers founded on our FSP platform technology. The Aurora system&#151;our most advanced and comprehensive offering&#151;is available with three to five lasers and is
suitable for customers seeking to access more than 24 colors (the Aurora system is able to reach 40 different colors and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers.) The Northern Lights system&#151;our entry-level
offering&#151;is available with one to three lasers and is suitable for customers seeking to access up to 24 colors. Both instruments are reconfigurable based on the desired number of lasers. In June 2021, we began shipping the Aurora CS, which
leverages our FSP technology to rapidly isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers. We believe the Aurora CS is the only sorter able to accommodate the same number of parameters with the same
sensitivity as the Aurora system. Each system is supported by our highly intuitive, proprietary embedded SpectroFlo software, our reagents, and our service offerings to provide a comprehensive, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform of solutions for our customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Within the life sciences
technology market, flow cytometry technologies currently provide solutions largely within cell proliferation, cell counting, cell identification, cell quality control and single-cell applications, and they represent an initial total addressable
market of nearly $8&nbsp;billion. However, we believe that, driven by enhanced capabilities, our FSP platform has the potential to capture an increasingly greater share of the broader </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cell analysis market, which according to MarketsandMarkets Research Private Ltd. is expected to grow from roughly $16&nbsp;billion in 2019 to approximately $23&nbsp;billion by 2024, approximately
$5 billion of which represents revenue from hospitals and diagnostic laboratories and $1.5 billion of which comes from the United States. Our Northern Lights system has been approved for clinical use in the European Union and China. In the United
States, our products are currently labeled and promoted, and are, and in the near-future are expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products for
non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical diagnostic tests. We plan to continue generating supporting publications and data, as well as pursue any required regulatory approvals for
clinical use for our products in the United States. Our ability to penetrate the clinical markets in the United States will depend in part on our ability to receive 510(k) clearance, <I>de novo</I> classification, or approval of a pre-market
approval application from the FDA. Further, we believe our differentiated platform will enable us to expand the use of cell analysis into new markets, well beyond current applications addressed by prior flow cytometry technologies and other cell
analysis technologies and creating a larger potential total addressable market. New and existing markets addressable by our platform include applications within immunotherapy, immuno-oncology, <FONT STYLE="white-space:nowrap">bio-processing,</FONT>
infectious diseases, and immuno-deficiencies. In addition, the combination of our platform with complementary, downstream cell analysis technologies is expected to provide areas for new applications. Combining FSP technology with NGS, for example,
has demonstrated an improved ability to predict leukemia relapse after therapy (such as minimal residual disease (&#147;MRD&#148;) testing) and served to support the use of our technology within personalized medicine. As our FSP platform is further
validated through the continued acceleration of peer-reviewed publications in new applications, we expect our total addressable market to expand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the combination of our people and our global reach across the United States, Europe and Asia will enable us to
continue to execute on our growth strategies, stay ahead of competition and remain at the forefront of innovation in cell analysis. Our leadership team has extensive track records in the life sciences and technology sectors. As of March&nbsp;31,
2021, we employed a multidisciplinary group of over 390 employees, with more than 110 advanced degrees, including over 70 PhDs and MDs, with expertise across optics, electronics, fluidics, computer sciences, chemistry, biology, and medical sciences.
Our worldwide commercial team of more than 120 employees and our research and development team of more than 100 employees have significant expertise, industry experience and collaborative relationships with key opinion leaders (&#147;KOLs&#148;),
industry leaders, innovators and potential customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a long history of providing high-quality and efficient
customer service and our product development efforts reflect our deep understanding of our customers&#146; needs. One of our key differentiators is our customer-facing technical team, which collaborates closely with our customers to identify and
find solutions for unmet needs across the market. We collaborate closely with KOLs, generating relevant data and publications to demonstrate not only the feasibility, but also the quality of our FSP approach. We plan to continue executing on our
strategy to accelerate our growth by driving adoption of our FSP solutions, inspiring innovation, investing in integrated workflow solutions, and driving application development and adoption in clinical markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our financial results reflect the significant market demand for our offerings and adoption of our FSP technology:
our strong financial profile is differentiated by the combination of our scaled revenue base, high revenue growth and profitability. Our revenue reached $57.9&nbsp;million, $92.8&nbsp;million and $24.3 million for fiscal years 2019 and 2020, and the
three months ended March 31, 2021, respectively, and has realized a 112% CAGR from fiscal year 2018 to fiscal year 2020. We generated a net loss of $16.8&nbsp;million for fiscal year 2019 and a net income of $19.4&nbsp;million and $102,000 for
fiscal year 2020 and the three months ended March&nbsp;31, 2021, respectively. Our Adjusted EBITDA was $3.3&nbsp;million, $14.9&nbsp;million and $1.8 million for fiscal years 2019 and 2020, and the three months ended March&nbsp;31, 2021,
respectively. Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> generally accepted accounting principle (&#147;GAAP&#148;) financial measure. For a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial
measure, information about why we consider Adjusted EBITDA </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
useful and a discussion of the material risks and limitations of these financial measures, please see &#147;Prospectus Summary&#151;Summary Consolidated Financial Data.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We aim to transform the cell analysis market by building on our success as a leading platform of innovative FSP solutions and
continuing to leverage our key competitive strengths, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our novel, patented FSP platform delivers high-resolution, high-content and high-sensitivity cell analysis by
utilizing the full spectrum of fluorescent signatures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our solutions address many of our customers&#146; unmet needs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our complete FSP offering is available across a range of price points while consistently delivering high
performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our diversified customer base and breadth of relationships and scientific validation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our global scale and reach. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
strategy includes the following core elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate adoption of our FSP solutions.</I></B> To continue driving adoption of our solutions and to
support our leading global brand, we intend to further expand our sales infrastructure by hiring additional, highly qualified and reputable sales representatives, technical applications specialists and customer support staff, and by increasing
marketing efforts. This investment will also support our entry into new markets as we rollout new solutions and applications and appropriately manage inbound interest from new customers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to innovate and offer our customers <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> FSP solutions.</I></B><B> </B>Our development efforts focus on value-additive features and enhancements to meet the growing needs of the cell analysis market. These efforts drive continued
innovation across our proprietary reagents, software and services offerings, in addition to new instrumentation releases, such as the beginning of shipment of the Aurora CS in June 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Invest in integrated workflow solutions to drive pull-through from our consumables and services.
</I></B>Our overarching goal is to become a comprehensive solutions provider to our customers by delivering a fully-integrated offering of instruments, consumables, software and services enabled by our FSP technology. As we continue to penetrate our
addressable markets, we can leverage our growing installed base to drive consumable pull-through and recurring revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Drive application development and adoption in clinical markets.</I></B> We are deeply committed to
developing our platform&#146;s applications within the clinical market, and in particular, within disease detection, diagnosis and treatment monitoring. We also focus on areas where we can leverage the combination of our FSP platform with
complementary cell analysis technologies (such as NGS) to produce differentiated outcomes with greater sensitivity, such as with MRD testing. We can provide insights to clinicians to facilitate personalized medicine for patients, as well as
facilitate biopharma&#146;s research and development efforts to develop the next generation of targeted therapies. Our Northern Lights system has been approved for clinical use in the European Union and China, and we plan to continue generating
supporting publications and data, as well as to pursue any required regulatory approvals for clinical use in the United States. In the United States, our products are currently labeled
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and promoted, and are, and in the near-future are expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products
for non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical diagnostic tests. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Market Opportunity and Industry Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our market opportunity.</I></B> Within the life sciences technology market, flow cytometry technologies currently provide
solutions, including cell proliferation, cell counting, cell identification, cell quality control and single-cell applications, largely within the global cell analysis market. However, we believe that the enhanced capabilities of our FSP platform
relative to conventional flow cytometry (&#147;CFCs&#148;), mass cytometry and early approaches to spectral flow cytometry enable us to capture an increasingly greater share of the total addressable market by accessing the entire cell analysis
market, which according to MarketsandMarkets Research Private Ltd. is expected to grow from roughly $16&nbsp;billion in 2019 to approximately $23&nbsp;billion by 2024, approximately $5 billion of which represents revenue from hospitals and
diagnostic laboratories and $1.5 billion of which comes from the United States. Our Northern Lights system has been approved for clinical use in the European Union and China. In the United States, our products are currently labeled and promoted, and
are, and in the near-future are expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products for non-diagnostic and non-clinical purposes, and are not currently
designed, or intended to be used, for clinical diagnostic tests. We plan to continue generating supporting publications and data, as well as pursue any required regulatory approvals for clinical use for our products in the United States. Our ability
to penetrate the clinical markets in the United States will depend in part on our ability to receive 510(k) clearance, <I>de novo</I> classification, or approval of a pre-market approval application from the FDA. Further, we believe our
differentiated platform will enable us to expand the use of cell analysis into new markets, well beyond current applications addressed by prior flow cytometry technologies and other cell analysis technologies, and creating a larger potential total
addressable market. New and existing markets addressable by our platform include applications within immunotherapy, immuno-oncology, <FONT STYLE="white-space:nowrap">bio-processing,</FONT> infectious diseases and immuno-deficiencies. In addition,
the combination of our platform with complementary, downstream cell analysis technologies is expected to provide additional areas for new applications. Combining FSP technology with NGS, for example, has demonstrated an improved ability to predict
leukemia relapse after therapy (such as MRD testing) and served to support the use of our technology within personalized medicine. As our FSP platform is further validated through the continued acceleration of peer-reviewed publications in new
applications, we expect our total addressable market to expand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Complementary technologies to FSP and multi-omics
applications.</I></B> Since our FSP platform provides highly complex data down to single-cell resolution at a rapid speed, it is inherently well-suited to drive more targeted and efficient downstream analyses for other single-cell technologies, such
as NGS, single-cell capture and sample preparation, high-resolution microscopy (such as mass imaging cytometry, super resolution microscopy, confocal microscopy and high-throughput screening platforms), and micro and optofluidic systems. FSP is
highly complementary to single-cell genomics applications utilizing NGS as it can be used earlier in workflows to rapidly phenotype and isolate living cell populations to the single-cell level with highly multiplexed proteomic data. These cells can
then be transferred from our instrument into NGS systems to correlate proteomic and genomic expression, which in turn enables researchers to develop novel drug targets for therapeutics and clinicians to drive outcomes for patients through more
informed treatment decision-making. For example, a peer-reviewed article published in the <I>Biology of Blood and Marrow Transplantation </I>journal recognized that combining multiparameter flow cytometry with NGS resulted in an improved ability to
predict leukemia relapse after therapy, demonstrating strong potential utility in the large and growing market for MRD testing. With MRD, end users require high sensitivity and standardization, which makes our FSP technology ideal for addressing
these challenges. According to a global MRD testing market report by BIS Research in December 2020, flow cytometry technology has the largest market share in MRD testing among relevant technologies, including NGS, polymerase chain reaction and
others. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Importance of cell analysis at the single-cell level.</I></B> Due to
the heterogeneity within tissues, understanding cellular biology, particularly at the single-cell level, is necessary to unravel mechanisms that might otherwise not be detectable in bulk assays. Deep cellular analysis is a key application that we
expect to enable a new age of healthcare delivery, and in particular, personalized medicine. Emerging and chronic infectious diseases, an aging population with a myriad of chronic diseases, and the need for more effective and targeted therapeutics
all demand that the global healthcare market have advanced cell analysis technologies to research therapeutic and diagnostic solutions. These primary market forces, among others, will drive the direction for cell analysis applications that provide
new possibilities for novel drug development and improved patient outcomes through enhanced disease detection, diagnosis, and treatment monitoring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary unaudited
estimated results as of and for the three months ended June 30, 2021 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect preliminary unaudited revenue, net,
for the three months ended June&nbsp;30, 2021 to be approximately $30.0 million to $31.0 million, income from operations to be approximately $3.6 million to $4.6&nbsp;million, gross profit margin to be approximately 64% to 67% and instruments
shipped to be approximately 100 to 105. As of June 30, 2021, we expect our cash and cash equivalents to be approximately $158.0 million to $160.0 million. We have provided a range for the preliminary and unaudited financial results and operating
metrics described above primarily because our financial closing procedures for the three months ended June&nbsp;30, 2021 are not yet complete. As a result, there is a possibility that our final results will vary from these preliminary estimates. We
undertake no obligation to update or supplement the information provided above until we release our results of operations for the three months ended June&nbsp;30, 2021. The preliminary estimates for the three months ended June&nbsp;30, 2021
presented above have been prepared by, and are the responsibility of, management. Deloitte &amp; Touche LLP, our independent registered public accounting firm, has not audited, reviewed, compiled, or performed any procedures with respect to such
preliminary information. Accordingly, Deloitte &amp; Touche LLP does not express an opinion or any other form of assurance with respect thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. These
risks are described more fully in the section titled &#147;Risk Factors.&#148; These risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and only recently launched our commercial products, which may make it
difficult to evaluate the prospects for our future viability and predict our future performance. We have limited experience marketing and selling our products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are highly dependent on a limited number of product offerings. Our revenue has been primarily generated
from sales of our core Aurora and Northern Light systems, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue. Our future success depends on our ability to develop and successfully introduce new and enhanced
products that meet the needs of our customers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on single source suppliers and, in some cases, sole source suppliers, for certain components and
materials used in our systems and may not be able to find replacements or immediately transition to alternative suppliers, which could have an adverse effect on our business, financial condition and results of operations. We do not have long-term
supply contracts with these suppliers, and there are no minimum purchase or payment requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our results of operations will be harmed if we are unable to accurately forecast customer demand for our
products and manage our inventory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is dependent on adoption of our products by academic and government institutions, clinical
research organizations, pharmaceutical companies and clinical laboratories for their research </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and development activities focused on cell analysis. If academic and government institutions, clinical research organizations, pharmaceutical companies and clinical laboratories are unwilling to
adopt our products, it will negatively affect our business, financial condition, prospects and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to manufacture our products in high-quality commercial quantities successfully and
consistently to meet demand, our growth will be limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success is dependent upon our ability to increase penetration in our existing markets and expand
into adjacent markets. If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, technical applications specialists and customer support staff, our business may be adversely
affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may
result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements. Our products may become subject to more onerous regulation by the FDA or other regulatory agencies in the future,
which could increase our costs and delay or prevent sales of our products or commercialization of new products and product enhancements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Concentration of ownership of our common stock among our executive officers, directors and principal
stockholders may prevent new investors from influencing significant corporate decisions. Based on shares outstanding as of March 31, 2021 and including the shares to be sold in this offering and shares issuable upon the conversion of our preferred
stock into our common stock upon the closing of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock will, in the aggregate, beneficially own approximately 46.1% of our common stock
(assuming no exercise of the underwriters&#146; option to purchase additional shares of common stock). These stockholders, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election
and removal of directors and any merger or other significant corporate transactions after completion of this offering. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent or other intellectual property protection for any of our
current or future products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to
successfully commercialize our current or future products may be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business currently depends significantly on research and development spending by academic institutions and
government-owned institutions, a reduction in which could limit demand for our solutions and adversely affect our business and operating results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">International operations and expansion of our international business exposes us to business, regulatory,
political, operational, financial and economic risks associated with doing business outside of the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market for cell analysis technologies and life sciences tools, including flow cytometry, is rapidly
evolving and highly competitive. If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors, make strategic and operational decisions to
prioritize certain markets, technology offerings or partnerships, and develop and capitalize on markets, technologies or partnerships, our business could suffer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our products do not perform as expected, our operating results, reputation and business will suffer.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to expand or leverage the number of peer-reviewed articles published using data generated by
our products or otherwise increase brand awareness, the demand for our products and our business may be adversely affected. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have increased the size of our organization and expect to further increase it in the future, and we may
experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on distributors for sales of our products in certain geographies outside of the United States. If we
are unable to secure additional distributors or maintain good relationships with our existing distributors, or if such distributors do not perform adequately or effectively, our business could suffer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified a material weakness in our internal control over financial reporting. If we are unable to
remediate this material weakness, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or
results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to
predict and could cause our operating results to fall below expectations or any guidance we may provide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may need to raise additional capital beyond the proceeds of this offering to fund our existing operations,
develop our products and/or expand our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had and could continue to have an adverse
impact on our business, operations, and the markets and communities in which we, our partners, and customers operate. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications
of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a company with less than $1.07&nbsp;billion
in revenue during our last fiscal year, we qualify as an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). For as long as we are an emerging growth company, we will not be
required to comply with certain requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the
&#147;Sarbanes-Oxley Act&#148;) and may also take advantage of the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and the exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we may take advantage of certain reduced reporting obligations, including a requirement to
have only two years of audited consolidated financial statements and only two years of related management&#146;s discussion and analysis of financial condition and results of operations disclosure in this prospectus. We may choose to take advantage
of some but not all of these reduced reporting obligations. We have taken advantage of many of these reduced reporting obligations in this prospectus and intend to do so in future filings. As a result, the information that we provide stockholders
may be different than what you might get from other public companies in which you hold equity. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until those standards apply to
private companies. We have elected to avail ourselves of this exemption, and, as a result, our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new
or revised accounting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of
the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a &#147;large accelerated
filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company,&#148; as defined in the
Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take
advantage of these scaled disclosures for so long as our voting <FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $250.0&nbsp;million
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting
<FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated under the laws of the state of Delaware in December 2014 under the name Cytoville, Inc. In August 2015, we
changed our name to Cytek Biosciences, Inc. Our principal executive offices are located at 46107 Landing Pkwy, Fremont, California 94538. Our telephone number is (877) <FONT STYLE="white-space:nowrap">922-9835.</FONT> Our website is
www.cytekbio.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Company,&#148; &#147;Cytek,&#148;
&#147;Registrant,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Cytek Biosciences,&nbsp;Inc., a Delaware corporation, and its direct and indirect subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Cytek,&#148; &#147;SpectroFlo,&#148; &#147;DxP Athena&#148; and &#147;QBsure&#148; are registered trademarks in the
United States. &#147;SpectroFlo&#148; is also a registered trademark in Australia, the European Union, China and Canada. &#147;FSP,&#148; &#147;Full Spectrum Profiling,&#148; &#147;Northern Lights,&#148; &#147;cFluor,&#148; &#147;Complexity&#148;
and &#147;Similarity&#148; have pending trademark applications in the United States. All other service marks, trademarks and tradenames appearing in this prospectus are the property of their respective owners. We do not intend our use or display of
other companies&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, the trademarks and tradenames referred to in this prospectus appear
without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,764,706 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,799,929 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have granted the underwriters an option
exercisable for a period of 30 days after the date of this prospectus to purchase up to&nbsp;an additional 2,184,695 shares of our common stock from us at the initial public offering price per share less the underwriting discounts and
commissions.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">130,808,856 shares (or 132,993,551 shares if the underwriters exercise their option to purchase additional shares of common
stock in full).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds to us from the sale of our common stock in this offering will be approximately
$180.8&nbsp;million (or approximately $215.3&nbsp;million if the underwriters exercise their option to purchase additional shares in full), based on the assumed initial public offering price of $17.00&nbsp;per share, the midpoint of the price range
set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to continue
funding commercial expansion, marketing initiatives, research and development efforts, manufacturing and activities and the remainder for capital expenditures, strategic investments, working capital and other general corporate purposes. See the
section titled &#147;Use of Proceeds&#148; for additional information. We will not receive any of the proceeds from any sale of shares by the selling stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling stockholders; concentration of ownership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The selling stockholders identified in this prospectus are selling an aggregate of 2,799,929 shares of common stock in this
offering. Following this offering, our executive officers, directors and stockholders holding more than 5% of our outstanding shares, together with their affiliates, will hold, in the aggregate, approximately 46.1% of our outstanding capital stock
(or 45.3% of our outstanding capital stock following this offering if the underwriters exercise their option to purchase additional shares of common stock in full). See the section titled &#147;Principal and Selling Stockholders&#148; for additional
information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directed share program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At our request, the underwriters have reserved five percent of the shares of common stock to be issued by the company and
offered by this prospectus for sale, at the initial public offering price, to directors, officers, employees, business associates and other</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons related to the company. If purchased by our directors and officers, these shares will be subject to a 180-day
lock-up restriction. The number of shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares that are not so purchased will be offered by the
underwriters to the general public on the same basis as the other shares offered by this prospectus.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">See &#147;Risk Factors&#148; for additional information and a discussion of factors you should carefully consider before
deciding to invest in our common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed trading symbol on the Nasdaq Global Select Market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CTKB&#148;</P></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock that will be outstanding after this offering is
based on 119,044,150 shares of our common stock (including shares of our redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of March&nbsp;31, 2021, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,559,712 shares of our common stock issuable upon the exercise of options to purchase shares of our common
stock issued under our 2015 Equity Incentive Plan and outstanding as of March&nbsp;31, 2021, with a weighted-average exercise price of $1.30 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">473,966 shares of our common stock issuable upon exercise of stock options granted after March&nbsp;31, 2021,
with a weighted-average exercise price of $5.78 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,057,200 shares of our common stock reserved for future issuance under our 2015 Equity Incentive Plan as of
March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective in connection with this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18,000,000 shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan, which
includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering of which we intend to grant stock options to purchase 2,857,663 shares of our common stock to certain of our employees
and executive officers, contingent and effective upon the execution of the underwriting agreement for this offering, with an exercise price that is equal to the price per share at which our common stock is first sold to the public in this offering;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of our common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan,
which includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, the information in this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1.3333-for-1</FONT></FONT> stock split of
our common stock effected on July 16, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock outstanding
as of March&nbsp;31, 2021 into 87,268,694 shares of our common stock immediately upon the closing of this offering; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#146; option to purchase up to an additional 2,184,695 shares of our common
stock from us; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation in Delaware and the
adoption of our amended and restated bylaws upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth a summary of our historical consolidated financial data as of, and for the periods ended on,
the dates indicated. The consolidated statements of operations and comprehensive income (loss) data for the fiscal years ended December&nbsp;31, 2019 and 2020, are derived from our audited consolidated financial statements and related notes included
elsewhere in this prospectus. The consolidated statements of operations and comprehensive income (loss) data for the three months ended March&nbsp;31, 2020 and 2021 and the balance sheet data as of March&nbsp;31, 2021 are derived from our unaudited
interim consolidated financial statements included elsewhere in this prospectus. Our interim consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;), on
the same basis as our audited consolidated financial statements and, in our opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of our interim consolidated financial
statements as of and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and results for the three months ended March 31, 2021 are not necessarily
indicative of results for the full year ending December 31, 2021. Share and per share data in the table below has been retrospectively adjusted to give effect to the 1.3333-for-one stock split, effected on July 16, 2021. You should read this data
together with our consolidated financial statements and related notes appearing elsewhere in this prospectus and the information in &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations.&#148; The consolidated financial data in this section are not intended to replace our consolidated financial statements and the related notes and are qualified in their entirety by the consolidated financial
statements and related notes included elsewhere in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations and Comprehensive Income (Loss) Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, basic<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing net income (loss) per share, basic<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,126,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,557,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing net income per share, diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,599,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,757,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per share attributable to common stockholders &#150; basic (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per share attributable to common stockholders, diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,990,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,826,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,463,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,025,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial and operating data (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes stock-based compensation as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See Note 2 to our audited consolidated financial statements and Note 2 to our interim consolidated financial
statements, appearing elsewhere in this prospectus, for details on the calculation of our basic and diluted net income (loss) per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation
of unaudited pro forma basic and diluted net income (loss) per share attributable to common stockholders has been prepared to give effect, upon a qualified initial public offering, to the automatic conversion of all outstanding shares of our
redeemable convertible preferred stock into shares of our common stock as if the proposed initial public offering had occurred on January&nbsp;1, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure that we define as
net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
depreciation and amortization, legal settlement expenses and stock-based compensation expenses. See the section titled &#147;Selected Consolidated Financial Data&#148; for a reconciliation
between Adjusted EBITDA and net income (loss), the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of March 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interim Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The pro forma consolidated balance sheet data gives effect to (i)&nbsp;the conversion of 87,268,694 shares
of our redeemable convertible preferred stock outstanding as of March 31, 2021 into an equal number of shares of our common stock upon the closing of this offering and the related reclassification of the carrying value of our redeemable convertible
preferred stock to permanent equity in connection with the closing of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted consolidated balance sheet data further reflects our receipt of net proceeds from
the sale of 11,764,706 shares of common stock at the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, the
midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the amount of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $10.9 million, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares
we are offering. An increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) the amount of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $15.8 million,
assuming the assumed initial public offering price per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. The pro forma as adjusted information is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See Note&nbsp;5 to our interim
consolidated financial statements included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables reconcile the most directly comparable GAAP financial
measure to each of these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents the foreign exchange gains and losses for the remeasurement of non-functional monetary balances.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents the litigation settlement expense related to the settlement agreement entered into with Becton,
Dickinson and Company on October&nbsp;6, 2020. See Note&nbsp;15 to our audited consolidated financial statements appearing elsewhere in this prospectus for details on our litigation settlement expense. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents stock-based compensation expense related to option awards. See Note&nbsp;12 to our audited
consolidated financial statements and Note&nbsp;12 to our interim consolidated financial statements appearing elsewhere in this prospectus for details on our stock-based compensation expense. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_2"></A><A NAME="toc80783_2aa"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as
well as all of the other information contained in this prospectus, including our consolidated financial statements and related notes, before investing in our common stock. While we believe that the risks and uncertainties described below are the
material risks currently facing us, additional risks that we do not yet know of or that we currently think are immaterial may also arise and materially affect our business, financial condition, results of operations and prospects. If any of the
following risks materialize, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose some or all of your
investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited operating history and only recently launched our commercial products, which may make it difficult to evaluate the
prospects for our future viability and predict our future performance. We have limited experience marketing and selling our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a limited operating history and may encounter unforeseen expenses, difficulties, complications, delays and other known
and unknown obstacles. We launched our first core commercial product, the Aurora system, in June 2017. Our limited commercial and operating history makes it difficult to evaluate our current business and predict our future performance. Although we
have experienced significant revenue growth in recent periods, any assessment of our future revenue, profitability or prediction about our future success or viability is subject to significant uncertainty. We have encountered in the past, and will
encounter in the future, risks and uncertainties frequently experienced by growing companies with limited operating histories in emerging and rapidly changing industries, including scaling up our infrastructure and headcount. If our assumptions
regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations, and our
business, financial condition and results of operations could be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on a
limited number of product offerings. Our revenue has been primarily generated from sale of our core Aurora and Northern Lights systems, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Aurora system was commercially launched in June 2017 and our Northern Lights system was commercially launched in October
2018. Sales of the Aurora and Northern Lights systems together accounted for 91% of our revenue for the periods presented. We expect that, for at least the foreseeable future, sales of our Aurora and Northern Lights systems will continue to account
for a substantial portion of our revenue. The sales cycle for our flow cytometer instruments is slow and can take up to six months or longer to complete. As a result of this lengthy and unpredictable sales cycle, we will be prone to quarterly
fluctuations in our revenue as sales of the Aurora and Northern Lights systems are expected to continue to comprise a significant component of our revenue. Additionally, we experience seasonality in our business, with revenue in the fourth quarter
typically being higher as a result of higher sales volume due to marketing campaign closing activity. Quarterly fluctuations may make it difficult for us to predict our future operating results. Consequently, comparisons of our operating results on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of variability and unpredictability, we may also fail to meet the expectations of industry or financial analysts
or investors for any period. If our revenue or operating results fall short of the expectations of analysts or investors or any guidance we may provide, or if the guidance we provide falls short of the expectations of analysts or investors, the
price of our common stock could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance we may have provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently rely on single source suppliers and, in some cases, sole source
suppliers, for certain components and materials used in our systems and may not be able to find replacements or immediately transition to alternative suppliers, which could have an adverse effect on our business, financial condition and results of
operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have sourced and will continue to source certain components of the Aurora and Northern Lights
systems from a limited number of suppliers and, in some cases, sole source suppliers. Key components in our products that are supplied by sole or single source suppliers include certain lasers, semiconductors and mechanical components that are used
in our optical, electrical and fluidic subassemblies. We do not currently have long-term supply contracts with the sole and single source suppliers of these key components, and there are no minimum purchase or payment requirements. Additionally, we
believe we are not a major customer to most of our suppliers. Our suppliers may therefore give other customers&#146; needs higher priority than ours, and we may not be able to obtain adequate supply in a timely manner or on commercially reasonable
terms. While we are in the process of qualifying additional sources of supply, qualifications can take 12 to 24 months and, in some cases, longer. If we were to lose one or more of our sole or single source suppliers, it would take significant time
and effort to qualify alternative suppliers, if available. Moreover, in the event that we transition to a new supplier, particularly from any of our single source suppliers, doing so could be time-consuming and expensive, may result in interruptions
in our ability to supply our products to the market and could affect the performance of our products, resulting in increased costs and negative customer perception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we believe that we have stable relationships with our existing suppliers, we cannot assure you that we will be able
to secure a stable supply of components materials going forward. In the event that any adverse developments occur with our suppliers, in particular for those products that are sole-sourced, or if any of our suppliers modifies any of the components
they supply to us, our ability to supply our products may be temporarily or permanently interrupted. Obtaining substitute components could be difficult, time and resource-consuming and costly. Also, there can be no assurance that we will be able to
secure a supply of alternative components at reasonable prices without experiencing interruptions in our business operations. In addition, quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT>
and similar government orders related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other infectious disease outbreaks, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations
could occur, could impact the suppliers upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we cannot assure you that our suppliers have obtained and will be able to obtain or maintain all licenses,
permits and approvals necessary for their operations or comply with all applicable laws and regulations, and failure to do so by them may lead to interruption in their business operations, which in turn may result in shortages of components supplied
to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Supply interruptions have in the past arisen and could arise in the future from effects of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, shortages of raw materials, labor disputes or weather conditions affecting products or shipments, transportation disruptions, adjustments to our inventory levels or other factors within and beyond
our control, and such supply interruption risk is increased by the limited number of suppliers for certain of the components we use in our products. Our failure to maintain a continued supply of components that meets our quality control requirements
for any reason, including changes to or termination of our agreements with key suppliers, or to enter into new agreements with other suppliers, particularly in the case of single or sole source suppliers, could result in the loss of access to
important components and materials used in our products and impact our ability to manufacture and sell our products. Any delay or interruption in the supply of our materials could delay or suspend sales of our products and increase the costs of
manufacturing our products, which could have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our
results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To ensure adequate supply of our instruments and other products, we must forecast the inventory needs of our current and
prospective customers, and manufacture our products based on our estimates of future demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Our ability to accurately forecast demand for our products could be negatively affected by many factors, many of which are beyond our control, including our failure to accurately manage our
expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products or for products of our competitors, our failure to accurately forecast market acceptance of new products, changes in general market
conditions, including as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, seasonal demands, regulatory matters or weakening of general economic conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We seek to maintain sufficient levels of inventory of our instruments and other products to protect ourselves from supply
interruptions. We rely in part on our support organizations and distributors to supply forecasts of anticipated product orders in their respective territories. If we fail to accurately estimate customer demand for our products, our inventory
forecasts may be inaccurate, resulting in shortages or excesses of inventory. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and negatively
impact our business, prospects, financial condition and results of operations. Conversely, if we underestimate customer demand for our products, we may not be able to deliver products in a timely manner or at all, and this could result in reduced
revenue and damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, we may not have adequate manufacturing capacity to meet such demand, and additional supplies may not be available when
required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity to meet our increased requirements, all of which would negatively affect our business, financial condition and results of
operations. If we are unable to meet customer demand, we could lose our existing customers or lose our ability to acquire new customers, which would also negatively impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have limited experience manufacturing our products and if we are unable to manufacture our products in high-quality commercial
quantities successfully and consistently to meet demand, our growth will be limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have limited experience
manufacturing our products. We currently manufacture our instruments and reagents at our manufacturing facilities in Fremont, California, and Wuxi, China. To manufacture our products in the quantities that we believe will be required to meet the
currently anticipated market demand beyond the next several years, we will need to increase manufacturing capacity, which will involve significant challenges and may require additional quality controls and regulatory approvals. We may not
successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If there is
a disruption to our manufacturing operations, we will have no other means of producing our products until we resolve such issues with our manufacturing facilities, develop alternative manufacturing facilities, or contract with third-party
manufacturers capable of producing our products. Additionally, any damage to or destruction of our manufacturing facilities or equipment may significantly impair our ability to manufacture products on a timely basis. There may also be unforeseen
occurrences that increase our costs, such as increased prices of the components of our products, changes to labor costs or less favorable terms with third-party suppliers. There can be no assurance that we will not encounter such problems in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to manufacture products consistently and in sufficient quantities to meet anticipated customer
demand, our business, financial condition, results of operations and prospects would be harmed. As we continue to scale the commercial production of our products and increase our manufacturing capacity, we may encounter quality issues that could
result in product defects, errors or recalls. Manufacturing delays related to quality control could negatively impact our ability to bring our products to market, harm our reputation and decrease our revenue. Any defects, errors or recalls could be
expensive and generate negative publicity, which could impair our ability to market or sell our products, and adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the introduction of new products may require the development of new manufacturing sites, processes or procedures
as well as new suppliers. Developing new processes and negotiating supply agreements can be very time consuming, and any unexpected difficulty in doing so could delay the introduction of a product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future success is dependent upon our ability to increase penetration in our
existing markets and expand into adjacent markets. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our customer base includes academic and government
institutions, pharmaceutical and biotechnology companies, clinical research organizations and clinical laboratories focused on cell analysis. Approximately 49% and 42% of our revenue came from sales to academic and government-owned institutions and
51% and 58% of our revenue came from sales to pharmaceutical and biotechnology companies, distributors and CROs in the year ended December 31, 2020 and the three months ended March 31, 2021, respectively. Our success will depend upon our ability to
increase our market penetration. We cannot guarantee that we will be able to further penetrate our existing markets or that these markets will be able to sustain our current and future product and service offerings. Any failure to increase
penetration in our existing markets would adversely affect our ability to improve our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success will
also depend on our ability to further expand into adjacent markets, such as immunotherapy, immuno-oncology, <FONT STYLE="white-space:nowrap">bio-processing,</FONT> infectious diseases and immune-deficiencies, as well as areas outside of healthcare,
such as marine biology and alternative biofuels and other environmental fields. For example, in the United States, our products are currently labeled and promoted, and are, and in the near-future are expected to continue to be, sold primarily to
academic and research institutions and biopharmaceutical companies as research use only products for non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical diagnostic tests. We plan to continue
generating supporting publications and data, as well as pursue any required regulatory approvals for clinical use for our products in the United States. Our ability to penetrate the clinical markets in the United States will depend in part on our
ability to receive 510(k) clearance, <I>de novo</I> classification, or approval of a pre-market approval application from the FDA. Our failure to further expand in adjacent markets and attract new customers could adversely affect our ability to
improve our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business is dependent on adoption of our products by academic and government institutions,
clinical research organizations, pharmaceutical companies and clinical laboratories for their research and development activities focused on cell analysis. If academic and government institutions, clinical research organizations, pharmaceutical
companies and clinical laboratories are unwilling to change current practices to adopt our products, it will negatively affect our business, financial condition, prospects and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our primary strategy to grow our revenue is to take a stepwise approach to market our products across key stakeholders in flow
cytometry and cell analysis, such as academic and government institutions, clinical research organizations, pharmaceutical companies and clinical laboratories. While the number of customers using our products has increased in recent years, many
academic and government institutions, clinical research organizations, pharmaceutical companies and clinical laboratories have not yet adopted our products, and such institutions and companies may choose not to adopt our products for a number of
reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate recruiting or training of talented sales force in existing and new markets to facilitate outreach
and further adoption and awareness of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of experience with our products for cell analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived inadequacy of evidence supporting benefits or cost-effectiveness of our products over existing
alternatives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liability risks generally associated with the use of new products and processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the training required to use new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decrease or delay in the research and development activities using our products as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing products and alternatives; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introduction of other novel alternative products for cell analysis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that educating notable industry KOLs, representatives of academic
and government institutions, clinical research organizations, pharmaceutical companies and clinical laboratories, about the merits and benefits of our products for flow cytometry and cell analysis is one of key elements of increasing the adoption of
our products. If these institutions and companies do not adopt our products for any reason, including those listed above, our ability to execute our growth strategy will be impaired, and it will negatively affect our business, financial condition,
prospects and results of operations.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business currently depends significantly on research and
development spending by academic and government-owned institutions, a reduction in which could limit demand for our solutions and adversely affect our business and operating results. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approximately 49% and 42% of our revenue came from sales to academic and government-owned institutions in the year ended
December 31, 2020 and the three months ended March 31, 2021, respectively. Much of their funding was, in turn, provided by various state, federal and foreign government agencies. In the near term, we expect that a large portion of our revenue will
continue to be derived from sales to academic and government-owned institutions. As a result, the demand for our solutions may depend upon the research and development budgets of these customers, which are impacted by factors beyond our control,
such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreases in government funding of research and development, including as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to programs that provide funding to research laboratories, hospitals and related institutions,
including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of the funding process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">macroeconomic conditions and the political climate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scientists&#146; and customers&#146; opinions of the utility of new products or services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the regulatory environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences in budgetary cycles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitor product offerings or pricing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market-driven pressures to consolidate operations and reduce costs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of relatively new technologies, such as ours. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, various state, federal and foreign agencies that provide grants and other funding may be subject to stringent
budgetary constraints that could result in spending reductions, reduced grant making, reduced allocations or budget cutbacks, which could jeopardize the ability of these customers, or the customers to whom they provide funding, to purchase our
solutions. For example, congressional appropriations to the National Institutes of Health (the &#147;NIH&#148;) have generally increased year-over-year in recent years, but the NIH also experiences occasional year-over-year decreases in
appropriations. There is no guarantee that NIH appropriations will not decrease or halt in the future. A decrease in the amount or halt of, or delay in the approval of, appropriations to NIH or other similar United States or foreign organizations,
such as the Medical Research Council in the United Kingdom, could result in fewer grants benefiting life sciences research. These reductions or delays could also result in a decrease in the aggregate amount of grants awarded for life sciences
research or the redirection of existing funding to other projects or priorities, any of which in turn could cause our customers and potential customers to reduce or delay purchases of our solutions. Our operating results may fluctuate substantially
due to any such reductions and delays. Any decrease in our customers&#146; budgets or expenditures, or in the size, scope or frequency of their capital or operating expenditures, could materially and adversely affect our business, operating results
and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on distributors for sales of our products in certain geographies outside of
the United States. If we are unable to secure additional distributors or maintain good relationships with our existing distributors, or if such distributors do not perform adequately or effectively, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to selling our products through our direct sales force and support organizations in North America, Europe, China,
and several countries in the Asia-Pacific region, we sell our products through third-party distributors in certain regions of Asia, Europe, Latin America, the Middle East and Africa. If current or future distributors do not perform adequately or
effectively or fail to obtain or maintain any required regulatory approvals, we may not realize long-term international revenue growth and our business, operating results and financial condition may be harmed. We have limited control over our
distributors, which may not commit the necessary resources to market our products to the level of our expectations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
intend to continue to grow our business internationally and to do so we may choose to partner with additional distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or
retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms, which could affect our ability to expand into or further penetrate certain geographies and adversely impact our business,
operating results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>International operations and expansion of our international business exposes us to
business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have significant international operations and our business strategy incorporates further international expansion.
We currently maintain relationships with distributors and suppliers outside of the United States and may in the future enter into new distributor and supplier relationships outside of the United States. In addition, we currently have manufacturing
operations in both the United States and China. Doing business internationally involves a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and
import restrictions, tariffs, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or our distributors to obtain approvals to conduct our business in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities and difficulties in obtaining intellectual property protection, enforcing our intellectual
property and defending against third party intellectual property claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">logistics and regulations associated with shipping systems and parts and components for our products, as well
as transportation delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">travel restrictions that limit the ability of marketing, presales, sales, services and support teams to
service customers, including those resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">international trade disputes that could result in tariffs and other protective measures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest,
outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and
distributors&#146; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;), its books and records provisions, or its anti-bribery provisions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these factors could significantly harm our future international
expansion and operations and, consequently, our business, financial condition, results of operations and prospects. In addition, certain international markets are subject to significant political and economic uncertainty, including, for example, the
effect of the withdrawal of the United Kingdom from the European Union. Significant political and economic developments in international markets in which we currently or intend to operate, or the perception that any of them could occur, creates
further challenges for operating in these markets in addition to creating instability in global economic conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market for
cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain
profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face significant competition in the cell analysis and life sciences tools markets. We currently
compete with both established and early stage life sciences technology companies that design, manufacture and market conventional flow cytometry (&#147;CFCs&#148;), spectral flow cytometry and mass cytometry instruments, consumables and software for
cell analysis and/or provide services related to the same. An increasing number of applications for cell analysis, and more particularly flow cytometry, is leading to more companies offering competitive products and services. Our competitors include
Agilent Technologies, Beckman Coulter (Danaher Corporation), Becton, Dickinson and Company (&#147;BD&#148;), <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Fluidigm Corporation, Miltenyi Biotec, Sony Biotechnology (Sony Corporation),
and Thermo Fisher Scientific. Our target customers may also elect to develop their workflows using other technologies rather than implementing our platform or existing customers may decide to stop using our platform. In addition, there are many
large, established companies in the life sciences tools market that could develop instruments or other products that will compete with us in the future. These large, established companies have substantially greater financial and other resources than
us, including larger research and development staff or more established marketing and sales forces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our competitors and
potential competitors may enjoy a number of competitive advantages over us, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer operating histories; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger customer bases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater brand recognition and market penetration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater financial resources and capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater technological and research and development resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger intellectual property portfolios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">better system reliability and robustness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater selling and marketing capabilities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">better established, larger scale and lower cost manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with
larger, well-established and well-financed companies. Our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their
products and services than we can, secure key components from suppliers on more favorable terms, adopt more aggressive pricing policies or sell their products or offer services competitive with our products at prices and margins designed to win
significant levels of market share. We may not be able to compete effectively against these organizations. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption and sales of our
products, which could negatively impact our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future success depends on our ability to develop and successfully introduce new
and enhanced products that meet the needs of our customers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current products include instruments, consumables
and services to advance high-content and high-sensitivity cell analysis by utilizing our full spectrum profiling (&#147;FSP&#148;) technology. We cannot assure you that the market for our current products will continue to generate significant or
consistent demand. Demand for our current products could be significantly diminished by competitive technologies or products that replace them or render them obsolete or less desirable. Accordingly, we must continue to invest in research and
development to develop competitive products and enabling services. Restrictions resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic have had a negative impact on the work on some of our research and development programs due
to the inability of some personnel being able to work in our applicable regional facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future success depends
on our ability to anticipate our customers&#146; needs and develop new products and enhance current products and services to address those needs. Introduction of new products and product enhancements will require that we effectively transfer
production processes from research and development to manufacturing and coordinate our efforts with those of our suppliers to achieve the desired level of production. If we fail to transfer production processes effectively, develop product
enhancements or introduce new products or enabling services in sufficient quantities to meet the needs of our customers, or effectively coordinate with our suppliers, our net sales may be reduced and our business would be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The commercial success of all of our products and services will depend upon their acceptance by the life sciences and
biopharmaceutical industries. Some of the products and services that we are developing are based upon new technologies or approaches. As a result, there can be no assurance that these new products and services, even if successfully developed and
introduced, will be accepted by customers. If customers do not adopt our new products, services and technologies, our results of operations may suffer and, as a result, the market price of our common stock may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of
new products by competitors, make strategic and operational decisions to prioritize certain markets, technology offerings or partnerships, and develop and capitalize on markets, technologies or partnerships, our business could suffer. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently sell our products primarily in the cell analysis market, which is characterized by significant enhancements and
evolving industry and regulatory standards. As a result, our customers&#146; needs are rapidly evolving. If we do not appropriately innovate and offer our customers comprehensive solutions and otherwise invest in new technologies, our offerings may
become less desirable in the markets we serve, and our customers could move to new technologies offered by our competitors or make products themselves. Without the timely introduction of new instruments, consumables, software, services and
enhancements, our offerings may become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new
products and applications to further drive adoption of our platform. To the extent we fail to timely introduce new and innovative products, offer enhancements to our existing products, adequately predict our customers&#146; needs or fail to obtain
desired levels of market acceptance, our business may suffer and our operating results could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
believe our products have potential applications across a wide range of markets and we have targeted certain markets in which we believe our technology has significant advantages, or for which we believe we have a higher probability of success or
revenue opportunity. For example, we are committed to developing our platform&#146;s applications within the clinical market, and in particular, within disease detection, diagnosis, and treatment monitoring. We seek to maintain a process of
prioritization and resource allocation among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets and use cases for our technology. However, due to the significant resources required for the
development of products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or services for new markets, we must make decisions on which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development,
collaboration, management and financial resources toward particular markets, products or services may not lead to the development of any viable products or services and may divert resources away from better opportunities. Similarly, our potential
decisions to delay, terminate or collaborate with third parties in respect of certain markets may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. In particular, if we are unable to accelerate adoption of
our FSP solutions, it could slow or stop our business growth and negatively impact our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely
basis, or at all. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Products from our research and development programs will take time and considerable resources
to develop, and may include improvements or changes to our current products, and we may not be able to complete development and commercialization of new or enhanced products on a timely basis, or at all. There can be no assurance that our research
and development efforts will produce commercially viable products and solutions and before we can commercialize any new products, we will need to expend significant funds to, for example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct substantial research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain necessary regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and scale our laboratory, engineering and manufacturing processes to accommodate different
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">source and enter into agreements with new suppliers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and scale our infrastructure. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons,
including failure of the product to perform as expected and failure to reliably demonstrate the advantages of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we are successful in developing new products, it will require us to make significant additional investments in
marketing and selling resources to commercialize any such products. As a result, we may be unsuccessful in commercializing new products that we develop, which could adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our FSP systems are complex in design and may contain defects that are not detected until deployed by our customers,
which could increase our costs and reduce our net sales. If our products do not perform as expected or the reliability of the technology on which our products and services are based is questioned, our operating results, reputation and business will
suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success depends on our ability to provide reliable, high quality products that enable high-content
and high-sensitivity cell analysis through flexible, efficient and cost-effective solutions. Our FSP systems are complex in design and involve a highly complex and precise manufacturing process. As a result of the technological complexity of our
systems, changes in our or our suppliers&#146; manufacturing processes or the inadvertent use of defective materials by us or our suppliers could result in an adverse effect on our ability to achieve acceptable manufacturing yields and product
reliability. To the extent that we do not achieve and maintain our projected yields or product reliability, our business, operating results, financial condition and customer relationships would be adversely affected. We provide warranties on a
majority of our product sales, and reserves for estimated warranty costs are recorded during the period of sale. The determination of such reserves requires us to make estimates of failure rates and expected costs to repair or replace the products
under warranty. We typically establish warranty reserves based on historical warranty costs for each product line. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
actual repair and replacement costs differ significantly from our estimates, adjustments to cost of sales may be required in future periods which could have an adverse effect on our results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our customers may discover defects in our products after the products have been fully installed and operated.
In addition, some of our products include components from other vendors, which may contain defects. As a result, should problems occur, it may be difficult to identify the source of the problem. If we are unable to identify and fix defects or other
problems, we could experience, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of customers or orders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased costs of warranty expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to our brand reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to attract new customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of development, engineering and manufacturing resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory actions by governmental authorities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal actions by our customers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that customers in our target markets are likely to be particularly sensitive to product defects and errors. Our
reputation and the public image of our products, services and technologies may be impaired if our products or services fail to perform as expected. If our products do not perform, or are perceived to not have performed, as expected or favorably in
comparison to competitive products, our operating results, reputation, and business will suffer, and we may also be subject to legal claims arising from product limitations, errors, or inaccuracies. Any of the foregoing could have an adverse effect
on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although our products are tested prior to shipment,
defects or errors could nonetheless occur. Our operating results depend on our ability to execute and, when necessary, improve our quality management strategy and systems and our ability to effectively train and maintain our employee base with
respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment
malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We provide a <FONT STYLE="white-space:nowrap">one-year</FONT> assurance-type warranty on our instruments. Existing and future
warranties place us at the risk of incurring future repair and/or replacement costs. At the time revenue is recognized, we establish an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of
repairing and replacing defective products. We exercise judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor and overhead
costs. While we believe that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved
quality and reliability in our products and consumables could result in actual expenses that are below those currently estimated. As of March&nbsp;31, 2021, we had accrued approximately $1.2 million in expenses relating to product warranty accruals.
Substantial amounts of warranty claims could have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even after any underlying concerns or problems are resolved, any lingering concerns in our target markets regarding our
technology or any manufacturing defects or performance errors in our products or services could continue to result in lost revenue, delayed market acceptance, damage to our reputation and claims against us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Shipping is a critical part of our business and any changes in our shipping
arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently rely on third-party vendors for our shipping. If we are not able to negotiate acceptable pricing and other terms
with these entities or they experience performance problems or other difficulties, it could negatively impact our operating results and our customers&#146; experience. Additionally, our manufacturing operations in Fremont, California, and Wuxi,
China require global shipping services which are subject to certain factors outside of our control, such as delays passing through customs and disruptions to global shipping routes. We have also experienced shipping delays and difficulties due to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may again experience such delays or difficulties due to future quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and
similar government orders related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other infectious disease outbreaks or natural disasters. Moreover, there is no guarantee that our systems will not become damaged or lost in
transit, and we have experienced, and expect to continue to experience, delivery difficulties. If a system is damaged in transit, it may result in a substantial delay in the fulfillment of the customer&#146;s order, and depending on the type and
extent of the damage and whether the incident is covered by insurance, it may result in customer dissatisfaction and a substantial financial loss for us. If our products are not delivered in a timely fashion or are lost during the delivery process,
our customers could also become dissatisfied and cease using our products or services, which would adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives,
technical applications specialists and customer support staff, our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future
sales will depend, in large part, on our ability to develop and substantially expand our sales infrastructure, particularly as we enter into new markets, rollout new solutions and applications and manage inbound interest from new customers. We
distribute our products through our direct sales force and support organizations located in North America, Europe, China, and several countries in the Asia-Pacific region, and through distributors or sales agents in several European, Latin American,
Middle Eastern, and Asia-Pacific countries. Our sales and marketing efforts are targeted at academic and governmental institutions, pharmaceutical and biotechnology companies, clinical research organizations and clinical laboratories focused on cell
analysis. To continue driving adoption of our solutions and to support our global brand, we will need to further expand our sales infrastructure by hiring additional, highly qualified and reputable sales representatives, technical applications
specialists and customer support staff, in addition to increasing advertising efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Identifying and recruiting
qualified personnel with sufficient industry experience and training them requires significant time, expense and attention. We have limited experience in training our personnel to successfully market and sell our products. If we provide inadequate
training, fail to increase our sales and marketing capabilities or fail to develop broad brand awareness in a cost-effective manner, our business may be harmed. In addition, if our efforts to expand do not generate a corresponding increase in
revenue or result in a decrease in our operating margin, our financial results will be adversely impacted. If we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity
levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our technical applications specialists work closely with researchers and clinicians to optimize and implement
new panels and applications to meet their specific needs. Hiring these highly skilled specialists is competitive due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our
products at a technical level, and training such individuals requires significant time, expense and attention. Furthermore, we face intense competition in the labor market for such highly skilled specialists from competitors in our industry as well
as competition from companies in other industries. To effectively support current and potential customers, we will need to hire, maintain, train and grow </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the number of our technical application specialists and customer support staff. If we are unable to maintain, attract, train or retain the number of qualified support personnel that our business
needs, our business and prospects will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to expand or leverage the number of peer-reviewed articles
published using data generated by our products or otherwise increase brand awareness, the demand for our products and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on a significant base of peer-reviewed publications to showcase and validate the importance and application of our
technology in academic and clinical research settings. To date, there have been more than 210 peer-reviewed articles published, including many published in prominent journals, using data generated by our technology across a wide range of key
scientific research areas, including immunology and inflammation, infectious diseases, immuno-oncology, oncology and others. We believe that expanding the base of these publications, and otherwise developing and maintaining awareness of our brand in
a cost-effective manner is critical to achieving broad acceptance of our solutions and attracting new customers. Such publications and other brand promotion activities may not generate customer awareness or increase revenue and, even if they do, any
increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the customers necessary to realize a sufficient return on
our brand-building efforts, or to achieve the widespread brand awareness that is critical for broad customer adoption of our solutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on our senior management team and key personnel and our business could be harmed if we are unable to attract and
retain personnel necessary for our success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are highly dependent on our senior management team and key
personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales, marketing, scientific and technical professionals, and to integrate current and additional
personnel in all departments. The loss of members of our senior management, sales, marketing, scientific and technical professionals could result in lower than expected sales and delays in product development. If we are not successful in attracting
and retaining highly qualified personnel, it would have a negative impact on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified
personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued, and will in the future issue, equity awards that vest over time. The value to employees of
equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain
valuable employees, they may terminate their employment with us on short notice. Our employment arrangements with our employees provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave
our employment at any time, with or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the other cell analysis technology companies that we compete
against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities, better chances for career advancement and higher
compensation. Some of these characteristics are more appealing to high quality candidates than what we can offer. Further, if we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or
we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, job candidates and existing employees often consider the value of the equity awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are a public company or for
other reasons, it may harm our ability to recruit and retain highly skilled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
employees. Many of our employees have become or will soon become vested in a substantial amount of their equity awards. Our employees may be more likely to leave us if the equity they own have
significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future success also depends on our
ability to continue to attract and retain additional executive officers and other key employees as we expand our business and operations. If we fail to attract new personnel or fail to retain and motivate our current personnel, it will negatively
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have increased the size of our organization and expect to
further increase it in the future, and we may experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we had 390 full-time employees. As our sales and marketing strategies develop and as we transition
into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, while complying with our contractual obligations to
contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have experienced growth and anticipate further growth in our business
operations both inside and outside the United States. This future growth could strain our organizational, administrative and operational infrastructure, including quality control, operational, finance, customer service and sales organization
management. We expect to continue to increase our headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, engineers, technical
personnel and sales and marketing staff and improve and maintain our products to properly manage our growth. Rapid expansion in personnel could mean that less experienced people develop, market and sell our products, which could result in
inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in
retaining our employees, our business may be harmed. We may not be able to maintain the quality or expected turnaround times of our products, or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to
continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a
timely, efficient and effective manner could adversely affect our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have identified a material weakness in our
internal control over financial reporting. If we are unable to remediate this material weakness, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be
able to accurately or timely report our financial condition or results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the completion of
this offering, we have been a private company with limited accounting personnel to adequately execute our accounting processes to address our internal control over financial reporting. In connection with our financial statement close process for the
years ended December&nbsp;31, 2019 and 2020, we identified material weaknesses associated with our control environment and control activities components of the Committee of Sponsoring Organizations (&#147;COSO&#148;) framework related to
(i)&nbsp;the lack of sufficient qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
personnel within its accounting and IT function, and (ii)&nbsp;establishing policies and procedures to identify, select and apply GAAP in order to ensure that transactions were being
appropriately recorded; and the design of appropriate control activities over information technology systems and financial and reporting processes necessary to ensure the accuracy of financial reporting and the preparation of financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of its financial statements would not be prevented or detected on a timely basis. These deficiencies could result in additional material misstatements to our consolidated financial
statements that could not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that the measures we have
taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to our material weakness in our internal control over financial reporting or that they will prevent or avoid potential future
material weaknesses. In addition, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting because no such evaluation has been previously required. If we
are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be
negatively impacted, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial
reporting, and our stock price may decline as a result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may need to raise additional capital beyond the proceeds of this
offering to fund our existing operations, develop our products and/or expand our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current
planned operations, we expect that our existing cash and anticipated net proceeds from this offering will enable us to fund our operating expenses for at least 12 months from the date hereof. However, if our available cash balances, net proceeds
from this offering and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements or otherwise, we may seek to issue equity or convertible debt securities, enter into a credit facility or another form of third-party
funding, seek other debt financing or enter into collaborations or licensing arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may consider raising
additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to further scale up our manufacturing of our products, to increase our sales and
marketing efforts to drive market adoption of our products and address competitive developments, and to finance capital expenditures and general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our present and future funding requirements will depend on many factors, some of which are beyond our control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve and maintain revenue growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of expanding our operations, including our sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rate of progress in launching and commercializing new products, and the cost of the sales and marketing
activities associated with, establishing adoption of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rate of progress in, and cost of research and development activities associated with, products in research
and development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential cost of and delays in product development as a result of any regulatory oversight applicable to
our products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with any product recall that may occur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to domestic and international expansion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of attaining, defending and enforcing our intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of any other collaborative, licensing and other arrangements that we may establish.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional funding may not be available on acceptable terms, or at all. If we do raise additional
capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing
stockholders&#146; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If we raise additional funds through other third-party funding, collaborations agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or products or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions
and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, any resurgence, and actions taken to slow its spread,
including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate,
it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or
discontinue the development, manufacturing or commercialization of our products, or other research and development initiatives. If this were to occur, our ability to grow and support our business and to respond to market challenges could be
significantly limited, which could have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our
operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future
operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any of our products, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, manufacturing, regulatory approval
and commercialization activities relating to our products, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size, seasonality and customer mix of the cell analysis market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales and marketing efforts and expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate at which we grow our sales force and the speed at which newly-hired salespeople become effective;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the productivity of our sales force; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our distribution partners in selling our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive or negative coverage in the media or publications of our products or competitive products;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms
of our arrangements with our suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of competition in our industry and any change in the competitive landscape of our industry,
including the introduction of new products or enhancements or technologies by us or others in the cell analysis market and competition-related pricing pressures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in governmental regulations or in the status of our regulatory approvals or applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions to our business and operations or to the business and operations of our suppliers, distributors,
and other third parties with whom we conduct business resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other widespread health crises such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future global financial crises and economic downturns, including those caused by widespread public health
crises; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions and other factors, including factors unrelated to our operating performance or the
operating performance of our competitors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cumulative effects of factors discussed above could
result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis
may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or
investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of
our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The sizes of the markets for our products may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Within the life sciences technology market, flow cytometry technologies currently provide solutions largely within cell
proliferation, cell counting, cell identification, cell quality control and single-cell applications, representing an initial total addressable market (&#147;TAM&#148;) of nearly $8&nbsp;billion. However, we believe that the enhanced capabilities of
our FSP platform has the potential to capture an increasingly greater share of the broader cell analysis TAM, which according to MarketsandMarkets Research Private Ltd. is expected to grow from roughly $16&nbsp;billion in 2019 to approximately
$23&nbsp;billion by 2024, approximately $5 billion of which represents revenue from hospitals and diagnostic laboratories and $1.5 billion of which comes from the United States. Our Northern Lights system has been approved for clinical use in the
European Union and China. In the United&nbsp;States, our products are currently labeled and promoted, and are, and in the near-future are expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical
companies as research use only products for non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical diagnostic tests. We plan to continue generating supporting publications and data, as well as
pursue any required regulatory approvals for clinical use for our products in the United States. Our ability to penetrate the clinical markets in the United States will depend in part on our ability to receive 510(k) clearance, <I>de novo</I>
classification, or approval of a pre-market approval application from the FDA. Further, we believe our differentiated platform will enable us to expand the use of cell analysis into new markets, well beyond current applications addressed by prior
flow cytometry technologies and other cell analysis technologies. While we believe our assumptions and the data underlying our estimates are reasonable, we have not independently verified the accuracy of the third-party data on which we have based
our assumptions and estimates, and these assumptions and estimates may not be correct and significantly different than actual market sizes, and the conditions supporting our assumptions or estimates may change at any time, including as a result of
factors outside our control, thereby reducing the predictive accuracy of these underlying factors. If the actual number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
customers who would benefit from our products, the price at which we can sell products or the annual addressable market for our products is smaller than we have estimated, it may impair our sales
growth and have an adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our growth
strategy involves launching new solutions and expanding sales of existing solutions into new markets and geographies in which we have limited experience. For example, we intend to develop our platform&#146;s applications within the clinical market,
and in particular, within disease detection, diagnosis, and treatment monitoring. Sales of new or existing solutions into new market opportunities may take several years to develop and mature, and we cannot be certain that these market opportunities
will develop as we expect. As a result, the sizes of the annual total addressable market for new markets and new products are even more difficult to predict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our
existing products and limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The marketing, sale and use of
our products could lead to the filing of product liability claims where someone may allege that our products identified inaccurate or incomplete information or otherwise failed to perform as designed. We may also be subject to liability for errors
in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability claim could result in substantial damages and be costly and time-consuming for us to defend.
If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial litigation costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our products or new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to our business reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls or withdrawals from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of sales; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of existing agreements by our partners and potential partners failing to partner with us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain product liability insurance, but this insurance may not fully protect us from the financial
impact of defending against product liability claims. Any product liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any
defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We may not be successful in initiating appropriate market recall or market withdrawal efforts
that may be required in the future and these efforts may not have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also harm our reputation with
customers, which could negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Litigation and other legal
proceedings may harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have been, and may become, involved in legal proceedings relating to patent
and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal or state regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investigations, securities class actions and other legal proceedings or investigations, which could have a negative impact on our reputation, business and financial condition and divert the
attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments
or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or
investigations in the future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#146;
confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide could adversely affect our business. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners, and customers operate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be
adversely affected. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused general business disruption worldwide beginning in January 2020. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we
temporarily closed our headquarters and other offices, and our <FONT STYLE="white-space:nowrap">non-essential</FONT> employees and contractors continue to work remotely. We have also implemented travel restrictions and other significant changes in
how we operate our business. The operations of our partners and customers have likewise been altered. While the duration and extent of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic depends on future developments and potential
resurgences that cannot be accurately predicted at this time, such as the extent and effectiveness of containment actions and available vaccines, the pandemic has had an adverse effect on the global economy and the ultimate societal and economic
impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic remains unknown. The potential impact and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the global economy and our business are difficult to
assess or predict. Potential impacts, some of which we have already experienced, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our customer prospects and our existing customers may experience slowdowns in their businesses, and our
academic institution customers may experience decreases in government funding of research and development, which in turn may result in reduced demand for our products, lengthening of sales cycles, loss of customers, difficulties in collections, and
inaccurate inventory forecasting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of or delays in receiving supplies from the third parties we rely on to manufacture components to
our products, which may impair our ability sell our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of or delays in installation of our products for our customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of or delays in the shipments of purchased products to customers or to our distribution partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased employee productivity and morale, with increased employee attrition and risk of a cyberattack
resulting from our employees working from home; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions and significant costs to our growth planning, such as for facilities and international expansion;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs in fully returning to work from our facilities around the world, including changes to the workplace,
such as space planning, food service, and amenities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal liability for safe workplace claims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of critical vendors or third-party partners, which may go out of business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued cancellation of <FONT STYLE="white-space:nowrap">in-person</FONT> marketing events, including
industry conferences, and prolonged delays in our ability to reschedule or conduct <FONT STYLE="white-space:nowrap">in-person</FONT> marketing events and other sales and marketing activities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The impact of any of the foregoing, individually or collectively, could
adversely affect our business, financial condition, and results of operations.<B><I> </I></B>Moreover, to the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business, financial condition, and results of
operations, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our security measures, or those maintained on our behalf, are compromised now, or in the future, or the security, confidentiality,
integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, this could have a material adverse effect on our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we may collect, use, store, safeguard, disclose, share, transfer, secure
and otherwise process (collectively, &#147;Process&#148; or &#147;Processing&#148;) proprietary, confidential and sensitive data, including personal data (such as <FONT STYLE="white-space:nowrap">key-coded</FONT> data, health information and other
special categories of personal data), intellectual property, trade secrets and proprietary business information owned or controlled by ourselves, our customers and other parties (collectively &#147;Sensitive Information&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may use third-party service providers and subprocessors to help us operate our business and engage in Processing on our
behalf. We may also share Sensitive Information with our partners or other third parties in conjunction with our business. We manage and maintain our data utilizing a combination of <FONT STYLE="white-space:nowrap">on-site</FONT> systems and
cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. This data encompasses a wide variety of Sensitive Information, including research and development information, commercial
information and business and financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cybersecurity incidents compromising the confidentiality, integrity,
and availability of Sensitive Information or our systems could result from cyber-attacks, computer malware, viruses, social engineering (including phishing), ransomware, supply chain attacks, credential stuffing, efforts by individuals or groups of
hackers and sophisticated organizations, including state-sponsored organizations, errors or malfeasance of our personnel, and security vulnerabilities in the software or systems on which we rely. Such incidents are prevalent and continue to
increase. Due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, a significant portion of our workforce works remotely and this has increased the risk to our information technology assets and data. If we, our service providers,
partners or other relevant third parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or destruction; unauthorized access, acquisition, disclosure or exposure of Sensitive
Information; or compromise related to the security, confidentiality, integrity or availability of our (or their) information technology, software, services, communications or data (any, a &#147;Security Breach&#148;), it may result in a material
adverse effect on our business, financial condition and results of operations, including the diversion of funds to address the breach, and interruptions, delays, or outages in our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be required to expend significant resources, fundamentally change our business activities and practices, or modify our
operations or information technology in an effort to protect against Security Breaches and to mitigate, detect, and remediate actual and potential vulnerabilities. Various data privacy and security laws, regulations and standards, as well as
policies, contracts and other obligations, that apply to the Processing of personal data both by us and on our behalf (collectively, &#147;Data Protection Requirements&#148;) may require us to implement specific security measures or use
industry-standard or reasonable measures to protect against Security Breaches.&nbsp;Even if we were to take and have taken security measures designed to protect against Security Breaches, there can be no assurance that such security measures or
those of our service providers, partners and other third parties will be effective in protecting against all Security Breaches and material adverse effects that may arise from such Security Breaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable Data Protection Requirements may require us to notify relevant stakeholders of Security Breaches, including
affected individuals, partners, collaborators, customers, regulators, law enforcement agencies, credit reporting agencies and others. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to
material adverse effects on our business, financial condition and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
results of operations. There can be no assurance that any limitations or exclusions of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities
or damages if we fail to comply with Data Protection Requirements related to information security or Security Breaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any Security Breach could result in legal claims or proceedings, and liability under federal, state or foreign Data Protection
Requirements. We cannot be sure that our insurance coverage, if any, will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss,
data loss, regulatory actions or other material adverse effects arising out of our Processing operations, privacy and security practices, or Security Breaches we may experience. The successful assertion of one or more large claims against us that
exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large excess or deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements), could have
material adverse effects on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual or perceived Security
Breaches or vulnerabilities, and concerns regarding data privacy, security or Processing may cause some of our actual or prospective customers, collaborators, and/or partners to stop using our products or services or working with us. This
discontinuance, or failure to meet the expectations of such third parties, could result in material harm to our operations, financial performance or reputation and affect our ability to grow and operate our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations (including our manufacturing operations) and the operations of our distribution partners could be subject to
earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and pandemics, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions, for which we are predominantly self-insured. Our ability to obtain components for our products could be disrupted if the operations of our
suppliers were affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption, including interruptions related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In addition, our
corporate headquarters is located in Fremont, California, near major earthquake faults and fire zones, and the ultimate impact on us for being located near earthquake faults and fire zones and being consolidated in a certain geographical area is
unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We manufacture our products at our manufacturing facilities located in Fremont, California, and Wuxi, China, and we rely on
various suppliers in the United States, China and other countries. Should our manufacturing facilities or the facilities of our suppliers be damaged or destroyed by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters, such as
earthquakes, fires or other events, or should events such as political unrest unfold, it could take months to relocate or rebuild, during which time our manufacturing and the operations of our suppliers would cease or be delayed and our products may
be unavailable. Moreover, the use of a new facility or new manufacturing, quality control, or environmental control equipment or systems generally requires FDA review and approval. Because of the time required to authorize manufacturing in a new
facility under FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity in the event we lose our manufacturing
capacity. The inability to perform our manufacturing activities, combined with our limited inventory of materials and components and manufactured products, or the inability of our suppliers to continue their operations, may cause us to be unable to
meet customer demand or harm our reputation, and we may be unable to reestablish relationships with such customers in the future. Consequently, a catastrophic event or business interruption at our manufacturing facilities or at our suppliers&#146;
facilities could harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our insurance policies are expensive and protect us only from some business risks,
which leaves us exposed to significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not carry insurance for all categories of
risk that our business may encounter. Although we have general and product liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not
continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable
terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured
liabilities could negatively affect our business, financial condition and results of operations. We do not carry specific hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude
coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our
clinical trials or regulatory approvals could be suspended. Although we carry cyber insurance, the coverage may not be sufficient to cover our losses in the event of a Security Breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and
officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified
people to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require
us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We use
hazardous biological materials that require considerable expertise for handling, storage and disposal and may result in claims against us. We and third parties with whom we contract must comply with environmental laws and regulations, which can be
expensive and restrict how we do business, and could expose us to liability if our use of such hazardous materials cause injury. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development and manufacturing processes involve the controlled use of hazardous materials, including
flammables, toxics, corrosives and biologics. Our research operations produce hazardous biological and chemical waste products, and we largely contract with third parties for the disposal of these products. Federal, state and local laws and
regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by federal, state and local authorities to ensure compliance with applicable laws. Compliance
with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties. In the
event of accidental contamination or injury from these materials or wastes, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, because our product contains metals and electronic components which are purchased from third-party vendors, we
may be required under rules promulgated by the SEC governing disclosure of the use of &#147;conflict minerals&#148; (tin, tungsten, tantalum and gold) to determine whether those minerals are necessary to the functionality or production of our
products and, if so, conduct a country of origin inquiry with respect to all such minerals. If any such minerals may have originated in the Democratic Republic of the Congo, or DRC, or any of its adjoining countries, or covered countries, then we
must conduct diligence on the source and chain of custody of those conflict minerals to determine if they originated in one of the covered countries and, if so, whether they financed or benefited armed groups in the covered countries. Disclosures
relating to the products that may contain conflict minerals, the country of origin of those minerals and whether they are &#147;DRC conflict free&#148; must be provided in a Form SD (and accompanying conflict minerals report, if required, to
disclose the diligence undertaken by us in sourcing the minerals and our conclusions relating to such diligence). If we are required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
submit a conflict minerals report, that report must be audited by an independent auditor pursuant to existing government auditing standards. Compliance with this disclosure rule may be very
time-consuming for our management and personnel (as well as time-consuming for our suppliers) and could involve the expenditure of significant amounts of money by us and them. Disclosures mandated by this rule, which can be perceived by the market
to be &#147;negative,&#148; may cause customers to refuse to purchase our products. The cost of compliance with the rule could adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We
cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently maintain separate environmental liability coverage and any accidental contamination or discharge or any resultant injury from these
materials could result in significant cost to us in penalties, damages and suspension of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have received funding
under the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we executed a note
in favor of Wells Fargo Bank, National Association, evidencing an unsecured loan, (&#147;PPP loan&#148;), in the aggregate principal amount of $2,771,609, which was made pursuant to the Paycheck Protection Program, or the PPP. The PPP was
established under the CARES Act, which was enacted on March 27, 2020, and is administered by the U.S. Small Business Administration, or the SBA. We have used all of the proceeds from the loan to retain employees, maintain payroll and make lease and
utility payments and expect to repay the PPP loan in the second quarter of 2021. On May 4, 2021, we fully repaid the PPP loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The PPP loan application required us to certify, among other things, that the current economic uncertainty made the PPP loan
request necessary to support our ongoing operations. In 2020, the SBA, in consultation with the Department of Treasury, issued new guidance requiring borrowers to consider their ability to access other sources of liquidity before certifying in their
loan applications that current economic uncertainty makes this loan request necessary to support the ongoing operations. We made the certification in good faith after analyzing our financial situation and access to capital and believe that we
satisfied all eligibility criteria for the PPP loan. However, the SBA guidance and criteria are subject to interpretation, including by the new Biden Administration, and if we are found to have been ineligible, we could be subject to significant
penalties. If we become subject to penalties, it could result in harm to our business, results of operation and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to foreign currency exchange risk. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A substantial amount of our revenues is derived from international operations, and we anticipate that a significant portion of
our sales will continue to come from outside the United States in the future. The revenues we report with respect to our operations outside the United States may be adversely affected by fluctuations in foreign currency exchange rates. See the
section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; for additional information on the financial impact of exchange rate fluctuations and the ways and extent to which we may attempt to
address any impact. Any hedging activities we engage in may only offset a portion of the adverse financial impact resulting from unfavorable changes in foreign currency exchange rates. We cannot predict with any certainty changes in foreign currency
exchange rates or the degree to which we can mitigate these risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may acquire other businesses or form other joint ventures or
make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we currently have no agreements or commitments to complete any such transactions, we may pursue acquisitions of
businesses and assets in the future. We also may pursue strategic alliances and additional joint ventures that leverage products and industry experience to expand our offerings or distribution. We have limited experience with acquiring other
companies and forming strategic partnerships. We may not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate
these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets
or goodwill, any of which could have an adverse effect on our financial condition, results of operations and cash flows. In addition, any pursuit of an acquisition and any potential integration of an acquired company also may disrupt ongoing
operations and divert management attention and resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a negative effect on our results of
operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation and Our Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our products may become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase
our costs and delay or prevent sales of our products or commercialization of new products and product enhancements, thereby materially and adversely affecting our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Currently, our Northern Lights CLC system is available for clinical use in only China and the European Union. Our Aurora and
Northern Lights systems are otherwise available to customers as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">research-use-only</FONT></FONT> (&#147;RUO&#148;) products. RUO products are regulated by the FDA as medical devices.
Although medical devices are subject to stringent FDA oversight, products that are intended for RUO and are labeled as RUO are exempt from compliance with most FDA requirements, including premarket clearance or approval, manufacturing requirements
and others. A product labeled RUO but which is actually intended for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;), and subject to FDA enforcement
action. The FDA has indicated that when determining the intended use of a product labeled RUO, the FDA will consider the totality of the circumstances surrounding distribution and use of the product, including how the product is marketed and to
whom. The FDA could disagree with our assessment that our products are properly marketed as RUOs, or could conclude that products labeled as RUO are actually intended for clinical diagnostic use, and could take enforcement action against us,
including requiring us to stop distribution of our products until we are in compliance with applicable regulations, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial
condition. In the event that the FDA requires us to obtain marketing authorization of our RUO products in the future, there can be no assurance that the FDA will grant any clearance or approval requested by us in a timely manner, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of our growth strategy, we plan to seek approval to offer our Aurora and Northern Lights systems for clinical use in
the United States and in other countries. In the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive either clearance under
Section&nbsp;510(k) of the FDCA, or approval of a premarket approval application from the FDA, unless an exemption applies. The process of obtaining approval or clearance from the FDA for new products, or with respect to enhancements or
modifications to existing products, could take a significant period of time, require the expenditure of substantial resources, involve rigorous <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, require changes to products or
result in limitations on the indicated uses of products. There can be no assurance that we will receive the required approvals or clearances for any new products or for modifications to our existing products on a timely basis or that any approval or
clearance will not be subsequently withdrawn or conditioned upon extensive post-market study requirements. Moreover, even if we receive FDA clearance or approval of new products or modifications to existing products, we will be required to comply
with extensive regulations relating to the development, research, clearance, approval, distribution, marketing, advertising and promotion, manufacture, adverse event reporting, recordkeeping, import and export of such products, which may
substantially increase our operating costs and have a material impact on our business, profits and results of operations. Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
actions such as: warning letters, fines, injunctions, civil penalties, termination of distribution, recalls or seizures of products, delays in the introduction of products into the market, total
or partial suspension of production, refusal to grant future clearances or approvals, withdrawals or suspensions of current approvals, resulting in prohibitions on sales of our products, and in the most serious cases, criminal penalties. Occurrence
of any of the foregoing could harm our reputation, business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and our
suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any medical device we market will be subject to continued regulatory review, oversight, requirements, and periodic inspections
by the FDA and other domestic and foreign regulatory bodies. In particular, unless exempt, we and our suppliers are required to comply with the FDA&#146;s Quality System Regulation (&#147;QSR&#148;) and other regulations enforced outside the United
States which cover the manufacture of our products and the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of medical devices. Regulatory bodies, such as the FDA,
enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and
adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated expenditures to address or defend such actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications for repair, replacement or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall, detention or seizure of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing or delaying our requests for 510(k) clearance or PMA approval of new products or modified products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of 510(k) clearances on PMA approvals that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant export approval for our products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of these actions were to occur, our reputation would be harmed and our product sales and profitability would be
adversely impacted. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in
the required quantities, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Later discovery of previously unknown problems with our products, including
manufacturing problems, or failure to comply with regulatory requirements such as the QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or
mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties
which would adversely affect our business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any government investigation of alleged
violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to
commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory clearance or approval is withdrawn, it would have a material adverse effect on our business, financial condition and results of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our products or any component thereof may be subject to product recalls in the future.
A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has the authority to require the recall of commercialized products that are subject to FDA regulation. Manufacturers
may, under their own initiative, recall a product if any deficiency is found. For reportable corrections and removals, companies are required to make additional periodic submissions to the FDA after initiating the recall, and often engage with the
FDA on their recall strategy prior to initiating the recall. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable health risk, component failures, failures in laboratory processes,
malfunctions, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and adversely affect our business, results of operations, financial
condition and reputation. We may also be subject to liability claims, be required to bear other costs or take other actions that may negatively impact our future sales and our ability to generate profits. Companies are also required to maintain
certain records of corrections and removals, even if these do not require reporting to the FDA. We may initiate voluntary recalls involving our products. A recall announcement by us could harm our reputation with customers and negatively affect our
business, financial condition, and results of operations. In addition, the FDA or other agency could take enforcement action for failing to report the recalls when they were conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we initiate a recall, including a correction or removal, for one of our products, issue a safety alert, or undertake a
field action or recall to reduce a health risk, this could lead to increased scrutiny by the FDA, other governmental and regulatory enforcement bodies, and our customers regarding the quality and safety of our products, and to negative publicity,
including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports could be used against us by competitors and cause customers to delay purchase decisions or cancel orders, which would harm our
reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products may harm our reputation in the
marketplace, or result in injuries that lead to product liability suits, which could be costly to our business. Moreover, we could be subject to FDA sanctions if we are deemed to have engaged in <FONT STYLE="white-space:nowrap">off-label</FONT>
promotion. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our promotional materials and training methods must comply with FDA and other applicable laws and
regulations, including the prohibition on the promotion of an RUO device or medical device for an indication that has not been approved or cleared by the FDA, referred to as an <FONT STYLE="white-space:nowrap">off-label</FONT> use. We cannot prevent
our customers from using our products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, including in laboratory developed tests for clinical use. If the FDA determines that our promotional materials constitute the unlawful promotion of an <FONT
STYLE="white-space:nowrap">off-label</FONT> use, it could subject us to regulatory or enforcement actions, including civil money penalties, criminal fines and penalties, and exclusion from participation in federal health programs, among others.
Other federal, state or foreign governmental authorities might also take action if they consider our promotion or training materials to constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in
significant fines or penalties under other statutory authorities. In that event, our reputation could be damaged and the use of our products in the marketplace could be diminished. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, <FONT STYLE="white-space:nowrap">off-label</FONT> uses of our products may lead to performance issues or produce
erroneous results, which could harm our reputation in the marketplace and increase the risk of product liability. Product liability claims are expensive to defend and could divert our management&#146;s attention from our primary business and result
in substantial damage awards against us. Any of these events could harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in tariffs or other government trade policies may materially adversely affect our business and results of operations, including
by reducing demand for our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The imposition of tariffs and trade restrictions as a result of
international trade disputes or changes in trade policies may adversely affect our sales and profitability. For example, in 2018 and 2019, the U.S. government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
imposed and proposed, among other actions, new or higher tariffs on specified imported products originating from China in response to what it characterized as unfair trade practices, and China
responded by imposing and proposing new or higher tariffs on specified U.S. products. There can be no assurance that a broader trade agreement will be successfully negotiated between the United States and China to reduce or eliminate these tariffs.
These tariffs, and the related geopolitical uncertainty between the United States and China, may cause decreased&nbsp;demand for our products, which could have a material adverse effect on our business and results of operations. For example, certain
of our foreign customers may respond to the imposition of tariffs or threat of tariffs on products we produce by delaying purchase orders or purchasing products from our competitors. Ongoing international trade disputes and changes in trade policies
could also impact economic activity and lead to a general contraction of customer demand. In addition, tariffs on components that we may import from China or other nations will adversely affect our profitability unless we are able to exclude such
components from the tariffs or we raise prices for our products, which may result in our products becoming less attractive relative to products offered by our competitors. Future actions or escalations by either the United States or China that
affect trade relations may also negatively affect our business, or that of our suppliers or customers, and we cannot provide any assurances as to whether such actions will occur or the form that they may take. To the extent that our sales or
profitability are negatively affected by any such tariffs or other trade actions, our business and results of operations may be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to governmental export controls that could impair our ability to compete in international markets due to licensing
requirements and subject us to liability if we are not in compliance with applicable laws. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Exports of our
products are subject to export controls and sanctions laws and regulations imposed by the U.S. government and administered by the U.S. Departments of State, Commerce, and Treasury. U.S. export control laws may require a license or other
authorization to export products to certain destinations and end users. In addition, U.S. economic sanctions laws include restrictions or prohibitions on the sale or supply of certain products and services to U.S. embargoed or sanctioned countries,
governments, persons and entities. Obtaining export licenses can be difficult, costly and time-consuming and we may not always be successful in obtaining necessary export licenses, and our failure to obtain required export approval for our products
or limitations on our ability to export or sell our products imposed by export control or sanctions laws may harm our revenues and adversely affect our business, financial condition, and results of operations. Noncompliance with these laws could
have negative consequences, including government investigations, penalties and reputational harm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to stringent and
changing privacy laws, regulations and standards as well as policies, contracts and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to government enforcement actions
(that could include fines and penalties), a disruption of our business or commercialization of our products, private litigation, harm to our reputation, or other adverse effects on our business or prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The legislative and regulatory framework relating to the processing of personal data worldwide is rapidly expanding and
evolving and is likely to remain uncertain for the foreseeable future. Globally,&nbsp;virtually every jurisdiction in which we operate has established its own data privacy and security frameworks with which we must comply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the course of our operations, we process an increasing volume of personal data, including from our employees and third
parties with whom we conduct business. Accordingly, we are, and may increasingly become, subject to various Data Protection Requirements (as defined above), the number and scope of which are changing, subject to differing applications and
interpretations, may be inconsistent among jurisdictions, and may conflict with each other. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we fail, or are
perceived to have failed, to address or comply with Data Protection Requirements, this could result in government enforcement actions against us that could include investigations, fines, penalties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
audits and inspections, additional reporting requirements and/or oversight, temporary or permanent bans on all or some Processing of personal data, orders to destroy or not use personal data, and
imprisonment of company officials. Further, individuals or other relevant stakeholders could bring a variety of claims against us for our actual or perceived failure to comply with the Data Protection Requirements. Any of these events could subject
us to substantial fines or penalties; have material adverse effects on our reputation, business, or financial condition, and could lead to a loss of actual or prospective customers, collaborators or partners; result in an inability to Process
personal data or to operate in certain jurisdictions; limit our ability to develop or commercialize our products; or require us to revise or restructure our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Collectively, European data protection laws (including the European Union&#146;s General Data Protection Regulation (EU)
2016/679 (&#147;GDPR&#148;)) are wide-ranging in scope and impose numerous, significant and complex compliance burdens in relation to the Processing of personal data, including, among others: limiting permitted Processing of personal data to only
that which is necessary for specified, explicit and legitimate purposes; requiring the establishment of a legal basis for Processing personal data; broadening the definition of personal data to possibly include &#145;pseudonymized&#146; or <FONT
STYLE="white-space:nowrap">key-coded</FONT> data; creating obligations for controllers and processors to appoint data protection officers in certain circumstances; increasing transparency obligations to data subjects; establishing rights which may
be exercised by individuals; establishing limitations on the collection and retention of personal data through &#145;data minimization&#146; and &#145;storage limitation&#146; principles; formalizing a heightened and codified standard of data
subject consent; establishing obligations to implement certain technical and organizational safeguards to protect the security and confidentiality of personal data; introducing obligations to agree to certain specific contractual terms and to take
certain measures when working with <FONT STYLE="white-space:nowrap">third-party</FONT> processors or joint controllers; and introducing the obligation to provide notice of certain significant personal data breaches to the relevant supervisory
authority(ies) and affected individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the GDPR provides that European Economic Area (&#147;EEA&#148;)
member states may introduce specific requirements related to the Processing of special categories of personal data. This fact may lead to greater divergence on the law that applies to the Processing of such personal data across the EEA, which may
increase our costs and overall compliance risk. Such country-specific regulations could also limit our ability to Process relevant personal data in the context of our EEA operations ultimately having an adverse impact on our business, and harming
our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, certain European data protection laws restrict transfers of personal data
to the United States and most other countries outside Europe unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. There are mechanisms intended to permit the transfer of personal data
outside Europe, but there is uncertainty as to the future of such mechanisms, which have been under consistent scrutiny and challenge. For example, a decision of the Court of Justice of the European Union in July 2020 (known as &#147;Schrems
II&#148;) invalidated the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework, a means that previously permitted transfers of personal data from the EEA to companies in the United States that certified adherence to the Privacy
Shield Framework. It is currently unclear what, if any, arrangement may replace the Privacy Shield Framework. Standard contractual clauses approved by the European Commission to permit transfers from the EEA to third countries currently remain, in
principle, a basis on which to effect such transfers. However, the standard contractual clauses are also subject to legal challenge and the Court of Justice of the European Union made clear in the Schrems II decision that reliance on the standard
contractual clauses alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis
taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred personal data. At present, there are few, if any,
viable alternatives to the standard contractual clauses. If we are unable to implement a valid mechanism for personal data transfers from Europe, we will face increased exposure to regulatory actions, substantial fines and injunctions against
Processing personal data from Europe. Inability to export personal data may also: restrict our activities outside Europe; limit our ability to collaborate with partners as well as other service providers, contractors and other companies outside of
Europe; and/or require us to increase our Processing capabilities within Europe at significant expense or otherwise cause us to change the geographical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
location or segregation of our relevant systems and operations&#151;any or all of which could adversely affect our operations or financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">European data protection laws also provide for more robust regulatory enforcement and greater penalties for noncompliance than
previous data protection laws, including, for example, under the GDPR, fines of up to &#128;20&nbsp;million or 4% of global annual revenue of any noncompliant organization for the preceding financial year, whichever is higher. In addition to
administrative fines, a wide variety of other potential enforcement powers are available to competent supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers
to order temporary or permanent bans on all or some Processing of personal data carried out by noncompliant actors&#151;including permitting authorities to require destruction of improperly gathered or used personal data. The GDPR also confers a
private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. There is also uncertainty about
compliance with European data protection laws, with the possibilities that data protection authorities located in different EEA member states may interpret the GDPR differently, or requirements of national laws may vary between EEA member states, or
guidance on the GDPR and compliance practices may be often updated or otherwise revised. Any of these events will increase the complexity and costs of processing personal data in the EEA or concerning individuals located in the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Brexit has created uncertainty regarding the regulation of data protection in the United Kingdom. By operation of the so
called &#145;UK GDPR&#146; (the GDPR as it continues to form part of the law of the United Kingdom by virtue of Section&nbsp;3 of the EU (Withdrawal) Act 2018 as subsequently amended) the GDPR continues to apply in substantially equivalent form to
processing operations carried out in the United Kingdom or concerning individuals located in the United Kingdom. So, when we refer to the GDPR in this section, we are also making reference to the UK GDPR in the context of the United Kingdom, unless
the context requires otherwise. However, it is possible that either the United Kingdom or the EU, and consequently those further states that make up the remainder of the EEA, could elect to change their approach and create differences in legal
requirements and regulation in this area. This could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. In addition, uncertainty remains
regarding how data transfers to and from the United Kingdom will be regulated. As many of our employees providing services to EEA customers are located in the United Kingdom, changes to how data transfers to and from the United Kingdom are regulated
could impact how we provide services to our customers in the EEA. EEA customers may require that our employees who are providing services to them be based in the EEA due to data transfer restrictions, which could increase our costs in providing such
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other countries outside of Europe have enacted or are considering enacting similar comprehensive data privacy
and security laws and regulations, including similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. For example,
China&#146;s cybersecurity law, which took effect in June 2017, broadly regulates data privacy and security practices and its applicability and scope are evolving and aspects of the law are uncertain. As another example, Canada has enacted the
Personal Information Protection and Electronic Documents Act and Canada&#146;s Anti-Spam Legislation, which broadly regulate the Processing of personal data and imposes compliance obligations and penalties comparable to those of European data
privacy and security laws. Complying with these and other similar laws and regulations (to the extent applicable) may cause us to incur substantial operational costs or require us to change our business practices, and could lead to material fines,
penalties and liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, various states and the federal government have adopted, or are considering
adopting, laws and regulations relating to privacy and data security, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA. This patchwork of legislation and regulation may give rise to conflicts or differing views of
personal privacy rights. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, foreign or other state laws, and such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#147;CCPA&#148;), which increases data privacy and security
rights for California residents and imposes numerous obligations on covered businesses, came into effect on January&nbsp;1, 2020. Among other things, the CCPA gives California residents expanded rights related to their personal information,
including the right to access and delete their personal information, and receive detailed information about how their personal information is used and shared. The CCPA also created restrictions on &#147;sales&#148; of personal information that allow
California residents to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sharing of their personal information and may restrict the use of cookies and similar technologies for advertising purposes. The CCPA provides for civil penalties for
violations and creates a private right of action for certain data breaches that that is expected to increase data breach litigation. Additionally, a new California ballot initiative, the California Privacy Rights Act (&#147;CPRA&#148;) was recently
passed in California. The CPRA will restrict use of certain categories of sensitive personal information that we handle, further restrict the use of cross-context behavioral advertising techniques on which our platform relies, establish restrictions
on the retention of personal information, expand the types of data breaches subject to the private right of action, and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. The
majority of the CPRA&#146;s provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes will likely be required. Similar laws have been proposed in other states and at the
federal level, reflecting a trend toward more stringent data privacy and security legislation in the United States. New and evolving privacy and data security laws and regulations impose significant compliance and operational requirements that are
likely to increase over time, may require us to modify our data Processing practices and policies, divert resources from other initiatives and projects, and could restrict the way products and services involving data are offered, all of which may
harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to government regulation, privacy advocates
and industry groups have regularly proposed, and may propose in the future, self-regulatory standards by which we are or may become legally or contractually bound. For example, we are subject to the Payment Card Industry (&#147;PCI&#148;) Data
Security Standard, which is a standard designed to protect credit card account data as mandated by payment card industry entities. If we fail to comply with such standards or contractual obligations related to data privacy and security, we may face
public and regulatory scrutiny, substantial liability, and fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to public statements about our
use and disclosure of personal information through our privacy policies, information provided on our website and press statements, and contractual obligations to third parties relating to data privacy and security. Although we endeavor to comply
with our public statements, documentation, and contractual obligations, we may at times fail to do so or be alleged to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees,
third-party collaborators, service providers, contractors or consultants fail to comply with our policies, documentation, and contractual obligations. Such failures can subject us to potential foreign, local, state and federal government or legal
action, including if our policies and documentation are found to be deceptive, unfair or misrepresentative of our actual practices. Claims that we have violated individuals&#146; privacy rights or failed to comply with data privacy and security laws
or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business or have other material adverse effects on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we take reasonable efforts to comply with all Data Protection Requirements
and have invested and continue to invest human and technology resources into data privacy and security compliance efforts, there can be no assurance that our actual or perceived <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Data
Protection Requirements will not subject us to litigation, regulatory actions, fines, civil or criminal penalties, limited ability or inability to operate our business, offer our products and services, negative publicity, and harm to our business.
We or our third-party service providers could be adversely affected if legislation or regulations are expanded to require changes in our or our third-party service providers&#146; business practices or if governing jurisdictions interpret or
implement their legislation or regulations in ways that negatively affect our or our third-party service providers&#146; business, results of operations or financial condition. For example, we may find it necessary to establish alternative systems
to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
maintain personal data originating from the EEA, which may involve substantial expense and may cause us to divert resources from other aspects of our business, all of which may adversely affect
our results from operations. Further, any inability to adequately address privacy and data security concerns in connection with our solutions, or comply with applicable Data Protection Requirements, could result in additional cost and liability to
us, and adversely affect our ability to offer our solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Anticipated further evolution of regulations on this topic
may substantially increase the penalties to which we could be subject in the event of any <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Compliance with these laws is challenging, constantly evolving, and time consuming and federal
regulators, state attorneys general and plaintiff&#146;s attorneys have been and will likely continue to be active in this space. We may incur substantial expense in complying with the new legal obligations to be imposed by new regulations and we
may be required to make significant changes to our solutions and expanding business operations, all of which may adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign anti-corruption and anti-money laundering laws and regulations. We can face criminal
liability and other serious consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to
anti-corruption and anti-money laundering laws and regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and
anti-money laundering laws in the countries in which we conduct or may in the future conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other third-party collaborators
from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from persons in the public or private sector. The FCPA also requires public companies to make and
keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to selling our products internationally directly through our sales teams, we currently engage third parties
outside of the United States, and may engage additional third parties outside of the United States, to sell our products internationally and to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct
or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents,
contractors and other third-party collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and
penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to comply with U.S. federal and state fraud and abuse and other healthcare laws and regulations, including those relating to
kickbacks and false claims, we could face substantial penalties and our business operations and financial condition could be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to broadly applicable anti-fraud and abuse, anti-kickback, false claims and other healthcare laws and
regulations that may constrain our business, our arrangements and relationships with customers, and how we market, sell and distribute our products. We have a compliance program, code of conduct and associated policies and procedures, but it is not
always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent noncompliance may not be effective in protecting us from governmental investigations for failure to comply
with applicable fraud and abuse or other healthcare laws and regulations. The laws that may affect our ability to operate include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Anti-Kickback Statute, which prohibits, among other things, knowingly and willingly soliciting, offering,
receiving or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of a person, or the purchase, order or recommendation of, items
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
or services for which payment may be made, in whole or in part, under a federal healthcare program such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly
interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or a specific intent to violate. In addition, the government
may assert that a claim, including items or services resulting from a violation of the Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the FCA. There are a number of statutory exceptions and regulatory safe harbors
protecting certain business arrangements from prosecution under the Anti-Kickback Statute; however, those exceptions and safe harbors are drawn narrowly, and there may be limited or no exception or safe harbor for many common business activities.
Certain common business activities including, certain reimbursement support programs, educational and research grants or charitable donations, and practices that involve remuneration to those who prescribe, purchase or recommend medical devices,
including discounts, providing items or services for free or engaging such people as consultants, advisors or speakers, may be subject to scrutiny if they do not fit squarely within any available exception or safe harbor and would be subject to a
facts and circumstances analysis to determine compliance with the Anti-Kickback Statute. Our business may not in all cases meet all of the criteria for statutory exception or regulatory safe harbor protection from anti-kickback liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil False Claims Act, or the FCA, which prohibits, among other things, persons or entities from
knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds and knowingly making, using or causing to be made or used, a false record or statement to get a false claim paid or to avoid, decrease or
conceal an obligation to pay money to the federal government. A claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Actions under the FCA may be
brought by the government or as a qui tam action by a private person in the name of the government. These people, sometimes known as &#147;relators&#148; or, more commonly, as &#147;whistleblowers,&#148; may share in any monetary recovery. Many
medical device manufacturers have been investigated and have reached substantial financial settlements with the federal government under the FCA for a variety of alleged improper activities, including causing false claims to be submitted as a result
of the marketing of their products for unapproved and thus <FONT STYLE="white-space:nowrap">non-reimbursable</FONT> uses and interactions with prescribers and other customers, including those that may have affected their billing or coding practices
and submission of claims to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory monetary penalties for each false or fraudulent claim or statement.
Because of the potential for large monetary exposure, life sciences companies often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages and per claim penalties that may
be awarded in litigation proceedings. Settlements may require companies to enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance. Medical device manufacturers and other
healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to <FONT STYLE="white-space:nowrap">non-government</FONT> health benefit
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal and civil liability for, among other actions, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making a materially false, fictitious or
fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare
benefits, items or services. Similar to the federal healthcare Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act,
and their implementing regulations, also impose obligations, including mandatory contractual terms, on covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business
associates that perform certain services for them or on their behalf involving the use or disclosure of individually identifiable health information with respect to safeguarding the privacy, security and transmission of individually identifiable
health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">various state laws govern the privacy and security of personal information, including the California Consumer
Protection Act, or CCPA, which became effective January&nbsp;1, 2020, and gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information
about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT>
of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, implemented as Open Payments, requires manufacturers of drugs,
devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually, with certain exceptions to CMS, information related to payments or other
&#147;transfers of value&#148; made to physicians, as defined by such law, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by
physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held,
during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false
claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require medical device companies to comply with the industry&#146;s voluntary compliance guidelines and the
applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state beneficiary inducement laws, which are state laws that require
medical device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">State and federal regulatory and enforcement agencies continue to actively investigate violations of healthcare laws and
regulations, and the U.S. Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018, or the BBA, increased the criminal and civil penalties that can be imposed for violating certain federal
health care laws, including the Anti-Kickback Statute. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government agencies have increased regulatory scrutiny and enforcement activity with
respect to manufacturer reimbursement support activities, including bringing criminal charges or civil enforcement actions under the Anti-Kickback Statute, FCA and HIPAA&#146;s healthcare fraud and privacy provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available
under such laws, it is possible that some of our business activities, including certain sales and marketing practices of our products, could be subject to challenge under one or more such laws. If an arrangement were deemed to violate the
Anti-Kickback Statute, it may also subject us to violations under other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
fraud and abuse laws such as the federal civil FCA and civil monetary penalties laws. Moreover, such arrangements could be found to violate comparable state fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Achieving and sustaining compliance with applicable federal and state anti-fraud and abuse laws may prove costly. If we or our
employees are found to have violated any of the above laws we may be subjected to substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and
Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our financial results. Any action or investigation against us for the violation of these healthcare fraud and abuse laws, even if successfully defended, could result in
significant legal expenses and could divert our management&#146;s attention from the operation of our business. Companies settling FCA, Anti-Kickback Statute or civil monetary penalties law cases also may enter into a Corporate Integrity Agreement
with the U.S. Department of Health and Human Services Office of Inspector General, or the OIG, to avoid exclusion from participation (such as loss of coverage for their products) in federal healthcare programs such as Medicare and Medicaid.
Corporate Integrity Agreements typically impose substantial costs on companies to ensure compliance. Defending against any such actions can be costly, time-consuming and may require significant personnel resources, and may harm our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk that our employees, independent contractors, consultants, commercial partners, distributors and
vendors may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (1)&nbsp;the laws of the FDA and other similar
regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulators, (2)&nbsp;manufacturing standards, (3)&nbsp;healthcare fraud and abuse laws in the United States and similar foreign
fraudulent misconduct laws, or (4)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs. In particular, the
promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a code of business conduct and ethics that applies to our directors, officers and employees, but it is not
always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting
our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, additional integrity
reporting and oversight obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any
of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees and
reputational harm, and divert the attention of management in defending ourselves against any of these claims or investigations, which could harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to obtain and maintain patent or other intellectual property protection for any of our current or future products, or if
the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our current
or future products may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As with other flow cytometry companies, our success depends in large part on
our ability to obtain, maintain and solidify a proprietary position for our current and any future products, which will depend upon our success in obtaining effective patent protection in the United States and other countries that cover, and other
intellectual property with respect to, such products, their manufacturing processes and their intended methods of use and enforcing those patent claims once granted as well as our other intellectual property. In some cases, we may not be able to
obtain issued patent claims or other intellectual property covering our technologies which are sufficient to prevent third parties, such as our competitors, from utilizing our products and negate any competitive advantage we may have. Any failure to
obtain or maintain patent and other intellectual property protection with respect to our current and any future products or other aspects of our business could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to
protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents. Additionally, we cannot predict whether the patent
applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain,
enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent
protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our
employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby
jeopardizing our ability to seek and obtain patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends in part on whether the differences between our inventions and the prior art allow our inventions to
be patentable over the prior art. Furthermore, the publication of discoveries in scientific literature often lags behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until
18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to file for patent protection of such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we own seven issued U.S. patents and one issued foreign patent. There are 29 pending patent
applications, including 13 in the United States and 16 foreign applications. In April 2021, we filed two different provisional patent applications in the United States directed to technology integrated into our cell sorter. Assuming all maintenance
fees are paid, the U.S. issued patents are expected to expire between years 2023 and 2038. Patents covering intellectual property relating to design specific technologies invented by our researchers in Shanghai and Wuxi, China are filed in China and
owned by our China subsidiaries, respectively. As of March&nbsp;31, 2021, our Shanghai subsidiary owns 11 issued patents and has 12 pending patent applications, and our Wuxi subsidiary owns 17 issued patents and has nine pending patent applications.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at
all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third
parties. It is possible that others will design around our current or future patented technologies. It is possible that in the future the scope, validity and enforceability of our patents, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
licensed patents, patent applications, trademarks, and trademark applications may be challenged at the United States Patent and Trademark Office (&#147;USPTO&#148;) or in proceedings before the
patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents, patent applications, trademarks or trademark applications. Any successful third party challenge to our patents or trademarks
could result in the unenforceability or invalidity of such patents or trademarks and increased competition to our business. We may have to challenge the patents, patent applications, trademarks, or trademark applications of third parties. The
outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and
result in substantial cost, and may divert our efforts and attention from other aspects of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, in
some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties or that we may <FONT
STYLE="white-space:nowrap">jointly-own</FONT> with third parties in the future and are therefore reliant on our licensors or licensees, and may be reliant on future joint-owners, licensors or licensees, to protect certain of our intellectual
property used in our business. If our joint-owners, licensors or licensees fail to adequately protect this intellectual property or if we do not have exclusivity for the marketing of our products, whether because our joint-owners or licensors do not
grant us exclusivity or they do not enforce the intellectual property against our competitors, our ability to commercialize products could suffer. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a
manner consistent with the best interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Defects of form in the preparation or filing of our patents or
patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship and the like. If we or any of our current or future joint-owners, licensors or licensees fail to establish, maintain,
protect or enforce such patents and other intellectual property rights, such rights may be reduced or eliminated. If any current or future joint-owners, licensors or licensees are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation or prosecution of our patents or patent applications, such patents or applications may be invalid and/or
unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may impact our ability to commercialize our products and materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The strength of patent rights generally, and particularly the patent position of life sciences companies, involves complex
legal and scientific questions and can be uncertain, and has been the subject of much litigation in recent years. This uncertainty includes changes to the patent laws through either legislative action to changes to statutory patent law or court
action that may reinterpret existing law or rules in ways affecting the scope or validity of issued patents or the chances that patent applications will result in issued claims and the scope of any such claims. Our current or future patent
applications may fail to result in issued patents in the United States or foreign countries with claims that cover our current and any future products. Even if patents do successfully issue from our patent applications, third parties may challenge
the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to our patents could deprive us of the exclusive rights necessary for the successful
commercialization of our current and any future products, which may materially harm our business. Furthermore, even if they are unchallenged, our patents may not adequately protect our current and any future products, provide exclusivity for such
products or prevent others from designing around the claims of our patents. If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from
commercializing similar or identical technology and products would be adversely affected and would materially harm our business. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our current and any
future products is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our current and any future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years after
its effective filing date and the natural expiration of a design patent is generally 14 years after its issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
date, unless the filing date occurred on or after May&nbsp;13, 2015, in which case the natural expiration of a design patent is generally 15 years after its issue date. However, the actual
protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a
particular country and the validity and enforceability of the patent. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in
protecting our proprietary rights in these countries. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current and any future products and services, we
may be open to competition, which may harm our business prospects. Further, if we encounter delays in our development efforts, the period of time during which we could market our current and any future products and services under patent protection
would be reduced and, given the amount of time required for the development, testing and regulatory review of planned or future products, patents protecting our current and any future products might expire before or shortly after such products are
commercialized. As our patents expire, the scope of our patent protection will be reduced, which may reduce or eliminate any competitive advantage afforded by our patent portfolio. As a result, our patent portfolio may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the coverage claimed in a
patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own, currently or in the future, issue as patents, they may not issue in a form
that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own now or in the future may be challenged, narrowed,
circumvented or invalidated by third parties. Consequently, we do not know whether our current and any future products or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third
parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could harm our business, financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of our patents and patent applications may in the future be jointly-owned with third parties, including
certain universities and public institutions in the United States and China. If we are unable to obtain an exclusive license to any such third-party joint-owners&#146; interest in such patents or patent applications, such <FONT
STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any
such joint-owners patents to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may find it necessary or prudent to acquire or obtain licenses from third-party intellectual property
holders. However, we may be unable to acquire or secure such licenses to any intellectual property rights from third parties that we identify as necessary for our current and any future products. The acquisition or licensing of third-party
intellectual property rights is a competitive area, and our competitors may pursue strategies to acquire or license third-party intellectual property rights that we may consider attractive or necessary. Our competitors may have a competitive
advantage over us due to their size, capital resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable
to acquire or license third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property
rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant products, which could harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patents covering our current, and any future products, or our technologies could be
found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, which could harm our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be
challenged in the courts, the USPTO or patent offices abroad and may not provide us with adequate proprietary protection or competitive advantage against competitors with similar products. We may be subject to a third-party preissuance submission of
prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review (&#147;IPR&#148;), or interference proceedings or other similar proceedings challenging our patent rights. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our current and any future products and compete directly with
us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in post-grant challenge proceedings, such as oppositions in a foreign
patent office, that challenge features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, in loss of exclusivity or in patent claims being narrowed, invalidated or held
unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current and any future products or technologies. Such
proceedings also may result in substantial cost and require significant time from our management, even if the eventual outcome is favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if we initiate legal proceedings against a third party to enforce a patent covering our current and any future
products, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that
someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Defenses of these types of claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. Third parties may also raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even
outside the context of litigation, including through <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, IPR, derivation proceedings and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such
proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover or provide meaningful protection of our current and any future products or technologies. The outcome for any
particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant or other third-party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current and any future
products and technology. Such a loss of patent protection would harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely substantially on our trademarks and trade names. If our trademarks and trade names are not adequately protected, then we may not
be able to build name recognition in our markets of interest and our business may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely
substantially upon trademarks to build and maintain the integrity of our brand. Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on
other marks. We may not be able to protect our rights to these trademarks and trade names, which we rely upon to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties
may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
confusion and asserting claims against such third parties may be prohibitively expensive. In addition, there could be potential trade name or trademark infringement or dilution claims brought by
owners of other trademarks against us. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts
to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names or other intellectual property may be ineffective, could result in substantial costs and diversion of resources and could harm our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our intellectual property, including patent, protection depends on
compliance with various procedural, document submission, fee payment and other requirements imposed by government agencies, and our intellectual property, including patent, protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodic maintenance fees,
renewal fees, annuity fees and various other government fees on intellectual property registrations and applications will be due to be paid to the applicable government agencies, including with respect to patents and patent applications the USPTO
and similar agencies outside of the United States, over the lifetime of our intellectual property registrations and applications, including our patents and patent applications. The various applicable government agencies, including with respect to
patents and patent applications the USPTO and similar agencies outside of the United States, require compliance with several procedural, documentary, fee payment and other similar provisions during the application process. In some cases, an
inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in the abandonment or lapse
of the intellectual property registration or application, resulting in a partial or complete loss of intellectual property rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in
abandonment or lapse of an intellectual property registration or application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and
failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could harm our business, financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have limited foreign intellectual property rights outside the United States, selected countries in the European
Union, Japan and China and may not be able to protect our intellectual property and proprietary rights throughout the world, which could harm our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have limited intellectual property rights outside the United States, selected countries in the European Union, Japan and
China. Filing, prosecuting and defending patents or trademarks on our current and any future products in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same
extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions or utilizing our trademarks in all countries outside the United States, or from selling or importing products made
using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our current and any future products, and our patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems in
protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property
protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property
and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property
that we develop or license. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual
property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our
current and any future products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or interpretation of the patent laws in the
United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the
United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or
the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be
entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent
covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States
and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to file any patent application related to our current and any future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The America Invents Act also includes a number of significant changes that affect the way patent applications will be
prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant
proceedings, including post-grant review, IPR and derivation proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of a lower evidentiary standard in
USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though
the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if
first challenged by the third-party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. In addition, future actions by the U.S. Congress, the federal courts and the USPTO could cause the laws and regulations governing patents to change in unpredictable ways. Any of the foregoing could harm
our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, recent U.S. Supreme Court rulings have made and
will likely continue to make changes in how the patent laws of the United States are interpreted. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could
weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our
patents. Any similar adverse changes in the patent laws of other jurisdictions could also harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Third-party claims of intellectual property infringement, misappropriation or other
violation against us, the joint-owners of our intellectual property, or our collaborators may prevent or delay the sale and marketing of our current and any future products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The flow cytometry industry is highly competitive and dynamic. Due to the focused research and development that is taking
place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, we could become subject to significant intellectual property-related
litigation and proceedings relating to our or third-party intellectual property and proprietary rights. Such litigation and proceedings may cause us to incur significant expense, including the payment of damages, settlement payments and/or royalty
payments. For example, in February 2018, BD filed suit against us and certain of our employees in the United States District Court for the Northern District of California asserting a number of claims against us, including misappropriation of trade
secrets and copyright infringement. In October 2020, we entered into a settlement agreement with BD resulting in a dismissal of all claims and a release of all claims between the parties. Pursuant to the settlement agreement with BD, we are required
to make certain payments to BD, including royalty payments on sales of certain of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success
depends in part on our and any potential future collaborators&#146; ability to develop, manufacture, market and sell any products that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating
the patents and other intellectual property or proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us or any potential collaborators to alter our development or commercial strategies,
obtain licenses or cease certain activities. The medical device industry is characterized by extensive litigation regarding patents and other intellectual property rights, as well as administrative proceedings for challenging patents, including
interference, inter partes or post-grant review, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties, including our competitors, may currently have patents or obtain patents in the future and claim that the
manufacture, use or sale of our current and any future products infringes upon these patents. We have not conducted an extensive search of patents issued or assigned to other parties, including our competitors, and no assurance can be given that
patents containing claims covering our current and any future products, components of our current and any future products, technology or methods do not exist, have not been filed or could not be filed or issued. In addition, because patent
applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents which our current or
future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. As the number of
competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement claims against us escalates, increasing the risk that we will be required to incur significant expenses defending any
such claims or lose patent protection for our current or future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to claims that current
or former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship
disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our current and any future products. Litigation may be necessary to defend against these and other claims challenging inventorship of our
patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual
property that is important to our current and any future products. If we were to lose exclusive ownership of such intellectual property, other owners may be able to license their rights to other third parties, including our competitors. We also may
be required to obtain and maintain licenses from third parties, including parties involved in any such disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be
<FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of our current and any future products. The loss of exclusivity or the narrowing of
our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a
distraction to management and other employees. Any of the foregoing could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary
technology without authorization and initiates litigation against us, even if we believe such claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A
court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed by our current and any future products, which could harm our ability to commercialize any product we may develop and any other
technologies covered by the asserted third-party patents. To successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe third-party intellectual
property rights, including patents, and we are unsuccessful in demonstrating that such patents or other intellectual property rights are invalid or unenforceable, such third parties may be able to block our ability to commercialize the applicable
products or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at
all. Even if we are able to obtain a license, the license would likely obligate us to pay significant license fees and/or royalties, and the rights granted to us might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in
our competitors gaining access to the same technology. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, we may be unable to commercialize our current and any future products, or such
commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Defense of
infringement claims, regardless of their merit or outcome, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of
a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products and/or have to pay substantial damages for use of the asserted intellectual property, including treble damages and
attorneys&#146; fees were we found to willfully infringe such intellectual property. Claims that we have misappropriated the confidential information or trade secrets of third parties could harm our business, financial condition and results of
operations. We also might have to redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Engaging in litigation to defend against third-party infringement claims is very expensive, particularly for a company of our
size, and time-consuming. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have
a substantial negative impact on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we
can because of greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to
compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may become involved in lawsuits to protect or enforce our patents and other
intellectual property rights, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe
our patents, or the patents of any future licensing partners, or we may be required to defend against claims of infringement. In an infringement proceeding, a court may decide that our patent is invalid or unenforceable, or may refuse to stop the
other party from using the technology at issue on the grounds that our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to
incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments,
and if securities analysts or investors perceive these results to be negative, it could have a substantial negative impact on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could harm our ability to compete in the marketplace. Any of the foregoing could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.
If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their
current or former employers or claims asserting ownership of what we regard as our own intellectual property. Such claims could harm our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is common in the life sciences industry, our employees, consultants and advisors may be currently or previously employed or
engaged at universities or other life sciences companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may in the future become subject to claims that we or these people have, inadvertently or otherwise, used or disclosed intellectual property, including trade secrets or
other proprietary information, of their current or former employer. Also, we may in the future be subject to claims that these people are violating <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with their former employers.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could harm our business, financial
condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as
our own. The assignment of intellectual property rights may not be self-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of
what we regard as our intellectual property. Such claims could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to seeking patent protection for our current and any future products, we also rely upon unpatented trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain a competitive position, especially where we do not believe patent protection is appropriate or obtainable. Trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We seek to protect such proprietary information, in part, through <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with our employees,
collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with our consultants that require them to assign to us any inventions created as a result of
their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a
relationship with employees or third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that we have entered into such agreements with each
party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we
may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some
courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to
prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third-party, our competitive position would be materially and
adversely harmed. Furthermore, we expect these trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information to over time be disseminated within the industry through independent development, the publication of journal
articles describing the methodology and the movement of personnel from academic to scientific industry positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also
seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these people,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the
extent that our employees, consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and
inventions, which could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Failure of a key information technology
system, process, or site could have an adverse effect on our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely extensively on information
technology systems to conduct our business. These systems affect, among other things, ordering and managing materials from suppliers, shipping products, processing transactions, complying with regulatory, legal or tax requirements, data security and
other processes necessary to manage our business. Our systems and the data contained on them may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, social engineering (including phishing), supply chain attacks,
credential stuffing, efforts by individuals or groups of hackers and sophisticated organizations, including state-sponsored organizations, errors or malfeasance of our personnel, and security vulnerabilities in the software or systems on which we
rely, and failures during the process of upgrading or replacing software, databases or components thereof. If the confidentiality, integrity, or availability of our systems or our data is compromised due to these, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any number of causes, ranging from catastrophic events and power outages to security breaches, and our business continuity plans do not effectively compensate on a timely basis, we may experience
interruptions in our operations, including corruption of our data or release of our confidential information, which could have an adverse effect on our business. Furthermore, any breach in our information technology systems could lead to the
unauthorized access, disclosure and use of <FONT STYLE="white-space:nowrap">non-public</FONT> information, which may be protected by applicable laws. In addition, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has generally increased
the risk of cybersecurity intrusions. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#147;hackers&#148; hoping to use the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to
their advantage. Any such access, disclosure, or other loss of information could require substantial expenditures to remedy and could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and
damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our use of open source software could compromise our ability to offer our services and subject us to
possible litigation. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use open source software in connection with the software integrated in our instruments.
Companies that incorporate open source software into their products have, from time to time, faced claims challenging their use of open source software and compliance with open source license terms. As a result, we could be subject to lawsuits by
parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly
disclose all or part of the source code to the licensee&#146;s software that incorporates, links or uses such open source software, and make available to third parties for no cost, any derivative works of the open source code created by the
licensee, which could include the licensee&#146;s own valuable proprietary code. While we monitor our use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that
would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source license terms are often ambiguous. There is little legal precedent in this area and
any actual or claimed requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop products and services that are similar to or
better than ours. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This
Offering and Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our stock price may be volatile, and the value of our common stock may decline.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market price of our common stock may be highly volatile and may fluctuate or decline substantially as a
result of a variety of factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree and rate of market adoption of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variance in our financial performance from expectations of securities analysts or investors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our financial condition and results of operations, including as a result
of anticipated or unanticipated demand based on seasonal factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our projected operating and financial results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning our intellectual property or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative publicity associated with issues related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in senior management or key personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future sales of our common stock or other securities, by us or our stockholders, as well as the anticipation
of <FONT STYLE="white-space:nowrap">lock-up</FONT> releases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approvals for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments concerning any of our third-party distribution partners and suppliers, including our
single and sole-source suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant business developments, acquisitions, or new offerings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to engage additional distribution partners and establish collaborations, if needed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance or news releases by other companies in our industry including about adverse developments related
to safety, effectiveness, accuracy and usability of their products, reputational concerns, regulatory compliance, and product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, regulatory and market conditions, including economic recessions or slowdowns and the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Broad market and industry fluctuations, as well as general economic, pandemic, political, regulatory, and market conditions,
may negatively impact the market price of our common stock. In addition, given the relatively small expected public float of shares of our common stock on the Nasdaq Global Select Market (the &#147;Nasdaq&#148;), the trading market for our shares
may be subject to increased volatility. In the past, securities class action litigation has often been brought against companies that have experienced volatility or following a decline in the market price of its securities. This risk is especially
relevant for us, because life sciences companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources,
which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>There has been no prior market for our common stock. An active market may not develop or be
sustainable and investors may not be able to resell their shares at or above the initial public offering price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There has been no public market for our common stock prior to this offering. The initial public offering price for our common
stock will be determined through negotiations between the underwriters and us and may vary from the market price of our common stock following this offering. If you purchase shares of our common stock in this offering, you may not be able to resell
those shares at or above the initial public offering price, if at all. An active or liquid market in our common stock may not develop after this offering or, if it does develop, it may not be sustainable. As a result of these and other factors, you
may be unable to resell your shares of our common stock at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter
into strategic partnerships or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You will
experience immediate and substantial dilution in the net tangible book value of the shares of common stock you purchase in this offering. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public offering price of our common stock will be substantially higher than the pro forma net tangible book value
per share of our common stock immediately after this offering. If you purchase shares of our common stock in this offering, you will suffer immediate dilution of $14.25 per share representing the difference between our pro forma as adjusted net
tangible book value per share after giving effect to the sale of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stock in this offering and the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. To the extent outstanding
options are exercised, there will be further dilution to new investors. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything,
in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which
you do not agree and in ways that may not yield a return. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have broad discretion over the use of the net
proceeds from this offering. Investors may not agree with our decisions, and our use of the net proceeds may not yield any return on your investment. We currently intend to use the net proceeds from this offering to fund manufacturing activities,
sales and marketing activities, including the hiring and training of additional sales and marketing personnel, and the remainder for working capital and general corporate purposes, including research and development activities. In addition, a
portion of the net proceeds may also be used to acquire assets or complementary businesses.&nbsp;Our failure to apply the net proceeds from this offering effectively could impair our ability to pursue our growth strategy or could require us to raise
additional capital. In addition, pending their use, the net proceeds of this offering may be placed in investments that do not produce income or that may lose value. If we do not invest or apply the net proceeds from this offering in ways that
enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Participation in this offering by our existing stockholders and/or their affiliated entities may reduce the public float for our common
stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent certain of our existing stockholders and their affiliated entities participate in this
offering, such purchases would reduce the non-affiliate public float of our shares, meaning the number of shares of our common stock that are not held by officers, directors and principal stockholders. A reduction in the public float could reduce
the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to sell shares of common stock purchased in this offering. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Future sales and issuances of our common stock in the public market could cause the market price of our common stock to decline.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and issuances of a substantial number of shares of our common stock in the public market following the
closing of this offering, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the
effect that such sales and issuances may have on the prevailing market price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on shares of
common stock outstanding as of March&nbsp;31, 2021, upon the closing of this offering, we will have outstanding a total of 130,808,856&nbsp;shares of common stock. Of these shares, only the shares of common stock sold in this offering, plus any
shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering unless purchased by our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, all of our executive officers and directors, the selling stockholders and the holders of substantially all of our
equity securities are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements that restrict their ability to transfer shares of our common stock, stock options and other securities convertible into, exchangeable for, or exercisable for
our common stock during the period ending on, and including, the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus, subject to specified exceptions. Morgan Stanley&nbsp;&amp; Co. LLC, Goldman
Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and Cowen and Company, LLC may, in their discretion, permit our stockholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the
expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, all of such shares will be eligible for sale, of which 30,492,246 shares held by
directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, there were 6,559,712&nbsp;shares of common stock subject to outstanding stock options. We intend to
register all of the shares of common stock issuable upon exercise of outstanding stock options, and upon exercise or settlement of any options or other equity incentives we may grant in the future, for public resale under the Securities Act.
Accordingly, these shares will be able to be freely sold in the public market upon issuance as permitted by any applicable vesting requirements, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. These shares
of common will become eligible for sale in the public market to the extent such stock options are exercised, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and compliance with applicable securities laws. In
addition, after March 31, 2021, we have granted 476,466 stock options to our directors, officers and employees. In July 2021, we also approved the grant of stock options to purchase 2,857,663 shares of our common stock to certain employees and
executive officers, which grant is contingent and effective upon the effectiveness of execution of the underwriting agreement and will have an exercise price that is equal to the price per share at which our common stock is first sold to the public
in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, the holders of 87,268,694&nbsp;shares of our common stock will be entitled to
rights with respect to the registration of their shares under the Securities Act, subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See the section titled
&#147;Description of Capital Stock&#151;Registration Rights.&#148; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by
affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the trading price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new
investors from influencing significant corporate decisions. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the number of shares of common stock
outstanding as of March&nbsp;31, 2021 and including (i)&nbsp;the shares to be sold in this offering and (ii) 87,268,694&nbsp;shares of common stock issuable upon the automatic conversion of our redeemable convertible preferred stock outstanding as
of March&nbsp;31, 2021 into an equal number of shares of our common stock upon the closing of this offering, upon the closing of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock will,
in the aggregate, beneficially own approximately 46.1% of our common stock (assuming no exercise of the underwriters&#146; option to purchase an additional 2,184,695&nbsp;shares of common stock). These stockholders, acting together, will be able to
significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the
interests of other stockholders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of these persons or entities may have interests different than those of
investors purchasing shares in this offering. For example, because many of these stockholders purchased their shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer
period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will
depend on appreciation in the price of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our
capital stock, and we do not intend to pay any cash dividends in the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and may be restricted by the terms of any then-current debt
instruments. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an emerging growth company and a smaller reporting company and our compliance
with the reduced reporting and disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we expect to take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section&nbsp;404 reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved
and extended adoption period for accounting pronouncements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company,&#148; as
defined in the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled
disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal
year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We
designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of
the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the
market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws, upon the closing of this offering, will
contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members
of the board will be elected at one time; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be
taken at a meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors,
the chief executive officer, the president, or by a majority of the total number of authorized directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except
for cause and, in addition to any other vote required by law, upon the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of our voting stock then entitled to vote in the election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement of approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all
outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authority of the board of directors to issue redeemable convertible preferred stock on terms determined by
the board of directors without stockholder approval and which redeemable convertible preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporate Law, which may prohibit certain business antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or
potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These
provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control
transaction or changes in our board of directors could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and
restated certificate of incorporation and amended and restated bylaws upon the closing of this offering will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our
stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery
of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action or
proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders, (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current
or former directors, officers, or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, (iv)&nbsp;any action or
proceeding to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, (v)&nbsp;any action or proceeding as to which the Delaware General Corporation Law
confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&nbsp;any action asserting a claim against us or any of our directors, officers, or other employees governed by the internal affairs doctrine, in all cases to the fullest
extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions would not apply to suits brought to enforce a duty or
liability created by the Exchange Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction
to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation and
our amended and restated bylaws will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the
Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect
to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation and our amended and restated bylaws. This may require significant additional costs associated with
resolving such action in other jurisdictions and the provisions may not be enforced by a court in those other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation or
bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find either exclusive forum provision contained in our amended and restated
certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could
seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>As a result of being a public company, we are obligated to develop and maintain proper and effective internal control over financial
reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will be required, pursuant to Section&nbsp;404 of the Sarbanes&#150;Oxley Act, to furnish a report by management on, among
other things, the effectiveness of our internal control over financial reporting for the fiscal year ending December&nbsp;31, 2022, which is the year covered by the second annual report following the completion of our initial public offering. This
assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. In addition, our independent registered public accounting firm will be required to attest to the
effectiveness of our internal control over financial reporting in our first annual report required to be filed with the SEC following the date we are no longer an emerging growth company if we are not a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to conclude that our
internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the
accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness or
significant deficiency in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our estimates or judgments relating to our critical accounting policies are based
on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of our consolidated financial statements in conformity with generally accepted accounting
principles requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that
we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. For
example, in connection with the revenue accounting standard, Accounting Standards Codification, or ASC, Topic 606, management makes judgments and assumptions based on our interpretation of the new standard. The revenue standard is principle-based
and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice and guidance may evolve as we apply the standard. If our assumptions underlying our
estimates and judgments relating to our critical accounting policies change or if actual circumstances differ from our assumptions, estimates or judgments, our operating results may be adversely affected and could fall below our publicly announced
guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past, securities class action litigation has often been brought against companies following a decline in the market
price of its securities. This risk is especially relevant for us because life sciences companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of
management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur increased costs as a result of operating as
a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private
company. We expect such expenses to further increase after we are no longer an emerging growth company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable
securities rules and regulations impose various requirements on public companies. Furthermore, the senior members of our management team do not have significant experience with operating a public company. As a result, our management and other
personnel will have to devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and
costly. We cannot predict or estimate the amount of additional costs we will incur as a public company or the timing of such costs, which could negatively affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance
requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our
common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price
or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the listing requirements of Nasdaq.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities or industry analysts do not publish research or publish unfavorable or
inaccurate research about our business, our common stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price
and trading volume will be heavily influenced by the way analysts and investors interpret our financial information and other disclosures. If securities or industry analysts do not publish research or reports about our business, delay publishing
reports about our business or publish negative reports about our business, regardless of accuracy, our common stock price and trading volume could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts
publish about us or our business. We do not have any control over these analysts. We expect that only a limited number of analysts will cover our company following our initial public offering. If the number of analysts that cover us declines, demand
for our common stock could decrease and our common stock price and trading volume may decline. Even if our common stock is actively covered by analysts, we do not have any control over the analysts or the measures that analysts or investors may rely
upon to forecast our future results. Over-reliance by analysts or investors on any particular metric to forecast our future results may result in forecasts that differ significantly from our own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regardless of accuracy, unfavorable interpretations of our financial information and other public disclosures could have a
negative impact on our stock price. If our financial performance fails to meet analyst estimates, for any of the reasons discussed above or otherwise, or one or more of the analysts who cover us downgrade our common stock or change their opinion of
our common stock, our stock price would likely decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ability to use our net operating losses (&#147;NOLs&#148;) to offset
future taxable income may be subject to certain limitations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, we had no federal NOL
carryforwards and state NOL carryforwards of approximately $2.2 million. Certain state NOLs will begin to expire in the calendar year 2028, unless previously utilized. Certain NOL carryforwards subject to expiration could expire unused and be
unavailable to offset future income tax liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Tax Cuts and Jobs Act, or the Tax Act, as modified by the
Coronavirus Aid, Relief and Economic Security Act, or CARES Act, federal NOLs incurred in taxable years beginning after December&nbsp;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs in taxable years beginning
after December&nbsp;31, 2020 is limited to 80% of taxable income in such years. There is variation in how states have responded and may continue to respond to the Tax Act and CARES Act. In addition, for state income tax purposes, there may be
periods during which the use of NOLs is suspended or otherwise limited, such as recent California legislation limiting the usability of NOLs for tax years beginning in 2020 and before 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) if a corporation
undergoes an &#147;ownership change,&#148; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#146;s ability to use its
<FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws.
We determined that an ownership change occurred on September&nbsp;7, 2018 and October 23, 2020. As of March&nbsp;31, 2021, we had not experienced an ownership change subsequent to the ownership change on October 23, 2020. In addition, we may in the
future experience ownership changes, either as a result of this offering or other changes in our stock ownership (some of which are not in our control). If an ownership change occurs, our ability to utilize our NOL carryforwards and other tax
attributes to reduce future tax liabilities may be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in our effective tax rate or tax liability may have an adverse effect on our
results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our effective tax rate could increase due to several factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the relative amounts of income before taxes in the various jurisdictions in which we operate that
have differing statutory tax rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws, tax treaties, and regulations or the interpretation of them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to our assessment about our ability to realize our deferred tax assets that are based on estimates of
our future results, the prudence and feasibility of possible tax planning strategies, and the economic and political environments in which we do business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of current and future tax audits, examinations, or administrative appeals; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or adverse findings regarding our ability to do business in some jurisdictions.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, a tax authority may disagree with tax positions that we have taken, which could result in
increased tax liabilities. For example, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#145;&#145;permanent establishment&#146;&#146;
under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in tax law and regulations may have a material adverse effect on our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rules dealing with U.S. federal, state and local income taxation are constantly under review by the Internal
Revenue Service, the U.S. Treasury Department and other governmental bodies. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been
made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, financial condition, results of operations, and cash flow. We urge investors to consult with their legal
and tax advisers regarding the implication of potential changes in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes and
uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conduct business globally and file income tax returns in multiple jurisdictions. Our consolidated effective income tax rate
could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms under consideration; the practices of tax authorities in
jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes
would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and
paid or accrued on our statement of financial position, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have
operations, reduce <FONT STYLE="white-space:nowrap">post-tax</FONT> returns to our shareholders and increase the complexity, burden and cost of tax compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and
uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for
future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will&#148; or
&#147;would,&#148; or the negative of these words or other similar terms or expressions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based these
forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties, factors and assumptions described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus, regarding, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected future growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our products, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to accurately forecast demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our
sales, business, financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected future growth of our sales and marketing organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of, and our reliance on, third parties in connection with the commercialization of our
products, including single-source suppliers and, in some cases, sole source suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to accurately forecast and manufacture appropriate quantities of our products to meet commercial
demand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain regulatory approval for our products or obtain regulatory approval for new products in
the United States and in any foreign countries in which we make seek to do business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development for existing products and any future products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development, regulatory approval and commercialization of competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain and hire senior management and key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain our corporate infrastructure, including our ability to remediate our
existing material weakness and to design and maintain an effective system of internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance and capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our
products, as well as our ability to operate our business without infringing the intellectual property rights of others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the net proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These risks are not exhaustive. Other sections of this prospectus may include additional factors that could harm our business
and financial performance. We operate in a very competitive and rapidly changing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
environment where new risk factors may emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking
statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. These forward-looking statements speak
only as of the date of this prospectus. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence
of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based on information available to us as of the date of this prospectus. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements
by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_4"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain market, industry and competitive data included in this prospectus were obtained from our own internal estimates and
research, as well as from publicly available information, reports of governmental agencies and industry publications and surveys. In some cases, we do not expressly refer to the sources from which this data is derived. All of the market and industry
data used in this prospectus is inherently subject to uncertainties and involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including
those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in these publications and reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that we will receive net proceeds from this offering of approximately $180.8&nbsp;million (or approximately
$215.3&nbsp;million if the underwriters exercise their option to purchase additional shares in full) based on the assumed initial public offering price of $17.00 per share of common stock, the midpoint of the price range set forth on the cover page
of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive any of the proceeds from the sale of common stock in this offering by the selling stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $10.9&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Similarly, each increase (decrease) of
1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) the net proceeds to us from this offering by approximately $15.8&nbsp;million, assuming the assumed initial public offering price of $17.00 per share,
the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $112 million to $135 million to fund manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $44&nbsp;million to $53&nbsp;million to establish our commercial activities and to fund
marketing initiatives; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remaining amounts for working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may use a portion of the net proceeds for strategic investments in complementary businesses, services, products or
technologies. However, we do not have agreements or commitments to enter into any such acquisitions or investments at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate, based on our current operating plan, that our existing cash and cash equivalents, together with the estimated net
proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our
available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict with certainty all of the particular uses for the
proceeds of this offering or the amounts that we will actually spend on the uses set forth above. Accordingly, our management will have broad discretion in applying the net proceeds of this offering. The timing and amount of our actual expenditures
will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending their application, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade investments,
certificates of deposit or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash
dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay
dividends will be made at the discretion of our board of directors, subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash and cash equivalents and our capitalization as of March&nbsp;31, 2021 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis to give effect to (i)&nbsp;the conversion of 87,268,694 shares of our redeemable convertible
preferred stock outstanding as of March&nbsp;31, 2021 into an equal number of shares of our common stock upon the closing of this offering and the related reclassification of the carrying value of our redeemable convertible preferred stock to
permanent equity in connection with the closing of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments set forth above and
(ii)&nbsp;the issuance and sale of shares of common stock in this offering at the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this
information in conjunction with our interim consolidated financial statements and the related notes included elsewhere in this prospectus, the information set forth in the sections titled &#147;Selected Consolidated Financial Data&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value per share: 87,268,694 shares authorized,
actual, no shares pro forma and pro forma as adjusted; 87,268,694 shares issued and outstanding, actual; no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share: no shares authorized, issued and outstanding, actual;
10,000,000 shares authorized no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share: 215,000,000 shares authorized, 31,775,456 shares issued
and outstanding, actual; 1,000,000,000 shares authorized, 119,044,150 shares issued and outstanding, pro forma; 1,000,000,000 shares authorized, 130,808,856 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest in consolidated subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<BR></TD>
<TD VALIGN="bottom" ALIGN="right">179,562<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<BR></TD>
<TD VALIGN="bottom" ALIGN="right">179,562<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share of common
stock, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $10.9&nbsp;million, assuming that the number </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. We may also increase or decrease the number of shares we are offering. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us at the assumed initial public offering price per share would increase
(decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $15.8 million,
assuming the assumed initial public offering price of $17.00 per share of common stock remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering as reflected in the table above is based on
119,044,150 shares of our common stock (including shares of our redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of March&nbsp;31, 2021, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,559,712 shares of our common stock issuable upon the exercise of outstanding stock options as of
March&nbsp;31, 2021, with a weighted-average exercise price of $1.30 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">473,966 shares of our common stock issuable upon exercise of outstanding stock options granted subsequent to
March&nbsp;31, 2021, with a weighted-average exercise price of $5.78 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,057,200 shares of our common stock reserved for future issuance under our 2015 Equity Incentive Plan as of
March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective in connection with this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18,000,000 shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan, which
includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering of which we intend to grant stock options to purchase 2,857,663 shares of our common stock to certain of our employees
and executive officers, contingent and effective upon the execution of the underwriting agreement for this offering, with an exercise price that is equal to the price per share at which our common stock is first sold to the public in this offering;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of our common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan,
which includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the
difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we had a historical net tangible book deficit of approximately $15.4&nbsp;million, or $(0.49) per
share of common stock based on 31,775,456 shares of common stock outstanding as of such date. Our historical net tangible book deficit per share represents the amount of our total tangible assets less our total liabilities and redeemable convertible
preferred stock, which is not included within permanent equity, divided by the number of shares of our common stock outstanding as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2021, our pro forma net tangible book value was $178.9 million, or $1.50 per share of common stock. Pro forma
net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of shares of common stock outstanding as of March 31, 2021, after giving effect to the conversion of all outstanding shares of
redeemable convertible preferred stock into 87,268,694 shares of common stock upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After
giving further effect to the receipt of the net proceeds from our sale of 11,764,706 shares of common stock in this offering at an assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page
of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2021 would have been $360.0 million, or $2.75 per
share of common stock. This amount represents an immediate increase in pro forma as adjusted net tangible book value of $1.25 per share to our existing stockholders and an immediate dilution in pro forma as adjusted net tangible book value per share
of $14.25 per share to new investors purchasing shares of common stock in this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table
illustrates this dilution on a per share basis to investors in this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributed to investors purchasing shares
in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00
per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by $0.09 and dilution in pro forma as adjusted net
tangible book value per share to new investors by $0.91 assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase
(decrease) our pro forma as adjusted net tangible book value per share after this offering by $0.12 per share and decrease (increase) the dilution in pro forma as adjusted net tangible book value per share to investors participating in this offering
by $0.12 per share, assuming that the assumed initial public offering price remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares
in full, the pro forma as adjusted net tangible book value after the offering would be $2.97 per share, the increase in pro forma net tangible book value per share to existing stockholders would be $0.22 per share and the dilution per share to new
investors would be $0.22 per share, in each case assuming an initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales by the selling stockholders in this offering will cause the number of shares held by existing stockholders to be reduced
to 2.8 million shares, or 2.1% of the total number of shares of our common stock outstanding following the completion of this offering, and will increase the number of shares held by new investors to 2.8 million shares, or 2.1% of the total number
of shares outstanding following the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes, on the pro forma as
adjusted basis described above, as of March&nbsp;31, 2021, the differences between the number of shares of common stock purchased from us by our existing stockholders and common stock by new investors purchasing shares in this offering, the total
consideration paid to us in cash and the average price per share paid by existing stockholders for shares of common stock issued prior to this offering and the price to be paid by new investors for shares of common stock in this offering. The
calculation below is based on the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,044,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,872,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,764,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,808,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395,872,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Does not give effect to the sale of shares by the selling stockholders in this offering or the exercise by
the underwriters of the option to purchase additional shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The outstanding share information in the
table above is based on 119,044,150 shares of our common stock (including shares of our redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of March&nbsp;31, 2021, and excludes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,559,712 shares of our common stock issuable upon the exercise of outstanding stock options as of
March&nbsp;31, 2021, with a weighted-average exercise price of 1.30 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">473,966 shares of our common stock issuable upon exercise of outstanding stock options granted subsequent to
March&nbsp;31, 2021, with a weighted-average exercise price of 5.78 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,057,200 shares of our common stock reserved for future issuance under our 2015 Equity Incentive Plan as of
March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective in connection with this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18,000,000 shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan, which
includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering of which we intend to grant stock options to purchase 2,857,663 shares of our common stock to certain of our employees
and executive officers, contingent and effective upon the execution of the underwriting agreement for this offering, with an exercise price that is equal to the price per share at which our common stock is first sold to the public in this offering;
and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,000,000 shares of our common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan,
which includes an annual evergreen increase and will become effective upon the execution of the underwriting agreement for this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares in full, our existing stockholders would
own&nbsp;89.5% and the investors purchasing shares of our common stock in this offering would own&nbsp;10.5% of the total number of shares of our common stock outstanding immediately after the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth our selected consolidated financial data as of, and for the periods ended on, the dates
indicated. The selected consolidated statements of operations and comprehensive income (loss) data for the years ended December&nbsp;31, 2019 and 2020, and the selected consolidated balance sheet data as of December&nbsp;31, 2019 and 2020, are
derived from our audited consolidated financial statements and the related notes included elsewhere in this prospectus. The selected consolidated statements of operations and comprehensive income (loss) data for the three months ended March 31, 2020
and 2021, and the selected consolidated balance sheet data as of March 31, 2021 are derived from our unaudited interim consolidated financial statements and the related notes included elsewhere in this prospectus. Our interim consolidated financial
statements were prepared in accordance with U.S. GAAP, on the same basis as our audited consolidated financial statements and, in our opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair
presentation of our interim consolidated financial statements as of and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and results for the three
months ended March 31, 2021 are not necessarily indicative of results for the full year ending December 31, 2021. Share and per share data in the table below has been retrospectively adjusted to give effect to the 1.3333-for-one stock split,
effected on July 16, 2021. You should read these data together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the information in the section titled &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations.&#148; The selected consolidated financial data in this section are not intended to replace our consolidated financial statements and the related notes and are qualified in their entirety by
the consolidated financial statements and related notes included elsewhere in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations and Comprehensive Income (Loss) Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, basic<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.60)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing net income (loss) per share, basic<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,126,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,557,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing net income per share, diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,599,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,757,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per share attributable to common stockholders&#151;basic (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per share attributable to common stockholders, diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,990,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,826,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,463,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,025,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial and operating data (unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes stock-based compensation as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See Note 2 to our audited consolidated financial statements and Note 2 to our interim consolidated financial
statements, appearing elsewhere in this prospectus, for details on the calculation of our basic and diluted net income (loss) per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation
of unaudited pro forma basic and diluted net income (loss) per share attributable to common stockholders has been prepared to give effect, upon a qualified initial public offering, to the automatic conversion of all outstanding shares of our
redeemable convertible preferred stock into shares of our common stock as if the proposed initial public offering had occurred. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure that we define as
net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for income taxes, depreciation and amortization, litigation settlement and stock-based compensation expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness
of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across
reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation, or as a
substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful stock-based compensation expense in
the future. Other limitations include that Adjusted EBITDA does not reflect: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All expenditures or future requirements for capital expenditures or contractual commitments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in our working capital needs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provision for income taxes, which may be a necessary element of our costs and ability to operate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The costs of replacing assets being depreciated, which will often have to be replaced in the future;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">non-cash</FONT> component of employee compensation expense; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring
basis, of our ongoing operations. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, Adjusted EBITDA may not be comparable to similarly titled
measures used by other companies in our industry or across different industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables reconcile the most
directly comparable GAAP financial measure to each of these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents the foreign exchange gains and losses for the remeasurement of non-functional monetary balances.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents the litigation settlement expense related to the settlement agreement entered into with Becton,
Dickinson and Company on October&nbsp;6, 2020. See Note&nbsp;15 to our audited consolidated financial statements appearing elsewhere in this prospectus for details on our litigation settlement expense. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents stock-based compensation expense related to option awards. See Note&nbsp;12 to our audited
consolidated financial statements and Note&nbsp;12 to our interim consolidated financial statements appearing elsewhere in this prospectus for details on our stock-based compensation expense. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See Note 5 to our audited consolidated
financial statements and Note&nbsp;5 to the interim consolidated financial statements included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial condition and results of operations together with
the section titled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking
statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not
limited to, those discussed in the section titled &#147;Risk Factors.&#148; Please also see the section titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific
advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell
analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). Our novel approach harnesses the power of information
within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Our patented FSP technology optimizes sensitivity and accuracy through its novel optical and electronic designs that utilize an
innovative method of light detection and distribution. Our FSP platform includes instruments, reagents, software and services to provide a comprehensive and integrated suite of solutions for our customers. Since our first U.S. commercial launch in <FONT
STYLE="white-space:nowrap">mid-2017,</FONT> we have sold and deployed over 750 instruments&#151;primarily comprised of our Aurora and Northern Lights systems&#151;to over 620 customers around the world, including the largest pharmaceutical
companies, over 125 biopharma companies, leading academic research centers, and clinical research organizations (&#147;CROs&#148;). In June 2021, we began shipping the Aurora cell sorter (&#147;Aurora CS&#148;), which uses our FSP technology to
further broaden our potential applications across cell analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the combination of our people and our global
reach across the United States, Europe and Asia will enable us to continue to execute on our growth strategies, stay ahead of competition and remain at the forefront of innovation in cell analysis. Our leadership team has extensive track records in
the life sciences and technology sectors. As of March&nbsp;31, 2021, we employed a multidisciplinary group of over 390 employees, with more than 110 advanced degrees, including over 70 PhDs and MDs, with expertise across optics, electronics,
fluidics, computer sciences, chemistry, biology, and medical sciences. Our worldwide commercial team of more than 120 employees and our research and development team of more than 100 employees have significant expertise, industry experience and
collaborative relationships with key opinion leaders (&#147;KOLs&#148;), industry leaders, innovators and potential customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a long history of providing high-quality and efficient customer service and our product development efforts reflect
our deep understanding of our customers&#146; needs. One of our key differentiators is our customer-facing technical team, which collaborates closely with our customers to identify and find solutions for unmet needs across the market. We collaborate
closely with KOLs, generating relevant data and publications to demonstrate not only the feasibility, but also the quality of our FSP approach. We plan to continue executing on our strategy to accelerate our growth by driving adoption of our FSP
solutions, inspiring innovation, investing in integrated workflow solutions and driving application development and adoption in clinical markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We manufacture our instruments in our facilities in Fremont, California and in Wuxi, China. We have designed our operating
model to be capital efficient and to scale efficiently as our product volumes grow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our total revenue increased by 60% to $92.8&nbsp;million in the year ended
December&nbsp;31, 2020 as compared to $57.9&nbsp;million in the prior year and by 35% to $24.3 million in the three months ended March 31, 2021 as compared to $18.0 million in the three months ended March 31, 2020, primarily due to sales of our
Aurora and Northern Lights systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have adopted a direct sales model in North America, Europe and China, and
sell our products through third-party distributors in Asia <FONT STYLE="white-space:nowrap">(ex-China),</FONT> certain regions of Europe, South America, the Middle East, and Africa. Revenue from direct sales represented 83% of total revenue for the
year ended December&nbsp;31, 2020 and 82% of total revenue for the three months ended March 31, 2021. Revenue from distributors represented 17% of total revenue for the year ended December&nbsp;31, 2020 and 18% of total revenue for the three months
ended March 31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We focus a substantial portion of our resources on developing new products and solutions to meet
our customers&#146; needs. Our research and development efforts focus on developing new and complementary instruments, reagents and reagent kits, and continued operating software development. We incurred research and development expenses of
$8.9&nbsp;million and $13.7&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and $3.0 million and $5.1 million for the three months ended March 31, 2020 and 2021, respectively. We intend to continue to make significant
investments in research and development in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue&nbsp;to invest in our commercial
infrastructure through hiring additional employees with strong scientific and technical backgrounds to support growth in sales of our Aurora and Northern Lights instruments as well as our planned expansion of reagents offerings and panel design
capabilities. We also plan to continue to invest in sales, marketing and business development across the globe to drive commercialization of our products. We incurred sales and marketing expenses of $10.2&nbsp;million and $15.0&nbsp;million for the
years ended December&nbsp;31, 2019 and 2020, respectively, and $3.5 million and $4.3 million for the three months ended March&nbsp;31, 2020 and 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception in 2014, we have financed our operations primarily through private placements of our redeemable
convertible preferred stock, revenue from the sale of our products and services and proceeds from a loan under the Paycheck Protection Program (&#147;PPP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred net losses in each year except for the year ended December 31, 2020 and for the three months ended March 31,
2021 when we are in a net income position. Our net loss was $16.8&nbsp;million and our net income was $19.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. Our net loss was $839,000 and our net income was $102,000 for
the three months ended March 31, 2020 and 2021, respectively. The change from net loss for the year ended December&nbsp;31, 2019 to net income for the year ended December&nbsp;31, 2020 and for the three months ended March 31,&nbsp;2021 compared to
the three months ended March 31, 2020 resulted primarily from increased revenue driven by a continued demand for our Aurora and Northern Lights systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our expenses will increase substantially in connection with our <FONT STYLE="white-space:nowrap">on-going</FONT>
activities, as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invest in processes, commercial infrastructure; and supporting functions to scale our business and introduce
new products and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">support our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to expand geographically; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protect and defend our intellectual property; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make strategic investments in complementary businesses, services, products or technologies.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key factors affecting our results of operations and future performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by
multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address to sustain our growth and improve our results of operations. Our
ability to successfully address these challenges is subject to various risk and uncertainties, including those described under the heading &#147;Risk Factors&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Global customer adoption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our financial performance has largely been driven by our ability to increase the adoption of our FSP platform, a key factor on
which our future success depends. We plan to drive global customer adoption through business development efforts, direct sales and marketing and third-party distributions. We are investing in our direct sales organization and commercial support
functions and developing third-party distributor relationships to support global expansion and drive revenue growth. As part of this effort, we increased our direct sales force by 72% in the year ended December&nbsp;31, 2020 compared to the year
ended December&nbsp;31, 2019 and by 36% in the three months ended March 31, 2021 compared to the three months ended March 31, 2020. We intend to continue increasing our workforce in line with our growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recurring revenues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our expanding installed base of instruments to new and existing customers will provide us with greater leverage to
drive pull-through for reagent and service revenue, which are recurring by nature. Furthermore, as we develop and identify new applications and products, we expect to further increase pull-through across our installed base. We expect recurring
revenue on an absolute basis to increase and become an increasingly important contributor to our revenue as our installed base expands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue mix and gross margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our revenue is primarily derived from sales of our instruments and services with our core instruments recognizing higher gross
margins than our services. While there have been fluctuations in the mix between sales of our instruments and services, revenue generated from sales of our core instruments accounted for 87% and 92% of our total revenue for the years ended
December&nbsp;31, 2019 and 2020, respectively, and for 89% and 94% of our total revenue for the three months ended March 31, 2020 and 2021, respectively. Instrument sales as a percentage of total revenue have increased sequentially in each of the
years ended December&nbsp;31, 2019 and 2020 and the three months ended March 31, 2020 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we expect sales
of our core instruments to continue to represent the largest percentage of our revenue in the future, we expect reagent sales to increase as a percentage of our total revenue and our gross margins to experience a corresponding improvement as we grow
our installed base and increase our focus on commercializing reagents. We also expect a higher gross margin on our core instruments as we increase manufacturing efficiency, instrument reliability and training for personnel using our instruments,
which we expect to lead to a reduction in warranty claims. Our sales in certain regions, particularly outside of the United States, are realized through third-party distribution partners that typically receive discounted prices, thus resulting in
lower gross margins than those recognized by our direct sales organization. Furthermore, our gross margins and instrument selling prices may fluctuate in the future as we continue to grow our volume of third-party distribution partners in
geographies outside of the United States, introduce new products and reduce our production costs as a result of variability in the timing of new product introductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the near term, we expect the continued optimization of our manufacturing processes related to our instruments and the
expansion of product manufacturing distribution facilities to have the greatest impact on our gross margin. In addition to the impact of competing products entering the market, the future gross margin
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
profiles of our instruments, services and reagents will depend on the outcome of any royalties we are required to pay and the royalty rates and products to which such royalties apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expansion into new markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We focus our research and development efforts on the greatest value-additive FSP products to meet the growing and unmet needs
of the research and clinical markets. We work closely with researchers and clinicians to optimize and implement new panels and applications to meet their specific needs. We also gain valuable insight on potential new products, new applications and
enhancements to existing products, as well as biomarker combinations that would be beneficial in different fields, through collaborations with our customers, academic laboratories, KOLs and industry partners. We plan to continue to invest in new
product development and enhancements to support our expansion into new markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Northern Lights system obtained
clinical certification in China in 2019 and received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive in September 2020. With these achievements, our Northern Lights system is available for clinical diagnostic use in
hospitals, laboratories, and clinics in China and the European Union. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key business metrics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends
affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are representative of our current business; however, we anticipate these will change or may be substituted for additional or
different metrics as our business grows. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sales channel mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct sales channel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributor channel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Customer mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Academia and government</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology, pharmaceuticals, distributor and CRO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Distributors typically sell to end customers identified in other customer categories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth our cumulative instruments shipped as of the dates presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Instruments shipped:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to evolve rapidly and we intend to continue to
monitor it closely. In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and various resulting government directives, we took proactive measures to protect the health and safety of our employees, contractors, customers and
visiting vendors and suppliers. We continue to monitor the implications of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, as well as our customers&#146; and suppliers&#146; business. Some of the measures we have taken
are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an &#147;essential business&#148; under the criteria set forth in executive orders issued by the State of
California, we have continued operations during <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> within the applicable safety guidelines. In early March 2020, we promptly instituted protocols to have most of our personnel work
remotely. Certain employees engaged in research and development and manufacturing operations have continued to work <FONT STYLE="white-space:nowrap">on-site&nbsp;at</FONT> our facility in Fremont, California. Our employees in Wuxi and Shanghai,
China returned to normal activities in March 2020 to undertake research and development and manufacturing operations due to the lifting of local restrictions in the country. In the United States, we have implemented social distancing and other
protective measures in an effort to protect the health and safety of our personnel <FONT STYLE="white-space:nowrap">working&nbsp;on-site.</FONT> We have also restricted business travel and have limited access to our facilities to vendors, suppliers
and partners who are critical to our business operations. While these arrangements have not to date materially affected our ability to maintain our business operations, including the operation of financial reporting systems, internal control over
financial reporting and disclosure controls and procedures, given the considerable uncertainty around the duration and extent of the pandemic, the related financial and operational impact cannot be reasonably estimated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our production, shipping and customer service functions remain operational to maintain a continuous supply of
products and services to our customers and for our internal research and development activities. We are communicating regularly with our suppliers so that our supply chain remains intact, and we have not yet experienced any material supply issues.
Our customer service teams around the world are operating remotely and remain available to assist our customers and partners as needed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initially, as a result of travel restrictions
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;shelter-in-place&nbsp;orders,</FONT></FONT> we experienced some delay in our ability to ship and install our FSP systems, as well as train customers in certain geographies.
In March 2020, we began developing, and continue to develop, remote learning capabilities to help our customers and partners operate and reduce the number of required <FONT STYLE="white-space:nowrap">customer/partner&nbsp;on-site&nbsp;visits</FONT>
for our field application scientists and field support engineers to comply with travel restrictions and country-specific quarantine requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are actively reviewing and managing costs to navigate the current environment. To date, <FONT
STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> has not had a material adverse effect on our business or results of operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Potential impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, some of which we have already experienced,
include those described throughout the &#147;Risk Factors&#148; section, including &#147;A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide could adversely affect our business. The Covid-19 pandemic has had
and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners, and customers operate.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our results of operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total revenue, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently generate our total revenue, net from product revenue and service revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Product</I>. Our product revenue primarily consists of sales of our Aurora and Northern Lights systems, instrument
accessories, such as loaders and, to a lesser extent, consumables, such as reagents. We offer multiple versions of our Aurora and Northern Lights systems with different price points based on the number of lasers integrated in the systems. We also
derive revenue from sales of our conventional flow cytometry system, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
is available for sale in China. We recognize product revenue when control of the instrument is transferred to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Service</I>. Our service revenue primarily consists of post-warranty service contracts, installations and repairs which are
recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are recognized as they are delivered to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our revenue to increase in absolute dollars as we expand our sales organization and sales territories, broaden our
customer base, and expand awareness of our products with new and existing customers. Our revenue was $57.9&nbsp;million and $92.8&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and $18.0 million and $24.3 million for
the three months ended March 31, 2020 and 2021, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total cost of sales, gross profit and gross margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our total cost of sales is comprised of product cost of sales and service cost of sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Product. </I>Cost of sales associated with our products primarily consist of manufacturing-related costs incurred in the
production process, inventory write-downs, warranty costs, third party royalty costs, personnel and related costs, costs of component materials, overhead, packaging and delivery and depreciation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Service</I>. Cost of sales associated with our services primarily consists of personnel and related costs, expenses related
to product replacements, product updates and qualification validation of our products and depreciation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect
our total cost of sales to increase in absolute dollars in future periods, corresponding to our anticipated growth in revenue and employee headcount to support our manufacturing, operations, field service team and support organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross profit is calculated as revenue less total cost of sales. Gross margin is gross profit expressed as a percentage of
revenue. Our gross profit in future periods will depend on a variety of factors, including market conditions that may impact our pricing, sales mix changes among our instruments and service agreements, product mix changes between established
products and new products, excess and obsolete inventories, our cost structure for manufacturing operations relative to volume and product warranty obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operating expenses are primarily comprised of research and development, sales and marketing, and general and administrative
expenses, depreciation and amortization, and related overhead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and development</I>. Our research and
development expenses primarily consist of salaries, benefits, stock-based compensation costs for employees in our research and development department, independent contractor costs, laboratory supplies, equipment maintenance and materials expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to continue to invest in our research and development efforts, including hiring additional employees to enhance
existing products and develop new products. We expect research and development expense will increase in absolute dollars in future periods and vary from period to period as a percentage of revenue due to our continuing investment in product
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Sales and marketing</I>.&nbsp;Our sales and marketing expenses consist primarily of salaries, benefits,
and stock-based compensation costs for employees in our sales and marketing department, sales commissions, marketing material costs, travel expenses and costs related to trade shows, trainings and various workshops. We expect our sales and marketing
expense to increase in absolute dollars as we expand our commercial sales, marketing, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
business development teams, increase our presence globally and increase marketing activities to drive awareness and adoption of our platform. While these expenses may vary from period to period
as a percentage of revenue, we expect these expenses to increase as a percentage of sales in the short-term as we continue to grow our commercial organization to support anticipated growth of the business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and administrative</I>. Our general and administrative expenses primarily consist of salaries, benefits, and
stock-based compensation costs for employees in our executive, accounting and finance, legal and human resource functions, as well as professional services fees, such as consulting, audit, tax, legal, general corporate costs and allocated overhead
expenses. We expect our operating expenses to increase when we become a public company following this offering. In particular, we expect our accounting, legal, personnel-related expenses and directors&#146; and officers&#146; insurance costs
reported within general and administrative expense to increase as we establish more comprehensive compliance and governance functions, maintain IT costs, review internal controls over financial reporting in accordance with the Sarbanes-Oxley Act and
prepare and distribute periodic reports as required by the rules and regulations of the U.S. Securities and Exchange Commission. As a result, our historical results of operations may not be indicative of our results of operations in future periods.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect these expenses to vary from period to period as a percentage of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest expense.</I>&nbsp;Interest expense consists primarily of accretion of the present value of the litigation
settlement liability. See Note 15 included in the notes to our audited consolidated financial statements included elsewhere in this prospectus for further details regarding the settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest income. </I>Our interest income consists primarily of interest earned on our cash and cash equivalents which are
invested in cash deposits and in money market funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other income (expense), net. </I>Our other income (expense), net
consists primarily of foreign exchange gains and losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our provision for (benefit from) income taxes consists primarily of provision for federal taxes, local taxes and state minimum
taxes in the United States as well as foreign taxes. As we plan to expand the scale and scope of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for
income taxes in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the three months ended March&nbsp;31, 2020 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of operations presented below should be reviewed in conjunction with the unaudited interim consolidated financial
statements and related notes included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our interim consolidated results of
operations and comprehensive income (loss) data for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total revenue, net </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total revenue, net increased by $6.3&nbsp;million, or 35%, for the three months ended
March&nbsp;31, 2021 as compared to the three months ended March&nbsp;31, 2020. The increase in revenue was primarily driven by an increase in product revenue due to the continued adoption of our Aurora and Northern Lights systems and an increase in
the average selling price due to mixed product sales and higher unit sales of our core instruments, partially offset by a decrease in service revenue related to <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instrument service contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Product revenue increased by $6.6&nbsp;million, or 41%, to
$22.7&nbsp;million for the three months ended March&nbsp;31, 2021 as compared to the three months ended March&nbsp;31, 2020. The increase was primarily driven by an increase in our instrument sales due to higher unit sales of our Aurora and Northern
Lights systems and an increase in the average selling price due to mixed product sales and higher unit sales of our core instruments </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Service revenue decreased by $352,000, or 18%, to $1.6&nbsp;million for the three months ended March&nbsp;31, 2021 as compared
to the three months ended March&nbsp;31, 2020. The decrease of $352,000 was driven by reduced service contract revenue associated with <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments. While we have historically performed maintenance
services and support functions for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments, we ceased sales of service contracts for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments as of January 1, 2021 while continuing to honor <FONT
STYLE="white-space:nowrap">pre-existing</FONT> multi-year service contracts. We perform <FONT STYLE="white-space:nowrap">on-demand</FONT> professional services to support <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments provided that
resources are available. As a result of our decision to no longer service non-Cytek instruments, revenue associated with service contracts for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments decreased in the three months ended
March&nbsp;31, 2021. Our strategy was to shift resources in the anticipation of the increasing demand for our Aurora and Northern Lights instruments, and to allow us to fully support our instruments when they come out of warranty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total cost of sales, gross profit and gross margin </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Product:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Service:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(352)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(497)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(906)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(409)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total cost of sales increased by $173,000, or 2%, for the three months ended March 31, 2021 as
compared to the three months ended March 31, 2020 primarily due to an increase in adoption of our Aurora and Northern Lights systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross profit margin improved by 1,300 basis points from 47% and 60% as a percent of total revenue for the three months ended
March&nbsp;31, 2020 and 2021, respectively. The increase is primarily due to an increase of core instruments delivered to the <FONT STYLE="white-space:nowrap">end-customers</FONT> and an improved product mix for the three months ended March&nbsp;31,
2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have seen a significant increase in total gross profit margin, the
gross profit margin of our service revenue has decreased from (26)% in the three months ended March 31, 2020 to (58)% in the three months ended March 31, 2021 resulting from our decision to exit the <FONT STYLE="white-space:nowrap">non-Cytek</FONT>
instrument services market. As a result, our revenue associated with service contracts for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments will decrease as we shift resources to fully support our instruments when they come out of
warranty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $5.1&nbsp;million for the three months ended
March&nbsp;31, 2021 as compared to $3.0&nbsp;million for the three months ended March&nbsp;31, 2020. The increase of $2.1&nbsp;million in research and development expenses was primarily due to an increase in headcount and personnel-related expenses
of $895,000, an increase in stock-based compensation of $100,000 and a $1.1&nbsp;million increase in engineering expenses related to cell sorter and reagents developments of $891,000 and other costs related to research and development projects of
$192,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our research and development expense to increase in absolute dollars as we continue to develop new
products and enhance existing instruments and technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales and marketing </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and marketing expenses were $4.3&nbsp;million for the three months ended March&nbsp;31,
2021 as compared to $3.5&nbsp;million for the three months ended March&nbsp;31, 2020. The increase of $746,000 was due to an increase in headcount and personnel-related expenses of $1.0&nbsp;million partially offset by a reduction of $300,000 in
travel expenses as business travel, trade shows and other events were impacted by restrictions imposed due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The increase in personnel-related costs was primarily due to increased
commissions from increased sales and an increase in salary-related costs, including an increase of $98,000 in stock-based compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our sales and marketing expenses to increase in absolute dollars as we hire additional sales and marketing
personnel, expand our sales support infrastructure and invest in our brand and product awareness to further penetrate the United States and the international markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $4.0&nbsp;million for the three
months ended March&nbsp;31, 2021 as compared to $2.5&nbsp;million for the three months ended March&nbsp;31, 2020. The increase of $1.4&nbsp;million in general and administrative expenses was primarily due to an increase in general corporate,
headcount and personnel-related costs, professional fees relating to our financial audits and other services relating to our public offering securities and legal, consulting and IT services to support the growth of our overall operations. The
increase in personnel-related costs includes an increase of $69,000 in stock-based compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to
incur additional general and administrative expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and the Nasdaq Stock Market, additional insurance costs, investor
relations activities and other administrative and professional services. As a result, we expect general and administrative expenses to increase in absolute dollars in future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n/m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest expense was $375,000 for the three months ended March&nbsp;31, 2021 due to the
accretion of the present value discount related to the settlement agreement entered into with Becton, Dickinson and Company (&#147;BD&#148;). See Note 15 included in the notes to our unaudited interim consolidated financial statements included
elsewhere in this prospectus for further details regarding the settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest income </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income was $10,000 for the three months ended March&nbsp;31, 2021 as compared to
$86,000 for the three months ended March&nbsp;31, 2020. The decrease of $76,000 in interest income was the result of lower interest earned on our cash and short-term deposits due to a decline in interest rates in the three months ended
March&nbsp;31, 2021 as compared to three months ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other expense, net </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n/m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other expense, net was $615,000 for the three months ended March 31, 2021 as compared to an
expense of $37,000 for the three months ended March 31, 2020. The increase of $578,000 was the result of the gain recognized on the investment in Cytek Japan Kabushiki Kaisha (&#147;Cytek Japan&#148;) of $40,000 offset by the net impact of foreign
exchange gains and losses during the three months ended March 31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years ended December&nbsp;31, 2019 and
2020 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of operations presented below should be reviewed in conjunction with the audited consolidated
financial statements and related notes included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our consolidated results of operations data
for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other Income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total revenue, net </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total revenue, net increased by $35.0&nbsp;million, or 60%, for the year ended
December&nbsp;31, 2020 as compared to the year ended December&nbsp;31, 2019. The increase in revenue was primarily driven by an increase in product revenue due to the continued adoption of our Aurora and Northern Lights systems and an increase in
the average selling price due to mixed product sales and higher unit sales of our core instruments, partially offset by a decrease in service revenue related to <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instrument service contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Product revenue increased by $35.1&nbsp;million, or 70%, to
$85.3&nbsp;million for the year ended December&nbsp;31, 2020 as compared to the year ended December&nbsp;31, 2019. The increase was primarily driven by an increase of $33.4&nbsp;million in our instrument sales due to higher unit sales of our Aurora
and Northern Lights systems, and an increase of $1.7&nbsp;million in our refurbished instruments sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Service revenue
decreased by $155,000, or 2%, to $7.6&nbsp;million for the year ended December&nbsp;31, 2020 as compared to the year ended December&nbsp;31, 2019. The decrease was primarily driven by reduced service contract revenue of $292,000 associated with <FONT
STYLE="white-space:nowrap">non-Cytek</FONT> instruments, partially offset with higher professional services revenue of $137,000. While we have historically performed maintenance services and support functions for
<FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments, we ceased sales of service contracts for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments as of January&nbsp;1, 2021 while continuing to honor the <FONT
STYLE="white-space:nowrap">pre-existing</FONT> multi-year service contracts. We perform on demand professional services to support <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments provided that resources are available. Consistent with
our expectation, revenue associated with service contracts for <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instruments decreased in 2020. Our strategy was to shift resources in the anticipation of the increasing demand for our Aurora and
Northern Lights instruments, and to allow us to fully support our instruments when they come out of warranty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Total cost of sales,
gross profit and gross margin </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Product:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Service:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (155)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As we continued to scale our business, total cost of sales increased by $11.9&nbsp;million, or
41%, for the year ended December&nbsp;31, 2020 as compared to the year ended December&nbsp;31, 2019 due to increased adoption of our Aurora and Northern Lights systems consisting primarily of an increase of material costs of $8.7&nbsp;million and an
increase in headcount and personnel-related expenses of $3.2&nbsp;million. The increase in personnel-related costs was primarily due to increased salary-related costs, including an increase of $141,000 in stock-based compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross profit margin improved by 600 basis points from 50% and 56% as a
percent of total revenue for the years ended December&nbsp;31, 2019 and 2020, respectively. The increase is primarily due to an increase of core instruments delivered to the <FONT STYLE="white-space:nowrap">end-customers.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have seen a significant increase in total gross profit margin, the gross profit margin of our service revenue has
decreased from 18% to (17)% resulting from our decision to exit the <FONT STYLE="white-space:nowrap">non-Cytek</FONT> instrument services market. These results are consistent with our expectation that revenue associated with service contracts for
non-Cytek instruments will decrease as we shift resources to fully support our instruments when they come out of warranty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $13.7&nbsp;million for the year ended December&nbsp;31,
2020 as compared to $8.9&nbsp;million for the year ended December&nbsp;31, 2019. The increase of $4.8&nbsp;million in research and development expenses was primarily due to an increase in headcount and personnel-related expenses of
$3.6&nbsp;million, an increase in stock-based compensation of $51,000 and a $1.2&nbsp;million increase in other costs, including testing and qualification materials, engineering expenses and other costs related to research and development projects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our research and development expense to increase in absolute dollars as we continue to develop new products and
enhance existing instruments and technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales and marketing </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales and marketing expenses were $15.0&nbsp;million for the year ended December&nbsp;31, 2020
as compared to $10.2&nbsp;million for the year ended December&nbsp;31, 2019. The increase of $4.7&nbsp;million was due to an increase in headcount and personnel-related expenses of $4.8&nbsp;million, an increase in professional services of $200,000
and an increase in marketing and advertising of $200,000, partially offset by a reduction of $450,000 in travel expenses as business travel, trade shows and other events were impacted by restrictions imposed due to
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> The increase in personnel-related costs was primarily due to increased commissions from increased sales and an increase in salary-related costs, including an increase of
$116,000 in stock-based compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our sales and marketing expenses to increase in absolute dollars as we
hire additional sales and marketing personnel, expand our sales support infrastructure and invest in our brand and product awareness to further penetrate the United States and the international markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $9.4&nbsp;million for the year ended
December&nbsp;31, 2020 as compared to $6.7&nbsp;million for the year ended December&nbsp;31, 2019. The increase of $2.7&nbsp;million in general and administrative expenses was primarily due to an increase in general corporate, headcount and
personnel-related costs, business expenses, professional fees and other expenses related to legal, accounting, consulting, and IT services to support the growth of our overall operations. The increase in personnel-related costs includes an increase
of $33,000 in stock-based compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to incur additional general and administrative expenses as
a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and the Nasdaq Stock Market, additional insurance costs, investor relations activities and other administrative and
professional services. As a result, we expect general and administrative expenses to increase in absolute dollars in future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Litigation settlement </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Litigation settlement expenses were nil for the year ended December&nbsp;31, 2020, compared to
$20.0&nbsp;million for the year ended December&nbsp;31, 2019. The change was driven by the expenses related to the settlement agreement with BD. See Note 15 included in the notes to our audited consolidated financial statements included elsewhere in
this prospectus for further details regarding the settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n/m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest expense was $333,000 for the year ended December&nbsp;31, 2020 as compared to $735
for the year ended December&nbsp;31, 2019. The increase of $332,000 in interest expense was largely driven by accretion of the present value discount of the BD settlement. See Note 15 included in the notes to our audited consolidated financial
statements included elsewhere in this prospectus for further details regarding the settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest income </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income was $110,000 for the year ended December&nbsp;31, 2020 as
compared to $711,000 for the year ended December&nbsp;31, 2019. The decrease of $601,000 in interest income was the result of lower interest earned on our cash and short-term deposits due to a decline in interest rates in 2020 as compared to 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income (expense), net was $994,000 for the year ended December&nbsp;31, 2020 as compared
to $252,000 for the year ended December&nbsp;31, 2019. The increase of $742,000 was the result of the net impact of foreign exchange gains and losses during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Provision for (benefit from) income taxes </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="8"></TD>
<TD HEIGHT="1" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1035</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The change from a $533,000 provision for income taxes in 2019 to a $5.0&nbsp;million benefit
from income taxes in 2020 is primarily due to a $6.0 million release of the valuation allowance on deferred tax assets in 2020. Our benefit from income taxes in 2020 was also impacted by foreign income taxed at different rates and an increase of
research and development tax credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quarterly results of operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth our unaudited quarterly consolidated statements of operations and comprehensive income (loss)
data for each of the quarters indicated. The unaudited information for each of these quarters has been prepared in accordance with GAAP, on the same basis as our audited consolidated financial statements and includes, in our opinion, all
adjustments, consisting of normal recurring adjustments, that are necessary for the fair presentation of the results of operations for these periods. These quarterly results of operations are not necessarily indicative of the results we may or may
be expected to achieve in any future period. The following quarterly financial data should be read in conjunction with the audited consolidated financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly revenue trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The overall increase in quarterly revenue over the course of the periods presented was primarily due to an increase in the
volume of sales of our Aurora and Northern Lights instruments and an increase in the average selling price of our shipped instruments. The increase in the volume of our instrument sales was mainly driven by continued investments in sales and
marketing and expanded product offerings into new markets. Revenue in the fourth quarter is typically higher than other quarters as a result of marketing campaign closing activity and customer budget cycles. The decrease in revenue in the quarter
ended March&nbsp;31, 2021, as compared to the prior quarter, was mainly driven by a decrease in the volume of our instrument sales due to seasonality combined with a decrease of our service sales due to our decision to exit the business of servicing
non-Cytek instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly cost of revenue and gross margin trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our quarterly gross margin ranged from 43% to 64%. Gross margin increased in the quarter ended September&nbsp;31, 2020, as
compared to the prior quarter, due to sales mix changes among our instruments and service agreements, product mix changes within our product lines and better inventory management. Gross margin increased in the quarter ended December&nbsp;31, 2020,
as compared to the prior quarter, due to improved product mix, increased product selling price and an increase in our instrument sales volume. The decrease in gross margin in the quarter ended March&nbsp;31, 2021, as compared to the prior quarter,
was partially driven by seasonality but increased relative to the same period in 2020 due to a higher volume of our instrument sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly operating expenses trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The overall increase in quarterly operating expenses over the course of the periods presented was primarily due to increased
headcount in connection with the expansion of our business, increased investments in new product development and increased direct marketing, advertising and promotional expenses to promote our products and increase brand awareness. The decrease in
operating expenses in the quarter ended June&nbsp;30, 2020, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
as compared to the prior quarter, resulted from a decrease in travel, sales meetings and marketing activities due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic restrictions. <FONT
STYLE="white-space:nowrap">COVID-19</FONT> restrictions were partially lifted in China during the last quarter of 2020 contributing to the increase in operating expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly provision for (benefit from) income taxes trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase in the Company&#146;s benefit from income taxes in the quarter ended June&nbsp;30, 2020, as compared to the prior
quarter, was primarily the result of a $8.1 million release of the valuation allowance on the Company&#146;s U.S. federal and state deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase in the provision for income taxes in the quarter ended December&nbsp;31, 2020, as compared to the prior quarter,
was primarily the result of an increase in the Company&#146;s income before taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly other income (expense) trends
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase in other income (expense) in the quarter ended June&nbsp;30, 2020, as compared to the prior quarter,
was the result of the <FONT STYLE="white-space:nowrap">one-time</FONT> government subsidy for our Chinese subsidiaries. The increase in interest expense in the quarters ended December&nbsp;31, 2020 and March&nbsp;31, 2021, as compared to the prior
quarters, was related to the accretion of the present value discount of the BD settlement. See Note 15 to our audited consolidated financial statements and Note 15 to our unaudited interim consolidated financial statements included elsewhere in this
prospectus for details. The increase in other income (expense) in the quarters ended December&nbsp;31, 2020 and March&nbsp;31, 2021, as compared to the prior quarters, was the result of higher foreign exchange gains/losses caused by changes in
foreign exchange rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and capital resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, our primary sources of capital have been through private placements of our redeemable convertible preferred stock,
revenue from the sale of our products and services and a loan under the PPP. As of December&nbsp;31, 2020 and March 31, 2021, we had approximately $165.2&nbsp;million and $168.6 million, respectively, in cash and cash equivalents, which were
primarily held in U.S. short-term bank deposit accounts and money market funds. We have generated negative cumulative cash flows from operations since inception through December&nbsp;31, 2019. We have generated positive cumulative cash flows from
operations for the year ended December&nbsp;31, 2020 and the three months ended March 31, 2020 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate continuing to expend significant amounts of cash for fixed assets in the foreseeable future as we
continue to invest in research and development of our product offerings, commercialization of new products and services, and expansion into new markets. Our future capital requirements will depend on many factors including our revenue, research and
development efforts, the impacts of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> the timing and extent of additional capital expenditures to invest in existing and new facilities, as well as our manufacturing operations,
the expansion of sales and marketing and the introduction of new products. We have and may in the future enter into arrangements to acquire or invest in businesses, services and technologies, and any such acquisitions or investments could
significantly increase our capital needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently anticipate making additional capital expenditures during the next
12 months, which is expected to primarily include equipment to be used for manufacturing and investment in research and development, as well as spend associated with the expansion of our facilities in Wuxi, China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current business plan, we believe our existing cash and cash equivalents and anticipated cash flows from
operations will be sufficient to meet our working capital and capital expenditure needs over at least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the next 12 months from the date of this prospectus. Further, based on our existing cash balances, anticipated cash flow from operations and net proceeds from this offering, we currently do not
anticipate needing to raise additional funds from the issuance of equity, debt or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt financing in order to continue our planned
investments in research and development of our product offerings and application process to receive approval or clearance from the FDA for clinical use of our Aurora and Northern Lights systems. However, if our available cash balances, net proceeds
from this offering and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements or otherwise, we may seek to issue equity, debt or convertible debt securities, enter into a credit facility or another form of
third-party funding, seek other debt financing or enter into collaborations or licensing arrangements. We may also consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of
financing opportunities or for other reasons, including to further scale up our manufacturing of our products, to increase our sales and marketing efforts to drive market adoption of our products and address competitive developments, and to finance
capital expenditures and general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sources of liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have financed our operations primarily through private placements of our redeemable convertible preferred stock. Through
March 31, 2021, we raised a total of $200.1&nbsp;million from the sale of redeemable convertible preferred stock and common stock. We have also benefited from operating cash flows from the sale of our products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;7, 2020, we received loan proceeds in the amount of approximately $4.1&nbsp;million under the PPP. The PPP,
established as part of the CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. We have used $2.8&nbsp;million of this loan for eligible purposes,
including payroll, benefits, rent and utilities and we have repaid $1.3&nbsp;million as of March&nbsp;31, 2021. On May 4, 2021, we fully repaid the PPP loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by operating activities for the three months ended March 31, 2020 was $1.4 million consisting primarily of
our net loss of $839,000, an increase in inventories of $4.6 million directly attributable to increased sales and a decrease of trade accounts receivable of $5.7 million due to seasonality, with our first quarter typically being lower than our
fourth quarter due to marketing campaign closing activity. This was partially offset by an increase of deferred revenue of $706,000, an increase in the legal settlement liability of $465,000 and a decrease in accrued expenses and other liabilities
of $227,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by operating activities for the three months ended March
31, 2021 was $1.9 million consisting primarily of our net income of $102,000, an increase in inventories of $3.6 million, an increase in prepaid expenses and other assets of $477,000 and a decrease of trade accounts receivable of $2.2 million due to
seasonality with our first quarter typically being lower than our fourth quarter due to marketing campaign closing activity. This was partially offset by an increase in deferred revenue of $1.7 million and an increase in accrued expenses and other
liabilities of $135,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities for year ended December&nbsp;31, 2019 was
$13.7&nbsp;million consisting primarily of our net loss of $16.8&nbsp;million, an increase in accounts receivable of $12.6&nbsp;million and an increase in inventories of $14.6&nbsp;million directly attributable to increased sales. This was partially
offset by a legal settlement liability of $21.7&nbsp;million relating to the BD litigation settlement established during the year and an increase in accrued expenses and other liabilities of $5.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by operating activities for year ended December&nbsp;31, 2020 was $15.2&nbsp;million, consisting primarily
of net income of $19.4&nbsp;million, an increase in accrued expenses and other liabilities of $8.2&nbsp;million directly attributable to an increase in headcount and the corresponding personnel-related costs and an increase in inventories of
$5.7&nbsp;million to accommodate increase in sales volume. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities during the three months ended March 31, 2020 was $348,000 primarily driven by an increase
in the purchase of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities during the three months ended March 31,
2021 was $138,000 driven by an increase in the purchases of property and equipment of $509,000 partially offset by the payment for the additional investment in Cytek Japan, net of cash acquired of $371,000. See Note 16 included in the notes to our
interim consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities
during the year ended December&nbsp;31, 2019 was $973,000 primarily driven by an increase in capital expenditures of laboratory and computer equipment of $347,000 and an increase in leasehold improvements of $764,000, partially offset by a decrease
in the purchase of furniture and fixtures of $152,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities during the year ended
December&nbsp;31, 2020 was $1.5&nbsp;million primarily driven by an increase in capital expenditures for laboratory equipment of $1.1&nbsp;million and an increase in leasehold improvements of $344,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities during the three months ended March 31, 2020 and 2021 was $13,000 and $187,000,
respectively, primarily driven by the issuance of common stock upon option exercises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing
activities during the year ended December 31, 2019 was $93,000 driven by the issuance of common stock upon option exercises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities during the year ended December&nbsp;31, 2020 was $122.6&nbsp;million primarily
driven by the issuance of our Series D redeemable convertible preferred stock in October 2020 for net proceeds of $119.7&nbsp;million, net proceeds from the PPP loan of $2.8&nbsp;million and $169,000 from the issuance of common stock upon option
exercises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual obligations and commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our <FONT STYLE="white-space:nowrap">non-cancellable</FONT> contractual obligations at
December&nbsp;31, 2020 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;than&nbsp;1<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1 - 3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>4 - 5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More<BR>than 5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,233</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,887</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,931</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,833</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BD milestone payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,233</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,887</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,931</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,833</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lease commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We lease office facilities under various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases that expire at various
dates. Under certain leases, we are responsible for expenses related to operations, maintenance, repairs, and management fees that are accounted for as operating leases. The table above includes future minimum lease payments under <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> lease arrangements as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Licensing agreements </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;13, 2018, BD filed a lawsuit against us alleging trade secret misappropriation and copyright infringement.
On October&nbsp;6, 2020, we entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which we and BD agreed to a mutual release of all claims against each other as of the date thereof (the &#147;BD Agreement&#148;). As
part of the settlement, BD granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, perpetual, worldwide, and <FONT STYLE="white-space:nowrap">non-transferrable</FONT> license to certain BD patents and covenanted that it
would not enforce, or permit or encourage the enforcement of BD patents against us or our affiliates in connection with the development, manufacture, use, importation, offer for sale or sale of our then-current instruments. In exchange, we agreed
that we and our affiliates would not dispute or challenge in a legal proceeding the validity, enforceability or scope of the applicable BD patent claims and agreed to make certain payments to BD, including (i)&nbsp;a
<FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $2.0 million, (ii)&nbsp;a low single digit royalty payment for ten years, based on net sales of certain of our products, (iii)&nbsp;a $6.0 million milestone payment upon the
occurrence of a certain sales threshold, and (iv)&nbsp;a specified payment upon the closing of a change of control transaction, if any. We also issued 2,087,545 shares of our common stock to BD during the year ended December&nbsp;31, 2020 in
connection with the BD settlement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December 31, 2020, it was probable that the specified milestone would be
achieved within 12 months and therefore, the $6.0&nbsp;million milestone payment is included in the contractual obligations table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not have during the periods presented, and we
do not currently have, <FONT STYLE="white-space:nowrap">any&nbsp;off-balance&nbsp;sheet</FONT> financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured
finance or special purpose entities, that were established for the purpose of <FONT STYLE="white-space:nowrap">facilitating&nbsp;off-balance&nbsp;sheet</FONT> arrangements or other contractually narrow or limited purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and qualitative disclosures about market risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact
our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in foreign currency exchange rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market risk inherent in our financial instruments and in our financial condition represents the potential loss arising from
adverse changes in interest rates or exchange rates. As of December&nbsp;31, 2019 and December&nbsp;31, 2020, we had cash and cash equivalents of $30.1&nbsp;million and $165.2&nbsp;million, respectively, which consisted primarily of money market
funds and bank deposits and restricted cash of $368,000 and $888,000 as of December&nbsp;31, 2019 and 2020, respectively. As of March 31, 2021, we had cash and cash equivalents of $168.6&nbsp;million, which consisted primarily of money market funds
and bank deposits. The primary objective of our investment is to preserve principal and provide liquidity. These money market funds and bank deposits generate interest income at variable rates below 1%. As of March&nbsp;31, 2021, we had a PPP loan
which bears interest at a fixed rate of 1%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We therefore do not believe we are exposed to, nor do we anticipate being in
the near future exposed to, material risk due to changes in interest rates because of the short-term nature of our cash, cash equivalents and PPP loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our revenue has been generated across the globe, mainly in the United States, Europe and Asia. Our foreign currency risk
related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the renminbi and the euro, causes both our revenue and our operating results to be impacted by fluctuations in the exchange rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As we expand our presence in international markets, our results of operations and cash flows may increasingly be subject to
fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To date, we have not entered into any hedging arrangements intended to minimize the impact of these
fluctuations in the exchange rates. As our international operations grow, we intend to continue to reassess our approach to manage our risk relating to fluctuations in currency rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not believe that either inflation or foreign currency risk had a material effect on our business, financial condition,
or results of operations during the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical accounting policies, significant judgments and use of estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have prepared our consolidated financial statements in accordance with U.S. GAAP. Our preparation of these consolidated
financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We based
our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. The economic uncertainty in the current environment caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could limit our ability to accurately make and evaluate our estimates and judgments.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual results could therefore differ materially from these estimates under different assumptions or conditions. We
believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in Note 2 to our
audited consolidated financial statements and Note 2 to our interim consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are the most critical to understanding and evaluating our
reported consolidated financial results.<B><I> </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our product revenue consists of sales of our instrument systems and accessories. We recognize product revenue at the point in
time when control of the instrument is transferred to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our service revenue primarily consists of
post-warranty service contracts, installations and repairs which are recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are recognized as they are
delivered to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue is recognized when control of promised goods or services is transferred to a customer
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, we perform the following five steps:
(i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract;
and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Invoicing for products occurs
upon delivery and payment terms are 30 to 90&nbsp;days. Service contracts are invoiced upfront and payment terms are generally 30&nbsp;days. For those arrangements that have terms greater than one year, any payments received upfront are for reasons
other than financing. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration is not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of our sales contracts involve the delivery or performance of multiple products and services within contractually
binding arrangements. We have determined these performance obligations qualify as distinct performance obligations, as the customer can benefit from the good or service on its own or together with other resources that are readily available to the
customer, and our promise to transfer the good or service is separately identifiable from other promises in the contract. For these arrangements that contain multiple performance obligations, we allocate transaction price based on the relative
standalone selling price (&#147;SSP&#148;) method by comparing the SSP of each distinct performance obligation to the total value of the contract. We use a range of amounts to estimate SSP for products and services sold together in a contract to
determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, we determine the
SSP using information that may include market conditions and other observable inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Taxes, such as sales, value-add and
other taxes collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost and are included in cost of sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Product revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our standard arrangement for sales to end users is generally a purchase order or an executed contract. Product revenue is
recognized upon transfer of control of the product to the customer, which generally occurs at a point in time depending on the shipping terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our distributor arrangements with our customers include a purchase order. The purchase order is governed by terms and
conditions of the distributor agreements. Revenue is recognized upon transfer of control of the products to the distributor, which occurs at a point in time depending on the shipping terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Service revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our service revenue primarily consists of post-warranty service contracts, installations, and repairs which are recognized over
time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are recognized as they are delivered to the customer. Service contracts are typically between one and three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contract liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contract liabilities consist of fees invoiced or paid by our customers for which the associated services have not been
performed and revenue has not been recognized based on our revenue recognition criteria described above. Such amounts are reported as deferred revenue for service and customer deposits for instruments on the consolidated balance sheets. Deferred
revenue that is expected to be recognized during the following 12 months is recorded as a current liability and the remaining portion is recorded as&nbsp;noncurrent.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Assurance-type product warranties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We provide <FONT STYLE="white-space:nowrap">a&nbsp;one-year&nbsp;assurance-type</FONT> warranty that is included with the sale
of our instruments. At the time revenue is recognized for the products, we establish an accrual for estimated warranty expense based on historical data and trends of product reliability and costs of repairing and replacing defective products. We
exercise judgment in estimating the expected product warranty costs, using data such as the historical repair costs. While we believe that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues
or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in our products could result in actual expenses that are below those currently estimated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and intangible assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2017, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;2017-04,</FONT><I>&nbsp;Intangibles &#150;
Goodwill and Other: Simplifying the Test for</I><I></I><I> Goodwill</I><I></I><I> Impairment</I>, to simplify the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. We adopted this guidance during the year
ended December&nbsp;31, 2019, and the adoption did not have a material impact on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognize goodwill in accounting for business combinations based on the amount by which the total consideration
transferred, exceeds the fair value of identifiable assets acquired and liabilities assumed. Identifiable intangible assets other than goodwill are primarily comprised of patents and trademarks which amortize on a straight-line basis over an
assigned useful life based on management&#146;s estimate of the period the asset is expected to contribute to future cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We assess our goodwill and indefinite-lived intangible assets for impairment at least annually, or more frequently if factors
indicate impairment may exist. Our qualitative goodwill impairment analysis consists of assessing whether any events or circumstances listed in ASC
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">350-20-35-3A</FONT></FONT></FONT> (&#147;triggering events&#148;) existed or occurred in the year under review to the date of the financial
statements. The qualitative analysis assesses macroeconomic conditions, market, and industry considerations, change in cost factors, overall company financial performance, and any events affecting the reporting unit. Based on the qualitative
analysis results, we determined that it is more likely than not that the fair values of the reporting unit exceed the carrying value and that no triggering events were noted that would require a quantitative impairment assessment in the fiscal year.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Variable interest entities and voting interest entities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We determine whether we have a controlling financial interest in an entity by first evaluating whether the entity is a variable
interest entity (&#147;VIE&#148;) and therefore subject to the consolidation requirements under the VIE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
model. Only if the entity does not meet the definition of a VIE, the Company will apply the voting interest model (&#147;VOE&#148;) or other applicable GAAP. VOEs are entities in which the total
equity investment at risk is sufficient to enable the entity to finance itself independently and provides the equity holders with the obligation to absorb losses, the right to receive residual returns and the right to make decisions about the
entity&#146;s activities. We consolidate VOEs in which it has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. As defined in applicable accounting standards,
VIEs are entities that lack one or more of the characteristics of a voting interest entity. A controlling financial interest in a VIE is present when an enterprise has both the power to direct the activities of the VIE that most significantly impact
the VIE&#146;s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. We consolidate a VIE where it has been determined that we are the primary beneficiary of the
entity&#146;s operations. We do not currently hold an interest in a VIE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain an equity incentive compensation plan under which incentive stock options and nonqualified stock options are
granted primarily to employees <FONT STYLE="white-space:nowrap">and&nbsp;non-employee&nbsp;consultants.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense
over the vesting period. The fair value of stock-based awards is estimated using the Black-Scholes option pricing model. We record forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These
variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all stock options
granted, we calculated the expected term using the simplified method for standard stock option awards. We have no publicly available stock information; therefore, we have used the historical volatility of the stock price of similar publicly traded
peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues similar in duration to the expected term of the equity-settled award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the weighted-average assumptions used in estimating the fair value of stock options granted
during each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">7&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">6&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">0&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">8&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected volatility&#151;</I>Expected volatility is estimated by studying the volatility of
selected industry peers deemed to be comparable to our business corresponding to the expected term of the awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected term</I>&#151;Expected term represents the period that our stock-based awards are expected to be outstanding and
is determined using the simplified method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-free interest rate</I>&#151;The risk-free interest rate is based on
the U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issued in effect at the time of grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividend yield</I>&#151; The expected dividend yield is zero as we have never declared or paid cash dividends and have no
current plans to do so in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common stock valuation prior to our IPO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There was no public market for our common stock prior to this offering. As such, the estimated fair value of our common stock
was determined at each grant date by our board of directors, with input from management, based on the information known to us on the grant date and upon review of any recent events and their potential impact on the estimated per share fair value of
our common stock. As part of these fair value determinations, our Board of Directors obtained and considered valuation reports prepared by third-party valuation firms in accordance with the guidance outlined in the American Institute of Certified
Public Accountants Technical Practice Aid,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contemplation of an initial public offering of our common stock, we began using a hybrid approach in determining the fair
value of our common stock that includes a probability-weighted expected return method (&#147;PWERM&#148;) and an option pricing method (&#147;OPM&#148;). Under a PWERM, the fair market value of the common stock is estimated based upon an analysis of
future values for the enterprise assuming various future outcomes. Within one of those potential outcomes, we utilized the OPM. The OPM treats the rights of the holders of redeemable convertible preferred stock and common stock as equivalent to that
of call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of redeemable convertible preferred stock, as well as their rights to participation and conversion. Based on the
timing and nature of an assumed liquidity event in each scenario, a discount for lack of marketability either was or was not applied to each scenario, as appropriate. We then probability-weighted the value of each expected outcome to arrive at an
estimate of fair value per share of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to considering the results of these third-party valuation
reports, our board of directors used assumptions based on various objective and subjective factors, combined with management judgment, to determine the fair value of our common stock as of each grant date, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold shares of redeemable convertible preferred stock and the superior rights and
preferences of the redeemable convertible preferred stock relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences research and development industry and trends within the
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition and operating results, including our levels of available capital resources, and
forecasted results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments in our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equity market conditions affecting comparable public companies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general United States market conditions and the lack of marketability of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Application of these approaches involves the use of estimates, judgment and assumptions that are
subjective, such as those regarding our expected future revenue, expenses and future cash flows, discount rates, market multiples, the selection of comparable companies and the probability of possible future events. Changes in any or all of these
estimates and assumptions or the relationships between those assumptions impact our valuations as of each valuation date and may have a material impact on the valuation of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, our board of directors will determine the fair value of each share of underlying
common stock based on the closing price of our common stock as reported on Nasdaq on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation settlement liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not currently involved in legal proceedings at the date of this prospectus. In case we will be involved in legal
proceedings, we are required to assess the probability of loss and amount of such loss, if any, in preparing our consolidated financial statements. We evaluate the likelihood of a potential loss from legal proceedings to which we are a party. We
record a liability for such claims when a loss is deemed probable, and the amount can be reasonably estimated. Significant judgment may be required in the determination of both probability and whether an exposure is reasonably estimable. Our
judgments are subjective based on the status of the legal proceedings, the merits of our defenses and consultation with <FONT STYLE="white-space:nowrap">in-house</FONT> and outside legal counsel. As additional information becomes available, we
reassess the potential liability related to pending claims and may revise our estimates. Due to the inherent uncertainties of the legal processes in the multiple jurisdictions in which we operate, our judgments may be materially different than the
actual outcomes, which could have material adverse effects on our business, financial conditions, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income
taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We account for income taxes under an asset and liability method, which requires the recognition of deferred
tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the
financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized
in income in the period that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognize deferred tax assets to the extent that these
assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations. If we determine that we would be able to realize deferred tax assets in the future in excess of their net recorded amount, an adjustment to the deferred tax asset valuation allowance would
be made to reduce the provision for income taxes. Based on this guidance and additional analysis of all available positive and negative evidence, we released all valuation allowance except for one foreign subsidiary in 2020 as the deferred tax
assets are deemed more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record uncertain tax positions on the basis of a two-step
process in which determinations are made (i)&nbsp;whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii)&nbsp;for those tax positions that meet the
more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with a tax authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently adopted accounting pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited consolidated financial statements and Note 2 to our interim consolidated financial statements
included elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act accounting election and smaller reporting company status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the JOBS Act
provides that an &#147;emerging growth company&#148; may take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Therefore, an emerging growth
company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will not adopt
new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In addition, as an emerging growth company, we may take advantage of certain reduced disclosure and other
requirements that are otherwise applicable generally to public companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may take advantage of these exemptions until such earlier time that we
are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering;
(ii)&nbsp;the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.07&nbsp;billion; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three
years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company,&#148; as defined in the Exchange Act. We may continue to be a smaller reporting
company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our
voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual
revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited consolidated financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OVERVIEW</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel
technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and
Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish
fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). Our novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with
exquisite sensitivity. Our patented FSP technology optimizes sensitivity and accuracy through its novel optical and electronic designs that utilize an innovative method of light detection and distribution. Our FSP platform includes instruments,
reagents, software and services to provide a comprehensive and integrated suite of solutions for our customers. Since our first U.S. commercial launch in <FONT STYLE="white-space:nowrap">mid-2017</FONT> through March&nbsp;31, 2021, we have sold and
deployed over 750 instruments&#151;primarily comprised of our Aurora and Northern Lights systems&#151;to over 620 customers around the world, including the largest pharmaceutical companies, over 125 biopharma companies, leading academic research
centers, and clinical research organizations (&#147;CROs&#148;). In June 2021, we began shipping the Aurora cell sorter (&#147;Aurora CS&#148;), which uses our FSP technology to further broaden our potential applications across cell analysis. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Biological systems are highly complex, and the multitude of questions that remain unanswered sets many challenges for
scientists. Analysis at the single cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions.
It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. There is growing demand for deep content through high-dimensional cell analysis and
for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single cell through highly resolvable
multi-dimensional cell analysis. While flow cytometry is a widely used tool for single-cell analysis, conventional flow cytometry, mass cytometry and early approaches to spectral flow cytometry technologies have historically been challenged due to
limited dimensionality, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> resolution, low throughput, high cost for performance and/or significant technical expertise required to operate systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with
greater sensitivity, more flexibility and increased efficiency, all at a lower cost for performance. Our patented FSP technology is designed to optimize sensitivity and accuracy through its novel optical and electronic designs that utilize an
innovative method of light detection and distribution to a specifically selected number of detectors of a particular type. This patented optics design enables researchers to effectively collect the full range of light emissions in an extremely
compact space, resulting in higher resolution. Our platform also provides higher content by enabling development of highly complex assays with 40 different colors (individual fluorochromes) and, by combining multiple biomarkers with a fluorochrome,
more than 40 biomarkers, all accessible within just a single tube. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our solutions have enabled researchers to make
significant scientific advances in key areas of medical discovery (such as oncology, immunology and infectious diseases) and empowered improved downstream cell analysis with complementary cell analysis technologies (such as next-generation
sequencing (&#147;NGS&#148;)). We believe that our innovative FSP and targeted cell isolation technology has the potential to accelerate scientific discovery and to have a profound impact on the understanding of cell biology, immunotherapy, and
targeted therapeutic approaches (personalized medicine). Further, the rate of publications generated, showcasing our technology across a wide range of applications including oncology, infectious diseases, immunology,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
immunotherapy and immuno-oncology, has meaningfully accelerated. Over 210 peer-reviewed articles have been published over three years, including many articles that appear in prominent journals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our FSP platform was purpose-built to advance the next generation of cell analysis by delivering deep insights, high
throughputs and ease of use. Our FSP platform is designed to offer the following key benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ultra-sensitive:</I></B> resolve the most challenging cell populations (such as cells with high
autofluorescence or low levels of expression of key biomarkers) by providing high-resolution data at the single-cell level with an optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Deep, high-integrity content:</I></B> allow development of highly complex assays through access to 40
different colors and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers in a single tube without sacrificing precision and throughput to gain a deeper understanding of biological systems and arrive at faster and more
accurate diagnoses in clinical settings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Flexible and compatible:</I></B> enable a single configuration across a wide range of reagents and
applications, full backwards compatibility across panels, and greater leverage for downstream analysis with complementary technologies, including NGS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Efficient and compact:</I></B> improve costs and save time while maintaining industry-leading
performance and efficient workflows that limit consumables usage and reduce labor costs&#151;all within a highly compact footprint, minimizing space requirements for laboratories. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Integrated and intuitive:</I></B> provide fully-integrated workflows through a suite of solutions that
include instruments, reagents and kits, software and services. Our proprietary tools and the intuitive functionality of our proprietary SpectroFlo software, coupled with a user-friendly interface, allow for enhanced <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ease-of-use</FONT></FONT> and minimal operator training. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our core
instruments, the Aurora and Northern Lights systems, are full spectrum flow cytometers founded on our FSP platform technology. The Aurora system&#151;our most advanced and comprehensive offering&#151;is available with three to five lasers and is
suitable for customers seeking to access more than 24 colors (the Aurora system is able to reach 40 different colors and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers.) The Northern Lights system&#151;our entry-level
offering&#151;is available with one to three lasers and is suitable for customers seeking to access up to 24 colors. Both instruments are reconfigurable based on the desired number of lasers. In June 2021, we began shipping the Aurora CS, which
leverages our FSP technology to rapidly isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers. We believe the Aurora CS is the only sorter able to accommodate the same number of parameters with the same
sensitivity as the Aurora system. Each system is supported by our highly intuitive, proprietary embedded SpectroFlo software, our reagents, and our service offerings to provide a comprehensive, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform of solutions for our customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Within the life sciences
technology market, flow cytometry technologies currently provide solutions largely within cell proliferation, cell counting, cell identification, cell quality control and single-cell applications, and they represent an initial total addressable
market of nearly $8&nbsp;billion. However, we believe that, driven by enhanced capabilities, our FSP platform has the potential to capture an increasingly greater share of the broader cell analysis market, which according to MarketsandMarkets
Research Private Ltd. is expected to grow from roughly $16&nbsp;billion in 2019 to approximately $23&nbsp;billion by 2024, approximately $5 billion of which represents revenue from hospitals and diagnostic laboratories and $1.5 billion of which
comes from the United States. Our Northern Lights system has been approved for clinical use in the European Union and China. In the United States, our products are currently labeled and promoted, and are, and in the near-future are expected to
continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products for non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical
diagnostic tests. We plan to continue generating supporting publications and data, as well as pursue any required regulatory approvals for clinical use for our products in the United States. Our ability to penetrate the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical markets in the United States will depend in part on our ability to receive 510(k) clearance, <I>de</I><I> </I><I>novo</I><I> </I>classification, or approval of a pre-market approval
application from the FDA. Further, we believe our differentiated platform will enable us to expand the use of cell analysis into new markets, well beyond current applications addressed by prior flow cytometry technologies and other cell analysis
technologies and creating a larger potential total addressable market. New and existing markets addressable by our platform include applications within immunotherapy, immuno-oncology, <FONT STYLE="white-space:nowrap">bio-processing,</FONT>
infectious diseases, and immuno-deficiencies. In addition, the combination of our platform with complementary, downstream cell analysis technologies is expected to provide areas for new applications. Combining FSP technology with NGS, for example,
has demonstrated an improved ability to predict leukemia relapse after therapy (such as minimal residual disease (&#147;MRD&#148;) testing) and served to support the use of our technology within personalized medicine. As our FSP platform is further
validated through the continued acceleration of peer-reviewed publications in new applications, we expect our total addressable market to expand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the combination of our people and our global reach across the United States, Europe and Asia will enable us to
continue to execute on our growth strategies, stay ahead of competition and remain at the forefront of innovation in cell analysis. Our leadership team has extensive track records in the life sciences and technology sectors. As of March&nbsp;31,
2021, we employed a multidisciplinary group of over 390 employees, with more than 110 advanced degrees, including over 70 PhDs and MDs, with expertise across optics, electronics, fluidics, computer sciences, chemistry, biology, and medical sciences.
Our worldwide commercial team of more than 120 employees and our research and development team of more than 100 employees have significant expertise, industry experience and collaborative relationships with key opinion leaders (&#147;KOLs&#148;),
industry leaders, innovators and potential customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have a long history of providing high-quality and efficient
customer service and our product development efforts reflect our deep understanding of our customers&#146; needs. One of our key differentiators is our customer-facing technical team, which collaborates closely with our customers to identify and
find solutions for unmet needs across the market. We collaborate closely with KOLs, generating relevant data and publications to demonstrate not only the feasibility, but also the quality of our FSP approach. We plan to continue executing on our
strategy to accelerate our growth by driving adoption of our FSP solutions, inspiring innovation, investing in integrated workflow solutions and driving application development and adoption in clinical markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our financial results reflect the significant market demand for our offerings and adoption of our FSP technology:
our strong financial profile is differentiated by the combination of our scaled revenue base, high revenue growth and profitability. Our revenue reached $57.9&nbsp;million, $92.8&nbsp;million and $24.3 million for fiscal years 2019 and 2020, and the
three months ended March 31, 2021, respectively, and has realized a 112% CAGR from fiscal year 2018 to fiscal year 2020. We generated a net loss of $16.8&nbsp;million for fiscal year 2019 and a net income of $19.4&nbsp;million and $102,000 for year
ended December 31, 2020 and for the three months ended March&nbsp;31, 2021, respectively. Our Adjusted EBITDA was $3.3&nbsp;million, $14.9&nbsp;million and $1.8 million for fiscal years 2019 and 2020, and the three months ended March 31, 2021,
respectively. Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. For a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, information about why we consider Adjusted EBITDA
useful and a discussion of the material risks and limitations of these financial measures, please see &#147;Prospectus Summary&#151;Summary Consolidated Financial Data.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUR COMPETITIVE STRENGTHS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We aim to transform the cell analysis market by building on our success as a leading platform of innovative FSP solutions and
continuing to leverage our key competitive strengths, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our novel, patented FSP platform delivers high-resolution, high-content and high-sensitivity cell
analysis by utilizing the full spectrum of fluorescent signatures.</I></B> Our FSP platform provides high-resolution data at the single-cell level by optimizing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio; high-integrity content from </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
complex assays with 40 different colors (individual fluorochromes) and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers, all accessible within just a single tube;
flexibility through an adaptable single configuration that covers a wide range of reagents and applications; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> through our integrated and proprietary
SpectroFlo software; and an intuitive user interface that requires minimal operator training. Our platform empowers users to isolate living cell populations of interest from the most challenging samples (such as cells with high autofluorescence or
low levels of expression of key biomarkers), gain a deeper understanding of biological systems, arrive at faster and more accurate diagnoses in clinical settings, and use fewer samples, reagents and tubes. We believe that the combination of our
novel FSP instruments and our ability to standardize our platform through a suite of solutions is unique and will represent the future of flow cytometry, paving the way for the transformation of the cell analysis market. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our solutions address many of our customers&#146; unmet needs. </I></B>We market a suite of FSP
solutions that are purpose-built to address the unmet needs of our customers. Our solutions provide researchers with high-performing tools for complex cell analysis that are flexible, easy to use, reconfigurable based on the desired number of
lasers, and that fit within a compact footprint. We believe these features enable our customers to achieve significant cost and time savings and provide greater leverage for downstream analysis with complementary technologies (such as NGS). In June
2021, we began shipping the Aurora CS, which enables more efficient downstream analysis by leveraging our FSP technology to rapidly isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers. We believe the Aurora CS
is the only sorter able to accommodate the same number of parameters with the same sensitivity as the Aurora system. We believe our comprehensive solutions can expand the addressable user-base and <FONT STYLE="white-space:nowrap">end-market</FONT>
where flow cytometry can be utilized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our complete FSP offering is available across a range of price points while consistently delivering high
performance. </I></B>Our solutions address the full range of the cost continuum within the market, offering differentiated and cost-effective solutions while maintaining consistently industry-leading performance. We believe our diverse offering
maximizes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">performance-to-price</FONT></FONT> and allows us to increase our value to a greater mix of customers and attract demand from a variety of end markets. The Aurora system, our
most advanced and comprehensive instrument, featuring three to five lasers, is suitable for customers who want a flexible, intuitive, and ultra-sensitive full spectrum flow cytometer that can run a variety of cell analysis applications, including
highly multiplexed panels beyond 40 biomarkers. The Northern Lights system, our entry-level instrument, is suited to customers who are interested in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-three</FONT></FONT> laser
system, but who still need to run low to high complexity panels and access up to 24 biomarkers. Both offerings are reconfigurable and also offer savings not only on the cost of reagents and panels, but also on time, by eliminating the need for
redundant reagents and reducing sample preparation time, and both enable use of a single configuration to run any application with full backwards compatibility across panels, without compromising sample throughput and resolution.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our diversified customer base and breadth of relationships and scientific validation.</I></B><B> </B>We
are a leading cell analysis solutions company, offering products to hundreds of customers, including KOLs, and several key end markets. Our customers include the largest pharmaceutical companies, over 125 biopharma companies, leading academic
research centers, and CROs. Our customer mix is split close to evenly between biopharma and academia. Our instrument base has grown significantly since our initial commercial launch in 2017, with over 750 instruments sold and deployed as of
March&nbsp;31, 2021. Further, the rate of publications generated to showcase our technology has meaningfully accelerated, with over 210 peer-reviewed articles published, including many published in high-impact journals. These publications span a
wide range of applications including oncology, infectious diseases, immunology, immunotherapy and immuno-oncology, some of which are evergreen areas in which flow cytometry is used, thereby demonstrating how our FSP technology can expand into
additional end markets. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our global scale and reach.</I></B> We have a globally scaled footprint with eight facilities across the
United States, Europe and Asia. We employ dedicated applications, service and sales support specialists located around the world, and we provide service to customers in over 25 countries, affording us a uniquely diversified geographic revenue mix
relative to our size. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUR STRATEGY</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our strategy includes the following core elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate adoption of our FSP solutions.</I></B> To continue driving adoption of our solutions and to
support our leading global brand, we intend to further expand our sales infrastructure by hiring additional, highly qualified and reputable sales representatives, technical applications specialists and customer support staff, and by increasing
marketing efforts. This investment will also support our entry into new markets as we rollout new solutions and applications and appropriately manage inbound interest from new customers. In addition, while<B><I> </I></B>many notable industry KOLs
have already recognized our platform as<B><I> </I></B>setting the new standard in flow cytometry and cell analysis, we continue to focus on establishing new collaborations and relationships to explore additional applications for our platform, and
potential new product opportunities. We will continue to broaden our global recognition within the research and clinical communities to promote the breadth of cell analyses enabled by our platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to innovate and offer our customers <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> FSP solutions.</I></B><B> </B>We design comprehensive solutions for our customers, delivering a fully integrated offering of instruments, consumables, software and services enabled by our FSP
technology. Our development efforts focus on value-additive features and enhancements to meet the growing needs of the cell analysis market. These efforts drive continued innovation across our proprietary reagents, software and services offerings,
in addition to new instrumentation releases, such as the Aurora CS, which is a highly flexible, intuitive and ultra-sensitive cell sorter that leverages our FSP technology to isolate living cell populations from lower to higher complexity panels
beyond 40 biomarkers, which we began shipping in June 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Invest in integrated workflow solutions to drive pull-through from our consumables and services.
</I></B>Our overarching goal is to become a comprehensive solutions provider to our customers by delivering a fully integrated offering of instruments, consumables, software and services enabled by our FSP technology. Many of the reagents we are
developing will be specific to our instruments, thereby providing a more seamless experience for the end user. Further, as we continue to penetrate our addressable markets, we can leverage our growing installed base to drive consumable pull-through
and recurring revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Drive application development and adoption in clinical markets.</I></B> We are deeply committed to
developing our platform&#146;s applications within the clinical market, and in particular within disease detection, diagnosis and treatment monitoring. We also focus on areas where we can leverage the combination of our FSP platform with
complementary cell analysis technologies (such as NGS) to produce differentiated outcomes with greater sensitivity, such as with MRD testing. We can provide insights to clinicians to facilitate personalized medicine for patients, as well as
facilitate biopharma&#146;s research and development efforts to develop the next generation of targeted therapies. Our belief, which is supported by peer-reviewed publications, is that our Northern Lights system is uniquely positioned to enable
clinicians to efficiently perform high-level multi-parameter flow cytometry immunophenotyping on small amounts of blood and bone marrow samples to accurately detect, diagnose and monitor immune cell disorders where key biomarkers are expressed at
very low levels. The ability to perform high-level multi-parameter analysis on smaller sample sizes is particularly important when working with pediatric samples, which are often smaller but require the same size panels, and neurological diseases,
which are known to be hypocellular and require more markers on fewer cells. Our Northern Lights system has been approved for clinical use in the European Union and China and we plan to continue generating supporting publications and data, as well as
to pursue any required regulatory approvals for clinical use in the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUR MARKET OPPORTUNITY AND INDUSTRY BACKGROUND</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our market opportunity.</I></B> Within the life sciences technology market, flow cytometry technologies currently
provide solutions, including cell proliferation, cell counting, cell identification, cell quality control and single-cell applications, largely within the global cell analysis market. However, we believe that the enhanced capabilities of our FSP
platform relative to conventional flow cytometry (&#147;CFCs&#148;), mass cytometry and early approaches to spectral flow cytometry enable us to capture an increasingly greater share of the total addressable market by accessing the entire cell
analysis market, which according to MarketsandMarkets Research Private Ltd. is expected to grow from roughly $16&nbsp;billion in 2019 to approximately $23&nbsp;billion by 2024, approximately $5 billion of which represents revenue from hospitals and
diagnostic laboratories and $1.5 billion of which represents revenue from hospitals and diagnostic laboratories in the United States. Our Northern Lights system has been approved for clinical use in the European Union and China. In the United
States, our products are currently labeled and promoted, and are, and in the near-future are expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only products for
non-diagnostic and non-clinical purposes, and are not currently designed, or intended to be used, for clinical diagnostic tests. We plan to continue generating supporting publications and data, as well as pursue any required regulatory approvals for
clinical use for our products in the United States. Our ability to penetrate the clinical markets in the United States will depend in part on our ability to receive 510(k) clearance, <I>de novo</I> classification, or approval of a pre-market
approval application from the FDA. Further, we believe our differentiated platform will enable us to expand the use of cell analysis into new markets, well beyond current applications addressed by prior flow cytometry technologies and other cell
analysis technologies. Thus, we believe our potential total addressable market is larger than the current cell analysis market, which excludes new and existing markets addressable by our platform, such as applications within immunotherapy,
immuno-oncology, <FONT STYLE="white-space:nowrap">bio-processing,</FONT> infectious diseases and immuno-deficiencies. In addition, the combination of our platform with complementary, downstream cell analysis technologies is expected to provide
additional areas for new applications. Combining FSP technology with NGS, for example, has demonstrated an improved ability to predict leukemia relapse after therapy (such as MRD testing) and served to support the use of our technology within
personalized medicine. As our FSP platform is further validated through the continued acceleration of peer-reviewed publications in new applications, we expect our total addressable market to expand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our FSP platform to play a significant role in areas outside of healthcare, such as addressing the growing need to
understand and develop methods to address our current and future environmental threats. Flow cytometry has already begun to play a role in this emerging field and full spectrum flow cytometry is in its early days of contributing toward research in
marine biology, water supply contamination and development of alternative biofuels. Additionally, the field of nanoparticle characterization is developing into an enormous field of research for vaccine development, drug delivery, and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> biomarker discovery for numerous diseases (extracellular vesicles phenotyping). Our specialized small particle detection enhancement module has already become a valuable tool in this area of research.
Our collaborations with KOLs in this area continue to drive the development of new protocols and workflows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Complementary technologies to FSP and multi-omics applications.</I></B> Since our FSP platform provides highly complex
data down to single-cell resolution at a rapid speed, it is inherently well-suited to drive more targeted and efficient downstream analyses for other single-cell technologies, such as NGS, single-cell capture and sample preparation, high-resolution
microscopy (such as mass imaging cytometry, super resolution microscopy, confocal microscopy and high-throughput screening platforms), and micro and optofluidic systems. FSP is highly complementary to single-cell genomics applications utilizing NGS
as it can be used earlier in workflows to rapidly phenotype and isolate living cell populations to the single-cell level with highly multiplexed proteomic data. These cells can then be transferred from our instrument into NGS systems to correlate
proteomic and genomic expression, which in turn enables researchers to develop novel drug targets for therapeutics and clinicians to drive outcomes for patients through more informed treatment decision-making. For example, a peer-reviewed article
published in the <I>Biology of Blood and Marrow Transplantation </I>journal recognized that combining multiparameter flow cytometry with NGS resulted in an improved ability to predict leukemia relapse after therapy, demonstrating strong potential
utility in the large and growing market for MRD </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
testing. With MRD, end users require high sensitivity and standardization, which makes our FSP technology ideal for addressing these challenges. According to a global MRD testing market report by
BIS Research in December 2020, flow cytometry technology has the largest market share in MRD testing among relevant technologies, including NGS, polymerase chain reaction and others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Use of FSP with complementary single-cell technologies, as well as the ability to study specific cell populations of interest
by physically isolating these populations to perform further downstream detailed cell analysis, has already contributed to scientific advances in medicine, such as in immunology, infectious diseases, immune-response, immune-therapy and cancer
diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Importance of cell analysis at the single-cell level.</I></B> Due to the heterogeneity within tissues,
understanding cellular biology, particularly at the single-cell level, is necessary to unravel mechanisms that might otherwise not be detectable in bulk assays. Deep cellular analysis is a key application that we expect to enable a new age of
healthcare delivery, and in particular, personalized medicine. Emerging and chronic infectious diseases, an aging population with a myriad of chronic diseases, and the need for more effective and targeted therapeutics all demand that the global
healthcare market have advanced cell analysis technologies to research therapeutic and diagnostic solutions. These primary market forces, among others, will drive the direction for cell analysis applications that provide new possibilities for novel
drug development and improved patient outcomes through enhanced disease detection, diagnosis, and treatment monitoring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A brief history in the evolution of flow cytometry.</I></B> Flow cytometry has been one of the key technologies in cell
analysis since the 1980s and has been one of the most influential research tools for understanding key biological mechanisms of health and disease. A few notable areas of scientific evaluation and discovery that have been significantly advanced by
flow cytometry technologies include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Area of
scientific research</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Cell types</B></P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Applications</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Immune
cell mechanisms</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Human, animal</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Disease (infectious diseases, immuno-deficiency, cancer, autoimmunity, drug discovery)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Organ transplants</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Health (normal
development, ontogeny, homeostasis)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cellular biology</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Human, animal, microbial</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Proliferation/death</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Genetic
regulation/manipulation</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Developmental biology (prokaryotic, eukaryotic)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Drug targetable
mechanisms in disease</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#149;&#8195;&#8194;&#8202;Metabolomics</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Bio-engineering</FONT></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Human, animal, microbial</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Organoid development</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Stem cell
transplantation</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Tissue engineering</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Traditionally designed flow cytometers utilized fluorescence and laser
scatter as the key read-outs to interpret and analyze cellular properties. In general, laser scatter is used on individual cells to identify certain physical properties of those cells, such as their relative size, internal complexity and membrane
composition, while fluorescence from fluorochromes (such as detection reagents that absorb and emit light) associated with fluorescent-labeled antibodies (biomarkers when bound to receptor cells) were used to identify cellular phenotype (a
cell&#146;s protein expression relative to its morphology and function). The fluorescence was the result of fluorochrome excitation by specific wavelength photons from the onboard lasers. The fluorescent and side scattered photons were then
collected by photomultiplier tubes (&#147;PMTs&#148;) equipped with specific filters to collect defined wavelengths of photons, and the forward scattering light was detected by semiconductor photodiodes, which converted the light into an electrical
signal. Initial systems were equipped with a single laser wavelength and a few detectors to collect a few different wavelength bands of light. While the originally designed flow cytometer was a very powerful tool for its time, scientists quickly
realized that the heterogeneity of cells required many more different probes to differentiate one cell type from another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Multiple approaches to flow cytometry have been developed since the early days of cell analysis to accommodate higher
dimensionality. In the late 1970s, CFCs, the first cell analysis platform capable of going down to single-cell resolution, took hold in the research market and, ultimately, the clinical market. From the 1980s to late 2000s, only incremental changes
were introduced to flow cytometry (such as modest additions of lasers and detectors), while the number of new biomarkers discovered took a significant leap forward. As a result, CFCs were unable to analyze many of these new biomarkers in one sample
tube due to technical constraints, which ultimately led to the introduction of mass cytometry&#151;an approach introduced in 2011 that utilizes the combination of mass spectrometry and heavy metals as tags (in lieu of fluorescence) to expand the
number of individual biomarkers that could be measured simultaneously. However, while a novel approach, mass cytometry did not see broad adoption from the research community due to inherent shortcomings, such as overall cost, large footprint and
technical expertise required to operate the instrument. This led to the introduction of an early approach to spectral flow cytometry in 2012, purposed to address the historical limitations of CFCs and mass cytometry. However, this early approach was
limited by its inability to obtain a high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio from its detectors. The maximum number of biomarkers which could be multiplexed in a single tube was
therefore not significantly different from CFC. We began our full spectrum flow cytometry development in 2015, taking advantage of the full spectrum of fluorescent probes in flow cytometry to increase the number of fluorescent biomarkers that could
be analyzed together. The demand for higher complexity cell analysis tools that achieve single-cell resolution continue to expand as research discoveries are translated into the clinical and diagnostic arenas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With the rise in popularity of flow cytometry, highly complex phenotyping, and the subsequent desire to isolate these unique
subpopulations identified, cell sorting based on unique phenotypes and protein expression has become critical to providing additional capabilities to study specific cell populations of interest by physically isolating these populations to perform
further downstream detailed cell analysis (such as NGS). The addition of advanced cell isolation capabilities to an already well-accepted flow cytometry technology further expands the potential for new avenues of scientific discovery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other existing technologies and their limitations.</I></B> Flow cytometry is the most established and utilized
technology for cell analysis, often used in advance of other cell analysis technologies as part of a researcher&#146;s workflow. Since the early 1970s, flow cytometry has been a major player in driving our understanding of cellular biology and the
complex mechanisms of the immune system. The ability to phenotype, isolate, and assess the function of individual cells in a complex environment of different cell types has led to a deeper understanding of the heterogeneity of tissues and the role
individual cell types play in both health and disease. Without the insight provided by flow cytometry technologies, many of the other single-cell technologies are constrained and lack specificity across heterogeneous cell populations. Therefore,
even through innovation in other areas of single-cell analysis (such as NGS), flow cytometry will remain integral to the overarching workflow in driving all single-cell technologies forward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Flow cytometry technology can be categorized based on the type of signal
used to identify one biomarker from another, which are listed below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Conventional flow cytometry</I>. Most flow
cytometers in the field today are CFC, which (compared to earlier flow cytometers) add more laser wavelengths and additional PMTs to enable detection of more biomarkers and increase the ability to identify different cell types and their functional
subsets. The major limitations of CFCs are the cost associated with the need for additional lasers and detectors, and, in most cases, the increase in instrument footprint to accommodate the additional hardware and electronics. The number of
fluorochromes that can be multiplexed and detected with the filter configurations implemented by the manufacturer can result in significant fluorescence emission overlap and loss of population resolution. Accordingly, users have to purchase and
install alternative filter configurations to collect different wavelength bands, requiring not only revalidation of instrument performance but also sophisticated knowledge of light collection paths and the impacts on sensitivity and resolution
resulting from these changes. Even with the implementation of filter changes, there are still major constraints on the number of biomarkers that can be successfully multiplexed to define a cell population, with the maximum number of colors currently
published using CFC at less than 30. With fewer detectable biomarkers, the detection of <FONT STYLE="white-space:nowrap">co-expression</FONT> of certain biomarkers is limited. Multiple tubes are required to investigate all biomarkers when the number
exceeds an instrument&#146;s capabilities, leading to the use of more samples and reagents, more time, and additional costs. The use of multiple tubes may also lead to missing the identification of specific unique subsets of a cell type, and
ultimately false or lost discovery of a phenotype. CFCs also use older technology for light collection, such as PMTs, which are in vacuum glass tubes similar to the vacuum tube transistors obsoleted by the computer industry half a century ago, and
are known to be costly and less quantum efficient, to vary in performance from device to device, and to perform poorly in the longer wavelengths of photons. Additionally, CFCs that are capable of more than 21 biomarkers are generally less
cost-effective, have a large footprint and require additional laboratory space. These drawbacks persist even for newer generation, <FONT STYLE="white-space:nowrap">re-engineered</FONT> PMTs, at an even higher cost than previous designs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Mass cytometry.</I> Another category of flow cytometry is mass cytometry, where fluorescence biomarkers are replaced with
heavy metals as a means of marker detection. Rather than laser excitation of fluorochromes, cells in suspension labeled with antibodies conjugated with heavy metal isotopes are injected into a&nbsp;nebulizer, which aerosolizes the cells into
droplets which are then introduced into an Inductively Coupled Plasma Mass Spectrometer <FONT STYLE="white-space:nowrap">(&#147;ICP-MS&#148;),</FONT> where the metals are ionized. These ionized metals are then separated using their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mass-to-charge</FONT></FONT> ratio by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-of-flight.</FONT></FONT> Unlike fluorescent probes, which often have overlapping
peak emissions, the masses of the purified metal isotypes are quite distinct and in general do not overlap. This allows for multiplexing of many more biomarkers conjugated to heavy metal isotopes of the lanthanide series of elements, enabling
researchers to expand the number of biomarkers in a panel to <FONT STYLE="white-space:nowrap">30-40.</FONT> However, this technology has notable drawbacks that were quickly recognized and limited broad adoption, including overall cost, large
footprint, and technical expertise required to operate the instrument. From a cost perspective, the cost of mass cytometers is generally <FONT STYLE="white-space:nowrap">2-3</FONT> times that of most flow cytometers. Additionally, because a mass
cytometer has a very large footprint compared to even the most <FONT STYLE="white-space:nowrap">high-end</FONT> CFCs, additional lab space and highly specialized facility infrastructure to support the ventilation of the mass spectrometer are
required. Compared to CFCs, the technical expertise needed to operate a mass cytometer is significantly higher, requiring a dedicated and specialized technician and it is generally not suitable for direct use by researchers. Cell analysis using a
mass spectrometer is also more time-consuming given its slower speed relative to other technologies. Destruction of cells as part of its process is another key shortcoming. While mass cytometry offers an expanded number of biomarkers for analysis,
these drawbacks have precluded many laboratories from considering investment in systems utilizing this technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Early approaches to spectral flow cytometry.</I> To address the limitations of CFC and mass cytometry, spectral flow
cytometry was introduced in 2012. The concept was based on the use of the entire fluorochrome spectrum as a <FONT STYLE="white-space:nowrap">read-out</FONT> to define one fluorescent labelled antibody biomarker from another. Due to the broad
overlapping nature of the fluorescence from various fluorochromes, there was a desire to add more granularity to the &#147;signature&#148; of the fluorescence emission profile to highlight the uniqueness of each fluorochrome. The first spectral flow
cytometer was commercially launched in 2012 and, unlike CFCs, is capable of reading more of the spectral signature of a fluorochrome than just its peak emission, which is the case for CFC, by using PMT arrays to collect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
diffracted light emitted spectrum for each fluorochrome <FONT STYLE="white-space:nowrap">co-excited</FONT> by multiple lasers. While novel, this early approach to spectral flow cytometry is
limited by its inability to obtain a high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio from detectors. This loss of sensitivity in the detectors compromised the ability to distinguish the
number of fluorochromes labeled on the same cells, thereby reducing the number of detectable fluorescent labelled antibody biomarkers available for multiplexing in a panel. The use of traditional PMTs, the same technology as that used by the CFC,
has lower quantum efficiency in converting photons to photon electrons, especially in the longer wavelengths, which adversely impacted the quality of the data. Further, the number of fluorescent-labeled antibody biomarkers detected by this early
spectral flow cytometer does not exceed the number detected on a CFC. For these reasons, the technology has a low rate of adoption and, to date, a limited number of publications regarding its use. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUR SOLUTION AND TECHNOLOGY </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of full spectrum flow cytometry</I></B>. To address the shortfalls of existing flow cytometry technologies, we
introduced the first full spectrum flow cytometer able to advance high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on
single cells, significantly advancing high-content cell analysis without sacrificing sensitivity. The full spectrum of each reagent fluorochrome in an assay is calibrated with its unique full spectrum signature, which is used to unmix the signals
from the multicolor labeling of an assay. This approach allows users to discern dyes in a multicolor sample, even those with highly overlapping peak emission spectra, leading to deeper biological insights because of the wider choice of fluorescent
labeled dyes that can be used to identify more cell populations of interest in a single sample. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our unique optical
design.</I></B> Data from our FSP instrument is generated by the collection of fluorescence spectrum from multiple laser excitation and the fluorescence from each laser source is collected by each corresponding detector array module. Each laser in
our instrument has an independent optical path and the number of detectors used is selected specifically to provide an optimized balance between high-sensitivity and accuracy. Our patented fluorescence detector module is based on our revolutionary
optical course wavelength division multiplexing strategy, where fluorescence is focused across arrayed detectors without aberrations in its reflection.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that every photon counts and, therefore, our design is aimed at minimizing loss of light to maximize resolution and
accuracy. Our unique optical design yields a sharp focus of laser light to yield a high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio, higher resolution and reduced cell coincidence, which is
critical for small particle detection. We utilize a patented uniform intensity profile <FONT STYLE="white-space:nowrap">flat-top</FONT> beam design that provides instrument stability with greater width illumination. The uniform intensity also
results in an increase in the fluidics core stream for an ultra-high sample flow rate. In addition, we use semiconductor-based APD detectors to enable maximized sensitivity, performance consistency across devices and broad wavelength response. The
combination of our patented optical design with APD detectors yields high-resolution data at an optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Our Unique Optical Design </U></B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g63h04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman" ALIGN="justify">(A)&#8194;&#8202;The fluorescence spectrum from each laser source is collected from
multiple laser excitation.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman" ALIGN="justify">(B)&#8194;&#8202;The fluorescence from each laser source is collected by
each corresponding detector array module.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman" ALIGN="justify">(C)&#8194;&#8202;Use of APD detectors maximizes
sensitivity and enables broad wavelength responses.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman" ALIGN="justify">(D)&#8194;&#8202;The combination of our
patented optical design with APD detectors yields high-resolution data at an optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Use of highly overlapping dyes with optimal resolution.</I></B> Our FSP technology is
unique in its ability to utilize the autofluorescence of cells as an additional informational parameter, which is a limitation of CFCs wherein the signals from the antibodies bound to the cells are obscured by autofluorescence. In addition, with our
FSP technology, high-content data is greatly enhanced through multiplexing of fluorochromes that are not otherwise compatible for use with CFCs. CFCs use one detector per fluorescent tag and light collection is coupled to a specific optical filter.
Commonly used detectors in CFCs have low detection efficiency&#151;not all light detected is effectively converted into a signal that is measurable. Therefore, the total number of fluorochromes that can be effectively used in combination is limited
by the number of detectors and lasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In CFCs, the emitted light of an excited fluorescent tag is detected only at the
peak emission wavelength and only from the excitation of one of the lasers (referred to as primary excitation). Light emitted at other wavelengths or generated from the excitation of other lasers present in the instrument is not used and, therefore,
information associated with that emitted light is lost. If two fluorescent tags have the same peak emission (maximum emission of light at the same wavelength post excitation with the same laser), then they are indistinguishable by CFCs. This means
that if each tag is associated with a different biomarker, the information from the fluorochromes will be merged and it would be impossible to differentiate the signal coming from one fluorochrome versus the other. For example, as illustrated below,
phycoerythrin (PE), a fluorochrome commonly used in flow cytometry because of its relative brightness, and cFluor YG584, a fluorochrome we recently developed, are efficiently excited by a specific laser (known as yellow-green, excitation at 561nm)
and both have a peak of emission around 580 nm. Using a CFC, the light emitted from each of these fluorochromes is detected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by the same detector and highly overlaps. From these results, the user would not be able to differentiate the signals and would lose valuable information for further analysis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g74z75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contrast, our FSP approach detects emitted light from an excited fluorescent tag across
the full range of wavelengths, including the peak emission wavelength, for all lasers present in the system (referred to as the full spectrum signature of a fluorescent tag). Because the wavelengths emitted across the excitation of all lasers is
detected by many highly sensitive optical detectors coupled to very narrow band optical filters, all light detected is effectively converted into a signal that is measurable and all information associated with the emitted light is leveraged to
define the full spectrum signature of any particular fluorochrome. With our technology, two fluorescent tags having the same peak emission but different emission characteristics outside the peak emission range are fully distinguishable. Accordingly,
if fluorescent tags are associated to different biomarkers, the information from multiple biomarkers will be easily separated and can be analyzed independently. Using the example discussed above, the full spectrum signature of both fluorochromes is
taken into consideration when using our FSP technology and, as illustrated below, the results will show that the two fluorochromes are indeed different. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g10w05.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, when labeling two antibodies (as used in the example below,
anti CD4 and anti CD25) with each of these fluorochromes, our FSP technology can easily unmix and analyze their signals without any loss of resolution, which cannot be achieved using a CFC. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g63c42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>First <FONT STYLE="white-space:nowrap">40-color</FONT> Optimized Multicolor
Immunofluorescence Panel.</I></B> To further illustrate the role of our FSP technology in the advancement of cell analysis, our platform yielded the first <FONT STYLE="white-space:nowrap">40-color</FONT> Optimized Multicolor Immunofluorescence Panel
(&#147;OMIP&#148;), as published by <I>Cytometry Part A</I> in 2020. OMIPs are panels that have been developed and validated to reproducibly provide the best possible data from a given set of fluorescent antibody conjugates and reagents in an assay
run on a specific instrument. Using our FSP technology, this OMIP was the first publication to go beyond <FONT STYLE="white-space:nowrap">28-color</FONT> fluorescence flow cytometry, exceeding OMIP panels published using mass cytometry. Even with a
comparable number of detected parameters which may be available through mass cytometry, our FSP technology provides the added benefits of higher throughput, robust population resolution and lower cost. The
<FONT STYLE="white-space:nowrap">40-color</FONT> panel presents a powerful solution covering almost the entire cellular composition of the human peripheral immune system with a single tube and will be particularly useful for studies in which sample
availability is limited or unique biomarker signatures are sought. The publication set a deep immunophenotyping benchmark for full spectrum flow cytometry, not only because of the high number of parameters achieved, but because of the quality of the
data and the approach for panel design and optimization using our developed tools. It also publicized an assay that can be reliably reproduced on our Aurora system by end users in their laboratories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OMIP complexity development </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g58e87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><I>The chart indicates the number of OMIPs published since 2010 and the level of complexity
as shown by the number of simultaneously analyzed colors or metal isotope tags using different technologies including, as highlighted, our FSP technology. As shown, the OMIP with the highest complexity capability was achieved in 2020 using our FSP
technology. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our patented integrated vacuum fluidics system.</I></B>&nbsp;All flow cytometers include a fluidics
system to transport cells from the sample tube to a viewing orifice (flow cell). It is the primary function of the fluidics subsystem to ensure this transport in a stable and consistent manner, such that single cells travelling through the viewing
orifice do so in a highly reproducible manner.&nbsp;This is achieved by precise control of the path and speed of cells within a transport media (sheath solution) flowing through the orifice.&nbsp;Unlike the pressure-based fluidics systems, our
Aurora and Northern Lights cytometers use a thermally compensated vacuum fluidics system to draw the sample and sheath through the viewing orifice, which regulates the total pressure drop across the viewing orifice while allowing a continuously
variable proportion of sheath to sample flow rates. Our integrated vacuum fluidics system ensures constant cell velocities while permitting variable cell event rates (sample flow rates). Sheath to sample proportioning is achieved by using our novel
linear valve that varies the resistance of the sheath path as the system regulates total flow through the viewing orifice.&nbsp;Through the use of <FONT STYLE="white-space:nowrap">non-pressurized</FONT> sheath and sample vessels, our vacuum fluidics
system provides users with flexibility in sample container format. Additionally, because of the single feedback loop regulation of our vacuum system to drive both sample and sheath fluids, our system is simpler, more compact, and has a more robust
fluidics architecture as compared to pressure-based systems of other flow cytometers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our FSP platform fulfills an unmet need in the scientific and research
communities by addressing limitations with existing technologies. The advantages of our platform are exemplified through the below table: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of Flow and Mass Cytometry Technologies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g70q42.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I>Based on peer-reviewed publications. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Cost-to-Performance</FONT></FONT>
reflects performance based on accessible biomarkers, sensitivity, throughput and sorting capabilities, relative to costs associated with instruments, consumables, time, labor and ability to reconfigure over time. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our platform</I></B>. Focusing on the needs of researchers for high-performing yet cost-effective tools for complex cell
analysis, our technology was developed to execute the full spectrum approach in flow cytometry and to advance the next generation of cell analysis. While other existing cell analysis technologies play a role in the overall support of cell analysis,
they are unable to competitively deliver to the depth required to address the complexity of cellular studies. The key differentiating features of our patented technology include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ultra-sensitive:</I></B> resolves the most challenging cell populations (such as cells with high
autofluorescence or low levels of expression of key biomarkers) by providing high-resolution data at the single-cell level at an optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratio.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Deep, high-integrity content:</I></B> allows development of highly complex assays through access to 40
different colors (and, by combining multiple biomarkers with a fluorochrome, more than 40 biomarkers) in a single tube without sacrificing precision and throughput to gain a deeper understanding of biological systems and arrive at faster and more
accurate diagnoses in clinical settings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Flexible and compatible:</I></B> enables a single configuration across a wide range of reagents and
applications, full backwards compatibility across panels, data consistency across instruments and sites, and greater leverage for downstream analysis with complementary technologies (such as NGS). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Efficient and compact:</I></B> improves costs and saves time while maintaining industry-leading
performance and efficient workflows that limit consumables usage and save time and labor costs&#151;all within a highly compact footprint, minimizing space requirements for laboratories. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Integrated and intuitive:</I></B> provides fully integrated workflows through a suite of solutions that
include instruments, reagents and kits, software and services. Our unique tools and the intuitive functionality of our proprietary SpectroFlo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> software, coupled with a user-friendly interface,
allow for enhanced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> and minimal operator training. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Workflow on our FSP platform. </I></B>Unlike many other technologies, existing flow cytometry approaches have never been
fully automated, and although the individual technical solutions required to achieve complete integration now exist, companies have not been able to bring a fully integrated solution to market. The need for an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> solution has never been greater, as, with the availability of more complex single-cell cytometry assays, the ability to reliably reproduce an assay has become much more difficult. The sheer number
of manual steps involved in assay production introduces unnecessary variability and the potential for error. Our platform provides a standardized, fully integrated FSP workflow solution, incorporating instruments, reagents, software and services to
provide a seamless <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> experience that will increase usage of high-dimensional cell analysis techniques by more end users and accelerate market adoption of our
FSP technology. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g63m25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">In-depth</FONT> analysis from biological samples to
comprehensive data sets using our systems and reagents can be completed in five steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">1.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Sample collection, preparation and labeling</I></B><B>.</B> As the first step in the workflow, users
collect, prepare and label their samples, whether blood, tissue, cell lines or otherwise. Our systems are compatible with a variety of particles in a range of sizes and can detect polystyrene particles as small as 80 nm. Users will then prepare a
single cell suspension to quickly isolate cells and label them with fluorescent reagents for flow cytometric acquisition. We have developed a number of tools, such as singular full spectrum viewers and our Similarity and Complexity indices, that
allow users to perform fluorochrome selection to optimize the results. We also have antibody combinations, including our <FONT STYLE="white-space:nowrap">14-color</FONT> cFluor immunoprofiling kit and <FONT STYLE="white-space:nowrap">40-color</FONT>
Optimized Multicolor immunofluorescence Panel that provide users with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> protocols and antibodies. Our expansive offering and integrated solution, which
leverages a single configuration that is highly adaptable, coupled with our high throughput capabilities all through a single tube, leads to considerable times savings for the end user. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">2.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Run Automated Instrument Quality Control Software.</I></B><I> </I>When the sample is fully labeled and
ready for analysis, users run the automated instrument quality control software integrated into our platform to monitor for optimal instrument performance. The software also performs mathematical calculations to ensure that measurements present in
the software from previously stored fluorescent controls are adjusted as needed based on the instrument performance check. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">3.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Sample acquisition in our FSP analyzer</I></B><B>.</B> Once quality control has been completed, users
can then load their samples into the instrument. Our instruments provide users with flexibility in their choice of vessel and are compatible with standard 12 x <FONT STYLE="white-space:nowrap">75-mm</FONT> tubes,
<FONT STYLE="white-space:nowrap">96-well</FONT> plates and deep-well plates. Users will be guided through the acquisition of needed controls and the multicolor sample(s) by our intuitive SpectroFlo software. The software also includes our developed
quality control tools, such as benchmark signatures and the Similarity and Complexity indices, to ensure that the controls are adequate and can be used to obtain optimal results. When running particles labeled with fluorochromes, the fluorochromes
will be excited by the lasers onboard the instrument, resulting in emission of light </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(photons) at different wavelengths. The photons are then collected by corresponding detector arrays. Our proprietary course wavelength division multiplexing design enables the collection of the
entire range of light emissions in an extremely compact space and has been engineered to ensure efficient collection of photons (minimal loss of light), resulting in highly accurate data. This unique optical strategy results in the collection of the
full emission spectrum for each fluorochrome attached to every particle that is run through the instrument. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">4.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Live unmixing</I></B><B>.</B> With our unmixing wizard&#151;a tool within our SpectroFlo<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>software, users can then easily complete spectral unmixing. An unmixing matrix is generated in real time when multicolor samples are run in the instrument, using either newly acquired controls or
controls previously stored in the software. Unlike spectral flow cytometry platforms, the live unmixing process allows users to quickly visualize data and statistics in real time. For each sample that is run, both raw and unmixed data are saved. Raw
data, where no unmixing is performed, contains all fluorescence information for each detector and can be unmixed as many times as needed, using different unmixing algorithms or our visual filter tool that presents the data as if being acquired from
a CFC. Unmixed data has been spectrally deconvolved to separate fluorochromes present on each particle based on a set of reference fluorochrome spectra and is ready for analysis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">5.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Data analysis</I></B><B>.</B> The data can then be used for advanced/unsupervised analysis. The FCS
files generated in our SpectroFlo software are compatible with all third-party software. We collaborate with partners to provide users with multiple workflows for data cleaning, dimensionality reduction and clustering algorithms, and artificial
intelligence to allow users to gain <FONT STYLE="white-space:nowrap">in-depth</FONT> information from their assays. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Significant base of peer-reviewed publications with strong continued growth showcasing our platform. </I></B>Since
developing our FSP platform, peer-reviewed publications have served to validate the importance and application of our technology in academic and clinical research settings, noting the improved resolution and enhanced deep phenotyping capability
available with full spectrum flow cytometry.<B><I> </I></B>To date, there have been more than 210 peer-reviewed articles published, including many published in high-impact journals, relating to our technology across a wide range of key scientific
research areas, including immunology and inflammation, infectious diseases, immune-oncology, oncology and others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cumulative
Publications by Quarter </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g98d25.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Other includes: Drug discovery and development, cardiovascular, neuromuscular, computational methods,
development biology, flow cytometry, genetic disorders, genomics, hematological disorders, immunometabolism, metabolism, musculoskeletal disease, neurobiology, pulmonary injury and veterinary sciences. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Includes Immunotherapy. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Selected applications of our platform. </I></B>Our FSP platform has
been used and published in a wide range of applications and <FONT STYLE="white-space:nowrap">end-markets.</FONT> A couple of notable applications that have been recently supported by peer-reviewed publications include: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Leukemia and lymphoma diagnosis and minimum residual disease monitoring.</I> Multiparameter flow cytometry assays are widely
used in leukemia and lymphoma (&#147;L&amp;L&#148;) diagnosis and also in the identification of residual leukemia cells following therapy, termed minimal residual disease (&#147;MRD&#148;). Although a CFC has traditionally been the preferred tool
for MRD testing due to its quicker turn around, lower cost, and phenotypic-shift monitoring, CFCs are less sensitive in MRD testing compared to other technologies. Our FSP platform addresses these shortcomings and can significantly advance MRD
monitoring capabilities by providing greater sensitivity and improved laboratory operational efficiency. With our FSP technology, the screening and diagnosis tubes used in MRD monitoring can be combined into one screening tube to identify all
lineage biomarkers (such as CD45 and CD19 for <FONT STYLE="white-space:nowrap">B-cell</FONT> lineage tumors), followed by one diagnosis tube for each lineage biomarker. By increasing the number of biomarkers that can be detected in a single tube,
more cells can be collected and analyzed per sample, resulting in higher sensitivity for MRD detection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In a 2020 study
published in <I>Current Protocols in Cytometry</I>, the author successfully demonstrated the detection of acute myeloid leukemia (&#147;AML&#148;) MRD using a <FONT STYLE="white-space:nowrap">3-tube</FONT> panel on a CFC. In a comparative study
using our Northern Lights CLC system, we were able to convert the <FONT STYLE="white-space:nowrap">3-tube</FONT> panel into a single tube panel with all unique biomarkers retained after removing the redundant biomarkers from the original panel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Combining three tubes into one tube reduced overall testing costs and markedly increased the sensitivity of MRD detection, as
more cells were able to be efficiently analyzed in a single tube. Furthermore, less sample material was required by reducing the overall tubes from three to one. This is an important benefit when tissue samples are limited, such as when using
pediatric tissue specimens. This internal comparative study concluded that our Northern Lights CLC <FONT STYLE="white-space:nowrap">(&#147;NL-CLC&#148;)</FONT> system was able to extract the same information from our single tube assay as from the
original <FONT STYLE="white-space:nowrap">3-tube</FONT> AML MRD assay used in the published study. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparable performance between <FONT
STYLE="white-space:nowrap">3-tube</FONT> assays with CFC and <FONT STYLE="white-space:nowrap">1-tube</FONT> assays with <FONT STYLE="white-space:nowrap">NL-CLC</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g35x58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Highlighting other benefits of our FSP technology, in an external study done in a KOL
laboratory in China, a <FONT STYLE="white-space:nowrap">17-color</FONT> screening tube with cell surface and intracellular markers covering all leukocyte lineages was developed and tested <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">side-by-side</FONT></FONT> with an established <FONT STYLE="white-space:nowrap">10-biomarker</FONT> screening tube run on a competing flow </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cytometer. Results from over 30 samples labeled with both panels and tested on the respective instruments demonstrated that the <FONT STYLE="white-space:nowrap">17-biomarker</FONT> tube run on
our Northern Lights CLC system provided more information to support diagnosis than the <FONT STYLE="white-space:nowrap">10-color</FONT> tube run on a competing flow cytometer. The <FONT STYLE="white-space:nowrap">17-biomarker</FONT> tube could not
be run on the competing flow cytometer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Infectious diseases</I>. Our platform has been applied across a range of
infectious diseases, some of which include <FONT STYLE="white-space:nowrap">COVID-19,</FONT> dengue fever and HIV. Specifically, the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has led researchers across the globe to pursue an <FONT
STYLE="white-space:nowrap">in-depth</FONT> investigation of the immune response to the virus. Working with KOLs around the world, we are supporting several critical studies with our technology to help scientists and clinicians understand the
protective immunity against <FONT STYLE="white-space:nowrap">COVID-19,</FONT> predict which patients are likely to have a more severe disease course, support clinical trials testing vaccine efficacy, and assess the likely future course of the
pandemic. Our FSP technology enables researchers to create highly complex panels, minimizing the amount of patient sample needed while simultaneously interrogating a large number of biomarkers and cell types in a high throughput manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, an article published in <I>Science</I> presents results from a study of 188 patients for up to eight months after
infection where the memory B cell, CD8+ T cell and CD4+ T cell response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> was analyzed. Using the Aurora system in combination with the detection of SARS <FONT STYLE="white-space:nowrap">CoV-2</FONT>
specific antibodies, the scientists were able to enumerate and fully characterize <FONT STYLE="white-space:nowrap">COVID-19</FONT> specific memory B and <FONT STYLE="white-space:nowrap">T-cells.</FONT> It was found that there was a high degree of
heterogeneity in the magnitude of the immune response but that 95% of subjects have presence of memory T and B cells for more than five months after infection. Interestingly, it was demonstrated that hospitalized patients have increased memory B
cells and, in contrast, a decreased T cell memory compartment. This is consistent with indications from other studies that hospitalized cases of <FONT STYLE="white-space:nowrap">COVID-19</FONT> can be associated with poorer T cell responses in the
acute phase of the infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Another recent key publication in <I>Immunity</I> highlighted the value of being able to
integrate our FSP platform with other complementary technologies. In this study, a high-dimensional <FONT STYLE="white-space:nowrap">34-color</FONT> FSP panel, which included one of our cFluor reagents, was run on a
<FONT STYLE="white-space:nowrap">5-laser</FONT> Aurora system to assess paired airway and blood from patients with severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> in a longitudinal study. With the ability to achieve a high level FSP panel
within a single tube, all assays were performed on the same sample, minimizing the amount of sample required. As a result, the authors had ample samples to perform additional analyses using other complementary technologies and, ultimately,
identified airway immune responses that correlate with age and outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other
<FONT STYLE="white-space:nowrap">COVID-19</FONT> studies using our FSP technology have focused on the B&nbsp;cell response and its link to levels of circulating antibodies. As published in <I>Nature</I>, a study using our technology examined the
B&nbsp;cell compartment in critically ill patients, and showed that a strong B&nbsp;cell response and high production of antibodies can be linked to an enhanced inflammatory response and, therefore, increased disease severity. In these studies, the
scientists combined the use of our FSP technology with genomics (cell sorting, single cell and bulk sequencing), and proteomics (cytokine and <FONT STYLE="white-space:nowrap">COVID-19</FONT> specific antibody immunoassays) to bring together the
immunological picture from the gene to the cell and the secreted proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These studies are guiding our development of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> immunophenotyping kits that will include the most relevant biomarkers associated with infection severity and patient outcome. We believe these and other collaborations will provide critical information
needed to understand the immune response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other infectious diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Longitudinal Immune Monitoring.</I> The process of drug development often requires the monitoring of key cellular
biomarkers in clinical trials. This is particularly true for drug development in the areas of immuno-oncology and immune-related disorders. Longitudinal patient monitoring is often performed on an array of biomarkers which are critical to the
understanding of the drug&#146;s impact on the immune system. To successfully carry out these studies, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-perform,</FONT></FONT> high-dimensional (many biomarkers), robust and
reliable flow cytometric approach is needed. <I>Cytometry Part&nbsp;A</I> recently published an <FONT STYLE="white-space:nowrap">in-depth</FONT> analysis of the performance of a <FONT STYLE="white-space:nowrap">25-marker</FONT> full spectrum immune
monitoring assay using our Aurora system. The study investigated <FONT STYLE="white-space:nowrap">intra-run</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
precision, biomarker stability, and the effects of sample processing on results. The researchers were able to take advantage of our Similarity and Complexity indices to efficiently design a
predictable, robust panel, and our embedded SpectroFlo software quality control tools to monitor the performance of reagents over time. The quality of the data they obtained allowed them to utilize unsupervised high-dimensional data analysis
platforms to analyze their data. The authors concluded from this study that our technology &#147;inherently empowers straightforward assessment of <FONT STYLE="white-space:nowrap">pre-analytical</FONT> reagent stability and compatibility&#148; and
noted the advantage of our fixed optical configuration and <FONT STYLE="white-space:nowrap">pre-optimized</FONT> assay settings to easily achieve multi-instrument standardization. The publication also highlighted the reproducibility of the data that
the researchers were able to obtain during their longitudinal study and our FSP platform&#146;s workflow development efficiencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applications of our FSP technology that have been showcased in peer-reviewed publications include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER:1px solid #000000; padding-left:8pt"><B>Field of Use</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Applications</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>End Market</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immuno-Oncology</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g80783g10a10.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(29 publications)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection of checkpoint inhibitors on tumor cells for development
of new cancer therapies and companion diagnostics</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CRO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharma</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diagnosis and detection of leukemia/lymphoma minimal residual
disease (MRD)</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection of DNA aneuploidy in tumor cells</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Allergy and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Autoimmunity</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g80783g10b99.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(23 publications)</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diagnosis and monitoring of autoimmune diseases</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection of allergies with fluorescent labeled antigen
constructs</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Infectious Diseases</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g10i25.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(44 publications)</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Monitoring cytokine expression in virus-infected <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> patients associated with disease state and vaccine
efficacy</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Academia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CRO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharma</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immunotherapy / Transplantation</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g80783g10z99.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(22 publications)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection of chimeric antigen receptor&nbsp;modified cells <BR><FONT
STYLE="white-space:nowrap">(CAR-T,</FONT> <FONT STYLE="white-space:nowrap">CAR-NK,</FONT> <FONT STYLE="white-space:nowrap">UCAR-T)</FONT> for cancer treatment and monitoring</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Academia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CRO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharma</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receptor occupancy and efficacy monitoring of therapeutic humanized
monoclonal antibodies</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Academia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monitoring for organ and tissue transplant rejection</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Blood Cell Disorders</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g11b87.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(4 publications)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diagnosis and monitoring of nocturnal paroxysmal
hemoglobinuria</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Monitoring of fetal hemoglobin red cells in sickle cell anemia</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Clinical</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER:1px solid #000000; padding-left:8pt"><B>Field of Use</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Applications</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>End Market</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immunology and Immunodeficiencies</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g11x22.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(29 publications)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection and monitoring the activation, exhaustion, viability,
and function of white blood cells</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Academia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detection of the presence and induction of cellular apoptosis</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Academia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deep phenotyping and enumeration of blood
leukocyte populations and subpopulations in disease diagnosis</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Academia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CRO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharma</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our process for driving new applications</I></B><B>.</B> We focus our research and
development efforts on the greatest value-additive FSP products to meet the growing and unmet needs of the research and clinical markets. Our highly skilled technical applications specialists work closely with researchers and clinicians to optimize
and implement new panels and applications to meet their specific needs. We also gain valuable insight on potential new products, new applications and enhancements to existing products, as well as biomarker combinations that would be beneficial in
different fields, through collaborations with our customers, academic laboratories, KOLs and industry partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Development of new fluorophores and antibody conjugates</I>. We are working with industry partners and KOLs to explore and
potentially <FONT STYLE="white-space:nowrap">co-develop</FONT> new fluorophores and antibody conjugates with unique spectral characteristics for use on our Aurora and Northern Lights systems. We evaluate unique fluorophore prototypes on our systems
to consider future development of additional products or processes. The ultimate goal of these projects is to identify and develop a larger range of conjugated antibodies that can be combined across each laser to increase the number of colors that
can be effectively used together, with optimal resolution, in laboratory research and clinical diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Nanobiology.</I> In recent years the field of nanobiotechnology, also known as nanobiology, has begun to emerge as an
important area of research and development. From the use of synthetic lipid-based nanoparticles for targeted drug delivery in cancer and vaccine delivery, to the study of biologically produced nanoparticles called extracellular vesicles
(&#147;EVs&#148;), new discoveries and applications are developing rapidly. There is currently a strong interest in the identification of specific EVs for use as biomarkers in disease prediction, progression and therapeutic monitoring, as they are
found in all body fluids, including blood and urine, making them a promising <FONT STYLE="white-space:nowrap">non-invasive</FONT> approach to disease management. In addition, as has been seen with the recent implementation of messenger ribonucleic
acid (&#147;RNA&#148;) <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines, the delivery of specific cargo to cells using synthetically derived nanoparticles has been shown to be an effective mode of delivery with little to no side effects.
Most CFCs were designed around the necessary sensitivity required for detection of the number of epitopes found on cells larger than 5um. The fluorescence and scatter sensitivity required to detect signals from these nanoparticles, which are
typically less than 100nm, is challenging for most CFCs. Typically, other flow cytometers struggle to detect biological particles below 150nm. With our recently released customized nanoparticle detection enhancement module, the optics on our already
sensitive system are enhanced, enabling scientists to detect biological particles down to the 100nm range. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
collaboration with some of the world&#146;s leading experts in EV analysis is driving the development of new tools for novel assays and optimized instrument settings for detecting an array of nanoparticles, including EVs, viruses, and liposomes. As
published in <I>Special Issue Journal of Pharmaceutics focused on Nano-Vaccine Systems for Anti-Cancer Therapy</I> late last year, our Aurora system was used in a collaboration to measure the delivery of a liposomal tumor antigen vaccine targeted to
CD169+ antigen presenting cells. The approach is important because the vaccine can be specifically delivered to cells of the immune system that can, in turn, enhance the activation of tumor-specific immune cells to deliver a robust anti-tumor
response, without activating other cells of the immune system <FONT STYLE="white-space:nowrap">non-specifically</FONT> to reduce any potential bystander side effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUR PRODUCTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a leading cell analysis solutions provider that develops compact, cost-effective full spectrum profiling instruments
with high multiplexing capability, and we offer a wide range of services to support scientists and clinicians. Our products are used in the world&#146;s most renowned pharmaceutical and clinical research organizations, as well as premier academic
and research institutions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Core Products</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Key Attributes</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Aurora System</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80783g12q33.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Full spectrum flow cytometer</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Commercially launched
in June 2017</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Highly flexible, intuitive and ultra-sensitive</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Available with three
to five lasers; ability to reconfigure over time</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Detects over 40 biomarkers in one sample tube</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Northern Lights System</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g12x66.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Full spectrum flow cytometer</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Commercially launched
in October 2018</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Highly flexible, intuitive and ultra-sensitive</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Available with one to
three lasers; ability to reconfigure over time</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Detects over 24 biomarkers in one sample tube</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Approved for clinical
use in China and the EU</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Aurora Cell Sorter</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g12z99.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Shipment began in June 2021</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Accommodates the same
number of parameters with the same sensitivity as the Aurora system</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Able to isolate living cell populations from lower to higher complexity panels beyond 40
biomarkers</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Core Products</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Key Attributes</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Reagents and Kits</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g70q94.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Commercially launched in October 2020</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Additional options
when choosing biomarkers to run together in a panel</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Simplifies the workflow from sample preparation to data analysis</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Evaluating <FONT
STYLE="white-space:nowrap">6-color</FONT> reagent cocktails for Class&nbsp;3 registration in China</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Automated Micro-Sampling System
(AMS)</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g50v97.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;AMS commercially launched in 2018</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Integrates seamlessly
into the Aurora and Northern Lights systems</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Fully customizable</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Three throughput modes</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Automated Sample Loader System (ASL)</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g19p42.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ASL commercially launched in June 2021</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Integrates seamlessly
into the Aurora and Northern Lights systems</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Fully customizable</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Three throughput modes</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Compatible with
40-tube racks</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SpectroFlo Software</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g80783g90d81.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Intuitive workflow</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Streamlines assay setup, data acquisition, and file export</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Live unmixing during
acquisitions</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aurora and Northern Lights Systems </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Aurora and Northern Lights systems were commercially launched in June 2017 and October 2018 respectively. Both instruments
are highly flexible, intuitive, and ultra-sensitive full spectrum flow cytometers, utilizing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> optics and <FONT
STYLE="white-space:nowrap">low-noise</FONT> electronics to provide excellent sensitivity and resolution, allowing researchers to resolve rare cell populations that were previously challenging to resolve. The optics and electronics designs, combined
with <FONT STYLE="white-space:nowrap">flat-top</FONT> beam profiles and a unique vacuum fluidics system, translate to outstanding performance from low to high sample flow rate, analyzing up to 35,000 events per second with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
certain configurations. Additionally, our optical design and unmixing algorithm make the instrument amenable to a wide array of applications and fluorochrome options, all without needing to
reconfigure the instrument hardware as would otherwise be required on a CFC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Aurora system is available with three to
five lasers and can detect more than 40 biomarkers in one sample tube. The Northern Lights system is available with one to three lasers and can detect more than 24 biomarkers in one sample tube. Both instruments are reconfigurable based on the
desired number of lasers, which drives greater or less access to biomarkers. In addition, both instruments incorporate our SpectroFlo&nbsp;software, which offers an intuitive workflow from quality control to sample acquisition to data analysis, with
technology-enabling tools that simplify running applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Aurora and Northern Lights systems are used in the
study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, inflammation, and drug discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Northern Lights CLC system was certified under the European Union In Vitro Diagnostic Medical Devices Directive (&#147;IVDD&#148;) in September 2020 and is registered as an in vitro diagnostic medical device under Northern Lights Clinical Flow
Cytometer. The certification enables the Northern Lights CLC system to be sold into in vitro diagnostic laboratories in the European Union and in other countries around the world that accept this specific certification. The Northern Lights CLC
system is also certified for in vitro diagnostic use as a Class&nbsp;II device in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aurora Cell Sorter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Key to the discovery of unraveling cellular complexity is the ability to perform additional downstream genomic and proteomic
studies on the specific subsets identified using high-dimensional phenotyping approaches. In June 2021, we began shipping our Aurora CS, which is the first highly flexible, intuitive and ultra-sensitive cell sorter that leverages the detection and
sensitivity capabilities of our FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers. Our FSP technology enables the processing of a tremendous amount of highly complex information to provide
real-time unmixing and sorting capabilities at the field-programmable gate array level. The implications are significant in terms of flexibility and user experience, including experiment workflow transportability and assay reproducibility, enabling
a <FONT STYLE="white-space:nowrap">40-biomarker</FONT> assay to be run in both the Aurora system and the Aurora CS, with similar results. With our technology, users can first identify cell populations and then isolate the live cells for downstream
studies, such as single-cell RNA sequencing, proteomics, and cell biology. We believe this new technology will enable users to gain a deeper level of cell classification, take advantage of key trends and scientific expansion, and allow for greater
applications in the research and clinical settings, such as with MRD, cell analysis and disease discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unlike other
high-capacity sorters, we believe the Aurora CS is the only sorter that can accommodate the same number of parameters with the same sensitivity as the Aurora, system and isolate living cell populations of interest using the same panel and without
having to alter the optical configuration, while also being able to sort panels designed for conventional analyzers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reagents and Kits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recently launched our reagent products to provide additional options for researchers and clinical laboratories when choosing
which biomarkers to run together in a panel, particularly since our Aurora, Northern Lights and Aurora CS systems allow for more fluorochromes to be run together than was previously commercially available. Our technology informed our fluorochrome
development through the identification of areas within the spectrum for which there were currently no available fluorochrome options. Our cFluor reagents are fluorochrome conjugated antibodies used to identify cells of interest for analysis on our
instruments. We offer and continue to develop cFluor immunoprofiling kits, which include the cFluor reagents and tools necessary to simplify the workflow from sample preparation to data analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Class&nbsp;1 registered single-color reagents are sold in China and we
are evaluating <FONT STYLE="white-space:nowrap">6-color</FONT> reagent cocktails that identify and determine the percentages and absolute counts of T, B, and natural killer cells in peripheral blood (&#147;TBNK reagents&#148;). We are currently
seeking approval to test the TBNK reagents in clinical trials in China. If the necessary China regulatory approvals are obtained without material delays, we expect to commence the clinical trials in September 2021, which are expected to be completed
approximately six months thereafter. If the results of the trials are supportive, we plan to seek Class 3 registration for the TBNK reagents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect these recent and planned reagent and application solutions to be a significant driver of our future reagent revenue
and pull-through as our installed base of instruments grows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Automated Micro-Sampling System and Automated Sample Loader System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Automated Micro-Sampling (&#147;AMS&#148;) system and Automated Sample Loader (&#147;ASL&#148;) system were commercially
launched in 2018 and 2021, respectively. The AMS and ASL systems are automated plate loaders designed to integrate seamlessly into the Aurora and Northern Lights systems to increase sample throughput and add automation capabilities while using our
FSP systems. The systems offer preset and fully customizable settings that allow the loader to be fine-tuned to each researcher&#146;s experimental requirements. Their reliable <FONT STYLE="white-space:nowrap">96-well</FONT> plate acquisition
solution maximizes productivity. The ASL also provides compatibility with 40-tube racks and suggested settings for each carrier type, which are fully customizable for unique applications and cell types to provide added versatility to researchers.
Both systems have three throughput modes (high- throughput, default, low carryover) to meet changing customer priorities and provide optional automation capability for our Aurora and Northern Lights systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>SpectroFlo</I></B><B></B><B><I> Software</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary SpectroFlo software is integrated into our systems and is unique in that it offers an intuitive workflow from
quality control to data analysis for our Aurora and Northern Lights systems. The software was developed specifically to streamline assay setup, data acquisition and file export and includes an automated quality control module. With the ability to
import a previously designed experiment template, users are able to quickly set up their experiments and there is no need to <FONT STYLE="white-space:nowrap">re-enter</FONT> or recreate controls, acquisition criteria, reagent information or data
analysis worksheets. With our SpectroFlo software, users can conveniently and efficiently achieve live unmixing during acquisitions and autofluorescence extraction, and can obtain raw and unmixed FCS 3.1 files, the data standard for flow cytometry.
With the SpectroFlo experiment workflow, users can start an experiment and gain data in three simple guided steps. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Customer Support Tools
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We strive to continually innovate by developing new quantitative tools, which are integrated into our software or
available to our customers free of charge on our website, to enable users to independently create high-color panels for use with our systems, to support efficient workflow solutions and to provide an intuitive user experience. As fluorochrome
(color) selection is a key component of assay development and optimization, our full spectrum viewer is a unique tool capable of displaying the full emission spectrum of a fluorochrome (emission at different wavelengths post-excitation with multiple
lasers). Our FSP technology provides an <FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of the fluorescence emission characteristics of nearly every color available in the market, and our full spectrum viewer provides users with
comprehensive information regarding emission characteristics of the fluorochromes to optimize fluorochrome selection for assay development. As a complementary tool to our full spectrum viewer, we have developed the Similarity and the Complexity
indices, which provide unique metrics for assessing fluorochrome compatibility within a panel. The Similarity index compares the emission spectrum of two dyes, identifying whether the dyes have unique characteristics or if the dyes are identical.
This in turn determines whether they can be used together to analyze a sample in a flow cytometry assay. The Complexity index is a metric that predicts how well a panel of colors will work in combination to minimize loss of resolution and
sensitivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DxP Athena </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our DxP Athena conventional flow cytometry system commercially launched in 2016 and is currently available for sale only in
China. It is certified for clinical use by China National Medical Products Administration. The DxP Athena system incorporates DxP technology with efficient PMTs to enable high sensitivity and high resolution, and our proprietary QbSure software to
ensure optimal daily instrument performance. The system is available in multiple configurations with one to three lasers and up to 13 fluorescence detection channels. The automated monthly clean bleach cycle minimizes downtime, streamlines
maintenance and encourages compliance. Our AMS can also be integrated with the DxP Athena system to increase sample throughput and add automation capabilities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SALES AND MARKETING</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We distribute our products through our direct sales force and support organizations located in North America, Europe, China
and several countries in the Asia-Pacific region, and through distributors or sales agents in several European, Latin American, Middle Eastern and Asia-Pacific countries. Our sales and marketing efforts are targeted at academic and governmental
institutions, CROs, pharmaceutical companies and clinical laboratories focused on single-cell analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our sales process
often involves interactions and demonstrations with multiple people within an organization. Some potential customers conduct <FONT STYLE="white-space:nowrap">in-depth</FONT> evaluations of the system, including running experiments on our system and
competing systems. In addition, in many countries outside of North America, sales to academic or governmental institutions require participation in a tender process involving preparation of extensive documentation and a lengthy review process. As a
result of these factors and the budget cycles of our customers, the sales cycle on our instrument, the time from initial contact with a customer to our receipt of a purchase order, can be six months or longer. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MANUFACTURING AND SUPPLY</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our manufacturing operations are located in Fremont, California and Wuxi, China. We commenced manufacturing operations in
Fremont, California in 2015. Our Fremont facility maintains ISO 9001 certification and manufactures our Aurora, Northern Lights and Aurora CS systems, as well as our reagents and spare parts. Our Wuxi manufacturing facility commenced operations in
2017 and maintains ISO 9001 and ISO 13485 certification. Our Wuxi facility also manufactures our instruments, reagents and spare parts and delivers certain instruments to our Fremont facilities for final assembly and testing. Our instruments and
reagents for clinical use are currently manufactured only in our Wuxi facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We established a manufacturing facility
in Wuxi, China to take advantage of the skilled workforce, supplier and partner network, lower operating costs and available government support. We are able to hire skilled employees from China&#146;s existing in vitro diagnostic and optical product
industry. China also has a broad network of potential suppliers and partners for our manufacturing operations and we are able to locally source a large portion of the raw materials required for our manufacturing processes. We have received incentive
grants from the local Wuxi government for research, development, and manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that having dual sources
for our products would help mitigate the potential impact of a production disruption at any one of our facilities to ensure a reliable and stable supply chain and product availability for our customers. We expect to relocate our Fremont headquarters
and manufacturing facility in the third quarter of 2021 to provide us with capacity expansion capability that will be sufficient to support our growth. We expect that our existing manufacturing capacity for instrumentation and reagents will be
sufficient to meet our anticipated needs for at least the next several years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on a limited number of suppliers
for certain components and materials used in our systems. Key components in our products that are supplied by sole or limited source suppliers include certain lasers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
semiconductors and mechanical components that are used in our optical, electrical and fluidic subassemblies. We do not currently have long-term supply contracts with the sole and single source
suppliers of these key components, and there are no minimum purchase or payment requirements. While we are in the process of qualifying additional sources of supply, qualifications can take 12 to 24 months and, in some cases, longer. If we were to
lose one or more of our sole or limited source suppliers, it would take significant time and effort to qualify alternative suppliers. Additionally, we believe we are not a major customer to most of our suppliers. These suppliers may therefore give
other customers&#146; needs higher priority than ours, and we may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMPETITION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face significant competition within the life sciences tools market. We currently compete with established and emerging life
sciences companies developing or commercializing flow cytometry and mass cytometry instruments, as well as other companies that design, manufacture and market instruments, consumables, reagent kits and software for, among other applications, cell
analysis, immunophenotyping, and cell sorting, and/or provide services related to the same. Our direct competitors include Agilent Technologies, Beckman Coulter (Danaher Corporation), Becton, Dickinson and Company,
<FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Fluidigm Corporation, Miltenyi Biotec, Sony Biotechnology (Sony Corporation) and Thermo Fisher Scientific. Our target customers may also elect to develop their workflows on CFCs, or using
traditional methods, rather than implementing our platform and may decide to stop using our platform. In addition, there are many large, established companies in the life sciences tools market that we do not currently compete with but that could
develop instruments, tools or other products that will compete with us in the future. These companies have substantially greater financial and other resources than we do, including larger research and development staff or more established marketing
and sales forces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For further discussion of the risks we face relating to competition, see the section titled &#147;Risk
factors&#151; Risks Related to Our Business and Strategy&#151;The market for cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive, and if we cannot compete successfully with our competitors, we may be
unable to increase or sustain our revenue, or achieve and sustain profitability.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INTELLECTUAL PROPERTY</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for our
commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how;</FONT> to defend and enforce our parents; to operate without infringing, misappropriating or violating our proprietary rights. We have developed our own
portfolio of issued patents and patent applications directed at our core and system level technology, including claims directed to methods and apparatus of flow cytometers and cell sorters with excitation, fluidics, emission, mechanical, magnetic,
electronics, bio-safety and temperature control technology in configurations of our Aurora, Aurora CS, Northern Lights and Northern Lights CLC systems. We generally seek patent protection in the United States, Japan, China and selected countries of
the European Union, such as France, Germany and the United Kingdom. Notwithstanding these efforts, we cannot be sure that patents will be granted with respect to any patent applications we have filed or may license or file in the future, and we
cannot be sure that any patents we own or license or patents that may be licensed or granted to us in the future will not be challenged, invalidated or circumvented or that such patents will be commercially useful in protecting our technology. For
more information regarding the risks related to our intellectual property, please see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we own seven issued U.S. utility patents and one issued Japan utility patent. We have 29 pending
utility patent applications, including 13 utility patent applications in the United States, six utility patent applications in the European Union, six utility patent applications in China and four utility patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applications in Japan. In April 2021, we filed two different provisional patent applications in the United States directed to technology integrated into our cell sorter. Assuming all maintenance
fees are paid, the U.S. issued patents are expected to naturally expire between years 2023 and 2038. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents
covering intellectual property relating to design-specific technologies invented by our researchers in Shanghai and Wuxi, China are filed in China and owned by our China subsidiaries, respectively. As of March&nbsp;31, 2021, our Shanghai subsidiary
owns 14 issued utility patents and has 9 pending invention patent applications, and our Wuxi subsidiary owns 17 issued utility patents and has nine pending patent applications, including two pending utility patent applications and seven pending
invention patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To our knowledge, there are no third party claims or contested proceedings with the issued
patents or pending patent applications other than the ordinary course proceedings with pending patent applications before the respective patent offices. However, the patent positions of companies like ours are generally uncertain and involve complex
legal and factual questions. Our patents may not enable us to obtain or keep any competitive advantage. Our pending U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be advantageous to us. Any patents
we have obtained or do obtain may be challenged by <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition or other administrative proceeding, or may be challenged in litigation, and such challenges could result in a determination that
the patent is invalid. In addition, competitors may be able to design alternative methods or devices that avoid infringement of our patents. Furthermore, numerous U.S. and foreign-issued patents and patent applications owned by third parties exist
in the fields in which our products compete. Because patent applications can take many years to publish, there may be applications unknown to us, which may result, in issued patents that our existing or future products or technologies may be alleged
to infringe. To the extent our intellectual property protection offers inadequate protection, or is found to be invalid, we are exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection
against our competitors&#146; products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Furthermore,
the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to pursuing patents on our technology, we have taken steps to protect our intellectual property and proprietary
technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide
meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized
disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success may depend in part on our <FONT STYLE="white-space:nowrap">non-infringement</FONT> of the patents or
proprietary rights of third parties. Third parties have asserted and may assert in the future that we are employing their proprietary technology without authorization. Competitors may assert that our products infringe their intellectual property
rights as part of a business strategy to impede our successful entry into those markets and there has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. In addition, our competitors
and others may have patents or may in the future obtain patents and claim that use of our products infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending any of these
claims. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a
successful claim of infringement against us, we may be required to pay damages, obtain one or more licenses from third parties, or be prohibited from selling certain products. We may not be able to obtain these licenses at a reasonable cost, if at
all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>KEY AGREEMENTS, LICENSES AND COLLABORATIONS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biotium, Inc. Supply and License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;1, 2020, we entered into a Supply and License Agreement with Biotium, Inc. (&#147;Biotium&#148;) pursuant to
which Biotium agreed to supply, and we obtained a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to market and resell to our customers and distributors, certain Biotium products to conjugate proteins and/or antibodies and
to use such conjugates as a component in our cFluor reagent products, for research and analyte-specific reagents (as defined by 21 CFR 864.4020) use only (the &#147;Field of Use&#148;) (the &#147;Biotium Agreement&#148;). In consideration for such
rights, we paid Biotium an upfront fee of $20,000 and will pay Biotium royalties at a mid-to-high single digit percentage rate on worldwide net sales on licensed products within the Field of Use. The Biotium Agreement terminates on the expiration of
the last to expire of the valid claims of the Biotium patents subject to the Biotium Agreement. Either party may terminate the Biotium Agreement for the other party&#146;s bankruptcy or uncured material breach or if no Biotium product is purchased
for an extended period; however, if such termination is by Biotium, we will have the opportunity to make a purchase following written notice from Biotium to avoid such termination. Our license under the Biotium Agreement does not include diagnostic
use, which may be added through an amendment and additional payment to Biotium. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Becton, Dickinson and Company Settlement, License and Equity
Issuance Agreement </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;13, 2018, BD filed a lawsuit against us alleging trade secret
misappropriation and copyright infringement. On October&nbsp;6, 2020, we entered into a Settlement, License and Equity Issuance Agreement with BD, pursuant to which we and BD agreed to a mutual release of all claims against each other as of the date
thereof (the &#147;BD Agreement&#148;). As part of the settlement, BD granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, perpetual, worldwide, and <FONT STYLE="white-space:nowrap">non-transferrable</FONT> license to
certain BD patents, and covenanted that it would not enforce, or permit or encourage the enforcement of BD patents against us or our affiliates in connection with the development, manufacture, use, importation, offer for sale or sale of our
then-current instruments. In exchange, we agreed that we and our affiliates would not dispute or challenge in a legal proceeding the validity, enforceability or scope of the applicable BD patent claims and agreed to make certain payments to BD,
including (i)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $2.0 million, (ii)&nbsp;a low single digit royalty payment for ten years, based on net sales of certain of our products, (iii)&nbsp;a $6.0 million milestone
payment upon the occurrence of a certain sales threshold, and (iv)&nbsp;a specified payment upon the closing of a change of control transaction, if any. We also issued 2,087,545 shares of our common stock to BD during the year ended
December&nbsp;31, 2020 in connection with the BD settlement. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>HUMAN CAPITAL RESOURCES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are focused on developing innovative products to meet unmet market needs and maintaining a diverse and inclusive work
environment where employees are respected and encouraged to share their unique perspectives and ideas. As of March&nbsp;31, 2021, we had 391 employees, of which 390 are full-time employees, including 107 employees in research and development, 79
employees in sales and marketing, 167 employees in manufacturing and operations, and 38 employees in general and administrative. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified
personnel. None of our employees is represented by is a labor union or are a party to a collective bargaining agreement and we believe that we have strong employee relations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Culture and Values </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We seek to maintain high ethical standards and a culture that values honesty, integrity, accountability and transparency in all
that we do. We are committed to our employees and to the communities we serve worldwide. It is our philosophy to foster open communication and our employees are encouraged to provide input on ways to improve our business strategy and tactics, work
environment and organization. We believe that our ability to provide employees with a dynamic environment and professional growth opportunities drives a culture embedded in our values. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Ethics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are committed to conducting our business activities with employees, consultants, vendors, customers, communities and
stockholders with integrity and fairness and in accordance with the highest ethical standards. We believe that our conduct has a direct impact on our reputation, our brand and our stakeholders. We are focused on ensuring that our legal, compliance
and risk mitigation protocols further enhance our ability to comport ourselves with the highest levels of ethical standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Talent Attraction,
Retention and Engagement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By focusing on individual performance, as well as teamwork and collaboration, we believe
that we foster an environment that helps employees excel as individuals and as team members. To further engage and incentivize our workforce, we offer programs and avenues for support, motivation and professional development. For example, we utilize
both <FONT STYLE="white-space:nowrap">instructor-led</FONT> training and online learning to deliver proprietary, targeted training courses designed to position our commercial organization as the leading cell analysis solutions provider. For our
talent pipeline development, we work closely with individual business functions to provide training and <FONT STYLE="white-space:nowrap">hands-on</FONT> support for managers and leaders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Philosophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We strive to provide comprehensive compensation, including cash, equity, benefits and services that attract, motivate and
retain exceptional employees. Compensation is driven by local market conditions, internal equity and employee performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Health and Wellness
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We offer a comprehensive package including: 401(k) plan with a company-match component, medical, dental and vision
insurance, life insurance, <FONT STYLE="white-space:nowrap">short-</FONT> and long-term disability insurance, 18 paid vacation days per year or flexible time off (depending on employee level), paid days for illness and family emergencies, and health
savings and flexible spending accounts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FACILITIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently lease approximately 12,000 square feet of office and laboratory space at our headquarters in Fremont, California
on a month-to-month basis. We plan to relocate our headquarters in the third quarter of 2021 to another facility in Fremont, California with approximately 99,000 square feet of office and laboratory space pursuant to a lease that is expected to
expire in December 2028. We lease approximately 40,000 square feet of manufacturing<B> </B>and office space at our facility in Wuxi, China, under leases expiring in May and October 2022 respectively, and approximately 14,000 square feet of office
and laboratory space at our facility in Shanghai, China, under multiple leases expiring between November 2021 and October 2022. We also lease office space in Seattle, Washington; Bethesda, Maryland; Beijing, China; and Amsterdam, Netherlands. We
believe that our existing office, laboratory and manufacturing space, together with additional space and facilities available on commercially reasonable terms, will be sufficient to meet our current and future needs. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ENVIRONMENTAL MATTERS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development and manufacturing processes involve the controlled use of hazardous materials, including
flammables, toxics, corrosives and biologics. Our research operations produce hazardous biological and chemical waste products. We seek to comply with applicable laws regarding the handling and disposal of such materials. Given the small volume of
such materials used or generated at our facilities, we do not expect our compliance efforts to have a material effect on our capital expenditures, earnings and competitive position. However, we cannot eliminate the risk of accidental contamination
or discharge and any resultant injury from these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
materials. We do not currently maintain separate environmental liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages and
suspension of our operations. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LEGAL PROCEEDINGS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. There are
currently no claims or actions pending against us, the ultimate disposition of which we believe could have a material adverse effect on our results of operations. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GOVERNMENT REGULATION AND PRODUCT APPROVAL</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Northern Lights system has been approved for clinical use in the European Union and China and we plan to continue
generating supporting publications and data, as well as pursue any required regulatory approvals for clinical use in the United States. In the United States, our products are currently labeled and promoted, and are, and in the near-future are
expected to continue to be, sold primarily to academic and research institutions and biopharmaceutical companies as research use only (&#147;RUO&#148;) products, and are not currently designed, or intended to be used, for clinical diagnostic tests.
However, as we continue to expand our product lines and the applications and uses of our existing products into new fields, certain of our current or future products could become subject to regulation by the United States Food and Drug
Administration (the &#147;FDA&#148;) or comparable international agencies, including requirements for regulatory clearance, authorization or approval of such products before they can be marketed. Also, even if our products are labeled, promoted and
intended as RUO, the FDA or comparable international agencies could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with RUO products. For
example, our customers may independently elect to use our RUO labeled products in their own laboratory-developed tests (&#147;LDT&#148;) for clinical diagnostic use, which could subject our products to government regulation, even if clinical uses of
our RUO products by our customers were done without our consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA regulation of medical devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design, development and manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">testing, labeling, content and language of instructions for use and storage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing, sales and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-market&nbsp;clearance</FONT> and approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advertising and promotion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls and field safety corrective actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they
were to recur, could lead to death or serious injury; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market approval studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product import and export. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, numerous laws and regulations govern all the processes by which medical devices are brought to market
and marketed. These include the FDCA and the FDA&#146;s implementing regulations, among others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">FDA&nbsp;pre-market&nbsp;clearance</FONT> and approval requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each medical device we seek to commercially distribute in the United States must first receive 510(k)
clearance,<I> de novo</I> classification, or approval of a <FONT STYLE="white-space:nowrap">pre-market</FONT> approval (PMA) application, from the FDA, unless specifically exempted. Both the 510(k) clearance and PMA processes can be resource
intensive, expensive and lengthy, and require payment of significant user fees, unless an exemption is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA
classifies all medical devices into one of three classes&#151;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&#151;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to
ensure its safety and effectiveness. Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices, which include
compliance with the applicable portions of the Quality System Regulation(&#147;QSR&#148;), facility registration and product listing, reporting of adverse medical events, and truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT>
labeling, advertising, and promotional materials. Class&nbsp;II devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls
can include performance standards, post-market surveillance, patient registries and additional conditions set forth in FDA guidance documents. While most Class&nbsp;I devices are exempt from the 510(k)
<FONT STYLE="white-space:nowrap">pre-market</FONT> notification requirement, manufacturers of most Class&nbsp;II devices are required to submit to the FDA a <FONT STYLE="white-space:nowrap">pre-market</FONT> notification under Section&nbsp;510(k) of
the FDCA requesting permission to commercially distribute the device. The FDA&#146;s permission to commercially distribute a device subject to a 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notification is generally known as 510(k)
clearance. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices are placed in Class&nbsp;III, requiring approval of a PMA application. Some
<FONT STYLE="white-space:nowrap">pre-amendment</FONT> devices are unclassified, but are subject to the FDA&#146;s <FONT STYLE="white-space:nowrap">pre-market</FONT> notification and clearance process in order to be commercially distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our products are expected to be classified as Class&nbsp;II devices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>510(k) clearance process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To obtain 510(k) clearance, we must submit <FONT STYLE="white-space:nowrap">a&nbsp;pre-market&nbsp;notification</FONT> to the
FDA demonstrating that the proposed device is substantially equivalent to a previously-cleared 510(k) device, a device that was in commercial distribution before May&nbsp;28, 1976 for which the FDA has not yet called for the submission of PMA
applications, or is a device that has been reclassified from Class&nbsp;III to either Class&nbsp;II or I. In rare cases, Class&nbsp;III devices may be cleared through the 510(k) process. The FDA&#146;s 510(k) clearance process usually takes from
three to 12 months from the date the application is submitted and filed with the FDA, but may take significantly longer, particularly for a novel type of product. Although many 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notifications
are cleared without clinical data, in some cases, the FDA requires significant clinical data to support substantial equivalence. In reviewing a <FONT STYLE="white-space:nowrap">pre-market</FONT> notification submission, the FDA may request
additional information, including clinical data, which may significantly prolong the review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA agrees
that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#147;not substantially equivalent&#148; to a
previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance
with the<I> de novo</I> classification process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. Once a<I> de novo</I> application is reviewed and
approved, it results in the device having a Class&nbsp;II status and future devices from the company or a competitor may use the company&#146;s<I> de novo-</I>classified device as a 510(k) predicate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety
or effectiveness, or that would constitute a major change in its intended use, will require a new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
510(k) clearance or could require a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree with a
manufacturer&#146;s determination. If the FDA disagrees with a manufacturer&#146;s determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA is obtained.
Under these circumstances, the FDA may also subject a manufacturer to significant regulatory fines or other penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include
increased requirements for clinical data and a longer review period, or could make it more difficult and costly for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced
forthcoming steps that the FDA intends to take to modernize the <FONT STYLE="white-space:nowrap">pre-market</FONT> notification pathway under Section&nbsp;510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals
to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially
publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than ten years old. The FDA also announced that it intends to finalize guidance to establish a <FONT
STYLE="white-space:nowrap">pre-market</FONT> review pathway for &#147;manufacturers of certain well-understood device types&#148; as an alternative to the 510(k) clearance pathway and that such <FONT STYLE="white-space:nowrap">pre-market</FONT>
review pathway would allow manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical
devices to specific predicate devices in the clearance process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2019, the FDA solicited public feedback on its
plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates, including whether the FDA should publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence
to predicate devices that are more than ten&nbsp;years old. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as
predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. More recently, in September 2019, the FDA finalized the
aforementioned guidance to describe an optional &#147;safety and performance based&#148; <FONT STYLE="white-space:nowrap">pre-market</FONT> review pathway for manufacturers of &#147;certain, well-understood device types&#148; to demonstrate
substantial equivalence under the 510(k) clearance pathway, by demonstrating that such device meets objective safety and performance criteria established by the FDA, obviating the need for manufacturers to compare the safety and performance of their
medical devices to specific predicate devices in the clearance process. The FDA intends to maintain a list of device types appropriate for the &#147;safety and performance based pathway&#148; and develop product-specific guidance documents that
identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain
regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>De novo classification process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Medical device types that the FDA has not previously classified as Class&nbsp;I, II, or III are automatically classified into
Class&nbsp;III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class&nbsp;III due to
the absence of a predicate device called the &#147;Request for Evaluation of Automatic Class&nbsp;III Designation,&#148; or the<I> de novo</I> classification procedure. This procedure allows a manufacturer whose novel device is automatically
classified into Class&nbsp;III to request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA
application. Prior to the enactment of the Food and Drug Administration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Safety and Innovation Act (FDASIA) in July 2012, a medical device could only be eligible for<I> de novo</I> classification if the manufacturer first submitted a 510(k) <FONT
STYLE="white-space:nowrap">pre-market</FONT> notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the<I> de novo</I> classification pathway by permitting manufacturers to
request<I> de novo</I> classification directly without first submitting a 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notification to the FDA and receiving a not substantially equivalent determination. FDA is required to classify the
device within 120 days following receipt of the<I> de novo</I> application. If the manufacturer seeks reclassification into Class&nbsp;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable
assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device
is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Pre-market&nbsp;approval</FONT> process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A PMA application must be submitted if the
medical device is in Class&nbsp;III (although the FDA has the discretion to continue to allow <FONT STYLE="white-space:nowrap">certain&nbsp;pre-&nbsp;amendment</FONT> Class&nbsp;III devices to use the 510(k) process) or cannot be cleared through the
510(k) process. A PMA application must be supported by, among other things, extensive technical, preclinical, and clinical trials, as well as manufacturing and labeling data to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness
of the device. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research Use Only </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our products and operations may be subject to extensive and rigorous regulation by the FDA and other federal, state, or local
authorities, as well as foreign regulatory authorities. Certain of our products are currently marketed as RUO. An RUO product is one that is not intended for clinical diagnostic use and must be labeled &#147;For Research Use Only. Not for use in
diagnostic procedures.&#148; RUO products cannot make any claims related to safety, effectiveness or diagnostic utility and they cannot be intended for human clinical diagnostic use. Products that are intended for research use only and are properly
labeled as RUO are exempt from compliance with the FDA requirements discussed above, including the approval or clearance and most QSR requirements. A product labeled RUO but intended to be used diagnostically may be viewed by the FDA as adulterated
and misbranded under the FDC Act and is subject to FDA enforcement activities. The FDA may consider the totality of the circumstances surrounding distribution and use of an RUO product, including how the product is marketed, when determining its
intended use. In November 2013 the FDA issued a guidance document entitled &#147;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#148; (RUO Guidance) which highlights the FDA&#146;s
interpretation that distribution of RUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently offer it for clinical diagnostic use as a
laboratory developed test is in conflict with RUO status. The RUO Guidance further articulates the FDA&#146;s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to
clinical laboratories, conflicts with RUO status. If the FDA were to determine, based on the totality of circumstances, that our products labeled and marketed for RUO are intended for diagnostic purposes, they would be considered medical products
that will require clearance or approval prior to commercialization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Laboratory-developed tests (LDTs) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">LDTs have generally been considered to be tests that are designed, developed, validated and used within a single laboratory.
The FDA takes the position that it has the authority to regulate such tests as medical devices under the FDC Act. The FDA has historically exercised enforcement discretion and has not required clearance or approval of LDTs prior to marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;3, 2014, the FDA issued two draft guidance documents regarding oversight of LDTs. These draft guidance
documents proposed more active review of LDTs. The draft guidance documents have been the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subject of considerable controversy, and in November 2016, the FDA announced that it would not be finalizing the 2014 draft guidance documents. On January&nbsp;13, 2017, the FDA issued a
discussion paper which laid out elements of a possible revised future LDT regulatory framework, but did not establish any regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA&#146;s efforts to regulate LDTs have prompted the drafting of legislation governing diagnostic products and services
that sought to substantially revamp the regulation of both LDTs and <I>in vitro</I> diagnostics, or IVDs. Congress may act to provide further direction to the FDA on the regulation of LDTs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pervasive and continuing U.S. Food and Drug Administration regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After a medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the QSR, which requires manufacturers to follow design, testing, control, documentation and other quality
assurance procedures during the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration, which requires establishments involved in the production and distribution of
medical devices, intended for commercial distribution in the United States, to register with the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device listing, which requires manufacturers to list the devices they have in commercial distribution
with the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect
safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it
markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the new federal law and regulations requiring Unique Device Identifiers (UDI) on devices and
also requiring the submission of certain information about each device to the FDA&#146;s Global Unique Device Identification Database; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling regulations, which prohibit &#147;misbranded&#148; devices from entering the market, as well as
prohibit the promotion of products for unapproved <FONT STYLE="white-space:nowrap">or&nbsp;&#147;off-label&#148;&nbsp;uses</FONT> and impose other restrictions on labeling; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance including Medical Device Reporting, which requires manufacturers report to the FDA if
their device may have caused or contributed to a death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA enforces these requirements by inspection and market surveillance. Failure to comply with applicable regulatory
requirements may result in enforcement action by the FDA, which may include one or more of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications for repair, replacement or refunds; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, injunctions, consent decrees and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandatory recall or seizure of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administrative detention or banning of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing our request for 510(k) clearance or PMA of new product versions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revocation of 510(k) clearance or PMAs previously granted; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution and penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The regulatory review process for medical devices varies from country to country, and many countries also impose product
standards, packaging requirements, environmental requirements, labeling requirements and import restrictions on devices. Each country has its own tariff regulations, duties, and tax requirements. Failure to comply with applicable foreign regulatory
requirements may subject a company to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, criminal prosecution or other consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our portfolio of products is regulated in the European Union as a medical device per the European Union Directive 93/42/EEC,
also known as the Medical Device Directive, or MDD. The MDD sets out the basic regulatory framework for medical devices in the European Union. The system of regulating medical devices operates by way of a certification for each medical device. Each
certified device is marked with the CE Mark which shows that the device has a Certificat de Conformit&eacute;. There are national bodies known as Competent Authorities in each member state which oversee the implementation of the MDD within their
jurisdiction. The means for achieving the requirements for the CE Mark vary according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the
conformity assessment required before the CE Mark can be placed on a product. Conformity assessments for our products are carried out as required by the MDD. Each member state can appoint Notified Bodies within its jurisdiction. If a Notified Body <FONT
STYLE="white-space:nowrap">of&nbsp;one-&nbsp;member</FONT> state has issued a Certificat de Conformit&eacute;, the device can be sold throughout the European Union without further conformance tests being required in other member states. The CE Mark
is contingent upon continued compliance with the applicable regulations and the quality system requirements of the ISO&nbsp;13485 standard. Our current CE Mark is issued by&nbsp;The Ministry of Health, Welfare and Sport in the Netherlands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the product has received the CE Mark and been placed on the market in the EEA, a manufacturer must comply with a number
of regulatory requirements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">registration of medical devices in individual EEA countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing and reimbursement of medical devices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of post-marketing surveillance and adverse event reporting procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">field safety corrective actions, including product recalls and withdrawals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interactions with physicians. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices
Directive. Unlike directives, which must be implemented into the national laws of the EEA member States, the regulations would be directly applicable, without the need for adoption of EEA member State
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
laws implementing them, in all EEA member States and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation,
among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro diagnostic devices and ensure a high level of safety and health while supporting
innovation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Medical Devices Regulation will however only become applicable three years after publication. The
effective date was further postponed by the European Commission for one year due to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> to May 2021. Once applicable, the new regulations will among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish explicit provisions on manufacturers&#146; responsibilities for
<FONT STYLE="white-space:nowrap">the&nbsp;follow-up&nbsp;of</FONT> the quality, performance and safety of devices placed on the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improve the traceability of medical devices throughout the supply chain to the&nbsp;end user&nbsp;or patient
through a unique identification number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo
an additional check by experts before they are placed on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that our products
have already been certified under the existing regulatory framework, the MDR allows us to market them provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. Under
article 120(2) MDR, certificates issued by notified bodies before May&nbsp;25, 2017 will remain valid until their indicated expiry dates. By contrast, certificates issued after May&nbsp;25, 2017 will be void at the latest by May&nbsp;27, 2024.
Accordingly, before that date, we will need to obtain new CE Certificates of Conformity. Furthermore, the regulation introduces UDI, a bar code that must be placed on the label of the device or on its packaging and manufacturers will be obligated to
file adverse effects reports via the Eudamed platform in case there is an increase in the frequency or severity of incidents related to the medical device. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other healthcare laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current and future business activities are subject to healthcare regulation and enforcement by the federal government and
the states and foreign governments in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims and physician sunshine laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting,
receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce either the referral of an individual, for an item or service or the purchasing, leasing, ordering, or arranging for or recommending the
purchase, lease or order of any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs. Although there are a number of statutory exceptions
and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or
recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se
illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> based on a cumulative review of all
its facts and circumstances. Several courts have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the
Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the civil False Claims Act prohibits, among other things, knowingly presenting or causing the presentation of a
false or fraudulent claim for payment to, or approval by, the U.S. government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having
knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government intervenes and is ultimately successful in obtaining
redress in the matter, or if the plaintiff succeeds in obtaining redress without the government&#146;s involvement, then the plaintiff will receive a percentage of the recovery. The federal government is using the False Claims Act, and the
accompanying threat of significant liability, in its investigation and prosecution of life sciences companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing
practices. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The
government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements,
it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to
have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The majority of states also have anti-kickback laws which establish similar prohibitions and, in some cases, may apply to
items or services reimbursed by any third-party payor, including commercial insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">HIPAA created new federal criminal
statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, a person or entity no longer
needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare
company may violate one or more of the requirements. If our future operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without
limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Foreign Corrupt Practices Act</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and their representatives from directly or
indirectly offering, promising, authorizing or making corrupt payments, gifts or transfers to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business. The scope of
the FCPA would include interactions with certain healthcare professionals in many countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information for our executive officers and directors as of April&nbsp;15, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Executive Officers</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wenbin Jiang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ming Yan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrik Jeanmonod</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Barnett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allen Poirson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Marketing&nbsp;&amp; Corporate Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Ball<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tess Cameron<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Feng Deng<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gisele Dion<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Wenbin Jiang, Ph.D. </I></B>has served as the Chief Executive Officer and a member of our board of directors since
December 2014. Dr.&nbsp;Jiang is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of our company. In 1998, Dr.&nbsp;Jiang <FONT STYLE="white-space:nowrap">co-founded</FONT> E2O Communications, Inc., a fiber optic subsystems manufacturing
company, which was acquired by JDS Uniphase Corporation in 2004. Dr.&nbsp;Jiang is an inventor of more than 95 U.S. patents and an author of five book chapters and over 50 peer-reviewed technical papers. Dr.&nbsp;Jiang holds a B.S. in Physics and
M.S. in Optics&nbsp;&amp; Laser Physics from Fudan University and a Ph.D. in Electrical Engineering from University of California, Santa Barbara. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Jiang&#146;s extensive experience as an executive in the technology industry provides him with the
qualifications and skills to serve on our board of directors and as our Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ming Yan, Ph.D.
</I></B>has served as the Chief Technology Officer and a member of the board of directors since 2015. Dr.&nbsp;Yan is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of our company. Dr.&nbsp;Yan has over 20 years of experience in research
and development. Prior to joining our company, Dr.&nbsp;Yan held research and development positions at AT&amp;T Bell Laboratories, a research and development division of AT&amp;T Communications, a telecommunication company, Lawrence Livermore
National Labs, a federal research facility and BD Biosciences, a biotechnology company. Dr.&nbsp;Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents
and pending patent applications for his innovations. Dr.&nbsp;Yan holds a B.S. in Physics from Fudan University and a Ph.D. in Electrical Engineering from the City University of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Yan&#146;s extensive experience in the biotechnology field, and in particular, with flow cytometry,
provides him with the qualifications and skills to serve on our board of directors and as our Chief Technology Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patrik Jeanmonod</I></B> has served as the Chief Financial Officer since November 2018. Prior to joining our company,
Mr.&nbsp;Jeanmonod served as Vice President of Finance at Core Brands, LLC, an electronic manufacturing company, from 2013 to 2018. Mr.&nbsp;Jeanmonod held executive positions in finance at various companies, including three leading contract
research organizations: Covance Inc., a pharmaceutical company, Bridge Pharmaceuticals, Inc., a drug development research organization, and Synteract, Inc., a contract research organization. Mr.&nbsp;Jeanmonod holds an M.S. in Business Management
from the University of Geneva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Valerie Barnett</I></B> has served as the General Counsel since January 2021 and
Corporate Secretary since April 2021. Ms.&nbsp;Barnett served as Vice President, Legal and Corporate Secretary at Dermira, Inc., a biopharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
company focused on dermatologic diseases, from 2015 to 2020 until its acquisition by Eli Lilly and Company. Ms.&nbsp;Barnett also served as Associate General Counsel at Fluidigm Corporation, a
biotechnology tools company, from 2011 to 2015. Prior to that, Ms.&nbsp;Barnett practiced law as a corporate and securities attorney at Wilson Sonsini Goodrich&nbsp;&amp; Rosati. Ms.&nbsp;Barnett holds a B.A. in Political Science from the University
of California, Irvine and a J.D. from Cornell Law School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Allen Poirson, Ph.D. </I></B>has served the Senior Vice
President, Marketing and Corporate Development since April 2021. Dr.&nbsp;Poirson also served as a member of our board of directors from August 2018 to March 2021. Immediately prior to joining Cytek&#146;s operational team, Dr.&nbsp;Poirson was the
Senior Vice President of Business Development at twoXAR, Inc, a biopharmaceutical company. Dr.&nbsp;Poirson also previously served as Chief Executive Officer and Chair of Sony Biotechnology Inc., a biotechnology company. Dr.&nbsp;Poirson&#146;s
domain expertise includes analytic instruments, computational biotechnology, medical devices, in vitro diagnostics, chemistry and software. Dr.&nbsp;Poirson has formal scientific training in neuroscience and has held research positions at Howard
Hughes Medical Institute, a non-profit medical research organization and NASA, a federal aeronautics and space research agency. Dr.&nbsp;Poirson holds a B.A. and a Ph.D. in Psychology from Stanford University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jack Ball </I></B>has served as a member of our board of directors since September 2018. Mr.&nbsp;Ball also serves as the
President of Tyball Associates LLC and serves on the board of directors of Carterra, Inc., a biotechnology company, NanoCellect Biomedical, Inc., a biotechnology company. From October 2010 to March 2021, Mr. Ball served on the board of directors of
Swift Biosciences Inc., a biotechnology company. From September 2013 to December 2019, Mr.&nbsp;Ball served as Chief Executive Officer and a board member at Solulink Inc., a biotechnology company. From February 2006 to July 2011, Mr.&nbsp;Ball was
Chief Commercial Officer at Accuri Cytometers, Inc., a medical instruments company, which was sold to Becton Dickinson&nbsp;&amp; Co in March 2011. Prior to that, Mr.&nbsp;Ball was Chief Executive Officer at Amnis Corporation, a biotechnology
company, Chief Commercial Officer at Molecular Probes, Inc., a biotechnology company, Senior Vice President and General Manager at Orchid Biosciences, a DNA testing services biotechnology company and President for North America at Amersham
Biosciences Corp., a healthcare company. Mr.&nbsp;Ball holds a B.S. in Agriculture from the University of Georgia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
believe that Mr.&nbsp;Ball&#146;s extensive experience as executives in flow cytometry instrument and reagent companies provides him with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Tess Cameron</I></B> has served as a member of our board of directors since April 2021. Ms.&nbsp;Cameron is the
Principal, Strategic Finance at RA Capital Management, LP. From January 2018 to June 2020, Ms.&nbsp;Cameron served as the Head of Finance of Foghorn Therapeutics, Inc., a pharmaceutical company. From January 2017 to January 2018, Ms.&nbsp;Cameron
served as the Director, Financial and Business Planning at WAVE Life Sciences Ltd., a biotechnology company. Prior to that Ms.&nbsp;Cameron was the Associate Director, Finance Business Planning and Senior Finance Manager at Biogen Inc., a
biotechnology company and worked at McKinsey&nbsp;&amp; Company, a management consulting company. Ms.&nbsp;Cameron holds a B.A. in Economics and Peace Conflict Studies from Victoria University, University of Toronto and graduated from the <FONT
STYLE="white-space:nowrap">Mini-MBA</FONT> program at the Tuck School of Business, Dartmouth College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that
Ms.&nbsp;Cameron&#146;s extensive experience in finance provides her with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Feng Deng </I></B>has served as a member of our board of directors since August 2018. Mr.&nbsp;Deng founded Northern
Light Venture Capital in 2005. Mr.&nbsp;Deng also serves as a member of the board of directors of Burning Rock Biotech Limited, a biotechnology company. Prior to Northern Light Venture Capital, he was a
<FONT STYLE="white-space:nowrap">co-founder</FONT> of NetScreen Technologies, a network security company, which went public on NASDAQ and was later acquired by Juniper Networks, a network equipment manufacturing company in 2004. Mr.&nbsp;Deng has
extensive technical and managerial experiences in computer, communication and data networking industries and holds numerous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
patents of invention in computer system architecture and integrated circuit design. Mr.&nbsp;Deng holds a B.S. and M.S. in electrical engineering from Tsinghua University, an M.S. in computer
engineering from the University of Southern California and an M.B.A. from the Wharton School, University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Mr.&nbsp;Deng&#146;s extensive experience in entrepreneurship and venture investment provides him with the
qualifications and skills to serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Gisele Dion </I></B>has served as a member of our
board of directors since March 2021. Ms.&nbsp;Dion was the Senior Advisor to the Chief Financial Officer of Takeda Pharmaceutical Ltd., a pharmaceutical company from March 2021 to June 2021. Prior to that, she served as the Senior Vice President,
Chief Accounting Officer and Corporate Controller at Takeda Pharmaceutical Ltd. from January 2019 to March 2021. Prior to that, Ms.&nbsp;Dion was the Senior Vice President, Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals
LLC, a biopharmaceutical company, from January 2016 to January 2019. From 2007 to January 2016, she served as Corporate Controller and Senior Director of Technical Accounting of Biogen Inc., a biotechnology company. Ms.&nbsp;Dion received a B.S. in
Accounting and Management Information Systems from Fairfield University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Ms.&nbsp;Dion&#146;s extensive
experience in finance and accounting provides her with the qualifications and skills to serve as a director of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The members of our board of directors were elected pursuant to the provisions of an amended and restated voting agreement dated
October&nbsp;23, 2020, as amended, or the Voting Agreement. Under the terms of the Voting Agreement, the stockholders who are party to the Voting Agreement have agreed to vote their respective shares so as to elect: (A)&nbsp;one director designated
by Northern Lights Venture Capital V, Ltd., currently Feng Deng; (B)&nbsp;one director designated by CTKBS Holdings Limited, currently vacant, (C)&nbsp;one director designated by entities affiliated with RA Capital Management, currently Tess
Cameron; (D)&nbsp;one director designated by the holders of a majority of the outstanding shares of common stock, currently Ming Yan; (E)&nbsp;the then-serving Chief Executive Officer, currently Wenbin Jiang; (F)&nbsp;two directors not otherwise
affiliated with us or our stockholders who are mutually acceptable to the other members of the board, currently Jack Ball and Gisele Dion; and (G)&nbsp;one vacancy. The Voting Agreement will terminate upon the closing of this offering, following
which none of our stockholders will have any special rights regarding the election or designation of members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction
to our management. Our board of directors meets on a regular basis and additionally as required. Our board of directors currently consists of six directors. Our amended and restated certificate of incorporation upon the closing of this offering,
will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. In accordance with our amended and restated certificate of incorporation upon the closing of this offering,
immediately after this offering, our board of directors will be divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the
time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be Tess Cameron and Feng Deng, and their terms will expire at our first annual
meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be Ming Yan, Ph.D. and Jack Ball, and their terms will expire at our second
annual meeting of stockholders following this offering; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be Wenbin Jiang, Ph.D. and Gisele Dion, and their terms will expire at our
third annual meeting of stockholders following this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that any additional
directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The
division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of our Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors believes that our stockholders and the company currently are best served by having Wenbin
Jiang,&nbsp;Ph.D., our chief executive officer, serve as chairman of the board of directors and Jack Ball serve as our lead independent director. Our board of directors believes that this board leadership structure provides effective independent
oversight of management while allowing the board of directors and management to benefit from Dr.&nbsp;Jiang&#146;s executive leadership and operational experience, including familiarity with our business as a founder and chief executive officer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The chairman of the board of directors has the authority, among other things, to call and preside over board of directors
meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. The lead independent director will preside over periodic meetings of our independent directors, coordinate with the committee chairs regarding
meeting agendas and informational requirements, serve as a liaison between the chairman of our board of directors and the independent directors and perform additional duties as set forth in our bylaws and as our board of directors may otherwise
determine and delegate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the listing requirements and rules of the Nasdaq Global Select Market, or Nasdaq, independent directors must comprise a
majority of our board of directors as a listed company within one year of the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of
directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, our board of directors has determined that Jack Ball, Tess Cameron,
Feng Deng and Gisele Dion do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined
under the applicable listing standards. In making these determinations, our board of directors considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other
facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares held by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions
described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance
committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of
directors may establish other committees as it deems necessary or appropriate from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee consists of Gisele Dion, Jack Ball and Tess Cameron. Our board of directors has determined that each member
of the audit committee satisfies the independence requirements under the Nasdaq </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
listing standards and including the heightened independence standards for members of the audit committee under Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. The
chair of our audit committee is Gisele Dion. Our board of directors has determined that Gisele Dion is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations and &#147;financially sophisticated&#148; within the meaning
of the Nasdaq listing standards. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable listing standards. In arriving at these determinations, our board of directors has examined
each audit committee member&#146;s scope of experience and the nature of his or her employment. For a description of the education and experience of each member of the audit committee, see
<FONT STYLE="white-space:nowrap">&#147;&#151;Non-Employee</FONT> Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary purpose of the audit
committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent
registered public accounting firm. Specific responsibilities of our audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing and/or assessing the selection, engagement, qualifications, independence and performance of a
qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our policies on risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, with our independent registered public accounting firm, our internal quality control procedures,
any material issues with such procedures and any steps taken to deal with such issues; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> audit and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee will operate under a written charter, to be effective prior to the closing of this offering, that
satisfies the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee consists of Jack Ball, Feng Deng and Gisele Dion. The chair of our compensation committee is Jack
Ball. Our board of directors has determined that each member of the compensation committee satisfies the independence requirements under the listing standards of Nasdaq, and is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. For a description of the education and experience of each member of the compensation committee, see
<FONT STYLE="white-space:nowrap">&#147;&#151;Non-Employee</FONT> Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary purpose of our compensation
committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior
management, as appropriate. Specific responsibilities of our compensation committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our chief executive officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements,
profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other senior management; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including
our overall compensation philosophy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee will operate under a written charter,
to be effective prior to the closing of this offering, that satisfies the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate
Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our nominating and corporate governance committee consists of Feng Deng and Tess Cameron. The
chair of our nominating and corporate governance committee is Feng Deng. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence requirements under the listing standards
of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairpersonship
of the board of directors and committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing developments in corporate governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#146; performance, including committees of the board
of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our nominating and corporate governance committee will operate under a written charter,
to be effective prior to the closing of this offering, that satisfies the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a code of business conduct and ethics, or the &#147;Code of Conduct, that applies to our directors,
officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the closing of this offering, our code of business conduct and
ethics will be available under the Corporate Governance section of our website at www.cytekbio.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments
to, or waivers from, any provision of the Code of Conduct. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a
part of this prospectus. We have included our website in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks
and Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of the compensation committee is currently or has been at any time one
of our officers or employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a
member of our board of directors or compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding the compensation earned by or paid to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors during fiscal year ended December&nbsp;31, 2020. Each of Wenbin Jiang, our President and Chief Executive Officer, and Ming Yan, our Chief Technology Officer, is also a member of our
board of directors, but did not receive any additional compensation for service as a director. The compensation earned by or paid to Dr.&nbsp;Jiang and Dr.&nbsp;Yan as named executive officers for the fiscal year ended December&nbsp;31, 2020 is set
forth below under &#147;Executive Compensation&#151;Summary Compensation Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Ball</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tess Cameron<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Feng Deng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gisele Dion<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Levin, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allen Poirson, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jiecheng Zhang<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of the option awards granted during the
fiscal year ended December&nbsp;31, 2020 under our 2015 Plan, computed in accordance with Financial Accounting Standard Board Accounting Standards Codification, Topic 718, or ASC Topic 718. The assumptions used in calculating the grant-date fair
value of the stock options reported in this column are set forth in Note 12 to our audited consolidated financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2020, each of Mr.&nbsp;Ball and Mr.&nbsp;Poirson held 39,999 shares of our common
stock. None of our other <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held any shares of our common stock as of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Cameron joined our board in April 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Dion joined our board in March 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Levin and Mr.&nbsp;Zhang joined our board in October 2020 and resigned from our board in April
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In April 2021, Dr.&nbsp;Poirson resigned from our board and became our Senior Vice President, Marketing and
Corporate Development. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors has approved a policy for setting annual non-employee director
compensation, which will take effect upon completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commencing with the first calendar quarter
following the closing of this offering, each non-employee director will receive an annual cash retainer of $40,000 for serving on our board of directors and the lead independent director of our board of directors will receive an additional annual
cash retainer of $30,000. The chairperson of the audit committee of our board of directors will be entitled to an annual cash retainer of $20,000, and each other member of the audit committee will be entitled to an annual cash retainer of $10,000.
The chairperson of the compensation committee of our board of directors will be entitled to an annual cash retainer of $15,000, and each other member of the compensation committee will be entitled to an annual cash retainer of $7,500. The
chairperson of the nominating and corporate governance committee of our board of directors will be entitled to an annual cash retainer of $10,000, and each other member of the nominating and corporate governance committee will be entitled to an
annual cash retainer of $5,000. All annual cash compensation amounts will be payable in equal quarterly installments in arrears, on the last day of each fiscal quarter for which the service occurred, pro-rated for any partial months of service. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each new non-employee director who joins our board of directors following
the closing of this offering will receive an option to purchase shares of common stock under the 2021 Equity Incentive Plan (&#147;2021 Plan&#148;) having a grant date fair value for financial accounting purposes (computed in accordance with
Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC, Topic&nbsp;718&#148;)) of $300,000 based on the Black-Scholes option-pricing model and an exercise price per share equal to the per share fair
market value of the underlying common stock on the date of grant. One thirty-sixth of the shares subject to the option will vest on a monthly basis over the three-year period following the date of grant, subject to the non-employee director&#146;s
continuous service with us on each applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the date of each annual meeting of our stockholders
following the closing of this offering, each continuing non-employee director will receive an option to purchase shares of common stock under the 2021 Plan having a grant date fair value for financial accounting purposes of $160,000 based on the
Black-Scholes option-pricing model and a per share exercise price equal to the per share fair market value of the underlying common stock on the date of grant. The shares subject to this option will vest upon the one-year anniversary of the grant
date, subject to the non-employee director&#146;s continuous service with us on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All then outstanding
non-employee director options will vest upon a change in control of us, subject to the non-employee director&#146;s continuous service with us through the date of our change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers for the fiscal year ended December&nbsp;31, 2020, consisting of our principal executive officer
and the next two most highly compensated executive officers, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wenbin Jiang, Ph.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ming Yan, Ph.D., our Chief Technology Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patrik Jeanmonod, our Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents all of the compensation awarded to our named executive officers during the fiscal year ended
December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wenbin Jiang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">241,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ming Yan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrik Jeanmonod</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of payments pursuant to our 2020 cash incentive bonus plan further described below. The 2020 target
bonus for Dr. Jiang, Dr. Yan and Mr. Jeanmonod was 40%, 35% and 35% of each of their base salary, respectively. The amounts reflect payout at 104% of each of Dr. Jiang, Dr. Yan and Mr. Jeanmonod&#146;s target bonuses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our
named executive officers during the fiscal year ended December&nbsp;31, 2020 under our 2015 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 12
to our audited consolidated financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 401(k) matching contributions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards as of December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of
December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;Per<BR>Share<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wenbin Jiang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/28/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/28/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/23/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ming Yan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/28/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/28/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/27/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/23/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrik Jeanmonod</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/11/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/10/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/23/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each of the equity awards was granted under the 2015 Plan, the terms of which plan is described below under
&#147;&#151;Employee Benefit and Stock Plans.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares subject to each option award vest over a four-year period, with 25% of the total number of shares
subject to the option vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, and the balance of the shares vesting in 36 equal monthly installments thereafter, subject to continued service
through each such vesting date. The option award is subject to an early exercise provision and is immediately exercisable as of the grant date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company, as defined in the JOBS Act. As an emerging growth company, we will be exempt from certain
requirements related to executive compensation, including, but not limited to, the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief
Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not maintain any nonqualified deferred compensation benefits for any of our employees. Our board of directors may elect
to provide our officers and other employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension and Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not sponsor any pension or defined benefit retirement plans for any of our employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of our named executive officers has executed our standard confidential information and invention agreement. Of our named
executive officers, only Mr. Jeanmonod has entered into a formal offer letter setting forth the terms and conditions of his employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Cash
Incentive Bonus Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We adopted a cash incentive bonus plan in 2020 to ensure a pay-for-performance ethic by closely
aligning a significant portion of our employees&#146; 2020 total cash compensation to our 2020 corporate performance (the &#147;2020 Bonus Plan&#148;). The 2020 Bonus Plan included a target bonus amount for each participant based on a specified
percentage of base salary, with the actual bonus payout based on the level of achievement of our 2020 corporate goals. Our 2020 corporate goals included achievement of a targeted 2020 revenue (total weighting of 80%) and targeted 2020 EBITDA (total
weighting of 20%). The 2020 Bonus Plan provided that achievement of at least 80% of the corporate goals and 80% of the revenue goal was required for any payout. The maximum payout was set at 110% of the bonus target. In January 2021, the Board
reviewed our 2020 corporate performance relative to the corporate goals and determined that we exceeded our 2020 corporate goals and approved a payout at 104% of the bonus target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Severance Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We adopted an amended and restated Severance Benefit Plan (&#147;Severance Plan&#148;), in July 2021, to provide specified
severance benefits to eligible executives, including our named executive officers, selected by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Severance Plan provides that if the employment of a &#147;covered
employee&#148; is terminated outside the period beginning three months prior to the date of a &#147;change in control&#148; and ending on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the change in control, or the &#147;change
in control period,&#148; by the company without &#147;cause&#148; (as such terms are defined in the Severance Plan), the covered employee will receive the following benefits, subject to signing and not revoking a release and continued compliance
with certain restrictive covenants and other agreements between the covered employee and the company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a lump sum payment equal to nine months of the covered employee&#146;s base salary (in the case of our chief
executive officer) or six months (for our other named executive officers); and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of COBRA premiums for a period of nine months (in the case of our chief executive officer) or six
months (for our other named executive officers) following the date of such termination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, during the
change in control period, a covered employee&#146;s employment with the Company is terminated either (1)&nbsp;by the company without cause or (2)&nbsp;by the covered employee for &#147;good reason&#148; (as such terms are defined in the Severance
Plan), the covered employee will receive the following benefits, subject to signing and not revoking a release: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a lump sum payment equal to 24 months of the covered employee&#146;s base salary (in the case of our chief
executive officer) or 12 months (for our other named executive officers); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a lump sum payment equal to 100% of the covered employee&#146;s target bonus for the applicable year of
termination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of COBRA premiums for a period of 24 months (in the case of our chief executive officer) or 12 months
(for our other named executive officers) following the date of such termination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vesting acceleration of 100% of the shares subject to the covered employee&#146;s outstanding equity awards
(with performance-based awards vesting at the target level). </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our named executive officers are eligible to participate in our employee benefit plans, including our paid time off,
medical, dental, vision, life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Retirement Savings Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy
certain eligibility requirements. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we make matching contributions or discretionary contributions to the 401(k) plan up to a maximum of 4.5% of an
eligible employee&#146;s annual compensation. The 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan under the Code. Our named executive officers are eligible to participate in the 401(k)
plan on the same basis as our other employees and defer a portion of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through payroll contributions to the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Equity Incentive
Plan </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted the 2021&nbsp;Plan in July 2021, and our stockholders approved the 2021
Plan in July 2021. The 2021 Plan will become effective upon the execution of the underwriting agreement for this offering. The 2021 Plan will be the successor to our 2015 Equity Incentive Plan (&#147;2015 Plan&#148;), which is described below. Once
the 2021 Plan becomes effective, no further grants will be made under the 2015 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Types of</I><I> </I><I>A</I><I>wards</I>. Our 2021 Plan provides for the
grant of incentive stock options (&#147;ISOs&#148;), nonstatutory stock options (&#147;NSOs&#148;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based awards and other awards, or collectively, awards.
ISOs may be granted only to our employees, including our officers, and the employees of our affiliates. All other awards may be granted to our employees, including our officers, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and
consultants and the employees and consultants of our affiliates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. The maximum number of
shares of common stock that may be issued under our 2021 Plan is 18,000,000 shares. The number of shares of common stock reserved for issuance under our 2021 Plan will automatically increase on January&nbsp;1 of each year, beginning on
January&nbsp;1, 2022, and continuing through and including January&nbsp;1, 2031, by 4% of the total number of shares of common stock outstanding on December&nbsp;31 of the immediately preceding calendar year, or a lesser number of shares determined
by our board of directors prior to the applicable January&nbsp;1. The maximum number of shares that may be issued upon the exercise of ISOs under our 2021 Plan is 54,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares issued under our 2021 Plan will be authorized but unissued or reacquired shares of common stock. Shares subject to
awards granted under our 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2021 Plan. Additionally, shares
issued pursuant to awards under our 2021 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant
under our 2021 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In any fiscal year following the closing of our initial public offering, the maximum number of
shares of common stock subject to stock awards granted under the 2021 Plan or otherwise during any fiscal year to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees paid by us to such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director during such fiscal year for service on the board of directors, will not exceed $750,000 in total value (calculating the value of any such stock awards based on the grant date fair value of such
stock awards for financial reporting purposes). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan</I><I> Administration</I>. Our board of directors, or a duly
authorized committee of our board, may administer our 2021 Plan. Our board of directors has delegated concurrent authority to administer our 2021 Plan to the compensation committee under the terms of the compensation committee&#146;s charter. We
sometimes refer to the board of directors, or the applicable committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to
(1)&nbsp;designate employees (other than officers) to receive specified awards, and (2)&nbsp;determine the number of shares subject to such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike
price of awards, if any, the number of shares subject to each award, the fair market value of a share of common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any,
payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, subject to the terms of the 2021 Plan, the administrator also has the power to modify outstanding awards under our 2021 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel and <FONT
STYLE="white-space:nowrap">re-grant</FONT> any outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting
principles, with the consent of any materially adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>. ISOs and NSOs are
granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, within the terms and conditions of the 2021 Plan, provided that the exercise price of a stock option
generally cannot be less than 100% of the fair </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
market value of our common stock on the date of grant. Options granted under the 2021 Plan vest at the rate specified in the stock option agreement as specified in the stock option agreement by
the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines the term of stock options granted under the 2021 Plan, up to a maximum of
ten years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the
optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that either an exercise of the option or an immediate sale of shares acquired upon
exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability or
death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of
death. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the
administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if
it is an NSO and (5)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options may not be transferred to
third-party financial institutions for value. Unless the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order. An optionholder may
designate a beneficiary, however, who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tax Limitations
on ISOs</I>. The aggregate fair market value, determined at the time of grant, of common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed
$100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or
that of any of our parent or subsidiary corporations, unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five
years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards</I>. Restricted stock awards are granted pursuant to restricted
stock award agreements adopted by the administrator. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to us or our affiliates or any other form of legal consideration. Common stock
acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such
terms and conditions as set by the administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant&#146;s cessation of continuous
service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted pursuant to
restricted stock unit award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by
a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted
pursuant to stock appreciation right grant agreements adopted by the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of common stock on
the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of common stock on the date of exercise over the strike price,
multiplied by (2)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement
as determined by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines the term of stock appreciation rights granted under the
2021 Plan, up to a maximum of ten years. Unless the terms of a participant&#146;s stock appreciation right agreement provide otherwise, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than
cause, disability or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that
exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a
participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of
death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be
exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards</I>. Our 2021 Plan permits the grant of
performance-based stock and cash awards. The compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of certain
<FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or
otherwise based on, the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The performance goals may be based on any measure of performance selected by the
board of directors. The compensation committee may establish performance goals on a company-wide basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or relative to the
performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the
performance goals at the time the goals are established, the compensation committee will appropriately make adjustments in the method of calculating the attainment of the performance goals as follows: (1)&nbsp;to exclude restructuring and/or other
nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to
exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures;
(7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of
common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change,
or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with
potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally
accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other </I><I>A</I><I>wards</I>. The administrator may grant other awards based in
whole or in part by reference to common stock. The administrator will set the number of shares under the award and all other terms and conditions of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. In the event there is a specified type
of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2021 Plan; (2)&nbsp;the class
and maximum number of shares by which the share reserve may increase automatically each year; (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of ISOs and (4)&nbsp;the class and number of shares and exercise
price, strike price, or purchase price, if applicable, of all outstanding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. The
following applies to stock awards under the 2021 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise
expressly provided by the administrator at the time of grant. Under the 2021 Plan, a corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other
disposition of at least 50% of our outstanding securities, (3)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation or (4)&nbsp;a merger, consolidation or similar transaction following which we are
the surviving corporation but the shares of common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be assumed, continued or
substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or
acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the
effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the corporate transaction (contingent
upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with
respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable)
prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction.
In addition, the plan administrator may also provide, in its sole discretion, that the holder of a stock award that will terminate upon the occurrence of a corporate transaction if not previously exercised will receive a payment, if any, equal to
the excess of the value of the property the participant would have received upon exercise of the stock award over the exercise price otherwise payable in connection with the stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A stock award may be subject to additional acceleration of vesting and exercisability upon or after a change in control as may
be provided in an applicable award agreement or other written agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability</I>. A participant may not
transfer awards under our 2021 Plan other than by will, the laws of descent and distribution or as otherwise provided under our 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment or Termination</I>. Our board has the authority to amend, suspend or terminate our 2021&nbsp;Plan, provided
that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth
anniversary of the date our board adopted our 2021 Plan. No awards may be granted under our 2021 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors and our stockholders adopted the 2015 Plan in March 2015. The 2015 Plan was subsequently amended and
restated from time to time, most recently in October 2020. As of March&nbsp;31, 2021, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
under the 2015 Plan, options to purchase 6,559,712 shares of common stock were outstanding, and 6,057,200 shares of common stock remained available for future grants under our 2015 Plan. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effective date of the 2021 Plan, no additional awards will be granted under the 2015 Plan, which will be
terminated on such date. However, any outstanding awards granted under the 2015 Plan will remain outstanding, subject to the terms of the 2015 Plan and the applicable award agreements, until such outstanding options are exercised or until any awards
terminate or expire by their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>. The 2015 Plan provides for the grant of ISOs, NSOs, stock appreciation
rights, restricted stock awards, restricted stock unit awards and other stock awards, or collectively, awards. Awards may be granted to directors, employees and consultants; however, ISOs may be granted only to individuals who are employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. Our board of directors administers and interprets the provisions of the 2015 Plan. The board of
directors may delegate its authority to a committee of the board, and the board or the delegate is referred to as the &#147;plan administrator.&#148; Under our 2015 Plan, the plan administrator has the authority to, among other things, determine
award recipients, grant awards, establish all terms and conditions of awards (including, but not limited to, vesting, exercise and forfeiture provisions), adopt, amend and repeal such administrative rules, guidelines and practices relating to the
2015 Plan, correct any defect or ambiguity, and supply any omission or reconcile any inconsistency in the 2015 Plan or any award. The plan administrator has the authority to reprice&nbsp;any outstanding stock award, cancel <FONT
STYLE="white-space:nowrap">and&nbsp;re-grant&nbsp;any</FONT> outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting
principles, with the consent of any adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>. Stock options are generally
granted by our plan administrator pursuant to option grant notices and stock option agreements. The exercise price of a stock option will not be less than the market value of our common shares on the date of grant, in accordance with the terms and
conditions of the 2015 Plan. The plan administrator may attach other terms and conditions to a specific option grant, pursuant to the 2015 Plan. Our plan administrator determines the term of stock options granted under the 2015 Plan, up to a maximum
of ten years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the
optionholder may generally exercise any vested options for a period of three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider
trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally
exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options
for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. However, in no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards</I>. A restricted stock unit award may be settled by cash, delivery of stock, a combination of
cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration as determined by the Board and set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in
respect of shares covered by a restricted stock unit award, as determined by the Board and set forth in the restricted stock unit award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards</I>. The plan administrator determines the terms and conditions of restricted stock awards,
including vesting and forfeiture terms. Participants holding shares of restricted stock may be entitled to receive any dividends paid with respect to such shares subject to the same vesting and forfeiture restrictions as apply to the shares covered
by the restricted stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Stock Awards</I>. The plan administrator may grant other awards
based in whole or in part by reference to, or otherwise based on, our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. In the event of a capitalization adjustment, the board of directors will make appropriate
and proportionate adjustments to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2015 Plan, (2)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, and (3)&nbsp;the class and number
of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. For purposes of the 2015 Plan, capitalization adjustment generally means any change that is made in (or other events occurring with
respect to) our common stock subject to the 2015 Plan or any award without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, <FONT
STYLE="white-space:nowrap">large&nbsp;non-recurring&nbsp;cash</FONT> dividend, stock split, reverse stock split, liquidating dividend, combination or exchange of shares, change in corporate structure, or other similar equity restructuring
transaction (within the meaning of FASB&nbsp;ASC Topic&nbsp;718). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. Our 2015 Plan provides
that in the event of a corporate transaction, unless otherwise provided in an award agreement or other written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect to such
awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring
corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring
corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not
exercised (if applicable) at or before the effective time of the corporate transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the lapse of any reacquisition or repurchase rights held by us with respect to the stock award;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or exercised before the
effective time of the corporate transaction, in exchange for such cash consideration, if any, as the board of directors may consider appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make a payment equal to the excess, if any, of (1)&nbsp;the value of the property the participant would have
received on exercise of the award, over (2)&nbsp;any exercise price payable by the participant in connection with the exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator is not obligated to treat all stock awards in the same manner and is not obligated to treat all
participants in the same manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the 2015 Plan, a corporate transaction is generally defined as the consummation,
in a single transaction or in a series of related transactions, of: (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;the sale or disposition of at least 90% of our outstanding securities, (3)&nbsp;a merger or
consolidation where we do not survive the transaction, or (4)&nbsp;a merger, consolidation or similar transaction where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or
exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Change in Control</I>. A stock award may be subject to
additional acceleration of vesting and exercisability upon or after a change in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. Under the
2015 Plan, a change in control is generally defined as (1)&nbsp;the acquisition by a person or entity of more than 50% of the combined voting power of our then outstanding stock other than by merger, consolidation or similar transaction, (2)&nbsp;a
consummated merger, consolidation or similar transaction in which our stockholders immediately before the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as
their ownership immediately prior to such transaction, (3)&nbsp;our stockholders approve or our board of directors approves a plan of complete dissolution or liquidation or a complete dissolution or liquidation otherwise occurs except for a
liquidation into a parent corporation, (4)&nbsp;a consummated sale, lease, exclusive license or other disposition of all or substantially all of our consolidated assets other than to an entity more than 50% of the combined voting power of which is
owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction, or (5)&nbsp;a majority of the members of the board of directors is replaced by directors
whose appointment or election is not endorsed by a majority of the members of the board of directors serving immediately prior to such appointment or election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability</I>. Except as otherwise permitted by the plan administrator and the 2015 Plan terms, a participant may not
transfer stock awards under our 2015 Plan other than by will, the laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and
Termination</I>. Our plan administrator may (i)&nbsp;amend the 2015 Plan and the terms of any award granted under the 2015 Plan from time to time or (ii)&nbsp;terminate the 2015 Plan any time, provided that any amendment will not materially and
adversely affect participants without their consent. Certain material amendments also require the approval of our stockholders. No awards may be granted after the tenth anniversary of the date our board of directors adopted our 2015 Plan. As
described above, our 2015 Plan will be terminated upon the effective date of the 2021 Plan and no future awards will be granted under the 2015 Plan following the effectiveness of the 2021 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted the 2021 Employee Stock Purchase Plan (&#147;ESPP&#148;) in July 2021, and our stockholders
adopted the ESPP in July 2021. The ESPP will become effective upon the execution of the underwriting agreement for this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees and to
provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP includes two components. One component is designed to allow our eligible U.S. employees to purchase common stock in a manner
that may qualify for favorable tax treatment under Section&nbsp;423 of the Internal Revenue Code. In addition, purchase rights may be granted under a component that does not qualify for such favorable tax treatment when necessary or appropriate to
permit participation by our eligible employees who are foreign nationals or employed outside of the United States while complying with applicable foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>A</I><I>uthorized Shares.</I> The maximum aggregate number of shares of common stock that may be issued under our ESPP is
2,000,000 shares. The number of shares of common stock reserved for issuance under our ESPP will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2022 and continuing through and including January&nbsp;1,
2031, by the lesser of (1) 1% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year, (2) 5,000,000 shares and (3)&nbsp;a number of shares determined by our board. Shares subject to purchase
rights granted under our ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under our ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan</I><I> Administration. </I>Our board, or a duly authorized committee thereof, will administer our ESPP. The ESPP is
implemented through a series of offerings with specific terms approved by the administrator and under which eligible employees are granted purchase rights to purchase shares of common stock on specified dates during such offerings. Under the ESPP,
we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of common stock will be purchased for our eligible
employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Payroll Deductions</I>. Generally, all regular employees, including
executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to the maximum amount of their earnings (as defined in the ESPP) specified by our
board of directors for the purchase of common stock under the ESPP. Unless otherwise determined by the administrator, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share equal to the lower of
(a) 85% of the fair market value of a share of common stock on the first date of an offering or (b) 85% of the fair market value of a share of common stock on the date of purchase. For the initial offering, which we expect will commence upon the
execution and delivery of the underwriting agreement relating to this offering, the fair market value on the first day of the initial offering will be the price at which shares are first sold to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitations</I>. Our employees, including executive officers, or any of our designated affiliates may have to satisfy one
or more of the following service requirements before participating in our ESPP, as determined by the administrator: (1)&nbsp;customary employment with us or one of our affiliates for more than 20 hours per week and more than five months per calendar
year, or (2)&nbsp;continuous employment with us or one of our affiliates for a minimum period of time, not to exceed two years, prior to the first date of an offering. An employee may not be granted rights to purchase stock under our ESPP if such
employee (1)&nbsp;immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of common stock, or (2)&nbsp;holds rights to purchase stock under our ESPP that would accrue at a rate that exceeds
$25,000 worth of our stock for each calendar year that the rights remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital
Structure</I>. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash,
large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or similar transaction, the board of directors will make appropriate adjustments to (1)&nbsp;the class and number of
shares reserved under the ESPP, (2)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year, (3)&nbsp;the class and number of shares and purchase price of all outstanding purchase rights and
(4)&nbsp;the class and number of shares that are subject to purchase limits under ongoing offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate
Transactions</I>. In the event of certain corporate transactions, including: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or
consolidation where we do not survive the transaction, and (4)&nbsp;the consummation of a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or
exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving
or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of common stock within 10 business days
prior to such corporate transaction, and such purchase rights will terminate immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>ESPP </I><I>Amendment
or</I><I> </I><I>T</I><I>ermination</I>. The administrator has the authority to amend or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights
without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the
liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary
duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the
availability of equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of
incorporation upon the closing of this offering will authorize us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws that will be in effect upon the
closing of this offering will: (1)&nbsp;provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents; (2)&nbsp;provide that, on satisfaction of
certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding; and (3)&nbsp;permit us to secure insurance on behalf of any officer, director, employee or other agent
for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our
directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection
with any action, proceeding or investigation. We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as
directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation
of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They
may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the
extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers
or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
plans, in which they will contract with a broker to buy or sell shares of common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director
or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time.
Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information, subject to compliance with the terms
of our insider trading policy. Prior to the end of the 180th day after the date of execution of the underwriting agreement for this offering (subject to potential early release or termination without notice), the sale of any shares under such plan
would be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the director or executive officer has entered into with Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and
Cowen and Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of transactions since January&nbsp;1, 2018, to which we have been a participant in which the amount
involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest, other than compensation arrangements which are described in the sections titled &#147;Executive Compensation&#148; and &#147;Management&#151;Non-Employee Director Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred
Stock Financing </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2018, we issued and sold to investors in a private placement an aggregate of
6,110,957 shares of our Series B redeemable convertible preferred stock in a subsequent closing of our Series B redeemable convertible preferred stock financing at a purchase price of $0.75 per share for aggregate cash proceeds of approximately
$4.6&nbsp;million. Each share of Series B redeemable convertible preferred stock will automatically convert into one share of our common stock upon completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Series B redeemable convertible preferred stock purchased by holders of more than 5% of our
capital stock in January 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BC dcyto Limited, a BVI company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,666,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between September 2018 and December 2018, we issued and sold to investors in a private placement an aggregate of 23,303,456
shares of our Series C redeemable convertible preferred stock in our Series C redeemable convertible preferred stock financing at a purchase price of $2.40 per share for aggregate cash proceeds of approximately $55.9&nbsp;million. Each share of
Series C redeemable convertible preferred stock will automatically convert into one share of our common stock upon completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Series C redeemable convertible preferred stock purchased by holders of more than 5% of our
capital stock and entities affiliated with our directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BC dcyto Limited, a BVI company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Northern Light Venture Capital V,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wudaokou Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,709,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,499,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Feng Deng, a member of our board of directors, is the managing partner of Northern Light Venture Capital V,
Ltd. and may be deemed to have voting and dispositive power with respect to the shares held by Northern Light Venture Capital V, Ltd. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series D Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, we issued and sold to investors in a private placement an aggregate of 17,752,068 shares of our Series D
redeemable convertible preferred stock in our Series D redeemable convertible preferred stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
financing at a purchase price of $6.76 per share for aggregate cash proceeds of approximately $119.7&nbsp;million. Each share of Series D preferred stock will automatically convert into one share
of our common stock upon completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Series D redeemable
convertible preferred stock purchased by holders of more than 5% of our capital stock and entities affiliated with our directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B><br><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,999,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CTKBS Holdings Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,438,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BC dcyto Limited, a BVI company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,035,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Northern Light Venture Capital V,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wudaokou Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 5,150,751 shares of Series D redeemable convertible preferred stock purchased by RA Capital
Healthcare Fund, L.P., (ii) 998,553 shares of Series D redeemable convertible preferred stock purchased by RA Capital Nexus Fund II, L.P. and (iii) 507,724 shares purchased by Blackwell Partners LLC &#151;Series A. Tess Cameron, a member of our
board of directors is a Principal, Strategic Finance at RA Capital Management, LLC, the general partner of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Feng Deng, a member of our board of directors, is the managing partner of Northern Light Venture Capital V,
Ltd. and may be deemed to have voting and dispositive power with respect to the shares held by Northern Light Venture Capital V, Ltd. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are party to an amended and restated investors&#146; rights agreement, or the IRA, with certain holders of our capital
stock, including the holders of more than 5% of our outstanding capital stock, such as BC dcyto Limited, a BVI company, Easy Prosperity Limited, CTKBS Holdings Limited, Wudaokou Capital and entities affiliated with RA Capital Management. The IRA
provides the holders of our redeemable convertible preferred stock with certain registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are
otherwise filing. The IRA also provides these stockholders with information rights, which will terminate on the closing of this offering, and a right of first refusal with regard to certain issuances of our capital stock, which will not apply to the
shares issued pursuant to this offering and which will terminate immediately before the closing of this offering. In connection with this offering, the holders of up to 87,268,694 shares of our common stock issuable on conversion of outstanding
redeemable convertible preferred stock, will be entitled to rights with respect to the registration of their shares under the Securities Act under this agreement. For a description of these registration rights, see the section titled
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation upon the closing of this offering will contain provisions limiting the
liability of directors, and our amended and restated bylaws that will be in effect upon the closing of this offering will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our
amended and restated certificate of incorporation and amended and restated bylaws upon the closing of this offering will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by
the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have entered into an indemnification agreement with each of our directors and executive
officers, which requires us to indemnify them. For more information regarding these agreements, see the section titled &#147;Executive Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants to Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted stock options to our directors and executive officers, as more fully described in the section titled
&#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has adopted a related party transaction policy setting forth the policies and procedures for the
identification, review and approval or ratification of related party transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction,
arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and a related party were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or
from the related party or entities in which the related party has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and
circumstances as appropriate, such as the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction, management&#146;s
recommendation with respect to the proposed related party transaction and the extent of the related party&#146;s interest in the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed
Share Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At our request, the underwriters have reserved five percent of the shares of common stock to be issued
by the company and offered by this prospectus for sale, at the initial public offering price, to directors, officers, employees, business associates and other persons related to the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If purchased by our directors and officers, these shares will be subject to a 180-day lock-up restriction. The number of
shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on
the same basis as the other shares offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_15"></A>PRINCIPAL AND SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information with respect to the beneficial ownership of our capital stock as of March&nbsp;31,
2021, as adjusted to reflect the sale of our common stock offered by us in this offering assuming no exercise of the underwriters&#146; option to purchase additional shares, for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the selling stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole
investment power with respect to all shares that they beneficially own, subject to applicable community property laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable percentage ownership before the offering is based on 119,044,150 shares of common stock outstanding as of
March&nbsp;31, 2021, assuming the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into shares of common stock upon the closing of this offering. Applicable percentage ownership after the offering is based
on 130,808,856 shares of common stock outstanding immediately after the closing of this offering, assuming no exercise by the underwriters of their option to purchase additional shares. In computing the number of shares beneficially owned by a
person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable within 60 days of March&nbsp;31, 2021. However, except as described
above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Cytek Biosciences, Inc., 46107 Landing
Pkwy, Fremont, California 94538. We believe, based on information provided to us, that each of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws
where applicable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table does not reflect any potential purchases by our executive officers, directors,
their affiliated entities or holders of more than 5% of our common stock in this offering or any equity awards granted to our executive officers or directors contingent on this offering. If any shares are purchased by and to the extent any such
equity awards have been granted to these persons or entities, the number and percentage of shares of our common stock beneficially owned by them after this offering will differ from the amounts set forth in the following table. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned<BR>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wenbin Jiang<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ming Yan<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BC dcyto Limited, a BVI company<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,204,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,204,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Easy Prosperity Limited<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,300,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,300,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CTKBS Holdings Limited<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wudaokou Capital<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,634,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,634,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wenbin Jiang<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ming Yan<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrik Jeanmonod<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Ball<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tess Cameron<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,657,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Feng Deng<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,760,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,760,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gisele Dion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (9 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,492,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,492,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Selling Stockholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Next Generation DNA Investment
Ltd<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,666,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,666,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain Selling Stockholders<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">933,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 7,847,710 shares of common stock held by Wenbin Jiang, (ii) 2,666,600 shares of common stock
issuable upon conversion of our redeemable convertible preferred stock held by WYTJ LLC, and (iii)&nbsp;65,275 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 8,139,792 shares of common stock and (ii) 61,066 shares issuable pursuant to stock options
exercisable within 60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 9,204,215 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock. 3E Bioventures Capital, L.P. (&#147;3E Fund&#148;) is the registered sole shareholder of BC dcyto Limited. 3E Bioventures GP, LLC, or 3E GP, is the ultimate general partner of 3E Fund. Qianye Karen Liu, the sole director of 3E GP,
Jin Li, Yu Fang and Moonray Global Investments Limited are members of 3E GP, and each of them may be deemed to hold shared voting and dispositive power over the shares held by 3E Fund. The address of BC dcyto Limited is Trinity Chambers, PO Box
4301, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 7,300,878 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock. Ding Kui is the sole director of Easy Prosperity Limited (&#147;EPL&#148;). Shanghai Xincheng </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Investment Management Center (LLP) (&#147;SXIMC&#148;) is the sole shareholder of EPL. Ding Kui is the general partner of SXIMC. The address of Easy Prosperity Limited is Room 601, 6th Floor, Tai
Tung Building, No.&nbsp;8 Fleming Road, Wanchai, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 6,657,030 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock. CTKBS Holdings Limited is incorporated in the Cayman Islands and is wholly owned by Hillhouse Focused Growth Fund&nbsp;V, L.P. Hillhouse Capital Management, Ltd. (&#147;HCM&#148;) acts as the sole management company of Hillhouse
Focused Growth Fund V, L.P. HCM is deemed to be the beneficial owner of, and to control the voting power of, the shares held by CTKBS Holdings Limited. The address of CTKBS Holdings Limited is 27 Hospital Road, George Town, Grand Cayman <FONT
STYLE="white-space:nowrap">KY1-9008,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 6,634,688 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock. Jianguo Chao and Bin Yang are the general partners of Wudaokou Capital, a Cayman Islands company. Yong Shen, Weizhong Jiang and Jianjun Xue are the managing members of Wudaokou Capital, and each of them may be deemed to hold shared
voting and dispositive power over the shares held&nbsp;by Wudaokou Capital. The address of Wudaokou Capital is 15th Floor, Unit 22, Leighton Centre 77&nbsp;Leighton Road, Causeway Bay, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 5,150,751 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock held by RA Capital Healthcare Fund, L.P., (ii) 998,553 shares of common stock issuable upon redeemable conversion of our redeemable convertible preferred stock held by RA Capital Nexus Fund&nbsp;II, L.P., and (iii) 507,724 shares of
common stock issuable upon conversion of our redeemable convertible preferred stock held by Blackwell Partners LLC &#150; Series A. RA Capital Healthcare Fund GP, LLC is the general partner of the RA Capital Healthcare Fund, L.P., or RA Healthcare.
RA Capital Nexus Fund II GP, LLC is the general partner of RA Capital Nexus Fund II, L.P., or Nexus&nbsp;II. RA Capital Management, L.P., or RA Capital, is the investment manager for RA Healthcare, Nexus II, and Blackwell Partners LLC -
Series&nbsp;A. The general partner of RA Capital is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. RA Capital, RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah may be deemed to have
voting and investment power over the shares held of record by RA Healthcare and Nexus II. RA Capital, RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The address of RA Capital is 200 Berkeley Street, 18th&nbsp;Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 85,331 shares of common stock and (ii) 133,384 shares issuable pursuant to stock options
exercisable within 60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 37,776 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31,
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 4,760,510 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock held by Northern Light Venture Capital V, Ltd. Northern Light Venture Capital V, Ltd. (&#147;NLVC&#148;), serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light
Partners Fund V, L.P (together, the &#147;NLVC V Funds&#148;). Northern Light Partners III, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC is the general partner of Northern Light
Partners III, L.P. Feng Deng, a member of our board of directors, is the controlling shareholder of NLVC and may be deemed to have voting and dispositive power with respect to the shares held by NLVC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 30,192,523 shares of common stock and convertible preferred stock held directly or
indirectly by all current executive officers and directors as a group, and (ii) 299,723 shares of common stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021 held by all current executive officers and directors
as a group. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 2,666,599 shares of common stock issuable upon conversion of our redeemable convertible
preferred stock. The address of Next Generation DNA Investment Ltd is Suite&nbsp;1051, 10/F, Wharf T&amp;T Center, Harbour City, 7&nbsp;Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of a selling stockholder who owns less than 1% of our common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The description below of our capital stock and provisions of our amended and restated certificate of incorporation and amended
and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws upon the closing of this offering, which are filed as exhibits to the registration
statement of which this prospectus is part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, our amended and restated certificate of incorporation will authorize us to issue up to
1,000,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. As of March&nbsp;31, 2021, there were 31,775,456 shares of common stock issued and outstanding, held by 61
stockholders of record. As of March&nbsp;31, 2021, after giving effect to the conversion of all 87,268,694 shares of our redeemable convertible preferred stock outstanding on such date into an equal number of shares of common upon the closing of
this offering, there would have been 119,044,150 shares of our common stock outstanding, held by 94 stockholders of record. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our amended and restated certificate of incorporation, our stockholders will not have
cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to preferences that may apply to any then-outstanding redeemable convertible preferred stock, the holders of common
stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. We do not anticipate paying any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the
net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of redeemable
convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund
provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of redeemable convertible preferred
stock that we may designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All currently outstanding shares of our redeemable convertible preferred stock will be converted to common stock immediately
upon the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under our amended and restated certificate of incorporation upon the closing
of this offering, our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize
their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any series or the designation of such
series, any or all of which may be greater than the rights of common stock. Any issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders would receive dividend payments and
payments on liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock will be outstanding immediately following
the closing of this offering. We have no present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, options to purchase an aggregate of 6,559,712 shares of common stock were outstanding under our 2015
Plan. As of March&nbsp;31, 2021, 6,057,200 shares of common stock were reserved for future issuance under our 2015 Plan. All reserved shares will cease to be available for issuance at the time our 2021 Plan becomes effective upon the execution of
the underwriting agreement for this offering. For additional information regarding the terms of these plans, see the section titled &#147;Executive Compensation&#151;Employee Incentive Plans.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
March&nbsp;31, 2021, we had no warrants outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are party to the Rights Agreement which provides various rights to certain holders of shares of common stock, including
those shares of common stock that will be issued upon conversion of our redeemable convertible preferred stock in connection with this offering. These shares to be issued upon conversion are referred to as registrable securities. The holders of
these registrable securities possess registration rights pursuant to the terms of the Rights Agreement and are described in additional detail below. We, along with certain holders of at least 5% of our capital stock and entities affiliated with
certain of our directors, and other stockholders, are parties to the Rights Agreement. We entered into the Rights Agreement in connection with the issuance of shares of our Series D redeemable convertible preferred stock in October 2020. The
following summary discusses certain material provisions of the Rights Agreement and is qualified by the full text of the agreement, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain stockholders who are party to the Rights Agreement have waived their registration rights and the registration rights
of the other stockholders who are party to the Rights Agreement, in each case, with respect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
registration of shares of common stock pursuant to the exercise of registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared
effective. We will pay the registration expenses (other than underwriting discounts, selling commissions and stock transfer taxes) of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registrations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, in an underwritten offering, if we determine in good faith in consultation with
the underwriters, we have the right, subject to specified conditions, to limit the number of shares the holders may include to be registered. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described
below will terminate on the earlier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of (i)&nbsp;such time after the closing of this offering as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the holders&#146; shares without
limitation during a three-month period without registration, and (ii)&nbsp;the date that is three years following the closing of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of an aggregate of 87,268,694 shares of common stock, including shares issued or issuable upon conversion of
outstanding shares of our preferred, will be entitled to certain demand registration rights. Beginning on the date 180 days following the effective date of the registration statement of which this prospectus is a part, upon the written request of
the holders of at least 30% of our registrable securities then outstanding that we file a registration statement under the Securities Act with respect to an aggregate offering price, net of selling expenses, would exceed $10,000,000, we are
obligated to register the sale of all registrable securities that the holders may so request to be registered as soon as practicable, and in any event within 60 days of the request. We may postpone the filing of a registration statement for up to
120 days once in a 12-month period if in the good faith judgment of our board of directors such registration would materially interfere with a significant transaction, require premature disclosure of material confidential information that we have a
bona fide business purpose for preserving as confidential or cause us to be unable to comply with the requirements of the Securities Act or the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of an aggregate of 87,268,694 shares of common stock, including shares issued or issuable upon conversion of
outstanding shares of our redeemable convertible preferred stock, will be entitled to certain piggyback registration rights. If we register any of our securities for public sale solely for cash, we will also have to register all registrable
securities that the holders of such securities request in writing be registered. This piggyback registration right does not apply to a registration relating to any of our stock plans, stock purchase or similar plan, a transaction under Rule 145 of
the Securities Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale or a registration related to the offer and sale of debt
securities. We, based on consultation with the underwriters of any underwritten offering, will have the right to limit the number of shares registered by these holders to no less than 20% of the number of shares to be offered and sold if the
underwriters determine that fewer than all registrable securities requested to be registered can be included in such offering and if all other securities (other than those to be sold by us) have been entirely excluded from that underwritten
offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of an aggregate of 87,268,694 shares of common stock, including shares issued or issuable upon conversion of
outstanding shares of our redeemable convertible preferred stock, will be entitled to certain registration rights on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Upon the written request of at least 30% of our registrable securities then
outstanding, the holders of these shares can request that, as soon as practicable, and in any event within 45 days of the request, we register all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are eligible to
file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and the aggregate offering price, net of selling expenses, is in excess of $10,000,000. We may postpone the filing of a registration statement for up to
120&nbsp;days once in a 12-month period if in the good faith judgment of our board of directors such registration would materially interfere with a significant transaction, require premature disclosure of material confidential information that we
have a bona fide business purpose for preserving as confidential or cause us to be unable to comply with the requirements of the Securities Act or the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Anti-Takeover</FONT> Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a publicly held Delaware
corporation from engaging in any business combination with any interested stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding at the time the transaction began, excluding for purposes of determining the voting stock
outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1)&nbsp;by persons who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an
annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of
any stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the
stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an
&#147;interested stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or
more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A Delaware corporation may &#147;opt out&#148; of these
provisions with an express provision in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved
by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws to Be in Effect Upon the Closing of This Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of redeemable convertible preferred stock, with
any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors will be classified into three classes of directors; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of redeemable convertible preferred stock to elect
directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled
to vote generally at an election of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law,
be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate
candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairperson of our board of
directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amendment of any of these provisions would require approval by the holders of at least 66 2/3% of the voting power of all
of our then-outstanding capital stock entitled to vote generally in the election of directors, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of
directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing
stockholders or another party to effect a change in management. In addition, the authorization of undesignated redeemable convertible preferred stock makes it possible for our board of directors to issue redeemable convertible preferred stock with
voting or other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These
provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect
of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware
statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other
employees to us or our stockholders; (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers, or other employees, arising out of or pursuant to any provision of the Delaware General
Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce, or determine the validity of our amended and restated certificate of
incorporation or our amended and restated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
bylaws; (v)&nbsp;any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any action
asserting a claim against us or any of our directors, officers, or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the
indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal
and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary
rulings by different courts, among other considerations, our amended and restated certificate of incorporation and our amended and restated bylaws will further provide that the federal district courts of the United States of America will be the
exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring
a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of
incorporation and our amended and restated bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum provisions may limit a stockholder&#146;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum
provisions in other companies&#146; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find
either exclusive forum provision contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with
resolving such action in other jurisdictions, all of which could seriously harm our business.&nbsp;See &#147;Risk Factors&#151;Risks Related to this Offering and Ownership of Our Common Stock&#151;Our amended and restated certificate of
incorporation and amended and restated bylaws that will be in effect at the closing of this offering will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our
stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.&#148;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;CTKB.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock immediately prior to the closing of this offering will be American Stock
Transfer &amp; Trust Company, LLC. The transfer agent&#146;s address is 6201 15th Avenue, Brooklyn, NY 11219 and the telephone number is (800) 937-5449. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common
stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Furthermore, because only a limited number of shares of our common stock will be available for sale shortly after
this offering due to certain contractual and legal restrictions on resale described below, sales of substantial amounts of our common stock in the public market after such restrictions lapse, or the anticipation of such sales, could adversely affect
the prevailing market price of our common stock and our ability to raise equity capital in the future. Although we intend to apply to have our common stock listed on Nasdaq, we cannot assure you that there will be an active public market for our
common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, based on the number of shares of our common stock outstanding
as of March&nbsp;31, 2021 and assuming (1)&nbsp;the issuance of shares of common stock in this offering, (2)&nbsp;the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock, which will
automatically occur upon the closing of the offering, and (3)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares, we will have an aggregate of approximately 130,808,856 shares of common stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of these shares, all shares of common stock sold in this offering will be freely tradable without restriction or further
registration under the Securities Act, except for any shares of common stock purchased by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act or any shares subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The remaining shares of common stock outstanding after this offering will be &#147;restricted securities,&#148; as that term
is defined in Rule&nbsp;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule&nbsp;144 or
Rule&nbsp;701 under the Securities Act, each of which is summarized below and, if subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, may only be sold after the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. We expect that substantially all of these shares will be subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT
STYLE="white-space:nowrap">lock-up</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may issue shares of common stock from time to time as consideration for future acquisitions, investments or other corporate
purposes. In the event any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may also be significant. We may also grant registration rights covering those shares of common stock
issued in connection with any such acquisition, investment or other transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, shares of common stock that
are either subject to outstanding options or warrants or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below and Rules&nbsp;144 and 701 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule&nbsp;144 as currently in effect, once we have been subject to public company reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of Rule&nbsp;144, subject to
compliance with the public information requirements of Rule&nbsp;144. To be an eligible stockholder under Rule&nbsp;144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the
90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such
person is entitled to sell such shares without complying with any of the requirements of Rule&nbsp;144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule&nbsp;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates
will be entitled to sell shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90&nbsp;days after the date of this prospectus, within any three-month period, such stockholders may sell a
number of shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 1,308,089
shares immediately after this offering; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on Nasdaq&nbsp;during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to such sale, provided in each case that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales under Rule&nbsp;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain
manner of sale provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not
deemed to have been an affiliate of our company during the immediately preceding 90&nbsp;days, to sell these shares in reliance on Rule&nbsp;144, but without being required to comply with the public information, holding period, volume limitation or
notice provisions of Rule&nbsp;144. Rule&nbsp;701 also permits affiliates of our company to sell their Rule&nbsp;701 shares under Rule&nbsp;144 without complying with the holding period requirements of Rule&nbsp;144. All holders of Rule&nbsp;701
shares, however, are required by that rule to wait until 90&nbsp;days after the date of this prospectus before selling those shares under Rule&nbsp;701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described below and in &#147;Underwriters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the
Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under the 2015 Plan, the 2021 Plan and the ESPP. We expect to file the registration statement covering shares offered
pursuant to these stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by
affiliates in the public market subject to compliance with the resale provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreements </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the selling stockholders, our directors, executive officers and the holders of substantially all of
our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in &#147;Underwriting&#148; below, we or they will not, except with the
prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and Cowen and Company, LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to sale of or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand
that we file a registration statement related to our common stock, or enter into any swap </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are
subject to a market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreement with us which imposes similar restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right
to require us to register their shares under the Securities Act. See the sections titled &#147;Registration Rights&#148; below and &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to
such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering and the expiration or release from the terms of applicable
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, holders of an aggregate of 87,268,694 shares of our common stock, which includes all of the shares of common stock issuable upon the conversion of our redeemable convertible preferred stock
immediately prior to the closing of this offering, or their transferees, will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result
in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares subsequently purchased by affiliates. See the section titled &#147;Description of Capital
Stock&#151;Registration Rights&#148; for additional information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After to the completion of the offering, certain of
our employees, including our executive officers, and/or directors may enter into written trading plans that are intended to comply with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Securities Exchange Act of 1934. Sales under these
trading plans would not be permitted until the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements relating to the offering described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary describes the material U.S. federal income tax consequences of the acquisition, ownership and
disposition of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below).&nbsp;This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating
thereto, and does not deal state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular circumstances, nor does it
address U.S. federal tax consequences (such as gift and estate taxes) other than income taxes.&nbsp;Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are subject to
special treatment under the Internal Revenue Code of 1986, as amended, or the Code, such as financial institutions, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, broker-dealers and traders in securities, U.S.
expatriates, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state
thereof and the District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148;
&#147;synthetic security&#148; or integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons subject to the alternative minimum tax or federal
Medicare contribution tax on net investment income, &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, partnerships and
other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their own tax advisors to determine the U.S. federal, state,
local and other tax consequences that may be relevant to them.&nbsp;Furthermore, the summary below is based upon the provisions of the Code, and Treasury Regulations, rulings and judicial decisions thereunder as of the date hereof, and such
authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below.&nbsp;We have not requested a ruling from the U.S. Internal Revenue Service, or the
IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions.&nbsp;This discussion assumes that the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common stock
pursuant to this offering should consult their own tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any
consequences arising under the laws of any other taxing jurisdiction, including any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is, for U.S.
federal income tax purposes, a beneficial owner of common stock that is neither a U.S. Holder, nor a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or
formation).&nbsp;A &#147;U.S. Holder&#148; means a beneficial owner of our common stock that is for U.S. federal income tax purposes any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or
more U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described in the section entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders
of our common stock in the foreseeable future. However, if we do make distributions of cash or property, such distributions made on our common stock, such distributions will generally be treated as dividends for U.S. tax purposes to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) and will be subject to withholding tax at a 30% rate or such lower
rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts.&nbsp;To obtain a reduced rate of withholding under a treaty, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required to provide us with a properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (in the case of individuals) or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits
under that treaty. This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is an entity, Treasury
Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity.&nbsp;If a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder will be required to provide appropriate documentation to such agent.&nbsp;The <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s agent will then be required to provide certification to us or our paying agent, either directly or
through other intermediaries.&nbsp;If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely file the required certification, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generally are not required to withhold tax on dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
that are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent
establishment or fixed base that such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains in the United States) if a properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> stating that the dividends are so
connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent).&nbsp;In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular
rates applicable to U.S. residents.&nbsp;A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under
certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject
to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will
first reduce the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount distributed, and taxed in the same manner as
gain realized from a sale or other disposition of common stock as described in the next section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding backup withholding and foreign accounts, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively connected with
a trade or business of such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in
the United States), (b)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions
are met or (c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Section&nbsp;897(c)(2) of the Code at any time within the shorter of the five-year period preceding such disposition or such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period.&nbsp;In general, we would be a United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
States real property holding corporation if our interests in U.S. real property comprise (by fair market value) at least half of our business assets.&nbsp;We believe that we have not been and we
are not, and do not anticipate becoming, a United States real property holding corporation.&nbsp;Even if we are treated as a United States real property holding corporation, gain realized by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly, indirectly and constructively, no more than 5% of our common stock
at all times within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an
established securities market. There can be no assurance that our common stock will qualify or continue to qualify as regularly traded on an established securities market. If any gain on a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s disposition is taxable because we are a United States real property holding corporation and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s ownership of our common stock exceeds 5%, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be taxed on such disposition generally in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business (subject to the provisions under an applicable
income tax treaty), except that the branch profits tax generally will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (a)&nbsp;above will be required to pay tax on the net gain derived from the sale at regular U.S. federal income tax rates, and corporate
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.&nbsp;Gain described in
(b)&nbsp;above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income tax treaty, which gain may be offset by certain U.S.-source capital losses (even though the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such
losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, we must report information to the IRS with respect to any distributions we pay on our common stock (even if the
payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient, and the amount, if any, of tax withheld.&nbsp;A similar report will be sent to the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to whom any such distributions are paid.&nbsp;Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of
residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may
also be subject to U.S. backup withholding (currently at a rate of 24%). U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a properly executed IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-ECI</FONT> (as applicable), or otherwise establishes
an exemption. Notwithstanding the foregoing, backup withholding may apply if the payer has actual knowledge, or reason to know, that the holder is a U.S. person who is not exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our
common stock effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such requirements may be avoided if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or otherwise meets documentary evidence requirements for establishing <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption.&nbsp;Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
broker.&nbsp;Information reporting and backup withholding requirements, however, may apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person.&nbsp;For information
reporting purposes, certain brokers with substantial U.S. ownership or operations generally will be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against
the tax liability of persons subject to backup withholding, provided that the required information is timely furnished to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain
payments (including dividends) to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to
the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S.
owners).&nbsp;FATCA also generally imposes a federal withholding tax of 30% on certain payments, including dividends paid on, and the gross proceeds of a disposition of, our common stock to a <FONT STYLE="white-space:nowrap">non-financial</FONT>
foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the
entity.&nbsp;An intergovernmental agreement between the United States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution or <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from the rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% that otherwise would apply to the gross proceeds of a disposition of our common stock. In its
preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are encouraged to consult with their own tax advisors regarding the
possible implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS
OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters
named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and Cowen and Company, LLC are acting as representatives, have severally agreed to purchase, and we and the selling stockholders
have agreed to sell to them, severally, the number of shares indicated below: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,564,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and the selling stockholders and subject to prior sale. The
underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to
certain other conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered
by the underwriters&#146; over-allotment option described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters initially propose to offer part of
the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share under the public offering price. After the initial offering of the shares of common stock, the offering price and other selling terms may from
time to time be varied by the representatives. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted to the underwriters an option, exercisable for 30 days
from the date of this prospectus, to purchase up to 2,184,695 additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this
option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject
to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed next to
the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the per share and total public offering
price, underwriting discounts and commissions, and proceeds before expenses to us and the selling stockholders. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional
2,184,695 shares of common stock. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of the
underwriting discounts and commissions, are approximately $5,250,000. We have agreed to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority up to $50,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of
shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have applied to list our common stock on the Nasdaq Global Select Market under
the trading symbol&nbsp;&#147;CTKB.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the selling stockholders, and all directors and officers and the
holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and Cowen and Company,
LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, and will not cause or direct any of its affiliates to, or publicly disclose an intention to, in each case, during the period commencing on the
date of this prospectus and ending 180 days after the date of this prospectus (the &#147;restricted period&#148;): </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confidentially submit any draft registration statement or file any registration statement with the Securities
and Exchange Commission relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of shares of common stock; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction described above is to be settled by
delivery of shares common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, (i)&nbsp;the foregoing precludes hedging or other transactions designed or intended, or which could reasonably be
expected to lead to or result in, a sale or disposition of any shares of our common stock, or securities convertible into or exercisable or exchangeable for our common stock and (ii)&nbsp;without the prior written consent of Morgan
Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and Cowen and Company, LLC on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any
right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to certain exceptions, the restrictions described in the immediately preceding paragraph to do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the sale of shares to the underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transactions relating to shares of common stock or other securities acquired in this offering (other than
issuer-directed shares of our common stock purchased in this offering by our officers and directors) or in open market transactions after the completion of the offering of the shares; provided that no filing under Section&nbsp;16(a) of the Exchange
Act, is required or shall be voluntarily made in connection with subsequent sales of shares of common stock or other securities acquired in this offering or in such open market transactions, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers of shares of common stock or any security convertible into shares of common stock as a bona fide
gift charitable contribution in a transaction exempt under Section&nbsp;16(b) of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers of shares of our common stock or other securities by will or intestate succession upon the death
of the undersigned, including to the transferee&#146;s nominee or custodian; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers of shares of our common stock or other securities to an immediate family member or any trust for
the direct or indirect benefit of the undersigned or the immediate family of the undersigned; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers or distributions of shares of our common stock or any other securities by a stockholder that is a
trust to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">(1) distributions of shares of our common stock or other securities to limited partners, members,
stockholders or holders of similar equity interests in the undersigned (or in each case its nominee or custodian) or (2)&nbsp;transfers of shares of our common stock or other securities to another corporation, partnership, limited liability company,
trust or other business entity (or in each case its nominee or custodian) that is a direct or indirect subsidiary of the undersigned; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers of shares of our common stock or other securities by operation of law pursuant to a qualified
domestic order or in connection with a divorce settlement; provided that any filing required by Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances
described in this paragraph and such shares remain subject to this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; provided further that no other public announcement or filing shall be required or shall be voluntarily made during the
restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">dispositions or transfers of shares of our common stock upon the &#147;net&#148; or &#147;cashless&#148;
exercise of stock options or other equity awards outstanding as of the date of this prospectus and granted pursuant to an employee benefit plan; provided that the underlying shares of our common stock issued to the undersigned upon such exercise
shall continue to be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; provided further that, if required, any public report or filing under Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto
that the filing relates to such &#147;net&#148; or &#147;cashless&#148; exercise of stock options or other equity awards, as applicable, that no shares were sold by the reporting person and that the underlying shares issued to the undersigned upon
such exercise shall continue to be subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters of this offering; provided further that no other public announcement or filing shall be required or shall be voluntarily
made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">exercises solely with cash of a stock option granted under a stock incentive plan or stock purchase plan by
the undersigned, and the receipt by the undersigned from us of shares of our common stock upon such exercise, insofar as such option is outstanding as of the date of this prospectus, provided that the underlying shares of common stock shall continue
to be subject to the restrictions on transfer set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; provided further that, if required, any public report or filing under Section&nbsp;16 of the Exchange Act shall clearly
indicate in the footnotes thereto that the filing relates to the exercise of a stock option, that no shares were sold by the reporting person and that the shares received upon exercise of the stock option are subject to a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters of this offering; provided further that no other public announcement or filing shall be required or shall be voluntarily made during the restricted period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers to us of shares of our common stock or other securities in connection with the repurchase by us
from the undersigned of shares of our common stock or other securities pursuant to a repurchase right arising upon the termination of the undersigned&#146;s employment with us; provided that such repurchase right is pursuant to contractual
agreements with us; provided further that any filing required by Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances described in this paragraph; provided
further that no other public announcement or filing shall be required or shall be voluntarily made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transfers of shares of common stock or other securities pursuant to a bona fide third-party tender offer,
merger, consolidation or other similar transaction involving a change of control (as defined below) of the company which occurs after the consummation of this offering, is open to all holders of the our capital stock and has been approved by our
board of directors; provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the securities held by the undersigned shall remain subject to the provisions of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement (for purposes of this paragraph, &#147;Change of Control&#148; shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction the result
of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT
STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of at least 50% of total voting power of our voting stock); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the establishment or amendment of a trading plan on behalf of our stockholder, officer or director pursuant
to Rule 10b5 1 under the Exchange Act for the transfer of shares of our common stock, provided that (i)&nbsp;such plan does not provide for the transfer of our common stock during the restricted period and (ii)&nbsp;to the extent a public
announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of our common stock may be made under such plan during the restricted period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">provided that (i)&nbsp;in the case of any transfer or distribution pursuant to each of the clauses
(c)&nbsp;through (h), each donee or distributee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement signed by us and such other
persons, (ii)&nbsp;pursuant to each of the clauses (b)&nbsp;through (g), no filing under Section&nbsp;16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of common stock, and no other public announcement or filing
shall be required or shall be voluntarily made during the restricted period, and (iii)&nbsp;in the case of any transfer or distribution pursuant to each of clauses (c)&nbsp;through (g) above, such transfer or distribution shall not involve a
disposition for value. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, one of our stockholders may pledge a certain number of shares
in connection with a loan agreement without any sale or transfer restrictions applicable under the lock-up agreement. Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Piper Sandler&nbsp;&amp; Co. and Cowen and Company, LLC may
release the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain
or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is
no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In
determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell
shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters
are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the
underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or
retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the selling stockholders and the underwriters have agreed to indemnify each other against certain liabilities, including
liabilities under the Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on websites maintained
by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade debt and equity securities (or related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such
securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our shares of common stock. The initial public offering price will
be determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price are our future prospects and those of our industry in general, our sales, earnings and certain
other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At our request, the underwriters have reserved five percent of the shares of common stock to be issued by the company and
offered by this prospectus for sale, at the initial public offering price, to directors, officers, employees, business associates and other persons related to the company. If purchased by our directors and officers, these shares will be subject to a
<FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction. The number of shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such
reserved shares. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other shares offered by this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus has been prepared on the basis that any offer of shares of our common stock in any Member State of
the European Economic Area (each, a &#147;Member State&#148;), will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of shares of our common stock. Accordingly any person making
or intending to make an offer in that Member State of shares of our common stock which are the subject of the offering contemplated in this prospectus in relation to the offer of those shares of our common stock may only do so in circumstances in
which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation, in each case in relation
to such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer
of shares of our common stock in circumstances in which an obligation arises for the company or the underwriters to publish or supplement a prospectus for such offer. Neither the company nor the underwriters have authorized, nor do they authorize,
the making of any offer of shares of our common stock through any financial intermediary, other than offers made by the underwriters, which constitute the final placement of the shares of common stock contemplated in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each person in a Member State who receives any communication in respect of,
or who acquires any shares of our common stock under, the offers to the public contemplated in this prospectus, or to whom the shares of our common stock are otherwise made available, will be deemed to have represented, warranted, acknowledged and
agreed to and with each underwriter and the company that it and any person on whose behalf it acquires shares of our common stock is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a qualified investor within the meaning of Article 2(e) of the Prospectus Regulation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of any shares of our common stock acquired by it as a financial intermediary, as that term is used
in Article 5(1) of the Prospectus Regulation: (i)&nbsp;the shares of our common stock acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State
other than qualified investors, as that term is defined in the Prospectus Regulation, or in circumstances in which the prior consent of the representatives has been given to the offer or resale; or (ii)&nbsp;where shares of our common stock have
been acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those shares of our common stock to it is not treated under the Prospectus Regulation as having been made to such persons.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State, each underwriter has represented and agreed that it has not made and
will not make an offer of shares of our common stock to the public in that Member State except that it may make an offer of shares of our common stock to the public in that Member State at any time, </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to legal entities which are qualified investors as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation) subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares of our common stock shall require the company or the underwriter to publish a prospectus pursuant to
Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer of shares of our common stock to the public&#148; in
relation to any shares of our common stock in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of common stock to be offered so as to enable an investor to
decide to purchase or subscribe for the shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The expression &#147;Prospectus Regulation&#148;
means Regulation (EU) 2017/1129 (as amended or superseded). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus has been prepared on the basis that any offer of shares of our common stock in the United Kingdom will be made
pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of shares of our common stock. Accordingly any person making or intending to make an offer in the UK of shares of our common stock
which are the subject of the offering contemplated in this prospectus in relation to the offer of those shares of our common stock may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a
prospectus pursuant to section 85 of the Financial Services and Markets Act 2000 (as amended, the &#147;FSMA&#148;) or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation in each case in relation to such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares of our
common stock in circumstances in which an obligation arises for the company or the underwriters to publish or supplement a prospectus for such offer. Neither the company nor the underwriters have authorized,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
nor do they authorize, the making of any offer of shares of our common stock through any financial intermediary, other than offers made by the underwriters, which constitute the final placement
of the shares of our common stock contemplated in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each person in the UK who receives any communication
in respect of, or who acquires any shares of our common stock under, the offers to the public contemplated in this prospectus, or to whom the shares of our common stock are otherwise made available, will be deemed to have represented, warranted,
acknowledged and agreed to and with each underwriter and the company that it and any person on whose behalf it acquires shares of our common stock is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a qualified investor within the meaning of Article 2(e) of the UK Prospectus Regulation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of any shares of our common stock acquired by it as a financial intermediary, as that term is used
in Article 5(1) of the UK Prospectus Regulation, (i)&nbsp;the shares of our common stock acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in the UK other
than qualified investors, as that term is defined in the UK Prospectus Regulation, or in circumstances in which the prior consent of the representatives has been given to the offer or resale; or (ii)&nbsp;where shares of our common stock have been
acquired by it on behalf of persons in the UK other than qualified investors, the offer of those shares of our common stock to it is not treated under the UK Prospectus Regulation or FSMA as having been made to such persons. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has represented and agreed that it has not made and will not make an offer of shares of our common stock to
the public in the United&nbsp;Kingdom, except that it may make an offer of shares of our common stock to the public in the United&nbsp;Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 of the UK
Prospectus Regulation) in the United Kingdom subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time in any other circumstances falling within section 86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares of our common stock shall require the company or any underwriter to publish a prospectus pursuant to
section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the
purposes of this provision, the expression &#147;an offer of shares of our common stock to the public&#148; in relation to any shares of our common stock means the communication in any form and by any means of sufficient information on the terms of
the offer and the shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for the shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The expression UK Prospectus Regulation means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has represented, warranted and agreed as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received by it in connection with the issue or sale of the shares of our common stock in circumstances in which section 21(1) of the FSMA does
not apply to the company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters
relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Financial Promotion Order&#148;), (ii) are persons falling within Article 49(2)(a) to (d)
(&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity
(within the meaning of section 21 of the FSMA) in connection with the issue or sale of any shares of our common stock may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;relevant
persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant
persons and will be engaged in only with relevant persons. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the
Australian Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the
&#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any offer in Australia of the shares of our common stock may only be made to persons (the &#147;Exempt Investors&#148;) who
are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more
exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares of our common stock without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The common stock applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12
months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring common stock must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains general information only and does not take account of the investment objectives, financial
situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is
appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of
Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the
time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority (&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus The
prospectus to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of our common stock offered should conduct their own due diligence on the prospectus. If you do not
understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our common stock may have not been offered or sold and will not be offered or sold in Hong Kong, by means of any
document other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances
which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong), or the CO, or which do not constitute an offer to the public
within the meaning of the CO. No advertisement, invitation or document relating to the shares of our common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or
elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of our common stock which
are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless
otherwise specified before an offer of shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as
defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice
<FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each representative
has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each representative has represented and agreed that it has not offered or sold any shares of our common stock or
caused the shares of our common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares of our common stock or cause the shares of our common stock to be made the subject of an invitation for
subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares
of our common stock, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of
Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA
and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a
relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not and will not register with the Swiss Financial Market Supervisory Authority (&#147;FINMA&#148;) as a foreign
collective investment scheme pursuant to Article 119 of the Federal Act on Collective Investment Scheme of 23&nbsp;June 2006, as amended (&#147;CISA&#148;), and accordingly the securities being offered pursuant to this prospectus have not and will
not be approved, and may not be licenseable, with FINMA. Therefore, the securities have not been authorized for distribution by FINMA as a foreign collective investment scheme pursuant to Article 119 CISA and the securities offered hereby may not be
offered to the public (as this term is defined in Article 3 CISA) in or from Switzerland. The securities may solely be offered to &#147;qualified investors,&#148; as this term is defined in Article 10 CISA, and in the circumstances set out in
Article 3 of the Ordinance on Collective Investment Scheme of 22&nbsp;November 2006, as amended (&#147;CISO&#148;), such that there is no public offer. Investors, however, do not benefit from protection under CISA or CISO or supervision by FINMA.
This prospectus and any other materials relating to the securities are strictly personal and confidential to each offeree and do not constitute an offer to any other person. This prospectus may only be used by those qualified investors to whom it
has been handed out in connection with the offer described herein and may neither directly or indirectly be distributed or made available to any person or entity other than its recipients. It may not be used in connection with any other offer and
shall in particular not be copied and/or distributed to the public in Switzerland or from Switzerland. This prospectus does not constitute an issue prospectus as that term is understood pursuant to Article 652a and/or 1156 of the Swiss Federal Code
of Obligations. We have not applied for a listing of the securities on the SIX Swiss Exchange or any other regulated securities market in Switzerland, and consequently, the information presented in this prospectus does not necessarily comply with
the information standards set out in the listing rules of the SIX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SIX Swiss Exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of
1948, as amended) (the &#147;FIEL&#148;) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or
indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional Investors
(&#147;QII&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph 2, Article 4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT
STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of
common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the
FIEL) in relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, Article
<FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of
common stock may only be transferred en bloc without subdivision to a single investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, Palo
Alto, California. The underwriters are being represented by Shearman&nbsp;
&amp; Sterling LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements of Cytek Biosciences, Inc. and subsidiaries as of December&nbsp;31, 2020 and 2019, and for each of
the two years in the period ended December&nbsp;31, 2020, included in this Registration Statement have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such
financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits
and schedules, under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration
statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any
contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all
respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You can read our SEC filings, including the registration statement, over the internet at the
SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, we will be subject to the information reporting
requirements of the Securities Exchange Act of 1934, as amended, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection at the website of
the SEC referred to above. We also maintain a website at www.cytekbio.com, at which, following the closing of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80783_23"></A>CYTEK BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page(s)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited financial statements as of December 31, 2019 and 2020 and for the years ended December
31, 2019 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_1">Report of independent registered public accounting firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated financial statements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_3">Consolidated balance sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_4">Consolidated statements of operations and comprehensive income
(loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_5">Consolidated statements of redeemable convertible preferred stock and stockholders&#146;
 deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_6">Consolidated statements of cash flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_7">Notes to consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited interim financial statements as of March 31, 2020 and 2021 and for the three months
ended March 31, 2020 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interim consolidated financial statements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_9">Consolidated balance sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_10">Consolidated statements of operations and comprehensive income
(loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_11">Consolidated statements of redeemable convertible preferred stock and stockholders&#146;
 deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_12">Consolidated statements of cash flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin80783_13">Notes to interim consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin80783_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Stockholders and the Board of Directors of Cytek Biosciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
have audited the accompanying consolidated balance sheets of Cytek Biosciences, Inc., and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2020 and 2019, the related consolidated statements of<I> </I>operations and comprehensive income
(loss), redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows, for each of the two years in the period ended December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;financial
statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for each of the
two years in the period ended December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control
over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ DELOITTE&nbsp;&amp; TOUCHE LLP </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;21, 2021 (July 18, 2021, as
to the effects of the stock split described in Note 2) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_3"></A>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated balance sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 30,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;165,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 70,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 219,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 37,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 41,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value; 70,212,570 and 87,268,694 shares
authorized as of December&nbsp;31, 2019 and 2020, respectively; 69,516,626 and 87,268,694 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively; aggregate liquidation preference of $79,230 and $199,230 as of
December&nbsp;31, 2019 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0,001 par value; 133,330,000, and 153,329,500 authorized shares at
December&nbsp;31, 2019 and 2020, respectively; 28,397,955, and 31,241,916 issued and outstanding shares at December&nbsp;31, 2019 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(41,701)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(16,028)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 70,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 219,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_4"></A>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated statements of operations and comprehensive income (loss) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 85,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 14,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(16,827)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: net income allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(16,827)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(0.60)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(0.60)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in calculating net income (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,126,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in calculating net income (loss) per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,599,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(16,827)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(16,852)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_5"></A>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(In&nbsp;thousands,<BR>except&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>convertible</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">paid-in</FONT></B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated<BR>other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>comprehensive</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>stockholders&#146;</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>income (loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 74,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,561,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(25,191)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(122)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(25,211)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">836,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 74,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,397,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (42,018)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (147)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (41,701)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $334</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">756,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock issuance for litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,241,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;6,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (22,607)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (16,028)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statement </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_6"></A>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated statements of cash flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to cash (used in) provided by operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for excess and obsolete inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense for accretion of legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from Paycheck Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Paycheck Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(33<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(587<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash&nbsp;investing</FONT> and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option exercise in accounts receivable at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock issuance for legal settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statement </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_7"></A>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to consolidated financial statements </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Description of business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cytek Biosciences, Inc. (&#147;Cytek&#148; or the &#147;Company&#148;) is a life sciences technology company advancing the next
generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical
applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has successfully developed and manufactured its full spectrum flow cytometry platform
(&#147;instrument(s)&#148; or &#147;product(s)&#148;). The Company believes its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity
cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). The Company&#146;s novel approach harnesses the
power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. The Company&#146;s FSP platform includes instruments, reagents, software, and services to provide a
comprehensive and integrated suite of solutions for its customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated in the state of Delaware
in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Basis of presentation and summary of significant accounting policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has prepared the accompanying financial statements in accordance with accounting principles generally accepted in
the United States of America (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards
Updates (&#147;ASUs&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The consolidated financial statements include the accounts of Cytek Biosciences, Inc., and its wholly-owned subsidiaries, Cytek
Limited (HK), Cytek Biosciences B.V. (Europe), Cytek (Shanghai) Biosciences Co., Ltd., Cytek Biosciences (Wuxi) Co. Ltd., Cytoville Biosciences Shanghai Co., Ltd. and Cytek (Shanghai) Software Development Technology Co., Ltd. All intercompany
accounts and transactions have been eliminated in consolidation. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July 16, 2021, the Company effected a 1.3333-for-1 stock split of its common stock and redeemable convertible preferred
stock. All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of
estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s consolidated financial statements and
accompanying notes as of the date of the consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is subject to risks and uncertainties as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.
The future impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic remains uncertain as the response to the pandemic is in its incipient stages and information is rapidly evolving. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, a novel strain of coronavirus, which causes the disease known
<FONT STYLE="white-space:nowrap">as&nbsp;COVID-19,&nbsp;was</FONT> reported to have surfaced in Wuhan, China. Since <FONT STYLE="white-space:nowrap">then,&nbsp;COVID-19&nbsp;coronavirus</FONT> has spread globally. In March 2020, the World Health
Organization declared <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;outbreak</FONT> a pandemic. <FONT STYLE="white-space:nowrap">The&nbsp;COVID-19&nbsp;pandemic</FONT> has and may continue to impact the Company&#146;s manufacturing
facilities (in Fremont, California and Wuxi, China) and its third-party manufacturers and suppliers, which could disrupt its supply chain or the availability or cost of materials. The effects of the public health directives and the Company&#146;s
work-from-home policies may negatively impact productivity, disrupt its business and delay Company&#146;s operations, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the
Company&#146;s ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company&#146;s operations could negatively impact business, results of operations and financial condition, including
its ability to obtain financing. For the years ended December&nbsp;31, 2019 and 2020, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and is not aware of any specific related event or
circumstances that would require the Company to revise its estimates reflected in these consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company cannot be certain what the overall impact of
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> will be on its business and prospects. The extent to which <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> will further directly or indirectly impact its
business, results of operations, financial condition, liquidity and research and development costs will depend on future developments that are highly uncertain including as a result of new information that may emerge
<FONT STYLE="white-space:nowrap">concerning&nbsp;COVID-19,&nbsp;the</FONT> actions taken to contain or treat it, and the duration and intensity of the related effects. In addition, the Company could see some limitations on employee resources that
would otherwise be focused on its operation including but not limited to sickness of employees or their families, the desire of employees to avoid contact with large groups of people, and increased reliance on working from home. If the financial
markets and/or the overall economy are adversely impacted for an extended period, the Company&#146;s business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise about which separate discrete information is available for
evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#146;s Chief Executive Officer, who is the chief operating decision maker, reviews financial
information on an aggregate basis for allocating and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency translation and transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has determined that the functional and reporting currency for its operations across the globe is the functional
currency of the Company&#146;s international subsidiaries. Accordingly, all foreign balance sheet accounts have been translated into U.S. dollars using the rate of exchange at the respective balance sheet date. Components of the consolidated
statements of operations and comprehensive income (loss) have been translated at the average exchange rate for the year or the reporting period. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a
component of stockholders&#146; deficit. Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in the consolidated statements of operations
and comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, cash equivalents and restricted cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash
equivalents. Cash equivalents are carried at cost, which approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s cash and cash
equivalents consist of money held in demand depositary accounts and money market funds. The carrying amount of cash and cash equivalents was $30.1&nbsp;million and $165.2&nbsp;million as of December&nbsp;31, 2019 and 2020, respectively, which
approximates fair value and was determined based upon Level&nbsp;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&nbsp;1. The Company limits its credit risk
associated with cash and cash equivalents by maintaining its bank accounts at major and reputable financial institutions. The Company&#146;s cash and cash equivalents balance exceeded the federally insured limit of $250,000 as of December&nbsp;31,
2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company classifies restricted cash as current and noncurrent on the accompanying consolidated balance
sheets based upon the term of the remaining restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides a reconciliation of cash, cash
equivalents and restricted cash on the consolidated balance sheets to the totals presented on the consolidated statements of cash flows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents&#151;money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash as presented on the consolidated statements of
cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade accounts receivable, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for
doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company&#146;s
customers&#146; respective financial conditions, the amounts of receivables in dispute and the current receivables aging and current payment patterns. To the extent identified, account balances are charged off against the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. To date, the Company&#146;s customers have primarily been large pharmaceutical companies, biopharmaceutical companies, leading academic research centers and
clinical research organizations and therefore, the Company has not had any material write-offs or allowance for doubtful accounts for the presented periods. The Company recorded no activity for its allowance for doubtful accounts for the year ended
December&nbsp;31, 2019. The allowance for doubtful accounts was $175,000 for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost, which approximates
actual cost on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;first-in,&nbsp;first-out&nbsp;basis.</FONT></FONT> Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable
value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of sales and establish a new cost basis for the inventory. Inventories include raw materials, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">work-in-process</FONT></FONT> and finished goods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line
method based on the estimated useful lives of the depreciable property or, for leasehold </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improvements, the remaining term of the lease, whichever is shorter. Assets not yet placed in use are not depreciated. The Company&#146;s estimated useful lives of its property and equipment are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated Useful
Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shorter of expected lease term or estimated useful
life</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon sale or retirement of the assets, the cost and related accumulated depreciation are
removed from the accounts and the resulting gain or loss is recognized in the statement of operations and comprehensive income (loss). Expenditures for general maintenance and repairs are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and intangible assets, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2015, the Company entered into a purchase agreement with Cytek Development&nbsp;Technology (&#147;Cytek Tech&#148;)
involving the acquisition of substantially all assets of Cytek Tech for the aggregate purchase amount of $900,000 in cash and the assumption of Cytek Tech liabilities. The Company recorded goodwill of $476,000 and intangible&nbsp;assets of $476,000
at the transaction date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwill represents the excess of the purchase price over the fair value of the net tangible and
identifiable intangible assets acquired in a business combination. Intangible assets resulting from the acquisition of entities are estimated by management based on the fair value of assets received. Intangible assets are amortized on a
straight-line basis over the estimated useful lives. The Company&#146;s estimated useful lives of its intangible assets are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated Useful
Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 years</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 years</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwill and intangible assets are tested for impairment on an annual basis or whenever events
or changes in circumstances indicate the carrying amount of these assets may not be recoverable. The Company has a single operating segment and a single reportable segment. The Company is also treated as one reporting unit, the level at which
impairment testing is performed. The Company conducts its annual goodwill impairment test on October 1. There was no impairment of goodwill or intangible assets recorded for the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value of financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price)
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and
the last is considered unobservable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no
market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is
significant to the fair value measurement. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, restricted cash, trade
accounts receivable, net, trade accounts payable and accrued expenses approximate their fair values. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s product revenue consists of sales of its instrument systems and accessories. The Company recognizes product
revenue at the point in time when control of the instrument is transferred to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s service
revenue primarily consists of post-warranty service contracts, installations and repairs which are recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are
recognized as they are delivered to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue is recognized when control of promised goods or services is
transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance
obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Invoicing for products occurs upon delivery and payment terms are 30&nbsp;to 90&nbsp;days. Service contracts are invoiced
upfront and payment terms are generally 30&nbsp;days. For those arrangements that have terms greater than one year, any payments received upfront are for reasons other than financing. Revenue is recognized only to the extent that it is probable that
a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration is not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of the Company&#146;s sales contracts involve the delivery or performance of multiple products and services within
contractually binding arrangements. The Company has determined these performance obligations qualify as distinct performance obligations, as the customer can benefit from the good or service on its own or together with other resources that are
readily available to the customer, and the Company&#146;s promise to transfer the good or service is separately identifiable from other promises in the contract. For these arrangements that contain multiple performance obligations, the Company
allocates transaction price based on the relative standalone selling price (&#147;SSP&#148;) method by comparing the SSP of each distinct performance obligation to the total value of the contract. The Company uses a range of amounts to estimate SSP
for products and services sold together in a contract to determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In instances where SSP is not directly observable, such as when the
Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to
governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s standard arrangement for sales to end users is a purchase order or an executed contract. Revenue is
recognized upon transfer of control of the product to the customer, which occurs at a point in time depending on the shipping terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s arrangements with its distributors include a purchase order. The purchase order is governed by terms and
conditions set forth in the applicable distribution agreement. Revenue is recognized upon transfer of control of the products to the distributor, which occurs at a point in time depending on the shipping terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company&#146;s service revenue primarily consists of post-warranty service contracts, installations and repairs, which are recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations
and repair services are recognized as they are delivered to the customer. Service contracts are typically between one and three years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract
liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contract liabilities consist of fees invoiced or paid by the Company&#146;s customers for which the
associated services have not been performed and revenue has not been recognized based on the Company&#146;s revenue recognition criteria described above. Such amounts are reported as deferred revenue for service and customer deposits for instruments
on the consolidated balance sheets. Deferred revenue that is expected to be recognized during the following 12 months is recorded as a current liability and the remaining portion is recorded as&nbsp;noncurrent.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assurance-type product warranties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company provides <FONT STYLE="white-space:nowrap">a&nbsp;one-year&nbsp;assurance-type</FONT> warranty that is included with
the sale of its instruments. At the time revenue is recognized for the products, the Company establishes an accrual for estimated warranty expense based on historical data and trends of product reliability and costs of repairing and replacing
defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the historical repair costs. While management believes that historical experience provides a reliable basis for estimating such
warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company&#146;s products could result in actual expenses that are
below those currently estimated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred offering costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred offering costs, which consist of direct incremental legal, consulting, banking and accounting fees relating to the
Company&#146;s planned initial public offering (&#147;IPO&#148;), are capitalized, and will be offset against proceeds from the IPO upon the effectiveness of the offering. In the event an anticipated offering is terminated, deferred offering costs
will be expensed. As of December&nbsp;31, 2019 and 2020, there were no capitalized deferred offering costs. To date, the Company incurred approximately $372,000 of deferred offering costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development expenses to date consist primarily of
salaries, benefits, stock-based compensation, independent contractor costs, laboratory supplies, equipment maintenance, materials expenses, and software license fees. Payments made prior to the receipt of goods or services to be used in research and
development activities are recorded as prepaid expenses until the related goods or services are received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advertising costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cost of advertising, marketing and media is expensed as incurred. For the years ended December&nbsp;31, 2019 and 2020,
advertising, marketing and media expenses totaled $751,000 and $976,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options
to purchase common stock are granted to employees <FONT STYLE="white-space:nowrap">and&nbsp;non-employee&nbsp;consultants.</FONT> Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as
expense over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company records forfeitures as they occur. The weighted-average assumptions used in
estimating the fair value of stock options granted during each of the periods presented are: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected
Volatility</I>&#151;Expected volatility is estimated by studying the volatility of selected industry peers deemed to be comparable to our business corresponding to the expected term of the awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Term</I>&#151;Expected term represents the period that our stock-based awards are expected to be outstanding and
is determined using the simplified method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividend Yield</I>&#151; The expected dividend yield is zero as we have
never declared or paid cash dividends and have no current plans to do so in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-Free Interest
Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issued in effect at the time of grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company accounts for income taxes under an&nbsp;asset and liability&nbsp;approach. Deferred income taxes comprise the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts
recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credit carryforwards measured by applying currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an
amount that is more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determines whether a tax position is more likely than not
to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses <FONT STYLE="white-space:nowrap">a&nbsp;two-step&nbsp;approach</FONT> to recognize
and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority
examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company&#146;s
policy for interest and penalties related to uncertain tax positions is to recognize interest and penalties, if any, as a component of the provision for income taxes in the consolidated statements of operations and comprehensive income (loss) and to
include accrued interest and penalties within the consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company files income tax returns in
the U.S. federal jurisdiction, various U.S. state jurisdictions and foreign jurisdictions. The U.S. state and foreign jurisdictions have statutes of limitations that generally range from three to five years. The Company&#146;s federal, state and
foreign income tax returns are subject to examination unless the statutes of limitations close. The Company is not currently under examination for federal, state, and foreign income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company intends to reinvest its undistributed earnings of its foreign
operations. Following enactment of the 2017 Tax Cuts and Jobs Act, the repatriation of cash to the United States is generally no longer taxable for federal income tax purposes. However, the repatriation of cash held outside the United States could
be subject to applicable foreign withholding taxes and state income taxes. The Company may remit foreign earnings to the United States to the extent it is tax efficient to do so. It does not expect the tax impact from remitting these earnings to be
material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net income (loss) attributable to common stockholders per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net income (loss) attributable to common stockholders per share and diluted net income (loss) attributable to common
stockholders per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net income (loss) per share attributable to common stockholders is calculated using the
<FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines net income (loss) per share for the holders of shares of the Company&#146;s common stock and participating securities. The
Company&#146;s redeemable convertible preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities include a contractual obligation to participate in the
income of the Company and are included in the calculation of net income per share in the periods in which net income is recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Diluted net income attributable to common stockholders per share is computed using the more dilutive of (a)&nbsp;the <FONT
STYLE="white-space:nowrap">two-class</FONT> method or (b)&nbsp;the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company allocates earnings first to preferred stockholders based on
<FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend rights if and when declared and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation
of diluted net income attributable to common stockholders per share gives effect to all potentially dilutive common stock equivalents, including outstanding options and redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock equivalents are excluded from the computation of diluted net income (loss) attributable to common stockholders
per share if their effect is antidilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS
Act&#148;). Under the&nbsp;JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the&nbsp;JOBS Act, until such time as those standards apply to private companies. The Company
has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging
growth company or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the&nbsp;JOBS Act. The Company has, however, elected to early-adopt as permitted certain new or revised accounting standards as of dates
that may or may not coincide with the effective dates of public companies. These standards include the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May
2014, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09</FONT> <I>Revenue from Contracts with Customers (Topic</I><I></I><I>&nbsp;606)</I> (&#147;Topic&nbsp;606&#148;). Topic&nbsp;606 and its related amendments supersede Revenue
Recognition (Topic&nbsp;605), issued in June 2010, and provides principles for recognizing revenue for goods and services in a manner consistent with the transfer of control of those goods and services to the customer<B><I>. </I></B>The Company
adopted the requirements of Topic 606 using the modified retrospective method on January&nbsp;1, 2018 with such adoption not having a material impact to the Company&#146;s financial statements. Under the modified retrospective method, this guidance
is applied to those contracts that were not completed as of January&nbsp;1, 2019, with no restatement of contracts that were commenced and completed within fiscal years prior to January&nbsp;1, 2019, and the prior period comparable financial
information continues to be presented under the guidance of ASC 605, <I>Revenue Recognition</I> (&#147;ASC 605&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2018-07,</FONT> <I>Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting </I>(&#147;Topic 718&#148;). This ASU expanded the scope of Topic 718 to include share-based
payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> for goods or services. The Company adopted the requirements of Topic 718 on January&nbsp;1, 2018 with such adoption not having a material impact to the Company&#146;s
consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU 2018-13, <I>Fair</I><I> </I><I>Value
Measurement</I><I> </I><I>(Topic</I><I> </I><I>820):</I><I> </I><I>Disclosure Framework&#151;Changes </I><I></I><I>to </I><I></I><I>the </I><I></I><I>Disclosure </I><I></I><I>Requirements </I><I></I><I>for </I><I></I><I>Fair </I><I></I><I>Value
</I><I></I><I>Measuremen</I><I>t</I>, which amends the disclosure requirements for fair value measurements by removing, modifying, and adding certain disclosures. This new standard was effective for the Company January 1, 2020. This will require
application of the new accounting guidance at the beginning of the earliest comparative period presented in the year of adoption. The Company adopted the requirements of Topic 820 on January 1, 2020 with such adoption not having a material impact to
the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent accounting pronouncements not yet adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842)</I>, as
subsequently amended (&#147;Topic&nbsp;842&#148;), to improve financial reporting and disclosures about leasing transactions. This ASU requires companies that lease assets to recognize on the balance sheet the assets and liabilities for the rights
and obligations created by those leases, where the lease terms exceed 12 months. The recognition, measurement and presentation of expense and cash flows arising from a lease by a lessee will depend primarily on its classification as a finance or
operating lease; both types of leases will be recognized on the balance sheet. This ASU also requires disclosures to help financial statement users to better understand the amount, timing and uncertainty of cash flows arising from leases. On
June&nbsp;3, 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-05,</FONT> which amended the effective dates of Topic 842 to give immediate relief from business disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic and provides a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of the effective date for nonpublic companies. Therefore, for public companies, the effective date is still December&nbsp;15, 2018, while the effective date for
private companies will now be&nbsp;fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. The Company is currently evaluating the impact of this standard on its
consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic</I><I></I><I>&nbsp;326): Measurement of Credit Losses on Financial Instruments</I>, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal year beginning
January&nbsp;1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;2019-12,</FONT><I>&nbsp;Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes</I>, which removes certain exceptions related to intra-period tax allocations and deferred tax accounting on outside basis differences in foreign subsidiaries and equity method investments.
Additionally, it provides other simplifying measures for the accounting for income taxes. <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;is</FONT> effective for the Company in the first quarter of 2021 and early adoption is permitted. The
Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Concentrations of credit risk and other risks and uncertainties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash
equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository
institutions in which these deposits are held and of the money market funds in which these investments are made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Revenue from contracts with customers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disaggregation of revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table depicts the disaggregation of revenue by sales channel mix and customer mix as defined by the nature of
workflows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sales channel mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct sales channel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributor channel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Customer mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Academia and government</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology, pharmaceutical, distributor and CRO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue by geographical markets are presented in Note 19 Geographic areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Remaining performance obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table includes estimated revenues expected to be recognized in the future related to performance obligations that
are unsatisfied (or partially satisfied) as of December&nbsp;31, 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Greater&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract balances </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides information about receivables, customer deposits and deferred revenue from contracts with
customers (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer deposit, which are included in &#145;Other current liabilities&#146;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a rollforward of the contract liabilities (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contract liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,745</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Balance sheet details </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following table shows the components of inventory (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Work-in-process</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid expenses and other current assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of prepaid expenses and other current assets (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax refund receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other noncurrent assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of other noncurrent assets (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the income taxes analysis refer to Note&nbsp;14. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of accrued expenses (in thousands):<B><I> </I></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product warranty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the product warranty analysis refer to Note 17. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other current liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of other current liabilities (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paycheck Protection Program loan (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and use tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Fair value of financial instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in
an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The
following table sets forth the fair value of the Company&#146;s financial assets and liabilities by level within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;prices<BR>in&nbsp;active<BR>markets&nbsp;for<BR>identical<BR>assets<BR>(level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>unobservable<BR>inputs<BR>(level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;prices<BR>in&nbsp;active<BR>markets&nbsp;for<BR>identical<BR>assets<BR>(level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>unobservable<BR>inputs<BR>(level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;prices<BR>in&nbsp;active<BR>markets&nbsp;for<BR>identical<BR>assets<BR>(level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>unobservable<BR>inputs<BR>(level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not have any transfers of financial assets measured at fair value on a
recurring basis to or from Level&nbsp;1, Level&nbsp;2 or Level&nbsp;3 for any of the periods presented. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Property and equipment, net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of property and equipment, net (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total depreciation expense for the years ended December&nbsp;31, 2019 and 2020 was $211,000
and $532,000, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Goodwill and intangible assets, net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no changes in goodwill for the fiscal years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of intangible assets, net (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total amortization expense for the years ended December&nbsp;31, 2019 and 2020 was $98,000 and
$71,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Legal settlement liability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of the legal settlement liability (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Refer to Note 15 Commitments and contingencies for a description of the litigation settlement.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Redeemable convertible preferred stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2015, the Company entered into a Series A Preferred Stock Purchase Agreement (&#147;Series A Agreement&#148;) with
certain investors pursuant to which it sold and issued 9,799,755 shares of Series A&nbsp;redeemable convertible preferred stock (&#147;Series A shares&#148;) at a purchase price of $0.38 per share in the initial closing. In July 2015,&nbsp;the
Company sold and issued an additional 8,166,462 Series A shares at&nbsp;a purchase price of $0.38 per share pursuant to a subsequent closing under the Series A Agreement. In October 2015, the Company sold and issued an&nbsp;additional 14,699,632
Series A shares at a purchase price of $0.38 per&nbsp;share pursuant to a milestone closing under the Series A Agreement. A total of 32,665,849 Series A shares were issued for&nbsp;$12.2&nbsp;million, net of issuance costs of $89,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2016, the Company entered into a Series B Preferred Stock Purchase&nbsp;Agreement (&#147;Series B Agreement&#148;)
with certain investors pursuant to which it sold and issued 9,888,639 shares of&nbsp;Series B convertible redeemable preferred stock (&#147;Series B shares&#148;) at a purchase price of $0.75 per share in the initial closing. In&nbsp;January 2018,
the Company sold and issued an additional 6,110,957 Series B&nbsp;shares at a purchase price of $0.75 per share pursuant to a milestone closing&nbsp;under the Series B Agreement.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2018, the Company entered into a Series C Preferred Stock Purchase&nbsp;Agreement (&#147;Series C
Agreement&#148;) with certain investors pursuant to which it sold and issued 18,717,804 shares&nbsp;of Series C convertible redeemable preferred stock (&#147;Series C shares&#148; and together with Series A shares, Series B shares and Series C
shares, the &#147;2018 Preferred Stock&#148;) at a purchase price of $2.40 per share in the initial closing.&nbsp;In November and December 2018, the Company sold and issued an additional 2,501,265 and 2,084,387 Series C shares, respectively, at a
purchase price of $2.40 per share pursuant to subsequent closings under the Series C Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2018, the
Company repurchased 2,452,270 Series A shares at a price per share of $2.04 (&#147;Series&nbsp;A Repurchase&#148;), for an aggregate purchase&nbsp;price of $5.0&nbsp;million. In connection with the Series A&nbsp;Repurchase, the Company filed a
Certificate of Retirement with the Secretary of State in&nbsp;the State of Delaware to (i)&nbsp;cancel and retire the repurchased shares as required by the Company&#146;s Amended and Restated Certificate of Incorporation, (ii)&nbsp;reduce the number
of 2018 Preferred Stock authorized under the Company&#146;s Amended&nbsp;and Restated Certificate of Incorporation to 70,212,570 from 72,664,850 and (iii)&nbsp;reduce the number of Series A shares authorized under the&nbsp;Company&#146;s Amended and
Restated Certificate of Incorporation 30,213,574 from 32,665,849. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, under the amended and restated
certificate of incorporation dated October&nbsp;22, 2020 (&#147;October COI&#148;), the Company issued 17,752,068 shares of Series D redeemable convertible preferred stock (&#147;Series D shares&#148; and together with Series A shares, Series B
shares, Series C shares, the &#147;Preferred Stock&#148;) at a purchase price of $6.76 per share for net proceeds of $119.7&nbsp;million and authorized the reduction of the Series C to 23,303,456. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock at December&nbsp;31, 2019 consists of the following (in
thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>issued and<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>issue&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,999,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,212,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock at December&nbsp;31, 2020 consists of the following (in thousands,
except shares and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>issued and<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>issue&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 11,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has classified its Preferred Stock as temporary equity in the accompanying
consolidated balance sheets due to terms that allow for redemption of the shares upon certain change in control events that are outside of the Company&#146;s control, including sale or transfer of control of the Company, as holders of the Preferred
Stock could cause redemption of the shares in these situations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rights, preferences and privileges of the holders of
Preferred Stock, respectively: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of Series D shares, in preference to the holders of Series C shares, Series B shares, Series A shares and common stock,
shall be entitled to receive, when, as and if declared by the Board of Directors of the Corporation (the &#147;Board&#148;) cash or stock dividends at the rate of 8% of the Series D Original Issue Price (as defined below) per annum on each
outstanding Series D shares. Holders of Series C shares, in preference to the holders of Series B shares, Series A shares and common stock, shall be entitled to receive, when, as and if declared by the Board, cash or stock dividends at the rate of
8% of the Series C Original Issue Price (as defined below) per annum on each outstanding Series C shares. Holders of Series B shares, in preference to the holders of Series A shares and common stock, shall be entitled to receive, when, as and if
declared by the Board, cash or stock dividends at the rate of 8% of the Series B Original Issue Price (as defined below) per annum on each outstanding Series B shares. Holders of Series A shares, in preference to the holders of common stock, shall
be entitled to receive, when, as and if declared by the Board, cash or stock dividends at the rate of 8% of the Series A Original Issue Price (as defined below) per annum on each outstanding Series A shares. The dividends are <FONT
STYLE="white-space:nowrap">non-cumulative.</FONT> Through December&nbsp;31, 2020, no cash dividends have been declared by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock is convertible, at the option of the holder, at any time, into shares of common stock.
The number of shares is determined by dividing the original issuance price by the conversion price, which is also equal to the original issuance price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The conversion price of the Preferred Stock is subject to adjustment to
prevent dilution in the event that the Company issues additional shares of common stock at a price per share less than the applicable conversion price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock will automatically convert into shares of common stock at the then effective conversion price
for each such share immediately upon the earlier of (i)&nbsp;the Company&#146;s sale of its common stock in an underwritten public offering pursuant to a registration statement under the&nbsp;Securities Act 1933, as amended,&nbsp;resulting in
aggregate gross proceeds to the Company of at least $50.0&nbsp;million, or (ii)&nbsp;the date specified by the written consent of the holders of a majority of the then outstanding shares of Preferred Stock, consenting or voting together as a single
class on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon liquidation, dissolution, or winding up of the Company, or upon a change of control or a sale of substantially all of the
Company&#146;s assets, the holders of the outstanding Series D shares shall be entitled to receive, prior and in preference to any distribution to the holders of the Series C shares, Series B shares, Series A shares and common stock, an amount per
share equal to the greater of (i)&nbsp;one times the original issue price plus any dividends accrued but unpaid thereon, or (ii)&nbsp;an amount that would have been paid had such shares been converted into common stock immediately prior to such
liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to the Series D holders, holders of the Series C shares shall be entitled to receive,
prior and in preference to any distribution to the holders of Series B shares, Series A shares and common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any dividends accrued but unpaid thereon, whether
declared, together with any other dividends declared but unpaid, or (ii)&nbsp;an amount that would have been paid had such share been converted into common stock immediately prior to such liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to the Series C holders, holders of the Series B shares shall be entitled to receive, prior and in
preference to any distribution to the holders of shares of Series A shares and common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any dividends declared but unpaid, or (ii)&nbsp;an amount that would have
been paid had such share been converted into common stock immediately prior to such liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to
the Series B holders, holders of the Series A shares shall be entitled to receive, prior and in preference to any distribution to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any
dividends declared but unpaid thereon, or (ii)&nbsp;an amount that would have been payable had such share been converted into common stock immediately prior to such liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The remaining assets will be distributed to holders of the Company&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which such holder&#146;s shares of Preferred Stock are convertible as of the record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time when at least 1,666,625 Series D shares (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination, or other similar recapitalization with respect to the Series D) are outstanding, the holders of record of Series D shares, voting exclusively and as a separate class, shall be entitled to elect one director of the Company
(the &#147;Series D Director&#148;). The holders of record of Series&nbsp;A shares and Series&nbsp;B shares, voting together as a single class (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis in accordance with the
terms of the October COI), are entitled to elect two directors of the Company. The holders of record of Series&nbsp;C shares, voting exclusively as a separate class, are entitled to elect two directors of the Company. The holders of record of the
shares of common stock, voting exclusively and as a separate class, are entitled to elect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
four directors of the Company. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting
together as a single class (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis in accordance with the terms of the October COI), are entitled to elect the balance of the total number of directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred
Stock is redeemable by the Company at a price equal to the applicable original issue price per share, plus any dividends declared but unpaid, commencing on or after the seventh anniversary of the original issue date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Common stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Company has authorized 153,329,500 shares of common stock at $0.001 par value. Holders of
common stock are entitled to one vote per share, and to receive dividends, only and if declared by the Board of Directors and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders,
subordinate to the rights, preferences and privileges of any outstanding Preferred Stock with respect to dividends and in connection with a liquidation, winding up and dissolution of the Company. The holders have no preemptive or other subscription
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2015, the Board approved the 2015 Equity Incentive Plan (&#147;2015 Plan&#148;). The maximum number of
shares of common stock reserved for issuance under the 2015 Plan is 15,157,681. As of December&nbsp;31, 2020 the total number of shares of common stock available for issuance under the 2015 Plan was 6,975,704 shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value of common stock</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the shares of common stock underlying the stock options has historically been determined by the Board.
Because there has been no public market for the Company&#146;s common stock, the Board has determined fair value of the common stock at the time of the option grant by considering a number of objective and subjective factors including valuation of
comparable companies, sales of redeemable convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, amongst others. In
determining the fair value of the common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting
Practice Aid,&nbsp;Valuation of&nbsp;Privately-Held-Company Equity Securities Issued as Compensation. The fair value of the underlying common stock will be determined by the Board, after consideration of a third-party valuation report, until the
Company&#146;s common stock is listed on an established stock exchange or national market system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Stock-based compensation plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows stock option activity during the periods indicated (in thousands except share and per share data):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>options<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,219,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(756,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,174,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,131,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,042,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair value of options granted during the years ended
December&nbsp;31, 2019 and 2020 was $0.44 and $0.97 per share, respectively. There was $0.8&nbsp;million and $1.9&nbsp;million of unrecognized stock-based compensation expense related to unvested stock options as of December&nbsp;31, 2019 and 2020,
respectively. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 2.63 years as of December&nbsp;31, 2020. The total fair value of options vested during the years ended December&nbsp;31, 2019 and 2020 was
$0.2&nbsp;million and $0.5&nbsp;million, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company currently uses authorized and unissued shares to
satisfy option exercises. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the years ended December&nbsp;31, 2019 and 2020, the Company granted 1,423,271 and
1,748,320 options, respectively. The aggregate intrinsic value of options exercised was $486,718 and $918,968 for the years ended December&nbsp;31, 2019 and 2020, respectively. The aggregate intrinsic value is calculated as the difference between
the exercise price and the estimated fair value of the Company&#146;s common stock at the date of exercise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation expense
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the allocation of stock-based compensation expense related to the Company&#146;s
stock-based awards (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company uses the Black-Scholes option pricing model to determine the fair value of stock
options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted-average period of time that the options granted are
expected to be outstanding), volatility of the Company&#146;s common stock and an assumed-risk-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
free interest rate. The following table shows the weighted-average valuation assumptions used in determining the fair value of employee stock options: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Employee benefit plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) retirement savings plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company currently maintains a 401(k) retirement savings plan the covers substantially all of its employees (&#147;401(k)
Plan&#148;). The 401(k) Plan permits voluntary contributions by employees, a portion of which are matched by the Company. The Company&#146;s contributions to the 401(k) Plan were approximately $320,00 and $584,000 for the years ended
December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Income taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2019 and 2020, income from continuing operations before taxes consisted of amounts
related to U.S. operations and income associated with the Company&#146;s foreign operations. The geographical breakdown of the Company&#146;s income (loss) before provision for (benefit from) income taxes is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Income tax expense (benefit) attributable to income from continuing operations consists of (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current tax expense (benefit) .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax rate reconciliation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents a reconciliation of the federal statutory rate to the Company&#146;s effective tax rate: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal tax benefit at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign income taxed at different rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign-derived intangible income deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax impact of foreign earnings and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior year true up due to tax rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Significant components of deferred taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets
and deferred tax liabilities at December&nbsp;31, 2019 and 2020 are presented below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory valuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting method changes for tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company assesses the available positive and negative evidence to estimate if sufficient
future taxable income will be generated to utilize the existing deferred tax assets. During 2020 the Company&#146;s increased U.S. profitability resulted in cumulative profits over the trailing 12 quarters ending June&nbsp;30, 2020. The Company
viewed this historical income as strong objective positive evidence. The Company also considered its projections for future income as additional positive evidence. Based on this evaluation, as of December&nbsp;31, 2020, the full valuation allowance
against U.S. net deferred tax assets has been released in the amount of $6.0&nbsp;million as the deferred tax assets are deemed more likely than not to be realized. The net valuation allowance decreased by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$7.7&nbsp;million for the year ended December&nbsp;31, 2020 as a result of the valuation allowance release for federal and state purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Company maintained a valuation allowance with respect to one of its foreign
subsidiary&#146;s net operating loss that it believes is not more likely than not to be realized. The Company will continue to reassess the valuation allowance annually and if future evidence allows for a partial or full release of the valuation
allowance, a tax benefit will be recorded accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019 and 2020, the Company had federal net
operating loss carryforwards of $700,000 and $0, respectively. As of December&nbsp;31, 2019 and 2020, the Company had federal tax credit carryforwards of $400,000 and $0, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019 and 2020, the Company had state net operating loss carryforwards of $2.5&nbsp;million and
$2.2&nbsp;million, respectively, to reduce future taxable income. The state net operating loss begins to expire in 2028 if not utilized. As of December&nbsp;31, 2019 and 2020, the Company had state tax credit carryforwards of $200,000 and $100,000,
respectively, to offset future tax liability. The credit carryforwards are not subject to expiration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Internal Revenue
Code Section&nbsp;382 places a limitation on the amount of taxable income that can be offset by net operating loss carryforwards and tax credit carryforwards after a greater than 50% change in control in ownership. California has similar rules. The
Company had performed a Section&nbsp;382 analysis and determined that its capitalization have resulted in such a change in prior year and current year. Utilization of the net operating loss carryforwards and tax credit carryforwards had been subject
to the annual limitations under IRC Section&nbsp;382 and similar state provisions. The annual limitation may result in the expiration of the state net operating loss carryforwards before utilization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Uncertain Tax Positions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits as of the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits as of the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for uncertain tax positions under ASC&nbsp;740. As of December&nbsp;31,
2019 and 2020, there was approximately $234,000 and $737,000 of unrecognized tax benefits, respectively. Of the unrecognized tax benefits, $222,000 and $642,000 represents the amount that if recognized, would favorably affect the effective income
tax rate in 2019 and 2020, respectively. The Company does not expect a significant change to its unrecognized tax benefits or recorded liabilities over the next twelve months. The unrecognized tax benefits may increase or change during the next year
for items that arise in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company files income tax returns in U.S. federal
jurisdiction, various state jurisdictions and foreign jurisdictions. The U.S., state and foreign jurisdictions have statutes of limitations that generally range from three to five years. The Company&#146;s federal, state and foreign income tax
returns are subject to examination unless the statutes of limitations close. The Company is not currently under examination for federal, state or foreign income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Commitments and contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company leases office facilities under various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases that expire at various dates. Under certain leases, the Company is responsible for expenses related to operations, maintenance, repairs, and
management fees that are accounted for as operating leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the future minimum lease payments
for the operating leases as of December&nbsp;31, 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Operating<BR>leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rent expense totaled $881,000 and $1.3&nbsp;million for the years ended December&nbsp;31, 2019
and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal proceedings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates the status of each legal matter, if any, and assesses potential financial exposure. If the potential loss
from any legal proceedings or litigation is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether
the amount of the loss is reasonably estimated. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based on the information available at the
time. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;13, 2018, Becton, Dickinson, and Company (&#147;BD&#148;) filed a lawsuit against the Company
alleging trade secret misappropriation and copyright infringement.<I> </I>On October&nbsp;6, 2020, the Company entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which the Company and BD agreed to a mutual release
of all claims against each other as of the date thereof (the &#147;BD Agreement&#148;). Additionally, BD granted Cytek a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, perpetual, worldwide and
<FONT STYLE="white-space:nowrap">non-transferrable</FONT> license to certain BD patents and covenanted that it would not enforce or permit or encourage the enforcement of BD patents against Cytek or its affiliates in connection with the development,
manufacture, use, importation, offer for sale or sale of its then-current instruments. In exchange, the Company agreed that Cytek and its affiliates would not dispute or challenge in a legal proceeding the validity, enforceability or scope of the
applicable BD patent claims and agreed to make certain payments to BD, including (i)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $2.0 million, (ii)&nbsp;a low single digit royalty payment for ten years, based on net
sales of certain of its products, (iii)&nbsp;$6.0 million milestone payment upon the occurrence of a certain sales threshold, and (iv)&nbsp;a specified payment upon the closing of a change of control transaction, if any. The Company also issued
2,087,545 shares of the Company&#146;s common stock to BD during the year ended December&nbsp;31, 2020 in connection with the BD settlement. As of December&nbsp;31, 2020, it was probable that the specified sales milestone would be achieved within
12&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the present value of the consideration payable under the agreement was
$27.9&nbsp;million. The total consideration included $2.0&nbsp;million of cash, 2,087,545 shares of common stock with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
fair value of $5.2&nbsp;million, $6.0&nbsp;million of cash due upon achievement of a specified sales milestone and $14.7&nbsp;million of payments for future licensing rights over ten years. The
Company separated the settlement agreement into two elements, the litigation settlement and future licensing rights. The Company could not readily determine the fair value of the litigation settlement of prior infringement claims between the Company
and BD. Therefore, the Company applied the residual method and allocated the difference between the total present value consideration payable under the BD Agreement and the estimated fair value of the future licensing rights to the litigation
settlement element. The Company determined the estimated fair value of the future licensing rights based on the relief from royalty method was $4.5&nbsp;million with the remaining $23.4&nbsp;million allocated to the litigation settlement. The
significant assumptions used in deriving the fair value of the future licensing rights were the market royalty rate estimated as a royalty rate that a market participant would pay to license the BD intellectual property, the average remaining useful
life of the patents, forecasted sales subject to the market royalty rate and the discount rate. Although the market participant royalty rate is higher than the contractual royalty rate, the average remaining useful life of patents was shorter than
the 10-year contractual term, resulting in the fair market value of the future licensing rights ($4.5&nbsp;million) being less than the total contractual royalty payments ($14.7&nbsp;million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recorded general and administrative expense of $20.0&nbsp;million related to the settlement and $1.7&nbsp;million
product cost of sales related to royalty expense for the year ended December&nbsp;31, 2019. The Company recorded $2.5 million product cost of sales related to royalty expense for the year ended December 31, 2020 and $323,000 of interest expense to
accrete the present value discount of the payment streams over the payment period of ten years from the settlement date using the effective interest rate method. The Company made a one-time upfront payment and issued 2,087,545 shares of the
Company&#146;s common stock to BD during the year ended December&nbsp;31, 2020.&nbsp;The Company recorded legal settlement liability on the consolidated balance sheets of $21.7&nbsp;million and $17.2&nbsp;million as of December&nbsp;31, 2019 and
2020, respectively, and will record licensing expense in future periods. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is not currently involved in
legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material effect on the Company&#146;s financial position, results of operations or liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paycheck Protection Program Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was enacted to,
amongst other provisions, provide emergency assistance for individuals, families and businesses affected by <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> The CARES Act includes a Paycheck Protection Program
(&#147;PPP&#148;) administered through the Small Business Association (&#147;SBA&#148;). Under the PPP, beginning April&nbsp;3, 2020, small businesses and other entities and individuals could apply for loans from existing SBA lenders and other
approved regulated lenders that enroll in the program, subject to numerous limitations and eligibility criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
May&nbsp;7, 2020, the Company received gross proceeds in the amount of approximately $4.1&nbsp;million under the PPP. The PPP, established as part of the CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average
monthly payroll expenses of the qualifying business. As of December&nbsp;31, 2020, the Company has used $2.8&nbsp;million of this loan for eligible purposes, including payroll, benefits, rent and utilities and has returned $1.3&nbsp;million. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Related party transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2017, the Company entered into an agreement with a third-party manufacturing company whereby an executive officer
of the Company was also then a member of the third-party manufacturer&#146;s board of directors. During the years ended December&nbsp;31, 2019 and 2020, the Company paid the third-party manufacturing company $51,000 and $306,000, respectively, for
the purchase of inventory. The Company&#146;s executive officer resigned from the third-party manufacturer&#146;s board of directors in February 2020. As of December&nbsp;31, 2019 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
2020, the Company&#146;s open balances were $45,000 and $41,000, respectively, and are reflected in trade accounts payable and accrued expenses.</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Product warranty </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the activity in the product warranty accrual included in accrued expenses on the consolidated balance
sheets (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual for current year warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warranty cost incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Net income (loss) attributable to common stockholders per share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted income (loss) attributable to common stockholder per share are computed pursuant to <FONT
STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method.</FONT> Under <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method,</FONT> the Company attributes net income (loss) to common stock and other participating rights (including those
with vested share-based awards). Basic&nbsp;net&nbsp;income (loss)&nbsp;attributable to common stockholders per&nbsp;share&nbsp;is calculated by taking net income (loss), less earnings allocated to participating rights, divided by the basic weighted
average common stock outstanding. Diluted&nbsp;net&nbsp;income (loss)&nbsp;attributable to common stockholders per&nbsp;share&nbsp;is calculated using the more dilutive of the treasury-stock method and
<FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method.</FONT> The following table shows the computation of&nbsp;net&nbsp;income&nbsp;(loss) attributable to common stockholders per&nbsp;share&nbsp;on a basic and diluted basis (in thousands
except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: net income allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders, basic and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,126,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,473,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, attributable to common stockholders, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,932,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,599,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, the Company&#146;s potentially dilutive securities were
redeemable convertible preferred stock and options to purchase common stock. Based on the amounts outstanding as of the year ended December&nbsp;31, 2019, the Company excluded the following potential common shares from the computation of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,219,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Geographic areas </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company sells its products worldwide and attributes revenue to the geography where the product is delivered. The
geographical distribution of revenue for the years ended December&nbsp;31, 2019 and 2020 was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EMEA includes Europe, the Middle East and Africa; APAC includes Asia and the Pacific
countries; Other includes Canada and South America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2019 and 2020, the Company had
no major customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019 and 2020, the Company&#146;s long-lived assets by geographic area were
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019 and 2020, substantially all of the Company&#146;s long-lived
assets are located in the United States and in Wuxi, China. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Subsequent events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated all events occurring through April&nbsp;21, 2021, the date on which the consolidated financial
statements were issued, and with respect to the stock split discussed in Note 2, through July 18, 2021, during which time, nothing has occurred outside the normal course of business operations that would require disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_9"></A>Consolidated balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><I>(Unaudited)</I><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">224,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value; 87,268,694 shares authorized as of
December&nbsp;31, 2020 and March&nbsp;31, 2021; 87,268,694 shares issued and outstanding as of December&nbsp;31, 2020 and March&nbsp;31, 2021; aggregate liquidation preference of $199,230 as of December&nbsp;31, 2020 and March&nbsp;31, 2021</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0,001 par value. 153,329,500 authorized shares at December&nbsp;31, 2020 and
March&nbsp;31, 2021; 31,241,916 and 31,775,456 issued and outstanding shares at December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">224,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these interim consolidated financial statements. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_10"></A>Consolidated statements of operations and comprehensive income (loss) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 16,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: net income allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in calculating net income (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,557,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in calculating net income (loss) per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,757,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:68pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these interim consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_11"></A>Consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In&nbsp;thousands,<BR>except&nbsp;share&nbsp;data)</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>convertible<BR>preferred&nbsp;stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,397,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,516,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,495,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In&nbsp;thousands,<BR>except&nbsp;share&nbsp;data)</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>convertible<BR>preferred&nbsp;stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>Comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interest in<BR>consolidated<BR>subsidiary</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,241,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,775,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_12"></A>Consolidated statements of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to cash provided by (used in) operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for excess and obsolete inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses for accretion of legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for additional investment in Cytek Japan, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash&nbsp;investing</FONT> and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred financing costs in accounts payable at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option exercise in accounts receivable at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:52pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these interim consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cytek Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin80783_13"></A>Notes to interim consolidated financial statements </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Description of business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cytek Biosciences, Inc. (&#147;Cytek&#148; or the &#147;Company&#148;) is a life sciences technology company advancing the next
generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical
applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has successfully developed and manufactured its full spectrum flow cytometry platform
(&#147;instrument(s)&#148; or &#147;product(s)&#148;). The Company believes its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high- sensitivity
cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (&#147;Full Spectrum Profiling&#148; or &#147;FSP&#148;). The Company&#146;s novel approach harnesses the
power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. The Company&#146;s FSP platform includes instruments, reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated in the state of Delaware
in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Basis of presentation and summary of significant accounting policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has prepared the accompanying interim consolidated financial statements in accordance with accounting principles
generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and
Accounting Standards Updates (&#147;ASUs&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of consolidation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The interim consolidated financial statements include the accounts of Cytek Biosciences, Inc., its wholly-owned
subsidiaries, Cytek Limited (HK), Cytek Biosciences B.V. (Europe), Cytek (Shanghai) Biosciences Co., Ltd., Cytek Biosciences (Wuxi) Co., Ltd., Cytoville Biosciences Shanghai Co., Ltd. and Cytek (Shanghai) Software Development Technology Co., Ltd.
and its majority-owned subsidiary, Cytek Japan Kabushiki Kaisha (&#147;Cytek Japan&#148;). The noncontrolling interest is presented in stockholders&#146; deficit in the consolidated balance sheets and consolidated statements of redeemable
convertible preferred stock and stockholders&#146; deficit. All intercompany accounts and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock split </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
July&nbsp;16, 2021, the Company effected a 1.3333-for-1 stock split of its common stock and redeemable convertible preferred stock. All share and per share information has been retroactively adjusted to reflect the stock split for all periods
presented. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Variable interest entities and voting interest entities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a
variable interest entity (&#147;VIE&#148;) and therefore subject to the consolidation requirements under the VIE model. Only if the entity does not meet the definition of a VIE, the Company will apply the voting interest model (&#147;VOE&#148;) or
other applicable GAAP. VOEs are entities in which the total equity investment at risk is sufficient to enable the entity to finance itself independently and provides the equity holders with the obligation to absorb losses, the right to receive
residual returns and the right to make decisions about the entity&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
activities. The Company consolidates VOEs in which it has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights.
As defined in applicable accounting standards, VIEs are entities that lack one or more of the characteristics of a voting interest entity. A controlling financial interest in a VIE is present when an enterprise has both the power to direct the
activities of the VIE that most significantly impact the VIE&#146;s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. The Company consolidates a VIE where it
has been determined that the Company is the primary beneficiary of the entity&#146;s operations. The Company does not currently hold an interest in a VIE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the interim consolidated financial statements in conformity with U.S. GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s interim consolidated financial statements and accompanying notes as
of the date of the interim consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited interim financial statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements
and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company&#146;s financial position as of March&nbsp;31, 2021, and its results of operations and comprehensive
income (loss), cash flows and stockholders&#146; deficit for the three months ended March&nbsp;31, 2020 and 2021. The financial data and the other financial information contained in these notes to the interim consolidated financial statements
related to the three-month periods are also unaudited. The results of operations and comprehensive income (loss) for the three months ended March&nbsp;31, 2021 are not necessarily indicative of the results to be expected for the year ending
December&nbsp;31, 2021 or for any other future annual or interim period. These interim consolidated financial statements should be read in conjunction with the Company&#146;s audited consolidated financial statements included elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is subject to risks and uncertainties as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.
The future impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic remains uncertain as the response to the pandemic is in its incipient stages and information is rapidly evolving. In December 2019, a novel strain of coronavirus,
which causes the disease known as <FONT STYLE="white-space:nowrap">COVID-19,</FONT> was reported to have surfaced in Wuhan, China. Since then, <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus has spread globally. In March 2020, the World
Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has and may continue to impact the Company&#146;s manufacturing facilities (in
Fremont, California and Wuxi, China) and its third-party manufacturers and suppliers, which could disrupt its supply chain or the availability or cost of materials. The effects of the public health directives and the Company&#146;s work-from-home
policies may negatively impact productivity, disrupt its business and delay Company&#146;s operations, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#146;s ability to
conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company&#146;s operations could negatively impact business, results of operations and financial condition, including its ability to obtain
financing. For the three months ended March&nbsp;31, 2020 and 2021, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and is not aware of any specific related event or circumstances that
would require the Company to revise its estimates reflected in these interim consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on its business and prospects. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will further
directly or indirectly impact its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
business, results of operations, financial condition, liquidity and research and development costs will depend on future developments that are highly uncertain including as a result of new
information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, and the duration and intensity of the related effects. In addition, the Company could see some limitations on employee
resources that would otherwise be focused on its operation including but not limited to sickness of employees or their families, the desire of employees to avoid contact with large groups of people, and increased reliance on working from home. If
the financial markets and/or the overall economy are adversely impacted for an extended period, the Company&#146;s business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise about which separate discrete information is available for
evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#146;s Chief Executive Officer, who is the chief operating decision maker, reviews financial
information on an aggregate basis for allocating and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency translation and transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has determined that the functional and reporting currency for its operations across the globe is the functional
currency of the Company&#146;s international subsidiaries. Accordingly, all foreign balance sheet accounts have been translated into U.S. dollars using the rate of exchange at the respective balance sheet date. Components of the interim consolidated
statements of operations and comprehensive income (loss) have been translated at the average exchange rate for the year or the reporting period. Translation gains and losses are recorded in accumulated other comprehensive income as a component of
stockholders&#146; deficit. Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in the interim consolidated statements of operations and
comprehensive income (loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, cash equivalents and restricted cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash
equivalents. Cash equivalents are carried at cost, which approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s cash and cash
equivalents consist of money held in demand depositary accounts and money market funds. The carrying amount of cash and cash equivalents was $165.2&nbsp;million and $168.6&nbsp;million as of December&nbsp;31, 2020 and March&nbsp;31, 2021,
respectively, which approximates fair value and was determined based upon Level&nbsp;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&nbsp;1. The Company limits
its credit risk associated with cash and cash equivalents by maintaining its bank accounts at major and reputable financial institutions. The Company&#146;s cash and cash equivalents balance exceeded the federally insured limit of $250,000 as of
December&nbsp;31, 2020 and March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company classifies restricted cash as current and noncurrent on the
accompanying consolidated balance sheets based upon the term of the remaining restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides
a reconciliation of cash, cash equivalents and restricted cash on the consolidated balance sheets to the totals presented on the consolidated statements of cash flow (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents&#151;money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade accounts receivable, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for
doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company&#146;s
customers&#146; respective financial conditions, the amounts of receivables in dispute and the current receivables aging and current payment patterns. To the extent identified, account balances are charged off against the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. To date, the Company&#146;s customers have primarily been large pharmaceutical companies, biopharmaceutical companies, leading academic research centers and
clinical research organizations and therefore, the Company has not had any material write-offs or allowance for doubtful accounts for the presented periods. The following is a summary of the accounts receivables allowance for doubtful accounts for
the year ended December&nbsp;31 and the three months ended March&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Allowance for doubtful account</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Utilization of allowance for doubtful account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Utilization of allowance for doubtful account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost, which approximates
actual cost on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on
assumptions about future demand and market conditions. Inventory write-downs are charged to cost of sales and establish a new cost basis for the inventory. Inventories include raw materials, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">work-in-process</FONT></FONT> and finished goods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line
method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter. Assets not yet placed in use are not depreciated. The Company&#146;s estimated useful lives
of its property and equipment are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated Useful
Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shorter of expected lease term or estimated useful
life</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon sale or retirement of the assets, the cost and related accumulated depreciation are
removed from the accounts and the resulting gain or loss is recognized in the consolidated statement of operations and comprehensive income (loss). Expenditures for general maintenance and repairs are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and intangible assets, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2015, the Company entered into a purchase agreement with Cytek Development Technology (&#147;Cytek Tech&#148;)
involving the acquisition of substantially all assets of Cytek Tech for the aggregate purchase amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$900,000 in cash and the assumption of Cytek Tech liabilities. The Company recorded goodwill of $476,000 and intangible assets of $476,000 at the transaction date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible
assets acquired in a business combination. Intangible assets resulting from the acquisition of entities are estimated by management based on the fair value of assets received. Intangible assets are amortized on a straight-line basis over the
estimated useful lives. The Company&#146;s estimated useful lives of its intangible assets are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated Useful
Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 years</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 years</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value of financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price)
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and
the last is considered unobservable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as
quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is
significant to the fair value measurement. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The carrying amounts reflected in the interim consolidated balance sheets for cash and cash equivalents, restricted cash,
trade accounts receivable, net, trade accounts payable and accrued expenses approximate their fair values. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s product revenue consists of sales of its instrument systems and accessories. The Company recognizes product
revenue at the point in time when control of the instrument is transferred to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s service
revenue primarily consists of post-warranty service contracts, installations and repairs which are recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are
recognized as they are delivered to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue is recognized when control of promised goods or services is
transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance
obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Invoicing for products occurs upon delivery and payment terms are 30 to 90
days. Service contracts are invoiced upfront and payment terms are generally 30 days. For those arrangements that have terms greater than one year, any payments received upfront are for reasons other than financing. Revenue is recognized only to the
extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration is not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of the Company&#146;s sales contracts involve the delivery or performance of multiple products and services within
contractually binding arrangements. The Company has determined these performance obligations qualify as distinct performance obligations, as the customer can benefit from the good or service on its own or together with other resources that are
readily available to the customer, and the Company&#146;s promise to transfer the good or service is separately identifiable from other promises in the contract. For these arrangements that contain multiple performance obligations, the Company
allocates transaction price based on the relative standalone selling price (&#147;SSP&#148;) method by comparing the SSP of each distinct performance obligation to the total value of the contract. The Company uses a range of amounts to estimate SSP
for products and services sold together in a contract to determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In instances where SSP is not directly observable, such as when the
Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales, <FONT STYLE="white-space:nowrap">value-add</FONT> and other taxes, collected from customers concurrent with revenue
generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s standard arrangement for sales to end users is a purchase order or an executed contract. Revenue is
recognized upon transfer of control of the product to the customer, which occurs at a point in time depending on the shipping terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s arrangements with its distributors include a purchase order. The purchase order is governed by terms and
conditions set forth in the applicable distribution agreement. Revenue is recognized upon transfer of control of the products to the distributor, which occurs at a point in time depending on the shipping terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Service revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s service revenue primarily consists of post-warranty service contracts, installations and repairs, which are
recognized over time. Post-warranty service contracts are recognized ratably over the term of the contract and installations and repair services are recognized as they are delivered to the customer. Service contracts are typically between one and
three years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contract liabilities consist of fees invoiced or paid by the Company&#146;s customers for which the associated services have
not been performed and revenue has not been recognized based on the Company&#146;s revenue recognition criteria described above. Such amounts are reported as deferred revenue for service and customer deposits for instruments on the consolidated
balance sheets. Deferred revenue that is expected to be recognized during the following 12 months is recorded as a current liability and the remaining portion is recorded as noncurrent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assurance-type product warranties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company provides a <FONT STYLE="white-space:nowrap">one-year</FONT> assurance-type warranty that is included with the sale
of its instruments. At the time revenue is recognized for the products, the Company establishes an accrual for estimated warranty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expense based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product
warranty costs, using data such as the historical repair costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in
future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company&#146;s products could result in actual expenses that are below those currently estimated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred offering costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred offering costs, which consist of direct incremental legal, consulting, banking and accounting fees relating to the
Company&#146;s planned initial public offering (&#147;IPO&#148;), are capitalized, and will be offset against proceeds from the IPO upon the effectiveness of the offering. In the event an anticipated offering is terminated, deferred offering costs
will be expensed. As of December&nbsp;31, 2020 there were no capitalized deferred offering costs. The Company incurred approximately $369,000 of deferred offering costs as of March&nbsp;31, 2021 which are recorded in other noncurrent assets on the
consolidated balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development expenses to date consist primarily of
salaries, benefits, stock-based compensation, independent contractor costs, laboratory supplies, equipment maintenance, materials expenses, and software license fees. Payments made prior to the receipt of goods or services to be used in research and
development activities are recorded as prepaid expenses until the related goods or services are received. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advertising costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cost of advertising, marketing and media is expensed as incurred. For the three months ended March&nbsp;31, 2020 and 2021,
advertising, marketing and media expenses totaled $313,000 and $197,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options
to purchase common stock are granted to employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants. Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense
over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company records forfeitures as they occur. The weighted-average assumptions used in estimating the
fair value of stock options granted during each of the periods presented are: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected Volatility&#151;Expected
volatility is estimated by studying the volatility of selected industry peers deemed to be comparable to our business corresponding to the expected term of the awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected Term&#151;Expected term represents the period that our stock-based awards are expected to be outstanding and is
determined using the simplified method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividend Yield&#151; The expected dividend yield is zero as we have never
declared or paid cash dividends and have no current plans to do so in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk-Free Interest
Rate&#151;The risk-free interest rate is based on the U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issued in effect at the time of grant for periods corresponding with the expected term of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes under an asset and liability approach. Deferred income taxes comprise the impact of
temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credit carryforwards measured by applying
currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution
of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a <FONT STYLE="white-space:nowrap">two-step</FONT> approach to recognize and measure uncertain tax positions. The first step is to
evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or
litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company&#146;s policy for interest and penalties related to uncertain tax
positions is to recognize interest and penalties, if any, in interest expense and other expense, respectively, in the accompanying consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued expenses in the
consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state
jurisdictions and foreign jurisdictions. The U.S. state and foreign jurisdictions have statutes of limitations that generally range from three to five years. The Company&#146;s federal, state and foreign income tax returns are subject to examination
unless the statutes of limitations close. The Company is not currently under examination for federal, state, and foreign income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company intends to reinvest its undistributed earnings of its foreign operations. Following enactment of the 2017 Tax Cuts
and Jobs Act, the repatriation of cash to the United States is generally no longer taxable for federal income tax purposes. However, the repatriation of cash held outside the United States could be subject to applicable foreign withholding taxes and
state income taxes. The Company may remit foreign earnings to the United States to the extent it is tax efficient to do so. It does not expect the tax impact from remitting these earnings to be material. The Company adopted this guidance on January
1, 2021 on a prospective basis, and the adoption did not have a material impact to the Company&#146;s interim consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net income (loss) attributable to common stockholders per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net income (loss) attributable to common stockholders per share and diluted net income (loss) attributable to common
stockholders per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net income (loss) per share attributable to common stockholders is calculated using the
<FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines net income (loss) per share for the holders of shares of the Company&#146;s common stock and participating securities. The
Company&#146;s redeemable convertible preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities include a contractual obligation to participate in the
income of the Company and are included in the calculation of net income per share in the periods in which net income is recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Diluted net income attributable to common stockholders per share is computed using the more dilutive of (a)&nbsp;the <FONT
STYLE="white-space:nowrap">two-class</FONT> method or (b)&nbsp;the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company allocates earnings first to preferred stockholders based on
<FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend rights if and when declared and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation
of diluted net income attributable to common stockholders per share gives effect to all potentially dilutive common stock equivalents, including outstanding options and redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock equivalents are excluded from the computation of diluted net
income (loss) attributable to common stockholders per share if their effect is antidilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently adopted accounting pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012
(&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The
Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an
emerging growth company or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company has, however, elected to early- adopt as permitted certain new or revised accounting standards as of
dates that may or may not coincide with the effective dates of public companies. These standards include the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2014, the FASB issued ASU 2014-09 <I>Revenue from Contracts with Customers (Topic 606)</I> (&#147;Topic 606&#148;).
Topic 606 and its related amendments supersede Revenue Recognition (Topic 605), issued in June 2010, and provides principles for recognizing revenue for goods and services in a manner consistent with the transfer of control of those goods and
services to the customer. The Company adopted the requirements of Topic 606 using the modified retrospective method on January&nbsp;1, 2018 with such adoption not having a material impact to the Company&#146;s interim consolidated financial
statements. Under the modified retrospective method, this guidance is applied to those contracts that were not completed as of January&nbsp;1, 2019, with no restatement of contracts that were commenced and completed within fiscal years prior to
January&nbsp;1, 2019, and the prior period comparable financial information continues to be presented under the guidance of ASC 605, Revenue Recognition (&#147;ASC&nbsp;605&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> <I>Compensation-Stock Compensation (Topic
718): Improvements to Nonemployee Share-Based Payment Accounting</I> (&#147;Topic 718&#148;). This ASU expanded the scope of Topic 718 to include share-based payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> for goods or
services. The Company adopted the requirements of Topic 718 on January&nbsp;1, 2018 with such adoption not having a material impact to the Company&#146;s interim consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU 2018-13, <I>Fair Value Measurement (Topic 820): Disclosure Framework&#151;Changes to the
Disclosure Requirements for Fair Value Measurement</I>, which amends the disclosure requirements for fair value measurements by removing, modifying, and adding certain disclosures. This new standard was effective for the Company January&nbsp;1,
2020. This will require application of the new accounting guidance at the beginning of the earliest comparative period presented in the year of adoption. The Company adopted the requirements of Topic 820 on January&nbsp;1, 2020 with such adoption
not having a material impact to the Company&#146;s interim consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, which removes certain exceptions related to intra-period tax allocations and deferred tax accounting on outside
basis differences in foreign subsidiaries and equity method investments. Additionally, it provides other simplifying measures for the accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2021, and
interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January&nbsp;1, 2021 on a prospective basis, and the adoption did not have a material impact to the
Company&#146;s interim consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2021, Congress issued American Rescue Plan Act 2021.
The objective of the plan is to expand upon some popular tax credit provisions and makes other changes to a key tax provision regarding compensation deduction limitations. There is no material impact to the Company&#146;s interim consolidated
financial statements due to the American Rescue Plan Act 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent accounting pronouncements not yet adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842)</I>, as
subsequently amended (&#147;Topic 842&#148;), to improve financial reporting and disclosures about leasing transactions. This ASU requires companies that lease assets to recognize on the balance sheet the assets and liabilities for the rights and
obligations created by those leases, where the lease terms exceed 12 months. The recognition, measurement and presentation of expense and cash flows arising from a lease by a lessee will depend primarily on its classification as a finance or
operating lease; both types of leases will be recognized on the balance sheet. This ASU also requires disclosures to help financial statement users to better understand the amount, timing and uncertainty of cash flows arising from leases. On
June&nbsp;3, 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-05,</FONT> which amended the effective dates of Topic 842 to give immediate relief from business disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic and provides a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of the effective date for nonpublic companies. Therefore, for public companies, the effective date is still December&nbsp;15, 2018, while the effective date for
private companies will now be fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. The Company is currently evaluating the impact of this standard on its interim
consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT>
<I>Financial Instruments&#151;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</I>, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal year beginning January&nbsp;1, 2023 and must be adopted using a modified retrospective approach, with certain
exceptions. The Company is currently evaluating the impact of this standard on its interim consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Concentrations of credit risk and other risks and uncertainties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash
equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository
institutions in which these deposits are held and of the money market funds in which these investments are made. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Revenue from contracts with customers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disaggregation of revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table depicts the disaggregation of revenue by sales channel mix and customer mix as defined by the nature of
workflows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months<BR>ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sales channel mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct sales channel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributor channel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Customer mix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Academia and government</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology, pharmaceutical, distributor and CRO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Revenue by geographical markets are presented in Note 20 Geographic areas. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Remaining performance obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table includes estimated revenues expected to be recognized in the future related to performance obligations that
are unsatisfied (or partially satisfied) as of March&nbsp;31, 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Greater&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract balances </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides information about receivables, customer deposits and deferred revenue from contracts with
customers (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer deposits, which are included in &#145;Other current liabilities&#146;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a rollforward of the contract liabilities (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contract liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Balance sheet details </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following table shows the components of inventory (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Work-in-process</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid expenses and other current assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of prepaid expenses and other current assets (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax refund receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other noncurrent assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of other noncurrent assets (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the income taxes analysis refer to Note 14. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of accrued expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product warranty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the product warranty analysis refer to Note 17. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other current liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of other current liabilities (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paycheck Protection Program loan (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and use tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Fair value of financial instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in
an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The
following table sets forth the fair value of the Company&#146;s financial assets and liabilities by level within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;prices<BR>in active<BR>markets for<BR>identical<BR>assets<BR>(level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>unobservable<BR>inputs<BR>(level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;prices<BR>in active<BR>markets for<BR>identical<BR>assets<BR>(level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>unobservable<BR>inputs<BR>(level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not have any transfers of financial assets measured at fair value on a
recurring basis to or from Level&nbsp;1, Level&nbsp;2 or Level&nbsp;3 for any of the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Property and equipment, net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of property and equipment, net (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total depreciation expense for the three months ended March&nbsp;31, 2020 and 2021 was $65,000
and $167,000, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Goodwill and intangible assets, net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no changes in goodwill for the fiscal year ended December&nbsp;31, 2020 and the three months ended March&nbsp;31,
2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total amortization expense for the three months ended March&nbsp;31, 2020 was $40,000. The
Company did not record any amortization expense for the three months ended March&nbsp;31, 2021. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Legal settlement liability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the components of the legal settlement liability (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total legal settlement liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Refer to Note 15 Commitments and contingencies for a description of the litigation settlement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Redeemable convertible preferred stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2015, the Company entered into a Series A Preferred Stock Purchase Agreement (&#147;Series A Agreement&#148;) with
certain investors pursuant to which it sold and issued 9,799,755 shares of Series A redeemable convertible preferred stock (&#147;Series A shares&#148;) at a purchase price of $0.38 per share in the initial closing. In July 2015, the Company sold
and issued an additional 8,166,462 Series A shares at a purchase price of $0.38 per share pursuant to a subsequent closing under the Series A Agreement. In October 2015, the Company sold and issued an additional 14,699,632 Series A shares at a
purchase price of $0.38 per share pursuant to a milestone closing under the Series A Agreement. A total of 32,665,849 Series A shares were issued for $12.2&nbsp;million, net of issuance costs of $89,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2016, the Company entered into a Series B Preferred Stock Purchase Agreement (&#147;Series B Agreement&#148;) with
certain investors pursuant to which it sold and issued 9,888,639 shares of Series B convertible redeemable preferred stock (&#147;Series B shares&#148;) at a purchase price of $0.75 per share in the initial closing. In January 2018, the Company sold
and issued an additional 6,110,957 Series B shares at a purchase price of $0.75 per share pursuant to a milestone closing under the Series B Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2018, the Company entered into a Series C Preferred Stock Purchase Agreement (&#147;Series C Agreement&#148;)
with certain investors pursuant to which it sold and issued 18,717,804 shares of Series C convertible redeemable preferred stock (&#147;Series C shares&#148; and together with Series A shares, Series B shares and Series C shares, the &#147;2018
Preferred Stock&#148;) at a purchase price of $2.40 per share in the initial closing. In November and December 2018, the Company sold and issued an additional 2,501,265 and 2,084,387 Series C shares, respectively, at a purchase price of $2.40 per
share pursuant to subsequent closings under the Series C Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2018, the Company repurchased 2,452,270
Series A shares at a price per share of $2.04 (&#147;Series&nbsp;A Repurchase&#148;), for an aggregate purchase price of $5.0&nbsp;million. In connection with the Series A Repurchase, the Company filed a Certificate of Retirement with the Secretary
of State in the State of Delaware to (i)&nbsp;cancel and retire the repurchased shares as required by the Company&#146;s Amended and Restated Certificate of Incorporation, (ii)&nbsp;reduce the number of 2018 Preferred Stock authorized under the
Company&#146;s Amended and Restated Certificate of Incorporation to 70,212,570 from 72,664,850 and (iii)&nbsp;reduce the number of Series A shares authorized under the Company&#146;s Amended and Restated Certificate of Incorporation 30,213,574 from
32,665,849. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, under the amended and restated certificate of incorporation dated October&nbsp;22, 2020
(&#147;October COI&#148;), the Company issued 17,752,068 shares of Series D redeemable convertible preferred stock (&#147;Series D shares&#148; and together with Series A shares, Series B shares, Series C shares, the &#147;Preferred Stock&#148;) at
a purchase price of $6.76 per share for net proceeds of $119.7&nbsp;million and authorized the reduction of the Series C to 23,303,456. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock at December&nbsp;31, 2020 consists of the following (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>issued&nbsp;and<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>issue&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock at March&nbsp;31, 2021 consists of the following (in
thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(unaudited)</B></P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>issued&nbsp;and<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Original<BR>issue&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,213,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,752,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,268,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has classified its Preferred Stock as temporary equity in the accompanying
interim consolidated balance sheets due to terms that allow for redemption of the shares upon certain change in control events that are outside of the Company&#146;s control, including sale or transfer of control of the Company, as holders of the
Preferred Stock could cause redemption of the shares in these situations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rights, preferences and privileges of the
holders of Preferred Stock, respectively: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of Series D shares, in preference to the holders of Series C shares, Series B shares, Series A shares and common stock,
shall be entitled to receive, when, as and if declared by the Board of Directors of the Corporation (the &#147;Board&#148;) cash or stock dividends at the rate of 8% of the Series D Original Issue Price (as defined below) per annum on each
outstanding Series D shares. Holders of Series C shares, in preference to the holders of Series B shares, Series A shares and common stock, shall be entitled to receive, when, as and if declared by the Board, cash or stock dividends at the rate of
8% of the Series C Original Issue Price (as defined below) per annum on each outstanding Series C shares. Holders of Series B shares, in preference to the holders of Series A shares and common stock, shall be entitled to receive, when, as and if
declared by the Board, cash or stock dividends at the rate of 8% of the Series B Original Issue Price (as defined below) per annum on each outstanding Series B shares. Holders of Series A shares, in preference to the holders of common stock, shall
be entitled to receive, when, as and if declared by the Board, cash or stock dividends at the rate of 8% of the Series A Original Issue Price (as defined below) per annum on each outstanding Series A shares. The dividends are <FONT
STYLE="white-space:nowrap">non-cumulative.</FONT> Through March&nbsp;31, 2021, no cash dividends have been declared by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock is convertible, at the option of the holder, at any time, into shares of common stock.
The number of shares is determined by dividing the original issuance price by the conversion price, which is also equal to the original issuance price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The conversion price of the Preferred Stock is subject to adjustment to prevent dilution in the event that the Company issues
additional shares of common stock at a price per share less than the applicable conversion price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred
Stock will automatically convert into shares of common stock at the then effective conversion price for each such share immediately upon the earlier of (i)&nbsp;the Company&#146;s sale of its common stock in an underwritten public offering pursuant
to a registration statement under the Securities Act 1933, as amended, resulting in aggregate gross proceeds to the Company of at least $50.0&nbsp;million, or (ii)&nbsp;the date specified by the written consent of the holders of a majority of the
then outstanding shares of Preferred Stock, consenting or voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon liquidation, dissolution, or winding up of the Company, or upon a change of control or a sale of substantially all of the
Company&#146;s assets, the holders of the outstanding Series D shares shall be entitled to receive, prior and in preference to any distribution to the holders of the Series C shares, Series B shares, Series A shares and common stock, an amount per
share equal to the greater of (i)&nbsp;one times the original issue price plus any dividends accrued but unpaid thereon, or (ii)&nbsp;an amount that would have been paid had such shares been converted into common stock immediately prior to such
liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to the Series D holders, holders of the Series C shares shall be entitled to receive,
prior and in preference to any distribution to the holders of Series B shares, Series A shares and common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any dividends accrued but unpaid thereon, whether
declared, together with any other dividends declared but unpaid, or (ii)&nbsp;an amount that would have been paid had such share been converted into common stock immediately prior to such liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to the Series C holders, holders of the Series B shares shall be entitled to receive, prior and in
preference to any distribution to the holders of shares of Series A shares and common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any dividends declared but unpaid, or (ii)&nbsp;an amount that would have
been paid had such share been converted into common stock immediately prior to such liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After distribution to
the Series B holders, holders of the Series A shares shall be entitled to receive, prior and in preference to any distribution to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price plus any
dividends declared but unpaid thereon, or (ii)&nbsp;an amount that would have been payable had such share been converted into common stock immediately prior to such liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The remaining assets will be distributed to holders of the Company&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which such holder&#146;s shares of Preferred Stock are convertible as of the record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time when at least 1,666,625 Series D shares (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination, or other similar recapitalization with respect to the Series D) are outstanding, the holders of record of Series D shares, voting exclusively and as a separate class, shall be entitled to elect one director of the Company
(the &#147;Series D Director&#148;). The holders of record of Series A shares and Series B shares, voting together as a single class (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis in accordance with the terms of
the October COI), are entitled to elect two directors of the Company. The holders of record of Series C shares, voting exclusively as a separate class, are entitled to elect two directors of the Company. The holders of record of the shares of common
stock, voting exclusively and as a separate class, are entitled to elect four directors of the Company. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Preferred Stock), exclusively
and voting together as a single class (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis in accordance with the terms of the October COI), are entitled to elect the balance of the total number of directors of the
Company. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock is redeemable by the Company at a price equal to the applicable original issue price per share, plus any
dividends declared but unpaid, commencing on or after the seventh anniversary of the original issue date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Common stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, the Company has authorized 153,329,500 shares of common stock at $0.001 par value. Holders of common
stock are entitled to one vote per share, and to receive dividends, only and if declared by the Board of Directors and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders, subordinate to
the rights, preferences and privileges of any outstanding Preferred Stock with respect to dividends and in connection with a liquidation, winding up and dissolution of the Company. The holders have no preemptive or other subscription rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2015, the Board approved the 2015 Equity Incentive Plan (&#147;2015 Plan&#148;). The maximum number of shares of
common stock reserved for issuance under the 2015 Plan is 15,157,681. As of March&nbsp;31, 2021 the total number of shares of common stock available for issuance under the 2015 Plan was 6,057,200 shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value of common stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the shares of common stock underlying the stock options has historically been determined by the Board.
Because there has been no public market for the Company&#146;s common stock, the Board has determined fair value of the common stock at the time of the option grant by considering a number of objective and subjective factors including valuation of
comparable companies, sales of redeemable convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, amongst others. In
determining the fair value of the common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting
Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The fair value of the underlying common stock will be determined by the Board, after consideration of a third-party valuation report, until the
Company&#146;s common stock is listed on an established stock exchange or national market system. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Stock-based compensation plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows stock option activity during the periods indicated (in thousands except share and per share data):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>options<BR>outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,174,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,559,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair value of options granted during the three months
ended March&nbsp;31, 2020 and 2021 was $0.60 and $3.49 per share, respectively. There was $1.0&nbsp;million and $4.9&nbsp;million of unrecognized stock-based compensation expense related to unvested stock options as of March&nbsp;31, 2020 and 2021,
respectively. The unrecognized stock-based compensation expense as of March&nbsp;31, 2021 is estimated to be recognized over a period of 2.83 years. The total fair value of options vested during the three months ended March&nbsp;31, 2020 and 2021
was $55,000 and $193,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-based compensation expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the allocation of stock-based compensation expense related to the Company&#146;s stock-based awards
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company uses the Black-Scholes option pricing model to determine the fair value of stock
options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted-average period of time that the options granted are
expected to be outstanding), volatility of the Company&#146;s common stock and an assumed-risk free interest rate. The following table shows the weighted-average valuation assumptions used in determining the fair value of employee stock options:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Employee benefit plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) retirement savings plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company currently maintains a 401(k) retirement savings plan the covers substantially all of its employees (&#147;401(k)
Plan&#148;). The 401(k) Plan permits voluntary contributions by employees, a portion of which are matched by the Company. The Company&#146;s contributions to the 401(k) Plan were approximately $132,000 and $170,000 for the three months ended
March&nbsp;31, 2020 and 2021, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Income taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provision for income taxes consists primarily of federal, state, and foreign income taxes. The Company&#146;s income tax
provision may be significantly affected by changes to the Company&#146;s estimates for tax in jurisdictions in which it operates and other estimates utilized in determining the global effective tax rate. Actual results may also differ from the
Company&#146;s estimates based on changes in economic conditions. Such changes could have a substantial impact on the income tax provision. The Company reevaluates the judgments surrounding its estimates and adjusts, as appropriate, each reporting
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s effective tax rate differs from the U.S. federal statutory income tax rate due to state taxes,
global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income, foreign tax rate differences, technology and development tax credits, and <FONT STYLE="white-space:nowrap">non-deductible</FONT> stock-based compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Realization of the Company&#146;s deferred tax assets is dependent primarily on the generation of future taxable income. In
considering the need for a valuation allowance, the Company considers its historical, as well as future projected, taxable income along with other objectively verifiable evidence. Objectively verifiable evidence includes the Company&#146;s
realization of tax attributes, assessment of tax credits, and utilization of net operating loss carryforwards during the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The effective income tax rate was 33% for the three months ended
March&nbsp;31, 2021. The income tax expense for the three months ended March&nbsp;31, 2021 differs from the statutory rate due to nondeductible stock-based compensation, global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income, a
lower tax rate in certain foreign countries where the Company operates, partially offset by a deduction for foreign-sourced revenue, and federal and state research credits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provision for income taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the provision for income taxes for the three months ended March&nbsp;31, 2020 and 2021 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The difference between the effective tax rate in 2020 of (27)% and the federal statutory
income tax rate of 21% was primarily due to foreign income tax on subsidiaries which generate a profit due to intercompany transfer pricing despite the overall loss for the quarter. For the three months ended March 31, 2020, the Company maintained a
full valuation allowance on U.S. and one foreign subsidiary&#146;s deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, the
Company had $906,000 of long-term income tax liabilities related to uncertain tax positions. Because of the high degree of uncertainty regarding the settlement of these liabilities, the Company is unable to estimate the years in which future cash
outflows may occur. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Commitments and contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company leases office facilities under various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases that expire at various dates. Under certain leases, the Company is responsible for expenses related to operations, maintenance, repairs, and
management fees that are accounted for as operating leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the future minimum lease payments
for the operating leases as of March&nbsp;31, 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Operating&nbsp;leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rent expense totaled $302,000 and $415,000 for the three months ended March&nbsp;31, 2020 and
2021, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal proceedings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates the status of each legal matter, if any, and assesses potential financial exposure. If the potential loss
from any legal proceedings or litigation is considered probable and the amount can be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is
reasonably estimated. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based on the information available at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;13, 2018, Becton, Dickinson, and Company (&#147;BD&#148;) filed a lawsuit against the Company alleging trade
secret misappropriation and copyright infringement. On October&nbsp;6, 2020, the Company entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which the Company and BD agreed to a mutual release of all claims against
each other as of the date thereof (the &#147;BD Agreement&#148;). Additionally, BD granted Cytek a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, perpetual, worldwide and <FONT STYLE="white-space:nowrap">non-transferrable</FONT>
license to certain BD patents and covenanted that it would not enforce or permit or encourage the enforcement of BD patents against Cytek or its affiliates in connection with the development, manufacture, use, importation, offer for sale or sale of
its then-current instruments. In exchange, the Company agreed that Cytek and its affiliates would not dispute or challenge in a legal proceeding the validity, enforceability or scope of the applicable BD patent claims and agreed to make certain
payments to BD, including (i)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $2.0&nbsp;million, (ii)&nbsp;a low single digit royalty payment for ten years, based on net sales of certain of its products,
(iii)&nbsp;$6.0&nbsp;million milestone payment upon the occurrence of a certain sales threshold, and (iv)&nbsp;a specified payment upon the closing of a change of control transaction, if any. The Company also issued 2,087,545 shares of the
Company&#146;s common stock to BD during the year ended December&nbsp;31, 2020 in connection with the BD settlement. As of March&nbsp;31, 2021, it was probable that the specified sales milestone would be achieved within 9 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the present value of the consideration payable under the agreement was $27.9&nbsp;million. The
total consideration included $2.0&nbsp;million of cash, 2,087,545 shares of common stock with a fair value of $5.2&nbsp;million, $6.0&nbsp;million of cash due upon achievement of a specified sales milestone and $14.7&nbsp;million of payment for
future licensing rights over ten years. The Company separated the settlement agreement into two elements, the litigation settlement and future licensing rights. The Company could not readily determine the fair value of the litigation settlement of
prior infringement claims between the Company and BD. Therefore, the Company applied the residual method and allocated the difference between the total present value consideration payable under the BD Agreement and the estimated fair value of the
future licensing rights to the litigation settlement element. The Company determined the estimated fair value of the future licensing rights based on the relief from royalty method was $4.5&nbsp;million with the remaining $23.4&nbsp;million
allocated to the litigation settlement. The significant assumptions used were the market royalty rate estimated as a royalty rate that a market participant would pay to license the BD intellectual property, the average remaining useful life of the
patents, forecasted sales subject to the market royalty rate and the discount rate. Although the market participant royalty rate is higher than the contractual royalty rate, the average remaining useful life of patents was shorter than the 10-year
contractual term, resulting in the fair market value of the future licensing rights ($4.5&nbsp;million) being less than the total contractual royalty payments ($14.7&nbsp;million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recorded $465,000 and $682,000 product cost of sales related to royalty expense for the three months ended
March&nbsp;31, 2020 and 2021, respectively, and $0 and $375,000 of interest expense for the three months ended March&nbsp;31, 2020 and 2021, respectively, to accrete the present value discount of the payment streams over the payment period of ten
years from the settlement date using the effective interest rate method. The Company made a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment and issued 2,087,545 shares of the Company&#146;s common stock to BD during the year ended
December&nbsp;31, 2020. The Company recorded legal settlement liability on the consolidated balance sheets of $17.2&nbsp;million and $18.0&nbsp;million as of December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively, and will record licensing
expense in future periods. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is not currently involved in legal actions, nor is management aware of any
potential claims or legal actions, for which the ultimate disposition could have a material effect on the Company&#146;s financial position, results of operations or liquidity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paycheck Protection Program Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was enacted to,
amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The CARES Act includes a Paycheck Protection Program (&#147;PPP&#148;)
administered through the Small Business Association (&#147;SBA&#148;). Under the PPP, beginning April&nbsp;3, 2020, small businesses and other entities and individuals could apply for loans from existing SBA lenders and other approved regulated
lenders that enroll in the program, subject to numerous limitations and eligibility criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;7, 2020, the
Company received gross proceeds in the amount of approximately $4.1&nbsp;million under the PPP. The PPP, established as part of the CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll
expenses of the qualifying business. As of March&nbsp;31, 2021, the Company has used $2.8&nbsp;million of this loan for eligible purposes, including payroll, benefits, rent and utilities and has returned $1.3&nbsp;million. On May 4, 2021, the
Company fully repaid the PPP loan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Investment in Cytek Japan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2019, the Company jointly formed Cytek Japan with TOMY Digital Biology (&#147;TOMY&#148;). Cytek Japan was created for
the purpose of expanding the Company&#146;s presence in Japan. The Company and TOMY each purchased $46,000 of common stock of Cytek Japan. The Company previously accounted for its 50% interest in Cytek Japan as an equity method investment. The
Company recorded $40,000 for its proportionate share of Cytek Japan&#146;s earnings which is included in other expense, net in the consolidated statements of operations and comprehensive income (loss) for the three months ended March&nbsp;31, 2021.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2021, the Company purchased an additional $688,000 of common stock of Cytek Japan and TOMY purchased an
additional $229,000 of common stock of Cytek Japan. The Company&#146;s interest in Cytek Japan increased from 50% to 73% giving the Company controlling interest. The Company consolidated Cytek Japan as of March&nbsp;31, 2021 under the VOE model as
Cytek Japan does not meet the definition of a VIE and as TOMY does not have substantive voting, participating or liquidation rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognized net assets of $1.1 million, consisting primarily of $1.0 million cash. The Company recorded
noncontrolling interest of $315,000 on the consolidated financial statements. The net income attributable to noncontrolling interest was de minimis. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Related party transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2017, the Company entered into an agreement with a third-party manufacturing company whereby an executive officer
of the Company was also a member of the third-party manufacturer&#146;s board of directors. The executive officer of the Company resigned from the third-party manufacturer&#146;s board of directors in February 2020. During the three months ended
March&nbsp;31, 2020, the Company paid the third-party manufacturing company $105,000 for the purchase of inventory. As of December&nbsp;31, 2020 the Company&#146;s open balance was $41,000 and is reflected in trade accounts payable and accrued
expenses. As of March&nbsp;31, 2021, there are no open balances to the third-party manufacturing company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Product warranty </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the activity in the product warranty accrual included in accrued expenses on the consolidated
balance sheets (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual for current year warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warranty cost incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Net income (loss) attributable to common stockholders per share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the computation of the Company&#146;s basic and diluted net income (loss) attributable to
common stockholders per share for the three months ended March&nbsp;31, 2020 and 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss), basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: net income allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,557,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,199,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, attributable to common stockholders, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,454,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,757,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2020 and 2021, the Company&#146;s potentially dilutive securities
were redeemable convertible preferred stock and options to purchase common stock. Based on the amounts outstanding as of March&nbsp;31, 2020 and 2021, the Company excluded the following potential common shares from the computation of diluted net
income (loss) per share attributable to common stockholders because including them would have had an anti- dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">69,516,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,579,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Geographic areas </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company sells its products worldwide and attributes revenue to the geography where the product is delivered. The
geographical distribution of revenue for the three months ended March&nbsp;31, 2020 and 2021 was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EMEA includes Europe, the Middle East and Africa; APAC includes Asia and the Pacific
countries; Other includes Canada and South America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2020 and 2021, the Company
had no major customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020 and March&nbsp;31, 2021, the Company&#146;s long-lived assets by
geographic area were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020 and March&nbsp;31, 2021, substantially all of the Company&#146;s
long-lived assets are located in the United States and in Wuxi, China. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Subsequent events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated all events occurring through June&nbsp;14, 2021, the date on which the condensed consolidated
financial statements were issued, and with respect to the stock split discussed in Note 2, through July 18, 2021, during which time, nothing has occurred outside the normal course of business operations that would require disclosure except for the
following events. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>PPP loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May 4, 2021, the Company repaid in full the outstanding balance of $2.8 million of the PPP loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (25 days after the date of this prospectus), all dealers that effect transactions in the these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.
</I></B></P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>14,564,635 Shares </I></P>  <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80783g77t73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>PRELIMINARY
PROSPECTUS </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><I>MORGAN STANLEY </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><I>GOLDMAN
SACHS&nbsp;&amp; CO. LLC </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><I>PIPER SANDLER </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><I>COWEN </I></P>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table indicates the expenses to be incurred in connection with the offering described in this registration
statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the exchange
listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,850,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#146;s board of
directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our
amended and restated certificate of incorporation upon the closing of this offering permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our
amended and restated bylaws that will be in effect upon the closing of this offering provide that we will indemnify our directors and officers and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by
the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with our directors and officers,
whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to
be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of Cytek Biosciences, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer
reasonably believed to be in, or not opposed to, the best interest of Cytek Biosciences, Inc. At present, there is no pending litigation or proceeding involving a director or officer of Cytek Biosciences, Inc. regarding which indemnification is
sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since January&nbsp;1, 2018, we have issued the following unregistered securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of Preferred Stock </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In January 2018, we sold an aggregate of 6,110,957 shares of Series B redeemable convertible preferred stock
to accredited investors at a purchase price of $0.75 per share for aggregate cash proceeds of approximately $4.6&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">From September 2018 to December 2018, we sold an aggregate of 23,303,456 shares of Series C redeemable
convertible preferred stock to accredited investors at a purchase price of $2.40 per share for aggregate cash proceeds of approximately $55.9&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In October 2020, we sold an aggregate of 17,752,068 shares of Series D redeemable convertible preferred
stock to accredited investors at a purchase price of $6.76 per share for aggregate cash proceeds of approximately $120.0&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option and Common Stock Issuances </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Since January 2018, we granted to certain employees, consultants and directors options to purchase an
aggregate of 6,312,546 shares of our common stock under our 2015 Plan at exercise prices ranging from $0.27 to $6.85 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">From January 2018 through June 2021, we issued an aggregate of 2,661,708 shares of our common stock upon the
exercise of options granted under our 2015 Plan, at exercise prices ranging from $0.09 to $0.92 per share, for an aggregate exercise price of approximately $0.6&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In July 2021, we approved the grant of stock options to purchase 2,857,663 shares of our common stock to
certain employees and executive officers, which grant is contingent and effective upon the effectiveness of this registration statement and will have an exercise price that is equal to the price per share at which our common stock is first sold to
the public in this offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In October 2020, we issued 2,087,545 shares of our common stock to Becton, Dickinson and Company pursuant to
the terms of the BD Agreement. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the foregoing transactions involved any underwriters,
underwriting discounts or commissions, or any public offering. Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act
(and Regulation D or Regulation S promulgated thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to
compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to, or for sale in connection with, any
distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were
made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex11.htm">Form of Underwriting Agreement. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex31.htm">Amended and Restated Certificate of Incorporation of Cytek Biosciences, Inc., as currently in effect.
 </A></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex32.htm">Form of Amended and Restated Certificate of Incorporation of Cytek Biosciences, Inc., to be effective
 on the completion of this offering. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex33.htm">Bylaws of Cytek Biosciences,
 Inc., as currently in effect. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex34.htm">Form of Amended and Restated Bylaws of Cytek Biosciences, Inc., to be effective on the completion
 of this offering. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex41.htm">Form of common stock certificate of Cytek Biosciences, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex51.htm">Opinion of Cooley LLP. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex101.htm">Amended and Restated Investors&#146;
 Rights Agreement, by and among Cytek Biosciences, Inc. and certain of its stockholders, dated October&nbsp;23, 2020. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex102.htm">Cytek Biosciences, Inc. 2015
 Equity Incentive Plan, as amended. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex103.htm">Forms of Option Agreement,
 Notice of Stock Option Grant and Exercise Notice under Cytek Biosciences, Inc. 2015 Equity Incentive Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex104.htm">Cytek Biosciences, Inc. 2021 Equity Incentive Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex105.htm">Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan.
</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex106.htm">Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex107.htm">Form of Indemnification Agreement, by and between Cytek Biosciences, Inc. and each of its directors
 and executive officers. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.8+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex109.htm">Offer letter, by and between
 Cytek Biosciences, Inc. and Patrik Jeanmonod, dated October 5, 2018. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex109.htm">Cytek Biosciences, Inc. Amended and Restated Severance Benefit Plan. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.10#+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex1011.htm">Supply and License Agreement,
 by and between Biotium, Inc. and Cytek Biosciences, Inc., dated as of September&nbsp;1, 2020. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.11#+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex1012.htm">Settlement, License, and Equity
 Issuance Agreement, by and between Becton, Dickinson and Company and Cytek Biosciences, Inc., dated October&nbsp;5, 2020. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.12+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex1013.htm">Lease, by and between Crest
 Properties LLC and Cytek Biosciences, Inc., dated as of July 24, 2015. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.13+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783dex1014.htm">Lease, by and between SNH
 Medical Office Properties Trust and Cytek Biosciences, Inc., dated November 20, 2020. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex211.htm">List of Subsidiaries of Cytek Biosciences, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm.
</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d80783dex51.htm">Consent of Cooley LLP (included in Exhibit 5.1). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">24.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831915/000119312521207678/d80783ds1.htm">Power of Attorney. Reference is
 made to the signature page of the original filing of this Registration Statement. </A></P></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> portions of this
exhibit have been omitted as the registrant has determined that the omitted information is both not material and is the type that the registrant treats as private and confidential. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is
shown in the consolidated financial statements or the notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting
agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant under the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. If a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) For the purpose of determining any liability under the Securities
Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 2 to the
Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on July&nbsp;19, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CYTEK BIOSCIENCES, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/&nbsp;&nbsp;Wenbin Jiang, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wenbin Jiang, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="sig"></A>Pursuant to the requirements of the Securities Act of
1933, this Amendment No. 2 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;Wenbin Jiang,
Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President, Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wenbin Jiang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(Principal Executive Officer) </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;Patrik
Jeanmonod&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patrik Jeanmonod</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(Principal Financial and Accounting Officer) </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Technology Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ming Yan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jack Ball</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tess Cameron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Feng Deng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;19,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gisele Dion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Patrik Jeanmonod</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patrik Jeanmonod</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attorney-in-Fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d80783dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[&#149;] Shares </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK (PAR VALUE $0.001 PER SHARE) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;], 2021
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters named in
Schedule II hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1585 Broadway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10036
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">200
West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper
Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">345 Park Avenue, Suite 1200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10154 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company, LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New
York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cytek
Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several Underwriters named in Schedule&nbsp;II hereto (the &#147;<B>Underwriters</B>&#148;), and certain shareholders of the Company (the
&#147;<B>Selling Shareholders</B>&#148;) named in Schedule I hereto severally propose to sell to the several Underwriters, an aggregate of [&#149;] shares of the common stock (par value $0.001 per share) of the Company (the &#147;<B>Firm
Shares</B>&#148;), of which [&#149;] shares are to be issued and sold by the Company and [&#149;] shares are to be sold by the Selling Shareholders, each Selling Shareholder selling the amount set forth opposite such Selling Shareholder&#146;s name
in Schedule I hereto. As used in this Agreement, the term &#147;<B>Foreign Selling Shareholder</B>&#148; shall mean and include Next Generation DNA Fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also proposes to issue and sell to the several Underwriters not more than an additional [&#149;] shares of its common stock (par
value $0.001 per share) (the &#147;<B>Additional Shares</B>&#148;) if and to the extent that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;), Goldman Sachs&nbsp;&amp; Co. LLC (&#147;<B>Goldman Sachs</B>&#148;), Piper
Sandler&nbsp;&amp; Co. (the &#147;<B>Piper Sandler</B>&#148;) and Cowen and Company, LLC (together with Morgan Stanley, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Goldman Sachs and Piper Sandler, the &#147;<B>Representatives</B>&#148;) as Representatives of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to
purchase such shares of common stock granted to the Underwriters in Section&nbsp;3 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<B>Shares</B>.&#148; The shares of common stock (par value
$0.001 per share) of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; The Company and the Selling Shareholders are hereinafter sometimes
collectively referred to as the &#147;<B>Sellers</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257663),</FONT> including a preliminary prospectus, relating to the Shares. The
registration statement as amended at the time it becomes effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act of 1933, as
amended (the &#147;<B>Securities Act</B>&#148;), is hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters
by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>.&#148; If the Company has filed an abbreviated registration statement to register additional
shares of Common Stock pursuant to Rule&nbsp;462(b) under the Securities Act (a &#147;<B>Rule</B><B></B><B>&nbsp;462 Registration Statement</B>&#148;), then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be deemed
to include such Rule&nbsp;462 Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the
meaning set forth in Rule 405 under the Securities Act, &#147;<B>preliminary prospectus</B>&#148; shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted information pursuant to Rule
430A under the Securities Act that was used after such effectiveness and prior to the execution and delivery of this Agreement, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus contained in the Registration Statement at
the time of its effectiveness together with the documents and pricing information set forth in Schedule III hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule 433(h)(5)
under the Securities Act that has been made available without restriction to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and &#147;Prospectus&#148;
shall include the documents, if any, incorporated by reference therein as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley has agreed to reserve a
portion of the Shares to be purchased by it under this Agreement for sale to the Company&#146;s directors, officers, employees and business associates and other parties related to the Company (collectively, &#147;<B>Participants</B>&#148;), as set
forth in each of the Time of Sale Prospectus and the Prospectus under the heading &#147;Underwriters&#148; (the &#147;<B>Directed Share Program</B>&#148;). The Shares to be sold by Morgan Stanley and its affiliates pursuant to the Directed Share
Program, at the direction of the Company, are referred to hereinafter as the &#147;<B>Directed Shares</B>&#148;. Any Directed Shares not orally confirmed for purchase by any Participant by the end of the business day on which this Agreement is
executed will be offered to the public by the Underwriters as set forth in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Representations and Warranties of the Company. The Company represents and warrants to
and agrees with each of the Underwriters that:</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Registration Statement has become effective; no stop order
suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section&nbsp;8A under the Securities Act are pending before or, to the Company&#146;s knowledge, threatened by the
Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) The Registration Statement, when it became effective, did not contain and, as amended or supplemented,
if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
(ii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will, as of the date of such amendment or supplement, comply in all material respects with the Securities Act and the applicable rules and
regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the
Closing Date (as defined in Section&nbsp;5) and any Option Closing Date (as defined in Section&nbsp;3), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iv)&nbsp;each broadly available road show, if any, when considered together with the Time
of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (v)&nbsp;the
Prospectus, as of its date, does not contain and, as amended or supplemented, if applicable, will not contain, as of its date and at the Closing Date and any Option Closing Date, any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the
Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being
understood and agreed that the only such information furnished by any Underwriter consists of the Underwriter Information (as defined in Section&nbsp;11(b) herein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company is not an &#147;ineligible issuer&#148; in connection with
the offering pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance
with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or
that was prepared by or on behalf of or used or referred to by the Company complies or will comply, as of the date of such filing, in all material respects with the applicable requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule III hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared,
used or referred to, and will not, without the Representatives&#146; prior consent, prepare, use or refer to, any free writing prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in
good standing would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each subsidiary of the Company has been duly incorporated, organized or formed, is validly existing as a corporation or
other business entity in good standing (or its jurisdictional equivalent) under the laws of the jurisdiction of its incorporation, organization or formation, has the corporate or other business entity power and authority to own or lease its property
and to conduct its business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction (to the extent the concept of good
standing is applicable in such jurisdiction) in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly
or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary of the Company have been duly and validly authorized
and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (to the extent such concepts are applicable in such jurisdiction under relevant law) and are owned directly or indirectly by the Company, free and clear of all
liens, encumbrances, equities or claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) This Agreement has been duly authorized, executed and delivered by the
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The authorized capital stock of the Company conforms as to legal
matters, in all material respects, to the description thereof contained in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The shares of Common Stock (including the Shares to be sold by the Selling Shareholders) outstanding prior to the issuance
of the Shares to be sold by the Company have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Shares to be sold by the Company have been duly authorized and, when issued, delivered and paid for in accordance with
the terms of this Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of the Shares will not be subject to any preemptive or similar rights, except as have been duly and validly
waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The execution and delivery by the Company of, and the performance by the Company of its obligations under,
this Agreement will not contravene (i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or bylaws of the Company, (iii)&nbsp;any agreement or other instrument binding upon the Company or any of its subsidiaries, or
(iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except that in the case of clauses (i), (iii) and (iv)&nbsp;as would not, singly or in the aggregate,
reasonably be expected to have a material adverse effect on the Company and its subsidiaries taken as a whole, and no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required for the
performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states or the rules and regulations of the Financial Industry Regulatory Authority
(&#147;<B>FINRA</B>&#148;) in connection with the offer and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its
subsidiaries is (i)&nbsp;in violation of its certificate of incorporation, bylaws or similar organizational document, (ii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any
contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the
properties or assets of the Company or any subsidiary is subject, or (iii)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency
or other authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations, except that in the case of clauses (ii)&nbsp;and (iii) as would not, singly or in the
aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries taken as a whole, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There has not occurred any material adverse change, or any development
involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business, or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) There are no legal or governmental proceedings pending or, to the Company&#146;s knowledge, threatened to which the Company
or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in each of the Registration Statement, the
Time of Sale Prospectus and the Prospectus and proceedings that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the
Company to perform its obligations under this Agreement or to consummate the transactions contemplated by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii)&nbsp;that are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described in all material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration
Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described in all material respects or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment
thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940, as
amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Neither the Company nor any controlled affiliate of the Company, nor to the Company&#146;s knowledge, any
other affiliate, has taken, nor will the Company or any controlled affiliate, or to the Company&#146;s knowledge, any other affiliate, take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which
constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Common Stock or to result in a violation of Regulation M under the Securities Exchange Act of 1934, as amended (the
&#147;<B>Exchange Act</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The Company and each of its subsidiaries (i)&nbsp;are in compliance with
any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental
Laws</B>&#148;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such
permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would
not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or
operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential
liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) There are no contracts, agreements or understandings between the Company and any person granting such person the right to
require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement,
except those contracts, agreements and understandings described in the Time of Sale Prospectus and the Prospectus, all of which have been validly waived in connection with the issuance and sale of the Shares contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) (i) None of the Company or any of its subsidiaries or controlled affiliates, or to the Company&#146;s knowledge, any other
affiliate, or any director, officer, or employee thereof, or, to the Company&#146;s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer,
payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office)
(&#147;<B>Government Official</B>&#148;) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and each of its subsidiaries, controlled affiliates, and to the
Company&#146;s knowledge, each of its other affiliates, have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed
to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment
or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) The
operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by
Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and
each of its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money
Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) (i) None of the Company, any of its subsidiaries, or any
director, officer or employee thereof, or any controlled affiliate, or to the Company&#146;s knowledge, any other affiliate, or to the Company&#146;s knowledge, any agent or representative of the Company, any of its subsidiaries, or any affiliate,
is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#146;s Office of Foreign
Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation,
Crimea, Cuba, Iran, North Korea and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company will not, directly or indirectly, use the proceeds of the
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in any other manner that will result in a violation of
Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Except pursuant to applicable license, the Company and each of its
subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject
of Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) Subsequent to the respective dates as of which information is given in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its subsidiaries, taken as a whole, have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction;
(ii)&nbsp;the Company has not purchased any of its outstanding capital stock, other than from its employees or other service-providers in connection with the termination of their service pursuant to equity compensation plans or agreements described
in the Time of Sale Prospectus or in connection with the exercise of the Company&#146;s right of first refusal upon a proposed transfer, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than
ordinary and customary dividends; and (iii)&nbsp;there has not been any material change in the capital stock (other than the exercise, grant or forfeiture of any equity awards in each case granted pursuant to the equity compensation plans described
in the Time of Sale Prospectus), short-term debt or long-term debt of the Company and its subsidiaries, taken as a whole, except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The Company and each of its subsidiaries do not own any real property. The Company and each of its
subsidiaries have good and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, taken as a whole, in each case free and clear of all liens, encumbrances and defects except
such as are described in the Time of Sale Prospectus or such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and
any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and, to the Company&#146;s knowledge, enforceable leases with such exceptions as are not material and do not materially
interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) (i) The Company and its subsidiaries own or have a valid license to use or can acquire on commercially reasonable terms all
patents, patent applications, inventions, registered and unregistered copyrights (including copyrights in software), community designs, invention disclosures, rights in utility models and industrial designs, rights in technology, software, data and <FONT
STYLE="white-space:nowrap">know-how</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(including trade secrets and other patentable, unpatented and/or unpatentable proprietary or confidential information, systems or procedures), Internet domain names, social media accounts,
trademarks (both registered and unregistered), service marks, trade names, logos, trade dress, design rights, any other designations of source or origin, and any applications (including provisional applications), registrations, or renewals for any
of the foregoing, together with the goodwill associated with any of the foregoing, and rights to publicity and privacy and/or other intellectual property (collectively, &#147;<B>Intellectual Property Rights</B>&#148;) used in or reasonably necessary
for the conduct of their businesses as currently conducted and as their businesses are proposed to be conducted as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, except where the failure to own, possess,
have the right to use or the ability to acquire any of the foregoing would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; (ii)&nbsp;the Intellectual Property Rights owned by the
Company and its subsidiaries and, to the Company&#146;s knowledge, the Intellectual Property Rights exclusively licensed to the Company and its subsidiaries are duly maintained, valid, subsisting and enforceable, except where the failure to do so
would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; (iii)&nbsp;(a) there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by any
third party challenging the validity, ownership, registrability, scope or enforceability of any such Intellectual Property Rights, and (b)&nbsp;neither the Company nor any of its subsidiaries or employees has received any notice, alleging any
infringement, misappropriation or other violation of, or conflict regarding, any Intellectual Property Rights of a third party, and there is no pending or threatened action, suit, proceeding or claim by any third party against the Company or any of
its subsidiaries or employees regarding the foregoing; which with respect to clauses (a)&nbsp;and (b), singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse
effect on the Company and its subsidiaries, taken as a whole, and the Company is unaware of any other fact which would form a reasonable basis for any such claim; (iv)&nbsp;to the Company&#146;s knowledge, no third party is infringing,
misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by the Company or any of its subsidiaries and there is no pending or threatened action, suit, proceeding or
claim by the Company or any of its subsidiaries against a third party regarding the foregoing; (v)&nbsp;to the Company&#146;s knowledge, neither the conduct of the Company&#146;s nor its subsidiaries&#146; respective businesses infringes,
misappropriates or otherwise violates, or has infringed, misappropriated or otherwise violated, any Intellectual Property Right or any third party, except as would not reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole; (vi)&nbsp;all employees or contractors who are, were or are expected to be involved in the development of Intellectual Property Rights for or on behalf of the Company or any of its subsidiaries have executed a valid,
written invention assignment agreement whereby such employees or contractors effectively, presently and validly assign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
all of their right, title and interest in and to such Intellectual Property Rights to the Company or applicable subsidiary, except where the failure to have such an agreement would not reasonably
be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; and (vii)&nbsp;the Company and its subsidiaries use, and have used, all commercially reasonable efforts necessary to appropriately maintain and
protect the confidentiality of all information intended to be maintained as confidential, including any trade secrets and other confidential Intellectual Property Rights, and, to the Company&#146;s knowledge, the confidentiality of such trade
secrets and confidential information has not been compromised or disclosed to or accessed by any third party except pursuant to appropriate nondisclosure and confidentiality agreements. No university, military, educational institution, research
center, governmental entity or other organization has funded, sponsored or contributed to research and development conducted in connection with the business of the Company or any of its subsidiaries that (1)&nbsp;has any claim of right to, ownership
of or other lien on any Intellectual Property Rights or (2)&nbsp;would affect the proprietary nature of any Intellectual Property Rights owned by the Company or restrict the ability of the Company or any of its subsidiaries to enforce, license or
exclude others from using any Intellectual Property Rights owned by the Company or its subsidiaries, except as would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) (i) The Company and its subsidiaries use and have used any and all software and other materials distributed under a
&#147;free,&#148; &#147;open source,&#148; or similar licensing model (including but not limited to the MIT License, Apache License, Microsoft Public License, GNU General Public License, GNU Lesser General Public License and GNU Affero General
Public License) (&#147;<B>Open Source Software</B>&#148;) in compliance with all license terms applicable to such Open Source Software, except where the failure to so be in compliance would not reasonably be expected to have a material adverse
effect on the Company and its subsidiaries, taken as a whole; and (ii)&nbsp;neither the Company nor any of its subsidiaries uses or distributes or has used or distributed any Open Source Software in any manner that requires or has required
(A)&nbsp;the Company or any of its subsidiaries to permit reverse engineering of any software code or other technology owned by the Company or any of its subsidiaries or (B)&nbsp;any software code or other technology owned by the Company or any of
its subsidiaries to be (1)&nbsp;disclosed or distributed in source code form, (2)&nbsp;licensed for the purpose of making derivative works or (3)&nbsp;redistributed at no charge. None of the software developed or owned by the Company or its
subsidiaries is currently held in escrow or subject to any escrow obligation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) (i) The Company and its subsidiaries
have complied and are presently in compliance with all contractual obligations, applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority, in each case, relating to
the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company of personal, personally identifiable or other regulated data (&#147;<B>Data </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<B>Security Obligations</B>&#148;, and such data, &#147;<B>Data</B>&#148;), except where the failure to so be in compliance would not reasonably be expected to have a material adverse effect on
the Company and its subsidiaries, taken as a whole; (ii)&nbsp;neither the Company nor its subsidiaries have received any notification or complaint regarding, and is unaware of any other facts that would reasonably indicate, <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation, which would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; and (iii)&nbsp;there is no action, suit
or proceeding by or before any court or governmental agency, authority or body pending or, to the Company&#146;s knowledge, threatened alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation which would
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) (i)
The Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, technology, data and databases (including Data and data and information of its customers,
employees, suppliers, vendors and any third party maintained, processed or stored by or on behalf of the Company or any subsidiary) used in connection with the operation of the Company and its subsidiaries&#146; business (&#147;<B>IT Systems and
Data</B>&#148;) are reasonably adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, except as would not reasonably be expected to have a
material adverse effect on the Company and its subsidiaries, taken as a whole, and (ii)&nbsp;the IT Systems and Data are free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants, except as would not
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. The Company and its subsidiaries have established, maintain and comply with commercially reasonable data protection controls, policies
and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans that are designed to provide reasonable assurance of protection against breach,
destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of such IT Systems and Data (&#147;<B>Breach</B>&#148;). There has been no Breach, nor to the Company&#146;s
knowledge, has any event occurred or does any condition exist that would reasonably be expected to result in a Breach, the effect of which would reasonably be expected to result in a material adverse effect on the Company and its subsidiaries, taken
as a whole and neither the Company nor its subsidiaries have been obligated to notify any third party, including, without limitation, any individual or data protection authority, of any Breach which would reasonably be expected to result in a
material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) No material labor dispute with the employees of the Company or any of
its subsidiaries exists, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that
would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are, in the reasonable judgment of the Company, prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought
or applied for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as
may be necessary to continue its business at a cost that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) The Company and its subsidiaries are and at all times have been, in compliance in all respects, except where <FONT
STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, with all applicable Health Care Laws
(defined herein) including, but not limited to, the rules and regulations of the Food and Drug Administration (&#147;<B>FDA</B>&#148;), the Office for Civil Rights, the Department of Justice, any Chinese regulatory agencies, including the National
Medical Products Administration (&#147;<B>NMPA</B>&#148;) and any other governmental agency or body having jurisdiction over the Company or any of its properties. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; shall mean all
health care laws applicable to the Company and its subsidiaries, each as amended from time to time, including, but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), and the regulations promulgated thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7b(b)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws relating to
health care fraud and abuse, including, but not limited to, 18 U.S.C. Sections 286, 287, 1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d
et seq.) (&#147;<B>HIPAA</B>&#148;), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Stark Law (42 U.S.C. &#167; 1395nn), the civil monetary penalties law (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7a),</FONT> and applicable laws governing government funded or sponsored healthcare programs; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act (42 U.S.C. &#167;17921 et seq.); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv) licensure, quality, safety and accreditation requirements under applicable federal,
state, local or foreign laws or regulatory bodies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi) all other laws and regulations applicable to ownership, testing, development,
manufacture, packaging, processing, use, distribution, storage, import, export or disposal of the products distributed by the Company; including, but not limited to, the FDA&#146;s current good manufacturing practice regulations at 21 CFR Part 820;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vii) the rules, directives and regulations promulgated pursuant to such laws, or any other similar federal, state, local or foreign
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Company nor any of its subsidiaries has received any written notification or correspondence of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any court, arbitrator, governmental or regulatory authority or third party of potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of, the
Company or its subsidiaries under any Health Care Laws nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened (&#147;<B>Action</B>&#148;), which singly or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a
whole, (i)&nbsp;the Company and its subsidiaries have filed, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and
(ii)&nbsp;all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent
submission). Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement
orders, plans of correction, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none of the Company or any of its subsidiaries or controlled affiliates, or to the Company&#146;s knowledge, any other
affiliate, or any director, officer, or employee thereof, or, to the Company&#146;s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has been excluded, suspended, disqualified or debarred from
participation in any U.S. federal health care program or is subject to a governmental inquiry, investigation, proceeding, or other similar action that could result in debarment, suspension, disqualification or exclusion, or has been convicted of any
crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law. The Company has not received any warning letter, untitled letter or other correspondence or written
notice from any court or arbitrator or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental or regulatory authority alleging or assert noncompliance with (x)&nbsp;any Health Care Laws or (y)&nbsp;any Licenses (as defined below) required by any such Health Care Laws, which
singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) To the knowledge of Company, the manufacturing facilities and operations of its suppliers, are operated in compliance with
all Health Care Laws, except as would reasonably be expected to result in a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) Each of the Company and its subsidiaries possesses, and is in compliance with the terms of, all applications,
certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations materially necessary to conduct their respective businesses (collectively, &#147;<B>Licenses</B>&#148;), issued by
governmental authorities, including, without limitation, all Licenses required by the FDA, NMPA or any component thereof and/or by any other U.S., state, local or foreign government or regulatory agency (collectively, the &#147;<B>Regulatory
Agencies</B>&#148;), except here the failure to hold such Licenses and be in compliance would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. All
Licenses are in full force and effect and neither the Company nor any of its subsidiaries is in violation of any term or conditions of any License other than for such violations which would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to the Licenses, except where the failure to have performed such
obligations would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. No event has occurred which allows, or after notice or lapse of time would allow, revocation or termination
thereof or results in any other impairment of the rights of the holder of any License, other than such events which would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. Neither
the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Licenses and no Regulatory Agency has taken any action to limit, suspend or revoke any License possessed by the Company,
the revocation, modification, limitation or suspension of which would singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The financial statements included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus,
together with the related notes thereto, comply in all material respects with the applicable accounting requirements of the Securities Act and present fairly in all material respects the consolidated financial position of the Company and its
subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
generally accepted accounting principles in the United States (&#147;<B>U.S. GAAP</B>&#148;) applied on a consistent basis throughout the periods covered thereby except for any normal <FONT
STYLE="white-space:nowrap">year-end</FONT> adjustments in the Company&#146;s quarterly financial statements. The other financial information included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus has been
derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Deloitte&nbsp;&amp; Touche LLP, who has certified certain financial statements of the Company and its subsidiaries and
delivered its report with respect to the audited consolidated financial statements filed with the Commission as part of the Registration Statement and included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is
an independent registered public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board
(United States). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) The statistical, industry-related and market-related data included in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they are
derived, in each case in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The Company has taken all necessary actions to ensure that, upon the
effectiveness of the Registration Statement, it will be in compliance with all provisions of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof (the &#147;<B>Sarbanes-Oxley
Act</B>&#148;) that are then in effect and with which the Company is required to comply as of the effectiveness of the Registration Statement, and is actively taking steps to ensure that it will be in compliance with other provisions of the
Sarbanes-Oxley Act not currently in effect, upon the effectiveness of such provisions, or which will become applicable to the Company at all times after the effectiveness of the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Except as disclosed in the Time of Sale Prospectus, the Company maintains a system of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Time of Sale Prospectus, since the end of the Company&#146;s most recent audited fiscal year,
there has been (i)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Except as described in the Registration Statement, the Company has not
sold, issued or distributed any shares of Common Stock during the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date hereof, including any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities
Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Neither the Company nor any of its subsidiaries nor any affiliate has any securities rated by any &#147;nationally
recognized statistical rating organization&#148; as such term is defined in the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Except as would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, the Company and its subsidiaries and any &#147;Employee Benefit Plan&#148; (as defined under the
Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations promulgated thereunder (collectively, &#147;<B>ERISA</B>&#148;)) for which the Company, its subsidiaries or their &#147;ERISA
Affiliates&#148; (as defined below) would have any liability (each, a &#147;<B>Plan</B>&#148;) are in compliance in all material respects with ERISA and each Plan is and has been operated and maintained in compliance with its terms and the
requirements of any applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&#147;<B>Code</B>&#148;). &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Code of which the Company or such subsidiary is a
member. Neither the Company nor any of its subsidiaries nor any ERISA Affiliate has ever sponsored, maintained, contributed to, or otherwise had any obligation or liability with respect to, an &#147;Employee Benefit Plan&#148; subject to Title IV of
ERISA. No Plan provides post-termination or retiree life insurance, health or other welfare benefits or coverage to any person except as may be required by Section&nbsp;4980B of the Code or any similar law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The Registration Statement, the Prospectus, the Time of Sale Prospectus and any preliminary prospectus comply, and any
amendments or supplements thereto will comply, with any applicable laws or regulations of foreign jurisdictions in which the Prospectus, the Time of Sale Prospectus or any preliminary prospectus, as amended or supplemented, if applicable, are
distributed in connection with the Directed Share Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) No consent, approval, authorization or order of, or qualification with,
any governmental body or agency, other than those obtained, is required in connection with the offering of the Directed Shares in any jurisdiction where the Directed Shares are being offered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) The Company has not offered, or caused Morgan Stanley or any Morgan Stanley Entity as defined in Section&nbsp;12 to offer,
Shares to any person pursuant to the Directed Share Program with the specific intent to unlawfully influence (i)&nbsp;a customer or supplier of the Company to alter the customer&#146;s or supplier&#146;s level or type of business with the Company,
or (ii)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or its products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed
through the date of this Agreement or have requested extensions thereof and have paid all taxes required to be paid thereon, including any assessments, fines or penalties (except for cases in which the failure to file or pay would not, singly or in
the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP have been created in the financial statements of
the Company), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax
deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) From the time of initial confidential submission of the Registration Statement to the Commission through the date hereof,
the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The Company (i)&nbsp;has not alone engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication with any person other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications with the consent of the Representatives with entities that are reasonably believed to be qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are reasonably believed to be
accredited investors within the meaning of Rule 501 under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication that is a written communication within the meaning of Rule 405 under the Securities Act other than those listed on Schedule III hereto.
&#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the
Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) As of the time of each sale of the Shares in connection with the
offering when the Prospectus is not yet available to prospective purchasers, none of (A)&nbsp;the Time of Sale Prospectus, (B)&nbsp;any free writing prospectus, when considered together with the Time of Sale Prospectus, and (C)&nbsp;any individual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or
omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) The Company (i)&nbsp;does not have any material lending or other relationship with any bank or lending affiliate of any
Underwriter and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Shares to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <I>Representations and Warranties of the Selling Shareholders. Each Selling Shareholder represents and warrants to and agrees with each of
the Underwriters that:</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement has been duly authorized, executed and delivered by or on behalf of such
Selling Shareholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery by such Selling Shareholder of, and the performance by such Selling
Shareholder of its obligations under, this Agreement, the Custody Agreement signed by such Selling Shareholder and American Stock Transfer&nbsp;&amp; Trust Company LLC, as Custodian, relating to the deposit of the Shares to be sold by such Selling
Shareholder (the &#147;<B>Custody Agreement</B>&#148;) and the Power of Attorney appointing certain individuals as such Selling Shareholder&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> to
the extent set forth therein, relating to the transactions contemplated hereby and by the Registration Statement (the &#147;<B>Power of Attorney</B>&#148;) will not contravene any provision of applicable law, or the organizational documents of such
Selling Shareholder, or any agreement or other instrument binding upon such Selling Shareholder or any judgment, order or decree of any governmental body, agency or court having jurisdiction over such Selling Shareholder, and no consent, approval,
authorization or order of, or qualification with, any governmental body, agency or court is required for the performance by such Selling Shareholder of its obligations under this Agreement or the Custody Agreement or Power of Attorney of such
Selling Shareholder, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Such Selling Shareholder has, and on the Closing Date will have, valid title to, or a valid &#147;security
entitlement&#148; within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;8-501</FONT> of the New York Uniform Commercial Code in respect of, the Shares to be sold by such Selling Shareholder free and clear of all security interests,
claims, liens, equities or other encumbrances and the legal right and power, and all authorization and approval required by law, to enter into this Agreement, the Custody Agreement and the Power of Attorney and to sell, transfer and deliver the
Shares to be sold by such Selling Shareholder or a security entitlement in respect of such Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Custody Agreement and the Power of Attorney have been duly
authorized, executed and delivered by such Selling Shareholder and are valid and binding agreements of such Selling Shareholder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Upon payment for the Shares to be sold by such Selling Shareholder pursuant to this Agreement, delivery of such Shares, as
directed by the Underwriters, to Cede&nbsp;&amp; Co. (&#147;<B>Cede</B>&#148;) or such other nominee as may be designated by the Depository Trust Company (&#147;<B>DTC</B>&#148;), registration of such Shares in the name of Cede or such other nominee
and the crediting of such Shares on the books of DTC to securities accounts of the Underwriters (assuming that neither DTC nor any such Underwriter has notice of any adverse claim (within the meaning of
<FONT STYLE="white-space:nowrap">Section&nbsp;8-105</FONT> of the New York Uniform Commercial Code (the &#147;<B>UCC</B>&#148;)) to such Shares), (A)&nbsp;DTC shall be a &#147;protected purchaser&#148; of such Shares within the meaning of <FONT
STYLE="white-space:nowrap">Section&nbsp;8-303</FONT> of the UCC, (B)&nbsp;under <FONT STYLE="white-space:nowrap">Section&nbsp;8-501</FONT> of the UCC, the Underwriters will acquire a valid security entitlement in respect of such Shares and
(C)&nbsp;no action based on any &#147;adverse claim&#148;, within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;8-102</FONT> of the UCC, to such Shares may be asserted against the Underwriters with respect to such security
entitlement; for purposes of this representation, such Selling Shareholder may assume that when such payment, delivery and crediting occur, (x)&nbsp;such Shares will have been registered in the name of Cede or another nominee designated by DTC, in
each case on the Company&#146;s share registry in accordance with its certificate of incorporation, bylaws and applicable law, (y)&nbsp;DTC will be registered as a &#147;clearing corporation&#148; within the meaning of
<FONT STYLE="white-space:nowrap">Section&nbsp;8-102</FONT> of the UCC and (z)&nbsp;appropriate entries to the accounts of the several Underwriters on the records of DTC will have been made pursuant to the UCC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Selling Shareholder is not prompted to sell the Shares by any information concerning the Company or its subsidiaries
which is not set forth in the Registration Statement, the Time of Sale Prospectus or the Prospectus to sell its Shares pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;the Registration Statement and the Prospectus comply and, as
amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale
of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;5), the Time of Sale Prospectus, as then amended or supplemented by the Company, if
applicable, will not, contain any untrue statement of a material fact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iv)&nbsp;each broadly available road
show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading and (v)&nbsp;the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I> that the representations and warranties set forth in this paragraph 2(g) are limited to statements or omissions made in reliance upon
information relating to the Selling Shareholder furnished to the Company in writing by the Selling Shareholder expressly for use in the Registration Statement, the Time of Sale Prospectus, the Prospectus or any amendments or supplements thereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Such Selling Stockholder has delivered to the Representatives an executed
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in substantially the form attached hereto as Exhibit A (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (i) None of such Selling Shareholder or any of its subsidiaries, or, to the knowledge of such Selling Shareholder, any
director, officer, employee, agent, representative, or affiliate thereof, is a Person that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any Sanctions, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation,
Crimea, Cuba, Iran, North Korea and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Such Selling Shareholder will not, directly or indirectly, use the
proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in any other manner that will result in a violation of
Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Such Selling Shareholder has not knowingly engaged in, is not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) (a) None of such Selling Shareholder or any of its subsidiaries, or, to the knowledge of such Selling Shareholder, any
director, officer, employee, agent, representative, or affiliate thereof has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment giving or receipt of money, property, gifts
or anything else of value, directly or indirectly, to any Government Official in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (b)&nbsp;such Selling Shareholder and each of its subsidiaries
have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with
the representations and warranties contained herein; and (c)&nbsp;neither the Selling Shareholder nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or
authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The operations of such Selling Shareholder and each of its subsidiaries are and have been conducted at all times in
material compliance with all applicable Anti-Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Selling Shareholder or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Selling Shareholder, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Such Selling Shareholder represents and warrants that it is not (i)&nbsp;an employee benefit plan subject to ERISA,
(ii)&nbsp;a plan or account subject to Section&nbsp;4975 of the Code or (iii)&nbsp;an entity deemed to hold &#147;plan assets&#148; of any such plan or account under Section&nbsp;3(42) of ERISA, 29 C.F.R.
<FONT STYLE="white-space:nowrap">2510.3-101,</FONT> or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Foreign Selling Shareholder represents and
warrants to and agrees with each of the Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No stamp, documentary, issuance, registration, transfer,
withholding, capital gains, income or other taxes or duties are payable by or on behalf of the Underwriters, the Company or any of its subsidiaries in Hong Kong, China or to any taxing authority thereof or therein in connection with (i)&nbsp;the
execution, delivery or consummation of this Agreement, (ii)&nbsp;the sale and delivery of the Shares to the Underwriters or purchasers procured by the Underwriters, or (iii)&nbsp;the resale and delivery of the Shares by the Underwriters in the
manner contemplated herein; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Foreign Selling Shareholder has the power to submit, and pursuant
to Section&nbsp;21(a) has, to the extent permitted by law, legally, validly, effectively and irrevocably submitted, to the jurisdiction of the Specified Courts (as defined in Section&nbsp;21(a)), and has the power to designate, appoint and empower,
and pursuant to Section&nbsp;21(b), has legally, validly and effectively designated, appointed and empowered an agent for service of process in any suit or proceeding based on or arising under this Agreement in any of the Specified Courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Agreements to Sell and Purchase. </I>Each Seller, severally and not jointly, hereby agrees to sell to the several Underwriters, and each
Underwriter, upon the basis of the representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase from such Seller at $[&#149;] a share (the
&#147;<B>Purchase Price</B>&#148;) the number of Firm Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the number of Firm Shares to be sold by such Seller as
the number of Firm Shares set forth in Schedule II hereto opposite the name of such Underwriter bears to the total number of Firm Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to
sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly, up to [&#149;] Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for
any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares. The Representatives may exercise this right on behalf of the
Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date
on which such Additional Shares are to be purchased. Each purchase date must be at least one business day after the written notice is given and may not be earlier than the closing date for the Firm Shares or later than ten business days after the
date of such notice. Additional Shares may be purchased as provided in Section&nbsp;5 hereof solely for the purpose of covering over-allotments made in connection with the offering of the Firm Shares. On each day, if any, that Additional Shares are
to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may
determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule&nbsp;II hereto opposite the name of such Underwriter bears to the total
number of Firm Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <I>Terms of Public Offering. </I>The Sellers are advised by the Representatives that the Underwriters propose
to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the Representatives&#146; judgment is advisable. The Sellers are further advised by the
Representatives that the Shares are to be offered to the public initially at $[&#149;] a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by the Representatives at a price that represents a concession not in excess of $[&#149;] a share under the
Public Offering Price, and that any Underwriter may allow, and such dealers may reallow, a concession, not in excess of $[&#149;] a share, to any Underwriter or to certain other dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Payment and Delivery. </I>Payment for the Firm Shares to be sold by each Seller shall be made to such Seller in Federal or other funds
immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00&nbsp;a.m., New York City time, on [&#149;], 2021, or at such other time on the same or such other date, not
later than [&#149;], 2021, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against
delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00&nbsp;a.m., New York City time, on the date specified in the corresponding notice described in Section&nbsp;3 or at such other time on the same or on
such other date, in any event not later than [&#149;], 2021, as shall be designated in writing by the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Firm Shares
and Additional Shares shall be registered in such names and in such denominations as the Representatives shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may
be. The Firm Shares and Additional Shares shall be delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters. The Purchase Price payable by the
Underwriters shall be reduced by (i)&nbsp;any transfer taxes paid by, or on behalf of, the Underwriters in connection with the transfer of the Shares to the Underwriters duly paid and (ii)&nbsp;any withholding required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Conditions to the Underwriters</I><I>&#146;</I><I> Obligations. </I>The obligations of the Sellers to sell the Shares to the
Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the Registration Statement shall have become effective not later than [&#149;][a.m.][p.m.] (New
York City time) on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The several obligations of the Underwriters are subject to the following further conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose
or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any change, or any development involving
a prospective change, in the condition, financial or otherwise, or in the earnings, business, or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in the Representatives&#146;
judgment, is material and adverse and that makes it, in the Representatives&#146; judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed on behalf of the
Company by an executive officer of the Company, to the effect set forth in Sections&nbsp;6(a)(i) and 6(a)(ii) above and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the
Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Cooley LLP, in its
capacity as outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Underwriters shall have received on the Closing Date an opinion of Alford Law Group, Inc., United States intellectual
property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters shall have received on the Closing Date an opinion of Wuxi Shengyang Patent and Trademark Office (China),
intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Underwriters shall have received on the Closing Date an opinion of Shanghai Greatpower Intellectual Property Law Office
(General Partnership) (China), intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Shearman&nbsp;&amp;
Sterling LLP, counsel for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Underwriters shall have received on the Closing Date, a Chief
Financial Officer&#146;s certificate, dated the Closing Date and signed on behalf of the Company by the Chief Financial Officer of the Company, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Underwriters shall have received on the Closing Date an opinion of [&#149;], counsel for the Selling Shareholders,
dated the Closing Date, in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Underwriters shall have
received on the Closing Date an opinion of Cooley LLP, in its capacity as counsel for Jiang Gift Trust for Carrie, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the negative assurance letters to be delivered pursuant to Sections&nbsp;6(c), 6(g) and 6(j) above, Cooley LLP, in its
capacity as counsel for the Company and Shearman&nbsp;&amp; Sterling LLP may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus and the Prospectus
and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except as specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions of Cooley LLP, Alford Law Group, Inc., Wuxi Shengyang Patent and Trademark Office and Shanghai Greatpower Intellectual Property
Law Office (General Partnership) described in Sections&nbsp;6(c), 6(d), 6(e) and 6(f) above (and any opinions of counsel for any Selling Shareholder referred to in the immediately preceding paragraph) shall be rendered to the Underwriters at the
request of the Company or one or more of the Selling Shareholders, as the case may be, and shall so state therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance reasonably satisfactory to the Underwriters, from Deloitte&nbsp;&amp;
Touche LLP, independent registered public accounting firm, containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148;
not earlier than the date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each
substantially in the form of Exhibit A hereto (with any such modifications as the Representatives shall have previously agreed to), between the Representatives and certain shareholders, officers and directors of the Company relating to restrictions
on sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to the Representatives on or before the date hereof (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</B>&#148;), shall
be in full force and effect on the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The Shares shall have been approved for listing on the NASDAQ Global
Market, subject only to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) FINRA shall have confirmed that it has not raised any objection
with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to the
Representatives on the applicable Option Closing Date of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a certificate, dated the Option Closing Date
and signed on behalf of the Company by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section&nbsp;6(b) hereof remains true and correct as of such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an opinion and negative assurance letter of Cooley LLP, outside counsel for the Company, dated the Option Closing Date,
relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(c) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an opinion of Alford Law Group, Inc., United States intellectual property counsel for the Company, dated the Option
Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(d) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) an opinion of Wuxi Shengyang Patent and Trademark Office (China), intellectual property counsel for the Company, dated the
Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(e) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) an opinion of Shanghai Greatpower Intellectual Property Law Office (General Partnership) (China), intellectual property
counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(f) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) an opinion and negative assurance letter of Shearman and Sterling LLP, counsel for the Underwriters, dated the Option
Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(g) hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) a letter dated the Option Closing Date, in form and substance
reasonably satisfactory to the Underwriters, from Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;6(k)
hereof; <I>provided</I> that the letter delivered on the Option Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than two business days prior to such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) a Chief Financial Officer&#146;s certificate, dated the Option Closing Date and signed on behalf of the Company by the
Chief Financial Officer of the Company, in substantially the same form and substance as the certificate required by Section&nbsp;6(h) hereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) an opinion of [&#149;], counsel for the Selling Shareholders, dated the Option Closing Date, relating to the Additional
Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(i) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The Underwriters shall have received on the Closing Date an opinion of Cooley LLP, counsel for Jiang Gift Trust for Carrie,
dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;6(j) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) such other documents as the Representatives may reasonably request with respect to the good standing of the Company, the
due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Covenants of the Company. The Company covenants with each Underwriter as follows:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To furnish to the Representatives, without charge, at the request of the Representatives, signed copies of the Registration
Statement (including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to the Representatives in New York City, without charge, prior to
10:00&nbsp;a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section&nbsp;7(e) or 7(f) below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements
and amendments thereto or to the Registration Statement as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Before amending or supplementing the Registration Statement, the Time of
Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representatives reasonably object, and to file with the
Commission within the applicable period specified in Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To furnish to the Representatives a copy of each proposed free writing prospectus to be prepared by or on behalf of, used
by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Not to take any action that would result in an Underwriter or the Company being required to file with the Commission
pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet
available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the opinion of counsel for the Underwriters,
it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments
or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser,
be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If, during such period after the first date of the public offering of the Shares as in the opinion of counsel for the
Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is
delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its
own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company) to which Shares may have been sold by the Representatives on behalf of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that
the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be
misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To endeavor to
qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request; <I>provided, however</I>, that nothing contained herein shall require the Company to qualify to do
business in any jurisdiction, to execute or file a general consent to service of process in any jurisdiction or to subject itself to taxation in any jurisdiction in which it is not otherwise subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To make generally available (which may be satisfied by filing with the Commission on its Electronic Data Gathering Analysis
and Retrieval System) to the Company&#146;s security holders and to the Representatives as soon as practicable an earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after
the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To comply with all applicable securities and other laws, rules and regulations in each jurisdiction in which the Directed
Shares are offered in connection with the Directed Share Program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) If any Seller is not a U.S. person for U.S. federal
income tax purposes, the Company will deliver to each Underwriter (or its agent), on or before the Closing Date, (i)&nbsp;a certificate with respect to the Company&#146;s status as a &#147;United States real property holding corporation,&#148; dated
not more than thirty (30)&nbsp;days prior to the Closing Date, as described in Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.897-2(h)</FONT> and <FONT STYLE="white-space:nowrap">1.1445-2(c)(3),</FONT> and (ii)&nbsp;proof of
delivery to the IRS of the required notice, as described in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time
prior to the later of (i)&nbsp;completion of the distribution of the Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the Restricted Period (as defined below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) If at any time following the distribution of any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act there occurred or occurs an event or development
as a result of which such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own
expense, such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also covenants with each Underwriter that, without the prior written consent of
the Representatives on behalf of the Underwriters, it will not, and will not publicly disclose an intention to, during the period ending on and including the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of the
Prospectus (the &#147;<B>Restricted Period</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise or (3)&nbsp;confidentially submit any draft registration statement or file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained in the preceding paragraph shall not apply to (A)&nbsp;the Shares to be sold
hereunder, (B)&nbsp;the issuance by the Company of shares of Common Stock or securities convertible into or exercisable for Common Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of options
(including net exercise) or the settlement of restricted stock units (including net settlement), in each case outstanding on the date hereof and described in the Time of Sale Prospectus and Prospectus, provided that, prior to the issuance of any
such shares of Common Stock or securities convertible into or exercisable for Common Stock, the Company shall cause each recipient of such issuance pursuant to this clause (B)&nbsp;to execute and deliver a &#147;lock up&#148; agreement,
substantially in the form of Exhibit A hereto or, (C)&nbsp;grants of stock options, stock awards, restricted stock, restricted stock units or other equity awards and the issuance of Common Stock or securities convertible into or exercisable for
Common Stock upon the exercise of such stock options, stock awards, restricted stock, restricted stock units or other equity awards) to employees, officers, directors, advisors, or consultants of the Company pursuant to the terms of a plan in effect
on the date hereof and described in the Time of Sale Prospectus and Prospectus provided that, prior to the issuance of any such shares pursuant to this clause (C)&nbsp;or the grant of any such options, stock awards, restricted stock, restricted
stock units or other equity awards pursuant to this clause (C), the Company shall cause each recipient of such grant or issuance pursuant to this clause (C)&nbsp;to execute and deliver a &#147;lock up&#148; agreement, substantially in the form of
Exhibit A hereto, (D)&nbsp;the sale or issuance of or entry into an agreement providing for the sale or issuance of Common Stock or securities convertible into, exercisable for or which are otherwise exchangeable for or represent the right to
receive Common Stock in connection with (x)&nbsp;the acquisition by the Company or any of its subsidiaries of the securities, business, technology, property or other assets of another person or entity or pursuant to an employee benefit plan assumed
by the Company in connection with such acquisition, and the issuance of any Common Stock or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities convertible into, exercisable for or which are otherwise exchangeable for or represent the right to receive Common Stock pursuant to any such agreement or (y)&nbsp;the Company&#146;s
joint ventures, commercial relationships and other strategic transactions, provided, that the aggregate number of shares of Common Stock and securities convertible into, exercisable for or which are otherwise exchangeable for or represent the right
to receive Common Stock that the Company may sell or issue or agree to sell or issue pursuant to this clause (E)&nbsp;shall not exceed 5% of the total number of shares of Common Stock outstanding immediately following the completion of the
transactions contemplated by this Agreement, and provided, further, that all recipients of any such securities shall enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of Exhibit A, (F)&nbsp;the
establishment or amendment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, provided that (x)&nbsp;such plan or amendment does not provide for the
transfer of Common Stock during the Restricted Period and (y)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment or amendment of such plan,
such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period, or (G)&nbsp;the filing of any registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date hereof and described in the Time of Sale Prospectus or any assumed benefit plan contemplated by clause (E). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Representatives, in their sole discretion, agree to release or waive the restrictions on the transfer of Shares set forth in a <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver,
the Company agrees to announce the impending release or waiver at least two business days before the effective date of the release or waiver by a press release substantially in the form of Exhibit B hereto through a major news service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Covenants of the Sellers. Each Seller, severally and not jointly, covenants with each Underwriter as follows:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Seller will deliver to each Underwriter (or its agent), prior to or at the Closing Date, a properly completed and
executed Internal Revenue Service (&#147;<B>IRS</B>&#148;) Form <FONT STYLE="white-space:nowrap">W-9</FONT> or an IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as appropriate, together with all required attachments to such form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Seller will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly
completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and each Seller undertakes to provide such additional supporting documentation as each Underwriter may
reasonably request in connection with the verification of the foregoing Certification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Foreign Selling Stockholder, severally and not jointly, covenants
with each Underwriter as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) All sums payable by the Foreign Selling Shareholder under this Agreement shall be
paid free and clear of and without deductions or withholdings of any present or future taxes or duties, unless the deduction or withholding is required by law, in which case the Foreign Selling Shareholder shall pay such additional amount as will
result in the receipt by each Underwriter of the full amount that would have been received had no deduction or withholding been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) All sums payable to an Underwriter shall be considered exclusive of any value added or similar taxes. Where the Foreign
Selling Shareholder is obliged to pay value added or similar tax on any amount payable hereunder to an Underwriter, the Foreign Selling Shareholder, as the case may be, shall in addition to the sum payable hereunder pay an amount equal to any
applicable value added or similar tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Expenses. </I>Whether or not the transactions contemplated in this Agreement are consummated
or this Agreement is terminated, the Sellers agree to pay or cause to be paid all expenses incident to the performance of their obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel,
the Company&#146;s accountants and counsel for the Selling Shareholders in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the
Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing,
including all printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery of
the Shares to the Underwriters, including any issue, transfer or other taxes payable thereon, (iii)&nbsp;the reasonable, documented cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of
the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section&nbsp;7(g) hereof, including filing fees and the reasonable documented
fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv)&nbsp;all filing fees and the reasonable fees and disbursements of counsel to the
Underwriters incurred in connection with the review and qualification of the offering of the Shares by the FINRA, provided that the amount payable by the Company pursuant to these clauses (iii)&nbsp;and (iv) with respect to the fees of counsel shall
not exceed $50,000 in the aggregate, (v)&nbsp;all fees and expenses in connection with the preparation and filing of the registration statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT> relating to the Common Stock and all costs and
expenses incident to listing the Shares on the Nasdaq Global Select Market, (vi)&nbsp;the cost of printing certificates representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary, (viii)&nbsp;the costs
and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares (with the Underwriters agreeing to pay all costs and expenses related to their
participation in investor presentations on any &#147;road show&#148; undertaken in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the marketing of the offering of the Shares), including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the
production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the officers of the Company and any such
consultants, and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show (with the Underwriters agreeing to pay for the other fifty percent (50%)), (ix) the document production charges and expenses associated with
printing this Agreement , (x) all fees and disbursements of counsel incurred by the Underwriters in connection with the Directed Share Program, up to an amount not to exceed $25,000, and stamp duties, similar taxes or duties or other taxes, if any,
incurred by the Underwriters in connection with the Directed Share Program and (xi)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section.
It is understood, however, that except as provided in this Section, Section&nbsp;11 entitled &#147;Indemnity and Contribution&#148; , Section&nbsp;12 entitled &#147;Directed Share Program Indemnification&#148; and the last paragraph of
Section&nbsp;14 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any
offers they may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Covenants of the Underwriters. </I>Each Underwriter, severally and not jointly, covenants with the Company
not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the
Company thereunder, but for the action of the Underwriter<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Indemnity and Contribution. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter
within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each affiliate of any Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses,
claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) that arise out of, or are based upon, any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as
defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any &#147;road show&#148; as defined in Rule 433(h) under the Securities
Act (a &#147;road show&#148;), the Prospectus or any amendment or supplement thereto, or any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or arise out of, or are based upon, any
omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
as such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by the
Underwriters through the Representatives consists of the information described as such in paragraph (c)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Each Selling Shareholder agrees to indemnify and hold harmless the each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and
each affiliate of any Underwriter within the meaning of Rule&nbsp;405 under the Securities Act , from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in
connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time
of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act, any road show or the Prospectus or any amendment or supplement thereto, or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or caused by any
omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, but only with reference to information relating to the Selling Shareholder furnished in writing
by or on behalf of the Selling Shareholder expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment or supplement
thereto. The liability of each Selling Shareholder under the indemnity agreement contained in this paragraph shall be limited to an amount equal to the aggregate Public Offering Price of the Shares (less any underwriting discounts and commissions)
sold by such Selling Shareholder under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, the Selling Shareholders, the directors of the Company, the officers of the Company who sign the Registration Statement and each person, if any, who controls the Company or any Selling Shareholder within the
meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information relating to such Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show, or the
Prospectus or any amendment or supplement thereto; it being understood and agreed that the only such information furnished </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by any such Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: (i)&nbsp;the names and corresponding share amounts set forth in the table
of Underwriters in the first paragraph of text under the caption &#147;Underwriting&#148; in the Prospectus; (ii)&nbsp;the third paragraph of text under the caption &#147;Underwriting&#148; in the Prospectus concerning the terms of the offering by
the Underwriters; (iii)&nbsp;the seventh paragraph of text under the caption &#147;Underwriting&#148; in the Prospectus concerning sales to discretionary accounts; and (iv)&nbsp;the twelfth paragraph of text under the caption
&#147;Underwriting&#148; in the Prospectus concerning stabilization and overallotments by the Underwriters (the &#147;<B>Underwriter Information</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of
which indemnity may be sought pursuant to Section&nbsp;11(a), 11(b) or 11(c), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the &#147;<B>indemnifying
party</B>&#148;) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may
designate in such proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed in writing to the retention of such counsel or (ii)&nbsp;the named parties to any
such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between
them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for (i)&nbsp;the fees and expenses
of more than one separate firm (in addition to any local counsel) for all Underwriters and all persons, if any, who control any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act or
who are affiliates of any Underwriter within the meaning of Rule&nbsp;405 under the Securities Act, (ii)&nbsp;the fees and expenses of more than one separate firm (in addition to any local counsel) for the Company, its directors, its officers who
sign the Registration Statement and each person, if any, who controls the Company within the meaning of either such Section and (iii)&nbsp;the fees and expenses of more than one separate firm (in addition to any local counsel) for all Selling
Shareholders and all persons, if any, who control any Selling Shareholder within the meaning of either such Section, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the
Underwriters and such control persons and affiliates of any Underwriters, such firm shall be designated in writing by the Representatives. In the case of any such separate firm for the Company, and such directors, officers and control persons of the
Company, such firm shall be designated in writing by the Company. In the case of any such separate firm for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Selling Shareholders and such control persons of any Selling Shareholders, such firm shall be designated in writing by the persons named as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> for the Selling Shareholders under the Powers of Attorney. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if
settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the
foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the
indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid
request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement
(x)&nbsp;includes an unconditional release of such indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include
any statements to or any admission of fault, culpability or failure to act by or on behalf of any indemnified party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
To the extent the indemnification provided for in Section&nbsp;11(a) or 11(b). is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under
such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is
appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand from the offering of the Shares or (ii)&nbsp;if the allocation provided by
clause&nbsp;11(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;11(d)(i) above but also the relative fault of the indemnifying party or parties
on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The
relative benefits received by a Seller on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares
(after deducting underwriting discounts and commissions but before deducting expenses) received by each Seller and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of
the Prospectus, bear to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
aggregate Public Offering Price of the Shares. The relative fault of the Sellers on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Sellers or by the Underwriters and the parties&#146; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;11 are several in proportion to the respective number of Shares they
have purchased hereunder, and not joint. The liability of each Selling Shareholder under the contribution agreement contained in this paragraph shall be limited to an amount equal to the aggregate Public Offering Price of the Shares (less any
underwriting discounts and commissions) sold by such Selling Shareholder under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Sellers and the
Underwriters agree that it would not be just or equitable if contribution pursuant to this Section&nbsp;11 were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in Section&nbsp;11(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;11(d)
shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions
of this Section&nbsp;11, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of
any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section&nbsp;11 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any indemnified party at law or in equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The indemnity and contribution provisions
contained in this Section&nbsp;11 and the representations, warranties and other statements of the Company and the Selling Shareholders contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any
termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter, by or on behalf of any Selling Shareholder or any person controlling any
Selling Shareholder or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>Directed Share Program Indemnification.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless Morgan Stanley, each person, if any, who controls Morgan Stanley within
the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of Morgan Stanley within the meaning of Rule&nbsp;405 of the Securities Act (&#147;<B>Morgan Stanley Entities</B>&#148;) from and
against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim)&nbsp;(i) that arise out of, or are
based upon, any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or arise out of
or are based upon any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;that arise out of, or are based upon, the failure of any
Participant to pay for and accept delivery of Directed Shares that the Participant agreed to purchase; or (iii)&nbsp;related to, arising out of, or in connection with the Directed Share Program, other than losses, claims, damages or liabilities (or
expenses relating thereto) that are finally judicially determined to have resulted from the bad faith or gross negligence of Morgan Stanley Entities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In case any proceeding (including any governmental investigation) shall be instituted involving any Morgan Stanley Entity
in respect of which indemnity may be sought pursuant to Section&nbsp;12(a), the Morgan Stanley Entity seeking indemnity, shall promptly notify the Company in writing and the Company, upon request of the Morgan Stanley Entity, shall retain counsel
reasonably satisfactory to the Morgan Stanley Entity to represent the Morgan Stanley Entity and any others the Company may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such
proceeding, any Morgan Stanley Entity shall have the right to retain its own counsel, but the reasonably incurred fees and expenses of such counsel shall be at the expense of such Morgan Stanley Entity unless (i)&nbsp;the Company shall have agreed
to the retention of such counsel or (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the Company and the Morgan Stanley Entity and representation of both parties by the same counsel would be
inappropriate due to actual or potential differing interests between them. The Company shall not, in respect of the legal expenses of the Morgan Stanley Entities in connection with any proceeding or related proceedings in the same jurisdiction, be
liable for the reasonably incurred fees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and expenses of more than one separate firm (in addition to any local counsel) for all Morgan Stanley Entities. Any such separate firm for the Morgan Stanley Entities shall be designated in
writing by Morgan Stanley. The Company shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Company agrees to indemnify
the Morgan Stanley Entities from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time a Morgan Stanley Entity shall have requested the Company to reimburse it for the
reasonably incurred fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the Company agrees that it shall be liable for any settlement of any proceeding effected without its written consent if
(i)&nbsp;such settlement is entered into more than 30 days after receipt by the Company of the aforesaid request and (ii)&nbsp;the Company shall not have reimbursed the Morgan Stanley Entity in accordance with such request prior to the date of such
settlement. The Company shall not, without the prior written consent of Morgan Stanley, effect any settlement of any pending or threatened proceeding in respect of which any Morgan Stanley Entity is or could have been a party and indemnity could
have been sought hereunder by such Morgan Stanley Entity, unless such settlement includes an unconditional release of the Morgan Stanley Entities from all liability on claims that are the subject matter of such proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent the indemnification provided for in Section&nbsp;12(a) is unavailable to a Morgan Stanley Entity or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then the Company in lieu of indemnifying the Morgan Stanley Entity thereunder, shall contribute to the amount paid or payable by the Morgan Stanley Entity as
a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Morgan Stanley Entities on the other hand from the offering of the
Directed Shares or (ii)&nbsp;if the allocation provided by clause&nbsp;12(c)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;12(c)(i) above but
also the relative fault of the Company on the one hand and of the Morgan Stanley Entities on the other hand in connection with any statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant
equitable considerations. The relative benefits received by the Company on the one hand and the Morgan Stanley Entities on the other hand in connection with the offering of the Directed Shares shall be deemed to be in the same respective proportions
as the net proceeds from the offering of the Directed Shares (after deducting underwriting discounts and commissions but before deducting expenses) and the total underwriting discounts and commissions received by the Morgan Stanley Entities for the
Directed Shares, bear to the aggregate Public Offering Price of the Directed Shares. If the loss, claim, damage or liability is caused by an untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact, the relative fault of the Company on the one hand and the Morgan Stanley Entities on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement or the omission or alleged
omission relates to information supplied by the Company or by the Morgan Stanley Entities and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company and the Morgan Stanley Entities agree that it would not be
just or equitable if contribution pursuant to this Section&nbsp;12 were determined by <I>pro rata</I> allocation (even if the Morgan Stanley Entities were treated as one entity for such purpose) or by any other method of allocation that does not
take account of the equitable considerations referred to in Section&nbsp;12(c). The amount paid or payable by the Morgan Stanley Entities as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph
shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by the Morgan Stanley Entities in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section&nbsp;12, no Morgan Stanley Entity shall be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares distributed to the public were offered to the public exceeds the
amount of any damages that such Morgan Stanley Entity has otherwise been required to pay. The remedies provided for in this Section&nbsp;12 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any
indemnified party at law or in equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The indemnity and contribution provisions contained in this Section&nbsp;12
shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Morgan Stanley Entity or the Company, its officers or directors or any person
controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Directed Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Termination. </I>The Underwriters
may terminate this Agreement by notice given by the Representatives to the Company, if after the execution and delivery of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i)&nbsp;trading generally
shall have been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market or other relevant exchanges, (ii)&nbsp;trading of any securities of the Company
shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in
the United States shall have occurred, (iv)&nbsp;any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, or
any change in financial markets or any calamity or crisis that, in the Representatives&#146; judgment, is material and adverse and which, singly or together with any other event specified in this clause&nbsp;(v), makes it, in the
Representatives&#146; judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Effectiveness; Defaulting Underwriters. </I>This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or
refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of the Shares to be purchased on such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedule&nbsp;II bears to the aggregate
number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as the Representatives may specify, to purchase the Shares which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this
Section&nbsp;14 by an amount in excess of <FONT STYLE="white-space:nowrap">one-ninth</FONT> of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to
purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Firm Shares to be purchased on such date, and
arrangements satisfactory to the Representatives, the Company and the Selling Shareholders for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter, the Company or the Selling Shareholders. In any such case either the Representatives or the relevant Sellers shall have the right to postpone the Closing Date, but in no event for longer
than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter
or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of
Additional Shares to be purchased on such Option Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares to be
sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters would have been obligated to purchase in the absence of such default.
Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of any Seller to
comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason any Seller shall be unable to perform its obligations under this Agreement, the Sellers will reimburse the Underwriters or such Underwriters as have so
terminated this Agreement with respect to themselves, severally, for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including the fees and disbursements of their counsel) reasonably
incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Entire Agreement.
</I>(a)&nbsp;This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between
the Company and the Selling Shareholders, on the one hand, and the Underwriters, on the other, with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase
and sale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and each Selling Shareholder acknowledges that in connection
with the offering of the Shares: (i)&nbsp;the Underwriters have acted at arm&#146;s length, are not agents of, and owe no fiduciary duties to, the Company, any of the Selling Shareholders or any other person, (ii)&nbsp;the Underwriters owe the
Company and each Selling Shareholder only those duties and obligations set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent not superseded by this Agreement), if any, (iii)&nbsp;the
Underwriters may have interests that differ from those of the Company and each Selling Shareholder and (iv)&nbsp;none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation,
investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person.&nbsp;The Company and each Selling Shareholder waives to the full extent permitted by applicable law any claims it may have against the
Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each
Selling Shareholder further acknowledges and agrees that, although the Underwriters may provide certain Selling Shareholders with certain Regulation Best Interest and Form CRS disclosures or other related documentation in connection with the
offering, the Underwriters are not making a recommendation to any Selling Shareholder to participate in the offering or sell any Shares at the Purchase Price, and nothing set forth in such disclosures or documentation is intended to suggest that any
Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <I>Recognition of the U.S. Special Resolution Regimes. </I>(a)&nbsp;In the event that
any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States<I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Section a &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;<B>Covered Entity</B>&#148; means any of the
following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C.F.R. &#167; 382.2(b). &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as
applicable. &#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <I>Counterparts. </I>This Agreement may be signed in two or more counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail or other electronic transmission method (including any electronic
signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the New York Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com), and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <I>Applicable Law. </I>This Agreement shall be governed by and construed in accordance with the internal laws of the State of New
York<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <I>Headings. </I>The headings of the sections of this Agreement have been inserted for convenience of reference only and
shall not be deemed a part of this Agreement<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <I>Notices. </I>All communications hereunder shall be in writing and effective
only upon receipt and if to the Underwriters shall be delivered, mailed or sent to the Representatives c/o Morgan Stanley&nbsp;&amp;&nbsp;Co. LLC, 1585&nbsp;Broadway, New York, New York&nbsp;10036, Attention: Equity Syndicate Desk, with a copy to
the Legal Department; c/o Goldman Sachs&nbsp;&amp; Co. LLC at 200 West Street, New York, New York 10282-2198, Attention: Registration Department; Piper Sandler&nbsp;&amp; Co. at 345 Park Avenue, 12th Floor, New York, New York 10154, Attention:
Equity Capital Markets; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, Attention: General Counsel; and if to the Company shall be delivered, mailed or sent to 46107 Landing Pkwy, Fremont, California 94538, Attention: General
Counsel; and if to the Selling Shareholders shall be delivered, mailed or sent to [&#149;]<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <I>Submission to Jurisdiction;
Appointment of Agents for Service. </I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Foreign Selling Shareholder irrevocably submits to the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of any New York State or United States Federal court sitting in The City of New York (the &#147;<B>Specified Courts</B>&#148;) over any suit, action or proceeding arising out of or
relating to this Agreement, the Time of Sale Prospectus, the Prospectus, the Registration Statement or the offering of the Shares (each, a &#147;<B>Related Proceeding</B>&#148;). The Foreign Selling Shareholder irrevocably waives, to the fullest
extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any Related Proceeding brought in such a court and any claim that any such Related Proceeding brought in such a court has been brought in an
inconvenient forum. To the extent that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Foreign Selling Shareholder has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to
itself or its property, the Foreign Selling Shareholder irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit, action or proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Foreign Selling Shareholder hereby irrevocably appoints [&#149;], with offices at [&#149;] as its agent for service of
process in any Related Proceeding and agrees that service of process in any such Related Proceeding may be made upon it at the office of such agent. The Foreign Selling Shareholder waives, to the fullest extent permitted by law, any other
requirements of or objections to personal jurisdiction with respect thereto. The Foreign Selling Shareholder represents and warrants that such agent has agreed to act as the Foreign Selling Shareholder&#146;s agent for service of process, and the
Foreign Selling Shareholder agrees to take any and all action, including the filing of any and all documents and instruments, that may be necessary to continue such appointment in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <I>Judgment Currency</I>. If for the purposes of obtaining judgment in any court it is necessary to convert a sum due hereunder into any
currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Underwriters could purchase
United States dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given. The obligation of the Foreign Selling Shareholder with respect to any sum due from it to any Underwriter or
any person controlling any Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by such Underwriter or controlling person of any sum in such
other currency, and only to the extent that such Underwriter or controlling person may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the
sum originally due to such Underwriter or controlling person hereunder, the Foreign Selling Shareholder agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter or controlling person against such loss. If
the United States dollars so purchased are greater than the sum originally due to such Underwriter or controlling person hereunder, such Underwriter or controlling person agrees to pay to the Foreign Selling Shareholder an amount equal to the excess
of the dollars so purchased over the sum originally due to such Underwriter or controlling person hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <I>Taxes. </I>If any sum
payable by the Foreign Selling Shareholder under this Agreement is subject to tax in the hands of an Underwriter or taken into account as a receipt in computing the taxable income of that Underwriter (excluding net income taxes on underwriting
commissions payable hereunder), the sum payable to the Underwriter under this Agreement shall be increased to such sum as will ensure that the Underwriter shall be left with the sum it would have had in the absence of such tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Signature Pages Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CYTEK BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The Selling Shareholders named in Schedule I hereto, acting severally,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-Fact</FONT></FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting severally on behalf of themselves and the several Underwriters named in Schedule&nbsp;II hereto </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Morgan Stanley&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Goldman Sachs&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Piper Sandler&nbsp;&amp; Co.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cowen and Company, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE&nbsp;I </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Selling Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares<BR>To Be Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Next Generation DNA Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jiang Gift Trust for Carrie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule&nbsp;II </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares<BR>To Be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Time of Sale Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Prospectus issued [&#149;], 2021 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[identify all free writing prospectuses filed by the Company under Rule 433(d) of the Securities Act]
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[free writing prospectus containing a description of terms that does not reflect final terms, if the Time of
Sale Prospectus does not include a final term sheet] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[orally communicated pricing information such as price per share and size of offering if a Rule 134 pricing
term sheet is used at the time of sale instead of a pricing term sheet filed by the Company under Rule 433(d) as a free writing prospectus] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters listed in
Schedule II to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Underwriting Agreement referred to below </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;1585 Broadway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;New
York, NY 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;New
York, NY 10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;345 Park Avenue, Suite 1200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;New York, NY 10154 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company,
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&nbsp;New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned understands that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;), Goldman Sachs&nbsp;&amp; Co. LLC
(&#147;<B>Goldman Sachs</B>&#148;), Piper Sandler&nbsp;&amp; Co. (&#147;<B>Piper Sandler</B>&#148;) and Cowen and Company, LLC (together with Morgan Stanley, Goldman Sachs and Piper Sandler, the &#147;<B>Representatives</B>&#148;) propose to enter
into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Cytek Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by the
several Underwriters named in Schedule II to the Underwriting Agreement (the &#147;<B>Underwriters</B>&#148;), of shares (the &#147;<B>Shares</B>&#148;) of the common stock, par value $0.001 per share, of the Company (the &#147;<B>Common
Stock</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the undersigned will not, and will not publicly disclose an intention to, and
will not cause or direct any of its affiliates to, or publicly disclose an intention to, in each case, during the period commencing on the date hereof and ending 180 days after the date of the final prospectus (the &#147;<B>Restricted
Period</B>&#148;) relating to the Public Offering (the &#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934,
as amended (the &#147;<B>Exchange Act</B>&#148;)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock (the &#147;<B>Securities</B>&#148;)<B> </B>or (2)&nbsp;enter into any swap or
other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Common
Stock or such other Securities, in cash or otherwise. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions designed or intended, or which could reasonably be expected
to lead to or result in, a sale or disposition of any shares of Common Stock, or securities convertible into or exercisable or exchangeable for Common Stock, even if any such sale or disposition transaction or transactions would be made or executed
by or on behalf of someone other than the undersigned. The foregoing shall not apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transactions relating to shares of Common Stock or other Securities acquired in the Public Offering (other
than issuer-directed shares of Common Stock purchased in the Public Offering by officers and directors of the Company) or in open market transactions after the completion of the Public Offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers of shares of Common Stock or other Securities as a bona fide gift or charitable contribution in a
transaction exempt under Section&nbsp;16(b) of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers of shares of Common Stock or other Securities by will or intestate succession upon the death of
the undersigned, including to the transferee&#146;s nominee or custodian; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers of shares of Common Stock or other Securities to an immediate family member or any trust for the
direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage or
adoption, not more remote than first cousin); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers or distributions of shares of Common Stock or any other Securities by a stockholder that is a
trust to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity,
(1)&nbsp;to distributions of shares of Common Stock or other Securities to limited partners, members, stockholders or holders of similar equity interests in the undersigned (or in each case its nominee or custodian) or (2)&nbsp;to transfers of
shares of Common Stock or other Securities to another corporation, partnership, limited liability company, trust or other business entity (or in each case its nominee or custodian) that is a direct or indirect subsidiary of the undersigned;
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers of shares of Common Stock or other Securities by operation of law pursuant to a qualified domestic
order or in connection with a divorce settlement;<I> provided</I> that any filing required by Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances
described in this clause (g)&nbsp;and such shares remain subject to this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; <I>provided further</I> that no other public announcement or filing shall be required or shall be voluntarily made
during the Restricted Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the disposition or transfer of shares of Common Stock to the Company upon the
&#147;net&#148; or &#147;cashless&#148; exercise of stock options or other equity awards outstanding as of the date of the Prospectus and granted pursuant to an employee benefit plan described in the Prospectus; <I>provided</I> that the underlying
shares of Common Stock issued to the undersigned upon such exercise shall continue to be subject to this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; <I>provided</I> <I>further</I> that, if required, any public report or filing under
Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to such &#147;net&#148; or &#147;cashless&#148; exercise of stock options or other equity awards, as applicable, that no shares were sold by
the reporting person and that the underlying shares issued to the undersigned upon such exercise shall continue to be subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters of the Public Offering;
<I>provided</I> <I>further</I> that no other public announcement or filing shall be required or shall be voluntarily made during the Restricted Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the exercise solely with cash of a stock option granted under a stock incentive plan or stock purchase plan
described in the Prospectus by the undersigned, and the receipt by the undersigned from the Company of shares of Common Stock upon such exercise, insofar as such option is outstanding as of the date of the Prospectus, <I>provided</I> that the
underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; <I>provided</I> <I>further</I> that, if required, any public report or filing
under Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the exercise of a stock option, that no shares were sold by the reporting person and that the shares received upon exercise of the
stock option are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters of the Public Offering; <I>provided</I> <I>further</I> that no other public announcement or filing shall be required or shall be
voluntarily made during the Restricted Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers to the Company of shares of Common Stock or other Securities in connection with the repurchase by
the Company from the undersigned of shares of Common Stock or other Securities pursuant to a repurchase right arising upon the termination of the undersigned&#146;s employment with the Company; <I>provided</I> that such repurchase right is pursuant
to contractual agreements with the Company; <I>provided</I> <I>further</I> that any filing required by Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances
described in this clause (j); <I>provided</I> <I>further</I> that no other public announcement or filing shall be required or shall be voluntarily made during the Restricted Period; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transfers of shares of Common Stock or other Securities pursuant to a bona fide third-party tender offer,
merger, consolidation or other similar transaction involving a Change of Control (as defined below) of the Company which occurs after the consummation of the Public Offering, is open to all holders of the Company&#146;s capital stock and has been
approved by the board of directors of the Company; <I>provided</I> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Securities held by the undersigned shall remain subject to the
provisions of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (for purposes of this clause (k), &#147;<B>Change of Control</B>&#148; shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other
similar transaction the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT>
and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of at least 50% of total voting power of the voting stock of the Company); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the establishment or amendment of a trading plan on behalf of a stockholder, officer or director of the
Company pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that (i)&nbsp;such plan does not provide for the transfer of Common Stock during the
Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such
announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales of shares of Common Stock to the Underwriters pursuant to the terms of the Underwriting Agreement;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any transfer or distribution pursuant to each of the clauses (b)&nbsp;through (g) above, each
donee, trustee, distributee or transferee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the Representatives substantially in the form of this agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any transfer or distribution pursuant to each of the clauses (a)&nbsp;through (f) above, no
filing under Section&nbsp;16 of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, and no other public announcement or filing shall be required or shall be voluntarily made during the Restricted Period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any transfer or distribution pursuant to each of clauses (b)&nbsp;through (f) above, such
transfer or distribution shall not involve a disposition for value; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(z)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of any transfer or distribution for which a public filing under Section&nbsp;16 of the Exchange
Act or any other public filing or announcement is permitted hereunder, the undersigned covenants and agrees to use commercially reasonable efforts to give the Representatives written notice at least one business day (which, for the avoidance of
doubt, shall be at least a twenty-four (24)&nbsp;hour period) before such transaction and such filing or announcement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned agrees that, without the prior written consent of the
Representatives on behalf of the Underwriters, the undersigned will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any other Securities. The undersigned
also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company (whether as of the date hereof or at the time of receiving any issuer-directed
Shares in the Public Offering), the undersigned further agrees that the foregoing restrictions shall be equally applicable to any issuer-directed Shares the undersigned may purchase in the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company (whether as of the date hereof or at the time of receiving any shares of Common
Stock), (i) the Representatives agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, the Representatives will notify the
Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective
date of the release or waiver. Any release or waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this
paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration or to an immediate family member as defined in FINRA Rule 5130(i)(5) and (b)&nbsp;the transferee has agreed in writing to be
bound by the same terms described in this agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become,
currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to lead to or result in any activity prohibited by this agreement during the Restricted Period. If the undersigned is not a
natural person, the undersigned represents and warrants that no single natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act), other than a natural person, entity or &#147;group&#148; (as
described above) that has executed a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in substantially the same form as this agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of
the voting power, in the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this agreement
in proceeding toward consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any
recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Shares and the undersigned has consulted their own legal, accounting, financial, regulatory and tax
advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with
the Public Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is
intended to suggest that any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Public Offering actually occurs depends on a
number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. Notwithstanding anything to the
contrary contained herein, this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement will automatically terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of
(i)&nbsp;the Company advises the Representatives in writing before the execution of the Underwriting Agreement that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Company withdraws the registration statement related to the
Public Offering before the execution of the Underwriting Agreement, (iii)&nbsp;the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the shares of
Common Stock to be sold thereunder and (iv)&nbsp;September&nbsp;30, 2021, in the event that the Underwriting Agreement has not been executed by such date (provided that the Company may by written notice to the undersigned on or before
September&nbsp;30, 2021 extend such date for a period of up to an additional three months, in the event that the Underwriting Agreement has not been executed by such date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter may be executed by facsimile, PDF or other electronic means, which signatures will be accepted as if they were original execution
signatures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page
follows</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDER:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>please print complete name of
shareholder)</I></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>duly authorized
signature</I>)</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>please print full name</I>)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>please print full
title</I>)</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WAIVER OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PRESS RELEASE </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d80783dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B>, a corporation organized and existing under and by virtue of the
provisions of the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY
CERTIFY: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is Cytek Biosciences, Inc., and that this corporation was originally incorporated
pursuant to the General Corporation Law on December&nbsp;15, 2014 under the name Cytoville, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors
duly adopted resolutions proposing to amend and restate the Amended and Restated Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its
stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to
read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Cytek Biosciences, Inc. (the &#147;<B>Corporation</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is 850 New Burton Road, Suite 201, City of
Dover, County of Kent 19904. The name of its registered agent at such address is COGENCY GLOBAL INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>The nature of the
business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 215,000,000
shares of Common Stock, $0.001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 87,268,694 shares of Preferred Stock, $0.001 par value per share (&#147;<B>Preferred Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective immediately upon the filing of this Amended and Restated Certificate of Incorporation (this &#147;<B>Restated Certificate</B>&#148;)
with the Secretary of State of the State of Delaware (the &#147;<B>Effective Time</B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each one outstanding share of Common
Stock shall be converted into 1.3333 fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of outstanding Common Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each one outstanding share of Series A Preferred Stock shall be converted into 1.3333
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of outstanding Series A Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Each one
outstanding share of Series B Preferred Stock shall be converted into 1.3333 fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of outstanding Series B Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Each one outstanding share of Series C Preferred Stock shall be converted into 1.3333 fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of outstanding Series C Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Each one outstanding share of
Series D Preferred Stock shall be converted into 1.3333 fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of outstanding Series D Preferred Stock ((i)-(v), collectively, the &#147;<B>Forward Stock Split</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Forward Stock Split shall be effected for each class or series of Common Stock and Preferred Stock on a stock certificate by stock
certificate basis. No fractional shares of Common Stock or any series of Preferred Stock shall be issued upon the subdivision of any such shares in the Forward Stock Split. If the Forward Stock Split would result in the issuance of any fractional
share, the Corporation shall, in lieu of issuing any fractional share, pay cash equal to the product of such fraction multiplied by the fair market value (as determined by the Board of Directors of the Corporation) of one share of Common Stock or
such series of Preferred Stock, as applicable, as of the Effective Time (after giving effect to the foregoing Forward Stock Split), rounded up to the nearest whole cent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Forward Stock Split shall occur whether or not the certificates representing such shares of Common Stock or Preferred Stock are
surrendered to the Corporation or its transfer agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specifically noted in this Restated Certificate, all share numbers
and prices per share have been adjusted to reflect the Forward Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the
powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.
<U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders
(and written actions in lieu of meetings). There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote
of the holders of one or more series of Preferred Stock that may be required by the terms of this Restated Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the
votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30,213,574 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated &#147;<B>Series A Preferred
Stock</B>&#148;, 15,999,596 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated &#147;<B>Series B Preferred Stock</B>&#148;, 23,303,456 shares of the authorized and unissued Preferred Stock of the
Corporation are hereby designated &#147;<B>Series C Preferred Stock</B>&#148;, and 17,752,068 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated &#147;<B>Series D Preferred Stock</B>&#148;, with the
following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part B of this Article Fourth refer to sections and
subsections of Part B of this Article Fourth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1 <U>Dividend Preference</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.1.1 Holders of Series D Preferred Stock, in preference to the holders of Series C Preferred Stock, Series B Preferred Stock, Series A
Preferred Stock and Common Stock, shall be entitled to receive, when, as and if declared by the Board of Directors of the Corporation (the &#147;<B>Board</B>&#148;), but only out of funds that are legally available therefor, cash or stock dividends
at the rate of eight percent (8%) of the Series D Original Issue Price (as defined below) per annum on each outstanding share of Series D Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board and shall be <FONT
STYLE="white-space:nowrap">non-cumulative.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.1.2 Holders of Series C Preferred Stock, in preference to the holders of Series B
Preferred Stock, Series A Preferred Stock and Common Stock, shall be entitled to receive, when, as and if declared by the Board, but only out of funds that are legally available therefor, cash or stock dividends at the rate of eight percent (8%) of
the Series C Original Issue Price (as defined below) per annum on each outstanding share of Series C Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board and shall be
<FONT STYLE="white-space:nowrap">non-cumulative.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.1.3 Holders of Series B Preferred Stock, in preference to the holders of
Series A Preferred Stock and Common Stock, shall be entitled to receive, when, as and if declared by the Board, but only out of funds that are legally available therefor, cash or stock dividends at the rate of eight percent (8%) of the Series B
Original Issue Price (as defined below) per annum on each outstanding share of Series B Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board and shall be <FONT STYLE="white-space:nowrap">non-cumulative.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.1.4 Holders of Series A Preferred Stock, in preference to the holders of Common Stock, shall be entitled to receive, when, as and if
declared by the Board, but only out of funds that are legally available therefor, cash or stock dividends at the rate of eight percent (8%) of the Series A Original Issue Price (as defined below) per annum on each outstanding share of Series A
Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board and shall be <FONT STYLE="white-space:nowrap">non-cumulative.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 The &#147;<B>Series A Original Issue Price</B>&#148; shall mean $0.3750 per share, subject to appropriate adjustment in the event of any
stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock after the Effective Time. The &#147;<B>Series B Original Issue Price</B>&#148; shall mean $0.7500 per share, subject to
appropriate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock after the Effective Time. The
&#147;<B>Series C Original Issue Price</B>&#148; shall mean $2.3987 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series C Preferred
Stock after the Effective Time. The &#147;<B>Series D Original Issue Price</B>&#148; shall mean $6.7597 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with
respect to the Series D Preferred Stock after the Effective Time. The &#147;<B>Original Issue Price&#148;</B> shall mean the Series A Original Issue Price, the Series B Original Issue Price, the Series C Original Issue Price, or the Series D
Original Issue Price, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.3 So long as any shares of Preferred Stock are outstanding, the Corporation shall not pay or
declare any dividend (whether in cash or property), or make any other distribution on the Common Stock, or purchase, redeem or otherwise acquire for value any shares of Common Stock, until all dividends as set forth in Section&nbsp;1.1 above on the
Preferred Stock shall have been paid or declared and set apart, except for: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.3.1 acquisitions of Common Stock by the Corporation
pursuant to agreements that permit the Corporation to repurchase such shares at no more than cost upon termination of services to the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.3.2 acquisitions of Common Stock in exercise of the Corporation&#146;s right of first refusal to repurchase such shares; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.3.3 distributions to holders of Common Stock in accordance with Section&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.4 In the event dividends are paid on any share of Common Stock, the Corporation shall pay an additional dividend on all outstanding shares
of Preferred Stock in a per share amount equal (on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> to Common Stock basis) to the amount paid or set aside for each share of Common Stock. For this
purpose each holder of shares of Preferred Stock is to be treated as holding the greatest whole number of shares of Common Stock then issuable upon conversion of all shares of Preferred Stock held by such holder pursuant to Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.5 The provisions of Sections 1.3 and 1.4 shall not apply to: (i)&nbsp;a dividend payable solely in Common Stock to which the provisions of
Section&nbsp;4.6 hereof are applicable or (ii)&nbsp;any repurchase of any outstanding securities of the Corporation that is approved by<B> </B>the Board, including a majority of the Preferred Directors (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the
holders of shares of Series D Preferred Stock then outstanding shall be entitled to be paid out of the assets or proceeds of the Corporation available for distribution to its stockholders before any payment shall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be made to the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal to the
greater of (i)&nbsp;one times the Series D Original Issue Price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series D Preferred Stock been converted into Common Stock
pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up of the
Corporation or Deemed Liquidation Event, the assets or proceeds of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series D Preferred Stock the full amount to which they shall be
entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.1</U>, the holders of shares of Series D Preferred Stock shall share ratably in any distribution of the assets or proceeds available for distribution in proportion to the respective amounts
which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event and
after the payment of all preferential amounts required to be paid to the holders of shares of Series D Preferred Stock, the holders of shares of Series C Preferred Stock then outstanding shall be entitled to be paid out of the assets or proceeds of
the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Series B Preferred Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal to
the greater of (i)&nbsp;one times the Series C Original Issue Price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series C Preferred Stock been converted into Common
Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up
of the Corporation or Deemed Liquidation Event, the assets or proceeds of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series C Preferred Stock the full amount to which they
shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.2</U>, the holders of shares of Series C Preferred Stock shall share ratably in any distribution of the assets or proceeds available for distribution in proportion to the respective
amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.3 In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event and
after the payment of all preferential amounts required to be paid to the holders of shares of Series D Preferred Stock and Series C Preferred Stock, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out
of the assets or proceeds of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal
to the greater of (i)&nbsp;one times the Series B Original Issue Price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred Stock been converted into
Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event. If upon any such liquidation, dissolution or
winding up of the Corporation or Deemed Liquidation Event, the assets or proceeds of the Corporation available for distribution to its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.3</U>,
the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the assets or proceeds available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by
them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.4 In the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event and after the payment of all preferential amounts required to be paid to the holders of shares of Series D Preferred Stock, Series C
Preferred Stock and Series B Preferred Stock, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets or proceeds of the Corporation available for distribution to its stockholders before any
payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;one times the Series A Original Issue Price, plus any dividends declared but unpaid thereon or
(ii)&nbsp;such amount per share as would have been payable had all shares of Series&nbsp;A Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such voluntary or involuntary
liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets or proceeds of the Corporation available for
distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.4</U>, the holders of shares of Series A
Preferred Stock shall share ratably in any distribution of the assets or proceeds available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all
amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock as set forth in
Section&nbsp;2.1 above, the remaining assets or proceeds of the Corporation available for distribution to its stockholders shall be distributed pro rata among the holders of shares of Common Stock based on the number of shares of Common Stock held
by each such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#147;Deemed Liquidation Event&#148; unless the holders of a
majority of the outstanding shares of Preferred Stock (voting together as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), including the holders of a majority of the outstanding shares of Series D Preferred Stock
unless the consideration payable on each share of Series D Preferred Stock is equal to or greater than (A) 1.5 times the Series D Original Issue Price if such event occurs prior to the date that is twelve months following the Original Issue Date or
(B) 1.75 times the Series D Original Issue Price if such event occurs on or after the date that is twelve months following the Original Issue Date, elect otherwise by written notice sent to the Corporation at least twenty (20)&nbsp;days prior to the
effective date of any such event: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation in which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which
the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately
following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) (1) the sale, lease,
transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken
as a whole (including, without limitation, the sale or exclusive license of all or substantially all of the Corporation&#146;s intellectual property), or (2)&nbsp;the sale or disposition (whether by merger, consolidation or otherwise, and whether in
a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except
where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2
<U>Effecting a Deemed Liquidation Event</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred
to in <U>Subsection 2.3.1(a)(i)</U> unless the agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the consideration payable to the stockholders of the Corporation shall be
allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the
event of a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such
Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Deemed Liquidation Event
advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause; (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (iii)&nbsp;if the holders of a
majority of the then outstanding shares of Preferred Stock (voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), including the holders of a majority of the outstanding shares of Series D Preferred
Stock unless the consideration payable on each share of Series D Preferred Stock is equal to or greater than (x) 1.5 times the Series D Original Issue Price if such event occurs prior to the date that is twelve months following the Original Issue
Date or (y) 1.75 times the Series D Original Issue Price if such event occurs on or after the date that is twelve months following the Original Issue Date, so request in a written instrument delivered to the Corporation not later than one hundred
twenty (120)&nbsp;days after such Deemed Liquidation Event, the Corporation shall use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good
faith by the Board),<B> </B>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#147;<B>Available</B><B>
Proceeds</B>&#148;), on the one hundred fiftieth (150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the amount
payable to the holders of each series of Preferred Stock, pursuant to Subsection 2.1 and Subsection 2.2, as applicable. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not
sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall ratably redeem each holder&#146;s shares of Preferred Stock to the fullest extent of such Available Proceeds (with such redemption being made in accordance with
Subsection 2.1 and Subsection 2.2, as applicable), and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. The provisions of <U>Section</U><U></U><U>&nbsp;6</U> shall apply,
with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this <U>Subsection 2.3.2(b)</U>. Prior to the distribution or redemption provided for in this <U>Subsection
2.3.2(b)</U>, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation
upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders by the Corporation or the
acquiring person, firm or other entity pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board, including a majority of the Preferred Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Subsection
2.3.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the Merger Agreement shall provide that
(a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections
2.1</U> and 2.2 as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable to the stockholders of the Corporation upon
satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and 2.2 after taking into account the previous payment of the Initial Consideration as part of the
same transaction. For the purposes of this <U>Subsection 2.3.4</U>, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event
shall be deemed to be Additional Consideration.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of
stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as
of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Restated Certificate, holders of Preferred Stock shall vote together with the holders of Common Stock as a
single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. At any time when at
least 1,650,000 shares of Series&nbsp;D Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series D Preferred Stock after the
Effective Time) are outstanding, the holders of record of the shares of Series D Preferred Stock, voting exclusively and as a separate class, shall be entitled to elect one director of the Corporation (the &#147;<B>S</B><B>eries D
Director</B>&#148;). The holders of record of the shares of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, voting together as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis,
shall be entitled to elect two directors of the Corporation (the &#147;<B>Prior Preferred Directors</B>,&#148; and together with the Series D Director, the &#147;<B>Preferred Directors</B>&#148;). The holders of record of the shares of Common Stock,
voting exclusively and as a separate class, shall be entitled to elect two directors of the Corporation. Any director elected as provided in this <U>Subsection</U><U></U><U>&nbsp;3.2</U> may be removed without cause by, and only by, the affirmative
vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of
stockholders. If the holders of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a
separate class, pursuant to this <U>Subsection</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock or Common Stock, as the case may be, elect a person to fill such
directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship,
voting exclusively and as a separate<B> </B>class.<B> </B>The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the
holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum and votes needed for the purpose of electing such director. Except as otherwise provided in this
<U>Subsection</U><U></U><U>&nbsp;3.2</U>,<B> </B>a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any
remaining director or directors elected by the holders of such class or series pursuant to this <U>Subsection</U><U></U><U>&nbsp;3.2</U>. The rights of the holders of the Preferred Stock and the rights of the holders of the Common Stock under this
<U>Subsection</U><U></U><U>&nbsp;3.2</U> shall terminate on the first date following the Original Issue Date (as defined below) on which there are no shares of Preferred Stock (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination, or other similar recapitalization with respect to the Preferred Stock after the Effective Time) issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when any shares of Preferred Stock are outstanding, the Corporation shall not,
either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative vote
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the holders of a majority of the then outstanding shares of Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation, effect any merger or
consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter, waive or repeal any
provision of this Restated Certificate or Bylaws of the Corporation in a manner that adversely affects the powers, preferences or rights of any Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital stock
unless the same ranks junior to any Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption, or increase the authorized number of
shares of any Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 (i) reclassify, alter, waive or amend any existing security of the Corporation that is pari passu
with any Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such
other security senior to any Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to any Preferred Stock in respect of the distribution
of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with any
Preferred Stock in respect of any such right, preference or privilege; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 purchase or redeem (or permit any subsidiary to purchase or
redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on any Preferred Stock as expressly authorized herein,
(ii)&nbsp;dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed
services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof, or (iv)&nbsp;as approved by the Board, including
the approval of a majority of the Preferred Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 create, or authorize the creation of, or issue, or authorize the issuance
of any debt security, or permit any subsidiary to take any such action with respect to any debt security, if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $2,000,000 other
than equipment leases or bank lines of credit unless such debt security has received the prior approval of the Board, including the approval of a majority of the Preferred Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries)
by the Corporation, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively
license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 increase or decrease the authorized number of directors constituting the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 authorize or consummate in any way a public offering of any securities of the Corporation or any of its subsidiaries; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 cause, or permit any of its subsidiaries to, without the prior approval of the Board, including the approval of a majority of the
Preferred Directors, sell, issue, sponsor, create or distribute any digital tokens, cryptocurrency or other blockchain-based assets (collectively, &#147;<B>Tokens</B>&#148;), including through a <FONT STYLE="white-space:nowrap">pre-sale,</FONT>
initial coin offering, token distribution event or crowdfunding, or through the issuance of any instrument convertible into or exchangeable for Tokens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, any change in capital structure of the Corporation that would adversely affect the rights, powers, privileges or preferences of
any holder of Preferred Stock in a manner that is materially different from and disproportionate to any other similarly situated holder of Preferred Stock would require the consent of such holder of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series D Preferred Stock Protective Provisions</U>. At any time when any shares of Series D Preferred Stock are outstanding, the
Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative
vote of the holders of a majority of the then outstanding shares of Series D Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) exclusively and as a separate class: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1 amend, alter or repeal any provision of this Restated Certificate or Bylaws of the Corporation in a manner that adversely affects the
powers, preferences or rights of the Series D Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2 increase or decrease the authorized number of shares of Series D
Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.3 create, or authorize the creation of, or issue or obligate itself to issue shares of any additional class or
series of capital stock that (i)&nbsp;is pari passu or senior to the Series D Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption
and (ii)&nbsp;has an original issue price that is equal to or less than the Series D Original Issue Price; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.4 reclassify, alter or
amend any existing security of the Corporation that is pari passu with any Series D Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of
redemption, if such reclassification, alteration or amendment would render such other security senior to any Series D Preferred Stock in respect of any such right, preference, or privilege </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to any Series D Preferred Stock in respect of the distribution of assets on the liquidation,
dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with any Series D Preferred Stock in respect
of any such right, preference or privilege; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.5 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business
and affairs of the Corporation, effect any Deemed Liquidation Event, or consent to any of the foregoing, unless the consideration payable on each share of Series D Preferred Stock is equal to or greater than (i) 1.5 times the Series D Original Issue
Price if such event occurs prior to the date that is twelve months following the Original Issue Date or (ii) 1.75 times the Series D Original Issue Price if such event occurs on or after the date that is twelve months following the Original Issue
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional</U><U> Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the applicable Original Issue Price for such series of
Preferred Stock by the Conversion Price (as defined below) for such series in effect at the time of conversion. The &#147;<B>Conversion Price</B>&#148; per share for each series of Preferred Stock shall initially be equal to the applicable Original
Issue Price of such series. The Conversion Price for each series, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock pursuant to
<U>Section</U><U></U><U>&nbsp;6</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid
on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion
Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; <I>provided</I> that, the foregoing termination of
Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2
<U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such
fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares
of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own
transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#146;s shares are certificated,
surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the
Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required
by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its
attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate
affidavit and agreement) shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The
Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable
upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such
amount as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock
converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve
and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation
shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain
the requisite stockholder approval of any necessary amendment to this Restated Certificate. Before taking any action which would cause an adjustment reducing the applicable Conversion Price of a series of Preferred Stock below the then par value of
the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted applicable Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3
<U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and
terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in
<U>Subsection</U><U></U><U>&nbsp;4.2</U> and to receive any dividends declared but unpaid thereon. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may
thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of such Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the applicable Conversion Price shall be made for any declared
but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5
<U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of any Preferred Stock pursuant to this
<U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which
the shares of the Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established,
to the satisfaction of the Corporation, that such tax has been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments</U><U> to Conversion Price for Diluting
Issues</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Option</B>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Original Issue Date</B>&#148; shall mean the date on which the first share of Series D Preferred
Stock was issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness, shares or other securities
directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Additional Shares of
Common Stock</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Effective Time, other than (1)&nbsp;the following shares of
Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B>Exempted Securities</B>&#148;):
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on any Preferred
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board, including one of the Preferred Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board, including a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers
in connection with the provision of goods or services pursuant to transactions approved by the Board, including a majority of the Preferred Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the
acquisition of another corporation by the Corporation by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, <U>provided</U> that such issuances are approved by the Board of Directors, including
a majority of the Preferred Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board, including a majority of the Preferred Directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock issued in the Corporation&#146;s first underwritten public offering under the Securities
Act of 1933, as amended. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Conversion Price</U>. No adjustment in the applicable Conversion
Price of a series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of such
series, agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Effective Time shall issue any Options or Convertible Securities (excluding
Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum
number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the applicable Conversion Price
pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms
pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the
Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the
occurrence of a record date with respect thereto) shall be readjusted to such Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding
the foregoing, no readjustment pursuant to this clause&nbsp;(b) shall have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (i)&nbsp;the applicable Conversion Price in effect immediately prior to the
original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances
of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted
Securities), the issuance of which did not result in an adjustment to the applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration per share (determined pursuant to <U>Subsection 4.4.5</U>) of
the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Effective Time), are revised after the Effective
Time as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such
Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the
consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in
<U>Subsection 4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon
the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the applicable
Conversion Price pursuant to the terms of <U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, the applicable Conversion Price shall be readjusted to such Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof)
never been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or
Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon
subsequent events, any adjustment to the applicable Conversion Price provided for in this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of
consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common
Stock issuable upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at
all at the time such Option or Convertible Security is issued or amended, any adjustment to the applicable Conversion Price that would result under the terms of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or
amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the applicable Conversion
Price that such issuance or amendment took place at the time such calculation can first be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Conversion Price
Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation shall at any time after the Effective Time issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>Subsection</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a consideration per share less than the applicable Conversion Price in effect immediately prior to such issuance or deemed issuance, then the applicable Conversion Price shall
be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A +
C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>&#148; shall mean the applicable Conversion Price in effect immediately
after such issuance or deemed issuance of Additional Shares of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)
&#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148; shall mean the applicable Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of
Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible
Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date
Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, then, upon the final
such issuance, the applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such
subsequent issuances within such period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any
time or from time to time after the Effective Time effect a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of
Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the
Effective Time combine the outstanding shares of Common Stock, the applicable Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of
each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the
subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the
Corporation at any time or from time to time after the Effective Time shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in
additional shares of Common Stock, then and in each such event the applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as
of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, the applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the applicable Conversion Price shall be adjusted pursuant to this subsection as of the time
of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the
number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the
Effective Time shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then
and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such
securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2.3</U>, if there shall occur any
reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a
transaction covered by <U>Subsections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of
the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of such share of
Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good
faith by the Board) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in
this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or
other property thereafter deliverable upon the conversion of the Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the
occurrence of each adjustment or readjustment of the applicable Conversion Price pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten
(10)&nbsp;days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and
amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable
after the written request at any time of any holder of such series of Preferred Stock (but in any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the
applicable Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of such series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common
Stock of the Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon the earlier of (a)&nbsp;the closing of the sale of shares of Common Stock to the public in a firm-commitment
underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation (a &#147;<B>Qualified IPO</B>&#148;); or (b)&nbsp;the
date and time or the occurrence of an event specified by vote or written consent of the holders of a majority of the then outstanding shares of Preferred Stock, consenting or voting (as the case may be) together as a single class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis (the time of the closing of a Qualified IPO or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;<B>Mandatory
Conversion Time</B>&#148;), then (x)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1.</U> and
(y)&nbsp;such shares may not be reissued by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of
Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent
in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such
holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on
account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by
written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted
pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon
surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory
Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees,
a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of
a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as
shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1
<U>General</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.1 <U>Preferred Stock</U>. Unless prohibited by Delaware law governing distributions to stockholders, shares of a
series of Preferred Stock shall be redeemed by the Corporation (except for any shares of such series for which a holder gives notice to the Corporation of opting out of the redemption within ten (10)&nbsp;days of the notice from the Corporation of
the applicable Redemption Request) at a price equal to the Original Issue Price per share applicable to such series, plus any dividends declared but unpaid thereon<B> </B>(the &#147;<B>Redemption Price</B>&#148;), commencing at any time on or after
the date seven (7)&nbsp;years from the Original Issue Date, upon receipt of written notice from the holders of a majority of the then outstanding shares of such series of Preferred Stock requesting redemption of all shares of such series (a
&#147;<B>Redemption Request</B>&#148;). Within five (5)&nbsp;days upon receipt of a Redemption Request, the Corporation shall give written notice (the &#147;<B>Redemption Notice</B>&#148;) of such Redemption Request to the holders of record of each
other series of Preferred Stock and the holders of record of each other series of Preferred Stock may choose to exercise their rights under this Section&nbsp;6 by giving the Corporation a Redemption Request within fifteen (15)&nbsp;days upon receipt
of a Redemption Notice (the &#147;<B>Notice Period</B>&#148;). Upon the expiration of the Notice Period, the Corporation shall apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by
Delaware law governing distributions to stockholders. The date of the payment shall be not more than sixty (60)&nbsp;days after the expiration of the Notice Period and shall be referred to as a &#147;<B>Redemption Date</B>&#148;. On a Redemption
Date, the Corporation shall redeem, on a pro rata basis in accordance with the number of shares of such series of Preferred Stock owned by each holder. If, on the Redemption Date, Delaware law governing distributions to stockholders prevents the
Corporation from redeeming all shares of such series of Preferred Stock to be redeemed, the Corporation shall ratably redeem the maximum number of shares that it may redeem consistent with such law, and shall redeem the remaining shares as soon as
it may lawfully do so under such law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.2 <U>Priority of Redemption</U>. Notwithstanding the foregoing, no payment shall be made
pursuant to this <U>Section</U><U></U><U>&nbsp;6.1</U> on the Redemption Date unless all payments contemplated by this Section&nbsp;6.1 are made in accordance with the liquidation preferences set forth in Section&nbsp;2.1 above, taking into account
all Redemption Requests received on or prior to the expiration of the Notice Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Redemption Notice</U>. Each Redemption Notice shall state: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date specified in the
Redemption Notice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the Redemption Date and the Redemption Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) the date upon which the holder&#146;s right to convert such shares terminates (as determined in accordance with <U>Subsection 4.1</U>);
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place
designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Surrender of
Certificates; Payment</U>. On or before the Redemption Date, each holder of shares of Preferred Stock to be redeemed on the Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in
<U>Section</U><U></U><U>&nbsp;4</U>, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such
certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears on such certificate or
certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a certificate are redeemed, a new certificate, instrument, or book entry representing the unredeemed shares of Preferred Stock shall
promptly be issued to such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Rights Subsequent to Redemption</U>. If the Redemption Notice shall have been duly given, and
if on the Redemption Date the Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available
therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to
accrue after the Redemption Date and all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of any such
certificate or certificates therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are redeemed or
otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting
or other rights granted to the holders of Preferred Stock following redemption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Except where a series of Preferred Stock is required to vote as a separate
class herein, any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein that are generally applicable to all series of Preferred Stock may be waived on behalf of the holders of Preferred Stock by the affirmative
written consent or vote of at least a majority of the outstanding shares of Preferred Stock (voting as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). Any of the rights, powers, privileges or preferences that
are specific to any particular series of Preferred Stock may be waived on behalf of all holders of that series of Preferred Stock only by the affirmative written consent or vote of at least a majority of the shares of that series of Preferred Stock
then outstanding (voting as a separate class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). Notwithstanding the foregoing, this Restated Certificate may not be amended and the observance of any term hereunder may not be
waived with respect to a holder of any series of Preferred Stock without the written consent of such holder if such amendment or waiver materially and adversely affects such holder in a different and disproportionate manner relative to other holders
of such series of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be
given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General
Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote
required by this Restated Certificate or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being
offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such
holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH: </B>For purposes of Section&nbsp;500 of the California Corporations Code (to the extent applicable), in connection with any
repurchase of shares of Common Stock permitted under this Restated Certificate from employees, officers, directors or consultants of the Corporation in connection with a termination of employment or services pursuant to agreements or arrangements
approved by the Board of Directors (in addition to any other consent required under this Restated Certificate), such repurchases may be made without regard to any &#147;preferential dividends arrears amount&#148; or &#147;preferential rights
amount&#148; (as those terms are defined in Section&nbsp;500 of the California Corporations Code). Accordingly, for purposes of making any calculation under California Corporations Code Section&nbsp;500 in connection with such repurchases, the
amount of any &#147;preferential dividends arrears amount&#148; or &#147;preferential rights amount&#148; (as those terms are defined therein) shall be deemed to be zero (0). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>Subject to any additional vote required by this Restated Certificate, the
number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH:
</B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B>Meetings of
stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by
the Board or in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH: </B>To the fullest extent permitted by law, a director of the Corporation
shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the
stockholders of this Article Eleventh to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent
permitted by the General Corporation Law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Eleventh
by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of
such director occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH: </B>To the fullest extent permitted by applicable law, the
Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification)
through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Twelfth shall not adversely affect any right or protection
hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRTEENTH:
</B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state
court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of actions
or proceedings under Delaware statutory or common law: (A)&nbsp;any derivative action or proceeding brought on behalf of the Corporation; (B)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former
director, officer or other employee of the Corporation, to the Corporation or the Corporation&#146;s stockholders; (C)&nbsp;any action or proceeding asserting a claim against the Corporation or any current or former director, officer or other
employee of the Corporation, arising out of or pursuant to any provision of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DGCL, this Restated Certificate or the Bylaws of the Corporation (as each may be amended from time to time); (D) any action or proceeding to interpret, apply, enforce or determine the validity of
this Restated Certificate or the Bylaws of the Corporation (including any right, obligation, or remedy thereunder); (E) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and
(F)&nbsp;any action or proceeding asserting a claim against the Corporation or any current or former director, officer or other employee of the Corporation, governed by the internal affairs doctrine, in all cases to the fullest extent permitted by
law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. This Article Thirteenth shall not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as
amended (the &#147;1933 Act&#148;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum,
to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act. Any person or entity
holding, owning or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to the provisions of this Restated Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this Corporation in
accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That this Restated Certificate, which restates and integrates
and further amends the provisions of this Corporation&#146;s Amended and Restated Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[R<SMALL>EMAINDER</SMALL> O<SMALL>F</SMALL> P<SMALL>AGE</SMALL> I<SMALL>NTENTIONALLY</SMALL> L<SMALL>EFT</SMALL> B<SMALL>LANK</SMALL>]
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 16th day of July, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>YTEK</SMALL> B<SMALL>IO</SMALL>S<SMALL>CIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wenbin Jiang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Wenbin Jiang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>d80783dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wenbin Jiang hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ONE:</B> The name of this corporation is Cytek Biosciences, Inc., and the original Certificate of Incorporation of this corporation was
filed with the Secretary of State of the State of Delaware on December&nbsp;15, 2014 under the name Cytoville, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TWO:</B> He is the
duly elected and acting Chief Executive Officer of Cytek Biosciences, Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THREE:</B> The Certificate of
Incorporation of this corporation is hereby amended and restated to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Cytek Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
registered office of the Company is 850 New Burton Road, Suite 201, City of Dover, County of Kent, Delaware 19904 and the name of the registered agent of the Company at such address is The Cogency Global Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the
Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (&#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> This
Company is authorized to issue two classes of stock to be designated, respectively, &#147;<B><I>Common Stock</I></B>&#148; and &#147;<B><I>Preferred Stock</I></B>.&#148; The total number of shares which the Company is authorized to issue is
1,010,000,000 shares. 1,000,000,000 shares of which shall be Common Stock, having a par value per share of $0.001. 10,000,000 shares of which shall be Preferred Stock, having a par value per share of $0.001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the
&#147;<B><I>Board of Directors</I></B>&#148;) is hereby expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such
series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and
expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of
shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence,
the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or
decreased (but not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a
separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the
stockholders of the Company for their vote; <I>provided, however</I>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation
(including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either
separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any
series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of
the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> <B>M<SMALL>ANAGEMENT</SMALL> <SMALL>OF</SMALL> B<SMALL>USINESS</SMALL>. </B>The management of the business and the conduct of the
affairs of the Company shall be vested in its Board of Directors. The number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors
constituting the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> <B>B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>. </B>Subject to the
rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, upon the filing of this Amended and Restated Certificate of Incorporation, the directors shall be divided into three classes
designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the
first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the
second annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of
stockholders following such initial classification, the term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders,
directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified
or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. R<SMALL>EMOVAL</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances,<B> </B>neither
the Board of Directors nor any individual director may be removed without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> Subject to any limitation imposed by
applicable law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and two-thirds percent (66 2/3%) of the voting power of all
then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> <B>V<SMALL>ACANCIES</SMALL>. </B>Subject to any limitations imposed by applicable
law and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from
any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be
filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold
office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E. B<SMALL>YLAW</SMALL> A<SMALL>MENDMENTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Company.<B> </B>Any adoption, amendment or
repeal of the Bylaws of the Company by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Company; <I>provided,
however, </I>that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Amended and Restated Certificate of Incorporation, such action by stockholders shall require the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled
to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> The directors of the Company need not be
elected by written ballot unless the Bylaws so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> No action shall be taken by the stockholders of the Company except at
an annual or special meeting of stockholders called in accordance with the Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any
meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.</B> In the event
that a member of the Board of Directors of the Company who is not an employee of the Company, or any partner, member, director, stockholder, employee or agent of such member, other than someone who is an employee of the Company (collectively, the
&#147;<B><I>Covered Persons</I></B>&#148;), acquires knowledge of any business opportunity matter, potential transaction, interest or other matter, unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in connection with such individual&#146;s service as a member of the Board of Directors of the Company (a &#147;<B><I>Corporate Opportunity</I></B>&#148;), then the
Company, pursuant to Section&nbsp;122(17) of the DGCL and to the maximum extent permitted from time to time under Delaware law, (i)&nbsp;renounces any expectancy that such Covered Person offer an opportunity to participate in such Corporate
Opportunity to the Company and (ii)&nbsp;to the fullest extent permitted by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by such Covered Person to the Company or any of its
affiliates. No amendment or repeal of this paragraph shall apply to or have any effect on the liability or alleged liability of any officer, director or stockholder of the Company for or with respect to any opportunities of which such officer,
director or stockholder becomes aware prior to such amendment or repeal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of
expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or
disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase
the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> Unless
the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located
within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the
following claims or causes of action under the Delaware statutory or common law: (A)&nbsp;any derivative claim or cause of action brought on behalf of the Company; (B)&nbsp;any claim or cause of action for breach of a fiduciary duty owed by any
current or former director, officer or other employee of the Company, to the Company or the Company&#146;s stockholders; (C)&nbsp;any claim or cause of action against the Company or any current or former director, officer or other employee of the
Company , arising out of or pursuant to any provision of the DGCL, this Amended and Restated Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret,
apply, enforce or determine the validity of this Amended and Restated Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause
of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&nbsp;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company,
governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to
claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#147;<B><I>1933 Act</I></B>&#148;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the
federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Unless the Company consents in writing to the selection of an alternative forum, to
the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action
asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other
professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Any person or entity holding, owning or otherwise acquiring any interest in any
security of the Company shall be deemed to have notice of and consented to the provisions of this Amended and Restated Certificate of Incorporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The
Company reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this
Article&nbsp;VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>
Notwithstanding any other provisions of this Amended and Restated Certificate of Incorporation or any provision of applicable law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any
particular class or series of the capital stock of the Company required by law or by this Amended and Restated Certificate of Incorporation or any certificate of designation filed with respect to a series of Preferred Stock, the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then outstanding shares of capital stock of the Company entitled to
vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOUR:</B> This
Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIVE:</B> This
Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of the Company in accordance with Section&nbsp;228 of the DGCL. This Amended and Restated Certificate of Incorporation has been duly
adopted in accordance with the provisions of Sections 242 and 245 of the DGCL by the stockholders of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, Cytek
Biosciences, Inc. has caused this Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this ___ day of _______, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Wenbin Jiang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>d80783dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE I OFFICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Registered Office</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Offices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE II CORPORATE SEAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Corporate Seal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE III STOCKHOLDERS&#146; MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Place of Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Special Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Notice of Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Quorum</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjournment And Notice Of Adjourned Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Voting Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Joint Owners of Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>List of Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Action Without Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Organization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE IV DIRECTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number And Term Of Office</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Powers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Classes of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vacancies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Resignation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Removal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Quorum and Voting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Action Without Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;24.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fees and Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;25.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Committees.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;26.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lead Independent Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;27.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Organization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE V OFFICERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;28.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Officers Designated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;29.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tenure And Duties Of Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;30.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Delegation Of Authority</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;31.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Resignations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;32.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Removal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VI EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY
THE CORPORATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;33.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Execution Of Corporate Instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;34.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Voting Of Securities Owned By The Corporation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VII SHARES OF STOCK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;35.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Form And Execution Of Certificates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;36.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lost Certificates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;37.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transfers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;38.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixing Record Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;39.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Registered Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VIII OTHER SECURITIES OF THE CORPORATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;40.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Execution Of Other Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE IX DIVIDENDS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;41.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Declaration Of Dividends</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;42.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Dividend Reserve</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE X FISCAL YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;43.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fiscal Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE XI INDEMNIFICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;44.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors, Executive Officers, Other Officers, Employees and Other
Agents.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE XII NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;45.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Notices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE XIII AMENDMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;46.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Amendments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE XIV LOANS TO OFFICERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;47.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loans To Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Registered Office</B><B>.</B> The registered office of the corporation in the State of
Delaware shall be in the City of Dover, County of Kent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Other Offices</B><B>.</B> The corporation
may also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may
from time to time determine or the business of the corporation may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Corporate Seal</B><B>.</B> The Board of Directors may adopt a corporate seal. If adopted, the
corporate seal shall consist of a die bearing the name of the corporation and the inscription, &#147;Corporate Seal-Delaware.&#148; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Place of Meetings</B><B>.</B> Meetings of the stockholders of the corporation may be held at such
place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead
be held solely by means of remote communication as provided under the Delaware General Corporation Law (&#147;DGCL&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. Annual Meetings.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&nbsp;pursuant to the corporation&#146;s notice of meeting of stockholders (with respect to
business other than nominations); (ii) brought specifically by or at the direction of the Board of Directors; or (iii)&nbsp;by any stockholder of the corporation who was a stockholder of record at the time of giving the stockholder&#146;s notice
provided for in Section&nbsp;5(b) below, who is entitled to vote at the meeting and who complied with the notice procedures set forth in Section&nbsp;5. For the avoidance of doubt, clause (iii)&nbsp;above shall be the exclusive means for a
stockholder to make nominations and submit other business (other than matters properly included in the corporation&#146;s notice of meeting of stockholders and proxy statement under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the
Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &#147;1934 Act&#148;)) before an annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> At an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under
Delaware law and as shall have been properly brought before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> For nominations for the election to the Board of
Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the
corporation on a timely basis as set forth in Section&nbsp;5(b)(iii) and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each nominee
such stockholder proposes to nominate at the meeting: (1)&nbsp;the name, age, business address and residence address of such nominee, (2)&nbsp;the principal occupation or employment of such nominee, (3)&nbsp;the class and number of shares of each
class of capital stock of the corporation which are owned of record and beneficially by such nominee, (4)&nbsp;the date or dates on which such shares were acquired and the investment intent of such acquisition, (5)&nbsp;such other information
concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required
to be disclosed pursuant to Section&nbsp;14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&#146;s written consent to being named as a nominee and to serving as a director if elected); and (B)&nbsp;the
information required by Section&nbsp;5(b)(iv). The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director
of the corporation or that could be material to a reasonable stockholder&#146;s understanding of the independence, or lack thereof, of such proposed nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Other than proposals sought to be included in the corporation&#146;s proxy materials pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of
Section&nbsp;5(a), the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&nbsp;5(b)(iii), and must update and supplement such written notice on a
timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the
meeting, the reasons for conducting such business at the meeting, and any material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the corporation&#146;s capital stock, that is
material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&nbsp;the information required by Section&nbsp;5(b)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To be timely, the written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) must be received by the Secretary at the principal
executive offices of the corporation not later than the close of business on the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day nor earlier than the close of business on the one hundred twentieth (120<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however,</I> that, subject to the last sentence of this Section&nbsp;5(b)(iii), in the event that the
date of the annual meeting is advanced more than thirty (30)&nbsp;days prior to or delayed by more than thirty (30)&nbsp;days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be timely must be so
received not earlier than the close of business on the one hundred twentieth (120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)<B> </B>day prior to such annual meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public announcement of the date of such meeting is
first made. In no event shall an adjournment or a postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as
described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) shall also set forth, as of the date of the
notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#147;Proponent&#148; and collectively, the &#147;Proponents&#148;): (A) the name and address of each
Proponent, as they appear on the corporation&#146;s books; (B)&nbsp;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&nbsp;a description of any agreement, arrangement or
understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the
agreement, arrangement or understanding, with any of the foregoing; (D)&nbsp;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting and intend
to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section&nbsp;5(b)(i)) or to propose the business that is specified in the notice (with respect to a notice under
Section&nbsp;5(b)(ii)); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#146;s voting shares to elect such nominee or nominees
(with respect to a notice under Section&nbsp;5(b)(i)) or to carry such proposal (with respect to a notice under Section&nbsp;5(b)(ii)); (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal
on the date of such stockholder&#146;s notice; and (G)&nbsp;a description of all Derivative Transactions (as defined below) by each Proponent during the previous twelve (12)&nbsp;month period, including the date of the transactions and the class,
series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Sections 5 and 6, a &#147;Derivative Transaction&#148; means any agreement, arrangement,
interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(w) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the corporation,
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(x) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of
securities of the corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(y) the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price
changes, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(z) which provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or
associates, with respect to any securities of the corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which agreement, arrangement, interest or understanding may include, without limitation,
any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares
(whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the corporation held by any general or limited partnership, or any limited
liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> A stockholder
providing written notice required by Section&nbsp;5(b)(i) or (ii)&nbsp;shall update and supplement such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material
respects as of (i)&nbsp;the record date for the meeting and (ii)&nbsp;the date that is five (5)&nbsp;business days prior to the meeting and, in the event of any adjournment or postponement thereof, five (5)&nbsp;business days prior to such adjourned
or postponed meeting. In the case of an update and supplement pursuant to clause (i)&nbsp;of this Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than
five (5)&nbsp;business days after the record date for the meeting. In the case of an update and supplement pursuant to clause (ii)&nbsp;of this Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal
executive offices of the corporation not later than two (2)&nbsp;business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two (2)&nbsp;business days prior to such adjourned or postponed meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding anything in Section&nbsp;5(b)(iii) to the contrary, in the event that the number of directors in an Expiring
Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the corporation at least ten (10)&nbsp;days before the
last day a stockholder may deliver a notice of nomination in accordance with Section&nbsp;5(b)(iii), a stockholder&#146;s notice required by this Section&nbsp;5 and which complies with the requirements in Section&nbsp;5(b)(i), other than the timing
requirements in Section&nbsp;5(b)(iii), shall also be considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timely, but only with respect to nominees for any new positions in such Expiring Class&nbsp;created by such increase, if it shall be received by the Secretary at the principal executive offices
of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation. For purposes of this section, an &#147;Expiring Class&#148; shall mean a class of
directors whose term shall expire at the next annual meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> A person shall not be eligible for election or <FONT
STYLE="white-space:nowrap">re-election</FONT> as a director, unless the person is nominated in accordance with either clause (ii)&nbsp;or (iii) of Section&nbsp;5(a). Except as otherwise required by law, the chairperson of the meeting shall have the
power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or
business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E), to declare that such proposal or nomination shall not be presented for stockholder action
at the meeting and shall be disregarded, notwithstanding that proxies in respect of such nominations or such business may have been solicited or received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notwithstanding the foregoing provisions of this Section&nbsp;5, in order to include information with respect to a stockholder
proposal in the proxy statement and form of proxy for a stockholders&#146; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to
affect any rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any references in these
Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section&nbsp;5(a)(iii) of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> For purposes of Sections&nbsp;5 and 6, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;public announcement&#148; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press
or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;affiliates&#148; and &#147;associates&#148; shall have the meanings set forth in Rule 405 under the Securities Act of 1933,
as amended (the &#147;1933 Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. Special Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action
under Delaware law, by (i)&nbsp;the Chairperson of the Board of Directors, (ii)&nbsp;the Chief Executive Officer, or (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors
(whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board of Directors shall determine the time and place, if any, of such
special meeting. Upon determination of the time and place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7. No business may
be transacted at such special meeting otherwise than specified in the notice of meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B></B>Nominations of persons for
election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the corporation who is a
stockholder of record at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by
Section&nbsp;5(b)(i). In the event the corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may
be), for election to such position(s) as specified in the corporation&#146;s notice of meeting, if written notice setting forth the information required by Section&nbsp;5(b)(i) of these Bylaws shall be received by the Secretary at the principal
executive offices of the corporation not later than the close of business on the later of the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such meeting or the tenth (10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The
stockholder shall also update and supplement such information as required under Section&nbsp;5(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been
made, commence a new time period for the giving of a stockholder&#146;s notice as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding the
foregoing provisions of this Section&nbsp;6, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&nbsp;6. Nothing in these Bylaws
shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any
references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to
<B></B>Section&nbsp;6(c) of these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Notice of Meetings</B><B>.</B> Except as otherwise
provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder entitled to
vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be
deemed to be present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the
corporation. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting,
and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Quorum</B><B>.</B> At all meetings of stockholders, except where otherwise provided by statute or by
the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a
quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairperson of the meeting or by vote of the holders of a majority of the shares represented thereat,
but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough
stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative
vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided
by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote
generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of
such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise
provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote
communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Adjournment and Notice of Adjourned Meetings</B><B>.</B> Any meeting of stockholders, whether annual
or special, may be adjourned from time to time either by the chairperson of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting is
adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may
transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned
meeting shall be given to each stockholder of record entitled to vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Voting
Rights</B><B>.</B> For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record date, as provided in Section&nbsp;12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in
person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3)&nbsp;years from its date
of creation unless the proxy provides for a longer period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Joint Owners of Stock</B><B>.</B> If
shares or other securities having voting power stand of record in the names of two (2)&nbsp;or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two
(2)&nbsp;or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the
relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a)&nbsp;if only one (1)&nbsp;votes, his or her act binds all; (b)&nbsp;if more than one (1)&nbsp;votes, the act of the majority so voting
binds all; (c)&nbsp;if more than one (1)&nbsp;votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the
DGCL, Section&nbsp;217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection&nbsp;(c) shall be a majority or even-split in interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>List of Stockholders</B><B>.</B> The Secretary shall prepare and make, at least ten (10)&nbsp;days
before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder.
Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the
notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take
reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13. Action Without Meeting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws,
and no action shall be taken by the stockholders by written consent or by electronic transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14. Organization.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At every meeting of stockholders, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed
or is absent, the President, or, if the President is absent, a chairperson of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairperson. The Secretary, or, in his or
her absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board of Directors of the corporation shall be entitled to make such rules or
regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairperson of the meeting shall have the right and authority
to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an
agenda or order of business for the meeting, with consultation by the Lead Independent Director (as defined below), rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such
meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairperson shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof,
limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls
for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairperson of the meeting, meetings of stockholders shall not be required
to be held in accordance with rules of parliamentary procedure. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Number and Term of Office</B><B>.</B> The authorized number of directors of the corporation shall be
fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be
elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. Each director shall serve until his or her successor is duly elected and qualified or until his or her
earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Powers</B><B>.</B> The business and affairs of the corporation shall be managed by or under the
direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Classes of Directors</B><B>. </B>Subject to the rights of the holders of any series of Preferred
Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign members
of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the
Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;II directors
shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors
shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing provisions of this Section&nbsp;17, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board
of Directors shall shorten the term of any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B> <B>Vacancies</B><B>. </B>Unless
otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes
and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be
filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <I>provided, however</I>, that whenever the
holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless
the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by
a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and
until such director&#146;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Resignation</B><B>.</B> Any director may resign at any time by delivering his or her notice in
writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at the time of delivery to the Secretary. When one
or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take
effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the unexpired portion of the term of the Director whose place shall be vacated and until his or her successor shall have been duly
elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20. Removal. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the rights of holders of any series of Preferred Stock to elect additional directors under specified circumstances<B>
</B>neither the Board of Directors nor any individual director may be removed without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to any limitation imposed by applicable law, any individual director or
directors may be removed with cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all
then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21.
Meetings. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Regular Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of
the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone,
including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Special Meetings. </B>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the
Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairperson of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Meetings by Electronic Communications Equipment. </B>Any member of the Board of Directors, or of any committee thereof, may
participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in
person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Notice of Special Meetings. </B>Notice of the time and place of all special meetings of the Board
of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means,
during normal business hours, at least twenty-four (24)&nbsp;hours before the date and time of the meeting. If notice is sent by US mail, it shall be sent by first class mail, charges prepaid, at least three (3)&nbsp;days before the date of the
meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express
purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Waiver of Notice. </B>The transaction of all business at any meeting of the Board of Directors, or any committee thereof,
however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not
present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;22. Quorum and Voting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification
arising under<B> </B>Section&nbsp;44 for which a quorum shall be <FONT STYLE="white-space:nowrap">one-third</FONT> of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the exact
number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum be present or otherwise, a majority of the directors present may
adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the
affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23.</B> <B>Action Without Meeting</B><B>.</B> Unless otherwise restricted by the Certificate of Incorporation or
these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent
thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are
maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;24.</B> <B>Fees and Compensation</B><B>.</B> Directors shall be entitled to such compensation for their services
as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any
meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;25. Committees. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Executive Committee.</B> The Board of Directors may appoint an Executive Committee to consist of one (1)&nbsp;or more members of
the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the
business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or adopting, or
recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylaw of the
corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Committees.</B> The Board of Directors may, from time to time, appoint
such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1)&nbsp;or more members of the Board of Directors and shall have such powers and perform such duties as may be
prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Term.</B> The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of
subsections&nbsp;(a) or (b)&nbsp;of this Section&nbsp;25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his or
her death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by
death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of
the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously
appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B>Meetings.</B> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&nbsp;25 shall be held at such times and places as are determined by the
Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any
place which has been determined from time to time by such committee, and may be called by any Director<B> </B>who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the
manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission
at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee
shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;26.</B> <B>Lead Independent Director</B><B>. </B>The Chairperson of the Board of Directors, or if the
Chairperson is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (&#147;Lead Independent Director&#148;). The
Lead Independent Director will: serve as chairperson of Board of Directors meetings in the absence of the Chairperson of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the committee chairs
regarding meeting agendas and informational requirements; preside over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or
discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is presented or discussed; and coordinate the activities of the other independent directors and perform such other duties
as may be established or delegated by the Chairperson of the Board of Directors<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;27.</B>
<B>Organization</B><B>.</B> At every meeting of the directors, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent<B>,</B>
the Chief Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a
chairperson of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his or her absence, any Assistant Secretary or other officer or director or other person directed to do so by the
Chairperson of the Board, the Lead Independent Director or the President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;28.</B> <B>Officers Designated</B><B>.</B> The officers of the corporation shall include, if and when designated
by the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries and Assistant
Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any
number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;29. Tenure and Duties of Officers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>General.</B> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been
duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled
by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Duties of Chief Executive Officer.</B> The Chief Executive Officer shall preside at all meetings
of the stockholders (subject to Section&nbsp;14) and at all meetings of the Board of Directors, unless the Chairperson of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an officer has been appointed
Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President
shall be deemed references to the Chief Executive Officer. <B></B>The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors
shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Duties of President.</B> The President shall preside at all meetings of the stockholders
(subject to Section&nbsp;14) and at all meeting of the Board of Directors<B>, </B>unless the Chairperson of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another
officer has been appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control
of the business and officers of the corporation.<B> </B>The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time
to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Duties of Vice Presidents.</B> The Vice Presidents may assume and perform the duties of the President in the
absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board
of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Duties of Secretary.</B> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall
record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee
thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall
designate from time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties
commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Duties of Chief Financial Officer.</B> The Chief Financial Officer shall keep or cause to be kept the books of account of the
corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order
of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed
references to the Chief Financial Officer. <B></B>The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant
Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Duties of Treasurer.</B> Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer
shall be the Chief Financial Officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form
and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.<B> </B>The Treasurer shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;30.</B> <B>Delegation of Authority</B><B>.</B> The Board of Directors may from time to time delegate the powers
or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;31.</B>
<B>Resignations</B><B>.</B> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the
person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation
shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;32.</B> <B>Removal</B><B>.</B> Any officer may be removed from office at any time, either with or without cause,
by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer or by other superior officers upon whom
such power of removal may have been conferred by the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;33.</B> <B>Execution of Corporate Instruments</B><B>.</B> The Board of Directors may, in its discretion,
determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without
limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All checks and drafts drawn on banks or other depositaries on funds to the credit of the
corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any
power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;34.</B> <B>Voting of Securities Owned By The Corporation</B><B>.</B> All stock and other securities of other
corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in
the absence of such authorization, by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;35.</B> <B>Form and Execution of Certificates</B><B>.</B> The shares of the corporation shall be
represented by certificates or shall be uncertificated. Certificates for the shares of stock, if any, of the corporation shall be in such form<B> </B>as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock
represented by certificate<B> </B>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairperson of the Board of Directors, or the President or any Vice President and by the Treasurer or
Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who
has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer,
transfer agent, or registrar at the date of issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;36.</B> <B>Lost Certificates</B><B>.</B> A new
certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the
certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the
owner&#146;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the
corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;37. Transfers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by
attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The corporation shall have power to enter into and perform any agreement with any
number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;38. Fixing Record Dates. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable
law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting
of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of
stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which
record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60)&nbsp;days prior to such action. If no record date is fixed, the record date for determining
stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;39.</B> <B>Registered Stockholders</B><B>.</B> The corporation shall be entitled to recognize the exclusive
right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person
whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER SECURITIES OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;40.</B> <B>Execution of Other Securities</B><B>.</B> All bonds, debentures and other corporate securities of the
corporation, other than stock certificates (covered in Section&nbsp;35), may be signed by the Chairperson of the Board of Directors, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the
corporate seal impressed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant
Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such
bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons.
Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized
by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or
on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by
the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;41.</B> <B>Declaration of Dividends</B><B>.</B> Dividends upon the capital stock of the corporation,
subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the
capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;42.</B>
<B>Dividend Reserve</B><B>.</B> Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think
proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the
corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;43.</B> <B>Fiscal Year</B><B>.</B> The fiscal year of the corporation shall be fixed by resolution of the Board
of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;44. Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Directors</B><B> </B><B>and Executive Officers</B><B>. </B>The corporation shall indemnify its directors and executive officers
(for the purposes of this Article&nbsp;XI, &#147;executive officers&#148; shall have the meaning defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the 1934 Act)<B> </B>to the extent not prohibited by the DGCL or any
other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by individual contracts with its directors and executive officers; and, <I>provided, further,</I> that the corporation shall not be
required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made by law, (ii)&nbsp;the proceeding was
authorized by the Board of Directors of the corporation, (iii)&nbsp;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or
(iv)&nbsp;such indemnification is required to be made under subsection (d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Officers,</B><B> </B><B>Employees and
Other Agents.</B> The corporation shall have power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether
indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Expenses.</B> The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by
reason of the fact that he is or was a director or executive officer, of the corporation, or is or was serving at the request of the corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other
enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or executive officer<B> </B>in connection with such proceeding provided, however, that if the DGCL requires, an
advancement of expenses incurred by a director or executive officer<B> </B>in his or her capacity as a director or executive officer<B> </B>(and not in any other capacity in which service was or is rendered by such indemnitee, including, without
limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an &#147;undertaking&#148;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall
ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#147;final adjudication&#148;) that such indemnitee is not entitled to be indemnified for such expenses under this section or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&nbsp;(e) of this section, no advance shall be
made by the corporation to an executive officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding,
whether civil, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&nbsp;by a majority vote of directors who were not parties to the proceeding, even if not a
quorum, or (ii)&nbsp;by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors, or such directors so direct, by independent legal counsel in a
written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not
opposed to the best interests of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Enforcement. </B>Without the necessity of entering into an express
contract, all rights to indemnification and advances to directors and executive officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and
the director or executive officer. Any right to indemnification or advances granted by this section to a director or executive officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if
(i)&nbsp;the claim for indemnification or advances is denied, in whole or in part, or (ii)&nbsp;no disposition of such claim is made within ninety (90)&nbsp;days of request therefor. To the extent permitted by law, the claimant in such enforcement
action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the
claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. Neither the failure of the corporation (including its Board of
Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct
set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct,
shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><FONT
STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights. </B>The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of
the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding office. The corporation is
specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Survival of Rights. </B>The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be
a director<B> </B>or executive officer<B> </B>and shall inure to the benefit of the heirs, executors and administrators of such a person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Insurance. </B>To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the
Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Amendments. </B>Any repeal or modification of this section shall only be
prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Saving Clause. </B>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent
jurisdiction, then the corporation shall nevertheless indemnify each director and executive officer to the full extent not prohibited by any applicable portion of this section that shall not have been invalidated, or by any other applicable law. If
this section shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and executive officer<B> </B>to the full extent under any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Certain Definitions. </B>For the purposes of this Bylaw, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The term &#147;proceeding&#148; shall be broadly construed and shall include, without limitation, the investigation, preparation,
prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The term &#147;expenses&#148; shall be broadly construed and shall include, without limitation, court costs, attorneys&#146;
fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> The term the &#147;corporation&#148; shall include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person
who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, shall stand in the same position under the provisions of this section with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had
continued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> References to a &#147;director,&#148; &#147;executive officer,&#148; &#147;officer,&#148; &#147;employee,&#148;
or &#147;agent&#148; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another
corporation, partnership, joint venture, trust or other enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> References to &#147;other enterprises&#148; shall include
employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#147;serving at the request of the corporation&#148; shall include any service
as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an
employee benefit plan shall be deemed to have acted in a manner &#147;not opposed to the best interests of the corporation&#148; as referred to in this section. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;45. Notices. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notice to Stockholders. </B>Written notice to stockholders of stockholder meetings shall be given as provided in Section&nbsp;7
herein. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other
than stockholder meetings may be sent by US mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Notice to Directors. </B>Any notice required to be given to any director may be given by the method stated in
subsection&nbsp;(a), as otherwise provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall
have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Affidavit of Mailing. </B>An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or
its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was
or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Methods of Notice. </B>It shall not be necessary that the same method of giving notice be employed in respect of all recipients
of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Notice to Person with Whom Communication is Unlawful. </B>Whenever notice is required to be given, under any provision of law or
of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or
agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had
been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was
given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Notice to Stockholders Sharing an Address. </B>Except as otherwise prohibited
under DGCL, any notice given under the provisions of DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address
to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within sixty (60)&nbsp;days of having been given notice by the corporation of its intention to
send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;46.</B> <B>Amendments. </B>Subject to the limitations set forth in Section&nbsp;44(h) of these Bylaws or the
provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation;
<I>provided, however, </I>that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the
holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled
to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;47.</B> <B>Loans to Officers</B><B>.</B> Except as otherwise prohibited by applicable law, the corporation may
lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a Director of the corporation or its subsidiaries, whenever, in the
judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as
the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common
law or under any statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>I hereby certify that: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I
am the duly elected and acting Secretary of <B>Cytek Biosciences, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attached hereto is a complete and accurate copy of the Bylaws of the Company as duly adopted by the Board of Directors of the Company by
Unanimous Written Consent dated<B> </B>[____________], 2021 and said Bylaws are presently in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Certificate of Secretary may be
executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to
have been duly and validly delivered and be valid and effective for all purposes. Signed on [____________], 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Valerie Barnett</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Secretary</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>6
<FILENAME>d80783dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g169497g66w01.jpg" ALT="LOGO">

 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 23285D 10 9 SEE REVERSE FOR CERTAIN DEFINITIONS AND
LEGENDS This certifies that is the record holder of CYTEK BIOSCIENCES, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This CERTIFICATE Certificate is
not valid until countersigned by the Transfer Agent OF and registered STOCK by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers. Dated: CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL
OFFICER COUNTERSIGNED AND REGISTERED: AMERICAN STOCK TRANSFER &amp; TRUST COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT AND REGISTRAR BY: AUTHORIZED SIGNATURE </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g169497g66w02.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences
and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the
Corporation&#146;s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM &#150; as tenants in common TEN
ENT &#150; as tenants by the entireties JT TEN &#150; as joint tenants with right of survivorship and not as tenants in common COM PROP &#150; as community property UNIF GIFT MIN ACT &#150; Custodian (Cust) (Minor) under Uniform Gifts to Minors Act
(State) UNIF TRF MIN ACT &#150; Custodian (until age ) (Cust) (Minor) under Uniform Transfers to Minors Act (State) Additional abbreviations may also be used though not in the above list FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s)
unto PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) Shares of the capital stock represented by within Certificate, and do hereby irrevocably
constitute and appoint attorney-in-fact to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises Signature(s) Guaranteed: NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND
WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER By THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS
AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S E C RULE 17Ad-15 GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE SIGNATURE GUARANTEES MUST NOT BE DATED </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>7
<FILENAME>d80783dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g169497snap0005.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gordon K. Ho </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T:<I> </I>+1
650 843 5190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gho@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;19, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytek Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">46107 Landing Parkway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fremont, CA 94538-6407 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Cytek Biosciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the filing by the
Company of a Registration Statement (No. <FONT STYLE="white-space:nowrap">333-257663)</FONT> on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) with the Securities and Exchange Commission,
including a related prospectus filed with the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), covering an underwritten public offering of up to 16,749,330 shares of the Company&#146;s common stock, par value $0.001
(&#147;<B><I>Shares</I></B>&#148;), which consists of (i)&nbsp;up to 13,949,401 Shares (the &#147;<B><I>Company Shares</I></B>&#148;) to be sold by the Company (including up to 2,184,695 Shares that may be sold by the Company upon exercise of an
option to purchase additional shares to be granted to the underwriters) and (ii)&nbsp;2,799,929 Shares to be sold by the selling stockholders identified in such Registration Statement (the &#147;<B><I>Stockholder Shares</I></B>&#147;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have (i)&nbsp;examined and relied upon (a)&nbsp;the Registration Statement and Prospectus, (b)&nbsp;the Company&#146;s
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect as of the date hereof, (c)&nbsp;the form of the Company&#146;s Amended and Restated Certificate of Incorporation and the Company&#146;s Amended
and Restated Bylaws, filed as Exhibits 3.1 and 3.3, respectively, to the Registration Statement, each of which is to be in effect upon the closing of the offering contemplated by the Registration Statement and (d)&nbsp;originals or copies certified
to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below and (ii)&nbsp;assumed that the Shares will be sold at a
price established by the Board of Directors of the Company or a duly authorized committee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed the genuineness of all signatures, the
authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution
and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the
Company and have not independently verified such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of
Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that (1)&nbsp;the Company Shares, when sold and issued against payment therefor
as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable and (ii)&nbsp;the Stockholder Shares have been validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT>
except with respect to Stockholder Shares that are to be sold by certain selling stockholders upon the conversion of outstanding preferred stock of the company in accordance with the terms of such preferred stock, which will be validly issued, fully
paid and nonassessable upon such conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: +1 650 843 5000 f: +1 650 849 7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g169497snap0005.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;19, 2021</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Page Two</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus included in the
Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gordon K. Ho</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gordon K. Ho</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175 Hanover
Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: +1 650 843 5000 f: +1 650 849 7400 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>8
<FILENAME>d80783dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: _______, 2021
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: _______, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Defined Terms. </B>Except as otherwise provided, any capitalized term shall have the meaning provided in Section&nbsp;14 of this
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Successor to and Continuation of Prior Plan.</B> The Plan is the successor to and continuation of the Prior Plan. As
of the Effective Date, (i)&nbsp;no additional awards may be granted under the Prior Plan; and (ii)&nbsp;all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan. All Awards granted under this Plan will
be subject to the terms of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and retain the
services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit
from increases in value of the Common Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Available Awards.</B> The Plan provides for the
grant of the following Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to
the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as
necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 18,000,000 shares. In addition, subject to any adjustments as necessary to implement any
Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of ten years commencing on January&nbsp;1, 2022 and
ending on (and including) January&nbsp;1, 2031, in an amount equal to 4% of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year; provided, however, that the Board may act prior to January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Aggregate Incentive Stock Option Limit.</B> Notwithstanding anything to the contrary in Section&nbsp;2(a) and subject to any
adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 54,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Share Reserve Operation.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares
of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition
as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for
issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The
following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion
of an Award without the shares covered by such portion of the Award having been issued, (2)&nbsp;the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than Common Stock), (3) the withholding of shares that
would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award, or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock
previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or
repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares, (2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award, and
(3)&nbsp;any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligible Award Recipients.</B> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive
Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or
a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate fair market value (determined at the time of
grant) of the shares of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any &#147;parent corporation&#148; or
&#147;subsidiary corporation&#148; thereof, as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code) exceeds $100,000 (or such other limit established in the Code), or any Incentive Stock Options otherwise do not comply with the rules
governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding
any contrary provision of the applicable Option Agreement(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Limitations on Incentive Stock Options Granted to Ten
Percent Stockholders.</B> A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii)&nbsp;the Option
is not exercisable after the expiration of five years from the date of grant of such Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Limitations on Nonstatutory Stock Options and SARs.</B> Nonstatutory Stock
Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company (as such term is defined in Rule&nbsp;405) unless the stock underlying such Awards is
treated as &#147;service recipient stock&#148; under Section&nbsp;409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of
Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of Common Stock that
may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, in each case following the IPO Date, to any individual for service as a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any fiscal year, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for his or her service as a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed $750,000 in total value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option and SAR will have such terms and conditions as determined by the Board. Each
Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option, and the shares
purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that
each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the
expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award.
Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for
another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to exercise an Option, the Participant must provide
notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of
payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by
Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a &#147;cashless exercise&#148; program developed under Regulation T as promulgated by the United States Federal
Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales
proceeds; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already
owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common
Stock is publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or
agreement restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum
period necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if the Option is a Nonstatutory Stock
Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does
not exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the
Participant in cash or other permitted form of payment; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of consideration that may be acceptable to the
Board and permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise Procedure and Payment of Appreciation Distribution for
SARs</B><B>.</B> In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not
be greater than an amount equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such
SAR, over (ii)&nbsp;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the
Board and specified in the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability.</B> Options and SARs may not be transferred to third party
financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability
of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to
be a Nonstatutory Stock Option as a result of being transferred: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Transfer.</B> An Option or SAR will not be
transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner
that is not prohibited by applicable tax and securities laws upon the Participant&#146;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code
and applicable U.S. state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the
execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the
Participant&#146;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous Service for Cause.</B> Except as explicitly otherwise
provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Options and SARs will terminate and be
forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and
the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#146;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable,
such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as
set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> three months following the date of such termination if such termination is a termination
without Cause (other than any termination due to the Participant&#146;s Disability or death); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> 12 months following the date of
such termination if such termination is due to the Participant&#146;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> 12 months following the date of such
termination if such termination is due to the Participant&#146;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> 12 months following the date of the
Participant&#146;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or,
if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in terminated Award, the shares of Common Stock subject
to the terminated Award, or any consideration in respect of the terminated Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Exercise; Extension of Exercisability. </B>A Participant may
not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the
Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period, the exercise of the
Participant&#146;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law (as determined in the sole discretion of the Board), then the applicable Post-Termination
Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any
of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration
of its maximum term (as set forth in Section&nbsp;4(a)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>.
No Option or SAR, whether or not vested, granted to an Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the United States Fair Labor Standards Act of 1938, as amended, will be first exercisable for any
shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the United States Worker Economic Opportunity Act, any vested portion of such Award may
be exercised earlier than six months following the date of grant of such Award in the event of (i)&nbsp;such Participant&#146;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted,
(iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#146;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#146;s then
current employment policies and guidelines). This Section&nbsp;4(j) is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR
will be exempt from his or her regular rate of pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Whole Shares</B>. Options and SARs may be exercised only with respect
to whole shares of Common Stock or their equivalents. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock Awards and
RSU Awards.</B> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of
the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Form
of Award.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> RSAs: To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election, shares of Common
Stock subject to a Restricted Stock Award may be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until such shares become vested or any other restrictions lapse, or (ii)&nbsp;evidenced by a certificate, which certificate
will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSUs: A RSU Award represents a Participant&#146;s right to be issued on a future date the number of shares of Common
Stock that is equal to the number of restricted stock units </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the RSU Award. As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#146;s unfunded obligation, if any, to issue shares of
Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a
Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a
vested RSU Award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> RSA: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money order payable to the
Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU: Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the
Participant&#146;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#146;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award
as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#146;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Termination of Continuous Service.</B> Except as otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason, (i)&nbsp;the Company may receive through a forfeiture condition or a repurchase right
any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (ii)&nbsp;any portion of his or
her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in
respect of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Dividends and Dividend Equivalents. </B>Dividends or dividend equivalents may be paid or
credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B>Settlement of RSU Awards</B>. A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination
thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the
vesting of the RSU Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance Awards</B>. With respect to any Performance Award, the length of
any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by
the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Other Awards</B>. Other Awards may be granted either alone or in addition to Awards provided for under
Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be
granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a), (ii) the class(es) and maximum number of
shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b), and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to
outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to
implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions
of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution or Liquidation</B>. Except as otherwise provided in the Award Agreement, in the event of a
dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Corporate Transaction. </B>The following provisions will apply to Awards in the event of a Corporate Transaction except as set
forth in Section&nbsp;11, and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of
grant of an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a Corporate Transaction, any surviving corporation or
acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not
limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards
may be assigned by the Company to the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or
continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue, or substitute the Awards held by some, but not all Participants. The terms of any assumption, continuation or
substitution will be set by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Awards Held by Current Participants.</B> In the event of a Corporate
Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not
been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#147;<B>Current Participants</B>&#148;), the vesting
of such Awards (and, with respect to Options and SARs, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate
Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or
prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the
vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the
Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction. With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate
Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Awards Held by Persons other than Current Participants.</B> In the event of a Corporate Transaction in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or
substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase
rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not
exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board,
equal in value, at the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award),
over (2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Appointment of Stockholder
Representative.</B> As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#146;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Restriction on Right to Undertake Transactions</B>. The grant of any Award under the Plan and the issuance of shares pursuant
to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or
options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution
or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power,
subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to time: (1)&nbsp;which
of the persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be
identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award
will be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including
the amount of cash payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan
and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a
manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all
controversies regarding the Plan and Awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate the time at which an Award may first be exercised
or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock (including, but not limited to, any Corporate Transaction), for reasons of administrative convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and
obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B>
To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award
granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To submit any amendment to the Plan for stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not
limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that, a
Participant&#146;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests
of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> To adopt such procedures and <FONT
STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with
the laws of the relevant <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> To effect, at any time and from
time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding
Option or SAR and the grant in substitution therefor of (A)&nbsp;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common
Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as determined by the Board); or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to Committee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee to which
it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time,
revest in the Board some or all of the powers previously delegated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
Compliance.</B> To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, the Award will be granted by
the Board or a Committee that consists solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT> of the Exchange Act and thereafter any action
establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Effect of Board</B><B>&#146;</B><B>s Decision.</B> All determinations,
interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Delegation to an Officer.</B> The Board or any Committee may delegate to one or more Officers the authority to do one or both of
the following (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and
(ii)&nbsp;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the
total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most
recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer
who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding
from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. and/or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state or local tax or social
insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the grant, vesting, exercise, or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an
Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its
sole discretion, satisfy any U.S. and/or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state or local tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means:
(i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&nbsp;withholding cash from an
Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a &#147;cashless exercise&#148; pursuant to a program developed under Regulation T as
promulgated by the United States Federal Reserve Board; or (vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes; No Liability to Claims. </B>Except as required by Applicable Law, the Company has no
duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an
Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax
consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such
Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant
acknowledges any Option or SAR granted under the Plan is exempt from Section&nbsp;409A only if the exercise or strike price is at least equal to the &#147;fair market value&#148; of the Common Stock on the date of grant as determined by the United
States Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not to make any claim
against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the United States Internal Revenue Service asserts that such exercise price or strike price is less than the &#147;fair market value&#148; of the
Common Stock on the date of grant as subsequently determined by the United States Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Withholding
Indemnification. </B>As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#146;s and/or its Affiliate&#146;s withholding obligation in connection with such Award was greater than the amount actually
withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Use of Proceeds from Sales of Common Stock.
</B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes)
documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the
Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect
to, any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to
such Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Employment or Other Service Rights.</B> Nothing in the Plan, any
Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time
the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Award (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement
with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or
commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the
Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Change in
Time Commitment</B>. In the event a Participant&#146;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee
of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted
by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in
lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or
extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant
agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#146;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other
regulatory requirements, in each case at the Plan Administrator&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Electronic Delivery and Participation</B>.
Any reference herein or in an Award Agreement to a &#147;written&#148; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the
Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award, the Participant consents to receive documents by electronic delivery and to participate in the Plan
through any <FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock
certificate or electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Clawback/Recovery</B>. All
Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under
Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of
previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#146;s right to voluntarily terminate
employment upon a &#147;resignation for good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Securities Law Compliance. </B>A Participant will not be issued any shares in
respect of an Award unless either (i)&nbsp;the shares are registered under the Securities Act; or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must
comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement,
Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards, after the issued shares have vested,
the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and
Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined
upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#146;s benefits under any employee benefit plan sponsored by the Company or any Affiliate,
except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of
Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made
in accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Section 409A. </B>Unless otherwise expressly provided for in an
Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt, in compliance with
the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions
necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.
Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#147;deferred
compensation&#148; under Section&nbsp;409A is a &#147;specified employee&#148; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A
without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date of the
Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid
thereafter on the original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Choice of Law.</B> This Plan and any controversy arising out of or relating to this
Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Compliance with Law.</B> The Company will seek to obtain from each regulatory commission or agency, as
may be deemed necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not
require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such
regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell
Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance
would be in violation of any Applicable Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Application. </B>Unless the
provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#146;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares
be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting
date, or (ii)&nbsp;the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#146;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as of the date of grant, then the shares will be earlier issued in settlement of such <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#146;s Separation from Service in accordance with the terms of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the date of the Participant&#146;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations
contained in Section&nbsp;409A applicable to &#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#146;s
Separation from Service, or, if earlier, the date of the Participant&#146;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>
If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#146;s Separation from Service, and
such vesting acceleration provisions were not in effect as of the date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award on the date of grant, then such acceleration of vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set
forth in the Grant Notice as if they had </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vested in the ordinary course during the Participant&#146;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such
issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under United States Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for Employees and
Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in
connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> If the Corporate Transaction
is also a Section&nbsp;409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control, the settlement of the
Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company
may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume,
continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares
made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each
applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Acquiring Entity will not assume, substitute or continue any Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in
respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the
Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further
provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited without payment of any consideration to the affected
Participants if the Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> The foregoing treatment shall apply with respect to all Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon
any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of
a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the
Corporate Transaction is also a Section&nbsp;409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change in
Control, the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect
to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Any exercise by the Board of
discretion to accelerate the vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Company explicitly reserves the right to earlier settle any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the
extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available in United States Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent the terms of any
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control
or Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provides that it will be settled upon a
termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a &#147;separation from service&#148; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to
&#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#146;s Separation From Service, or, if earlier, the
date of the Participant&#146;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The provisions in this subsection (e)&nbsp;for
delivery of the shares in respect of the settlement of a RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the
Participant in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>EVERABILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid
shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth
anniversary of the earlier of: (i)&nbsp;the Adoption Date, or (ii)&nbsp;the date the Plan is approved by the Company&#146;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Acquiring Entity</I></B>&#148; means the surviving or acquiring corporation (or its parent company) in connection with
a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Adoption Date</I></B>&#148; means the date the Plan is first approved by the Board or
Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or
&#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the
foregoing definition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Applicable Law</I></B>&#148; means the Code and any applicable U.S.
or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation,
judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization
such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
&#147;<B><I>Award</I></B>&#148; means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance
Award or any Other Award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a
Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is
provided to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Board</I></B>&#148; means the board of directors of the
Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all
Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur
with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock
dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring
transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company
will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Cause</I></B>&#148;<B><I> </I></B>has the meaning ascribed to
such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:
(i)&nbsp;such Participant&#146;s actual or attempted commission of, or participation in, a fraud or act of dishonesty against the Company or an Affiliate; (ii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement
between the Participant and the Company or an Affiliate or of any statutory duty owed to the Company or an Affiliate; (iii)&nbsp;such Participant&#146;s unauthorized use or disclosure of the Company&#146;s or any of its Affiliate&#146;s confidential
information or trade secrets; or (iv)&nbsp;such Participant&#146;s gross misconduct. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to
Participants who are executive officers of the Company and by the Company&#146;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a
Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Change in Control</I></B>&#148; or &#147;<B><I>Change of Control</I></B>&#148; means the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, such
event or events, as the case may be, also constitute a Section&nbsp;409A Change in Control: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities
of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall
not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act
Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level
of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the
Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the
Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control shall be deemed to occur; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger,
consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the
combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such transaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or
substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more
than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> individuals who, on the date the Plan is adopted by the Board, are members of
the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member
was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any
Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written
agreement, the foregoing definition shall apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as
amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Committee</I></B>&#148; means the
Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Company</I></B>&#148; means Cytek Biosciences, Inc., a Delaware corporation, and any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Compensation Committee</I></B>&#148; means the Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.<B><I> </I></B>Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; provided, however, that if the
Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#146;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an
Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive
officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick
leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an
Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent
required for exemption from or compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of
&#147;separation from service&#148; as defined under United States Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as determined by
the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at least 50% of the
outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the
surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving
corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in
the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>determine</I></B>&#148;<B><I> </I></B>or<B><I> </I></B>&#147;<B><I>determined</I></B>&#148;<B><I> </I></B>means as
determined by the Board or the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Disability</I></B>&#148; means,
with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be
expected to last for a continuous period of not less than 12 months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Effective Date</I></B>&#148; means the IPO Date, provided this Plan is approved by the Company&#146;s stockholders
prior to the IPO Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However,
service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Employer</I></B>&#148; means the Company or the Affiliate that employs the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&nbsp;any natural person,
Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting
power of the Company&#146;s then outstanding securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, unless
otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (i)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;U.S. federal, state, local, municipal, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other government; (iii)&nbsp;governmental or regulatory body, or
quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any
court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the
Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Grant Notice</I></B>&#148; means the notice provided to a Participant
that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if
any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Incentive Stock
Option</I></B>&#148; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>IPO Date</I></B>&#148; means the date of execution of the underwriting agreement between the Company and the
underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Materially Impair</I></B>&#148;<B><I> </I></B>means any amendment to the terms of the Award that materially adversely
affects the Participant&#146;s rights under the Award. A Participant&#146;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as
a whole, does not materially impair the Participant&#146;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#146;s rights under the Award: (i)&nbsp;imposition of reasonable
restrictions on the minimum number of shares subject to an Option that may be exercised, (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iii)&nbsp;to change the terms of an
Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the manner of exemption from, or to bring the
Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director</I></B>&#148;<B> </B>means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services
rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the
Securities Act (&#147;<B><I>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered
a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148;<B><I> </I></B>means any Award that is subject
to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company or (ii)&nbsp;the terms of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B>
&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#148; means a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement</I></B>&#148; means a severance
arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#146;s termination of employment or separation from
service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#147;<B><I>Separation from Service</I></B>&#148;)) and such severance benefit does not satisfy the
requirements for an exemption from application of Section&nbsp;409A provided under United States Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;4 of the
Plan that does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer
of the Company within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive
Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B>
&#147;<B><I>Option Agreement</I></B>&#148; means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement
containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Other Award</I></B>&#148; means an award valued in whole or in part
by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant), that is not an
Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Other Award Agreement</I></B>&#148;<B><I> </I></B>means a written
agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#147;<B><I>Own,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>means that a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or
Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Participant</I></B>&#148; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan
or, if applicable, such other person who holds an outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#147;<B><I>Performance Award</I></B>&#148; means an
Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of
Section&nbsp;5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment
of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board will select for purposes of
establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including
earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; net income/loss adjusted for interest expense, interest income, other income/expenses, net
provision for/benefit from income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses; other earnings measures; total stockholder return; return on equity or average stockholder&#146;s equity; return
on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; <FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow;
sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per
share; share price performance; debt reduction; customer satisfaction; stockholders&#146; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; operations
within or below <FONT STYLE="white-space:nowrap">pre-determined</FONT> annual budget, sales of certain number of instruments, reagents and/or service contracts; financing; regulatory milestones, including approval of a compound; stockholder
liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner satisfaction; budget management;
clinical achievements; regulatory achievements; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; research progress, including the development of programs; investor relations,
analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives related to process development activities); strategic partnerships or transactions (including <FONT
STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property; establishing relationships with commercial entities with respect to the marketing, distribution and sale of the
Company&#146;s products (including with group purchasing organizations, distributors and other vendors); supply chain achievements (including establishing relationships with key manufacturers or suppliers);
<FONT STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and
other measures of performance selected by the Board or Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#147;<B><I>Performance Goals</I></B>&#148; means, for a Performance Period, the
one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award Agreement at the time the
Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance
Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles;
(4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting
principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period
following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting
principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board retains the discretion to reduce or eliminate the
compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the
payment or vesting corresponding to the degree of achievement as specified in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#147;<B><I>Performance
Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to vesting or exercise of an Award. Performance
Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#147;<B><I>Plan</I></B>&#148; means
this Cytek Biosciences, Inc. 2021 Equity Incentive Plan, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#147;<B><I>Plan
Administrator</I></B>&#148; means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#146;s other equity incentive programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#147;<B><I>Post-Termination Exercise Period</I></B>&#148; means the period following termination of a Participant&#146;s
Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#147;<B><I>Prior
Plan</I></B>&#148; means the Company&#146;s 2015 Equity Incentive Plan, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B> &#147;<B><I>Restricted Stock
Award</I></B>&#148; or &#147;<B><I>RSA</I></B>&#148; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a written
agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the
agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the
terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(eee)</B> &#147;<B><I>RSU Award</I></B>&#148; or &#147;<B><I>RSU</I></B>&#148;<B><I> </I></B>means
an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(fff)</B> &#147;<B><I>RSU Award Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of a RSU
Award evidencing the terms and conditions of a RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which
is provided to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ggg)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hhh)</B> &#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jjj)</B> &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#148;
means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#146;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and United States Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kkk)</B>
&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(lll)</B> &#147;<B><I>Share
Reserve</I></B>&#148; means the number of shares available for issuance under the Plan as set forth in Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mmm)</B>
&#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nnn)</B> &#147;<B><I>SAR Agreement</I></B>&#148; means a written agreement between the Company and a holder of a SAR evidencing the terms
and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the
Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ooo)</B>
&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation
(irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and
(ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ppp)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or
is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qqq)</B> &#147;<B><I>Trading Policy</I></B>&#148; means the Company&#146;s policy permitting certain individuals to sell Company shares
only during certain &#147;window&#148; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rrr)</B> &#147;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(sss)</B> &#147;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>9
<FILENAME>d80783dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE </SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytek Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2021 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;), has granted
to you (&#147;<B><I>Optionholder&#148;) </I></B>an option to purchase the number of shares of the Common Stock set forth below (the &#147;<B><I>Option</I></B>&#148;). Your Option is subject to all of the terms and conditions as set forth in this
Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;), the Global Stock Option Agreement, including any additional terms and conditions for your country included in the appendix attached thereto (together, the &#147;<B><I>Option
Agreement</I></B>&#148;), the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement shall have the
meanings set forth in the Plan or the Option Agreement, as applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" align="left"></P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares of Common Stock Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Incentive Stock Option] <U>OR</U> [Nonstatutory Stock Option]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise and Vesting&nbsp;Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the Optionholder&#146;s Continuous Service through each applicable vesting date, the Option will vest as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Optionholder Acknowledgements:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Option is governed by this Grant Notice, and the provisions of the Plan, the Option Agreement and the Notice
of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Option Agreement may not be modified, amended or revised except in a writing signed by you and a duly authorized Officer of
the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you)
cannot be first <I>exercisable </I>for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You consent to receive this Grant Notice, the Option Agreement, the Plan, the Prospectus and any other
Plan-related documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You have read and are familiar with the provisions of the Plan, the Option Agreement, the Notice of Exercise and
the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of
Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance
agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for
all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Signature</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN </SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>G<SMALL>LOBAL</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reflected by your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) Cytek Biosciences, Inc. (the
&#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2021 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the
&#147;<B><I>Option</I></B>&#148;). Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable. The terms of your Option as
specified in the Grant Notice and this Global Stock Option Agreement, including any additional terms and conditions for your country included in the appendix attached hereto, constitute your Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general terms and conditions applicable to your Option are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>G</B><B>OVERNING </B><B>P</B><B>LAN </B><B>D</B><B>OCUMENT</B><B>. </B>Your Option is subject to all the provisions of the Plan.
Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the Option Agreement and the provisions of
the Plan, the provisions of the Plan shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>E<SMALL>XERCISE</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by
delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic
submission. Please review the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> To the extent permitted by Applicable Law, you may pay your Option exercise price as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> cash, check, bank draft or money order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> subject to Company and/or Committee consent at the time of exercise, pursuant to a &#147;cashless exercise&#148; program as
further described in the Plan if at the time of exercise the Common Stock is publicly traded; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> subject to Company and/or
Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in the Plan; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &#147;net
exercise&#148; arrangement as further described in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>T</B><B>ERM</B><B>. </B>You may not exercise your Option before
the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination of your Continuous Service for Cause; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> three months after the termination of your Continuous Service for any reason other than Cause, Disability or death; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> 12 months after the termination of your Continuous Service due to your Disability; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> 12 months after your death if you die during your Continuous Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate
Transaction, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the Expiration Date indicated in your Grant Notice; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> the day before the 10th anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if you die during the period provided in Section&nbsp;3(b) or 3(c) above, the term of your Option shall not
expire until the earlier of (i)&nbsp;twelve months after your death, (ii)&nbsp;upon any termination of the Option in connection with a Corporate Transaction, (iii)&nbsp;the Expiration Date indicated in your Grant Notice, or (iv)&nbsp;the day before
the tenth anniversary of the Date of Grant. Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You acknowledge that, regardless of any action taken by the Company, or if different, the Affiliate employing you (the
&#147;<B><I>Employer</I></B>&#148;), the ultimate liability for all income tax (including U.S. federal, state, and local taxes and/or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes), social insurance, payroll tax, fringe benefits tax,
payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to your participation in the Plan and legally applicable to you (&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) is
and remains your responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer. You further acknowledge that the Company and/or the Employer (i)&nbsp;make no representations or undertakings regarding the
treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the Option, including the grant of the Option, the vesting of the Option, the exercise of the Option, the subsequent sale of any shares of
Common Stock acquired pursuant to the Option and the receipt of any dividends; and (ii)&nbsp;do not commit to and are under no obligation to reduce or eliminate your liability for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Further,
if you become subject to taxation in more than one country, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items
in more than one country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate
arrangements satisfactory to the Company and/or the Employer to satisfy all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to
satisfy any applicable withholding obligations with regard to all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by one or a combination of the following: (i)&nbsp;withholding from your wages or other cash compensation paid to you by the
Company and/or the Employer; (ii)&nbsp;allowing or requiring you to make a cash payment to cover the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items; (iii)&nbsp;withholding from proceeds of the sale of shares of Common Stock acquired upon
exercise of this Option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); (iv) withholding from the shares of Common Stock to be issued to you
upon exercise of this Option; or (v)&nbsp;any other method of withholding determined by the Company and permitted by applicable law; provided, however, that that if you are a Section&nbsp;16 Officer of the Company under the Exchange Act, then the
Plan Administrator shall establish the method of withholding from alternatives (i)-(iv) herein and, if the Plan Administrator does not exercise its discretion prior to the applicable withholding event, then you shall be entitled to elect the method
of withholding from the alternatives above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company and/or the Employer may withhold or account for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering applicable statutory withholding amounts or other applicable withholding rates, including minimum and maximum rates applicable in your jurisdiction. In the event of over-withholding
you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent amount in shares of Common Stock) from the Company or the Employer; otherwise, you may be able to seek a refund from the local tax authorities. In
the event of under-withholding, you may be required to pay any additional <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the exercised Option,
notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> You agree to pay to the Company or the Employer any amount of <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may
refuse to issue or deliver the shares of Common Stock, or the proceeds of the sale of shares of Common Stock, if you fail to comply with your obligations in connection with the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>I</B><B>NCENTIVE </B><B>S</B><B>TOCK </B><B>O</B><B>PTION </B><B>D</B><B>ISPOSITION </B><B>R</B><B>EQUIREMENT</B><B>. </B>If your
Option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within two years after the date of
your Option grant or within one year after you acquired such shares of Common Stock upon exercise of your Option. The Company may require that such shares of Common Stock be retained with a particular broker or agent for a designated period of time
and/or may establish other procedures to permit tracking of qualifying and disqualifying dispositions of such shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>N</B><B>ATURE OF </B><B>G</B><B>RANT</B><B>. </B>In accepting the Option, you acknowledge, understand and agree that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Plan is established voluntarily by the Company, it is discretionary in nature, and may be amended, suspended or terminated by
the Company at any time, to the extent permitted by the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the grant of the Option is exceptional, voluntary and occasional
and does not create any contractual or other right to receive future grants of options or benefits in lieu of options, even if options have been granted in the past; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> all decisions with respect to future Options or other grants, if any, will be at the sole discretion of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> the Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming or amending
an employment or service contract with the Company, the Employer or any Affiliate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> you are voluntarily participating in the
Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the Option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not
intended to replace any pension rights or compensation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> the Option and any shares of Common Stock acquired under the Plan, and
the income from and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> the future value of the shares of Common Stock underlying the Option is unknown, indeterminable, and cannot be predicted with
certainty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> if the underlying shares of Common Stock do not increase in value, the Option will have no value;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> if you exercise the Option and acquire shares of Common Stock, the value of such shares of Common Stock may increase or
decrease in value, even below the exercise price; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> for purposes of the Option, your Continuous Service will be considered terminated
as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction
where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in the Option Agreement or determined by the Company, (i)&nbsp;your right to vest in the Option under the Plan, if any, and
(ii)&nbsp;the period (if any) during which you may exercise the Option after such termination of Continuous Service will terminate as of such date. However, unless otherwise determined by the Company, the Option will continue to vest through any
statutory notice period or any period of &#147;garden leave&#148; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any; the Plan Administrator shall have the
exclusive discretion to determine when you are no longer actively providing services for purposes of the Option (including whether you may still be considered to be providing services while on a leave of absence); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from your termination of
Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed, or the terms of your employment agreement, if any); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> unless otherwise agreed with the Company in writing, the Option and any shares of Common Stock acquired under the Plan, and the
income from and value of same, are not granted as consideration for, or in connection with, any service you may provide as a Director of the Company or a member of the board of directors of any Affiliate; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> neither the Company, the Employer or any Affiliate shall be liable for any foreign exchange rate fluctuation between your local
currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the exercise of the Option or the subsequent sale of any shares of Common Stock acquired upon exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>E</B><B>LECTRONIC </B><B>D</B><B>ELIVERY AND </B><B>P</B><B>ARTICIPATION</B>. The Company may, in its sole discretion, decide to
deliver any documents related to current or future participation in the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or a third party designated by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>T</B><B>RANSFERABILITY</B><B>. </B>Except as otherwise provided in the Plan, your Option is not transferable, except by will or
by the applicable laws of descent and distribution, and is exercisable during your life only by you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>C</B><B>ORPORATE
</B><B>T</B><B>RANSACTION</B><B>. </B>Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that
is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>N</B><B>O
</B><B>L</B><B>IABILITY FOR </B><B>T</B><B>AXES</B>. As a condition to accepting the Option, you hereby (a)&nbsp;agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities
arising from the Option or other Company compensation and (b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or
knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section&nbsp;409A for U.S. tax purposes only if the exercise price is at least equal to the &#147;fair market value&#148; of the Common Stock
on the date of grant as determined by the U.S. Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim
against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the U.S. Internal Revenue Service asserts that such exercise price is less than the &#147;fair market value&#148; of the Common Stock on the date of
grant as subsequently determined by the U.S. Internal Revenue Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>S</B><B>EVERABILITY</B>. If any part of this Option Agreement or the Plan is
declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option
Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful
and valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>W</B><B>AIVER</B><B>. </B>You acknowledge that a waiver by the Company of a breach of any provision of this
Option Agreement shall not operate or be construed as a waiver of any other provision of this Option Agreement, or of any subsequent breach of this Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>N</B><B>O </B><B>A</B><B>DVICE </B><B>R</B><B>EGARDING </B><B>G</B><B>RANT</B><B>. </B>The Company is not providing any tax,
legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock. You should consult with your own personal tax, legal and
financial advisors regarding your participation in the Plan before taking any action related to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>
<B>D<SMALL>ATA</SMALL> P<SMALL>RIVACY</SMALL> N<SMALL>OTICE</SMALL> <SMALL>AND</SMALL> C<SMALL>ONSENT</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Data Collection and Usage</B>. The Company and the Employer collect, process and use certain personal information about you,
including, but not limited to, your name, home address, email address and telephone number, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares of Common Stock or directorships
held in the Company, details of all Options or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#147;Data&#148;), for the purposes of implementing, administering and
managing the Plan. The legal basis, where required, for the processing of Data is your consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Stock Plan Administration
Service Providers</B>. The Company transfers Data to E*TRADE Financial Corporate Services, Inc. and certain of its affiliated companies (the &#147;Designated Broker&#148;), an independent service provider based in the United States, which is
assisting the Company with the implementation, administration and management of the Plan. The Company may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. You
may be asked to agree on separate terms and data processing practices with the Designated Broker or other service providers, with such agreement being a condition to the ability to participate in the Plan. The Company and the Designated Broker are
based in the United States. Your country or jurisdiction may have different data privacy laws and protections than the United States. The Company&#146;s legal basis, where required, for the transfer of Data is your consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Data Retention</B>. The Company will hold and use the Data only as long as is necessary to implement, administer and manage your
participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax, exchange control, labor and securities laws. This period may extend beyond your period of employment with the Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Voluntariness and Consequences of Consent Denial or Withdrawal</B>. Participation in the Plan is voluntary and you are providing
the consents herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your salary from or employment or other service with the Employer will not be affected; the only consequence of refusing or
withdrawing your consent is that the Company would not be able to grant Options or other equity awards to you or administer or maintain such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Data Subject Rights</B>. You may have a number of rights under data privacy laws in your jurisdiction. Depending on where you
are based, such rights may include the right to (i)&nbsp;request access or copies of Data the Company processes, (ii)&nbsp;rectification of incorrect Data, (iii)&nbsp;deletion of Data, (iv)&nbsp;restrictions on processing of Data,
(v)&nbsp;portability of Data, (vi)&nbsp;lodge complaints with competent authorities in your jurisdiction, and/or (vii)&nbsp;receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these
rights or to exercise these rights, you can contact your local human resources representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>L</B><B>ANGUAGE</B><B>.
</B>You acknowledge that you are sufficiently proficient in the English language, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Option Agreement. If you
have received this Option Agreement or any other documents related to the Plan translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>G</B><B>OVERNING </B><B>L</B><B>AW</B><B>/V</B><B>ENUE</B><B>. </B>The Option
Agreement and any controversy arising out of or relating to the Option Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in
any application of any law other than the law of the State of Delaware. For purposes of any action, lawsuit or other proceeding brought to enforce this Agreement, relating to it, or arising from it, the parties hereby submit to and consent to the
sole and exclusive jurisdiction of the courts of Alameda County, California, or the federal courts for the United States for the Northern District of California, and no other courts where this grant is made and/or to be performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>I</B><B>NSIDER </B><B>T</B><B>RADING </B><B>R</B><B>ESTRICTIONS </B><B>/ M</B><B>ARKET </B><B>A</B><B>BUSE
</B><B>L</B><B>AW</B><B>. </B>You may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions, including the United States, your country
and the designated broker&#146;s country, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (<I>i.e., </I>Options) or rights linked to the value of the shares of
Common Stock under the Plan during such times as you are considered to have &#147;inside information&#148; regarding the Company (as defined by the laws in the applicable jurisdiction(s)). Local insider trading laws and regulations may prohibit the
cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i)&nbsp;disclosing the inside information to any third party, which may include fellow employees and (ii)
&#147;tipping&#148; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company&#146;s insider
trading policy, or any other applicable insider trading policy then in effect. You acknowledge that you are responsible for complying with any applicable restrictions and are encouraged to speak with your personal legal advisor for further details
regarding any applicable insider-trading and/or market-abuse laws in your country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>F</B><B>OREIGN
</B><B>A</B><B>SSET</B><B>/A</B><B>CCOUNT</B><B>, E</B><B>XCHANGE </B><B>C</B><B>ONTROL AND </B><B>T</B><B>AX </B><B>R</B><B>EPORTING</B><B>. </B>You may be subject to foreign asset/account, exchange control and/or tax reporting requirements as a
result of the acquisition, holding and/or transfer of shares of Common Stock or cash (including dividends and the proceeds arising from the sale of shares of Common Stock) derived from your participation in the Plan in, to and/or from a
brokerage/bank account or legal entity located outside your country. The Applicable Laws in your country may require that you report such accounts, assets and balances therein, the value thereof and/or the transactions related thereto to the
applicable authorities in such country. You may also be required to repatriate sale proceeds or other funds received as a result of your participation in the Plan to your country through a designated bank or broker within a certain time after
receipt. You acknowledge that it is your responsibility to be compliant with such regulations and you are encouraged to consult with your personal legal advisor for any details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>C</B><B>OUNTRY</B><B>-S</B><B>PECIFIC </B><B>P</B><B>ROVISIONS</B><B>. </B>Notwithstanding any provisions of the Option
Agreement to the contrary, the Option shall be subject to any terms and conditions for your country of residence (and country of employment, if different) set forth in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;). Further,
if you transfer residence and/or employment to another country reflected in the Appendix, the terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms
and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of the Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>I</B><B>MPOSITION OF </B><B>O</B><B>THER </B><B>R</B><B>EQUIREMENTS</B><B>. </B>The Company reserves the right to impose other
requirements on your participation in the Plan, on the Option and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to
sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>O</B><B>THER
</B><B>D</B><B>OCUMENTS</B><B>. </B>You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you
acknowledge receipt of the Company&#146;s Insider Trading Policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Q</B><B>UESTIONS</B><B>. </B>If you have questions regarding these or any
other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>TO</SMALL> <SMALL>THE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN </SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>G<SMALL>LOBAL</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan, the Grant Notice and/or the Global Stock
Option Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms and Conditions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Appendix includes additional terms and conditions that govern the Option granted to you under the Plan if you are an employee that works
or resides outside the U.S. and/or in one of the countries listed below. If you are a citizen or resident of a country other than the one in which you are currently working and/or residing, transfer employment and/or residency to another country
after the date of grant, are a consultant, change employment status to a consultant position, or are considered a resident of another country for local law purposes, the Company shall, in its discretion, determine the extent to which the special
terms and conditions contained herein shall be applicable to you. References to your Employer shall include any entity that engages your services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Appendix also
includes information regarding exchange controls and certain other issues of which you should be aware with respect to your participation in the Plan. The information is provided solely for your convenience and is based on the securities, exchange
control and other laws in effect in the respective countries as of February 2021. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of
information relating to the consequences of your participation in the Plan because the information may be out of date by the time you vest in or exercise the Option or sell any shares of Common Stock acquired upon exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company
is not in a position to assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the applicable laws in your country may apply to your situation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and/or working, transfer to
another country after the date of grant, or are considered a resident of another country for local law purposes, the notifications contained herein may not be applicable to you in the same manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>10
<FILENAME>d80783dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: _____________,
2021 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: ______________, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IPO D<SMALL>ATE</SMALL>: ______________, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain eligible Employees of designated Related
Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to such Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to
grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
The Plan includes two components: a 423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock
Purchase Plan. The provisions of the 423 Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. Except as otherwise provided in the Plan or determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
The Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its
Related Corporations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board or the Committee will administer the Plan. References herein to the Board shall be deemed to refer to the Committee except
where context dictates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express
provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which
need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time (A)&nbsp;which Related Corporations will be eligible to participate in
the Plan as Designated 423 Corporations, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporations, and (C)&nbsp;which Designated
Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe
and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to
the extent it deems necessary or expedient to make the Plan fully effective. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and Affiliates and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the
Board specifically is authorized to adopt rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#147;earnings,&#148; handling and
making of Contributions, establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures
and handling of share issuances, any of which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation, do not have to comply with the requirements of
Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan and any Offering Document to the Board will thereafter be to the Committee or subcommittee), subject, however, to such
resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its
authority under the Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. References
in this Plan to the Board will thereafter be to the Committee or any delegate of the Committee or Board. The Board may retain the authority to concurrently administer the Plan with the Committee (or its delegate) and may, at any time, revest in the
Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee (or its delegate), the Board will have the final power to determine all questions of policy and expediency that
may arise in the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good
faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> <SMALL>OF</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>
Subject to the provisions of Section&nbsp;11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 2,000,000 shares of Common Stock, plus the number of shares of
Common Stock that are automatically added on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of up to ten years, commencing on January&nbsp;1, 2022 and ending on (and including) January&nbsp;1, 2031, in an
amount equal to the lesser of (i) 1% of the total number of shares of Common Stock outstanding on December 31<SUP STYLE="font-size:85%; vertical-align:top">st </SUP>of the preceding calendar year, and (ii)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
5,000,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur
pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section&nbsp;3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining
portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The stock purchasable under the
Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.
G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board
may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such
form and will contain such terms and conditions as the Board will deem appropriate, and, with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have
the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include
(through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date,
and the substance of the provisions contained in Sections 5 through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase
Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a &#147;<B><I>Company Designee</I></B>&#148;): (i) each form will apply to all of his or her
Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a
Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the
first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first
Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in
the employ of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company or the Related Corporation or an Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period
of continuous employment be equal to or greater than two years. In addition, the Board may (unless prohibited by Applicable Law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date,
such Employee&#146;s customary employment with the Company, the Related Corporation, or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with
Section&nbsp;423 of the Code with respect to the 423 Component. The Board may also exclude from participation in the Plan or any Offering Employees who are &#147;highly compensated employees&#148; (within the meaning of Section&nbsp;423(b)(4)(D) of
the Code) of the Company or a Related Corporation or an Affiliate or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board
may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs
thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that
Offering, as described herein, except that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted will be the &#147;Offering
Date&#148; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee will be eligible for the grant of
any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of
any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase
Rights and options will be treated as stock owned by such Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an
Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such
Eligible Employee&#146;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds U.S. $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and
which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will
not be eligible to participate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of
an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion,
that participation of such Eligible Employee(s) is not advisable or practical for any reason (unless prohibited by Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Notwithstanding anything in this Section&nbsp;5 or the remaining provisions of the Plan to the contrary, in the case of an Offering
under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the Board may provide that Consultants of a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation are eligible to participate in the Plan, provided the Consultants
otherwise meet the eligibility criteria set forth in this Section&nbsp;5, as determined by the Board (unless prohibited by Applicable Law) Any references in this Plan to Employees and Eligible Employees shall encompass references to Consultants, as
appropriate, and any reference to employment shall encompass references to services as a Consultant, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>URCHASE</SMALL>
R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each Eligible Employee,
pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings (as defined by the Board in each Offering) or with a maximum
dollar amount, as designated by the Board, during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the
end of the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted
for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In
connection with each Offering made under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a maximum aggregate number of
shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If
the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each
Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions
by completing and delivering to the Company or a Company Designee, within the time specified for the Offering, an enrollment form provided by the Company or Company Designee. The enrollment form will specify the amount of Contributions not to exceed
the maximum amount specified by the Board. Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where Applicable Law
requires that Contributions be held separately or deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll
date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce
(including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions
through payment by cash, check or wire transfer prior to a Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making
Contributions and withdraw from the Offering by delivering to the Company or a Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such
Participant&#146;s Purchase Right in that Offering will immediately terminate and the Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&#146;s Purchase
Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to
deliver a new enrollment form to participate in subsequent Offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Unless otherwise required by Applicable Law, Purchase
Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable
Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions, without interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate
rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; however, if a
Participant transfers from an Offering under the 423 Component to an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Purchase Right will be qualified under the 423 Component only
to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the
Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may establish different and additional rules governing transfers between separate
Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> During a Participant&#146;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not
transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Unless otherwise specified in the Offering or as required by Applicable Law, the
Company will have no obligation to pay interest on Contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the
purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically
provided for in the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in
a Participant&#146;s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after
the final Purchase Date of such Offering as soon as practicable without interest (unless otherwise required by Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan
are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, and other securities, exchange
control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be
delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the
Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all Applicable Law, as determined by the Company in its sole discretion, no Purchase Rights
will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment of interest is otherwise required by Applicable Law). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state or other regulatory
commission, agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion,
that doing so is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of
Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon
exercise of such Purchase Rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the
Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole
discretion, may deliver such shares of Common Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#146;s spouse, dependents or relatives, or if no spouse,
dependent or relative is known to the Company, then to such other person as the Company may designate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. A<SMALL>DJUSTMENTS</SMALL>
<SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and
maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es)
and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The
Board will make these adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate
Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right
to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase
Rights or does not substitute similar rights for such Purchase Rights, then the Participants&#146; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such
other period specified by the Board) prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.
However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted
before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted, (ii)&nbsp;as
necessary to facilitate compliance with Applicable Law, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance issued
thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as necessary to obtain or maintain
favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the
requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Law. Notwithstanding anything in the Plan or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Offering Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit
Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or
accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase
Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code with respect to the 423 Component; and (v)&nbsp;establish other limitations or
procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as
they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. T<SMALL>AX</SMALL>
Q<SMALL>UALIFICATION</SMALL>; T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Although the Company may endeavor to
(i)&nbsp;qualify a Purchase Right for special tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly
disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax
impact on Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Participant will make arrangements, satisfactory to the Company and any applicable Related
Corporation or Affiliate, to enable the Company or the Related Corporation or Affiliate to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#146;s
sole discretion and subject to Applicable Law, such withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#146;s salary or any other cash payment due to the Participant from the Company or a Related
Corporation or Affiliate; (ii)&nbsp;withholding from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed
acceptable by the Board. The Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and until the
Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent) and all tax withholding obligations have been
satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the
Plan or in the Offering will in any way alter the at will nature of a Participant&#146;s employment or amend a Participant&#146;s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any
Participant to continue in the employ of the Company or a Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#146;s conflicts of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>423 Component</I></B>&#148; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Affiliate</I></B>&#148; means any entity, other than a Related Corporation, whether now or subsequently established,
which is at the time of determination, a &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or
&#147;subsidiary&#148; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Applicable Law</I></B>&#148; means
the Code and any applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, federal, state, , material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree,
rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the Nasdaq Stock
Market or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Board</I></B>&#148;<I> </I>means the board of directors of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur
with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar
equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Code</I></B>&#148;<I> </I>means the Internal Revenue Code of 1986, as
amended, including any applicable regulations and guidance thereunder<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Committee</I></B>&#148;<I> </I>means
a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Company</I></B>&#148; means Cytek Biosciences, Inc., a Delaware corporation, and any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by a Related Corporation or an
Affiliate to render consulting or advisory services or to otherwise act as a service provider and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of a Related Corporation or an Affiliate and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.<B><I> </I></B>Notwithstanding the foregoing, a
person is treated as a Consultant under this Plan only if a Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to
such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Contributions</I></B>&#148; means the payroll deductions, contributions made by Participants in case
payroll deductions are not permissible or problematic under Applicable Law and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make
additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions or other
contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series
of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or
substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at least 50% of the outstanding securities of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Designated 423 Corporation</I></B>&#148; means any Related Corporation selected by the Board to
participate in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Designated Company</I></B>&#148;<B> </B>means any Designated <FONT
STYLE="white-space:nowrap">Non-423</FONT> Corporation or Designated 423 Corporation, provided, however, that at any given time, a Related Corporation participating in the 423 Component shall not be a Related Corporation participating in the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Designated <FONT STYLE="white-space:nowrap">Non-423</FONT>
Corporation</I></B>&#148; means any Related Corporation or Affiliate selected by the Board to participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation, or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>
&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the United States Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common
Stock determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established
market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of
determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales
price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the absence of such markets for the Common Stock, the
Fair Market Value will be determined by the Board in good faith in compliance with Applicable Law and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common
Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company&#146;s initial public offering as specified in the final prospectus for that initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (i)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, local, municipal, or other government; (iii)&nbsp;governmental or regulatory body, or
quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any
court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market and the Financial Industry Regulatory
Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>IPO Date</I></B>&#148;<I> </I>means the date of the underwriting
agreement between the Company and the underwriters managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-423</FONT> Component</I></B>&#148; means the part of the Plan, which excludes the
423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within
the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee
who holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Plan</I></B>&#148;<I> </I>means this Cytek Biosciences, Inc. 2021
Employee Stock Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more dates during an Offering selected by the Board on which Purchase
Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the Offering
Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the United States Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#146;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>11
<FILENAME>d80783dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> I<SMALL>NDEMNITY</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B>Agreement</B>&#148;) dated as of
____________, 2021, is made by and between <B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>., a Delaware corporation (the &#147;<B>Company</B>&#148;), and ____________ (&#147;<B>Indemnitee</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> The Company&#146;s amended and restated bylaws (the &#147;<B>Bylaws</B>&#148;) require that the Company indemnify its directors
and officers, and empowers the Company to indemnify its employees and agents, as authorized by the Delaware General Corporation Law, as amended (the &#147;<B>Code</B>&#148;), under which the Company is organized and such Bylaws expressly provide
that the indemnification provided therein is not exclusive and contemplates that the Company may enter into separate agreements with its directors, officers and other persons to set forth specific indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Indemnitee does not regard the protection currently provided by applicable law, the Bylaws, the Company&#146;s other governing
documents, and available insurance as adequate under the present circumstances, and the Company has determined that Indemnitee and other directors, officers, employees and agents of the Company may not be willing to serve or continue to serve in
such capacities without additional protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> The Company desires and has requested Indemnitee to serve or continue to serve
as a director, officer, employee or agent of the Company, as the case may be, and has proffered this Agreement to Indemnitee as an additional inducement to serve in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B> Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee or agent of the Company, as the case may
be, if Indemnitee is furnished the indemnity provided for herein by the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the mutual covenants and agreements set forth herein,
the parties hereto, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Definitions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Agent</B>. For purposes of this Agreement, the term &#147;Agent&#148; of the Company means any person who: (i)&nbsp;is or was a
director, officer, employee, agent, or other fiduciary of the Company or a subsidiary of the Company; or (ii)&nbsp;is or was serving at the request or for the convenience of, or representing the interests of, the Company or a subsidiary of the
Company, as a director, officer, employee, agent, or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Change in Control</B>. For purposes of this Agreement, a &#147;<B>Change in Control</B>&#148; shall be deemed to have occurred
if (i)&nbsp;any &#147;person&#148; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a
corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, is or becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under said Act), directly or indirectly, of securities of the Company representing 20% or more of the total voting power represented by the Company&#146;s then outstanding Voting Securities,
(ii)&nbsp;individuals who on the date of this Agreement are members of the Board (the &#147;<B>Incumbent Board</B>&#148;) cease for any reason to constitute at least a majority of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the members of the Board (<I>provided</I>, <I>however</I>, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote
of the members of the Incumbent Board then still in office, such new member shall be considered as a member of the Incumbent Board), or (iii)&nbsp;the stockholders of the Company approve a merger or consolidation of the Company with any other
corporation, other than a merger or consolidation which would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities
of the surviving entity) at least 80% of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a
plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Expenses</B>. For purposes of this Agreement, the term &#147;Expenses&#148; shall be broadly construed and shall include,
without limitation, all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys&#146;, witness, or other professional fees and related disbursements, and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of whatever nature) actually and reasonably incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding or establishing or enforcing a right to
indemnification under this Agreement, the Code or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Enterprise</B>. For purposes of this Agreement, the term
&#147;Enterprise&#148; means any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity for which Indemnitee is or was serving at the request of the Company as a director, officer,
employee, or Agent </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Independent Counsel</B>. For purposes of this Agreement, the term &#147;Independent Counsel&#148; means
a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company or
Indemnitee in any matter material to either such party, or (ii)&nbsp;any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent Counsel&#148; shall not include
any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement. The
Company will pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its
engagement pursuant hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Liabilities</B>. For purposes of this Agreement, the term &#147;Liabilities&#148; shall be
broadly construed and shall include, without limitation, judgments, damages, deficiencies, liabilities, losses, penalties, excise taxes, fines, assessments and amounts paid in settlement, including any interest and any federal, state, local or
foreign taxes imposed as a result of the actual or deemed receipt of any payment under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Proceedings</B>. For
purposes of this Agreement, the term &#147;proceeding&#148; shall be broadly construed and shall include, without limitation, any threatened, pending, or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate
dispute resolution mechanism, investigation, inquiry, administrative hearing, or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or
investigative nature, and whether formal or informal in any case, in which Indemnitee was, is or will be involved as a party, potential party, <FONT STYLE="white-space:nowrap">non-party</FONT> witness, or otherwise by reason of: (i)&nbsp;the fact
that Indemnitee is or was a director or officer of the Company; (ii)&nbsp;the fact that any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#146;s part while acting as an
Agent; or (iii)&nbsp;the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise, and in any
such case described above, whether or not serving in any such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses may be provided under this Agreement. If the Indemnitee
believes in good faith that a given situation may lead to or culminate in the institution of a proceeding, this shall be considered a proceeding under this paragraph. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Subsidiary</B>. For purposes of this Agreement, the term
&#147;subsidiary&#148; means any corporation, limited liability company, or other entity, of which more than 50% of the outstanding voting securities or equity interests are owned, directly or indirectly, by the Company and one or more of its
subsidiaries, and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as an Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Voting Securities</B>. For purposes of this Agreement, &#147;<B><I>Voting Securities</I></B>&#148; shall mean any securities of
the Company that vote generally in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Agreement to Serve</B>. Indemnitee will serve, or continue to
serve, as the case may be, as an Agent, faithfully and to the best of his or her ability, at the will of such entity designated by the Company and at the request of the Company (or under separate agreement, if such agreement exists), in the capacity
Indemnitee currently serves such entity, so long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of the governance documents of such entity, or until such time as Indemnitee tenders his or her
resignation in writing; provided, however, that nothing contained in this Agreement is intended as an employment agreement between Indemnitee and the Company or any of its subsidiaries or to create any right to continued employment of Indemnitee
with the Company or any of its subsidiaries in any capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that it has entered into this Agreement and assumes
the obligations imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as an Agent, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as an Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Indemnification in Third Party Proceedings</B>. Subject to Section&nbsp;10 below, the Company shall indemnify Indemnitee to the
fullest extent permitted by the Code, as the same may be amended from time to time (but, to the fullest extent of the law, only to the extent that such amendment permits Indemnitee to broader indemnification rights than the Code permitted prior to
adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding, other than a proceeding by or in the right of the Company to procure a judgment in its favor, for any and all
Expenses and Liabilities (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses and Liabilities) incurred by Indemnitee in connection with the investigation, defense, settlement or
appeal of such proceeding, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to believe
that Indemnitee&#146;s conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any
indemnification provided by the Certificate of Incorporation of the Company, the Bylaws, vote of its stockholders or disinterested directors, or applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Indemnification in Derivative Actions and Direct Actions by the Company</B>. Subject to Section&nbsp;10 below, the Company shall
indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, fullest extent permitted by applicable law, only to the extent that such amendment permits Indemnitee to broader indemnification
rights than the Code permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding by or in the right of the Company to procure a judgment in its favor,
against any and all Expenses actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement, or appeal of such proceedings, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to
be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;3(b) in respect of any claim, issue or matter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as to which Indemnitee shall have been finally adjudged by a court competent jurisdiction to be liable to the Company, unless and only to the extent that the Chancery Court of the State of
Delaware or any court in which the proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Indemnification of Expenses of Successful Party</B>. To the fullest extent permitted by law, the Company shall indemnify
Indemnitee against all Expenses in connection with a proceeding to the extent that Indemnitee has been successful on the merits or otherwise in defense of any proceeding or in defense of any claim, issue or matter therein, in whole or part,
including the dismissal of any action without prejudice. If Indemnitee is not wholly successful in such proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such proceeding, the
Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee or on Indemnitee&#146;s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Partial Indemnification; Witness Indemnification</B>. If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of any Expenses and Liabilities incurred by Indemnitee in the investigation, defense, settlement or appeal of a proceeding, but is precluded by applicable law or the specific terms of this
Agreement to indemnification for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Notwithstanding any other provision of this Agreement, to the fullest extent
permitted by applicable law and to the extent that Indemnitee is, by reason of Indemnitee&#146;s acting as an Agent, a witness or otherwise asked to participate in any proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified
against all Expenses incurred by Indemnitee or on Indemnitee&#146;s behalf in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Advancement of
Expenses</B>. To the extent not prohibited by law, the Company shall advance the Expenses incurred by Indemnitee in connection with any proceeding, and such advancement shall be made within twenty (30)&nbsp;days after the receipt by the Company of a
statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to
expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice). Advances shall be unsecured, interest free and without regard to Indemnitee&#146;s ability to repay the
Expenses. Advances shall include any and all Expenses incurred by Indemnitee pursuing an action to enforce Indemnitee&#146;s right to indemnification under this Agreement or otherwise and this right of advancement, including expenses incurred
preparing and forwarding statements to the Company to support the advances claimed. Indemnitee acknowledges that the execution and delivery of this Agreement shall constitute an undertaking providing that Indemnitee shall, to the fullest extent
required by law, repay the advance (without interest) if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the
Company. The right to advances under this Section shall continue until final disposition of any proceeding, including any appeal therein. This Section&nbsp;6 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to
Section&nbsp;10(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Notice and Other Indemnification Procedures</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notification of Proceeding</B>. Indemnitee will notify the Company in writing promptly upon being served with any summons,
citation, subpoena, complaint, indictment, information or other document relating to any proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The written notification to the Company shall include
a description of the nature of the proceeding and the facts underlying the proceeding. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or
otherwise and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Company will be entitled to participate in the proceeding at its own expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Request for Indemnification Payments</B>. To obtain indemnification under this
Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent
Indemnitee is entitled to indemnification under the terms of this Agreement, and shall request payment thereof by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Determination of Right to Indemnification Payments</B>. Upon written request by Indemnitee for indemnification pursuant to the Section&nbsp;7(b) hereof, a determination with respect to Indemnitee&#146;s entitlement thereto shall be made in the
specific case by one of the following four methods, which shall be at the election of the Board of Directors: (1)&nbsp;by a majority vote of the disinterested directors, even though less than a quorum, (2)&nbsp;by a committee of disinterested
directors designated by a majority vote of the disinterested directors, even though less than a quorum, (3)&nbsp;if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the
Board of Directors, a copy of which shall be delivered to the Indemnitee, or (4)&nbsp;if so directed by the Board of Directors, by the stockholders of the Company; <I>provided</I>, <I>however</I>, that if there has been a Change in Control, then
such determination shall be made by Independent Counsel selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). For purposes hereof, disinterested directors are those members of the board of directors
of the Company who are not parties to the action, suit or proceeding in respect of which indemnification is sought by Indemnitee. Indemnification payments requested by Indemnitee under Section&nbsp;3 hereof shall be made by the Company within sixty
(60)&nbsp;days after the later or (1)&nbsp;receipt of the written request of Indemnitee and (2)&nbsp;the final disposition of the Proceeding for which Indemnification is sought. Claims for advancement of Expenses shall be made under the provisions
of Section&nbsp;6 herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Application for Enforcement</B>. In the event the Company fails to make timely payments as set
forth in Sections 6 or 7(c) above, Indemnitee shall have the right to apply to the Chancery Court of the State of Delaware for the purpose of enforcing Indemnitee&#146;s right to indemnification or advancement of Expenses pursuant to this Agreement.
In such an enforcement hearing or proceeding, the burden of proof shall be on the Company to prove that indemnification or advancement of Expenses to Indemnitee is not required under this Agreement or permitted by applicable law. Any determination
by the Company (including its Board of Directors, a committee thereof, Independent Counsel) or stockholders, that Indemnitee is not entitled to indemnification hereunder, shall not be a defense by the Company to the action nor create any presumption
that Indemnitee is not entitled to indemnification or advancement of Expenses hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Indemnification of Certain
Expenses</B>. The Company shall indemnify Indemnitee against all Expenses incurred in connection with any hearing or proceeding under this Section&nbsp;7 unless the Company prevails in such hearing or proceeding on the merits in all material
respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Presumptions and Effect of Certain Proceedings</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;7 of this Agreement,
and the Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to
the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or
Independent Counsel) that Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If the determination of the Indemnitee&#146;s entitlement to indemnification has not made pursuant to Section&nbsp;7 within sixty
(60)&nbsp;days after the later of (i)&nbsp;receipt by the Company of Indemnitee&#146;s request for indemnification pursuant to Section&nbsp;7 and (ii)&nbsp;the final disposition of the Proceeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for which Indemnitee requested Indemnification (the &#147;Determination Period&#148;), the requisite determination of entitlement to indemnification will, to the fullest extent not prohibited by
law, be deemed to have been made and Indemnitee will be entitled to such indemnification, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially
misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. The Determination Period may be extended for a reasonable time, not to exceed an additional thirty
(30)&nbsp;days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating
thereto; and provided, further, the Determination Period may be extended an additional fifteen (15)&nbsp;days if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section&nbsp;7(c) of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or
upon a plea of <U>nolo</U> <U>contendere</U> or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not
act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#146;s
conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> For purposes of any determination of good faith, Indemnitee will be deemed to have acted in good faith
if Indemnitee acted based on the records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Company, its subsidiaries,
or an Enterprise in the course of their duties, or on the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or on information or records given or reports made to the Company or an Enterprise by an independent certified
public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise. Further, Indemnitee will be deemed to have acted in a manner &#147;not opposed
to the best interests of the Company,&#148; as referred to in this Agreement if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit
plan. The provisions of this Section&nbsp;8(d) is not exclusive and does not limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or
employee of the Enterprise may not be imputed to Indemnitee for purposes of determining Indemnitee&#146;s right to indemnification under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Insurance</B>. To the extent that the Company maintains an insurance policy or policies providing liability insurance for Agents
or for agents of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Agent or agent under such policy or policies. If, at the
time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect or otherwise potentially available, the Company shall give prompt notice of the commencement of such
proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as
a result of such proceeding in accordance with the terms of such policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Exceptions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Matters</B>. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the
terms of this Agreement to indemnify Indemnitee on account of any proceeding with respect to: (i)&nbsp;remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such remuneration was in violation of law
(and, in this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to
appropriate courts for adjudication, as indicated in Section&nbsp;10(d) below); (ii) a final judgment rendered against Indemnitee for an accounting, disgorgement or repayment of profits made from the purchase or sale by Indemnitee of securities of
the Company against Indemnitee pursuant to the provisions of Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or other provisions of any federal, state or local statute or rules and regulations thereunder; or (iii)&nbsp;a final
judgment or other final adjudication that Indemnitee&#146;s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct (but only to the extent of such specific determination); or (iv)&nbsp;on account
of conduct that is established by a final judgment as constituting a breach of Indemnitee&#146;s duty of loyalty to the Company or resulting in any personal profit or advantage to which Indemnitee is not legally entitled. For purposes of the
foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with which indemnification is sought or a separate proceeding or action to establish rights and liabilities under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Claims Initiated by Indemnitee</B>. Any provision herein to the contrary notwithstanding, the Company shall
not be obligated to indemnify or advance Expenses to Indemnitee with respect to proceedings or claims initiated or brought by Indemnitee against the Company or its Agents and not by way of defense, except (i)&nbsp;with respect to proceedings brought
to establish or enforce a right to indemnification or advancement under this Agreement or under any other agreement, provision in the Bylaws or Certificate of Incorporation or applicable law, or (ii)&nbsp;with respect to any other proceeding
initiated by Indemnitee that is either approved by the Board of Directors or Indemnitee&#146;s participation is required by applicable law. However, indemnification or advancement of Expenses may be provided by the Company in specific cases if the
Board of Directors determines it to be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Unauthorized Settlements</B>. Any provision herein to the contrary
notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee under this Agreement for any amounts paid in settlement of a proceeding effected without the Company&#146;s written consent. Neither
the Company nor Indemnitee shall unreasonably withhold consent to any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for indemnification hereunder in
respect of) any proposed settlement if the Company is also a party in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Securities Act Liabilities</B>. Any provision herein to the contrary notwithstanding, the Company shall not be obligated
pursuant to the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the
&#147;<B>Act</B>&#148; ), or in any registration statement filed with the SEC under the Act. Indemnitee acknowledges that paragraph (h)&nbsp;of Item 512 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> currently generally requires the
Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of Indemnitee&#146;s rights under this Agreement in connection with any liability under the Act on public policy grounds
to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Prior Payments</B>. The Company shall not be obligated pursuant to the terms of this Agreement to indemnify or advance
Expenses to Indemnitee under this Agreement for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except to the extent made by the Associated Party (as defined below) as
provided in Section&nbsp;13 and except with respect to any excess beyond the amount paid under any insurance policy or indemnity policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Nonexclusivity and Survival of Rights</B>. The provisions for indemnification and advancement of Expenses set forth in this
Agreement shall not be deemed exclusive of any other rights which Indemnitee may at any time be entitled under any provision of applicable law, the Company&#146;s Certificate of Incorporation, Bylaws or other agreements, both as to action in,
Indemnitee&#146;s official capacity and Indemnitee&#146;s action as an Agent, in any court in which a proceeding is brought, and Indemnitee&#146;s rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereunder shall continue after Indemnitee has ceased acting as an Agent and shall inure to the benefit of the heirs, executors, administrators and assigns of Indemnitee. The obligations and
duties of the Company to Indemnitee under this Agreement shall be binding on the Company and its successors and assigns until terminated in accordance with its terms. The Company shall require any successor (whether direct or indirect, by purchase,
merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform
if no such succession had taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or
restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To the extent that a change in the Code, whether by
statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#146;s Certificate of Incorporation, Bylaws and this Agreement, it is the intent of the parties hereto that
Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in
addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the concurrent
assertion or employment of any other right or remedy by Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Term</B>. This Agreement shall continue until and
terminate upon the later of: (a)&nbsp;ten (10) years after the date that Indemnitee shall have ceased to serve as an Agent; or (b)&nbsp;one (1) year after the final termination of any proceeding, including any appeal then pending, in respect to
which Indemnitee was granted rights of indemnification or advancement of Expenses hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Other Rights to
Indemnification or Advancement; Subrogation</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company hereby acknowledges that Indemnitee may have certain rights to
indemnification, advancement of Expenses and/or insurance provided by one or more other Persons, other than an Enterprise, with whom or which Indemnitee may be associated (including, without limitation, [insert name], (the &#147;<B>Associated
Party</B>&#148;)). The relationship between the Company and such other Persons with respect to the Indemnitee&#146;s rights to indemnification, advancement of Expenses, and insurance is described by this subsection, subject to the provisions of
subsection (b)&nbsp;of this Section&nbsp;13 with respect to a proceeding concerning Indemnitee&#146;s status with an Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Company hereby acknowledges and agrees: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> the Company is the indemnitor of first resort with respect to any request for indemnification or advancement of Expenses made
pursuant to this Agreement concerning any proceeding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> the Company is primarily liable for all indemnification and
indemnification or advancement of Expenses obligations for any Proceeding, whether created by law, organizational or constituent documents, contract (including this Agreement) or otherwise; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> any obligation of any other Persons with whom or which Indemnitee may be associated (including, without limitation, the Associated
Party) to indemnify Indemnitee and/or advance Expenses to Indemnitee in respect of any proceeding are secondary to the obligations of the Company&#146;s obligations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(4)</B> the Company will indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without
regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated (including, the Associated Party) or insurer of any such Person; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Company irrevocably waives, relinquishes and releases (A)&nbsp;any other
Person with whom or which Indemnitee may be associated (including, without limitation, the Associated Party) from any claim of contribution, subrogation, reimbursement, exoneration or indemnification, or any other recovery of any kind in respect of
amounts paid by the Company to Indemnitee pursuant to this Agreement and (B)&nbsp;any right to participate in any claim or remedy of Indemnitee against any Person (including, without limitation, the Associated Party), whether or not such claim,
remedy or right arises in equity or under contract, statute or common law, including, without limitation, the right to take or receive from any Person (including, without limitation, the Associated Party), directly or indirectly, in cash or other
property or by <FONT STYLE="white-space:nowrap">set-off</FONT> or in any other manner, payment or security on account of such claim, remedy or right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the event any other Person with whom or which Indemnitee may be associated (including, without limitation, the Associated
Party) or their insurers advances or extinguishes any liability or loss for Indemnitee, the payor has a right of subrogation against the Company or its insurers for all amounts so paid which would otherwise be payable by the Company or its insurers
under this Agreement. In no event will payment by any other Person with whom or which Indemnitee may be associated (including, without limitation, the Associated Party) or their insurers affect the obligations of the Company hereunder or shift
primary liability for the Company&#146;s obligation to indemnify or advance of Expenses to any other Person with whom or which Indemnitee may be associated (including, without limitation, the Associated Party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Any indemnification or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated
(including, without limitation, the Associated Party) is specifically in excess over the Company&#146;s obligation to indemnify and advance Expenses or any valid and collectible insurance (including but not limited to any malpractice insurance or
professional errors and omissions insurance) provided by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company&#146;s obligation to indemnify or advance
Expenses hereunder to Indemnitee for any proceeding concerning Indemnitee&#146;s status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such Enterprise. The Company
and Indemnitee intend that any such Enterprise (and its insurers) be the indemnitor of first resort with respect to indemnification and advancement of Expenses for any proceeding related to or arising from Indemnitee&#146;s status with such
Enterprise. The Company&#146;s obligation to indemnify and advance Expenses to Indemnitee is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and desirable action to
obtain from an Enterprise indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee&#146;s corporate status with such Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee from any insurance carrier or Enterprise. Indemnitee shall, at the request and expense of the Company, execute all papers required and shall do everything that may be reasonably necessary to secure such rights, including the
execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>
<B>Interpretation of Agreement</B>. It is understood that the parties hereto intend this Agreement to be interpreted and enforced so as to provide indemnification and advancement of Expenses to Indemnitee to the fullest extent now or hereafter
permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Severability</B>. If any provision of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever, (a)&nbsp;the validity, legality and enforceability of the remaining provisions of the Agreement (including without limitation, all portions of any paragraphs of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b)&nbsp;to the fullest extent possible, the provisions of this Agreement (including,
without limitation, all portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the
intent manifested by the provision held invalid, illegal or unenforceable and to give effect to Section&nbsp;14 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Amendment and Waiver</B>. No supplement, modification, amendment, or
cancellation of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Notice</B>. Except as otherwise provided herein, any notice
or demand which, by the provisions hereof, is required or which may be given to or served upon the parties hereto shall be in writing and, if by electronic transmission, shall be deemed to have been validly served, given or delivered when sent, if
by overnight delivery, courier or personal delivery, shall be deemed to have been validly served, given or delivered upon actual delivery and, if mailed, shall be deemed to have been validly served, given or delivered three (3)&nbsp;business days
after deposit in the United States mail, as registered or certified mail, with proper postage prepaid and addressed to the party or parties to be notified at the addresses set forth on the signature page of this Agreement (or such other address(es)
as a party may designate for itself by like notice). If to the Company, notices and demands shall be delivered to the attention of the Secretary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Governing Law</B>. This Agreement shall be governed exclusively by and construed according to the laws of the State of Delaware,
as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B>
<B>Counterparts</B>. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart
need be produced to evidence the existence of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Headings</B>. The headings of the sections of this Agreement
are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>Entire Agreement</B>. Subject to Section&nbsp;11 hereof, this Agreement constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, written and oral, between the parties with respect to the subject matter of this Agreement; provided, however, that this Agreement is a
supplement to and in furtherance of the Company&#146;s Certificate of Incorporation, Bylaws, the Code and any other applicable law, and shall not be deemed a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Contribution</B>. To the fullest extent permissible under applicable law, if the indemnification provided for in this
Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be
paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such proceeding in order to
reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such proceeding; and/or (ii)&nbsp;the relative fault of the Company and Indemnitee in connection with
such event(s) and/or transaction(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>Consent to Jurisdiction</B>. This Agreement and the legal relations among the parties
shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or
proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the &#147;<B>Delaware Court</B>&#148;), and not in any other state or federal court in the United States of America
or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with this Agreement, (iii)&nbsp;agree to appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, an agent in the State of Delaware as
such party&#146;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv)&nbsp;waive
any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an
improper or inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have entered into this Agreement effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>C<SMALL>YTEK</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>W<SMALL>ENBIN</SMALL> J<SMALL>IANG</SMALL></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>INDEMNITEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Signature of Indemnitee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Print or Type Name of Indemnitee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Indemnity Agreement]</I> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>12
<FILENAME>d80783dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 AMENDED AND RESTATED SEVERANCE BENEFIT PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY PLAN
DESCRIPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Effective January 1, 2020; as amended and restated on _____________, 2021) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Introduction</U>. The purpose of this Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan (the
&#147;<U>Plan</U>&#148;) is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an &#147;employee welfare
benefit plan,&#148; as defined in Section&nbsp;3(1) of ERISA (as defined below). This Plan shall supersede any individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether
written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for severance benefits upon the Covered Employee&#146;s separation from the
Company. This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Definitions</U>. For purposes of the Plan, the terms below are defined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1. &#147;<U>Administrator</U>&#148; means the Board or Compensation Committee prior to a Change in Control; or, after a Change in Control,
one or more members of the successor Board or Compensation Committee or other persons designated by the Board or Compensation Committee prior to such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2. &#147;<U>Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3. &#147;<U>Cause</U>&#148; means the termination of a Covered Employee&#146;s employment with the Company or its subsidiaries due to
(i)&nbsp;commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof (or local laws for international Covered Employees, as applicable); (ii) attempted commission of,
or participation in, a fraud or act of dishonesty against the Company; (iii)&nbsp;intentional, material violation of any contract or agreement between the Covered Employee and the Company or of any statutory duty owed to the Company;
(iv)&nbsp;unauthorized use or disclosure of the Company&#146;s confidential information or trade secrets; or (v)&nbsp;gross misconduct. The determination that a termination of the Covered Employee&#146;s employment is either for Cause or without
Cause will be made by the Company, in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4. &#147;<U>Change in Control</U>&#148; shall be as defined in the
Company&#146;s 2021 Equity Incentive Plan (as amended or amended and restated from time to time, the &#147;<U>2021 Plan</U>&#148;), other than with respect to changes to the Incumbent Board (as defined in the 2021 Plan), which shall not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5. &#147;<U>Change in Control Period</U>&#148; means the time period beginning on the date that is three (3)&nbsp;months prior to when a
Change in Control becomes effective and ending on the first anniversary of the effective date of such Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6.
&#147;<U>COBRA</U>&#148; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7. &#147;<U>Company</U>&#148;
means Cytek Biosciences, Inc. and any successor. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8. &#147;<U>Compensation Committee</U>&#148; means the Compensation Committee of the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9. &#147;<U>Covered Employee</U>&#148; means an employee of the Company (i)&nbsp;with a title of Vice President or above, or
(ii)&nbsp;if not covered by (i), has been designated by the Board to participate in the Plan, provided that in each case, such employee has timely and properly executed and delivered a Participation Agreement to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10. &#147;<U>Covered Termination</U>&#148; means a Covered Employee&#146;s termination of the employment either (i)&nbsp;at any time, by the
Company (or any parent or subsidiary of the Company) without Cause or (ii)&nbsp;during the Change in Control Period, by such Covered Employee for Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11. &#147;<U>Effective Date</U>&#148; means _____________, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.12. &#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.13. &#147;<U>Good Reason</U>&#148; means the Covered Employee&#146;s resignation from all positions the Covered Employee then holds with the
Company (and all parents and subsidiaries of the Company) within 30 days following expiration of the cure period for the following events taken without the Covered Employee&#146;s express written consent, provided that the Covered Employee has given
the Board written notice of such event within 90 days after the first occurrence of such event setting forth the basis for the Covered Employee&#146;s resignation and the Company has not reasonably cured such event within 30 days after the
Board&#146;s receipt of such written notice: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material reduction in the Covered Employee&#146;s duties or responsibilities, provided
that neither (A)&nbsp;a change in title nor (B)&nbsp;a change in the Covered Employee&#146;s reporting relationships, in either case, by virtue of the Company being acquired or made part of a larger entity will be deemed a &#147;material
reduction&#148; in and of itself; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material reduction in the Covered Employee&#146;s base salary, unless such reduction is made in
connection with a similar action affecting all senior executives of the Company; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a relocation of the Covered Employee&#146;s
principal place of employment to a place that increases the Covered Employee&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than 50 miles as compared to the Covered Employee&#146;s then-current principal place of employment
immediately prior to such relocation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.14. &#147;<U>Participation Agreement</U>&#148; means the individual agreement (as will be
provided in separate cover as <U>Appendix A</U>) provided by the Administrator to a Covered Employee under the Plan, which has been signed and accepted by the Covered Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.15. &#147;<U>Severance Benefits</U>&#148; means the compensation and other benefits the Covered Employee will be provided pursuant to either
Section&nbsp;4 or 5, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.16. &#147;<U>Termination Date</U>&#148; means the Covered Employee&#146;s last day of employment
with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.17. &#147;<U>Tier 1 Covered Employee</U>&#148; means the Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.18. &#147;<U>Tier 2 Covered Employee</U>&#148; means a Covered Employee who is not the Chief Executive Officer of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility for Severance Benefits</U>. An individual is eligible for severance
benefits under the Plan, in the amounts set forth in Sections 4 and 5, only if such individual is a Covered Employee as of the consummation of a Change in Control or during the three month period prior to a Change in Control, and remains an employee
of the Company or an affiliate of the Company on the date such individual experiences a Covered Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severance
Benefits</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1. <U>Covered Termination Outside of the Change in Control Period</U>. If, at any time other than during the Change in
Control Period, a Covered Employee experiences a Covered Termination, then, subject to such Covered Employee&#146;s compliance with Section&nbsp;6, such Covered Employee shall receive the following Severance Benefits from the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.1. <U>Cash Severance Benefits</U>. The Covered Employee shall receive cash severance in an amount equal to the Covered Employee&#146;s
base salary for the number of months set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 1 Covered Employee: 9 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 2 Covered Employee: 6 months </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash
amount shall be paid in a single lump sum payment on the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.2. <U>COBRA Premiums</U>. Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation
coverage pursuant to COBRA, the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee&#146;s dependents) for such coverage following the date of the Covered Employee&#146;s Covered Termination for up to the number
of months set forth below (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee&#146;s
dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company promptly after the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered
Employee&#146;s dependents are no longer eligible for COBRA coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 1 Covered Employee: 9 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 2 Covered Employee: 6 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Change in Control Severance Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>Covered Termination During the Change in Control Period</U>. If, at any time during the Change in Control Period, a Covered Employee
experiences a Covered Termination, then, subject to the Covered Employee&#146;s compliance with Section&nbsp;6, the Covered Employee shall receive the following Severance Benefits from the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.1. <U>Cash Severance Benefits</U>. The Covered Employee shall receive cash severance in an amount equal to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Covered Employee&#146;s base salary (as in effect immediately prior to any reduction giving rise to Good Reason) for the number of
months set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 1 Covered Employee: 24 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 2 Covered Employee: 12 months; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) 100% of such Covered Employee&#146;s bonus target for the year in which such
termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash amount shall be paid in a single lump sum payment on the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day
following the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.2. <U>COBRA Premiums</U>. Provided the Covered Employee is eligible for and timely makes the
necessary elections for continuation coverage pursuant to COBRA the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee&#146;s dependents) for such coverage following the date of the Covered Employee&#146;s
Covered Termination for up to the number of months set forth below (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee
and the Covered Employee&#146;s dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent
employer or if the Covered Employee&#146;s dependents are no longer eligible for COBRA coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 1 Covered Employee: 24 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Tier 2 Covered Employee: 12 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.3. <U>Equity Vesting</U>. Each of the Covered Employee&#146;s then outstanding equity awards shall accelerate and become vested and
exercisable as to 100% of the unvested shares subject to the equity award, except any award granted after the Effective Date that explicitly overrides this provision in writing. Subject to Section&nbsp;6, the accelerated vesting described in this
paragraph shall be effective as of the Termination Date. For purposes of this Section&nbsp;5.1.3, any equity awards subject to performance-based vesting shall accelerate based on target performance. Notwithstanding anything herein to the contrary,
nothing in the Plan shall limit the Company&#146;s ability to accelerate vesting and/or exercisability of outstanding equity awards pursuant to the terms of the applicable equity incentive plan of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions to Receipt of Severance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Release Agreement</U>. As a condition to receiving the Severance Benefits, a Covered Employee must sign a waiver and release of all
claims in favor of the Company and its subsidiaries and affiliates (the &#147;<U>Release</U>&#148;) in such form as may be provided by the Company. The Release will include specific information regarding the amount of time the Covered Employee will
have to consider the terms of the Release and return the signed agreement to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Other Requirements</U>. A Covered
Employee&#146;s receipt of Severance Benefits pursuant to Section&nbsp;4 or 5 will be subject to such Covered Employee continued material compliance with the terms of the Release, the Participation Agreement, any confidential information agreement,
proprietary information and inventions agreement and any other agreement between the Covered Employee and the Company. Severance Benefits under this Plan shall terminate immediately for a Covered Employee if such Covered Employee is in material
violation, at any time, of any legal or contractual obligation owed to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <U>Section 280G</U>. Any provision of the Plan to
the contrary notwithstanding, if any payment or benefit a Covered Employee would receive from the Company and its subsidiaries or an acquiror pursuant to the Plan or otherwise (a &#147;<U>Payment</U>&#148;) would (i)&nbsp;constitute a
&#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise Tax</U>&#148;), then such Payment will
be equal to the Higher Amount (defined below). The &#147;<U>Higher Amount</U>&#148; will be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y)&nbsp;the largest
portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate),
results in Covered Employee&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Higher Amount, reduction will occur in the manner that results
in the greatest economic benefit for a Covered Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. In no event will the Company, any subsidiary or any stockholder be
liable to any Covered Employee for any amounts not paid as a result of the operation of this Section&nbsp;6.3. The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to
provide its calculations, together with detailed supporting documentation, to a Covered Employee and the Company within 15 calendar days after the date on which such Covered Employee&#146;s right to a Payment is triggered (if requested at that time
by such Covered Employee or the Company) or such other time as requested by such Covered Employee or the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U><FONT
STYLE="white-space:nowrap">Non-Duplication</FONT> of Benefits</U>. Notwithstanding any other provision in the Plan to the contrary, the Severance Benefits provided to a Covered Employee are intended to be and are exclusive and in lieu of any other
severance and change in control benefits or payments to which such Covered Employee may otherwise be entitled, either at law, tort, or contract, in equity, or under the Plan, in the event of any termination of such Covered Employee&#146;s
employment. The Covered Employee will be entitled to no severance or change in control benefits or payments upon a termination of employment that constitutes a Covered Termination other than those benefits expressly set forth herein and those
benefits required to be provided by applicable law or as negotiated in accordance with applicable law (including any severance benefits that may be included in a severance agreement, employment agreement or similar contract between the Company or a
subsidiary of the Company and the Covered Employee). Notwithstanding the foregoing, if a Covered Employee is entitled to any benefits other than the benefits under the Plan by operation of applicable law or as negotiated in accordance with
applicable law, such Covered Employee&#146;s benefits under the Plan shall be provided only to the extent more favorable than such other arrangement. The Administrator, in its sole discretion, shall have the authority to reduce or otherwise adjust a
Covered Employee&#146;s benefits under the Plan, in whole or in part, by any other severance benefits, pay and benefits in lieu of notice, or other similar benefits payable to such Covered Employee under the Plan that become payable in connection
with the Covered Employee&#146;s termination of employment pursuant to (i)&nbsp;any applicable legal requirement, including the Worker Adjustment and Retraining Notification Act (the &#147;<U>WARN Act</U>&#148;), the California Plant Closing Act or
any other similar state law, or (ii)&nbsp;any policy or practice of the Company providing for the Covered Employee to remain on payroll for a limited period of time after being given notice of termination. The benefits provided under the Plan are
intended to satisfy, in whole or in part, any and all statutory obligations of the Company that may arise out of a Covered Employee&#146;s termination of employment, and the Plan Administrator shall so construe and implement the terms of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section 409A</U>. Notwithstanding anything to the contrary in the Plan, no severance payments or benefits will become payable until
the Covered Employee has a &#147;separation from service&#148; within the meaning of Section&nbsp;409A of the Code and the final regulations and any guidance promulgated thereunder (&#147;<U>Section</U><U></U><U>&nbsp;409A</U>&#148;). Further, if
some or all of the Covered Employee&#146;s Severance Benefits are subject to Section&nbsp;409A and such Covered Employee is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A at the time of such Covered Employee&#146;s
separation from service (other than due to death), then such Severance Benefits otherwise due to such Covered Employee on or within the <FONT STYLE="white-space:nowrap">six-month</FONT> period following such Covered Employee&#146;s separation from
service will accrue during such <FONT STYLE="white-space:nowrap">six-month</FONT> period and will become payable in a lump sum payment (less applicable withholding taxes) on the date six months and one day following the date of the Covered
Employee&#146;s separation from service if necessary to avoid adverse taxation under Section&nbsp;409A. All subsequent payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding
anything herein to the contrary, if the Covered Employee dies following such Covered Employee&#146;s separation from service but prior to the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of such Covered Employee&#146;s date of
separation, then any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments delayed in accordance with this paragraph will be payable in a lump sum (less applicable withholding taxes) to the Covered Employee&#146;s estate as soon as administratively practicable
after the date of such Covered Employee&#146;s death and all other benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under the Plan is intended to constitute a
separate payment for purposes of Section&nbsp;409A. It is the intent of this Plan to comply with or be exempt from the requirements of Section&nbsp;409A so that none of the severance payments and benefits to be provided hereunder will be subject to
the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be interpreted to so comply. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under the Plan comply with
Section&nbsp;409A, and in no event shall the Company or any of its representatives be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Covered Employee on account of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Withholding</U>. The Company will withhold from any
Severance Benefits all federal, state, local and other taxes required to be withheld therefrom and any other required payroll deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Administration</U>. The Plan will be administered and interpreted by the Administrator (in the Administrator&#146;s sole discretion).
The Administrator is the &#147;named fiduciary&#148; of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to
the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. Any decision made or other
action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document that (i)&nbsp;does not affect the benefits payable under the Plan shall not be
subject to review unless found to be arbitrary and capricious or (ii)&nbsp;does affect the benefits payable under the Plan shall not be subject to review unless found to be unreasonable or not to have been made in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Amendment or Termination</U>. The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any
time, without advance notice to any Covered Employee and without regard to the effect of the amendment or termination on any Covered Employee or on any other individual. Any amendment or termination of the Plan will be in writing. Notwithstanding
the foregoing, a Covered Employee&#146;s rights to receive payments and benefits pursuant to this Plan in connection with a Covered Termination during a Change in Control Period may not be adversely affected, without the Covered Employee&#146;s
written consent, by an amendment or termination of this Plan occurring during such Change in Control Period. Unless sooner terminated by the Administrator, the Plan will automatically terminate on the tenth anniversary of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Claims Procedure</U>. Claims for benefits under the Plan shall be administered in accordance with Section&nbsp;503 of ERISA and the
Department of Labor Regulations thereunder. Any employee or other person who believes they are entitled to any payment under the Plan (a &#147;<U>claimant</U>&#148;) may submit a claim in writing to the Administrator within 90 days of the earlier of
(i)&nbsp;the date the claimant learned the amount of such claimant&#146;s severance benefits under the Plan or (ii)&nbsp;the date the claimant learned that they will not be entitled to any benefits under the Plan. In determining claims for benefits,
the Administrator or its delegate has the authority to interpret the Plan, to resolve ambiguities, to make factual determinations, and to resolve questions relating to eligibility for and amount of benefits. If the claim is denied (in full or in
part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice will also describe any additional information or material that
the Administrator needs to complete the review and an explanation of why such information or material is necessary and the Plan&#146;s procedures for appealing the denial (including a statement of the applicant&#146;s right to bring a civil action
under Section&nbsp;502(a) of ERISA following a denial on review of the claim, as described below). The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time (up to 90 days),
written notice of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the extension will be given to the claimant (or representative) within the initial <FONT STYLE="white-space:nowrap">90-day</FONT> period. This notice of extension will indicate the special
circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim. If the extension is provided due to a claimant&#146;s failure to provide sufficient information, the time frame for
rendering the decision will be tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information. The Administrator has delegated the claims review
responsibility to the Company&#146;s Chief Executive Officer or such other individual designated by the Administrator, except in the case of a claim filed by or on behalf of the Company&#146;s Chief Executive Officer or such other individual
designated by the Administrator, in which case, the claim will be reviewed by the Chair of the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Appeal Procedure</U>. If the claimant&#146;s claim is denied, the claimant (or such claimant&#146;s authorized representative) may apply in writing to an appeals official appointed by the Administrator (which may be a person, committee or other
entity) for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of a claim denial or else the claimant will lose the right to such review. A request for
review must set forth all the grounds on which such request is based, all facts in support of the request, and any other matters that the claimant feels are pertinent. In connection with the request for review, the claimant (or representative) has
the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit written comments, documents, records and other information relating to such claimant&#146;s claim. The
review shall take into account all comments, documents, records and other information submitted by the claimant (or representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit
determination. The appeals official will provide written notice of its decision on review within 60 days after it receives a review request. If special circumstances require an extension of time (up to 60 days), written notice of the extension will
be given to the claimant (or representative) within the initial <FONT STYLE="white-space:nowrap">60-day</FONT> period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the appeals
official expects to render its decision. If the extension is provided due to a claimant&#146;s failure to provide sufficient information, the time frame for rendering the decision on review is tolled from the date the notification is sent to the
claimant about the failure to the date on which the claimant responds to the request for additional information. If the claim is denied (in full or in part) upon review, the claimant will be provided a written notice explaining the specific reasons
for the denial and referring to the provisions of the Plan on which the denial is based. The notice shall also include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all
documents and other information relevant to the claim and a statement regarding the claimant&#146;s right to bring an action under Section&nbsp;502(a) of ERISA. The Administrator has delegated the appeals review responsibility to the Company&#146;s
Chief Executive Officer, except in the case of an appeal filed by or on behalf of the Company&#146;s Chief Executive Officer, in which case, the appeal will be reviewed by the Chair of the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Arbitration</U>. No arbitration proceeding shall be brought to recover benefits under the Plan until the claims procedures described in
Sections 12 and 13 have been exhausted and the Plan benefits requested have been denied in whole or in part. Notwithstanding any other provision of the Plan, to ensure the timely and economical resolution of disputes, all disputes, claims, or causes
of action arising from or relating to the enforcement, breach, performance or interpretation of this Plan will be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Fremont,
California, conducted by JAMS, Inc. (&#147;<U>JAMS</U>&#148;) under the then-applicable JAMS rules (available at the following web address: https://www.jamsadr.com/rules-employment). By agreeing to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this arbitration procedure, each Covered Employee and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. Covered Employees will
have the right to be represented by legal counsel at any arbitration proceeding. In addition, all claims, disputes, or causes of action under this section, whether by a Covered Employee or the Company, must be brought in an individual capacity, and
shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more
than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found
unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to
award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision, to include the arbitrator&#146;s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to
award any or all remedies that a Covered Employee or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#146; arbitration fees in excess of the amount of court fees that would be required of a Covered Employee if
the dispute were decided in a court of law. Nothing in this paragraph is intended to prevent either a Covered Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. Any arbitration must be commenced within one year after the Covered Employee&#146;s
receipt of notification that their appeal was denied. The foregoing provisions shall apply to the extent consistent with and permitted by ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Source of Payments</U>. All severance benefits will be paid in cash from the general funds of the Company; no separate fund will be
established under the Plan, and the Plan will have no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Inalienability</U>. In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell,
transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>No Enlargement of Employment Rights</U>. Neither the establishment nor maintenance of the Plan, any amendment of the Plan, nor the
making of any benefit payment hereunder, will be construed to confer upon any individual any right to be continued as an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without
cause. However, as described in the Plan, a Covered Employee may be entitled to benefits under the Plan depending upon the circumstances of such Covered Employee&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Successors</U>. Any successor to the Company of all or substantially all of the Company&#146;s business or assets (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company
would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term &#147;<U>Company</U>&#148; will include any successor to the Company&#146;s business or assets which become bound by the terms of
the Plan by operation of law, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Applicable Law</U>. The provisions of the Plan will be construed, administered and
enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the State of California (except its conflict of laws provisions). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Severability</U>. If any provision of the Plan is held invalid or unenforceable, its
invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Headings</U>. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Additional Information</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan Sponsor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cytek Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46107 Landing Parkway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fremont, California 94538</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(877) 922-9835</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Identification Numbers:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">EIN: 47-2547526</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan Year:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company&#146;s fiscal year ending December 31</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan Administrator:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cytek Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Administrator of the Cytek Biosciences, Inc. 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Severance Benefit Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46107 Landing Parkway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fremont, California 94538</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(877) 922-9835</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agent for Service of Legal Process:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cytek Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Administrator of the Cytek Biosciences, Inc. 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Severance Benefit Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46107 Landing Parkway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fremont, California 94538</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(877) 922-9835</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Service of process may also be made upon the Administrator.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Type of Plan:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance Plan/Employee Welfare Benefit Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan Costs:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The cost of the Plan is paid by the Company.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Statement of ERISA Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Covered Employee under the Plan, you have certain rights and protections under ERISA: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of
Labor. These documents are available for your review at the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) You may obtain copies of all Plan documents and other Plan
information upon written request to the Administrator. A reasonable charge may be made for such copies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to creating rights
for Covered Employees, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan (called &#147;<U>fiduciaries</U>&#148;) have a duty to do so prudently and in the interests of you and the
other Covered Employees. No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for
a severance benefit is denied, in whole or in part, you have a right to know why it was denied, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. The claim review
procedure is explained in Section&nbsp;12 and Section&nbsp;13 above. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ERISA, there are steps you can take to enforce the above rights. For instance, if you
request a copy of Plan documents and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the
materials, unless the materials were not sent because of reasons beyond the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are
discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court
may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your
rights under ERISA, you may contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security
Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits
Security Administration at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-444-3272.</FONT></FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTEK BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEVERANCE BENEFIT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Participation Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cytek Biosciences, Inc. (the &#147;<U>Company</U>&#148;) is pleased to inform you, [<I>name</I>], that you have been selected to participate
in the Company&#146;s 2021 Amended and Restated Severance Benefit Plan (the &#147;<U>Plan</U>&#148;) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all
of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to [<I>name</I>] no
later than [<I>date</I>]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits
and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the
Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section&nbsp;6.1 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Section&nbsp;7 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you
related to your termination of employment with the Company and/or a change in control of the Company and will supersede and replace any severance and/or change in control benefits to which you otherwise would eligible to participate in any other
Company severance and/or change in control policy, plan, agreement or other arrangement (whether or not subject to ERISA). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By your
signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (i)&nbsp;you have received a copy of the Plan;
(ii)&nbsp;you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section&nbsp;7 of the Plan; and (iii)&nbsp;decisions and determinations by the Administrator under
the Plan will be final and binding on you and your successors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>CYTEK BIOSCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>COVERED EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Signature</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attachment: Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>13
<FILENAME>d80783dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of Cytek Biosciences, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytek (Shanghai) BioSciences Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytek (Wuxi) BioSciences Co. Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytek (Shanghai) Software Development Technology Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytek Biosciences B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Netherlands</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytek Japan Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japan</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>14
<FILENAME>d80783dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">



<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We consent to the use in Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-257663</FONT> on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> of our report dated April&nbsp;21, 2021 (July&nbsp;18, 2021 as to effects of the stock split described in Note 2) relating to the financial statements of Cytek Biosciences, Inc. We also consent to the reference
to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;18, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g169497g66w01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g169497g66w01.jpg
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M$0 _ /OXZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
MZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
MZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
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M@.@.@.@.@.@.@.@.@.@.@M*]_P!/R?15_AW7^W^"=N@N] = = = = = = =
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M/VM0 I3\0R[VMXLA,S@CPK?8<@!Y&P]M-H85M,J+634<A:[%87=7$E%)(<^
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MH27]=^4L?Q-R):9^;E@9[$V6$W7%W*/(DZ^)9NQ]YR92A-FMMF<G%B^=#QO
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M]^_051%5%1W_ &O^UT'GX_\ 3_Q=!<Z Z Z Z Z"T[Y/+Z(JI_/R1.W^KO\
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MK3Z=!5C?!O95[_5>@]] = = = = = = = = = = = = = = = = = = = =
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MI/P_L^U^G;H#_*5ZS?C_ (#<4=_KW5,32_55147Z_;=^_9?QZ _RE>LOU_\
M-"\3_7MY?^1-)]?'_9^GVOT[=D_GT%4]2_69.R_X#<4=T[I_YA5)^"]^Z)_N
MB]OQZ _RE^LWT5>!N*/)/Y8JD1$7NJJB?[K^'=?]70)MCZF^L8XYG+P)Q([Q
MB2T[OQ=*SP:L8J*B/2.B"8Y.Z.=^5$;_ !Z#YV_=KGDG$=3S-Q;QHM&NT]GH
M>#JN%WP#P2LQ.&Q?&Q,1RUSQ(A>*AJ<=Q)4R)<&GDF;Y7&KD0XT57*(BH'%K
M'<5VV[TLG+X^ED461A0*VG;8297AG<#QY2T,2!7BTMF5 CAO'G(+5CQRN?\
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MV-8A#V/#/&\@JL:-$&(8NZ"&)OY "&P;?RM3H)F] = = =!\ZWL%)JP?MLU
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M*^NHZ.DK%*L"HJ(Q#2)#A")((8\F00TN?+*21((\CU7H'Z;^"=_Y?P^O05Z
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M>KRBZ/;"HDR$0I R+QT<M<RX;%$4+D5%C(3Z?[/0I#S_ -[0_M=__GD<8_\
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M_9$V/,FTY]=$X>XC#-0$[2V0>,<D(FCT3Q*Z328"BD*BS9OCYG>B1HZ.._\
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MV?W8F(E6?!-CH/E#_P#/J'_\&/II_P#C*Y8__P!/S?4EG)U<_8X_]]6^H_\
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M)N=>8./.8H_%^83CFKW<OCS;VF'+K[',O-8O)/I\J:/.D1DD*-GFYPT\>R]
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M:RJUNXQ5'M:[)ZCE.SN=MR .@IJ32QX]G99^'"DB)YM8\)$[-!4].9QX'O\
M:'B,V?XXQ>-]?!MR/#F$XUY5+"S^-RNQX5T.IO(2>NUL,NPL+2[M2.E6')5K
M(+,O9*J,Z>2(G0?3UZV?^9M[)_Z>2<6O_#PKQO\ R_+V[)_#_EZ"670'0'0'
M0?/CR_&#8^BW'=::WH*(1>$ZQ9MWJZJ%=9NHAN]DN-_N;.[IK1&UEK6PP#>\
MT8ZH(XVJUZ*U5Z#EAQQZ0:?CVMLL;:>X'[>]W7U/(G)N]J-5E^5\]Q=3:6=O
M[\EQ CLXF@+(K^-@TJF<-D>(:1" ;LX*,9V;T#:>TW!NF=OI7(&)ON.>;X_)
MT2/O?9+A3UBWE%RWRE@N:8N5?D)?.7$M,.3"L.7.*>6*:NA?UM55[!W-1<B=
M,$(T<SFH#?<0:K=5V>NZ;#83F+8"IX4*+)O^;J+=>L'J[AB2 5(95]R1R/RQ
M6T,T556_8%>M+GH,ZWE$7XQ-;Y?(@3#7T@Q.RA1=/M?=KC'D373JN#/!8X'V
MWX[]:N/\V\R_.>CR/&T?/ZBS;$@*3XFV-W-DS[%GB\HV*Y6H$=.>O4+_  G3
M/3N-.5N*/:X<^/*;H>.,5R#@KGVDB1W1?NK:1ABXT\'(^P(ZH '&-4GA5EY*
M8COM'&?_ '2A/O+\B/V'[9F2=5-@ZJ,W=3J'#[&$]L04#/2X[G7<.P!8+#2@
MDPI,!\2SCR/@-5$$\<AK%;VZ!<_9_P#4:3S5K!^WFVC%'Q9D :7'>KL&1#^W
M9I(%R1E-RY[#NB$:$\-_(GV+\UD2*W^YR\>7+&J.L&N4/J#%4U+! 9^EUS&Q
MQL"%J08K4"(3&L:(;4$C1,&UJ(C6]D1$3MT"@A&_R<OC]&JB)]$_E_#^'0>F
MJBM5$1>S4_[KZ+W[+]?I].@MC^KU1?JG?_T/0757Z_7O_+^3?HJ_Q3Z_3H.
M'[GW _$7-GM#C:CF*!S;*J;SUE+QY4+PKL)^0E2C:WF6"ZVJ]G807?''R)DB
MQ#'D2$:,?P]FN157H)C?M_9")DO2GUMQ\&UKYL+'\:U^2ASVF.\<^'G)UA51
M);2 9\1O,$9O=R)W<J>2K]>@F$M:WOX_<UZM_CW+,5555145>X^ZJG0'Z>W\
M/N:[Z+W[?-+[=_K_  \.WXKW_MZ _36I_P"EZ[Z?Q4DM>R=^_P#WM?\ T/0-
M%S5P!Q[[ 9:AQG)H(UOF<]R'C>3@5+)1F0K+0X27)F4T"_BRHDJ)=9J466]L
MVO,-1R@N5KOP3L$%)?[.OJM"QE?Q[QKN.<N%,A!K.<,G8T7&O)!HT?3<:^PF
MWI>0N1N,;Z7>5EO,DY!-'11TJT:]LJLB>06&\5Z!U_\ WF+Z?_X@9_E9,#$'
MR?E]YE=Y2<@#LI3-/%/C!M'19PTK[=S96:C#1&*Q_>2H4\%*C/R=!'H'[(WJ
M0S(Z'&2-OS-,AV0./Z_/6\G4T7ZIDZOC/DBUY8R-?5Q@95E9>)"V5U((4]R&
M=(+&[ \_%5[@\.I_:O\ 67?[WC#F/DBSVO(_.O#@>+Q8#FS6W4*7N:HG$=S<
M7.:\V1JF/0'CVR7AH=I'+$>"1':-S&C,QKT#HR6$PAGE23!3Y5>0B(2<Q&F)
MV4C6(YJ]F_5/XKT%K].8G?M(KT[KW[H26J]O]*^'X?Z5[]!7]/9_"17HOX+V
M-,_#M]$^K%_GT%/TYOU_WBM[K]%7Y9?DO_L7AW[?S_GWZ"OZ>G?_ ,;@M5SD
M[JTTU._?Z+W[,_,OT3^?TZ#A5^X=H=-7^XM-A(E[Q*[#:3U-J]-K:78DE%V:
MKD>5M8E;HN-HHT^-[*HUJX-N27YQ?LY7@UOSN'V#LCZ O^3TD]4G?[NY%X!X
MO5'Q6-%%=_Y*U_TC#:UOQQD[?D;V3LWLG02^3\$_T_7_ %K^/_'T%>@.@.@.
M@.@.@.@X+_OX:;34'"/!<1@;8W&]WRM91=R.L17@+<Q,O)G8<%H%7C#)AJ<,
M\C!D7Q^X$-Z(KF-5/P?<'<Y=KVN.<36,Y5/V:/27\W^NY^A>C=EUNMAU<O2^
MKW4X=2<(N8SV3ETKBXN)F,OK$3R<E/VM/9?<\6^X_&.;S3["#Q=R]<1>-MKD
M2G[PK:7?.>'.:PD$:OAQ;S/7:@09AI\JPBG$YSFO[-\'],]R_L^L='MMUX=;
MJ1TYC_\ K2)^DU]'I;^./Y"]0C^0.S[3L\<^GZ%W>7_'ZG3RF/SY9_X=68B9
MB,L,HB(K79.43,W%?65R5[.\;<7Z4F5NV7]E:0XP)EO^@UHIH*8$@7SA2<4\
MN'YR7QU0OQ 0KT&Y%5$5S47QW^1_^QG\=?QAZQEZ'Z]EWG6[[H]*.IU_^/TH
MZD=#'*-T?N3EGA>6RL]G3C/+;,3,7,1/]+?:'\-^\/>GI$>M^F_\7H]CGG./
M2_?ZDX9=7+&=L[(QPSK&,KQW9SCCNB:FHF8@M^X1SKR8/*<.V7!.\O\ -XW8
M!T%Q*U>*.D"RL[&K=5CKZ.3/*'[J ",.4<AXW8;WE;XE:J#5O7SS_P!E_P#L
M-ZGZ=[=]K^O_ ,6^J8X^T?6\>XZL=[T?_P!<NC/3C'H[LL;Z>6&[.>ITIC'/
M=C..<1LRA[^_ZT_QC[7[GUGU[L_Y#[#M^X]?]/RZ/2CMNYC?AT\.I^Y.?5C&
M)VYSE..$8=37&,9B<)_-$G7].:NA]E^/>/>=^=,!FM%SKQG<76.@<@2:]!S)
MP\_+2337RQ0?;UC[(46S:JO4#D!.:4@$%Y>*>X?X*[_VY_-7MCTW^4?<G8=O
MW'O7TWK=3M,>[G#;EE/1F)CJ1CC,83/_ )+B\<MG4WSAM>&_S?W?K/\ $7N+
MU3^,O8/J?=]M_'?JW0Z7==3L\<[PQGK8[>ITMV6[J1A,]/A&<;^E.&/4WU<]
M&^OIU\N.?O-_J9O-UI_:+5\?[.5DKOF;@3%<;X.R=R#R-'!C]U%N=G_7>K9G
M8L\^=H_UK-GS@!2*\"2GOJWHJ"\WD,6)-+"]5?=:GB^G<2FYWSK8OJ])E6&X
M#;:CD>TD^P4NWW3Z:VB:><11CA5$;A(DM:T%B&Z' O;%@AM1D"//6+<6UIGI
M1[<#D>T<*VY^M=)C>7L=RN/BVD@<K[?*:;CS8\@<]6^[B0HNK/E=/&JL?!X_
MB5<<31091899-C6B8L @BM47%GGH?7#V&B<AX+5;"_R6N!4^L.6XL86EY*Y5
MQM/Q#RY4Y3:U.WV>&X];'MZ3D:EY*GWU8-95_+#<5 :ECQ/*[LWJI%([V/H[
M[GEX#]=<7E>>(^+Y/XDQ_)%!R!8NY/Y O*#E&PWVBXVBRY=S;!S=1;37CQ]1
M>RZ^6:*DRHNG0_!QAEED6:KNA)_ACUUY\Q7MCROR_J=Y$=Q9J[7DN;69^)R)
MR!J)>JA:X_&Q./ZVXP6@@Q<-QZWB,64NVQI%063(L/Z@>PBC&+LZI,Q2QN?4
M[D^?I?9+2\<<D6&%N^8-[ZZW^(OF;/9W#\12\?[/%ZCE=L7+7Q+?'UTG4+13
M7 A1XKH%BADCS$9&(5B*U\BVD\2>J?LWBN6?6/7[WE('(E!Q7A^8L[R,25O]
M1%E:#3;;D;3Z7+;!N9?F"4=](@Y6UCP7A<6M2 YJBCJ^,(;%FOT69CZGCWW!
M7,M_[)W_ "94Z>(3'W'#)<+Q[:'Y VU+:>OF\_2N08=OLJ+BBOKY/'7*;MM*
MTE00Y[:1%F5_Z.U!*1O@WJI=0A[5>CGN3'X;D96EYSB\8[B'RA@>0<[^E<M<
MK\B4D>VP'"&GR6@N;G1:RK@Z*VI^<>7Y4"XOLV\7Z?%@(8@REGN5[BW%G\S7
MJQ[&U7)'%M].YF0O']%Z]96MY$RR:W:V$^\]F\7QC>\3U6GJY4T0PDXZMJ39
M2K*R:962I-Y35LUP'&1[V$M&RR]$O=H_KKZ]X/+<_1<5RSQ/C^6*7?7KN4N1
M+RCY2MN0I?'=4DN[M YNGN);1YBMOI4*4>.LVFN'PR">='27K*E;A+#1^J'(
MKMM[([+';,]1(Y:Y+]:=3C!R>1.1W"SV6XYV^ UO,M&E625.J,VN[3/63!AK
M!("4R6@3J(#WM068^?Z5^TMS,]DXA^8B9\7+&:Y*S==M:#E_E+^I-5,W'-]9
MNL)LCT)JX=%PQ?\ !W$0).1K!YY\L<_YT(1PA#8Q&I<,F9ZL>_!,WZ_ ![#X
MUVJX8Y?Y-YEVMD>XY!%7\W3[OE4TG&X>\!7MA_HF1)PY;6L>='..T@0;B:!L
M6&\<*/)92X3FX%R?+N+G\R5?)):*TS]SS!NMQQG?P-E?:*Z-D-K?V-W#SM]1
MW.<K(^27) ,&)&CPI]E%()%5JA1J,4RD/T!T!T!T!T!T!T!T'G_NNW^CO_K_
M  _Y.@Y5?NYP)]IZ[\95M=)F1#3O8_CR-(-! &7(6"7/[E)43[4ZM%*!8-1(
MY!JOYF%5$5%[*@-9^VEB\?C:'V>RF'=O:[.T'L+!K(M1RI,G3+FCF1.#N)HT
M^GH)4AKYC\?!G +^FM*]SA"<K6KX>/0=+OTYG?Z2*[^/_I26GX_3OV4:=E5.
M@/TYG\9%<O;OV[EEKV[_ (]N[%[?7Z_V] )7-3_YYK_P5/\ IIGX*G;M]&=E
M3M_R=!3]/1$7M)K_ *_3M\TSMV3\/HC/JJ?P_P!/00G]Q?V_^)?=^!GJKEO;
M;W-UF<JM1G%K\!;4D6OO:+6DJB6HK5E[G;:5#MF?I2,CV$ L:5'&YZ-=Y(U4
M#6Y7[7GJ.^]-LZ[(,H^2TY)F\J5_+558C;RK5:6=Q1(X7^R@\AEJBZ=N>K\5
M*<Z, AW*RP:R0O=Z?4&NIOV3OV]Z*AGXR+@=),XVO+'CB[U'%VAY$UFJPVET
M'&>9U^+H-/:1;DYIPKQ,MM9$8[XQ@,*H8KFM8L9B=!NO$O[6G!_!G)^9Y6XL
MY.Y;R=YGN,L7PU.I8=WGES^MXTX[J[VCR63TAGY9;AT2%47JCD+&.#[T\<,D
M_F9KG.#=_53]O/AKU!W'('(V!U>WV.LY%RE+CK>PY NJP@(M!G+^[U%=&CUF
M5S]!73[-UOH)"GL98S32@^,2D\6]N@G$M>U7*KI5<USD_.K23?)>Z(JIYH+R
M[=U_GT%/TYBKW257K_I^6:UW94^O=5'W5%Z"J5[45%^YKNZ?@OS2_P#]3^7T
M_LZ"OZ>UWT=+@_1%7R^:6Y43_G(CF=E<WO\ \'X=!QK_ 'RMB_C'T]R.XC:B
MISEYFN?,1:9&RFK%-3ILF5>A9EX>HCW;$!/S!;)6%FQT5"$$-&IW:KD4) _L
M^ZC;[;'>R>OY&D\866STW,M+;7=_PZV9_AYJ9)..,K%-I:0LQ[C2CVDN&7[D
M@_&,XS%^!$$C>@[#*G=R_3\5143^*+V_CV^G09'04[)_)._U7OV^J*J=NZ+_
M #[=!8-Y)V<-416N[N14_P!I%_[GO_!/K_R=!Q;_ '8_230\\8JOY0X=J:\_
M.'%<BVV'%XSI"AQ[W1SJP,':<1WLTR-1N4YZS$5*UWRN:&'HHU=+7ZJYW0<M
M/7'E+'<>?MV>P?)<W16U)C.4+&LP^9QDF)*E\M!YDT5F/.7?KIGN.ZQRZ.VY
MAEWE<ZK+G!B4SCC6251Q5<5 U/A'T0H=<TU][(\N\8\,S4LZ\<OUAR?*]/CM
M)00610&?2<R\W@C6&AN-E CO:L^CRB1:>N-YQGR"D:YW03'W7H/Z8[.BJ:_+
M[?CSAFUJIL.12\E<7^TFMC;G.RV_*"!9P6WQ;K-Z,CT<SY(EG%)#DI^0B?1%
MZ"$?(? _-TH&AP-I-?S+3T4B92+SGZ@2"/)NP"3PBPN:. XULS2X;8H 36R)
M],MG16GYG@9&1WBT(^\&?MN: 6Q=5\N4M7Q)P=8Z"OTMZ;FBVK</ON:B9H4,
ME;Q)F\W%L;&WP'%6BE5<8NMO[OX);Z]I*^&!5DO(H=HG9"U=8V-@/FWU30]R
M^RL;0(^79K$),L2FD36TD4<?],KP]B(!/-CFH%B(QJ=N@:+AG@ '&WMI?<N$
MYJX#Y#3FK16EG0<7\4T51>ZWCB'C.$+V@E75QR^=':^YJ+5[/I3>(:H12(5$
M<5.Z!W!]:E_\L_8Q%[HJ[_"%[+^/B7A3CER+]/R]U7NB]OXIT$M.@.@.@.@^
M:OE3:<H46#_;NS7'.TB9*KW''/-==O:.510;YNOI8E_G21*^.6WBSQPY=-:2
M&RV-=',,B-5KE8GYD!SLA35%7D*[<;N#F]_E3P[T%K$S]3BV<DS=4P0 YFHP
M>8=11AW09D\CF&-)C.$(@N_9&_3H/!K>/A#Y>RSO&6_)9YJJSFR/+#68:IU?
M)\O67(JJ=D,$;+9N+%@6N1AF5)_P/"1J,57-_P"<&UFEU][8R^/[#D+94"DY
M$!?Q-#SUI\]<YG4Y3LT=AD,FIZJ95#V-=*>,'QR!O,8S2HCT\45 ASR N_@:
MCB0>6T-#"R>D]A,9A=-(3@WC=\Z]SUON:_-W%4^TT>-;%KD%#FD4<N$QQ9/Q
M-<)Z]G=!W8_R2<.">0D)ME6S&O5T2SI:C$5-U5F5BM9*J;FNR<:SKYL4BH41
MA%:41$1S5141.@@)R;^S[FMCL-'657+/*V;X%Y7M(>B]A^%,OJ*&FP/.FNJ4
M&%FJVP4S)=5DK?4Q&,%J7Y.;5)J$;_OB(]Y2/#L;@L72X#-4^2H(\:+64E7
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MS_F"_P# _P#J7H#]-E_\P7^G^Y_#_P"3=!7]-E_\P?\ X#_U/T M=+_Y@O\
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M^G(SMCS0RPSY])3K:YQ^MS7'6XM<O&TL#S>^93ON0A^X&/Q(HNZM5%Z!@O\
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M%[=G(O9?JC:\_P"'9?YG7Z= (UOU^J_CW_-7G7_5]#)T'KQ9_%?_ &W2$_\
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MITEPFALH%.9Y13/E_P!T)XO[+VZ!OO\ SVU/NI/K!['V7(5UNM+>WOM1LM-
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M[>+2]O)$_P!/03%Z Z Z Z#@E'E54/'^ETJTS@M'<2_7_FBBSD,UU(S3J_\
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MMB[V-A?IU?+@U\^>N:WK(D*=8O\ B@UYI+J-HVS)Y5\1#3N17=T7MVZ!.?\
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M)$[NBK]'L[_[7U"Q8?N*^G52R>6V]G*>G%5"^:S?:Y[<P$K@*)LE),Y)%,Q
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M[?SZ"8_0'0'0'0?+9[)6VEJL;^V$F:JYE@R=D>= WMLDB>V-15,>USTI\F=
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M?9L87P<WYOO&L,S5:?T=/>C Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
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M>J=B_P!0H]GLHF+P&CVU#<"K)-AQY6V&:WQZZGU\W*Y_56DS(%QO']<6#+;
M/06%==UAISX<1CS@+4QS.9R3SUZO<(6*\=U?$M%>!YR]?N2N9+K-Q=1E!Y^]
MC"R&SY,SN%E4TFZLZ>;_ (NP,KKWCL*T1ZH)JMWSD>DR+YDB)G7S(FF]KN)]
M]I9F[=ZT5VOT/#7&>MY.W5CK;JBJ-GA*KAJOXNV&RQBUA*2VCW'(''>EY,*R
M)63Y<.%'M:PTJ-+$IPF<*F(XGJV?)G$&!S_-4>HX,I;FOXOPW /%)*9:P0JO
M8\?\K6+:O)84E1 S6CM!Y7+.UYU)6MK)Y',D%8",]Y/C<2(F:U-/$VG ^>U&
M7A%]<LOF5Q6FXUS^IT\2^O<I.S.KYZT3%R<.#'UF.PFHV'WCZ&KE61- *F[N
M>"+!;8R1MC]%UKB1H_M-Q-18[A[::KUBK,UCME@:J?3VL,=K&K^-\=PI2T/(
MO$472)N.-..TCT5/O=S K:J=3):U%/:V#)'W30*0K!MF])U6W<W<238V.M)'
MIQGY_P"IPM1B>& U"P-#;OJN >2(?&LVMN:&HQ$B^S=+EF[R99UXJ6+I)7V"
M3!BCI+(.-(%>:?'KS9X33<90-Y@,=0X>!R/=Z?<:*HSRU!8\G=W%]/%M[BQE
MTP@!L+VTT4,Y)IY @6#Y'E]X$$I#!&9G2=3W]$'0'0'0'0'0'0'0'0<?_P!Y
MS;BX[X#]?].Z?&K3A]RN#(-<2172;9LJSM!ZN# K&5L8H5ER+*49H6->[X^[
MOS?3H(Y9@M9SS6W<?;5O)G)+[&XQ&;S5+178:BRROE/$I[&>^++B#OL%2W45
MT@D5OF?LWXV-3M]0VNUQ?(,>#M[D6DP]U46W)A,ES._/U%O1W>HO(M9(_H[^
MC[#2QCPY,Z%;-"DM0A;\CD5CE<U$10SK+B[4RET=GRV;C/0:/)\=P9?.N6S\
M$V-D\C6?G"A8K$V6\,*%GXTUSA1G3OMWB4IQB>%OFCE4(5^YG-5#QEQARF&A
M=K<Y%;E(-)?4E;;GNH]#<RXX8,JES[)!ON+JV.V4,<H[QO5Z">X:+V5W0=Z/
M5A&-T'/#&N<XB:KBU2H_S^1CW< \6_0BO^OFJ)]>@F!T!T!T!T'S=<B92FU=
M'^VM&TDNA@ B8/F)\&5I&!(21<3M-DX42IIC.<,0+.P\U&WR5K7C[M[^70.+
M62;.MNZ_B+,T=31\H9ZVUO'$GE_(Z18DGC)\BM;*DU@<U->\,69>4T-HXL^4
M]1LE/15<UB^2@UUGN<9I/T$6PYAY(R-WHAUO&I@7)Q6%YP]/PN@'9_UCF39]
M6UP['<UD?L8;V%:\I7(PK^SF] X]=RG8NJ8')D\P.0,G9<CZ.-,H.5+Z"[.Y
M5V#C%?"YCR5K4/C?]?7#FJU&(%1FEE>1SVL;XJ#7;[ P;Z9ZV<C)?U=O;;#F
M3BWDG/\ Z#2C@-3'/Y7I''%>VRQ!1S7%>K4:9&'?(,UR.5O941 ^E0?;Y2I]
M$7NBK^**O?OV7\43LB?Z/Q_CT%_H#H#H#H#H#H#H#H#H/*/8KO%')Y(B*K>Z
M=T1W?Q[I^*=^WTZ"JN1/X_Q[?Z_Y?V]_^/H*>;?YI_'_ %=OJO?^79.@KY-^
MOU3Z+V7^U/Q3^WH!'(J=T7NG\/\ 3_9_/OVZ \D_FG\/[?K]4^GX_7H*>;.R
MKY-[-^J_5/HG\U_DG04^1G_.3^*_C_!%\57^Q'?3H*JYJ)W54[?S_E]43Z_R
M_'H!7-1%551$3OW[_P"CZK_Q?7^SH*JYJ=D[I^;_ &?K_M=OK]/Y_3H*>3?K
M]?P_'\?I_'_DZ"JN1.WU_'MV_P!?T3_AZ"GDWMW[IV_'O_H1>RK_ &(OX]!7
MR3\>_P#-?^#\?^#H*>;/^<GX]OQ_CV[]O[>R_AT%4<B_@O?_ (?Y=_\ C3_A
MZ"GFWNB=T55[]NWU[]D55_#^SH#S;_SD_P"'_C_L^G05\D_G_/\ XOHJ_P!B
M+T%/-OU_,GT[]_KW[=OHJ+_)47H*JYJ?BO\ /_B^J_\ %]?[.@HCFKW[*B]N
MW?M_#O\ A_P_P_GT CFJG='(J?3Z]T[?7\/K^'UZ \F_S3^/_$J(O_ J]O[>
M@%>Q._=R)V[]^Z_R5$7_ (%5._0'FU?P7OW3NG;NO=/]';\>@$>U4[HJ=N_;
M_7V[_P#)T!YM_#R3\>W^O\>W]JI^'\^@KY-7LJ*GU_#_ $]_P[?SZ#S\C.ZI
MY)W3LJM_[I$5>R*K?Q1%7H/7=/Y] *Y$_%?_ $/T3NOT_'Z)T%/)O?LBHJ]^
MW9/Q1>R+V5/X+V7H#R;_ #3\43_6[MV3_7WZ"ODWZ_5/IV_XU[)_PJG9/Y]
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MZVHJ8H84&(-Y"2"?%' UK$?(D$>4CU[O*5[GN5SW*JD+OX] = = = = = =
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M">A9D0'U[(EK6O(SY M!1%MM4151NENE*U831L?8BL'./&CN2'^6,9C+$TF
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M->498\^<)OP/9=,\8)IB.2(=%J[-OQO$5 3F[/3B8BOU5XU4;*!-CDGV%?'
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MN"<5BM<DD"B>)S!$$YAV2'-(5SJZ >-,GM:,SGM:L2)-E-:TZ-=56S4(@B]
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MH>?)F'BC<8 7-F&7[6^K -%\4241&V<9B+$G-^02*H2C'_LI]57_ $JG9?\
M6G\^@]] = = = = = = +^"_Q_T?SZ#GS^X'5!NZ;U;J)F17:PK/VYXVKY]3
M]W]FD6'.R7(D4]VI'.:)_P"AC-]P@G_D(K/%4[+T'+O68;6;K"ES]#3''?Y&
MUT>CU'*/(9:^!R/66N4,E;0YG.U!YC3(&/GH+OMSL 5'L 9WDT:IW#G3ZR\X
M^P_H#L=O7>ON+S_+U-R+45D\%&#)VLJ7J];8SG3AZ/DF^%(K+L%KFJ8,N-&'
M&3X90G-<JN7QZ#&XXJ>4_8SV"T?/._N(OZMR9LMIG(L>TRDF D+)7QDAM@;R
M]SX7U\"JIVPPP:9LIQ"_&BO.JD150.H&LH)L^BY+D6&8XMT.NR/K9R50/O<U
MK(!>$(4RIK"P\_67,<4P<>RY"95=W1C.:TB$7Q7MW[=!UC]47L?><[]O)KV:
MKB\91D:YIV/'P'Q>SL;NB,5R(G9O@JM\43^/?H)C= = = =!\XNYUL+(8;T"
M%:P;&QSNFXMY5KY8*P_Z4C#5F[R%M!DGLQG : &-.$+R4:*0K55B(O?H'4#1
M%T^ZA\YU0.**;4:WD4EU9\=0TE7VGY2@X6LL:U,QQ_\ :.+"23<0H"2Y<*2Q
M2(YJ(KE\OR@RUIC<M1ACWNOX;VEM>'FZ[G5^AT\"1F66<"NLF!#PF&J EO L
M=0CSN0HRM$@VM1OB]414!RVY U1#/EYG]3<-\+FVV)WD71<F82NM6YR5L!2A
MU_!Q:>N!(D6*6,B?WE_>/>@!L&1J,;^1 97EC4T.4LO7[B!\+! 9A_:?BZAP
M(*XI(%K15-GR=2R991@9/='%8:1Q"/;!8)R(!ODQJ,[KT'TSC_Z8WU3_ +C_
M .&_#_A5.@O] = = = = = = =!X[?BJ_P ^Z=_JG\ORHG^RO^G\>@YR[8A8
MV\T;E4WROM'RB$++JV*]K);X4*P99-8V(<B.?]I%L'HGV[E=7VC% 0)4!(&8
M*P_+YWQ@A8-0F0AJU:ML$W80V2U:674 J+ J^*O1TG.22?&1#UAT5 390W1%
M:PDB0 (6S'*)XSQOL?MWLD3_ !A5_8D:-%(Y)$N&!7NJCO;9UCGQ7D%T%UDF
M1XD":48_9'"((HXTIA1D[6$KY8L%Z1)8R 5IY$:*OA/'VLJM1R6E$H7S,64W
MXV'D$0Z>7QB<"Q>^1;L1'D*-?"-=3+*")&._")IXK?S(*R#WZ#$'/E"DC$\T
M@K&D"H_":.<A'RVK!BRX1K1'!F3)0FNC +)1C+$*.K++PEC"5P*C9)!C^4$F
M2 7FKTEAG.C!$@R+"@D;*EA=)KQUQU=%ARY37%K"J^LLVOBO$3H$\BRH[#.0
MSHR1S2"-&)RU;0.KD:KE$T:$FY\5'((KU7R?)S<MZO[GJCJUH94:=+&UP"21
M-C""4 P$C3!B8T"CLSPIT&N.=T2+&E$^[DQ8G<E29R6M6I(A2C:"A(9(G#<R
M64Y2_<.C*V4U)KE=+$V=,CSX,=6Q[5\X2,,4,5PP7('-LJ_PFC>Q036ODO<$
M3SR#-,X W1BM;<J-ELPC2,=\Q P[?]:B#\?![61]-&8C'_#;@:YP*42QD259
MXV$EID%#9$ELEE/Y%EL?!KGMESR(PZ$B-=!A3Y3'#DA:ZIMV(=!DZ!/.-0!(
M1J.:!BI,1HWRH88IH<A(3),(L]SRU JTY'!%).CRTAGNK[!"UYAO:&.-WVWU
M<9D=0I\@SDAMJ!M952QJ0!&#.:?5LK9QT[(U7R\O((A1?<5!U:T%)X62!D>K
M1QY4-93B-DQ(J,BH#_?9HBP:R0G:("65),V!&<KHY%;;U#_C4@N@2NTI&.&R
M.Q\MK4 >,:/"D)(=-BI.EA?&BD2):1K2.)),H47Q#> 1+"M^*R"83@4QR5D(
M-K3O(<A8YGN7]+LRJZ:Q6^8B%:*ON)%S$&@6D(C(VFA)]M(:*R#Y*&*^&53*
M=TT31D01W/;*@?W;94IT"O='GV2#"H#$(L.#)DC\6M1U-;HJ?"?H,./)?"<,
MBR!A$-WF!SSI$$!L.4Z @F'D-?-J(]8=ZQXYY+5E9TSTA34/7%&1 5SC:<9W
MN5HQQE-Y,<1:Q(1(#VE1>T019=/&K9!?E*-B$D4,IR2HKB5YG,Z#7S"-"^X;
M(*CW.^Z:\!8XG!EL8T=C/$6+6)W&5&*DJ?$AN5KWHVWJ%[H8"@H,^.3\+$DK
M)&=7N<B#CSRD+8#20_N*)X1[@MM&9\IV"4<:^CL25&4-B)['!CE$XZE&TJR"
MF42-(P@+%\U+,3PQRC--8D&RD644*A&8Z-CZ&*BPIGQV F/Z"W%F$BE&JF:1
M'HV0 PSM8]A/A?50U69<-<9PV'<L2'+EM1PG=ZBV3P^$W0*OP?+&=\C6A:)!
M&8@R/A.C.@HD>.2.1R%F4HX$DKALD%5Y\[(<L<_S5I6J@)[5D0I'@]KA.&Q6
MB*\*08Y8E6YTH\>7&C?(:O%7R2(8P8Z_<T,IR3J_Y:XQ&-!9 K9(VM(TXWL<
MHC D, 8S7E:MA,ARH-4Q!S$DJC9DF+&<T<AC6VM4]"H4:@FR0%^0SXR23$(6
M*24%S8MF^6>S\GF,L<9 P;J1>Q!H\PVJR'J(C6O!\%J'NX/,2:1KTE0YCS)(
M^WD"($RS''?8E+"C2H\J>YCI<B:$2Q4*5J1[X _TZQ8.P$,K@4B,;(C_ '4=
MZHCA"FK'A27A:/\ OT@0K.KFSFH2)\!'.CQY<M'/KW]ZFV8^,\9$!+^%1%1[
M9HA($!&1I*"D0 #6H*V.GE\I"&KEI995\$=WD9B0Y6.^>H/^4%&.Z.T4M)K6
M &!9K9HGQ),7],% <V1+:*-7R22H,*'*(R5)B1W/D5$EZ6=8KX1'CZ#'D1GB
M\'(/N<[G#(,\ <E\GN%+.;V!6'$&P)/$B29D2*[X;<?C:U2BEB*)P8J$5&,,
MQRR8QSM4@31ZVR+*9:14,\X^S@0[N1:""KC-:HX^DCC1[4#; 5' LD&EWV3Y
MWG4KQ'C2V$KY(I#)3!@@RHDN45K)T^2)B@C3)+6 N8Z.JK1C9+6/4$<R#:=H
MV.42A<LN+,AHR (:QI*P(L@$BS>4\ <0KUBQG2?(M.175MFA*\@BH&6"2QR$
MCD:D:1$9\BH-XJD &5I%8,XB*TUC2,HYIE=V3RE9N63\3514[!C3H:(5QAO&
MU&_=/-')#!%22, VS9HCUU>CBQDC3>\N;%B$\XAE;;U*J%Y@J%D)U<_Q>B$\
MBO\ G$] 3S_+)"EF8<F-7.;%LW6,9K9)HL;Q#:":EE6J.8,HN@ST5YW$=]PX
MQ9:A;_XQ#GOFI9#_ !;\@V0KB78PPJC7*@HFDBM1A4%9A1R@EN08&#E"D/>P
MQ &"0,ULD@2&:6!$**7:#^([C#18L63,:C);$=5VO]ZT)>@4(,@+G"[/:SX1
M17>02/A1WCB?)#CR /D><FK93RD=&!(-Y2J<KE@V#207B*@6)<4;6&-'>\+
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MX'I&8@'F2OA%^^LD\0?;HA(<.5,1WVRN)46Z/$X16@FKX =\K2/CCC._/$:
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M:P%9&_=)\941?F9*"1I8R">=WR-LIB%AP1]FRP>+94NOCN<P@U9<U#T7Y1=
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MX)_#Z=!,3H#H#H#H/GZ2K'*H/1"ZGV6/AMQG!G/.PMTUS)KW2<Q3ZG)FU?\
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MB<)6E(K#&@A;'B'2"*0&1/:^34K73#* !#H0]25SH-@U\,@R(%)T=@'/*"0
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M8JEE37]'*^,0VR7N=+ S\$:J=!UE]4$7]>YZ>[LCBZOBXOAV^K&/X#XP4/\
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MB/RYF08A.'G!!&,.X!5,<SQ<57,>Y?@^5$Z#Z$1_](;Z_BY/X_R3M]/P[?\
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MJ5&E1XC'R*P5?(>ARB$KI.>DN29 4M:5[& MN*P_SH9O]Y_UC%>V0"2]X'N
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M(DT(*@Q/MXY2H25FI!/M9*&JCM>P%)A@D:6++9$5K5G#_,A:\8F4Y!G-&F"
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M)M"W>@RLJS%<<H%V,*C.;(H'4S:^)P])X_@QK&FT,^[AM/HQ"/4T,WL5)+4
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M&R8 HVE=]F<(PV S,$.*0]9!?^JV<;YE:#Y'1*^?+9X,<Y:>X;X*,B FCD%
M)9C&I&^%@G' Z7+@L8.E(4#$(YP)$JAD4\@JA^1Z//F93_M#I(JCL(P%=7!,
M!7O7[=/A?&>A2SJP060C"L3Q)P ">>I%4RGH\P0?[QGI1&S8;B5Y7LZ!%E(Z
M#\HBJ4@2.E?<_?LDD/'-(.MI-B2JJ )7'*B,;+DPHKVLDL1MS3N^5IPJ&8)Q
M3#>Q5<61*5WT5J6B6#K(*O(QP0J&)?&NX(T(1@O"+HHK/N *"S ]BA[((,OX
MT5Y3C*YKV%"\UD]A)\18,9P9<QS(]J^V"Q8T:29$BZ".CJ^<@YPAO<&$A70S
MO1JKW:QCQJ(D@44XP-2MB&9-LAO<((BO^RB2I7]]#)WJ+5%"HC]!G-)"6&U/
M!K!!<-1$^21 6N_3"_[OY.>0LZDCU$XB@:\OR&SDI_Q&4]<9%0$V3%2$=&N"
M2*,8B(UJA?$^T2.?]0F,:"(XTB!"@R'I*FPXJO-3F5EG6J2(\HT"@2=D:)Z.
M5SR/%\)4<9)+3A66=KH4!?*U^_&Q)DJ/%5!SPHVVK58=A1=!D&$*<YJ,1TIQ
MB!:TCC19A7I9 5ODHD5E?;%O ,1%1'-AZ6&->RAM HC@Q(,DPY"?&C9#"N _
MQCS!S&2AF"L&)(AR)C1BG-EL:Z, \Q&MM&-=662#E""9P*(_!H0.$5K0(R&\
M!H\HPD0<>4Z)6%8>=YR((Q2G+&BS)2/?7E\JRT1\9PR(&"1K8@T>V2T0XXR*
M\;BFKQQF5ECY'5?(1Y-*.IG%[.:-KY.8E/[,^6J.J-#(BR55Q1OE#>QSI41C
MGQ@08<8$22MA8@L005^:!%@O>DB6*,]QJ<KTLZMSX;R#0,XX4D-3R(CI?^_1
MT%*&"6<QYP4EF@RX<)R0;(ME'&AY00N&&Y @[.M<V:-XW G*YJG*G<I/F4K2
M^1(MJ8S[6&T3!C\A##H'6\<*M:CT9%TT9GY_@M0(K@58LULDB#&7M((2,6%)
MCR0RGF:,3Z^M(DVP"P,_]18BQH$\Z(*T1'55L-AD&1P816-BA50HH1L^T*04
M60M<6(&&0\0<H)I BR:X4"4?X(Y3(IZ20]:Z>TM>09&A8'*'#^-'2RPGQ6HL
M9YY9ZH F4S2//'DJV,^501Z(YO(B#0DC+2R(1BGJC?0%(S!R!*,3G1IL9217
MB>,[7 4[F6LUAJ^"$DD(1-:DJQ@1E=]DY66]0K@J0?0)I%D%=X,1BR%D%&4)
MV&LRG2R_WN2U(U8T KQUM&;\[PQ%8*Y"B6<#XK )0N!29)62^.C32_D<]CT1
MLIUE(/)MX;X@2#.X8HE])M88GM8]R#AZB*WX3(&T"BJ&&@(P$>YDUJB1D-X&
M-FR3HJO$2NKCBD68%:>/):U\:)-GN:J]W4UMV[!*@6(I_P!.>!J%40 -&K'H
M:=$  ,)WV\8<B3-8^72CJ99_MPF.BR,_*7[&<AJ\PR] HECC+%*I/C$("O:1
MGPS8"0"0#I)?W2.\LZD!6'>AB!'\AL[*=]U'^6O*Y$!"/&2O^04CY/-[BN>%
MT8Y S!D>EE.8^MK7-5)2#1LZ7"@KW'^6XJG*BF"H*+5CRWHBO?($;R&1SFAL
M2*6Q"DHS/C"H8MA^J0&M,40D:#0@3[N)\5@)['!BF$Z3W:USB*=PU1Z$BRW3
MDG1G1HSAEDJR%;R;>(Q0!(9&QK^,QT29\-B)KU#P":2+W8A_[I!,-$D)+<%P
M$<YU?$=]W9C<U!C\5APYLMBJ)?*HMV_41^@5W-$HT88X!?!W(SPE.KA14KR_
M$V2PDE72J4-48O@)_9\B@F/6-)0E>5KD!,?\T-Q6'<$;ALD!:0Q308K@P3#E
MGARP0?DDUHJTKT.80?*5G9*_>P5-7%>Q@++7#DM(TO9A6_?QS ,@_F"\H66-
MA&E!@D0*^ VME2XL7NPX_&VJE0B$'T"9, J.>9HU17G,Z2!J1[,TMUE6_(=!
MB1C(US*MX0/-PA>,;3Q6_<"<&U#V4/$:7V?\L*20BO?'D,^(@;$IB2X;(4:9
M&9):.-92[&(#[4!3^(;X3'P;)HK$3'N!65(A8XY<5S'B;]E(,V--4(FBCJ^!
M$M:J?.&X\8,(CUB1)1V><(WG4VK7 <,C031(R.3Y5D_:-" #H\MSW4P8\:ID
MO>X;C/#(DT4:DF&1'D,UTS,R"J%ZR*DW=@90RQ?L7!>)6#^,S)45PG0/LOMI
M'WTHJ183"2ZR# EN;)EQ8KGOHWN2RK7$AE>Q M31D8XGR(5%DLEO. HQG0QI
MBLE3T0-8QHB&F1A,E2X4-Z"L0,9;57C+84:A:"=!F 8<D\D,PQ%?':=;@LA;
ME?)DR,0 AQ+T]Q##^9J*$6GCB4@_@M0.:X%4: L$#(*9SW^<>2R6*Q%/++/)
M=(K:PT65/CCB$F20L=%BR3I\5W'0E79(V6-CU!(17_)V8U6+$&-\*5$ES(XQ
MMK>]<"1%)+#\T.+6F>Z(T\U%-3G>M39(2$01T#,C2FD&01V)&-#=YN7YK2J$
MQE6=%^Y Q6_=TGZ4=_;S:I3YB4]&=S59NZ!B38GB\Q M57,;+BK'(R;'"J,E
MCM+ 985>XI(I81O$\V##3YJXG:VJE>!Y1=!9"1KG/^7\[7O,%XWC^Z<TTEC9
MLT+Q5Q Q[+[X"-ER 1O$-L)K;.N5LL90J&8]C#C+V_WDTA5>_P 6MLR3TLXS
MA,<GR**OMY%Q%'XH1R,C:B(SP7XK(/=032M''0)0.5["*(PS1SN>YA3!2NC$
MC2K%&MEJ=&K#B2)3?":-JU5JC#-$7H%2',&\PWM&)A4$!S/CD.C"<R$K8E?)
M$>P:AX;XDHCHH9)F_+4'<M?8-)#>(O08QH;& 60$+(XHZ_'_ 'C2U\< ($I3
MK&FQV.+-IP4LPG=WU?(S4M4*!2UI5:T+ S,8][2M(QC6F 0<D2B6+\:?>R(<
M^- =VCA"7_?Y4>$KGQE[6M4]PG&"@*:N#* P3WN.IW_&8!%C25E$G15D$$0$
M9S(]R6XCC0TB.)61+R(Q)\!63V/'T"=_?QRB<!Z2"R',*T@C1+8SRV,5X0.*
MXZ"!?K<1Q?$%SU:#1QF* Z LP,>X%H1U,J&&5C2J&MD*H[$+2H42$@U\F)8V
M E9(=+5SXL.9+&W[E6NI[AJ$^(J!AD8)O94GI'8%D4T<PY!ZQXV5\US0M^26
M(AJMD&<18XSRE(;/R56#-0M:=CFAAQS?"7XTDQPL:[RG1N[ZSP95S7R'J1 Q
M7RJ05/+5KR_;_*?,RGH>+\]4=Z-!55$D1R"D*JL,"2([9@_%7$+X3I48T&I_
MWB#*"%C9,ZOB/5I&M'<57XE'T"?,"]WDQ5=*=(+(;&7L&R_46V81G<(P8XA1
M;F78PPH<H!*(>@ -)T10V07C<&9&L&#>PBJZ: IED*7[IL^2:9-$D&*:++F1
MQQ+.5;QE<.-(DM:#2Q@NAS4#9!8YP72"\7#DH5K7,9'-$FLDO$Q\=@BPH*PY
MMB%ST1I'+$CS);543O*GM4^-1$0$1OQQ$1[UEP6!9YG:DR;7#ALJD&%3@64
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M%^$!C^9Z4[W09R$KR#*@9\D4)X6">-X0"812L:PM<^N_33,D/\8XW%/5BH[
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M8P@U!-:KD*Y'*0[S/$I4[#MCJML$BN"U[W#CW:W<0/AYO0<;1QA?&J@M@]W
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MD+XP"CNBL5&/'&^U6-()%AR8<JP&=T%:\QW1H\F4U7TCU=76*%@E&1H68YC
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M0J(OF=EF2>LR.HD^OB.'8R;N&SLO?PBZ.*/L_P"&S%V4$Q[3H=AHZO>)SPF
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M#4Z+"CR8]A8HCW/<WO'AS93581B.I[9K2M$3H+$@# @11B:- L:X,D<N/ 8
M<.4H87VTN6A#4PJ^6]1QY$I'GHC/=!GM+7&:1H8;%!%?)\HK835<H9 3]J]
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M]^@F/T!T!T!T'S0\N<B_X:Y/]N,ZDH9@M-QOS+1I7:$JF;=S!:;+6$4,&K8
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MK/MXH'L9(.@XFB"Q8TCX;4+5<&6>()ZDG@(1',5CQ*L\(2?$,/Z=!8EI,&K
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M*M38(YLN-XN(]G02F$BM&QKE\E:U$5R]NZJB)W5>W9OX_P N@N= = = = =
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M1%7Z('<7U79X7_/"?+\BOU7%I'=U:KO-_ '%G=Z^*)XM(B(K6JGT3^WH)@]
M= = =!\UW)W',#D>F_;/CV,.I+(HL!S;9P)UM(96&AFFWN6KBQZ5C'-?(L+,
M!E$Z.Q55XU7Z.3Z= [F;LK;$R<_@<30ZG,<Y /LN/JN_K[4%_P <9V6^"AK
M.DJ"/;)T.E2HBOD0!21-$Z0]1M:KW=!IQMK+TD;'/'S^'$2;$4+'<? N<_$Q
M<KB'?8_0CF;;6S\U&86/8@U]0%Y$&1XCM^9&N8WZ*T-WC<GSK&-!T^E@SN2<
M!/Y<OQ1L^*/ XZ/B=WAX9I-KR<6TAJ:!;YVY:YY'PBG<TT@R!8U[6JY CQR7
MQ/#MM'ZX<DR18EL^YYXXKY!R,*A$*RLI^--RM3"9IE :1*2EDA8)62GA&)C%
M7LU$3ZJ'TWC7N4W^CP_BO\?+M]%_#Z)_9T%_H#H#H#H#H#H#H#H/'\5_A]>_
M?\?X?5/Q[)WZ#GSM?M3:O0B1H_%M[8PO@#%F-!'*]&SY\*13RU68U)8/$TJN
M8]PYHT2PKG)(&\?0:8<3SHY C*0\Q>TIK7Q;63.;:C^)48A?"GM76<&.G=2-
M^UT\5C6+\-H%%Z A3O!SGL>7M+1A &9-:=TE"(M=4N)(GQT'+?)CL^WARI2(
MV<-74]MX2!B*H*$AL4D<"@*4( JDD/Q2I$9*M\0BU\&2,LX;Y-:*JF$=&C2#
MM5U.1SJRQ:Z$5A.@2%[0CO$L!$&$9DDQN\BK \52X9''&,#7DK&T\LZ.*$?G
M+R<DGRQ_GJ3N1 5QDBFB+$EIW#XGAJ:; DC8'X_CM)M3:P*U>\:,,Q6GDQ8:
MJ2*3QMZERB4@T!/D ,)Z1YT4TGY5)#>$L8D\L@UN[]0G1)@8SD#:R+2(-LAX
MAJR%HPL^]@N#9!>QP>XTAP_A&5T@Q);GC'(6/$MWSWW8GL&,\B3\,*[-:P0?
M&*0]&ATL=KHTA V8$5P9-C'0H6GK@E%X_G:X97M$I'B9 JRI*EE57^(N\2NL
M9+5:YW_4URWP\"H&"QQHY5,)$$42E0P$"^J9\-<K(+&/?,\SU1:LYOC"XB/D
MYR0]8DM#5)AD:"B[[<P'J]&( 'RC(.2)U?\ $"J17&BS QRNE4D:HD$0BC"I
M)&=FO;,AJ6N*]$!'EQ'Q"+'?#DL&0C8RL+ %YPW-C%MY@I46ME^17N8X<J5"
MB.5LI?&YIW-?\P.@RQ%0[QB<-I3/>QBL<.+9_?CL!-DF$0$=PX-_,N8HD,<8
MO"+?QF_=Q_BL@N8H77?%(4GB-YF'<!S')(@32I*LU6.!XY4KXXMLZU@L2/',
M;M&T$5KJ^>@IXAN4$P3B15:5K0]N["L**8@V20/>6LC?%,L$5Z"\G.B0Y,WL
M2,3RJ;9'!4!>@6!.^08!H@0!$,9%<P;ZQL'].<X(T>PJFET<2LDJK!$7Y)&>
ME?W!T-6E:[H$B5%=%4S7Q@M!'>=5:X;8[8207MGR?]VB#+)KXT66]LF7$C>1
MZ:0[]1K?EA$(Q ]C([Y&C) :JO&^.\2PHQQS/N')93&+'@*-):RV-^]E@B>#
M)8VMM:M4*TH>@R#"=(8JL0I2O4HT[#@V,HTFU5'KW<Q!P+8UW#%W<B*R/I8C
M$<GPV8?J&" QXZN;^4GW#D5K G#+4Y93/L(\F :>!H);ID<*QP&D^ [AC75U
MB@Y@Q%<"FXC"#889&E:X22XIPS 1')]J@JV 0<R>U[PH$B_;Q)LI/D@E5U7:
MM4#QDZ##+WC$[B4@!1V/5_@_](0:5:-:,S"O0LFE_2I\A$8B-?)S,A_9?FJ3
MKXA4<J/&"H#(\; (2(X9PSA,:R"C;.?!EQ("2"5\2 9_SGCQG*2A*Y+6K4D$
MA!("J822'_:N22XCE=&(*8%LA_RR6+93ZZ5'C.:V4:WCHV7*$%Z!MQHEG6.9
M,&\:@EL>52L\0J=3$8)C4".Z<BW+5(G@)K1Q[U+:(+S_ "JR/J(PNZI'MXZ>
M0*X3I*$)Z_WT@K8Y8<W[LQ'2"V"$KX+?U.:U 62G09 P9TIK&6 F/JK9@Y+6
M$4,.4QX'*]G8: <UQ$7[J%]NZ&S]+A38QK'YGUC()BNC1I$I''J"/=76*$@%
M$5 QQH^&K!,$H$AN<)L@<8E0(8*9_P ;8CV.,61G85!*,K_%?EE9:65'-4]2
M=RH&>2(R<C&K%6,>&IF%8> ^*Z/]EVL)HCUL"4XX@*KFRIL2"KGUY5;;U+GA
M<0?0);0N<=K7,*THF"%+!(AAG"D$G"?;2FGCPS*"[;9!&V00,56CM0(EI6**
MP&8+@4HQ(\]3I\991"O&,[V.K+:0LBP'V:C2D(.-<2KF"WZ/<UD;4Q&J$R!L
MQ)W!/,T#0L=%BE5I_P#>D.,T1_BV8=*NM4$NQ(X<J.<+718<NP:@G-3](M_%
MZ!+T'D)WPW,1C7QQ_$B,,,K:U8H(95A1&O=.4AZ^'72%='CG.A#T,ARU\Y"U
MY1%Z#..&">*QA4^$ '&*\#_.I_2W5;_D(]T4*'F5 *::]#.:#Y).?DO^>/\
M-6F<B BE:Z+,:$L9I'^!X\H2L X4U@6I:3!R*^N<UB2([WI,F5T1WD-7I;5#
ME13A4,]JH<<AC@*9IGF0S%#&FD&6P8V9*$<,5PXM@^QC#0YA 5D>]C(DR&HY
MXWL4+10.,K'$$\Q)*-<UR%!8_?+9 ^V&@C'8&'9R+6$-0B>9&Q=%&9]K+^&Q
M$Q_08<:0T*!&KGC#\K21)8GB>HGNCOJZQXID\:(P2,8Z)#ES.R_C3V[45!%Z
M!<(H'=A^:!^%D9ZD8?\ 3ECL@M^ 4F/**BDK8]/)>@0E>UTBAE/6)*0U>5'H
M"6GR5Y!C(]0OBHP2?*#["(D2J<LF1%DQ@L)+I@51RM.0 W.D9R0Y)<%Q:TI&
M("ZPGW WB<Q1O;_NQQ2PQG$ 7LME.B2X5:JL&(P421+CP?[LB>-M5*KT*+H$
MT\0KR#,HEE?.SQE (D.P?)?;_P!X4@&0W #:R[.+':\H@_%$TL<:'!\-L%6J
M'B++*KP2@MDO4I7F\@%6QD%D6Q/LFR8AY @PKN79PQ*%A)2#;H([70)Z#L1,
M>X%0SP3!_/$8CVC9]R2/&F."HO#RJJ^SC6%@-KA#C(5\6+)D,<Z(Y7U%LU0N
M$5 1RM=#'Y"BM$^.J_9RQK-K!@!4O6,T*/,AY6;;42W?&KRH\V8D/^!ZFJ3M
M<T%IL@B^,4D9H1QR.4["U\Z$R".M>R5)5D"(8LN+7Q)QT)*!%5\JCDN;8URD
M@O<U QID OW!6NC_ "-)W9($2"L]9(Y'_6]@KZR!(8V08K1LERH4-6LLD8VV
MJ524PPG!@C<UWRF;&-)'/8K3-9&BW+C29T9\F1)$Q7 9>'N(0&D*-$%%TL=B
M&%\5J!S' KM\+(#3#"63-F-23&E1EAF>]TX#8D67&GR2@AR[&3!"Z/&E2&M!
M>QAK66+1S&-=T".H"(UKG> O$I)%>>.Q\)!#"5M77%A3K52/B#B$>Z,.1-1S
MJLSGU5IYPGA,T,Z/(4B-"=@@F&Q7$;XCK&?'6JL=DR.Y7DE5/Z/)?V&5%=,S
M,Q>SOFJS-5H8,N"D9CB_:H(PR'^Y:D4$=A7P!,GS0%B5QWFK'12*V3-A0U4M
M>=4M:ISXSRBZ"V%S&C^*2Q7#(KQF 84:68:G&VTE121JQ4#,20)5ER0QE05D
M)$LZQ62AE%T&>Y%*K$\%.8[V*O8D*=]X2R:3R>Q?C;%MY-W7C\>[_BC::(WL
M[X;,/U!-(Q4,PT=%()[FG"8<P,LK'S&O@1C!E6 OBEEEC:L:'*DHC)XVNJ[1
MK#M"1048LPCQJX;QC*S[9RE&5T)IT#_U7'-%G37/-'?&*BQXQ9;5D5!O*NL4
M?#*,B!:DQ' &$PP@1HA.&X9&%K!B%7&^9 G"-I)-2&LF%0G=OR'S<QR$&A:P
MJHT,,;T TH"1&B09$C/$6*(+XOVQQ6$J%-CUS/\ <PB*[[V6""KR0G*VVJG/
M"XH6@K_^-=V?;J]QQ/&5AHL:R=*681DV6$L2 K16AKB,Q)1P1U2-=@8EA!<*
M<)XU!.5LH9?F1Q'M.1SH[R$C63S/LT0#5?YM;#O76\8"C%\B,CZ2,Q!'4%J!
MCG K!EM.PTII'D<G:8@TDC>O^^*VLA2HEG8#$KON/%\>),F-3[AK75%LU"((
MBAC21H 3R,\F_!\A(APO= '%#!1T.,^/(D(IZL,.850 D2D<>A.YT&>A*TK'
MH&(Q61"D>H"@^'Y '81DVO'%#0C&8Q@MAF/*IVTDPJD5HN\O+2B?<1E-4F5$
M!7"8)Q(U1F,%Q)/R-+!,-IUC)^I6J'JX7<D<H"/;-G0X*_)\C6W-2Y6N(+H$
MU8ZJ9K5']VA" &0A(XK+]1=:#+9'CEC1S-C6!K2(/[@L5BL#HP,2;"<*T"X;
M@R8$LLC^[*!YF25CHX0W!L'HMH%XPR0GD.8&;.L8L=4$=[&Q-'%18LM!68FN
M<%TPG.",\<@T(=J2*V1'*1T=ZH_]+KCQ["R<OB9[$=%BSIC%0;5=47#?%1%0
M$QR?;>3Q10HQG@3XHH?TP<-M1); C3!OE/\ O*L-#+*K /,CI.;._P"TE-/6
M&81@2;]?&F>'2.(%P?A;$@L,2J@Q71B"0Q)$!'QR//6$"<CB&IS->",5ZDB$
M=&*Q$"4@^R,:B+W1$1._;M_#^7\._P#+^'0>^@.@.@.@.@.@XM&VLYGOZVO!
M^W5Q".1&Y\2ET7LS9\+3*7D -/=8&LB87D.AYGG\>AS.LU%RM9>RIA(ET]*V
MC@PJ<A5N)PHS3?Z>/)KI)C+#]QN)M]+QS3V.:JN5IV7P&EI\76Y45%;C^TXN
MO=9J+*JYN)HN2=;*VULE6"9;4'Z=7PGM=$JV$82R(7])VOWA,?$W7"'KYGIT
M&FF )[D<'SF_KUD.HKH,FL#K9T.R6T))C+#D090F$$\;D*CT3Q3OT<T?:I:C
MB"<3.MR.H%O*?D#'6&,/BM"L>'61=6Y8N;NN21V3HIY>9L[J8TZ0F_(%HV*1
MR]GJU0U#:[&YD4%S7[7F$5#:8B_T6>UF3G47^'I@<I:Z=&=B^9@2:P)CW5)3
MS1$&@B!&,CNS6*YKN_0+=]M[\\#D1FET%CSKE*J5QAQ]NJ*EJZ?$.Y,T-O,K
MOTOD:!MJP<\T6#7/CM)+,1P$$$;"D:UQ'= R?L_QE6\H\8<B\@@A\?U%-J['
M00,-$)91+VVN-;A*B5"NJ-HV23Q9UI62HJG2:R,G?_I%4CE[H':SU657:#GD
MBKY*_5<7>7=&H]I6<"<8L,PO9J.<5A$5%5?JO\D_#H)A] = = =!P,"X3,'Z
MAV\NHQ1ZC-^KWL9K5T'(+/N!8*VHM+DY.?V%1!\2GL+.NG/[J,;'.:/Z_1$[
M]!&[EK=KQ[Q7+Y"?3 "/D&AJ]T[V"SNN/!W.QEQD^?0Z:926"OJ(T, R)$\2
M-#)$%S&IYHGET$&^+>(?>#VN7<\D<.9"QJN/:C5SAZ5MS7T,RR+1T.2'J<U8
M<>6UL-SMGJ;F298KRP"""DDWPF[^*J@;IZE\V;:+9AXOT^/6XVM%4VM%/XWW
M\^CN, *?=V%Q'BW]R%") RMQ7SV"!:5QCN8Z2T@Q*J=FJ'1J4>3G 2^.H&CS
MA)F7Y:]5Y4"/,SGQXZGK+KDO/)O\]PYK"QT:KELGC D9C_A56+\;43H/H3'V
M^0JHJ=^Z(O;\/Q=V[_\ HR=!?Z Z Z Z Z Z Z Z#PJ(J*B]E155?K^"=D[=
M^R_1?KT'-_DB5^G:75S'M'(CP9UP=4%+GF"6/5B6UD0COD_#/@QZ]XOG>-[T
M/4%\9T)[XRF&@1IP'M9P#R598/*TW*&-'R#R3C:O<9_BTVBR=]K9%=J*(FS=
M&^RQMW=Y:ZLK?.Q76DB%364H5K7 _6Z9Z^#U4LXS'R-+RQ^X%ZR\6;_:\>:3
M;396NP'(?!''/)8J^#76L;)S?9%TD&3T5O;V-A75UAGX]?! E_)C(HIT.5&8
M43;;Q3HL893%_&AYJCVI]>ILKBV/"YRXPG&YI8R1Q&QFSJY$CD*.ZV)DD=GI
MDPZ-L)4F\$^FA'L6QTM9@7T=BS]0$QW1-N7AP;-NN?.$./\ 4P\1O>8N.L+M
M;"AFZFIS>BV%;G-+'S]' T)Y&K"*XDK8U>7J(&3M&,N)XVI3.@R*VP>2(HW=
M"(F=8C0VTWVZ]8\_AZ#D*V]AN(*_#:R\LJ+.W\S4Q:.BN+;/.!(N:Z 4A266
M;-D"2AGL6F&PN.,9A5<ZIEM3H;<N%:M[-[+^NKMCK^,;'G#BT6TX\SF@U.PS
M<K35$6PR>8SD.+H].750H5BH8E3FJZ4&TNH<4KRT82@NH?QQBN8HVY>&A@N2
MO?[U&XWR]7>FYIQF\#IKBCJL[0X&THMMI=6W4<G5?$K[2%3 L84#1U -Q8>,
MV5#../?1(1["M5;*(4;BQAE,G!W7N/P9PWSO#X%Y8W53@ME=\:UG*.>TFN)3
M Q^D@:79DXNAYR)H[6?%#>;2VT$9K7"-'!!OJYX62BQK-HU<(QF8N!RM[>^M
M7%T3F>=:<J9K0;/U_P"/M5R5R)QAE+VFN>4X=-A<W$NM'&K:*=9QV3KRGII@
M&!66]LF*"2RJOF#$0)^A&,S7F0KOW<]<,IRGQKQ*[D*DE<D<D:>LRO\ 2=98
M4<25Q\]W&&BY@A6?(9;"P9)P-;5XS/E[2#_='STB4"'-&2GE"D-&W*KY-ZB>
MW_JC.R=#KH_L5Q '*Z>\?AL[:R-725T*YU04KK#^CX,($EUNMS"2\AS618C7
MS:%DP%C7?<54CH;<O M[KFSACBO9YKCGD?E; 8_;[R1]GC<3I;J@IM!;/LK$
M-2C4I(DH1  NM(9HD:!0BG3G,GTA'2E+%<2IF+C@U;UP]J>-?:9G+TOB@EI;
M4W$G*FGX8MM+-_I.QJ=?JZ)KTT*YZ%27EA86-861$>-_ZA%J!ZP84G5S$E#5
MSA.,X\4CBC23&#VD.)\CQ/&X4F+8%^>P&Z)'* TD+16BV8VN$&3):R/?QT6!
M-0<X;"*1@,5\*1';]PU%:."5#-.B"*P1"5\.2"=,1',4!7NB1I<I'. O>IMF
M_$H3=!GC='^$CB%)%")!-0KG2J]*W[.6\+6H=[2R*T=).=X-4OE(SQB?$;YJ
MTR.0$V0!(R(USB!"QDE7H^.>$V$L0S9,U?BB,?,B1*TI$/(CQG.+2G>EA 4D
M(A!H%1O<CCC5ZJ1SI/E&6&(S7+([616+ K52.9#PU^\DQHS_ !F(GZK6.89I
M1=!D28C);55C7'[^96M& 5L^0>P$UZ,*[N*-;%M8K%>YC/&-HH[$>U160OJ&
M&,[X\AC7L<17H,Z=O&<LA)Z.K1S@RIJ#B6!K%C71@%D>(K8*.@62#FL$5P*B
M.1$841%:(2A>"0TBM'&%V? @O%-L6JZO% +Y10'EM4D,CEK+-K@.&1 3G!/&
M12-(R,R,]OR"5"UC!,K? (7">A"3ZH=+*<YRO7SDYP[_  ?\U2;\H9(#F!\@
MRC:( (DI/DEC,%6_#\,Z5"FQJ\Q"08T$Q4DGCQ7.)3E5+*L4D(A1(&<:&22X
M@GM<AT*Z(]31!%(]I1LGR*^9 BF$":AQ.;()'B.:RT'XV=:K)3"#4$A5)Y 7
MOW4KPC0+F M'H6RBD>[YF%>")<)<10JW\Z#C:4#/)WP6H/S LQ)#)/Q"^4BF
M04-L.6AQR_F).&^-7F9(LG-9)(<+%B1)LQOPV+$6LLVLD,&103B@$(9)+1HP
M8VA.1PG.C#BFBS&06$A'L%?(A"@G5X!3)"$-4%>ZML6D@O&1H6Q/4+E1TN.)
MX/!S"OB)5-#^G6+G/"16F/-K&U!RHUJ,5YLT8GFBGJC_ )04C"#)88WBL27%
M=8...1 $)0. 7[J5%-#K"*X<6-*<V3+@QG*:N(Y+>H<X"D'T"65I$:?XXO>2
MS[E),;X8)E(^:$<\HGQ8*L#8!MFM^Y*R.Y W+&)95ZBGC*)P*89'W040)!F<
M4ZO<QXZVS>]\\2#<C$,P4&_=;P44?=WA%U,9OQD05D%.X6C!.4R*D@96.8$R
M2!E@*$(R/*"-)C6%BUC% C52%%GR&]GJCJ:X9W^$W08<62^!\+G%8,(7B=',
MXJPTC_9G^R5GW$T1)-<. 8GVX3244]&1_P!C.0L$HRH"H<33-,QX_A$%I&>*
MO?7$@NK3(=/C:%II52RK.17.&Q72\W()]R%35Y7-0$-P9<5TEI"+Y$62K@&C
M*@Y;1M;92QLBUOYAF8Q&RI<>(JL:[M:U2JBF#T&:SRDL"CR_<,/\[E16LGN5
M\L#9I?E'#\8MF^U!XE* '@&\ -)D)13QO8H6)$97*\;5^Y<=6=G(UEE]XVP!
M\,=WE):R);R;6.BC88OA'O@,6-+^*Q$QZAX@221B@\U8]K_LW@E#<CGC)XNJ
MHZ+*L4:Y&D<[[.+*E-3NG>JLT14"9045 LB+Y'"P+!J!RD:*37J!T$C@BE1)
M,E3SZQM9**X#"&1YZ _>))0M<5'(&"C309'QD V,]@_C$]T0E>+[2K?]T^/(
M''(0U8.LD/:4C >4C/R'))BJ6N,]C05FM9):B%"]KFO*V0P\)JF:7S=93X,F
M'7D5DAY7*R6>)%5K7M1MM4N\E*+H$R3%,XDAX/G<I'^<J*\()S9)Y:J9[QQ
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M!M@(EA 4<T9&*"8@GPE0HQG*ABM8$JHRUD/):L1@4<I7CBW);T"H-I2^$31
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MDW&>T.(JBN.6>4YVT,TJ5K8$>F6,08G.[\SL^P/HPG._(?(&LK^7IN"Q?..
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M,R:QK)GB^IMVM*T9>@L%AQQ+\S&? 021G1)06@@B$.$K@-,"1*<:7 96G?\
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M'(Y?;[@B+@+W16>1S/(\KG7BA<E=;"F" "Y^EU,S0?HEUI,S!E)$D1FE+)+
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MV=K4VM7#8H<W7EARBS'2)C6/(XY<IB9N)BM#&_MF^HWO/^W;QYP.L3C29O\
M%\G48<Y[C^OECR)@I^^X7Y0H;&WAY;G?@+;V.I=D];QS<XY84'18EUO&;#.!
MEA2L:<DZ%(+GECG/X)U_NJ\'\J>P/#_KMGN+.(97,LC#>ZWJUS?OL/\ JW'M
M2V5Q;Q)R!&UF^C%;R/I,[F+B;+I@.C@KGR'-F&)X.[#\GH9PF(F;\)0'Y>]
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M/1<3?MG<I>H%39Z&#/MH-+SAL\MP129_D;*GFYN3,JJ&IF<5S".L1C!<1V&
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M/=W\!F#+B^3?)WT16]NZ_1.K=C)JLTZ#:'NIMI)L[*0!T9Y"""  Q*\;T8
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M[@H8@'J^-$#$"GQ/<QK'N>9SU>9R]E[=T1$1?PZ1-"]6YN76U,FG%<*:*0)
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ME8((67+S?Q+NM16Z*$L)HYEA%F3JEZJ6UBD#2)B:C+Q)'#'$;,U[E;S3[[C
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MSE$1.B8_1D= = = = = = = = = = = = = = = = = = = = = = = = =
M= = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
M= = = = = = = = = =!Q3V5;^K>WE/$DS. VFH/9Z#HZ[+%LY-7SLCW:SA
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M([;45,^U-\!&37D"J_M^.*^7+P\?E^,I+^I?&G&_ 'K'AL7REJ,XZ+R[J(@
M97D99,+*W&TLYD.BH<AB<CRC09G0W]A=#S\&?,=+JA2]!=EDW;XP?O5:VXQ$
M13&<SEE<<FK<47VO]1O=,TJDCZ[D&RW<J+:[EN:RU_SS[(\TY.6Z1 !I^>.;
M]A'P_!/J=Z_X20606AR=.X3WN@H\'9SR!))CE\?Z-1-XWRC[/I'&9?4-!FP[
M*%$L:^4"; GQ@384R*5AXTN)*$T\:3',-7#* X7HYCFJJ.:J*G7$970'0'0'
M0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0<H>1*F-
M9>X46\R$_CW:;:'RSP]27,BVXQYYY%T.!RE+-JK>_P U0[VPFZ7U\XMT$'-:
M.SE]HT*LGBCVQO[P<N6TKC?Z?)U>Z,#H#H.1W)4K,47N!45U"O#M-L=-SCQ%
M<W@;+A'G2)M+.FKI4>F--K>2+M\SA']2ENT)PI*AQ@CES#L8TGZLP!F&X_Q^
MA"IM/!J/?'<DJKG-U/+]MS#DLC;09VH]?ST>GX@FTT\AZ6N%<3Y?/2:G/4<!
MED\$&4!H+ZR#"97?ISSG<7]/DR.-=E S/N#R/5:GFWV.J:J[]I-%14-7@,'A
M(/I_-U]YD*:;1<2;G;.X<'K9G*MC&8X]@9+IT8ELX,']2^[[0NB3_CRX?5V&
M7_L[]&'(?]Y' CY*X,]><LZEFWA2^Z'!-E"B5\ML&4"PIF:RQ@SFRB(H!LAR
M8S7N^5'B5OT<UR+VZ!A<:3.\+O=%,3?9S:5O(^<%F*JKKXVEA[A+=2CHX>W.
M,2LS^4M]!,8T!"HT[V_)V<C%14!%N]=M+;)7 P:7C+*BK];J&<@4>:KPYRW%
M[!S9<<G'UOHF:5B1K7"@(A1&5BD_!P_+R5.X+NCY(T@)/)Q.0;*MM /3C#CW
MEFTX/HYM3R?;\A7=E #GIN.T<^2 ,C-6,N-XE&)[H3O!Y%_NWHG01K]N>$X_
M*''/+FJAXP0<E:'L)5.[4W"*NBN\O6E';UAJ1A&#D:&!<POED :\@GO'Y/:C
M4:G0=P/555??\[F56+\VHXL=W8WP[JW@+C!CO-ODJ-(CFJBHB(U$1.W03#Z
MZ Z Z#@6*)"L<?Z86$S)@U(,MZY>PFXJ;NWO29REQ&CS>ER<N@T.AEM/$4E4
M28J"*%RN:J+]6N_#H&.Y&Y$-QYE;?DD@-G3[79I6<C?XXUMM OL1<WLL3G7=
MWE,;)<)8E7"K'?:.FQG-1JJU3>#U5.@YK9NT]H_8>XV^KX4XJGZO$Y39VK-;
M=W>4F65SQV&CR;=>W7/;'N8[9%KKZ\BM^SK&3TEH\8U\2=FH#[>J7L):WL*K
MXYW&3U.PLV4UVPO"V@JYN?G6E]HS6Q(&F@6,$D.];4V@Q!;.CSB,EP4>\;E_
MNU<@3]*R31 #Q]]M@K?5<4\D>KT"GSQICWZ+B?#[/DB@D[&BHM"DLL?41::4
M1@&QE<10O5R(YZ]UZ#Z%!I_>F5?YM^G?Z]NW=%_EXK_P]^@O] = = = = =
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MI7B=--NO%UXZ.8Z Z#CK+E4EK^XO9UA@UG)HH6EPS#Z+1<QWG%MQ@KB)!NM
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MXW2ZFKD/(Z3)KG&>,Z=WO$=[4)T'7?U1:S]<YU>QR/1^GXL17M5JM>X? ?&
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MV>UW=7(G9>_?Q1%=V[=^_BB_7H/G0]_*+:9KW-#M:NFY7F97RQ%W8W68X/\
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MW5[ 'YUI'#^UG%[@81"-5.INA?V\O(Z]?[=\=W^/SF]QD+D#59'1\PY3A?\
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M<.\84$'B[VIS6+J+O2060\EQ%PCP_BX4>SMZR,:^L-GQ_6YJ])@]O,MT?(M
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M(OS/(=?%OY45>@C1R?RQ^X%%GRZWC?W7V$A(]I<B-)3A'BVZ*%*^L^<,*?\
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M^,N2MIL<M<<>[#0T5]-QK<O35DU;U+VX?+DQD9?YI%?"=*@O:PS&>/96$:-
M@P_]Q+2!CR!QKG<O/6<93LQ*=(IJN5DI?"[9,FOI=?;&/8,MCBD.8\3T:UCW
M# UX_)R.50G?D-CB-_CZ*])HJOC[0X_)X+C#%Z U>SE FUS]Q;TVF!)J%9*
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MOBE<OCXHOU_G^/0>?L9G?O\ 9U*?V4-O^'_JM3OT!]E-1>_VE4J?R6AMU_\
M\<O05^SF?7_<ZGZ_P_IZW7_DKD[=!1(4OZ_[E5?5.WTS]LB?\=>B]^@%AS$1
M$2'5I_;06Z_\E<O0"0Y?\8E7W_T9^W_^QO0>5ARN_;[*K7_3_3]M_P GZ;WZ
M"Y]G,_+_ +I5)XKW3_J"V_\ L:G\^@I]G-7M_N=2G\_^H+?O_P 'Z;^/0<N/
MW,[?@2FX1Y0@\\OR2V$CCZ/?\65MAE7VUG$W]-H11:G656=E%J)%I5YB3-&:
MT5I4"*+W<5%1$[AQU_;?L6T4R@N2[3"YJSE2=M%-KM13N=33:\\AB85^&J#/
M/_3U':S)CWQ7"5[SL\55PD0;T#JUQ?3<HY_B35U]<>)GA2&<@RBX6]UD;:\J
MC-%KB Y)Y'P,NV<>T\[R88I84:.@!1@G3Y/D:OGT$(O9<98_ W'+9" -"E9;
M4FK8EA7U=G["W4>PK9L?C.PU,"$WX@_;F8-KI#U:B!7^X1?SJ@*?[06G](LG
MPQRO6^Q3^$ZSF4U[0DV\K209L2OE4=CGDR.5K8DO6M_1*[DRQ*>=#LH=0=DL
MKWC4GDKFKT'.WA@_'D_V)Y,MN)OZ8J^,8^EB#X@IY^0;DZC+)7:\\8.4Y,S$
MB;*%?7M=G E<!QY R(#XR]U<J,4.\6-)KY_*NSW-/IL3*@W>'R\(V_O]/#_P
MKY#ITDLKLI@*#!V[@4&5FQ+/YQ2"I&\SJX;O&.O9[@:GD9^SBYSV/L+]8;=7
M#U+X\DO+0!QZ"%HI<CZU' [A#+-EP[7&(+YPM1[E(K6]VB7OT'-C]ORY]9<W
M[TZZP]GHV0AYBQ9L:KAK_$2JG M84BVK84BQ!O((XO\ 2!./G9^.98;[)%%"
MF*UK%1SN_09OOIL?6+2>]&:LO7B;ER8X@,9HN4+#CVHCTR:V==5\D7]:Y#D2
MNFR@SLR&B''@67V\=(T;XT&UKGN7H.@_'+M)K*+UW@5%CE[&QRNN(9@\+J%P
M,+B6Y*D@U-IMK7QC1@:P$C-*Y7!<3LIR^2D15^+H'HW8]7;<K\<_KTNFO 2<
M/J9U+85C<\SUWOLTME)+O+WD&9&B11@M)CDA2!D5C4&=RJ7LO;N'!3F[^A0^
MP7'E[S*F9L^(@W5@3FZR=&OX5%<5U-O(4]EEQS<Y43=18Z2+3,9X(-OR2GM4
M:(K'?4.DG[O&O]%]'PSQO"X*D\+.Y;E:0U)17&9R5=HHM)1WF?%J+C&[)*>7
M7%R>IW;9D0L-TH1)QIH_%514?T"-Z[2'KPGNLV"=76PK_'95MGQ^N@6IYIVM
ME65\,.RH(?(0P#L8$B,=XBB$P;1(POQ,8=$7Q";?(<?DJ)Q!0U5]?RKJ#72^
M+:G4?X/RZ^VY?R2&8UF7Q>CG'=(D65!$FF!]_(D%(BL0B!1I.S.@Y5_N2BN6
M_P!354*-QZ;0Y\_'=P!N'KTM<=GD=-9 V%+R(\059$JY!!N/*0+U(XSCH5Z.
M8UO03 S'(G[8(?VPI.=>7BZVT<#B^[<F5#0S-9OI7(>3MBO??YZDT!ZK:Z[C
M[';>U27&3YTK&P!/4:_&U4Z"%?[<=X2EN*B<[786CN!:'9V,[::6L;(Q[Z"W
MA1UR-EQSF9BS@43)=F]5?(&I7G*5516C3Y&!UTX7C\BU> UC:$]+GOU'4;>3
M$QNYV(MSK[JRC5C0[;>X"7*^YLZQTQSBOKHX$:Y%,GD\[.SFA#+GX!TX'XO?
M-BR)L710=+6A@Z>KAV/L5HZ>SIK:-FKC3P((GQ"GIKF.BA(OC&0*J@54G=.@
MU7]G+8^F6,Q'*\/V6E\-9WFEDC&GO9^Q;8"IV9?X2X_-B?*U 792HWLFSL),
M60*N>.>7Y/(B=NR]!!+!'XNF^T_+LKA<%+6\9U&DE5G%=7.R)\?48!T+>%9%
MSG(])-G26:6QCT;YA(Y#D"AXRL,54[L7H.ZV=?IYW)^AUU/K\;.J2\>P81N4
MI^B97<376;8ROI:OCT>!M4;3UEB+4,.PDC[1?G&J/4;%?\G0:/NV[98GLT6^
M)20[VM-&CR2\E';$P.>OEJF2ZB-P4] DM#ALZ*.Q)#&(I?D?XC_N>_0<M/3.
MU]>:K]PHUS[+0\S78RVFS/\ "R)N:>SC6D33ZG+5X0@L*NHANS4OBED=9Z._
M55^RB'5CW*CWM7H-M_<@UWJCL?<CC*3ZXS,6>AMJW)7_ "W98"F%$%LP?/(J
MX6BP.\K9!JK]-S&?A) M@#B?;QD5%5KGN14"<.%;>Z3C?@ZMJ+#,Z&70[B.L
M*BP.F3$RN-='9&5F+VNW+7DB-UD059%E_*TI5(JO:KWA\_CZ"2>OE;2SY6XQ
M';$H=#3R8&PG5<RF96/X,U-%$D35W=YRRL>/'@QK/Y@1R!541PB(JE[]!P)]
MITS4GF[#R^2F9BQXRJMAJ*CE^\&"^B8&;C9.OIK2&#CVZSL4>BL->/+^:0"H
MC2>85")51R=PZ]>^',G[>\?CKAJ\XMY!J,+N9OPXC/<J<,9:FTG)_!G'W)=+
M6:#:3JR+9R?M^*^4]QE8C(4>Z+!-??*=R#80K6LZU$UQ.'G"!8-G54W&:\9\
MIYN= X3S#>-N3\S5<2W![MWKI*;IX\/TSX8XYU,J)9F]EO=GFSD\@]/JFW#K
M"CAO<J3 O&X1C].7E\5]5YW'^7X^/RB(/-E^$-5.]EL,[CKE3>R^$<;:;^+J
M=KF>2'7>UUWL$77DT?M+HN:C4^JQK;#:"LZRCS4!8N>V&/BQ62:Q\.K*Z*\%
MK73@DY1MUC\W].7QI)=T7NF9?2\7*UWC<ORUSIH]9IL)G>!;;%:<9*36:^UU
M=E5\=;K'Q,S?;6G;CN"6.D:<X*XI),:/(5S5'(^K=^6^:;/SU=8^/QYF#Y1]
M]N'N)[2EML/ZD\7W4*\XBP?L)5ZZ+3T->>-A.3N(*+BOB#1R05N/61'ERN9+
MB+Q/8B&=7U](WNU_P]XC9NB.$-1AE/&9XU\?B>_2\I>RO.V@]M_6>FR.IP%+
M!==X/UOYPPM%JLYCJGE+B7+9+1:OB+D'7UEN&8W,[R_=+@"M*W])"&L^[K/G
M'/6(1]UFX3;CC$93KXP:!_#7$?#^&QEO[#7]GLMYQ#E^7]K25'!%C=4G+5OZ
M[RM317/M!P-LY@M+L8^GSWKMI=E\Q*7+7\6U7.USP \ RYX)4J.?)=V4S^7A
M/CX\I^OF3^5.2HNHU=)H/9'DJ/QABZ'59[^GM!@IENEID;<59)O_ %O]ZO0_
M51*N]FW61Y+PMBVAY!Q%@LN"^0AA':5B&9-F4^/QYPD5$5'QXQ/]);S^[A+]
M*A8'A[/>N4OB27S3^H; =IJ\CB:6RCVA9@&;'29FWFYR9 K\9RAL-=;MNXL9
M8KCFGH]7]FH[RYS-S8<[A9L6=P=R3B,[,B7M1H!TMPG&5?>+0\P;6N#6U4G:
MQ6<G 0<^+9T^A1WS/(G9L9/A^,S?SL@F5RJ?DU^&QT:QT[M!!K]ABH%C,X3;
M5V.[J+]]*PN,R.T4))<R3G8<HHQRB22G>82N<)_\$#D=^Y8EH2YL:Z!%XP%(
MK-5C$@LR4!L_BZOI6?(#74O(!@1B_;PFVY _($!%7^^4CG?(CF]!-W2\F_MC
MB_:ZCT5*[B^3I:WB^HD5M$+.NU/(T3D+-6C*X>O2BT1Z[8Z/%Y796IC1I<LK
MH;*]4(GD-.@AQ^W9I'47Z-+?JL-06[;#9U]SIM%&^2CC1)IF-PQN.ZIZ$7+5
MNAG2$:,PB/4S7L<K@-8CN@ZI<3UO)-!Q%J8-4D.@?8FY/M4P%YNHV[Y-,8+#
MKL-QQ_:6#338T^S.=YX8(_Q, PS&O4C.[^@A7[412OX/P4&0" >/<Y#7AIPR
M8PI/L!8QOT,ZXNZV5>",6(EFR:#X4(KOC9'*YX%>GGV!0_:(V/HOGN&>4ZGV
M -P;5<PS[RBE;%FA;)# ET&@SW]+96KIC:L:4==O+CYYL2=!I"LD'>YCC)Y.
M1>@YR\+R>/K'GKDN5QF2A@<;/THP\15T_,?T?4Y.NJ=;(8[,[_*3+&9&T>AK
MJ*.[[=9)PE%'\3.5SE:BAWCQ1=K9\G[O;TFQPX*VWS&6K)_(%YHQ?X5<@9Z3
M.CCQF$HL'/8RHHYU=W-&ER&C\2(]KE8'R1R@UW*3]A69CV4N+]L"/?U^N5EB
M[EI!CHQ6[2!+%HN W@$^?(S%EG>X#H]'&1_;NYH5\N@YQ^B5OZTY+WSV9?9E
M,O SLUNNKN'0\AT]A&M(AKBE@3[1-K7"C.R<CC.%2,.0)K5OVL24X?BY2.1_
M0'OIK?5[5^\F5O?7(V9DX0X\?JN7;'CJD_1_ZZDVM<0$;:XSDFIL9$.=D853
M'B5]FV-%0 'C42=WO7H.A7&QM+H*7UPJ:>US=G<9S0/)7I@]$/"4O%=XXLB>
M'2;NNC$C@V<>QR3',5AS.=\[41"L5RAZ!]M<[66W*_&27$K/:"/(P&UL:VPJ
MW4 /7N]R#9[Y.DTV[(Z-$5FF?-1KW/[>".54*C%[=PX"\YCR,;V#XLNN6Q9J
M7Q4.\FAYHM2U^BCX^SI*#D"+8K8<;6N5&W36.@BU0P(%1-5Q%'\2=QN[J'2/
M]W+=^BFEX:XXC<"FXA?S2FFDU%!8YK$ OFY>EO,[$UE_EM\&H/7S<1JMH"1!
MD0#30.FEF"5G^TY_0)/KDPH.#=IEXDV!:.TN:S(;'C<5FE#RUM'5D"*?D"GJ
MMU#:*76O;)>XK&M[ 1C5$QID<J-";F\;R; X7IZB\T?ZO&IC\6U=T+BF9"M>
M8,;9D4!L1BM#/D/DR#Y]SBM2R)),3Y&/?\2-*OBT.6'[D\;0"EZ*M@5V$_7*
MV;QS<A;@Z]EAALV\=F6%KJ_DB6:,0<*)9J?RFC$Y"D(%?N/%S4[A,# ;[]LR
M)^US(SEP+BV7I8/'.J^[S<6@L-3NIO)N6LG6,VZQ]%HWUNQVF+R6UM13@M85
M:S[1CFL7XD5.@@K^W):AI-#GKR7LL503':+;V(]E;5?? RL[]G"=FYN/S!VR
MEJ6GO'2G$>QY5>9[F#0;&J]H==>)H'*U#D=7'I"9O/3[Z^ULBNQ6OV3M9HMA
MHH-')_K?D/$$M"S)=>[X3--6Q(KF.:C_ *//V[M"*_-$I0<#<?R9O]Y7W)[>
M.C=C!KY'LI?4<P-Q IYLVK@Q2Q30:&Y=\L)Q$0:!#Y,<I6JWH&P_9KW?ICB,
M]RU_F6NN%Z/F)[<O+D6>T9,@U@,? ER:"C_7)6H$[)5'**7]A( 582BL)8U:
MY6JWLO00<K9_&1O;KEPW#D*DK.**6^MX7%&?GY<V/A8RQC[ )HE)R1"?:SWZ
MT9([YLNM;(,#[F.9I2.8WZ('=;(S+^QY;M-A4;/-!K8W%T..[D^5IP5?$DC&
M1B"J)>!7"R0,JX%J;7N>CROCD1Z(A$']?E4-#WP-B5/9]UBM9"O8U;6"NI')
M3(<?CG-Z^56?)3R>'B11NL)'RY6.+Y6B:YZK_P!"BC1>P<L/4*P]?J;]P"JT
M'L#%H(O%=M;M+QNS=U%M7W\+<:'(0H4202HI8Y: W%QCGL&2F6C?L([E85_^
MTWN#J_N6IZ\[SVSXDC>LE'3RV6E'D+[EVPP''4ID+6Y>#:OK(NEP_(U2U(<2
MCR5#"/&M_M8K8$<*M\WJ]>R!-7$YOD2ZXHX9I*.+'M[,&Y-*S]/FI5E@I&,L
M7&6NX_WFL* %>G(%.)D9YBC>]1N5[2^0/)6N"2>^A<GRN5.-8]ZW^JAS)6L?
M3R\U4-C\1ZN(TLEF_+S4/[&,$+HD6,+[9ZM&]5&U"N<Q450X%^XF<E.Y>S,C
M:8^"3"P-SJ(')ER_)ZF!Q+(Q]A;4D^MK,SIJ* VY_K1]%]S&KVPGD,Z0/XHS
M7*J=!T\_<FNO2+=>K.$A^MU#@M!R[53,C<89V=XX=K]!QS3Z[+J>7*Y;I0%@
MW64G[7.5:5XY=P-TTL]&B:U2HO8&F]-:;31.$M53PAR:F9?<;5%=.I[^NM:G
M;:_8EA*3;XRMY"6)&=CIC:R,HF 11K"([P5Y%>HU"<^IKN4:WU[A_=)?BQ24
MN3%)K,)+;><U<=XJ5?3[',9B-H9@R%N6^88RV!C%>-C&.:X0W(T?0<Z/W(*K
M:3:#],;1UDR^M<+0GJX7&N6/?:.5K06=7,V,OD"KKZZ4U2MIU)^I)%:LA?%[
M'O9^5%"4/J5>_M[1_P!N*ZSV[RN$T.EC9[DZ/R'G,WC]-I;K7;2M0>VT\#B,
M5W$AZ/59Z!+6&?[6ND)"C'8H7.9XJB!SM_;[AW5+?5NXT'V%5$-N8DH7(.JP
MDVLXYA<8SZELH&IH<_*AS*RK/,L!C"6<$A@NG>0PL=V5Z!V@X?I>7:@W*L^C
MC4U=8VN[L[27&VVD)IA\D:F556-A1;OC^OM'R3YB/^BGB-@P@>#R$9V:4BIX
M-"+/*]1K)G %!8%S]C.HY.VDC/)U^=);\Z7%+#:<>HBQXL&OD!_IRHV"R70A
MR4$'P:Y5<Y[4108C]H:?ZZ<7V_+MG[=4V0Q.QG546WR^LY4R^AI*4..H-&]"
MR]O<;&LC<=@Y +>V 25YHQ$F3(/B]G=K/H$-=6WA6Z]W^98_! ZRKXFJK3;U
MV9HH&5EY-U-M:TU42._7O+96*[G(:C2BES("D6,R<$JD_*)&)T'6G:/T]I0Z
MG:T>KS!XU?ZO;BE;RA373J;CG)54>A.S6<=3^/&(*L76/LR-;'F>)/%C5:K2
M_P#2H'7CU1(C[OG5J.:J,U7&#>S4[IY+P)Q@YSFO[)YL=W[IV_*G\/IT$QN@
M.@.@.@X%P3T0LMZ5&/0KI+\_K]SG3Y2)_4<C,K4$TFQRE7J],"X&US03*:C5
MQ O<[Z/3NWMV[]!I>GQF7@Z^RX;L;'%N-R!I\-@\'S1%O=!H>1=,V#7FMPS6
M1'#)2+64<UL@5F9'B4KG,^1%[(U0@G?>B)>0KJ9KH=.X4.YY@T.5@6@M2N!)
M#UU<]*T^S/EX\9L%@YX.SITN*K%>P_X,>WH)'\4<0Y[UXS;85\-ZZB#IUX5E
M\=ZS!2+K%3YEJXM@?;/K8]>2UU$0<RO Z98B.YSVD[D=V(CD"4F!E1HDWBR=
M?5?%%UM.1.2\'0\H4L.79UL#!V.*LGBX[#Q90%D''7V@QO\ *4QSF%CC56D8
M]5[]!UZD5\<12-*6(UWRO[H70B85'=U\O-KD:]J+X]^W9.W?_@ 2L"K?)'15
M;X^7E_4(_%K?JJ*]?P&U41?JOT^G0'Z8'LCO**K5:KT7^HA(BL^OYT<OT5OT
M_P"#H+38<)W=4D0/%%5.[M,!G9&_[3E\^WT:OT7^7072U81=U*L42(Q'HI="
M-GDQ>_B]ODC5<-R(JHJ=T[)T'@=?&?\ 1CXCN[O%$;HA?55541&IV57*J)].
MWX]!=2K"Y'*U8SO!Z#>K=&)4&]51/ CD14&_Z_1%[*O06?LX2/<UTB WP7\W
MEI1)X]OQ\O)$3NG\N@O+5C\/D_W;XU7LA?ZA'\7T1.[?D1OQ^:=T[IW[_7H+
M"0(;W*UI83G)W[I_4055$1WCW7LJ_P 51/[5[=!R$_<Q]<)//VQXEIZN'(+9
MX[$;?5'!&T/WGZY0P+FME6^9EYV.T9[H4X0_D$%KT85[/!S7JO;H&-HJB)Q_
MG@@P J33;;<92HV\.MY:X_++%C)]!;Q*)V<K P:R _*6$2L.28!)!&,&(#/'
MR:U>P2=@OX]S<"?6YO(9/DP&?@+=\47 =/=0=3.O^4B"B<G+,N"&DI74E6"2
M4]<-[B1WN U6N[_1 8#<8?)9_3W7%II&0G0-Y_A[QC@N7B7E_H.2)<RY=+*P
M\*&U7U+8.0GE4=B=KAD(YS6JB-5.X0PW_HV7?:S1ZB15&FUX.7S8[[Q-0+C<
MIM4 42OJ=W/RL:-]E,T C"9-<2.GF6,YHU5"JG02#XIX?I?7W/%'JSV#;["[
M]V")C])AGW>-OIFF>5EIO;&'&@&M-96N^9CI,@)W%<CF^2>*KV"3&*@X^1"K
MI?(M3QS=R.0+.9BN9,; EVM-!PV$S4]]EQZO&^8BE^:'H7/)'<[Q^.<$#?%6
MN[)XAA<A-@54J@Y4N\]@#5=]/T6GTN!W&ZO+*KXI%GZB3!I[BB/3Q7$>NBID
M:V/ .-!(<K4([R:B=!"SE?U&9RS8TX,Z>3HDL>(;7EEDN6Y<;-JLKJI\.SE8
M&+JQQW'M:\<$B*>++5W<[AHQ/)OCT%WA/U#K>,KB,N@F:+)Y;984.WS5A6'B
MZM(%7BHGG!XZOM9809%:(C;2.,38S!A$8I&-^B/1W03(Q^@@WGR[277\5UL[
M+U-/O>&,L*CNL.S7Z^7"/ TK.4FE^T9-%1P2N:1WVZ1#D7P3ZHBJ"]R)G,CH
M<AI1<:YBARM!@:4$C.T$K;VD3+<MV/(9 7'(N5+4$[V<"OHI$IX8!PJYK8BM
M4+5\$;T$3>7^+\OS=FIEWG/TH;YG(N(X5)A<C"D3LO3Z6N97S$VE%JKJ.Z_H
M_P!.:,<8<]G9YC]WO>Y4[] PN?\ 1.9Q_JY>LDT%J@\9R$ZMV0JRX_Q*L3ZF
MW$V!2;RNJU86.&1':OV;"D&;N;S<U416JH3@J8>3!=)Q$>XHG<9T-^7%\@\J
MW6=FQ>2$S-C7,L($VBVM;'JZJ<.SM7?8G$-B2.Z/3Q:1O90?@$#([2%#S4BC
MR^/T>BLOZ8V7(^5W-O5ASG'O&R#+QW;SITM/L;^UO@$=$MAL1)+QN17?['Y0
MBU/S5%M@2,!;P,GC-KBZ;EGE&Q'BEM=E-V]1$F,AHS55NG"2O8FJ% &>)#"X
MT9!F=\?;LKG!"X/[>$W3,SDV'03H,S6<=EV="%VM*M>[)@.^PL,+'QWQQ;.(
M&R(!SPPVE9Y(TK/%S'M3H)FY>NK.-LMF@XV%4:?7[FAF:857ROQV>95XJQPK
MHV>K*%D*JKX<[*BG4KE)$,9Z1G,&0C._9S>@E%52.-L]7R(E9E\)RL6GIDVO
M'MDFBM8.EM>4]JX<#?U#[#S.&JQ\6%*,2([S+&^037L5%3H&;Y!SF7Q=K98B
M\LLAHJ[8U/'F$S/)<[27&DY)JYVPT1S28%&..-:*<;':&,C9;T>)XXBHKE5B
M=W!"'DOT?%K]CR#K3ULNUK\UR?48.1;QKX''))^J$($:FWQ<_!KW5=Y)CEC+
M(?)8QSSQV(A?%ST=T#Y\0<$5?KS570]HVQ@Z#C380L^*@N\D^ZQ>]/R=9BK+
M;4R5D1+*RW<1\#Q-)>$[G@$K53\ODWH)68N!E),.MF<DUG%MI+V]X[C/E7(U
M1;BHJ<YP]%M'6^:N\EG1%^\9KI!QL(UA$%+ QWFC7-\50$O>0ZII,YR7,S>,
M=3S]S92M#QAR!N;VQSF IL10V \WM&$K4_4(XM2&&CC0Y#'#+(.WS[*B>00Y
MY#]7XW-\W!.QTN1H0[CC[6\MTSI9AXLM'0VT@QYN.#KCQ/N75<R/6O<2$=6-
M48Q=E:]_90UO@OTMK..K>@6\EZS!8SD;+RK#+7$*4#6ARM+F)DF<7C^]U=C7
MS8%=&-*B,5J?")DEIFH17(O?H)KX31U.K,[528'&E &FJ*#D+C*G_INVP5KI
M.3Z.7)@&K>2Y+4B1[&+#A#8LAP %B&0K45W^RO0;]K<]E+FAODPF;I,7"R6'
ML=&&OCZVTKLORER%OP#G<D8IV?=X3_LJV>]Q*^1&=XJU4^)'*O01!Y;P&0Y9
MQ>I/0P\Y%%37O&/"MOA\;6V%UD3W)V1K>/JX]Y<!DW=>>D<HPEF#&TD6:B+W
M<JKT$>:7T,L>.=;8[9V>T"NXRVL&+M@0M.G)=W;V]\,L+/;I:D84CNGYN$T,
M5AWC*Y/H1J-3OW">%3E,S56V0XK@3*?79?B/?V>Y#R!HLU)L.1J+2:+C?2/C
M<AXJX!51,>FAHK"])""LJ'*/#.0BHQKT5>K$S BU:>IH>,,]QI8U/(D'CK(F
MH^$N++JF;K3V.DX?]?N/N19O-7L>6RTM8BS-+S)[9\G0H++.Q$(#Y%>3\ZM(
M(@UW&4?+X_JNZ>,\=9^O"/I"Q_BS[RYO)CT%Q72Y^LL.*\GO/";3Q+V#2\F^
MU'NC%H<ADJN<(16+3<"^N"$!)& OVP62FE.KD1CDU&4_'S2<</I?W1']96>0
M.;^?@57)TK&\19%LVLQ7[DD;CTZ\95DMYP>K/+N%#Z_9]GW%>04ZOT\279RA
MPNRAL[!1RA,4HT=U;GEYD8XZ7,\OOXE_D"+[ <JZ[<8+2ZVUR/&NBY!YSX[E
MG!8QZ"9#X"YW]7\ALN*^3*EHB0I-C<\ ^P->2I;):JS!OE&&YSE^3M)GQG0C
M;$1,<=/NG^L-VP7KA.@P+GFW6W&;N.4J;9\+<]U5)$T+J_/S?8Q.*6<->SFE
MP5M"$>UD\9<OTJ 70U4FN&DDPI$EC7$>-XL3EX<5F>7+A]+N/L:QRAPUC.8,
MSEXV$B45?0V?*51P[FL1D:HT#$X"QPD9ITNL-I3B6?E:DTF:D:M>)@@C$U&O
M3P;UA#,X;T</@+ZGV<BMU$:GS>UN,7HY-%>-Y+N*S8791O=R+# R(X%4:57B
M>)TIPBE8T/DQ?S)T$ZZBCQI)\;B2?9XX'$U#>6^&W/)4F@L:;DV\A"&ZWS<B
MDVL(5;6V%)I+6,%&MB-<4GQN*Y$>I&H#YI%RN_KX-,VBR''NVT\U\ODGDC&;
M"9$J\W&X\!]KQH\[2#;$TAM)  P5B-GPG:1O<C43LO01'M\]2[FDN:&378_&
M:CCC%;CDJYI<"RSVI-9$L+:55$JM1"T(%@_J6GF35D-BA0H8\4G<;D1B.4(;
M1_VZ+:=*A&KZ-6VMAQG3[RK6/M9$RM_H>H0=M882NQBA%,:+^Z5T2 \B,& /
M96.:K4Z"<&;C X^IJL>/_1=1LMMDX>[6/S#A5E0LA/J;*+4-HH#::MA&RUE#
MJH228JRRH!H&(5%>BN1H23JY'&&6C6M-09/&\G.I*R18</7K]1/IM[<W_(LA
M@^43R+$YC!I*.J0RG@B*KH_R :YBHJIV!E]KELO17TSC.?;Y*X-MI&!P&/Y<
M6[T%WR&]]J\TQD-D4")33AYN=+*V=)<\;F-1J.3P\6N"">P])6[71:/8!K'S
M*:-RR3&Q;9-+'X^5=161(D"GWI<E&BMCI)&%6'(<2H^0C6M547MT#_<.<+4?
MKQG$B:<=B'4X+7K@RX>^R)+7)7\G2O+/N-\D<<"7;:-D4C12)QQ&(\37HB_W
M;E5H2OX^/B8E;6SN1*_B^U-M[+^C.9<L EI1Y_(8NADOEX$G'^40Q94322I#
MHY2L1S9,9.ZKY(J=@0]Z2#23LWR]<9G#EKKRYTE]J\!L]_>VM9Q7#H:*5$S]
MQ5/I!'>R-I(9O[JME!^))9O%_9R(G00AY)]2J_E"SS%?GEL-+#E\.6W+CKES
MA8R5$RMW)AR9.')K1QR29]6M?)']S#D/>]ORHP?Y^R(%[A3TYI.-K@#])*T6
M6S^\R8]=G+:&T&H!$K\()\V%QY?ZT\.1500Q;6$P#@*R-'DD>GDU5>UW03(P
M>D@:!";N94\5TDRAIX&\X@QWZ%<<??U+MYHSU5U%Y-CRO <RJK@F\'E;%2*]
M_P"3Z.[.4-OY(I,;>Y/1/X^R6;S5+B,:*5G*B%NK6%E>7+3:OC6>[S ZE%?9
M0X.<L)9DBFC/[_!V1O?LC>@B-R[Q=DN9<OH+/."SK6S>1^.^$9&'Q,*3;8JC
MTL4<24#3Y/2SHR7M:^$PHAOEQ6L?]RKE(CD:Y.@8G/>A\GCG:3]L6AT21,+O
MA5NQE5&G=R7;@U%O&!6AW,""D+[9\R.@_MWF4)U$1WEW:CFIT$X:>GRX;Q.'
M/UJ@9QWD-%*PV[Y0T.:-'Y#D8W15;;?[VBVL -762HT^RFI#;'14F">U6^"O
M3Z@^@P8W:Q*[,!SN7R&KO;\69V?)>)V<RO/D^/L 3_S76JL;*>Q&:"_O8QW1
M9[7C22GR>/9?'ZA&>PS6<U3Y&'DP<KE-9GO\7>3;"5B(]OKYV[IZ-Q:N2/7U
MF@&2 -=6#X'Q(XW/ 0:O\?\ :\N@@_'_ &][/25V.D55!(BV6ZQ%OK\Z5-P5
M8D7+,D?=7''C,*&/%ET\6ZDQ5<"(,C1L*!!-^1C^W036R^>@X;+P(^8;7:+9
M<B8^XLJ^AY9X_P#O(.*NN/2 JJ.EB5%;6PI6;)8193B02J9L4HQJ]7(JKW"3
M-)-XPRR28\7)8/EDD"E-R+AI_P#4TZ!I;+F[0("JVN6AE:64E!C05\@JQT8I
MXKBC1SE;V3L#-\A9?,XJXN<GH7Y#0TFKSV.Q]#R%>ZB]O>0ZJ]W>A\;#/YPE
M:KJB=.QD^2QYWO(,B1F>*?D[O<$(^3?1T.STO)=X^MDZ:IQ&_P O@;*VC7D;
MCM^ANH86!I=M-J$@MAZ"73RQ*4,UJ_,\04:]/-R+T#V<1\'UOK/7WS]4^P-I
M.*]=$D%S=IFWZ#%\@NY&L/TZ;J2'?"L)^P+'J9@Y<P@BJ4$=7^/;LY.@EQC(
M^('''+WD'A^SE:'1S^,^1L7"%H<WF:O@J1<+85.CS>6E222F;&>8+) 6*X1F
M#)Y"16*B(")R35U?RYWD>-D\9%J;#D00)W'/(N\N9V4R])C*:PC9S>D@4[7V
M46/IP1Q,?'D,<BR",^56IV[A"KDOUCJN?97&O]%&G3HO)&;W/+-*OC_1\O$0
M9+)*R\=6[=8B6$>%*;6R'&AR7O&^,P?=B+V3H&UO.)CT4KF]^;XLUF:SNP_;
MKQGJGC-920N0=MIM!KZ&XESK;)Y[6,N69*'DL^^2]Y)@H+'3OG13F5&.3H)$
MTN[X_P!)[1)R'.H[^)QQ2Y/BJ)A[NLP')=9R5I.1.*N')>:L0ZO03)M?DZCC
M+&S1R?(%7 )^HR9#5)Y/<-R!A:=]JSU\Y#J*2'N)DG3>JG"V*P/&M;+V,?#Y
M'24?(+;CE+&MEA9*O;387DHQ9C[=3//&"B"0:)].@;[E&%@VW3=UQ/ESW%CZ
MM<+^OO&6#XEKJ;?7/%59[+S^3=)N<MJ#:&_K[R99U_&S=0VXM+,L:8YDH/QN
M[N3L@>>2/5_$%WF@6WJ=W1XO@SW8F\Z\RGR^<U6B-R4;D;"-93W@(-/&);Z6
MNX+WDZP)G628DFK=]U\K M<Q40$J^=G+6-P1A!XK756+P1>89?),W?X/E':\
MJUG&G)?(L33T,;*V]589S)5W(N]A5K$M)$[O*J1%8S\B,\5"3//.LD3K3&\<
M9&EVJFK.$N7^$<UJ>$R7TO7YG/[[2\:EP]@7>W<>5@,9I9D/-2_ZEL; 3YE5
M7O<R*_R*JJ&L:CF"_P!%>UHHX]!QCRMEV\WY'@.-QS2ZO::!>/>-L]63J3D>
MXL#T$:K#;[#: F/C D??MN(DGY7N7R5C08[;\*5FLN\+S!GO7'43W\G>A'MI
M0.P%/J-%18^-SKRW;4N0M\308NB+$MLR/DZ%"//L 57VZ4@QD.QRHOT!U>-
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M2J>WARIKK"IK]!C/@M?<O';")-QUZ=A":!'6_&R?9[P(Q*QDP;?D:1S'^?\
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MA^,/6CWVI9J&Y XC]=+<+;7.3WN@^V(K,ZR:#R.DZJ6YX_[4L5SVC!'B,\T
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M+_-<YD>?771PR(T"XSK^/TKXDP#VO^ZFQW_+*\D[(Q._02Y/Q[[47E$N?U/
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M^4GUD_'_  +XS_#M_P"8K6_A_P"!_P!'0'^4GUE[JO\ @7QGW7\5_I6M^O\
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IT!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g169497g66w02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g169497g66w02.jpg
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M<9&C;%!S:B4>BM<"21F)RC !WO!MU=FU.$:4G]\<\+>F()RK"IO'+"LR2/\
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M.IP6C>R6I(VHB%(D2<Z QJ+4PT2M P+CY',D;3(Y9,)(NG"\Q:I.0(RTJ A
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M022MG9IJZ3_$!3V(UF&RAO//@_8'0!-[Q%=!O9VHQ(IE,051UL;G)&O"G1'
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M7!^W+/M%RES&TR&(0FQ&NX#HO &JMPHG!5*[#.?JA4H%  N2-L3^T>KM8+0
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M>M2(]GEE$+%F]F#+)=,DS+GBVIZ'NZ.<X4K8EVRML>GUFK]BVZ;C\<*2G/\
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M8(Q$U!49C!;>6^R^7S)P88M%(PS_ #BJ;VA$ME$SD:)"6<I.)2)MJ/4-& H
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M#(0*DB8Y3HFWASXX5I&?B-7!-JZH^:1+CA:Y/73-QSFJJ.B*N^(JVF.K57\
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M\A<L3HBG-(D='5A<TJMI=$+ZQ/;'(&)8W/D>D<;D#6E<&UP1*"%:%<E*/),
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M3&Y&%NKV].=8I7=>6LU-:I:<-0(V,L+VR'*M-R].,P@!QAG7)+P>7,+^))T
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M'28NV9N)G%86R.Y^ETE81&66=T>HY7M)!P?6%\TA6I-10\S7;'2,@>K.;WJ
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MI3'AF+5"V=(_NY[4X)MC1&H4[>YDC3^!G@H$=K1.A_K> Q<9Z1-&><URK0/
MX_,(2I;(FO$T2 ;/(&(Y!&G/U= $UO D2L2=F7^N9K6R#_3,\XO#R^.\)BJV
M=(Q1TYL& 7^*3L"]_IQ@FQ+#(6>8MONZC9;;0QQN>E\@"C6";EY;@CA24"%0
MH'X%Z*,]+?AL6%XS@M22O<'A;,J=YB[Q2)QX0M(EKG)5[0PLPA.*@W>DBI:Z
M&I4.Q+U2@>]%C%_>F&"^3>Q;\2<>B"!NNG-70V\^%RE@W;CG6Q]OML2*]':Q
M3 B'5-$]OR8X(?9S@G*AZ* 66(1HDY0A^7T@>.%Q<9Z*VL'L#F^M7JU8I(96
MD/D])I:/%8\79FL;J]1Y#>TW(@U7#$WDEZ&I2'R%82,_TO,%N(/+.-\FC"_,
M6:;[K\#-Z\%'55A@E\,W$TR<XM;.0O['N.ITB!::E4 52;2OYM*3HG'8RQZ&
M?H)9_F#OP%XZPF+R9@!T;*9MNY9K(7'A-A[B)S - !FVS*BA.*I=M:'>D.VQ
M02+9YAOF](8=['O>]?+A&$3RJN7%H>5B61PE<PM3@!CD*M.\,2EH;74GV),6
MT/)Y:@:)&X%>T)BPIS]A,#ZA8=!_6#K81Q);];.+D_E'/#4D:69FB[@7-G5<
MQIX7)&J9MSV\( QF2C<1I'H@MOCQYZG0?*6$O01AV,/FV$N*DZJ7UZA9F68K
M91#4<><-($D=E2I[9$[,NT_")*:TK*^'*0(5.GD?IA3@(-%[1ORZ!H7R8./)
M#(Q(ZPA2RP(BA1IH$W1>4J'=_<GXQ$S1Y^DMD)U]F/SJV.KBY#$Z*%1[DK4+
MA&:+V6:$S0=>F7XZ'%+7&:5LQ1QNF#O+(.S1%S^:=M,H<7UA;XXX>UE^=BVW
M/:E42V*_:2M^*3TC1></RE^.L)BL*W69!':V9-2J/1ILXB->0RU7<C;5O32&
M*6=(K!B[$K2.WEVE5+E[K6[MI22#?G 7HL8_'1H<+CAE)SGZ#_/YD24/,4]Z
M"X^:O-C)SBT?/X(J,T*<]:8S#.^<0Q\1Q>@#,V7[-L0=:WOQUX83CS>?[+\4
M/D>5.4?C\*!.9NOE\UN6,0Q!%X&%?J6H^<$J/=AV,R>JO2DCKAD=A$-C>\'[
M( O7!\$@3""QG@-[*WY3R>%JU$79U#@Q(7R1MWO1&XHZJFI+(U*9.46M5."!
MB,/$L.,:]JM;4&D &$@8M^86O'QV9XN\A?H@]NS^PMCU&W=]8#6\N4LR%Q:U
M[LRG*"_:6L#^W)SC5C<:>2#U$^E( ;$'7F!XZUXX3B.<@B$<=&I(\O<;87J8
M+ M;(F<W)L:W24."0K8P-S42J.(5O:Q,09O>B2=&C  7CX:UO IBLNDZENBW
M[KJ: B=)%).;GEEB]AR@#)KW.:9C)&1,^*(:R2@9H@N4C9VA6GVZ$D ]-,8;
MZ C!'%G%E%NFR9O5"VGN7EQTDK5&&BQV<TUZL>[JQ4/0=%(XNRSF@" 'V>@E
M,@5&)F]CT@V/04RA2()3AO81$"& 0!B+MK9=TDD+9@,R)Z?HNU%3!;IICZ1T
M=&I""4N3D 9^FUF(5GE!>UK@6,0]$D:-,-#O>_#>M[PRC%NV;6-'UI(K/MAY
M;8M7D$2(W%T=%;<J<@HQ[7)&QC1,[*U(G!U=W]S>%B9$UH$"8]<M7'DITQ1A
MQA8!%DMN(J*D^KZGO:3RB)$16SZOLB'1ULF+E!+[JB3U)-3Z^<7-:C:)ZR(Y
M<@3$O40,>FH\@P]*>88W+"O26%ICAEA&6Z;/PO$4^K$Z+"F0YI!#84[!5%BE
M0I''S(LY@2D*P+0"?-K-M*T*9*WGZ-UZHM +(,T+PT 7@9=M+*( ^.Q<=12*
M'O#Z0@6+2F)*[LK@[$M9!X6EP5EMA2@Y86@)5#TF.,T#183-Z+%OQWX8'(GE
ML&6K)&-))HFK<(2$2*7#3O+.>LB(#"O;QI)&(M2,]@",A-ZVRU7I:V OS^'@
M'QT&,U8=6E!CANIS "P21W<62)&:DT= %^?DJPQ"[M$<'[;K3H[IW#0R5*=-
MZAP#O$ PZ%XZPN*K9!TG3*J86/7L2=@R28599]=5G9L>BJ-.H7127VVBCSS'
MU;T4(])H39\VRA,H7+2]FZ)V$XO?G4$&E &+S6^5)X4<^O[21(8L;)H^W)%,
MH;"G9I&^LC2>68J0J']$!1MP;6XXH8S"1J @*$'>Q!WX>.\(Y(Y+(?)P+28C
M)8U(2V4U,A<2HX\M;L!I./2$K$B-:!L4J H#3D)Q9I99F@;$2,(@Z\N];P,R
M%O0 2:0 0HPH=?H1!3$A2:_O?6^1/H&B=?WWZ_Z/^+Y?TX'(-(D," !B5.8
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ML"HWH/@,LP(71G59>7>M<!\1W0=U/MV-H2N!*Q=U*>K5'>(YE&QV IHU2C/
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MA99Q9A)Q8#2C0"+-*,"$99A8P[",LP M;", P[WK>MZWK>MX'Z$(0!"  0@
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MGP6CVB@8)%>GK9IY4RU:[U.W2)WZ;D4N:)TSRNUY ;8>W=@V]2=>]-[?N,"
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M79?0=CHUU$<5<UREB:ZLNF=\]([ZM*0_2$P=$]"JGJM'ZOIG,"(;*(0TI4J
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M"C!E^&];W@DU7C$O7MO"MT.KCR2]1:A+"<W*,%=2N5#R&%QMWT?'[)ESR?\
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M++Y^:^=:0;1.LJZ"F<8JJ8S>1-[NIAD(J<M,NEMMR*R#8H>R+4S+,X7$U<6
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M0EM!SL"0(G621YO:?;P0=/'30+34*9>I=B1%A)-,LS?7%C2N_K/"^,$=+O\
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MA[,3)PIB-$)S-Z,#L9!6@>F4/83AZ\0ZUOP%O_?O [ B21["(918]@\/)L0
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MF" +P\/,$6];^3>\#]+3D%&'G%$$EG*1 &I-++  Q0,LL))8SQA#H1HBR0!
M'8M[WH.M:U\FL#Y"D2 V;L"5.'9P]&G;"26'9INA^IHPW>@ZV8/1FO-X[\=^
M/R_IP/G:%$("@H2-*(M8;ZRLO:<K8%1VPE@V:H!L'E/-V D&O,+QWX!UK_9K
M I1TYHHUZMI#>+I7[>KLUN$UGD/HG)^ WFN+&WN32Q/CA$RG4N'.LF8FQW4I
MT+HJ;SG%&29Y"3@!"'6BYN,=%Y **+WXEEE@WL( ;V  0[V O6]%@_5UK]4O
M6]^77Z->/R81Q%HTA6O I*G+UZOK>!9!0->ML0A;-\ AU_>^8>]^;]/CO?\
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MO_Q;\?TX U.G/": \@DX)Q(TYP32@&!-3F:WH9!NAAWHPD>A;\0[\0[\?T8
M*=. 6A!()"(._$(@E T+6_[SY=;T'6];_OA__P"V_P#?O ;3)]G;4;3D[4"
M46(_90-G"+(&8:27LWR^?8"3#1"#KQ\ B%O>OEWO X](400$EA1I0EISQ*DY
M>DY.@$*1B-&-02'0/*4>(1X][&'P%O8Q?+\N\#[TE3!$8,*8@(SCPJ31Z)+T
M(U0 L!(%!@M!\1G@**"'0]^(M!#K7CX:U@?GLB3U##?94_JG#"8:;Z)?J&F
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M4FG!*_\ PS#FQ)LHG19.PI BV#8]C$(F4KVE3;&49M.1LP@PPT@>R2]C)-.
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M3LT9!^B33,V7DG[UTAT#%N?Y_*'YBBVYW NE3*2>K"3UM.@P5FK(-A,C"X=
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M:2DI*^350S[C=,M[$4ZP5!5_0U;-T@M!N!-U1,^MAP^GQ0H<W[7S>F7 ;QE
M0DB6J#=#>VRJ_C)KJ;H9TN^+OT93-+NKNCS09)7B)J RM=M):#,+01EY;7L@
MEI$SOE(F*E._83"G'3V=XED&E[./)=69AJ*X?"/;USN0K.M]N^;PL#Q&R4A<
M+F;6-F2IYU=,VA:V--T<N5BAI3L0*XS2'X;FT.I+KMO]1,4W^U' ":WN>S_A
M-)YM#Y! 87=##745DD=)C3NT--.(?9T!Q?/M;4A\_LPX].8FXMSN(->%N!B;
MVC;8M+6Z(6IE6TB4X))KQQ6HJ^&VS%GLCTRS2(HI4U3:P[!7NBZHVU>FED@F
MG:5=]@-VY:2GD[<Y/9,=%!38X68:K$>(EP&K ,GR"3&DW>WQA.^>N%DE+UK=
M-4/\\02F!6D4B1L,68XBLCK)725N;5Z$MQ83)),9_)-NQZ@]*K 3IS*9VDYO
M(TU(4 /4",75FY5 Z_"S8GF%OD:=+E=W]V?39BH')9-"FUZ,0'V/0EQUY8YB
M!L&^$D@!/KOO%]L=R+V;Y!KSPMX/(442H++O7[27%S?45H,]N"DD;62P*[IM
MSE8HW7R>*$R11T=/JVG>D7M7O \.93-7QM?>QH"%)RT1B=0#]<K9&M&$NK,Q
M^&GUB_#NEM6Q:H'ND&>)VY*ZLB<)@)D$>X-!T4,D^VALZ-2/]@RJ)2F<16/R
MEQ<C;W\X"#7=*H0+$NE_J./]XWGFIKEYNQ$_A+HR:'C\ ?YW%&J>F0QQ9Y-(
M&ZMFY\3EJWWC*O\ EP<= K.=F5<_1&-OT%)?R"1^R 5A 4GT4F&6!2$;^/CY
M;3W[Q0=>T_C4U6S>+,I6X76L%G"$^L$\@=4K96EGEVPB=*1D2R5I%%02%]?/
M.A7J3"'P)J ",00!4H"31&9JQ&RU 5*DHBEJTIY"O2.J>NXDU1@+JA94\=3.
MAC>3H!SB!D2J%9#<):=L1@B]&F[\PM[V,6][WLEN;E<&$,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>7[W\.
MA5*; 0O,GM>-/->1RVYC:<9@"BHR#UP]6+V!4O8<N99?(E\Y7-\B*W+:Q,:&
M\PEI0 (0K"SCBU*A/O9QO=P\_&$$5?"G2'*6] DMUE;HN*1#D3D8CJ%O*L6/
MZ2*[J(98_45@%S$L%8QI$P7(84-*!M7ATM;Q'D;)+7J4^I@WK(YD^'#'^?IK
M ITY2V.S!V@H)N!,0GATL*2GJY'#:B@C-($1UAVM:KG'I&ULE4Z]H-0*"$QP
M5_H$DIR4P=&TNNU*IWQ')IHY3I@#<#8V4_,K3F5Y BVZY.5SMMLF7UT[0L:$
M<[U.$K0NK]#('83[I%\Q%.9AH-(]N&DV$FKW5;_XMHD0H1 ;)O'VMB0MM?HR
MXTDJIG*9-JH1'>:H^H</FXE^)0@/?@<ZE#-WHKS "Y:!L1FDH=FEWUW85\,M
MGCL[@<H?I[%)$R5A+V)WB["GI]K:%DI8F.36-,TJBX'@R4NI%B6:ED$^#M+(
MM(T 4VDIYP46U3BH- +KRR-6?#-A%6.%6/#3)8W\]5FCYG(T\MU6LC*ZO*GG
MY1=)SNX"<$CP-8B5V67< BUAGG.,) A\I@E03O L;[?Y_E8\]XWF$CF3RJB-
MW+()7DJNN.7R]LS6S3-'8;),VH$53R9OAD^B=JPYD%%)^ABH"ES?(X_(R$_M
MJO96MA,(+2DFJ=N.%$A^%>Q%1Q.QAGL,<3AI3F=X/D%-)G%$[QYQYDE'.3PV
M'IV^<LKJ6-67( .Q9@%X=E>B--K7F,"J*+O74P<3/S=SC%:/>[:1R9YB%XQ.
MZ&.3.L&/6-+07%[*:YZ3"F]N<IBXS%8F D2*$:=Z=)"Y/@#U/M1RA1H&D^R;
MN.?#!5AP";7]47E6A]D1X9]K\VQ[E]F>8;5B6#(V>(PR+6-&8W/YHQ)Y:[%3
M^W%^K'..>70)[6F6A1IR2$J0&A;$+JS<^44_\9K82_?.Z6W%04J"6.3A&&U1
M"4QP8K7WTRT7=,5JYK/!)"?_ +AALAJQZ D.V#0]^] Q>0.D8 'EW,$C^%TU
MQ=OK/<%G%;HG6MJMJ.N -<OH-GE=:RY?7U?797$BG,QK]',XV%YE$B:;D$I1
M'B7:-;SV[TCC5J=6<6$;^[%N?PI&M+$8VQ0BVD;#+(W.CY0WVP]5V:^V0E0&
MUA559$@^<F^<QUGD3PF1U80I,*D"%[CRW9X2CVD>DQ(]#?W>O6M;UK6M[V+>
MM:UL6_#6Q;UKY=[UK6M>._\ V:UK##]P& P& P& P& P& P& P& P& P& P&
M P& P& P& P/,#JHKNKZ>3@<[ZF[G!7JDI0QL:5.HK*,0.(60JA]G@0S=QD3
M\9('N3.J25&QL(&=:V-I01%E')7 9.W,C1N;<<>;#L*#N:Y;(E[F>[7%S[7F
MH_8KQ6#?(R:9).U-D-5\JMM<(Y\VLOO^X'1-39)EC+#T!*PLY0$(_6.+*]B*
MV/K)TK'>Q?$,V8\VL@CHD,[DL"K9S(JY>LJXYJCCE8$\Z!CCM6RV7ID8%[L'
MG"*RZ&R=49[4-(Z*&IQ*1"-,<!E['UY>O51YRCGQ#SYJ^1)LEEUIV<V:DQN:
M3M2*@BHOJK-]!52UU]+:#]-K72%)/3>=_>17,Q/2(THESVHV02(X+4#!]<(:
MDJ?N>Q+1;(I8+K>B6#PCI-VFL=NO3S3,8E+'%MTUU9"VUMC,70H9BU"1^C)X
MHF.>]&*2W 2P Q-3<M"O$67.F3ASQ_I! 2?XB1%AQV&*@V:R6E+:U*LI&RPA
MFH%O@Z^S&V'\?1==(;Q5K4HU9E;)9@IFB-Q U*!N0B0C G#L)33L(^N/7EMI
MUBY=T@Z*@!?.\=G@JR:T\!,D+B@=JQ/@KTVO3W+VNS27)C?DJ"3IWY@:#6<]
M.:)>?L6_*-"F#LI<,PFG;CCS:N61 /B/JZ7EM=/CST#8;7+*;* M71=3SHGL
M]9<\YYO3H%\35JG)!&XJEI9LN'3@6ZEDE@6)5*I+Z"@;9H[TBRZ,Y;7VI$>R
MDLCJ\VHWV:L,7KVDZ/$;$68VN3(I++,*N2'LUCL<TW)&]PDRYM;J8^<QC B6
M(R]A_O231K2R/*273U4K#8;W));%HQXM(70(XK KJJ:4V@F5O5+MI:BQE<2O
MB)VB? T<(.3*'[E!"ID<5,*2.6Q.H2-[/)+&I)6^4MVXX8SZ_EE[U5_$:7]#
MVFGJ1!:<9J8<7L"/,#R@#24S9RM:JMA=H!+()&G]?!E87\ZQ4CFE&F7N1RK0
MC!:4*223$!99)LQQYI;)8QV%-.<.6GLQEL=EO2NKS>'YW:QS>*J3WIG)A]UQ
M"M)';.DJ%A3+H"X/S_&E[ZR@">[-S889HX:M8E,.&/K+>V%$Q:,_%+?8$HT_
M3ZX6-]:(1>TH9]%QVBH]('*W&*LZR65E#7PQ4[V*@?H"^V\%_P!(_2"T@,3:
M-(,'IMVC'LOT2E6#XETKNV7-19-MU]5,FFD;:G!W3NU'NHXO'VOIJITJ]UKE
M:8T;VVMKSS:NDAYFAH' \KRZ":H.>" BV/ICRK.20;XD$862*7QY;T0_3=T8
MZN:U9*%UIA0PS-JK23].Q]I9U:P]:C*K64R5 NA3J[O+:QN:-4-7YEB#:7:P
MM)#Z>/6'O&RGN*EG:5+PA^:W90VH#W1L]L(<?FYQ-2E&+D/S@F(3)EWLBD0B
M_6+++ ;Y?,$(=;UK5<V2P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P/%Z153WZP7%>74%8LT5]Y[V9KAJ"-P-0H
MT"65_&83'5I?*TYDQTBF*ZKER)MD\*<EP4A"()R=5:9OM^SB$1VBCI]<8O1;
MG/K)>,=Z$5V=.&'K=Y@3Y1!,!BZ.W'VFGEW1NC!:TID!SA-8Q6BAG:6:0+6=
M]3@:U/@J5G-98@+3O6  L!FXQCAS>@ [ 5 \?_T>6*/P#O?ZC0T;\? L)GAK
MQ?\ 7ZV]B\NO_M:W_P"_"8?H[ 5 ",7T>6(/R!$+R@:&C8A^7VW]4&MO^O$0
MO8]>'CX?^L7_ +]^48?AM@JB@&CU7=BF^D%1O0"F=G$,WT"W<S02M"?PZ$)1
MMJ"$OQWKQ$K3^/AH8]@#]/GZDG:K6J]L0_V;2S>O0:&@6E7L@7X0=)?,_ \^
MU?S&'1/F\OFVN2^/E\X_3& Z?JB=*=ZKVQ#O9]J]:T2T- MJ?9?>?R[3>9_!
MY]*_=H'H^/E\WSFB\?+ZAGHD?A]@*B/:O"O+%/\ 9O;O#9#0T#]I]BU*MA]E
M\[^#S^W>[ /0\WE\WSHA\WE]4WT2X?2J?JDHE0=5[8:KV7V_P$E:&@P*KV'W
MJ\OLNQOQ6S/;_=@'L_FT'S_.J'S>7U3?1&!3/U*?2K>J]L-3[-M9K6DS0T#V
MJ]DU*MAVE\[\7Y]+/=@&B?-Y?-MT0^/E]4WT1A^*)^J(]?PKVQ#_ $!+ Z]G
M:&@?K^R"D00B(\[\#S!6?, =D^/E\VG!)X^7U#/2(_3I\I*VHUJOK#.]G$K#
MH1+0T"TH]E,?2PB3^9^!L85>F0(BO'R^8*Y+X^7SCT67 *?*0^I_^CZPQ>F(
MX.O*T-&_4]'3EO0B_%^UXA.^;]:!X^'CM23X^'F%Y"'O^J\VP_1[8?R#$'S?
M-#1Y1>4TTKSZW\_>/D%HKS:^3_A&'?Z=[UH'O^I\^@?1[8?RBT'S_-#1Y->)
MH2O-O?S]X^76A>;?R?\ #K>_T_)A< 9\I%Z?_P"CVPP^H,D&_,T-&O3]73?O
M8C/!^WX *]OWH>]>/AM.;X>/E#YA@*GRDT2<.Z^L,KV@:4&Q&M#0$*?VDQD+
MV-1L+\+R 3:>1"-\/-Y0HE/AX^0&C!A^$3]2?Z'C7MB$>L)'K?KM#0'T/:QQ
M\ A'^5^'Y0H_GX6SO#S>73>K\/-Z9?JD?J:?J5'LOC7MAIO:=HM;]I:&@'LO
MMFHOL6U7D?C/3TC]Y1Z.\OF\NVM;Y?-Z17K 2S]2J$DUNO;#2^U;0:V)4T-!
M84OMWNKYMJ_(_&;+TA]YQ^OY?-Y/FI=Y?-Z17K%?J2?*51B(L5?6$DTL&W $
M8K:&D!:/3AN*:$-;LM^-V6!N]Z![4^70]@TU+O+H?I%>L%A80P& P& P& P&
M P& P& P& P& P& P&!Y^WCUQ-ZPO@RFH)7S1/Y$]M5>"9DLOL4FOXFUB>ZW
MZZM%Y<SE[16DVDWM&VOFO:+TA!5E'&K21EA2A(4B4&I,S-]<B7]U)&9GYN>V
MB)1!O07S28.@5RZU;50UHTQZ#E&5,2MBT;>-1>3(YQ:I@K;3#1-.OF],K B-
MUM64(TC0QMYJ&1?$^E#[[L-T7I""/LBG["T3V)I";[]1H8(*\57T3:6FBV'5
MMJUU50:Y6I!SPK3+(R0D<R2CG#7@X"]C4ZT79Y=)T^*)/&]A<'$KG",J79BK
MF572^M(KVV0016##5?/%OH"VUSW51@%]@.3!T"0@-0#*(:TS@VC%IR-3'@-
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M5,+1)&@+F!L>T"9R0 >F)\C#L%*J+T:5IQCTE;FB0,RO0!?KIUB4A04+]48
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M$TI4.1C+_?'J(3.UQIPA V(QR],_>_ &RQ%W7.?7/+)I.)F-MO"IYZAD"U1
MZKF-VVR@C[TM/<7M58MT*4BI8PA,3)&UL%64??-JI(B3KM.#@GD0B!D'DIR
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MLLLDLLDDL!110 %E%%@"66666'00%E@#K00  '6M:UK6M:UK#+[P& P& P&
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MDA'F $MU++/WX^ @B&:MO"& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M"X\ -^/B$!P]:\-#%K8=,,:C@0F #'V0(#2 I30!:D&@F)@!1@ G,#HCP&0
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MI119)99))8"B2@ **** $LLHLL.@ ++ #6@@  .M:UK6M:UK6!]X# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M 'X# 8'SL8 ["$0@Z$+?@'6Q:UL6_ 6_ .M[\=[\ [W_ .[6\#ZP& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MDF=7AO<]'% -:@%%A*&$XPH?E"(68ZS*#VIW8"N;(N"O8[RUTU=">A6.+O\
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M!-A.U2'7'595K,+$9*'RLS;!B1=@,T:)1A<#I"ZPT;OJ1-[(2WC">-6:F 0
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M$0S20FI2C!QNZYF?EL6DXIOUJZ3A#F37W/+I5T0[VLGLXR_5$G>4]\.3#;$
MM-@5UJ.&_1X:E*>(8Z3=*T!<A2<U(MBC:A)"E).*V JINFWSC"6]F<86O?%X
MR&2Q:,59(*[L>JN4H1+%<Q?ST#RSK.<^U6;H)];CHUN&/:.4L,\KUR7I ;$O
M3>@M;BR3B3"E.C2":=6)Z[*3MKA+K6;=DL=GH"JU,J*)]<TM?L=5-MIGU\V)
M:X@L>CT:=(TNHJ)T<2":7.A$C5BU*)!,W @YG]%*F(2[+)*3EFJ33CKAC$_P
MN)PBH>E:Q2P&B%"Z&?#84\OV"RADDL@S/*[D(M#G.RD*DJ9UY'VZ7(6_3I6L
M@6H9)HLY4V/:TI8-N6 .5)S"[^-O'GDB?PY>H)57T8C-JRR'LKB-_P"RMIY
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MK*^?G3<IZ"B!<ALDRK8Q44BDARXBCTL^/+8F^XIK%(.RM>WY0(9VAK3%82=
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M_-$/?.H%'/4=D3_7-1)Z7(:F^G(S,WHH4_+F8["#>0QN2U>Q-A[2-G>G!+[
M4$Q/HPX!,3'Z;#U;9-YL7/74%J3N[X?-)%7$DZ,B$&7V+$XU6U<1=72,VL"'
ML+_.G:'E%K=,CQ\QHE#XH&,!:0LLX9(20>/A$N,XD4M"NI;R?G*/4B^V83!)
M])[39HK(K"L6M*P+>JV:'JGI)9C"T,JBN+1F]'6&[6:YQ903&EP51(TK>4J
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MPV7(M>^U;K653.]Q*:9>)=#;JLQRL^ZJ^I-7*E6ZU?:_9VJOVJ/5W/W&J"D
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MJE3T_04YA4+?D9EB<@.B">.<CA<]N%*LN*5%R\Z+(]M*.N3C"BGQ4:J5NIY
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M[Z7/_ .#Z^3VSOC_ $YR#^^ES_P#@^OD]L[X_P!.<@_OI<_\ X/KY/;.^/\
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M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# U*:O_ *[9W_\
MPE5-_P#MBNG)U:_\_MMKE9,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#5/N
MC_Z->G__ -1]C?\ Y9<,-:/^T;689,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@:E-7_ -=L[_\ X2JF_P#VQ73DZM?^?VVURLF
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M32\\LO#O#!-T,SW.$DQ6/#,FU6BEECD!J>P8\Y15U;Z24272V0H+6+3*DRU
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M7=-'RBX;,G! (*71>C"3@['YADDB++NM;(H8E&V^)(X(0T)#8@ACJ>)$L*\
MG1 ;&TS8!G+:%H'(2L3BD&V T29I1LW9P-[\^Q>._$RUS:^)N;VEH=V8J&/J
M\AT;8DR(U[]9EHR.10YC@+SN105DK24OTS<9+5S3#W_>EK:1'E;8!*I  8/
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M+NK;H@@E*02F3E%D)TY19!!)0= *))*!HLHHL =:" LL =:UK7R:UK#+EP&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MY?ESP9\0^S1.OOF]7_M'.7Y<\&?$/LT3K[YO5_[1SE^7/!GQ#[-$Z^^;U?\
MM'.7Y<\&?$/LT3K[YO5_[1SE^7/!GQ'YOFB=;UO7VSNL->.O#QTHYR\=?^W7
MCSGO7CK*F?$;.,C<>SLS0TJ7=TD"AL;$+>>_/>V_;R]'(TI2<UV=]M+>TM>W
M-Q&7LX_V9*F3^J,7IE%@\ :(RF P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M56$KZ^YWB,HYVB:VT(BXK>J)6_0^EG%BDL<=6"5.<<BSY*G!0F>B7C2(]N,
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MQ6$D=C,S&Q1"2-I0):S3630>/,S@P2&%IT!R2>.B%N;)*F<Y))X^V/3.02O
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MG,MC'?$\O;I6XXY#H]1#O:5V4,LZ'OE_@>T**X"WJHK"4L[3+(W*F>-RT[2
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M(VN7QOY^:4#M\P2MDV=MFDK-[<0?\VOS5M09[,K)\AY/G%Y!:\=X$CP& P&
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M6B(N:XMR<HNV2LU&-\01]P<2@'GHRCP)S30Z&(.Q:UO!FXQT3; 8# 8# 8#
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MZ6D$JI9ZMUR$\*FVSV4NDZX#'H^%D1N*(IZ6&/A:]08(92/2,VLXTYX];[,
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MXCIU_P _";O$]F.4\J1!$:F(6=,]6)#UCB6T(R5/3DQ(-5NQR0QP):TQ9JP
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ML/VDEQ&I+/\ /OSZ%X[P9O=V9%0=%3!^A,JEM+5+*916A*1/7,DD5<PY[?H
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MY/>_L_Z@^<_Q16%^5/!]>]]OD][^S_J#YS_%%87Y4\'U[WV^3WO[/^H/G/\
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MNU!:&EQ#+8\7'G]Z6HF0Q:X'(=%.I3<X^T(31;3:($0<:<TIP& P& P& P&
MP&!75P.3JRU+:+PQ'*T[XTUU-G)F4( [$N(=4,:<U3<<B"$LX0E92LH B]:
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MJYLLN!11X81(*%<V" VJYUXXM],.D%6*F6$1 3 SGQ^<H5@A/RXY)I08YEN
MP )B>,.>S;M[@*DCI6!$AG;9;-&2;D5$].K#&-H8#?R)I#U_9;Q*6#8FA4@
MQ='0:N8ZU25O3FZ&PO@3D =E^B0<HJR:<90%_P"CKOD]GCDTMMF6PVG[9LQW
ML& ,LVN61\GQV*5E(^?:Y?ZHB2B>L5:31\0N:EM&)Z5LJA/ZHWQS7:-- )*$
MC0DF.7'W77,KPZ5A$KGSO&)I-9[0DZN/A^FX:XQG:FP%E0NT@8>7WQQF+3/"
MV!$YS:H;P;9H_M+Z^+"-B;GHM(J\$Y3@LVE)B8\XK;6FXS+X5]N9\,LR\Y<H
MKZ:2J%5HAL.?2*7-S5'TO/M.V(D5L"!U+V2M<BYQ(W+TEW@>?H(Q)?/L!>@!
MC//#S7:[Q[@=*RJ>.)YS<:R:5!SQ><'G3ZFBX]/MXW#)^69/>=.S92 F.B ]
M2"*P9MC*@.D1119DHD"E((H9Y/HAK=FGCRX_[;/7ITF^V!))[*:FO<]IY_*>
M><8XFF&G>9UY5CM(-Q_HE^LZ#*K^BL"F+K2JQ1[7"SUS[[ K3 <4B-B4;3'.
M!H=$DG7FF]3)YO9MD\72]SLCJEE:)Y3=QRN:Q:1V$I;FQXD%/RBF66!N4B11
M6/16,.39)FU[<E(%!#<T%REO5%K5",L8ME%$N)GES3*>68:@Z5FS18UX7+6T
MK8;4IUHYTJ"OV7YP8K7K%_8*_/DSN**F19Q2V82_3IRDS1(W Q3L4-:FHM8
M39L'MBD8X<&IDQNZXT=02)_@MVW+(>IE]+=&N72M/J$1X&&A7B/4;9;VT.<:
M9-1((:M6P2YFR/LL24D&'CES<M$KV6[[%[<3%Q,]-N77<W/KM%.U5(;<;497
MM3?%.HVVL5O3L_=3Y)7CC0W3,K=;'9>KQ4>GD;3 )M,HHTM9S&%G/-:GV)F
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MW1N.0>IHE1HL@>U)0C=@ 2:<S*N)+W5<1];VM8,#JJN  K.K87>!"&<3:4)
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MBW_%ZRC,+B3K'9Q9:&'QF/DFV>DMDV#*:WB=B.EK*1JZ[^BC;3#FZ7I3GAN
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MEK%+ QI(5+:RAU./36DE<T3*15O7BJ4K(+&FYZ)D0'QD*B1TS</8%")20K(
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MU/M\?ZQ,CAL'<1>RN9/L V(<3;]A E]$L_V;7K!,\P_,,U!D/(G/2%^='[W
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M*U2I"E&>WL:4OTB-%$!]+Q"#0A"WLREV P& P& P& P& P& P& P& P& P&
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M!LI"7W1"5T)JNII;6%&C05D],SV88_P058LL@MY>CL+87TV-U^I5-XT[ !A
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M=CZ%.G?OJ23^1-+_ /9<&9V/H4Z=^^I)/Y$TO_V7!F=CZ%.G?OJ23^1-+_\
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M$%10^.%J5X#$+O\ _*JC%1C<A6HC0TVQ7:WLZTFY)%VB5U72U</%?$UZWRU
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M'HT\D6ZFV9PHY%WSUJ2[VDV6"N@%=R2%0>PGEEB>H&U&DK')H6VAIO/VVO\
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M-U<P^(JFBMC)F4G5OC7NR.;'&!QA4*, +&8K<YY-B-!4&:"2 WR&$%LT^O\
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..,!@,!@,!@,!@,!@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g169497snap0005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g169497snap0005.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6)7()'89Q4J7M8M(WGAY99B*4JCN]W;U.2^'?B6TT'[7HNK-]D8S%U>3@!L
M,K>GW1^M8T9J%XR/9SG U,5RXBA[VEM.VZ:^\Z?Q7XVT>ST.YBM+Z"[NIXVC
MC2%PX&1C)(X&*UJ58J-DSRLORO$5*\7.+C%.[OH8_@?P[<3> M420>6VI*PA
M#<<!<*WXG]*BE!NF_,[<UQD(X^FUKR;_ 'ZE#X=^)+70#>:)J[?9&,Q=7DX
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M6=1M$T1VN!Z9Z'\:<Z<9[F.$S'$8/2F].SV,:P^%V@6<XEE-Q=X.0DKC;^(
M&:A4(([JN?8JI'EC:/I_P;G9HB11K'&H1%&%51@ >@K?8\-MMW9Y3XMFD\7>
M/;30;9C]GMFV.1T!ZNWX 8^H]ZXZC]I4Y4?7Y=%9?@)8F>\MOT_S/5888[>"
M.&)0D<:A54=  , 5V)6T/D92<I.4MV/H)"@ H * "@ H * "@ H * "@ H *
M "@"*X$QMI1;E1,5.POT#8XS[4G>VA4.527-L<GX-\%R>';R[OKVY2YNYQM#
CKG@$Y;KW)Q^58TJ7(VV>QF69K%PC3IQM%?TCL:W/%"@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g80783g10a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g10a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2N64&AO=&]S:&]P(#,N,  X0DE-! 0
M    *WJ^$1,#A"24T$!       :1P!6@ #&R5'' %:  ,;)4<< @   EL%'
M)0  AR<C$Y-38W-AP"!0! 36EC<F]S;V9T(%=O<F0@+2 X,#<X,U]0<F]J96
M-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R871I;VX@4W1A=  X0DE-!"4
M   !#ZX\B[=BNR@&!=:;Q92>5J.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M   0 ".$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M   (H   "&          $                          0
M  A@   (H                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   (H     4F=H=&QO;F<   "&    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   "*     %)G:'
M1L;VYG    A@    -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    !CA"24T$#      @VP    $   "&    B@   90  -G(   @OP
M 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%
ME:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M !  #VU@ !     -,M2% @(
M                          $6-P<G0   %0    ,V1E<V,   &$    ;'
M=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M  %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M-,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V
M@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'
M1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;V
MUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M  $G-21T(@245#-C$Y-C8M,BXQ
M                                !865H@        \U$  0    $6S%
MA96B                      6%E:(        &^B   X]0   Y!865H@
M      8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M 6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R
M]W=W<N:65C+F-H
M               &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-B
MTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%
M9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)
MX    !6%E:(       3 E6 %    !7'^=M96%S          $
M             "CP    )S:6<@     $-25"!C=7)V        !      %
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M $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6
M5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M
M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@
MB"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E
M0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7
MQU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K
M8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1
M%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E%
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MMW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M   ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1#
MP,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 # 0 # 0             %!@<$  $" __$ "T1  (" @(" 00! P0#
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M, @5JE8A$3+).2$"<D:<=]I>./%!-OYCTCJ5EX?T"C\[L:'F]D7UYCSJYTT
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MEQN, 9,%F^2>#O8,>FC@M$T>]+!M -[.Y9*C$7I[INV0KP1 T%L,F/KP9+;
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>51<?*/D2A:%#+@4YH@<S^,,/[<S'%^OJ)^67S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g80783g10b99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g10b99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2O(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *ZR^$1@#A"24T$!       :1P!6@ #&R5'' %:  ,;)4<< @   EL%'
M)0  AR<C$Y-38W-AP"!0! 36EC<F]S;V9T(%=O<F0@+2 X,#<X,U]0<F]J96
M-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R871I;VX@4W1A=  X0DE-!"4
M   !#ZX\B[=BNR@&!=:;Q92>5J.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M   0 ".$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M   ),   "6          $                          0
M  E@   ),                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   ),     4F=H=&QO;F<   "6    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   "3     %)G:'
M1L;VYG    E@    -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    "#A"24T$#      A#@    $   "6    DP   <0  0.,   @\@
M 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%
ME:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M !  #VU@ !     -,M2% @(
M                          $6-P<G0   %0    ,V1E<V,   &$    ;'
M=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M  %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M-,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V
M@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'
M1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;V
MUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M  $G-21T(@245#-C$Y-C8M,BXQ
M                                !865H@        \U$  0    $6S%
MA96B                      6%E:(        &^B   X]0   Y!865H@
M      8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M 6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R
M]W=W<N:65C+F-H
M               &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-B
MTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%
M9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)
MX    !6%E:(       3 E6 %    !7'^=M96%S          $
M             "CP    )S:6<@     $-25"!C=7)V        !      %
MH #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P
M!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .
ML \ #V /L! 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0
M%\ 8,!BP&2 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B
M\". )! DL"5 )= F<"<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P
M,6 R$#+0,X T,#3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!"
M $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6
M5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M
M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@
MB"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E
M0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7
MQU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K
M8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1
M%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E%
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MMW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M   ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1#
MP,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@
MX.#A01# P,# P1$0P,#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M8^6;]O\ L]_!E\MZ_H7D:[^F?/L/YXT;USI=,U,ZXZIO>:G1SLI<X>R184U
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=-9N7)XT,<3V[D[V)OJ0_M8E9_"=]$JH8A2Q _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g80783g10i25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g10i25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2W&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +:J^$6D#A"24T$!       :1P!6@ #&R5'' %:  ,;)4<< @   EL%'
M)0  AR<C$Y-38W-AP"!0! 36EC<F]S;V9T(%=O<F0@+2 X,#<X,U]0<F]J96
M-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R871I;VX@4W1A=  X0DE-!"4
M   !#ZX\B[=BNR@&!=:;Q92>5J.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M   0 ".$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M   (<   "0          $                          0
M  D    (<                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   (<     4F=H=&QO;F<   "0    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   "'     %)G:'
M1L;VYG    D     -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    !#A"24T$#      C"P    $   "0    AP   ;   ./0   B[P
M 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%
ME:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M !  #VU@ !     -,M2% @(
M                          $6-P<G0   %0    ,V1E<V,   &$    ;'
M=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M  %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M-,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V
M@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'
M1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;V
MUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M  $G-21T(@245#-C$Y-C8M,BXQ
M                                !865H@        \U$  0    $6S%
MA96B                      6%E:(        &^B   X]0   Y!865H@
M      8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M 6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R
M]W=W<N:65C+F-H
M               &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-B
MTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%
M9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)
MX    !6%E:(       3 E6 %    !7'^=M96%S          $
M             "CP    )S:6<@     $-25"!C=7)V        !      %
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M $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6
M5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M
M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@
MB"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E
M0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7
MQU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K
M8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1
M%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E%
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MMW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M   ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1#
MP,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@
MX.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,#
MP,_\  $0@ AP"0 P$B  (1 0,1 ?_=  0 "?_$ 3\   $% 0$! 0$!
M    ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$
M !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6
M(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B
M>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     /_A0#9H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB
M[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR
M-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XQ+C$V("A7:6YD
M;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,2TP-"TQ-U0Q-SHT,3HU-"LP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 T+3$W5#$U
M.C(X.C U*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M971A9&%T841A=&4^,C R,2TP-"TQ-U0Q-SHT,3HU-"LP-3HS,#PO>&UP.DUE
M=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @
M(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T
M(%=O<F0@+2 X,#<X,U]0<F]J96-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R
M871I;VX@4W1A=&5M96YT(&]N($9O<FT@4RTQ+F1O8W@\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^<G(Q.34V-S8\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HR,#9!0D8Q,C<V.49%0C$Q.#,T,D4T
M-S5%0C1#1C@T03PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HV0T0U-T1#1C1&.49%0C$Q.#,T,D4T-S5%
M0C1#1C@T03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9#1#4W1$-&-$8Y1D5",3$X,S0R
M130W-45"-$-&.#1!/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HV0T0U-T1#1C1&.49%0C$Q.#,T,D4T-S5%0C1#1C@T03PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP-"TQ-U0Q-SHQ,3HS."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C%&-D%"1C$R
M-S8Y1D5",3$X,S0R130W-45"-$-&.#1!/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$W5#$W.C0Q
M.C4T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HR,#9!0D8Q,C<V.49%0C$Q.#,T,D4T-S5%0C1#1C@T03PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP-"TQ-U0Q-SHT,3HU-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HQ1C9!0D8Q,C<V.49%
M0C$Q.#,T,D4T-S5%0C1#1C@T03PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HV0T0U-T1#1C1&.49%
M0C$Q.#,T,D4T-S5%0C1#1C@T03PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9#1#4W
M1$-&-$8Y1D5",3$X,S0R130W-45"-$-&.#1!/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO
M=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( "L +@,!$0 "$0$#$0'_Q  <   " @(#
M           ("0 & PH$!0?_Q  H$  !!0$!   & @(#       % @,$!@<!
M"  )$105(1(3%B(C)#+_Q  < 0 " @(#               &!P,%  $"! C_
MQ  I$0 " P !! $$ @(#       " P$$!08 $1(3% <A(C$5(S)#%E%A_]H
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MF G)=[Q5F,39HV"8PSN<?;GZ9&AJ9LZ6!:HUHM^+063(,;;P"P/D#5B,B9#
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M+'(\V:61%C*L#1LV8>O.!5=#@NIU[KEVP70E9U74$^11[)0OW1_DPKQ)6/\
M)+'Z#]3-T]%%">CKH"DYV"6&: $IN74,*L-6[H=%-M,.1B^@E9]AMRDSF4D5
M#20QV8MQ;B>(!>7V)KU\+C4V_FNX_3>.@^'2]8:=Y\.L4T-\C@TT%!7J1(%Z
MX-;("(B.C3B:)L/V^0_%^&K<MI*BB50AAY])4J1;<KQ$@;=:=BS,''GZS613
M,E]AF].Y'4Z[ZI>E:NT*;QWT?8,IL0<[=2=N;RB#M.?)@5<S3=%#5ZP!0Y.1
M;<Y%#2^8O75,JK,WH"N-+A2DR9#$HAX[J6G\9@,PF3J\?1J(<FHNI.JS'O\
MLLIMYS;"'.6-30:U>G%& LS1=!B8^ D-%O9M9'(Y+1%?\7NOSK"76V6HS0UJ
M4+K-JWE5W)296:*UMSRN>=>+:9&1GO,$-_HG'_0F+>=<MPK!Q>WVW#6C9-Z]
M$XT1R!K[-[J5NBU[.90@E:S-EK-4R@[?G<\L@*L5,"P_)JXD^;[-@"WB*>W^
M#JX.SO:>UMMQZNR20BDHCAF3-"W4FS?6X*JJUJSJ(H?/K.LVGR(V6(3 FP0[
M46WE;63B9V1CAJV<CW,*XT E6I%RK9A% U,M-L5ZV<V[\)Z$54P15U.;YK7)
MSUFTB!L<&J^)(.[*F.:>Q@VW\L2"J3B[&R]RY89Q+=I?.F3\Z;8N?[*)369R
M!KSBD?C8<*%QB.C5 \D[/,#Q/#^,+;QOC2OTP@H^'LSY5A0E !7G_4N0EHC'
M]I$SRF>=L-0*_% V/*= <;7]\,]TV(GY>1VBR3FN)CX_V&)0LIG^L1#QB++Z
MMI4',=PN(G-;'I^=!#LSMR)5^A[)K=.K;EGM*W"EB,1JY7;L-!CI!@D\]/G(
M&P(C#TMUU_K7''%J5U.,WFZ&/4;?1FWG)&::WW<C*MV(K5>RJZBL6*3',%*A
MA82QAE 1 ]^T1U-R.DNAKVET'Z-%3C^4Q%/6U*J)L68AMAHH1<6E9-:1,/U@
M,$927;O,]>U^-L#S+8WI%IV.!:M@*TLBU-J[>M:9INF! \U*F5(F1JO>+@>K
M*I;2_HXS)?$//LN)0XTXA;:%)J>5;VEEB-;*95REVQ8NS.7FYN<]J^P]P*S2
MJ(L^$]Y@AAL043,%$Q,]6W&,:AID3],+.FRK*V5XTM#0T$J.9/\ ,:]RTY$G
M':)@B5,Q,=XF)^_3DTI2A*4(3Q*4)XE*4\YQ*4IY]$I3SGZYSG.<YSG/USGZ
MY\*K]_OIG?K]=5FY4RI:%6BU-O-;"VVJ'HW81FO6 =&*B"452DJ_JEPI;;K#
MO$K2EQI74?S9=0AYI2'4(6F>M;M4'KMTK#JMI!>Q-A#"4U9Q$QW$PF)C[3,3
M'?M,3,3$Q/;KKVJM:[7;5N(59K.'P:AX"Q3![]^Q 43$]IB)C[?:8B8^\=(3
M]$YP*Q?09=&RBU['0*:.:^HVKUG?MT&@AJ7'7%*9&C&M%^T'QN=_\18;3,9O
MGZ;:1S]?#KP])VM07<TJV3=ML[RRS8PL1CV3WF.[&SG^9E/:.Y',E,_>9F>D
M]M4%9ELZF?9U:=5<C"Z]?;V%I7$@,R*UC?\ $![S/81B!C]1$1VZ*_Y?.<UF
MP3+UI%M79[Y>!T2/21EBT:^7O1IHJJDGXIPB%$IO-DL$85%GEA0V=-Z/8C/2
MGH,;C[JT-(1P8YSH64KI4*WQJ5-AE<:C/I4L\&V5B2%N;-*O7)I+4U@!["(1
M@R[1$S,]$?"Z%=IV[]B;-RX 146^]=NWS7680N8I7S+#Q4)L6LS]<#)2 ^4S
%$1'7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g80783g10w05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g10w05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1*L4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M         %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L
M 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M                5&]P(%5N=$8C4FQT                4V-L(%5N=$8C
M4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!2
M96-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -
M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     GX   =-          $                          0
M   '30   GX                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   GX     4F=H=&QO;F<   =-    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )^     %)G
M:'1L;VYG   '30    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZUSP-P#U *]<8E5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M>"_(UKFWL$.O7G" B B B B B B B B B B B B B B B B B B B B B B
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MFO*^6&*2)CY)'/<6RO:]Y>7:N<2T6).@%@+ 6Z^=\&&A^I-MQ W&75M]8O\
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MK;F!SC=))!^-D?MU&4^V[?I4^"#65 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M%[$<BN1KJ5U%6U=&_P!.DJ9Z9W2\$KHR1?D<MQU%BO4&=:J B B B B B B
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MP,JJ>:FD%XYXGQ/Y'*]I:2#R(O<$:@@$;+-15<M#64M; <LU)/%41'].)X>
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ME$#4\.8S3;NH*K#\58.?=O<_#:FWK=4TCG':S!SL1((F%SJ B B B B B B
MB B BK[Q6F?^QOUG8(]ES\!O*IOWF[;L>RV4_2MV6A)%W/?8A-<._P#3N%GD
MRLBD/@(SWA.O0-)6Q2?QF'P>#[!<GZ I]81X;#+>VWAM-HV[;<J$IVZ>[80Q
M-R3U)/O*UURBB*/8;9T.H%A'+9%=FE<FU8W/9)9#2)9@V+:"[&Y-J%UTC;HI
M7LZ4[U^-RP\8\DQB9FC8<3@$[.0\LI@V*8#H9:<POMS[E[N171S.^,.'::4W
M=4X%5.HY-"3\6UY=/2N)_%@K6U,5[D#RF)FF@.$WT8L>XA,%R0EFU$S_  7)
MM/9R>57*_=8U+8S;&-S+9/B)JCS@DJ7S*,N5MLOC*,=G"[RC :ZGW?A];38B
MS6Q$%2UU%56\.]%$2-!S)L%S!TD:?QFEOM:<P\-B_P ?9=3P(19$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%@V I;56W4YHS-%
MGF&62R-1;&?A7<JO+_@D4$B1_().W3816$!I@J96DD38EB+P23<AM9+"+WUV
MB%OT;<K*?XB+VU5! \ .I<$P:$@7L,^'PU/,#6]1=WZ5^=ULU"4W#JJN]677
M',EH;0UD@EJ1&>G(J+%1$9I))%66DTU.*,DM(YG%;$C<J8P1%3P59_Q*MI)R
M;7M&Z44TYW %H)Y;N)LUMW'97<-AT]95X>W7XTPK$:,#-E#I64[JZE'B364=
M/9HU>;,&KEGG<2RYY 1 1 1 1 1 1 1 1 15IXOI+D;A_P P)DC4Y+N=.:M*
M$]W"M]3<.K%MD7GSHEJ29;'N1GT,3W#(!QJEN;!D5=+?D.ZP^KD!]A9]6BV:
M3^,,]4G3;NW]5980(V'[_6M9 18#J)&D(I6<A@-*>LL0GL9'$:;(S<?CQ4N,
M7,-)%NI1SJ.38QD((E;O+9425&DB$3C+'BE;61-<Z?#9F5T;6>D]D5VU,0&M
M^]I7S,L-2XMMK9=!PW+&:Z3#:A[8Z7&J:3"YGO(#(Y)BV2AG<3H!3XA%2RN)
M( 8UX) )4<\0,IB-@&.ZG0ED\C3/,\-U(:E-J+E^#S<PJ;+)'-OR> >"Y#D3
MCBU$M*6>9Q!<Z4*+L.&WLJJIU(UP?%C.'U%'&1JU[YHA4T);R\ZLAILNV8D-
M)L2N>JHGT[Y(Y6NCEIIBR5CA9S'12%DK7 VU: \$'6XVOHK!)4E:4K29*2HB
M4E1=C(^I&7S&780JJMP(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(L$RC-6L;R#$:=V/X
MC&0RY3$V67:L82EB-"E/;*(D,R;B; KC<7LE+DI'4C,A$U^*-H:S#J9[,S:V
M21DDFOW.P!C(I'D:!LE3)%!<V%Y!J+$J?PK WXIAV,UK)<C\,AAD@A(%ZR1Q
MDEGACYF2&BIZBJRMU+(G=+'.Q+* 0$0$0$0$0$0$0$0$0$0$0$6U:TH0I:C)
M*4I4I2C[)))&9J4?D1$6YF?0O,4) !)T %RJ@%Q#0+DD  ;DDV 'K*P;3);K
MV"8Y+?2:'["&Y9OD9<O,]9RI$]Q9%Y)<7(-Q/\E1;'ML(K BYV$T,CQ9TT1G
M=I:YJ)'SDVY9C)FMRNI_BIK(^(<4AC<'1T]0VEC(-_,I8HZ9K2>9:V(-)YD%
M91<U42]J;*FGH-<*TA28,E)'RJ-F2TII9I5^]4DE<R5?O5$1^0WZFGCJZ>:F
MF&:*>)\3P#8Y9&EIL>1 .AY'51-%5S8?64M=3D-FI)XJB(D7&>)X>T$<VDBQ
M',7"Q_!K2;.IUP+=:5WV/3'J&Y46Q>L281(./8DG?<F[: Y$LD>1>M&@C-2%
M;:>%3RRTQAJ#>KHI'4=2=;O?#;)/KK:HA,<X_P"\M<V4CCU)!!6BHHFEN'8E
M"S$*$'7NXIR[O:8N_"=1U#9J5U_./=!Q](+,Q)J$0$0$0$0$0$0$0$0$5;>*
MAQ"]-\=K'$$XB^UJT"I5(,_EIEZR84M1;=CV2PHS(^FQ'[A.</ ^73R V[G"
ML9EOM;+A=6!]+@!XK9I=)''\6*5W_L-OI(ZZ<E9(08T '1:R BVK2E:5(6DE
M(6DTJ29;DI*B,E),O,C(S(R\R @$$$7!T(.Q'0JH)!!!(((((-B"-001J"#L
M5$=-20\GP'+],[A)KCPV\CP.8A1ESG33HCB*IQ)K)S8SH;.#R.*)S9Q"E?&4
MDQ'\.U3Z(L:PVFP6O,3-?Y."1M11WU!RFE? -]0#KN!/\31B6KAQ%H^3QN@I
M\1)&WE,K708@VXL+MKX:DD"U@YN@!"Y="KJQO=(\#E72_$OX-$QCV2'R/-F6
M28NX[CF0$IN0I4A)^UZN8>SZC>,C)3A\QF.EQN&.#%J]D(M ^=U13BX/W-56
MJ:>Q;9I'=2L'FZ:6&RYR,DL:2;G* [^<-'?2"I9$4KT!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!%%4ZFA9ED^;0Y!\T>#C-;BR7"ZG&GV*GKV0\THNJ'XZ54<A!I^,AQI
MIPCWY=H"6FCQ&OQ.-Y\R*@@H X;QS2N=5O<#R>R]*\#JUIL.?6T];/@F%8%/
M%I)48K58L6G:6GI1'A\4;VD6='(1B$9O<%KWM(()6587=OWE!&>G)2W<0'7Z
M>^83V8NJMPXD\DET,F7W&REQ3,MUQ)#"^I*W.0PRJ?5TC'S -J8G/IJM@M9E
M5 >[FM;\%[AWD?6-[#SNHC&Z&.@Q&6.F+GT,[8ZW#Y7;R4-6WO:<GJ^-KC#+
MTFBD;R65C?42@(@(@(@(@(@(@(@(@(@(L?RV<59BV1V)]H-%;2SZ[?N$!]SO
MY=4EU(RV[_,>GB$O<4%;,?Y*DJ)?FX7OM[;6_6-U(X13FJQ;#*4;U&(44 .]
MN]J8V7MSMFNMV*P3K,8QVN-9N' HZF&:S(B-9QH##)J,B[<QHWV\MPP^+N:"
MBAOF[FDIXLVQ/=PL9<^)RZJF+U JL5Q.J RBIQ"MG#;WRB:IDD#0>8 =:_@O
M>&XH]1Q<(5C69U61M[IJLG*-B]\E)$3;%D2G5XY;.^6SCJWJ1]9]5',KN91(
M8Z0U3>BQ*GJVW%/79*&K ]%LXS&BJ"-@2XFE<=">\A!)# %TE&1B>"56&.L:
MO"C+BV'N/I24I#&XI1-TN<K&LQ"-M[#N*H@9GZR.)E<V@(@(@(@(@(@(@(@(
MJV\2:F7XVB-0X9^)<\1NDR(Z2V/G=H;*=F"MR/;<D,XXZ[TZER<W8C$[@5P[
M%I!M%@>)$GPFC92C_P!U0T>U;-,/XP>E-,=?$-;_ /MI;GX75DA!+60$0$4?
M)0JGU'4HB2B%F&/]>NQ>W,;>(NA'L1NS*B?Y;J-NI,SV2WUB #38R2-(L2I-
M>GE=$X>S-)337ZEM-X+HBYM9PR 0348)B/FZ7)H,5C)(OR9!6THM>PSUNGI*
M.,4<?TOU7O, G&M6(ZIV-[GNG\]S8FH&6/&FQSW"'%_^UF/+D9O2$KX[[$K(
MV$%R5*>;M:H-Q/"X*]G\;PN.##Z^,:E]+][H*T#HQH;13G4!S*=U[R%<P/,>
M66\UUW-Z!V[F^W5P]O@K$"!65 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M6HB,]WDIV/FV.(Q*:&JFPO#8IHI)<0Q2DC$;9F9GMIWFJ+;!U_/D@CB YND
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M*YL?#V-2%S6NDKL'IO.(%V.;B-0X"YY/IXR1ZN@OF$C(Z6?.]C,\D+1F<&W
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M'D+="XMN^NFU;J^,W:3DJ[?QDOD8E<+GF\H/RTNPWD<>OBN(XVI:/XL;:F@
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M-7ST(O;Q9L<]W;KW\/Y5E-41==MMC?,BW(BWV(C,N@S000$NO#$02?Y-IV!
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M/I'AZ67NH_E'[B_G.%]?7K]OC=>J89149%S24UMQ]SQ6V/Z&MN715@M\AO\
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M8<3OS6-RO1)\!<U1JD:,RW#/O_=#U'3_ -7*B$U%V6\%0BT>%2-'_CZ\^O\
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MHM_IVRPOJ]PE&=F_"#+!N&O _P#&UQVVO>I.O735;/\ SI.VZUCQ=&1T^(L
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M4>T.BTN&6#6ZY3<NR.!OI<C, 3J=3<'I=9^MB[,;WU%K @"Q&QWVVYC9==S
M>*&NU0T^QEO)=6(FGN-9ED\+#;.4C)<Z9F4-?JWDD]^)J1<0\^H53(%YI$='
MCU#?:E1,P;:BNRY-8R681F4V-0Z+*XD#,0"X ANMAZ-P=<UR0VWN5"UX( S6
M%P#OI<W#COJ+ $^SFI;X1L:U5PS,9F.9C1Y_\'H.B6D$!%ADLNVK<8P[(J/#
M<7JYN 8I1KMYN+Y&V]+1>9!99?15U;;5ULNRQW(7;".5 ZU9,YK@"W+J]YT]
M(@G<BP(Y  \A<<[7QAP<;@@!H TTTY#J.=]R;[VNOH$,"RH"("("("("("("
M("("("*JW%'2ZB1:S#=2M(*&3D6HN%VEUCT2IA(:.3/H-3**5B,CQ5NI-"*O
M'\N>PC.KE:U);:JL0F.JWY"2>6,M\YKB T@$D\BT@[:W-LP MK=8Y ?-(!)!
MMIT=H?=H;^"JYEN*ZSZ8-7N X>C6:!ISBM9:4.F$W2NC3-NK/.:+1312NTW7
M?.PZZ4](PNPREK4MR]L+MLL;=R1E$?)[&-!;BLGD!8ZSCDS$^=F-@ 7ON=[7
MRY= >=P+V5EG D7<  ;90=39MN1)U)!-C;;HO-KJCBIKM2,9IW'<GPJAN<[N
MLAMI>.XWE=MC%EDUSJJ;^;IMG<?ARX\6@M,/4PUC$_,95530XEC874&6Y;UJ
M4M7$Q%I(#20T  D @!MF@7(US7)L"3>QN%2TF8;@7-]#S.I-A;T=M1KJ"I&H
M<*R.OX4M!*7)</U.SB'@&<XI*UCP3*8]Q?9I=TV//7=?9(136C;TS.**@RYW
M'LPA4\,I[&18_0$JD1;FJ'"F8[CO)+%K<S2&N;HT.(%B"?1O8Z\COI=76^3;
M?,;.#G ZDC737<"XVY!='(<:SA_4]S5C17'=3,*Q^)5<-M'58A Q%_!*F^JT
MZ_9["U9BY#AMM3P):FX>%7MA=_AT:(59%M(V3L-E(>;D'<"TQY'EI=>4DDYB
M/,!80?%S<MA<Z[ E6FX=F:"UHRZ6RC<9@0HIPU/%KGK>519=CQ X1C;\?)<F
MH6YC-E7Y)7WSFCL:7!Q)5_DU+#NK2NJ=3&?"9<CU=-36]HS+BU4,\6GH9E7$
MQ"VD9-FM-M1Z>KN8!+-[GW$)\H?QP/.WN#Z.@.E[9K6M<^/7(\M+C+BXQ+S+
M'['4Z1EF1GF-9=8R[ :=I\8QABKT\L(\_%J"#!.3%R1HT9T6.S6#GW$ZQF+J
M64R_5JJ,P @U:2VP#2#K<NS.!!-[$9<MQ>W,<T/>[C->YTY6L.5AS)L=-EPN
MP.(*EQIW,$O:J9-?'!TR:;:J\9U H,IU HZ?4+B'EM:<3KEZC=R[%)-937N(
M.OYCE5)&B2UQ*=&6*AUF139R*?)DV&4#SKZM(:XM9J0-#K< -<3OE!-T\_?S
MN0&CKFQ.G*Q( N3H=5]7DF9I29I-)F1&:3,C-)F6YI,RW(S(^AF1F7N&JMA:
M@B B B B B B B B B^0>N/#?K?FNI_$/88YB&7659E2=0)6-';WVF[>G$^'
ME/#MB. Q)6*0E349U U.DYI0,TLV=>N5^*Q\)3>(22Y=E%=/;CE8UL8) RY2
M;-=>X>2;Z%I&5QV%\PNM=['%SB!>X-M0/P0-.=[BQOI:_591J1@7%UDK&18W
M05N?U-;2,:@P9ER>7TT^+GM+D/$QB>:UT'$ZN)J7B]LJ6UHHBYH(*[FXPA^
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M!E>- =";6+;MU+B-=&D;W5;/%K7)T.M@--+&Q(T'B;\KFX7UF&JLR B B B
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%1:@B_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g80783g10z99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g10z99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1RL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ')"^<Q(X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   );!1P"
M4  (<G(Q.34V-S8< @4 0$UI8W)O<V]F="!7;W)D("T@.# W.#-?4')O:F5C
M="!#>6-L;VYE("T@1')A9G0@4F5G:7-T<F%T:6]N(%-T870 .$))300E
M   0^N/(NW8KLH!@76F\64GE:CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  "(    D          !                          $
M )    "(                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "(     %)G:'1L;VYG    D     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    B     !29VAT
M;&]N9P   )     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     0X0DE-! P     $?(    !    D    (@   &P  #E@   $=8
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (@ D ,!
M(@ "$0$#$0'_W0 $  G_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDDE*3)U3ZKU
M&GIN%9EV\,'M;XN/T6H@$D =5$@"ST8=4ZSA=+J]3)?!/T:QJYW]5JY2[ZW=
M;ZA8:^F4;&QPUI>[[T'I72\KZRYUF=G/<,=IU/C_ ,%6NXP\+%PZA5C5MK8W
M00%.1CQ:$<<^O[L6 &>34'@AT_>D\3ZOUXCU(OC]V/\ OJ+1];^M=/L%?4Z-
M[?Y32QR[B @9>%B9E1JR:FV,<-9"'O1.DL<:_JZ%/LR'RS-^*'I?6,+JE/JX
MKY(^DPZ.!_E-5M[VL:7O(:UNI)T "X'JG3<WZL=09FX3B<9Q]I_]%6*?6OK#
MD=<-&!T]KFMM ]1HT)>?S/ZK$?N_$08']7+J?T?-'OT")CUCI^\Z?5OKQ52]
MU'3F>L\:>J?HS_);^>LS[=]=<LA];;6-=J-C=H_%=%T+ZL8?3:VOL:+LHCW/
M(D ^#%M@! Y,<-(0$OZTTC'DEK.9C_5B\%^U_KA@ V9%;W,;](V,)'WA;71_
MKGAYKQ1E#[->3#23[3_:_-71.:TB")![+F_K%]4Z,NM^5@-%64WW%C= ^/\
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M-63;I675V;O('W?D5GEY6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MGIG^._U7;IFE$522K^9ZU4C):,>?E,YO9$16I%EVWY59BAP2K)2Y%?.]$-?
M86._QT+KIG1^E.>;U^/KX[SWC-15N+*WZ.7:!3!%=^D+;*YBIIUP)@5[BX_B
M 6%!#(LZ#R\!]!=N'O<+Y#995FNQ-#2K&Q92VC;)=<XFSGV"$"?5/^DY6,B7
M8=GUYR?_ .03_F_'/_8W0_\ R85]7>"?P<J_WBC_ -;/J/S#^+C?^UW/^LCU
MJD14(U'BC'8+A!_Z8?LB"FFG.N#_ +"BD>LIJ;XVXO\ 5XWT?]MQ3?4):2Y^
MOSB/R_D^[O9K;!SS'7=T/F7$'JF.I\8&>*H7/4>7??C]]S,_?\NOKUL6D/\
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..EQ]]Q/\ (8_'7\_7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g80783g11b87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g11b87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2R84&AO=&]S:&]P(#,N,  X0DE-! 0
M    +'R^$3B#A"24T$!       :1P!6@ #&R5'' %:  ,;)4<< @   EL%'
M)0  AR<C$Y-38W-AP"!0! 36EC<F]S;V9T(%=O<F0@+2 X,#<X,U]0<F]J96
M-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R871I;VX@4W1A=  X0DE-!"4
M   !#ZX\B[=BNR@&!=:;Q92>5J.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M   0 ".$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M   (D   "4          $                          0
M  E    (D                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   (D     4F=H=&QO;F<   "4    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   ")     %)G:'
M1L;VYG    E     -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    !CA"24T$#      AW0    $   "4    B0   ;P  .V<   AP0
M 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%
ME:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M !  #VU@ !     -,M2% @(
M                          $6-P<G0   %0    ,V1E<V,   &$    ;'
M=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M  %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M-,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V
M@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'
M1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;V
MUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M  $G-21T(@245#-C$Y-C8M,BXQ
M                                !865H@        \U$  0    $6S%
MA96B                      6%E:(        &^B   X]0   Y!865H@
M      8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M 6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R
M]W=W<N:65C+F-H
M               &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-B
MTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%
M9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)
MX    !6%E:(       3 E6 %    !7'^=M96%S          $
M             "CP    )S:6<@     $-25"!C=7)V        !      %
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M $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6
M5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M
M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@
MB"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E
M0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7
MQU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K
M8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1
M%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E%
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MMW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M   ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1#
MP,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@
MX.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,#
MP,_\  $0@ B0"4 P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M    ,  0($!08'" D*"P$  04! 0$! 0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_\0 &@   P # 0              !P@)  8* O_$ "X0  $$ P  !00! @<
M      0" P4& 0<("1$2$Q0 %18A%QA1(B,D)7&!D?_$ !@!  ,! 0
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MZ=:(NP!HU="WFV,C2N7-1>="BL6L^]6!-?0:AJFQ?KYMH(&Y5@9GXD^<01>
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MS*Q?H1;"O4PJ)NU<(B[*&AA:LK;'1)9$]?\ B4.K/T=R.3[F#Y#F:#DH9/\
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+@H2=,!$#^_7K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g80783g11x22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g11x22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,R^8T@X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   );!1P"
M4  (<G(Q.34V-S8< @4 0$UI8W)O<V]F="!7;W)D("T@.# W.#-?4')O:F5C
M="!#>6-L;VYE("T@1')A9G0@4F5G:7-T<F%T:6]N(%-T870 .$))300E
M   0^N/(NW8KLH!@76F\64GE:CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  #E    B0         !                          $
M (D   #E                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   #E     %)G:'1L;VYG    B0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT
M;&]N9P   (D    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     @X0DE-! P     #BT    !    8    *    $@  "T    #A$
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MQ8][&@MW#Z0:2YN[:G1A*1J()\ELIQCK(@/+'_Q<_P#H?_WY>D]UY6>I8_\
MSC_:L.]#[3Z^V/?MF>/WEVF']=^CY>77BM%M;KG!C'O: W<?HM=#G;=RL\QC
MF1 B)/#'5KX)Q'&"0+EH]"DF3JHVE))))*4DDDDI22222G__T?5)7E]&%3G?
M6I^'?/I795K7[3!B7G1R#;3G]4ZY?CU/=9DW76;=SR!#2X\_F[6-5S_F3]8Y
MGT63X^JV5>QXXXKO( 9Q\J:>2<LE5 D1/G;T_P#S"Z!XW?\ ;G^Q<G9AU87U
MLKPZ)]*G+J:S<9,2QVKD?_F7]9?]&W_MX?WIO^8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2P1!VFE78DQA^)< $E=_0CT-R'''6D[/'K7L_P"./ST^7'V_P3S_ ,:B^?\
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M/57!FZ*")DT24;KO#5,!JK*XR@&6G"\$L$;,7,*6:T-CL\VW9A&TI52Q+<0
MQ8@DW3HG+VLYIG&9*Z5:U*DT<[H@19'KV):_<X#8*TBQJSA0%#E@H V -K2C
MTU]31T=31T=(I9@_*YD_^W]P_>!_K9.*^2\;]@I_=X^LBY/Y1O?;+?WB7KG)
M_D']/^PZG'W?VK^T=0>G%.G!_(JP5_44[^^%BUEG7_SOS7]?#]U@ZTYH;YJX
4C^IE^\S=&_I.Z;.IHZ.IHZ.O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g80783g12q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g12q33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '8R^=60X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   );!1P"
M4  (<G(Q.34V-S8< @4 0$UI8W)O<V]F="!7;W)D("T@.# W.#-?4')O:F5C
M="!#>6-L;VYE("T@1')A9G0@4F5G:7-T<F%T:6]N(%-T870 .$))300E
M   0^N/(NW8KLH!@76F\64GE:CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  *G   "GP         !                          $
M I\   *G                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   *G     %)G:'1L;VYG   "GP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "IP    !29VAT
M;&]N9P   I\    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     <X0DE-! P     $NT    !    G@   *    '<  $I@   $M$
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MVR-[2[7;O0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\0HS4G(7)F."&"4G-#5#1$5D9762HJ/2_\0 &P$  @,! 0$
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MTAVC!#_6(T!/I'6FW+\0_+N,#Y+M:GD#($6DNHR<XQF:Y$'OKJ1L#Q/R%_\
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MSL?_ "_]4WXNG]G-VBCS/.[FBT!U5:&^1C5ZE4_YO_,6FFM_;'].((1) ?0
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M8W#",^+E\[7C1DUB_+^F/=2KSNME*T@J1!KM2IS?4=B&H,F,@#4YPD=O31P
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M'6/WT%QI2;)2M:TZ8^0#&-=0#K^6<CO^'%X 2&&=^)$/Z>%*#]1!$_I['/B
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M&&6=0<W),DMIZV&;5BF<MN:-/0DN\N>8#X _B&GV9<E62V0,G"Z53)C:QO\
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M5UU&MU*3S"H=8E2:HN!95T\R(D&[:3:M+5(IJXLJ-4*;0J.S3#3N.A\:_JG
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M:=*IUF4RLP:O* 5"6!F 6+#=#Z EW/[4P&$LI> 4DD#>#*W_ *1O'> !2SD
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M]1^&_P"^_!IGVMU_>G=@ H27%@;G0%]'K,AW4D'&<#0C]?IOMIP,-*D2(9N
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MY#,;_AVJC7''L.OLCR7$K;\MM/EELO'S$XE8AWRQAV9R<X<90.%NM7!((!S
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MLRT[I%[&]XW?R.-7-NNY[>M6"]4;AJ\"D0F&W'7'ITEMA*6VT]2E)"E!:ND
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M_ YT%@27_4'#W9M<P?!Q%.* R24G<:XW]1Z;#'%2N;MV86X6\SG3IL3+DOE
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M+#*S<9UI2HE(2P"0082#]1$/F8.@R$L**UMX^?( .!Y[PV.B0L_*!Z8P-O\
M3B%EG$VRRF^K']J4D<K,UH-WCCEF-*NYX2W1_@&M=1QFZIF#IL*;3/3]^_&3
M$+J?AZFNEL?_  BUM\SF?I2[]8%6JX2M=<NWVK+"3XN;B/2E1?Y?62KI5@!9
M,"<R 58.$J+(258.!KN,<=O8 #@2'&^H'KE8ZF&L3K7(VW_CDW^A+"^9RYA^
M\Q$J^ >J7/6_"=R;J=WT1-NW*_1:VFKT5$M$]-.DQKNN&,&$S$(:3)26F&G$
M.AI!4E224!74"R 0&8)D_2"X$FQ9(Z 07#DTJP-YTE1LRB&)^D&0;.7#6A\Y
MNBDZ 8.<9U([_B>_L<<2IFF-6#^+6D\WYU :  ;.-&/5_"*]:X&=],X_IW^A
MX@DDD DL-1RLP#A]189U,L'O#MY9\C0ZBC^;34[9P!G(SKN1C/OG;M-_M+6R
MYC09CPH@=)B .)]S,1&9"L@'._OWU/Y[=_Z:J2Q9R&M=CQ,EY=\V>28HA0YC
MWVHXRY\P!U/OZCZYUQPR5 FS%I]/.D(W6(&9_:3 .MLVIQ0W<$=AD:?V]]1I
M[>G"DW2PAVUURUT%R0-::Q&CVX&S=06YY"N?W[:EW%W<IU*!(-ONZ8&I%1K.
M!GMOG]==,^1_J.<390!.YB\+%,3[>*])\$MM$!MY+-G=NP:&SK0].KU/IJ4J
MG3&8W6%!IGYG)#Q&>D,QV@N0^K0C#3:P ,J P2//)PE*A().9) 2,S]1@<G?
MF+]Q2TIN0+!L\@($G+*HLJ5K71S9N2DRK6I[;5*HBG(]4J=4EMQ8\7[Q);;<
M<0RB3(^5+3B@S':>E I47F&$ N<=#!Q<+8L+$3BK=6( 4)0"26>0[ N[;SI3
MH; X\5*]HQ$'#00E)*2I4"06?,6+.Y:XO3ZI'A[AQ:O+AU6MQI_P)0/BX[:Q
M#=4H(4?+0I14M!2I6 M7F+4$=#:5+2DUGX@5)"@DIM!,CBP83+Z<B*<;('(*
M@6+;PSFPES8VUUBK'V[RUMRE1VT140WUX2M#G4VXL* #@(4@ ]:4%/7@  -@
MK;2I94<.+M>*IW*@';-O5^!Z<*V8>RI2 VZ[.)!+AO,/8]9IVNVS&0@#I2D
M9 0$XP,')(Q@;$9'21A1(PX.*#BAY>1&IC,7RJ\X,68\W[Y::=@6295-I<&#
M43*<05J@22AI*2X\YU-J1HT@%P$$*)*BA*0VK^(%-I*@J)$ LQ=]/>CY<:@(
M2D_40"\)$O:&=P7XZVJO+-)G5RH-P(-)=3 Z4J>>26TN*2M?SI?D'J9BMI0
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M-F=SH20 ]G+C5F(=^4J5%5TDD@O)'XZ1QJ29+JE9!.!DXVP1G?3\?TVXL \
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'X**'!17_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g80783g12x66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g12x66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )X:^$!&#A"24T$!       :1P!6@ #&R5'' %:  ,;)4<< @   EL%'
M)0  AR<C$Y-38W-AP"!0! 36EC<F]S;V9T(%=O<F0@+2 X,#<X,U]0<F]J96
M-T($-Y8VQO;F4@+2!$<F%F="!296=I<W1R871I;VX@4W1A=  X0DE-!"4
M   !#ZX\B[=BNR@&!=:;Q92>5J.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%[
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  >P    $  @![
M   0 ".$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M   1    $F          $                          0
M !)@   1                       0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   1      4F=H=&QO;F<   $F    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   $0     %)G:'
M1L;VYG   !)@    -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    !3A"24T$#      <Z     $   "@    E    >   16    <S
M 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%
ME:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M !  #VU@ !     -,M2% @(
M                          $6-P<G0   %0    ,V1E<V,   &$    ;'
M=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M  %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M-,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V
M@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'
M1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;V
MUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M  $G-21T(@245#-C$Y-C8M,BXQ
M                                !865H@        \U$  0    $6S%
MA96B                      6%E:(        &^B   X]0   Y!865H@
M      8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M 6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R
M]W=W<N:65C+F-H
M               &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-B
MTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;V
MYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%
M9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)
MX    !6%E:(       3 E6 %    !7'^=M96%S          $
M             "CP    )S:6<@     $-25"!C=7)V        !      %
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M $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6
M5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M
M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@
MB"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E
M0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7
MQU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K
M8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1
M%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E%
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M"83)BXF229D)G\FFB:U9M"FZ^<')R)G/
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)RA3565S=862_\0 ' $  P$! 0$! 0            $" P0%!@<(_\0 /A$
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M'^JH'(%3R%X9Q<,!1,IR0CS2$5_CFOF(B4AAL'93\_S0-] RVTS8#_\ ;O\
M'308!N>]:UTC,8Q-@/?T>$U[C)7W@?+;I[(-@%,,+)'Q+LA]).N]@-CR@$WK
MY,HJ0NO['I"FQB"BRZ!?P7-*PEN\2LS/$@5%2"25'RFHZ"-=K^6K2YMH +;
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MJ3G]R+6Z70T2W3B),J-*AXD+ K*F1<&;)$) *+#F& 99B"#,$1TK*5=Z)FC
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M\&WJVQ';G2.%% K=+@1R84-RBRX[+"93PS)66WYK27FE(B2X]"-,D/>:$&&
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MQTW,5<SW4^'=-J-.X%0\DY%RYE]=:S_4V9;$E4AN::Q5:%EF#2*I*07%NSH
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M/W8],,@R4?9<F]8\LDH0SH.:CG4'_P"NZJ ((N,8D)ZM%!UKKGY:&WK'N%
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M+!0\JP-P;?F/4?G?H< I,;MYF,Y"% L^C[=1JQ11%6JK3_\ $GKIL JP%O\
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M#TU(_,? [G\,""J/G#2JDFZ(2ZYAEJ%"/S$#*I]D@<NIO?4;_$_?I?UN<.5
M#6R%2HV]PHA3!2H%#D%W2HO6JPTZU3DNN0D\MK36E6.Y*4ND&P];#ML?A7U
ML55'MD]E*:EH2F7Z18VRRN/LXBT'A$A"/G7-;EB/]WVD#_J"IS:B-]=!M;3T
M&^9D0K=BZWZ:LSJ*4!.2<PAH'J*<R!7D3%T*R1==KBU[FQL#M?3MOA2E6R5<
MEYE30FZK8M%34)<*179<VRO0->+0< R!DF22KD_QZ<+)U)_V6!K;L;:GOIB)
MZC;W,=GABN%_\CED,N]3$Y/ %!/4$$??;\\1'1'R]>+PTZ/XU>-M4K5&A5R#
M1\^Y2?--FQH[[$I$7AUD&HC^'+:=C+?9DO>?%+[3K")332G6UH2I)]L^%F\3
M\'F\/@K)BXN&91B T/$JHQ*!;A,\OG?$8V%@^/&+."91,#,$2Q"*ER?-RAB:
M/#7GBC9R@YLI5*S#Q#S4[E"11Z;.K7$>'EYFK.2)XJM43#:J5%C1I-7:I[,A
M$4RJD7BA+;33"DK$E./._P +?!O&?",''D\7B'$$^(9Y)RH4<4Q(X>*9$92M
M266O5\1\9@>)&%-@2\) 2851F*D2DEB@IF5BS#J4V(&MM/@2;'Z6Q]3,7!(M
M3F;_ (&58\BZD5?)5A-=0E)*1<;C7J ;7Z6]-]L2KJEUA3&IS4UIWM!-Q([$
M6!MK>_\ KBQ,0A4%4!/J$S"UNO1$:GEY_A'%C!1:>O;?Y8TA<24"YNG5<F7*
MZ)!=8%O6_;\3^MONQF!)* ]'R5*HT-4J@R?W*>D$G4; 7OOJ?EZ88*% 5&Q9
M^9?2^T7*4+W;SK3R@HX"+7&U[_3%K]37 JU.)=5Y=(OB"UJ@H=?P/."3I N2
M-_P&QTUZ$VW&$QT4E2CA2XIJ!D0JPE"9U.H4N'W&A"KD2XZ=!^&&'E9U!T55
MS7SBD^E [;*WDL>E13]D@@=]/R_,8F8HE ;NJ(B*E>8,09@&0L@5<J*Q%KP@
MYH2B30YD96OF.0- /YA/C$"U[D^MNYZ''+XPGY1"+D:DJ6+!'32SK'1X:;_5
M!+  A[DZH*9 /%=J?0DC.>8SY=B[E_*9V)NHU'-HO?>]C?8:CK?'S$X(+W);
M+N\>H2Y=4 7.G1$I[1*%'HH0I)*+V(UMTO\ 3[[Z>AO&7?G$336'7[:^GI)\
M&F\H2 + D: 7Z"^Y&EQI?UQ<LJU6A4]0@*H:ZL+O&>[]T;IGTATQ80"P.3:V
MFQOIH!KZ?UMBC+1T-RE==\RM7M#"!RYRH-_P^L.2'#057%@+W&FVMN_73H?3
M:P7R]?+\QIQK:Z(M:K:WO#@\E*4VT(Y"+*%P"!WOTZ?TQG%73)'W72Z..E!$
M3YP0D-N)%NQMJ-R>_3;Y$:6Q<LJ@NZ!^=QR6N41B,0=&KG%::@P@U5X@^FIW
MN;W[B^WY;8T1 !R7O\PB?J<N@0;HQL:E::$67(D-)"%$ @!6@/7H/6VA!]3T
MPP*#[G\F*4.!50I JX!-"GW2L+K;"+$<I'RW[[#?UMUZ==/EFY]_M$'Z4*@*
M5#TZY^:7@?V8%!/(>NMKW_"PM]_3?#$@&OES8P W)5$(4FFA5,NQ#8JL F53
M^4#67<$Z?98?7WOJ46)MUOTM@) (!!8FJ(+Y5 + 4IDN4\P4D(>+4$,FEK99
M19KPN0_9\SYI7RVM1HR1<]!*3IZ7M<#MTVPL28$ @("<QM1L_P!J(,.69?J4
M%[79PZVKS6T6HK*@$.I'O&Y)]!M\[?7ICG4!2'XC2B5K?V\HWF+<*$T'%TIF
MJ9UB?^!4UU&7)K(20@5&0ZD&X!*FX[9((W_X8UOZ6TQ,TW$51([?#CAPP+*W
M0 G<H\654 H$$7';7IJ-M=^V)C>/F%\<L=,;Q8<9C>YEU7+LM8&W,[D;*K.I
M"=241T!(&J>0#59U^J^%3KX>614 !=!O5%:B] *Q\WX]1XGZL,S&8RJ@"FH4
M!$+#(YJ!#4_9R9=SCEFF<>:=F3,4W-4";Q2.8\O5:>Y'\^-!KU-+SU$2PP$^
M1$HSK(C0VRA#:FE><@%UQY:]L/A&+B@8_P TB9> TPU)1&;0>Y)@QTX)#\LX
M91"LJ<2(XS-:+DH$=(G4)L2+D7UW^.^Y-^^O3MC68#-T%4SJ='CD+E"QIEU;
M+)+02>05&UM-[VUVU(MK??Z7TQE"(L>^GL7$$76P#8$G0[BVO3UM^OC0F2UU
MNV:*;]V1( $% #?WM?L036@WT&O77X6QJ"H7.$"Y5 &12':M7MR2 7$&PT!/
M4:;:[GM\#W[89 -8&M1+"^B7SK;6"#R4@ @6/Q)OKZD]\8<-37A/D57TUW@
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M4V(,0C#/Q##P<)"TIEPA@J#()@?ES%"91*TI$?O_ /\ D)@?X+\/A?X;P_\
M"$GPK#P)O"R3XTOPZ<XDT\TV"29\68DD33$@32JTW$C,.HKJV5 6)"K"XV!T
ML-/EK\]^O[30JM4 -:54H7;KLW\M_P 4(*D2R]>$ A[!UYF""@-=3;>XT]>@
MZ;;8F8*A J!H7*!?OYI O$A0 EV6\ +;O91)-N_XZW^\>F$92$0%QJ:YE!TW
MAF4A"FM"V^1_/,FM'\P&I)N /7^M]!?\<)RQ-F7E[7.0&4254>?1CZ9P4<;-
MK"^OI?UU^GZTQJ)@CD [Z[P (@R6NC9)3RYH4<;  MKZ ;[84Q!! /F@=:DV
M;FT*9P0$I2NWX@@\RHDV%N86^=NG3;?8#KC.B;]1[=\P?Q0LR'I6$YUL@*21
MJ+_R]?F-_@?OQ2JSO:G)02VX395B9@4+4OF<WS94-ZE$":ZV>8C6_:UMTD7U
M_5\!!#@42ZT JGG]GA J!*2U[(A!J]F%(3G$!))YB=AL;$[;G7[]/IARS. 0
M[Z:THL,R&JH>:=2](*J3SOQTD:+F0;#II*:.@&UK''-XI#AE#0'-4NJ(J\W>
MZ1T>&G,V+*H8 ^:;%*W@]2:<3F^O)Y?_ &'+)];FH9L^-R;';8"VF^/F<1 6
MHIID?OJ#['V1*LZ4 3-:   C*MM;))T*G $"P&HTMZC4]A^KVQDJ_F*8%!3V
M=%U:%YN$E.M]KW(%AN-+7[??;<X(1+U9$YFGH:'D*P8$5)L$I()%P?0==-[?
M3M@A$2FA*A0'-4+/MY5@@Y3GYDMFETZ*N;5)0 8C-I!2WSDI2](6#=II.I4I
M7O. %+ \T$8:G5NRB>D:8>"4!=*+FZCT<TW$68X<>%J \RU5LW)54J@ZGG4E
MY2_9V$J!/E1X_,&VT).A3RE2S93G,H\X7??GUCLEE %B;E!7IWY1/S' 3(S#
M8:318=MO^$"GETMUL-M>O7!2A-5J?OY4BD&0HE!]JZZ!(;5:\,>0*H#ST6"L
MJN/^"@6!WL2 KX:V'0"Y!.9WOU/[@X1D*)3VB'ZYX*<H/J4NGLJ@J(N@1GWV
MK'6W+R.J%[V-CR@6L;8:EGIY:5R_4+@E*A)0"H+)6I+>;Q$]9\&-=C^8:16I
M 2/>;0\AE]((U )4EIU6AZ.*MTO;%RXDTJNH2C5Z)&,WA<,FS*A 46V)U]HB
MZJ^&_BE2 L1VH,]"-_\ CL*4;V(%T.MI[[VOA_/FJC ."#=ZA!3)?5<#X*6U
M]<D-"58FZ7=:Q76>&?$6G/,F7E2:4L+4I9ANLO@@LK;NGG\DWLL&Q ^>^+..
M)B"004*HBN$&24RB3X(J4*K1Z<NW>)2X24+-\-^MHC4*8Q.J4>)%A*EL*1&:
M=\YSF>?L-4,I5YGED!+JK)20@K(>-B2'^)"F@%D >G-OR'@^&,I!(1+E<RK&
MM+YE<XZ+\&.%$?*D!,V>E4FKS'#*FS'5%3[SSJ4<ZG"5+Y.O\-'*V@60A*;&
M_-S/?[\A'>  $2E];G[?9%L:E(2     !\AH,$.$RL*<$%\-[E"M1N-K=^^O
MIAA%"T5]H#0I6T?/-XSN"W$NK<7LR9ZIN77JM2*M'I*/.C.M*?#E.IT6GK*X
M[BT+*0E@!"D<X*4W)21;'T/P_P =AX.!+A2X4LG^KQ3&9Y4#BI)*$"SLL>%\
M3\'B8F(<7!)E,Y'&?Y(.(<7"'<@(_"G$H0B(M\*U'&6<_P";H\^BJI-5JU!9
M5+<?C*C2'FZ9/1Y#:P6T>> 9ZCJM7EI2.4E)N>^7%P<6>8RF0S3SDGAPY)"$
ML>"H8L0*K4MYV)+XD\,DTV+-++,1A\<Q($J 5)+FX!1!0J!%^CRD7"MA8'O;
M8@;C[MCWOBYYA_%"3GZ&B9Y:0 %$,A!JK99W'1618#(![?KMVQ8PB@((L;G4
M:'H$S-V)"*-0@+<4LGVUOYR_]2OQ_IUM<]KX4TDX"DT.0\D*KE#2>] ]O+7*
M 7$NE7\,I4GH-!8?Y_EC)A_*;A.M\^]8RF$Z_2IS:^JB %-J^TM.O4C;TV/;
M"96(/?W:,SQA54>7I!9QC7E(VW]W\#O^%\,%LQH:5&1'/WAE1,44K5B0/<W9
MK$,D$U-<V@O?K\/CN!WWZ7ZX!<%K]AGR4T5%)$42"'I0IZ$E$%C2RI!-Z-;[
M0 ))N0+]K7V^[4>MS@U':]\Q:J(D@!0KO9'9>^940F/Q -4DW-B3L-K '0_+
M73J3@XJ,&HW6F=_)( %"RE#5W2J*KZ"C%81'XRPK4:E0.^@MKK^ (N/GAD!=
M#1^RV58:3@H9I42P=:W39$\X3V$$SH*>7150A) ]#)2-+WN-M!:W8XY_%I\H
MZR3+N@+M?,DKG'3@2#YDA#DJN[!/,^M%,/FDP@G-]<)3:U!RPH$__P AFP_G
M8:]+';7YH@S4-#-7?G'K\0$Q0?R$H;H=EV.<23'CIUY0-KG;?M\+[?4#0XS1
M%6S<P=OM"F*::CR=B/,;N(,.68:5S%(N;^FQVVUZ]- ?FU0!!F%2J_C-:[1
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MA"NFI$<_^0PNM.0*.H.:I]X;(R1Q/7YD*I93C\ZVE-ID0ISO(5+21JS)8!:
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7"",P01F"",P01F"",P01F"",P01__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g80783g12z99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g12z99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )H2^F& X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   );!1P"
M4  (<G(Q.34V-S8< @4 0$UI8W)O<V]F="!7;W)D("T@.# W.#-?4')O:F5C
M="!#>6-L;VYE("T@1')A9G0@4F5G:7-T<F%T:6]N(%-T870 .$))300E
M   0^N/(NW8KLH!@76F\64GE:CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (T   "\0         !                          $
M O$   (T                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (T     %)G:'1L;VYG   "\0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "-     !29VAT
M;&]N9P   O$    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     &^8    !    H    '@   '@  #A    &\H
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)"4S4E-58G*5TQDU0U22DZ+4X? F)S1%1U=F<X72\8;_Q  ; 0 !!0$!
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MXS'E0>=G-Y(QG]>+MN8V'GR1&\[9[F.)CP^N8\TGE4;W ^&_2<$*/#A(RN5
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M/[9LD-GJ]+A@)@Q*J22WME O(*B/@&GH#TG$_P!E>*JTA*:X&H%1]M&ERX
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M&7?M;I+,+!QBB[QI5*:OQ&7QGJGHT%HQ9'5&#?=6H![&8D2/\7\>,SQ.AI)
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MID=C!!@"._#FNN=3V>%039VCGN3OMB)HAP 6WER6!Z[]P=^)-?RE:@(]+ZX
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MV:E)).P);BQ4' )</,OBW7C(QE8J%^TI?_36K>6NF''[@RQ;+#=[XCX&XUE
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M!#ZFY[7L1(IIDS$9.P,YR9P)&<;C!VGB 0&L(/ </:]X<7VEL/\ >5&07 8
MA1&S;GO[C(Q@61,=$@$9R KL9._;$9V^7$?9HF /G^8[OA_O"F2"HD E@%$D
M-9N2^Y;I@ TP),**<;&#F<1$$C:9GWDG<:J()<>FWY-\L&1F"(U$/ U6O9M@
MVWO G&"J6-B(!&<"0".P'TQD?P/ S1/Z.S>IM]-O@J,P2JX5%DWVX?8].^V/
M#3@ **,'!]0(Q(F([0<"!\\<"- AV+V?X= TM+X<9E4E3@.;JM>T7-G/Q&/
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MI_.??@:J0(M(@#<][$!R9#VMMB7MW8D ;.QCGD>OHYQYTJ'2,]4XF-P2,3V
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MAY!#"&]_?XX-HUFXD]70U,?NN$=.Q)CJ(ZMHWS\MY!$I#P' +&7?J&?WX0S
M+L(D.08O(+S[G;@X-MZT<@$)2H]0'5UP<1(@_O9)(SV&.)^S )\RF(LQ+<3,
MOZ'<-B*\PD%+ %3%S(%S8;-: ^-</">E3]U\4%*I2_*9\0FI:QEM6[:KO;+?
M<'<;=*BM)F)4(49[>K?9M)1D0 /Q5-1!+'S4Z1<,&$R.MSSY7]I:B1XHLEP=
M $ Z6U* #N3($GH7W..FSXM/^3_[1X\FQLZQP?\ $<:+\RZ 'F+KY:(AS6&H
MED@R"M5TJ2L3M/7U"# !!&^WKG@I/['\+=XR&5%MO8H8]0S3^6/&_&*O_?'B
M27MFZ\CD5% NW$#Z.&3\&@)2E2NG>9"9$F ,S.>_OF.-$EMBY.V_2QO<2XD
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MBM0\J9)Z0H&8@D00".K(GW_&>*ZZ2E BP8D$%N6!L%.;D_KC9H9QV=3L/RL
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M\MEY"UI6BH>M[%6AM2%I(67%@$G<@@\25E:R4@J04ZG_ !1:#J$J#,Q)2SD
M<X*C,I2IA4<B 4EP&X/X7+\DGN,1X/%9R3><4VYJ*OI4=:4(<>L%XZ%=1@+3
MY-,XI* <J+B6PE()[9I5"$*4E2@""T@P88A3;QT /3%Q&:.E1!*N2H/+-=[
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MZG#I6:;Z9)N\O(ZOW;D%KX(5*/2J8$@ '?<8G ^A($D$GVX$4$#8L[_7QO\
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M"TJ*@V*1 *@H=2%]/4#TYZ2>*U2GEEO[9=!;-^-"C8Q=,L &>P #R<:5-=4
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M2$])'2"'%*3&W[I![.FE>M/W[*$L4F*H)$RI!)( 8NR7.]FLHJ52DTU*RF9
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M6!T]56U$B4A(0#WB3'%1=3+H<BFEP(":P)'7S$)),<LS@8T<O2KJU%2U))8
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MG=:P:,L.EFO.:U%874J4IQ;E%SGI65J,;-_I.C>"IZ$]+97DR"F25#FAEJY
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M!400,[\6DNF]VL[M:[SZ02?C3(]IY02SPIHW< ,0.\WVP6A0(([8& 2!N20
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M]'?!1Y#*D @)&2.J ,G*IDS&R9 S)(XMTE+4P=C,%3P+&TN&A^8@X1"DAB"
M" 7!!@O=HNV_3"<M: H@$1 *28(F,$R!&<;;$P1CBTDAS;@/8&[LQGMZ[LDP
M#!N(Y>(YPJ::J WJ;2_K0"YJG3S0@ R%7-@])&/O*B3 VG)B-+)+":6<)/XJ
M!0D1_$=F9[N>6F,4\ZE*Q0#L$U2;/'LUR_N5OUQ?/X4&6Z[F?4/N ==OTW<Z
MM@"!^T=JJ&C4HXS#52L8/[Q^0X\S^VBE4_"$I28JYNBA79**E3F'4@>[?&Q]
MFT(.=46FGEUE-KE24DVX41ZMMBR;CRG'<8YV?[)KU)0:5^SSLUTN#7Q*6N>^
MA#24A;6ZFIKV[1JIZC0MML%3C3;[:'WD1"FVBDD!1X[W_L\\3\&\$\:S/C7C
M*$UQX5X;F,YX9E%RG-^+(J44Y*F4MYA34I5>XT^R*W\H!P?M!EL]GLI0R.2=
M(SF:10SE9-Z&2-.JJNI]@O2FD;ZM8191(X-=-<R- TO+*X>;8+H.:-WO;K]1
M<:FXIJKG=4O4I?<N+%OHTH18[70K4JF936&L=J0':E/E(4&!H9_[:T<QD<WF
M\TNJKQCQ+/*S&>S"Z^E696M(]F*"$J"*.2RZ0*-"BK6HEU A2M(A1^S->KGZ
M**5$+R63RP1E:2*.M.7IH_&I3I5456J,*E6J2A*0 @E@,;P_8^/TSWC]Y?7=
MYPMUSUAYGO):2>IEQ%;I&Y)4$D^HK:4M4@Q.X R!G_8I=/->-9BHHE-966S5
M04V(2M*UTU%C$C<EH (#$X7VL2JCX1H#E"*^505%W<*)"B &(5  3<%KL<=F
MKE23ZDYD DB#\Y/<3W_'8\>IA+7+,[/[V'.PO:UR_FRB0 0'GX7<]/C.";CA
M,]2M\@)W .R?;ZC:#WQ)$B;&(=X[]7%AVY<1,OJ4" Q8#;;ZEH.""U@ J$[@
MP3DD':#]#,"(G)('$P^[?I'Z_6V!D."+/]?G_7 0ZW!B/>8'TCY8_$B!L)XD
MXB6?B\="SGL8G$0@R4I) #<@RXF>TWCO@)2%STB8_>@#V.),X'T$=_E($7@D
M%QR;/Q/#D\!VF)"G9BEQ(:-^[<&W.!D-)R"% #[H.)C&Y@1)$?AG?B*EGM^1
MF=VV'QQ)-,V8D]'9H([\R,#!"1)"-L&!_7L.\_QWXB5C<_%_S_KT<A[ HN""
MG<W %FV<CWCW8P+2E[I@I]L3G$QWB<&!D@28XB5AM_2/BUGC8X*FD$DDD29<
M!N-OZ[7& *ED]"0<28(Z<B!MG,YWF(,[\"6HCK8&0WS8R>?=L>GI4QTMIMN[
M%AV!:;*^+DU,$Y,9@"8D?.(&-@/ZQ 'J))#!H?ES<>ICD/+8LZHY?EB.NQ+0
M"SBXAL)=Q: :4$@DXQ&(&2 8B<@[2._MP2FHEIN7X@%O7LYO@-8#2HD2T1 W
M9K#^'GK+#%3'+,!CQ8ZP>!)ZKK1*A!/IZF42@@B<*D0.H2(!S/#9-2AE\V'*
M==12F$R*O>7*1U<-+XJYQ'[JBW\(*G;^Z3VW+OS VQ:<*QOH4I940$@$R" 8
M)  F<1\OYQP#O]-]>F* TF2-+7!YGWM-AT%L%GKHA"$H0L0LR4$@&![[9^DD
M'&\2HERS=9W^$2?=.)A),)#[L;#?:!:.),V*7452G/4%)$IR O,$;@=I.,9'
MMV,=:0&+P\N.G'Y_"7F*14Y46*2&%WMV[WV9H+I+CCI$EV3,@#I@#8"8.<$Q
MZHD?.!FH0& F2)X9W)[_ $TF332"3IFV^[GA[D.7'QP [4J0VJ"#(P9$P""3
M,D C?N0/;;B#ZGEWZ<O_ %_/!0@#:VT$-Z_TMW):M8ZXI2BI2B$JR! $1@XC
M.\3N#()GAA<@L7=V)(OM<,>G4=B ,0" P/$!QNWK;TPDNO) 5F"!TQU#"=QD
MD'ZG(@]AQ!1!9OZ>Y_T/=QBRFF8Z@/  !:=OGQL,(U6^A0(3(*@"<@8QD8GM
MD R1)V(XA]1\L6DTP!(&UH(;J+]=N^&U4/J4I2#"0#!@;@>YGM]8/R' U$VV
M+G:PF_:>>7P=*0P(^9#&P$;<_ M='=J^F0D*)F020,  DF(P!/S.,<0=[G;=
M^OS]WQP9-,J@=SI_I\NSX1ZNM<,$P")P 0!,1._:,09[[\3"RD.X=P0>/5X'
M2)-L$12\P )!$AGVO$O'-]]L)K]<H@-I),"9@ F!D 1(&,>X]L\&1F-) @D^
MX6F)G;>)M!5()'G)*7 +DQLSB-V#?*Q)=0()(.#F=Y./G.TX/OQ917,@ /#_
M -)ZBXC<8BK+I/\ $KLXGN6^3-Z8<&A@:_7>AZ1)Z2YJJU+ 5&13/"H5B#N&
MC$F(S(SQ>RU4*36>P02S_P!X, '8F.7#-;%3,T-%-O*9,J#LZ5(V'*@[">^+
M_?!^I*N8U[.).D:L@_+]*VD&)SV$[^\YXX+[</\ LO+_ /\ >1N;>QKL_P!<
M-TT?L\D#.5#+C+%+';SH>W88L@X\KQV6.=[^R7-%:HY@>!#1&F=)6:LO5TK/
M$+HA:F*1E2D4],WI[5Y75UM41\/04;:NA+M75+;:25I;"BXXA"J'B?BV2\$R
M-?Q'Q"NG+Y6BD!=0I4IU*4D(II0@%2UU%LE"4AU*( DXW_LU]G?%_M1XM0\'
M\$R:\[GZX6I%%*T4PFG3 -6M5J5"E"*-%#U*BU$!*1CDUY;\O/"AX?\ PT:K
MU=J[76E]>>(R[OIMQTK: B\.Z?>-7Y%-16XLMI-;34E%%?<[F7?@''"&FTE#
M(<5@>(9.C]LOLX,[0\/SOMLP@JR-+-G,>&ULN4U5)1F?*I)IB!4*EHJK729*
M$@$D^D^!>*YW_LN^V?[-S'B7AIRF673/C.<\+I93QREG:2J(J+R(540=8"_]
M7]E2J4 *NI=1;@89GV5=2TSX_.6%Q98^"I[G^OS+%)UA9IT733EU#-.%=*2X
M6@>A2@D!1250 >/5?^S6A5ROB63R]>M[:K0\*KTJU4WJU:>52%+EB2M:"9:X
M<;'Q+_M&S-'Q)/C&?R^6&5H9SQ7[W0RH(_U>C5SAJ(I^4D'V:%Z24P&A@ ,=
MF8+D$#TC'RC.PC/'MWEO$'N[C>YY9^,>-L6(!:8/2/SCMC IP2#M]8CY$1,=
M]HX=P.C@CBW=FN6])&(Z'8/[A?BV\F9[<^*+1$'Z; G.\]_Z.&!(!>^SGT[#
M<\G!$T]1$.!N7D#EI(],?=,D  )[X_I&2-AO[R/E E[S?@'HVPGZ9W*E(2 $
ML)W)(#WZXS\N8[&<@1!SVP3.T9^O"UD.VYX#_HYPXI!3 @$@,2Y.TMMZ?U;,
M,_+I.0%8D#$;$ Y&#N-CC!@53/>=QV@\AAQM&#"FD #CC])_5]\"AJ<",]6Y
M]Y[#/ML8F8'#!3]G $&?KX;WPE*"$N0[-[[7]._PQDEI*8QG)]]M]_:"1G?^
M#ZA+$>]K?EUG%514HNQ:&B.EH<O^6 *EN1(W!$F?<#VG&P^<#$'@=17E<3?9
MQNSF)N^X]!@]!)(+ZF!>!8LW%S;CL<$0P53'I!V)  )S@3!@]OYAW%K8EV.Q
M'Q?<&=GO$B<6-(<28=PP)XX+07O!Y.$ZZ4LL*R1W& ())&T2<P<_F,\3I'6H
M-!!L.QX '/N?$:D(58CN.)E@\$['CO3]RTE[Q1ZY<0""Q>$M=2BG/PKH;*T]
M*C(E/4"2, ]0&W"RZB*69#!M1  =_P"U49E@Q+&-PSM@-9U4Z+@RDF(L!OL\
M0!RQXLLIW>I,K6))(5(@#V],D2.QB<G' =:N6;\[WYZ8K&DF?)O'NER[D$$C
MT:+8]>"20E *C@@J(@'V(CMN!,9[\)2B0Y#W,7)%^8EMYGIAZ:&$ND$R!=GB
M?R9^DX+O] 04N!/40#$1':$F)^Z<;QCWP.X](!YZ_G@@2+A_@Q$";1W];G"*
M:8F96H23 "B  -L0F#TQG81G/$%$N QLY,;D" T ]3)@P1@B07B&O_21_2X+
MM@FY3U ,^?UI$J4E?I(3&X(S!$ R9]I XBI:0=,]+,2\@@BX+N PVQ8IT20D
MD#228)&HV$/ ]Y,=1A,?)"SYB#TJZ00DA24F#)C)WP)QB-L"8#  79[%R(W>
M-GG=QS@HH)*M3J_%*26$2P;8;;]>4QQMI0,@$$$0<CIG8[;3/X?0EB4EXD?'
MW'U)F/@<@LP81U]/3EW['#/KV"EPE/4I ,@$P4I5 B1][,D9D21'%<C4D'OT
M;Z;WS C!T))+2/> =S/PZ[<X27&7.GJ*B H1@@]QDGVV  .>V.(D.9)@3O:-
MF:POZG!="DB #L&>._7KWAVPD/4ZD22H*2# Q&_88@=C!DYP=X@_Z? '\_J,
M&0DW8I&D6,D@G@7(@\,YOA'J$ JE0D&3 2)F,2 1@8[Y@YVX<LQ>V^+.DA *
M!(#E0@7ML.1 %^N$)])#P2E+A\Q*U!00.@!, I6J?2I4^D'U* ,;<0"2*@+Z
M9>SVN&:_T\3(,M !: ')MT9_Z;"V"+O6B#!(B2DD8,>^<Y^G\_%D$ D@C=R.
M#R1VCJVQTX,FDD22_! )'HT/P+OS P\^5B0OFCR_228_6!"P" ?\'153N9^Z
M E)DB8(SVXO9=3!4?B24VF$J_,?(8J>(I!I$C8&& <E0'!+$.[#B^.@SP:6Q
MI[5FK+P5N!V@L-+0-H 'EK1=*Y+SJU$DDJ0;:T$9@=:M^.(^W=52<IDJ##34
MS*ZA)N#2I:0!M_M5$[LW7!OLZA)K9A?\2*:4<?B67C_T";<SBQ'CS+'68J5^
MVR\-O-[Q1^ 7F+R]Y$VBZZDYFV[46B]6V33%EKD4-RU)0V6^LIO]HI.M32:N
MI?LE57.4U"NIID53[3;:W8E"P5\KELT*:<S0I5TTJJ*]--5":B45J;Z*H2IT
MZT.2DD'22X8@$:'AWB>>\,J5EY'.9G)'-9>IE,RO+5%TEU<K5*55*"U(4E1I
M5%(1K2[* 8@B,<1ROL>?M.;;0*J%>#WFE4)0WU^31M:>>JU!1!Z$TZ;YUJ<S
M*D9,@[D$G1.9J)"0E08 ,X!*6# 3_7X0R:F7UJ4M1))=V5*G<K<#<R7)#SP!
M//@N^SF\>'([Q1<HN:_,_P *W-W0/+W2M\J:O5VK]0VBWTMFL-IJ+96T;E5=
M'VKH^XS3EY]I"EMLK];B9 2<=']CJJ:?CF4*EI"ZU+-40(\RZN7J)2ECN3"1
M )(8%VQB_:,HK>$YI"7)2:50, 1Y*R"3Q =1Z/SCIF1<:)83_=E*(DSY[0C/
M<!1))C^B(V]F4E3LQ.PW]/?T&/,$TBRG0VIY4@CXD.3>Q/Q)P(*NF($5E,HS
MG]J@_ETKF(P4B /H9X8/)(58\!]Y<>HWMZ,:>P2S=%&\/TGO#DVP.':0D*34
ML0D$ )=1[R0<F<^Q X9E,1I/N]7'R_I.%HVL8>"2Y#-ZNY[C9L#)=II_P[!^
M27$21^!^7\_MPQ!9V(BY$3];X0 #@$O8Q8CY;M/OP,AQ@Q#K,_\ W$SB9[F.
M\^WY2,E1ACQ8[L\VBSV(?$K<\&.W1SZ!L&4J;B?,;WC[P))]Q)$XV _F,\1(
M42['W'"(/!?8D%@=GB-H/2+8$]&3UHD#_&23(W'N,3 $]\QO'Z^OAA!+"9!+
M^YKMSW_KX.DYE/XD?,S^9W^?MPL2BS-W_P O1L8/)243U)]1 W]R=I(.\?3Z
M#,%EAM/U]';#IAP VY '&P<$.#ZQ[RZ V4 )*1C $9@RJ(/OWX%W?UPZG!?E
MY'P!CI;_ #P3KV4.TRR %$1&1/\ K"3&-S$&#^'!:2M*TG;?X\=(WZXBJ4D%
M[..']SQZR"9?%$_)JZ"T>(+GA75M1Y9H^9^NT(4^LK"6FM251:;1US#*$)#;
M:$>E"#THP.,X9DT:-<DEUYFLX)))2*I\J07\H8,SBT8TZ62&:*$LP30IG@@J
M2-C(?^NQQO>WS?M9GJJ:.828#O2#.V,"0<S!)/X<5OVI3!;0M_2'-RZ1UB(A
MGP8>!DB%*@$3T$;E]K6#8,_RO6@@Q54QD #]J(!!_P!;(^63W'$3XI3=@%$<
MND3VWZ?U+2_8:A=B&=4$-U<$=6#DMP(P(KFO;%A/[>D!C;S49*1)W)(D8 W[
M8!X=7B20[)6Y$. !'_I(W]<./!6)9FZ@P.A<E^(<>AQB>9U$1/GTJ0=@7$[
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M;;13LH6DN+6/]O>*%+?>"76I:BI*5:E$R2&#.P=MW9GQ-.0RR3Y4-Y0D,2&
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MC"I^QPTE3(4*+Q%\S4N  I76Z<TC5@%,G*&&*&9,3ZAW[F>)*^TV8((3EJ*
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#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g80783g19p42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g19p42.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!*^86(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !=
M KP          0                         !              *\   !
M=                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M=     !29VAT;&]N9P   KP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   70     4F=H=&QO;F<
M  *\     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MT-#F"LAH Y94Y];O=_A/_(*YG_TNSX_P"KH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ =P#@ P$1  (1 0,1 ?_$ !\   $#!0$! 0
M           '" D#! 4&"@(+ ?_$ $(0  $$ 0(% @0#!08$!04   ,! @0%
M!@<1  @2(3$300D446$5(G$*%B.!D3)2H;'!\!<D0N$8)2<ST4-58I/Q_\0
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M2QRPS^I/9'-7OY1=^'^&W!^$F?\ .CRP6?IGK0\<C90'_HO]/N(&^BW7-_S
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M,\JW4:CA0HU?!"&'7PAH*%!B#9'A1!)V:*-%"U@ ,:G@8AL:B>W??CJ&$ ,
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MMC('""\#3O##B',,#WE4BM1G5NJ*E5*"0I:H2 5*;DER8Y=P<1RHRH2()(
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MKU,5"OQ#2AKGJY55S&66J:#:NRHCFLZGJURL1R]:HYS_ ,O3I1D_[$=7^/\
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MRR0X?S94FV!,(*4HPHL8"27NAW-Q+ !(^%B=(!';Q%^>15 %.22TN "2#.#
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MI24VPDPO7J=I *>>'U9![%B373A %J6I0<I*0G29!.IP^[,.:2!@M'/YJ_\
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M VMW>9T].O=&L8T+8?9[G;(WN3\NZHBJCD\-7CQKI9CL-6W;EVY1MECZ-O?
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M;/4\1AE&BO(.NN+83-T:DA[D<B<RD)=EA3@Q@E^;O/)B>^:L.H9I)SR("2#
MGD&'K6M5\J9"_(]SV*F[7 D"85B+OW58\EA&-<G?9W0A&[KTN:NZH3 WB-^>
M6.WEL>U22VQ+G&_)L$$;/+N)@&G:\KTT)\JR,BQ@@*/%2"]0*E1I&DN*IZ=0
MRD-TO11+LX;V#5-D02+^9>R&!/.3GJ!]6'E5"Y;8.Q?G/I#$D[O&6<_D(P6
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MMUI[>%YWK#J[C]).T_TLFZ? NZZ%,=,S]T&UR2J24$921"T5)*FXW%M(3U<
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4B(G^7"IK]X4HX4HX4HX4HX4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g80783g35x58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g35x58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2="4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )R:^$ (CA"24T$)0      $                      X0DE-!#H
M   .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
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MUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M    !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8V
MMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M   $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F
M1456YT1B-2;'0               !";&0@56YT1B-2;'0
M!2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O; $     4&
M=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M       %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M          $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='
M1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296
M-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M      $ &/     0 ! 8\    !  $X0DE-!"8       X             /X
M   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M )           ! #A"24TG$       "@ !          $X0DE- _4      $
M@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M    8       $ -0    $ +0    8       $X0DE- _@      '   /____
M________________________\#Z     #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z   .$))300(       0     0   D    )      #
MA"24T$'@      !      X0DE-!!H      S4    &              1G
M )I          !                          $             ":0
M1G                      $                         $     $
M    !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M   %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M1G     %)G:'1L;VYG   )I     9S;&EC97-6;$QS     4]B:F,    !
M     %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&
M]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T
M=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M@       P    "/_         X0DE-!!$       $! #A"24T$%       !
M    @X0DE-! P     '2P    !    H    $D   '@  "(X   '1  &  !_]
MC_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@
M "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M
M8  0    #3+4A0("
M                   !%C<')T   !4    #-D97-C   !A    &QW='!T
M !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%
ME:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (
M9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M    QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M   $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D
M="($E%0S8Q.38V+3(N,0
M                          6%E:(        /-1  $    !%LQ865H@
M                   %A96B        !OH@  ./4   .06%E:(        &
M*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+F
MEE8RYC:
M        !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&
M-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M          9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6
M]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M           '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5
MA96B       $P)5@!0    5Q_G;65A<P         !
M       H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %
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MS0K42MN*XMKJ&O%J^+L "P=;#JL6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M\H96+*RZV 1H[UW_  &4OV/[-?9'NQ^XMUW.]UZTZ_WZ?<G9+3&O[?W\YO\
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ML,^A1@ V/D>3,#8&' _/(H/FM\5,>OP((/\ 3],],9/N#?8]>_RZ=?I]?+(
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M35FO!URK=SVO/JK3J,[=9J5QV#/9$+,"4MLL!6=SC+3]S&LU,^%ZM# HI<1
M =@2YWL^Z&8ZZ@NO70[:&N_J3 )UUECKO[NNW<Z [>I!]3W[_AB_L?%'W*SN
MFOGQIFQ:QB<-*^9U*>M$*VV%KY7BS4=#3/;9K.O;&LKV%'JO2'M?+=55"^FI
ME/WZZM*U:#9J\I-'W@W9CU@[  \GU"DC:];;UL?>>V07;J'J- '6O4[8?B0>
MV7:Z4[))VSUY4[HRG3UCSK5LC8U--9W-H&GL*BT:K7*E^6QZOIE^A=UQEI*W
M=/;ZU5NU-H)I&8S0#!DUEUZ&*]SK7<@#>QL$:+ CY$$@Y<0EALZ_+X?COXYJ
M^^U<_P M='?Q7V%_6],Y\X?;S_VOAK_YOE/_ +5'.0?:G_V_"?\ S7(?_;I9
MJ/Y\]YRC-NG3G<^X=.]1>"Y]&X40ZM8=[SLN[5'%$)#GIBO85/JR6Q_5&0R;
MJ%]&NMY4VRW858"">OUUQ\^,PC&5?[4^R=%?P#PVP>H+=":_XCR5XZU\>KIT
M/CO6L^@_ C%?"_%_(OR'5^ Y&SW_ "WOZUC.ZK\979"ZG8MOV%KT=C#M_;&U
M5G2%:-A+79UT;KK[H;;.E.H'_CTIS%L]PJNR;.^L]EL"OO5+R-XM-%FM44&E
MT5H5]T*==* R?'T9P[C9'8=([#0T1WWO>WB0C9(WMB!W(UV4@:T3\?7Y[S/'
M\;&SW255N$>NMITGKFOW3%C+9IUUJX'>M%J]=[@=NJ('Y2Z?KZ8MA_Y!U5Y#
M&H6FRU\5;)1+.R"9@ZL1Y !*]09NGTV/=8L@!.B>VF(][7<>G?62)">^M#8]
M-^G?UV/7TU^??,WM/C0OM-FE^6_7/T>WKD%=M-2ZCOU??T]OKNS=.]G;[JR5
MA<6FDUI!VF+?K]ZFMU$?IR=6>=7L(=@NZ69ZMJ!"&_=;8)ULJ000ZJ?1B->]
ML;W\M ]\&0CU'H-]CL=U)&QH'MZ? 'U^X9B???;NO]8>+_;]J3U=3;NH]Y7U
M_6:BOL\[-J.IJ/=7]5VXG&KGZ!I]K=4U3:;;8[9=_5*Y&P&KAVM&S!)=,\8,
M:%H5&].@).N['K<>FR 2%  !U\=;P&;I<G6P=#Y#L/C\1W_YY(.Q^WMT\.(]
M6U9478/B9W/=E-JVQ=9FK24L5*'1ZW6QWZ5(+JSK)H'R;:SOZK&N*[%7)5"Y
M[%K%YO-<B!3W855DV?=B4%1\2/>WHDLWPUW([_'I/?)+% !W??SU_#0_0'\C
MB:I_%CV?K>=WO;I >XTU.U8 -"X]6M46AU(_$'XGM/GMNWVVIZ;M%XE0T^K]
M;Z=K=@["CLE*\\5[R[-7HYV*_'68E.@#TD^@'<L?+B;I'4RC>V8@;V?0;[#*
M0Y'KH^A]=  LP[Z!/;0WV[=]G-F:K$&E5FAR'*#( L0D$L3AE PXDC(1H8Q$
MP\XEC,"QQB)(YQ/&,8SCGFR]GWXQGF$__*&/V7>%7^3G<']I]<<^A/L0_P#-
M/$?_ *QQG_W=[///_N?_ $O_ /G/.5SNF>?/5GX&NZ=QZ<\)'V?;R5PHAU6T
M?Q'/]VIN*(2'+3ENXHZO7[+FT9#)NH7T:\W97:+<ZK %R:^E<9L(S" 9 ?)7
MVDHK^->?V-O_ .3O+UO][_*ZA(T/^(*0-_'6O7/2&*K%WT"#U>GH-=_KY_=E
MO.J?%YV[9*]C$L]9JMSO;+<NT>Q](H;NZ5Z_KM/Z"U'JWI3?J;7V+5+6KUJT
MW0Z7:U#+(+5.$,VUG>YL;RMJZ=4.=%:)1KN5 558@=1,C,Z[UL:'NGMOT'8=
M\E7;OZ$]3:![:4 '78;WW^.]?')^3QQ.KA9OF>JX#TZVSMM9U^_C=,?E!L.R
MZ]#0YUB.Q4AM9"AJ51=RWL(#6^;ZY-2%IK KM;-4JQYT^1\ VR-%ATZ !ZO0
M[.R.GTT-['?UR1)V)(T-D#O\1KU^'QT?D1\?7)UK_B3[#V?>KCJ>HZKU:?9&
MD.WL>P M]EO*Z<I5U8M$;KV=.V#.@%M=G?MD.P*PQ$']:UT%0U762-@_&9JD
MEC!C4*'+GI;73I06V2=]2]?8#I/H3ZCMDAV/8 =0WON==M>AUO9W\M#XG%07
MQN;5;6FD;)K^ATR?5R]3LECV>:TO[!G<%[?5>C3=O;AJ&M5*.M%2/:Z3\BMI
M6CN62V+>^B]326J<*E;Y5Y(&P6/62 H &B"_2&)ZMZ;U].P[]]]H\PDC0[?'
M?W D]P".W;\_4@9-=9\76[VA^OH[/TB]H55N>[HZLQMNUV6ZTVI+KW(-'-01
MJGK?JZLLV;^^/M]A34RVQT^IZK<;#J5C3U>Y-GN-?R_!A7WM2!B%WTCI)[;W
MO3:^ /8L0#LCL<"0]MKK; ;).M'1'P]='XZ[_CK+U<L9=PXQGDU^UA_^&IO6
M?/R\M5Z]_;\O_BHC]V/N_'/_ '?C]_/L[[&O_0'C?_7.4_\ QLF?)'VL_P#I
MMR'_ *MQW_X*'-;)/O&7/_[N?W8_#/YN?O\ Q^_RS]_GGSS^&?V\<ZEG-L]5
MI_$ENG3&ZZQ7VK(K;JICPJ]2(ZIJ\4D0O2[^V&JWRSTNM!;0#%\T>R$-*;U!
M5%DY%A;"KKP:\4&[AC!_SYYB-7Y7EB 0_P#FW($GOKRQ:<,=?_PEMDZ]-[].
M_P!T\.Q7B.)[]CQ= >GHQJQZ[_?KTSK]>^,CLNET/JG4]M4USL?M'8-9V*MV
MS;A-7-*K5]B**]MV.ORV"IUWKUW4:+7+F'6OQU(3VA79&EG<NU^LV2Z#+9\<
MT*EF(VJ C2]B2NT!T2P)/O=]*0#ZD; S(!VT->]\"3O>R"0?30'IV/?\?@T=
M8\8>QAZ^IK?<]&IB[5!;JA6WQ1[0R.ILGNP^F'NUS6-7%[6PMK@5C7$KOI\P
MGSB<V"Q<F-'_  BDQ L0">G;:)&R-.$T='1]1WW^7?*P_8;&SI=Z^\$[].WI
M\?PS.Z9XL-UVC>]$T<_2-G$UW1]?W6]V.NV>T;+7:$/LZIN;[7,DNH=>5VL/
MJT]8A78VUBSV'7#KNV9@ZXEL@:PIV(:( ,>L:!8+L %N@@'MU$C9)Z=!MZ[Z
MP'.P.GY;T3H!MZUV[Z[;WK[@<S+/B MM#M.[KK<_;L]#TCQ'Z7UNQ9&.G4CZ
M^TG:^H>J;,5R20*V<KE8'86XCP_]2: =9"_:;Q9?%IU:PL>7OH _>,9<#1]X
MAF[#OV]T?_V^FSD=9!8GNH?6_D-#\O77Z_?L*LOC5[3()<Z'0%#"+A;&L K<
M]M,UE@K>U/0%1XAWE+5477#V%$X:V\YJ\6 E;<CMBJ\"UPZ5@]JE7Y*[_P"T
M/PWI/@9#'_Q>NQLCMV^_MCS&'JOZ$]ST]7R/P_CZZ'IT>RO&?NT-$[%O-3T5
M*CIPBVK4=(W&&VJV>TCW=7PVB\0=)8N:.]JF:8--BO(S1,%:V)P@;195HU:>
MJ<.9.5A7J4%M^A9>D@=)D\L[8'?W]AZ=M@Y!D)!(4 '8!WWWT]0[=OGH]^WK
M\,FS_B\W6N9VS5)]44!^P>NTNS-EW6MSV2<&LQTSK'5.L-O?=U[8YZ+%NUV:
MXKNV]751HG-?IZM6P5N_G;"!!9%RPI\I=!NH]+=(4](WU.6 V-_NCH8DCOK7
M;>QD]9]-#J&R1W]  >WWZ/IW[^OQUG,>+=R-+^J@WH5;6="AWYC0[+>;3<BJ
M;=222<:UQK8[G1_R6(DA1RWB*&O+>[MWS\I.1O6E%5YJJLQY7?I#;?IZ@H'8
M]MZ!WLG7?]W]>Y$AR>^AT[T3L[_,:[?Q]/O&*JN\9O<",-FEL7356[>W'8>J
M:EUOHVN7&[WEQ7CL?#UK_=NPU^ZFU_K"\L8V-<!^::K-10V"T[6P+7OXKJFC
MEL-E684.NF3L%)=F"@?OE!T[<=CKOO7PULG0I\QNX*]R1TCO\1OOH'^'WCT&
M\LUU#WM;]E[QMVGWVAFZY:H*/7M@JZ39K*R%O-E4W2BA26S5 76TZ*%,O8,&
MI_G:_MNS$4M4&JV_5HK'VDYVG0*H8-U;)!( Z01\ =[WKOW ['\":U8DD$=.
MAO1]?Q]-:^OF NOM%?\ X%/B"_D>G_K+1<T?[1/_ $)\1?\ J(_^_ASM_P#A
MR_\ VV_9[_\ UB?_ /UE_/&7SXCS]I,VK_9A;]<]8B\4N[:]\"%U4]4:LO6O
M6PI'IZ5J[W^IH8;)=+Q,O)BEUC%IG8;=?#*V3UM8T'Y*_K]X?>_L%4-RW.*=
MZ-"MZ?'5@G0^\^@SX:_QSG7@WP2?_P"9;OY;XN0;_+US>]M=3VA3=A]1]8+>
M(GL?"FYU';6QW&V2HNGOK<&-5I-$C3I8C+K2='&A6>M+2VRM&K%8E^=\4]T5
M-=:(_IM2A5W\M/=Z1TDOH@EMG]_>]:'R&MC1]?S0;>PO41O9)&AK0&@>WH>Y
MQ55'B*["I5^A.TMVN]P/IVYZ3M+6X)4^GZS9Z%MKVL:#MU[6K];UU$K8=I"[
M W4FJ_EU1IV+A]./J!'J=-AFX)68+48U/F(H&U8=))(8 D ]1[+TC>CVZNKO
MZ;RGK(Z6)V"#L =M@$@#X[.M_ :_+.WU'XO;];IW<.P.QUKG>[X'B*9T %1I
M.E;,ZOJ=)M&T:FM3:\8NO:F\PU^1E5M7T\%O8IP/N-M6P6$R%VW6"&7A'6JJ
M0H\O9+$;8@,20"WQT.W;I!].V2KG1V"QZM:'?6]:!(';6_O^6_3&)XN^R.S-
M<UGJ4G4C/8"-ONU[N$)5NG4FD1W!\=7TCV1N](@W7=JUQ:ZM56V*AI6]@3DN
MML.$U&ZY44FB35)1"JDOU].E"_O%M=W53W0[/8G7J/CDR$CIUOOOTT#Z=O7[
M_P /Z8HZ[QM7&JT1[ZZE1]FKVFUZVRMBDQL%,XMU\WUET!:W6S:S35.BWY#4
MH+[M!RWRWOUIJJB/U"NHW-A$RVDNM7Y&SKNN@=[T?>ZY  26'P0#W=GXZR/,
M]-=]Z_32[/8'Y_'0_JRZCQ,]G;5V9UQI]?I.EZP"R[IV[K_?:"_VC99;S3ZW
M3]>;AMU)8FJ2Z%7H(V5T#7L7M:6OM+W6+FOPFK4[.V%]ZQIZ/+4*S%B=("I
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MQ+7KNQ"-VSJI8DFXQ'W#BG+.?.CK?_B/[P;_ .D!H'\0/3*NE?E\"/CZ'U&
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M[CT8CMKU^&R?YDD?(^F5="_(?/Z^OY9DK#J+JZV"RM9Z!JCZS<]G(TNW2HG
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M!R1Z$ [SYT^T3P-XIYSQ3<Y'B^+-JG+!22.86Z,74T56..0=$]F*0=+J1LH
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MU0H@B,5-/7M673E[D9N34<<KILRKI06C497(4=1 77H3W(8L"?OV=_+8WZY
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M_!WB'POR'*S\S26I'9J01P.MFM.6DCFZR-02R,NE[[( [:!WGRK_ (K/M?\
ML\^TGPUX6H>#>?\ \XM<=SEJW=B_RWE:/DUY*#PI)U\A1J(_5(P7IC9W'J5
M[YM3GX9.@BUR%07JO5"UU6V^ZBL1,I(@+:(5U38B]<SR*5)VJIZJL9K33)7&
MKZ]-*:N5EQBCW/S9!L]9[^OY=Q^>_CZY\-]"GMKY_/X]C_#)BGU)UG7[<KOB
M.CZXIMR%>&KK[Q>M )JN17JQ480UHX8PM7R'2 #2Q.F #'T@<*SW<HXP#E)=
MB"I8Z)V1OU.R>_S[G??X]\GI&]Z]/3\O3MZ=LD:FI:NB&T74U^H""ZOI[3;
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M7;5_>YQC#Z7W9^_CJ_\ FNVK^]SC&'TONS]_'5_\UVU?WN<8P^E]V?OXZO\
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MNVK^]SC&'TONS]_'5_\ -=M7][G&,/I?=G[^.K_YKMJ_O<XQA]+[L_?QU?\
MS7;5_>YQC#Z7W9^_CJ_^:[:O[W.,8?2^[/W\=7_S7;5_>YQC#Z7W9^_CJ_\
MFNVK^]SC&'TONS]_'5_\UVU?WN<8P^E]V?OXZO\ YKMJ_O<XQF:ZZV"VV769
M/7N*_-LCLF[:TZ:J692KVRZAN=_JF'U4FW;)E.#XZ:#N5"V#LEIGD'#1XPP2
M3&3KC&)^ZV'?;+L6STC4+72J1>DTW7-H;9V#7[_9K!PNQ7.TU8P15K]BU).N
M45CK,B!/%^W8>*RQ RU9!(!+%C.Y]+[L_?QU?_-=M7][G&,/I?=G[^.K_P":
M[:O[W.,8?2^[/W\=7_S7;5_>YQC#Z7W9^_CJ_P#FNVK^]SC&'TONS]_'5_\
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MD!(/F:/IEZ\PXQC<XR!Z#\!AQDX<8PXQAQC#C&'&,.,8<8PXQBNI/TQ]B_R
MZH_MOMGD?$_@/Z_7_+&,^4HPQZIRC"/GC'JEG$<><LXC''GG.,><I9Q'&/V\
MYQC'WYQR<8N-N;5M2ZK*LN0FC4]@T K5:O,BY"93)%,&OLLXB<R4XAL:^V%
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M;+-4C8VH05-8#*R>MUS146,NAQC#C&'&,,XQG[LXQG'[F?O_  SYX_[,_?\
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M#B7Z\$II1+F 3K^UE?&1G4+*#4"9^1'$L>SF(LXQ$V1R(+$[H<$KH'WE+=]
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M,"M8VZ4:6#-'"&8O*Y",JP(L"(T*^_A^/DJP[FD<P6(;(2HJA$IF62,-&L\
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M&*\Z&[BVP!17-38X9;9Q&2ZR_P 0WO,'C*8XR"$?J(2,IPCF$<XE+$<YSR[
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MKTQQ.NI/>+DD,3T(2P(PC#U9C&.,SEZYRQ&.,SGZ8P]4\QQCU2],8Q]6?O\
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M"^O"V+T;RO9Z^^F$T_.JVT#8>U,=(]5+VRP: Z(I6YGK$L2,O-3($CKTZ/9
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M@O=7%F]62P-R:RB9&RO66NE)_@M06GZQ.DIFL20U8834Y*S()F2DM);!L1+
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M#V99+(1?>Q@GYHI#]'D3,X;J0=KH@ '; C?4-$:!V-'9!WW]-:[[&YD,2NB
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MC;?!<B]/Q3Q$,O\ F\+\?5YGCN5LU:G,7K"<Q<HM+Q%V_:I<=%-QM;F8J?\
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M1'8TD#(H3G[IB1-D4A"-%;S4#  A06'-<4)3'B4)GS(Y&"8,<V(EP' A#VL
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MB=O;-3U=#I]PK6-V6*RRN3)9!5TU4I8*K'-ED _B>A;%HH6"PY3<AAV&6HB
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M]:,NM9>A]C[Y9:63KBL0^LIJ1=D@FA7J8M3*$BP^<42* C86.:^T+"TA\GY
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MO]/KU_7X,GW&,U7?:44WC+<Z@[OL.D=SU+7M"4Z[U-@*QW$JW8<E3V*Q)V9
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MQAD<?+T"'$>(#QR(DL2S$DDDDD[)).R2?79/J<Z.%"C0T !H:&M #0  ^
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ME=U:P7(K,?KQF'M#Q(<L8-/&:@[!>D'2]0?0UOJ4$ []1H$^AU^>LI**6ZB
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M,CA,N(#5,VE%DS,AQ37%%B$I,LAS]\(S\K<[M'$[HI9@"0% )[ D *S*&9B
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M3M'.*QR&'\/1>&\0N B&"Z(57J)V1^T ZM:]U4*GT]?>]>WPUV/>GK)[=@=
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M=217@M0?9&NI+-AA0E@X6O!#+F2+>[F,B (&R@O +PS2R/CTU+O)^#.4X_\
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M4;IDU%5,( 6KZKR /Z>G\_Z^F,NCQC#C&*7LCL6LU!FII[0Y:U:ZB:#MH08
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MUIP8QF<8SYDG <,S*2 H1SCSG.481QYRQ&/G*?E''JSG$?+/XYSY8^_..02
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MF;"TM;]RXU=V%6Y7;.YC +"IK[45N2+#Z!:>M64!P=J6Z>D*HT1Z$ :&F[[
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MMD=;G7;!ARN'":D\B#>S 2U5LQSRHBH9A+*[).E/#'[9.?+:&RU=;<Q4H);
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M1;T&D]<;SM&KTUB/:"?3J;:;)DMJI64/O_*J#D:5,NR>VCL_#YZ[[U_4XSO
MKL&X[CX=VK;=]>7TOL1SLCN1':6\:K4Z=<7NQ([[L%;C?-LT:LV/:T-6W38E
MEDK?:=9QL#XJZXDRJ+*R6%U%V&&CH'X#O^(W\OZ8I^ANL^T]"\90'>PO$9L?
M>B=SX-=;KJ]2RK=?KZ.DO=8W;7:G:=IHR5,YO-FW]S +>U)83*,3*T!J&ECW
M(#9&9#QW^$P'=/7=6>A-,VZT6P)3JGK%6,R,JWEK55[50Q94]3.WS!NS9BX
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M2.0QDVK%QUL78DYU&EQE+CXY(JL/0DAB)5F,BCR5"QJH?J(6,*/+4'2: 4
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MKHRH6JP0K-:CU#% M2[<>U-1AA">S5NBN:U2*.&+'/\ A^',GFFX<8Q:;22
MMXU8A!@,,>F=D$(%G.<+EA NERF-C.!&S@$XXS$V<!+G$,R\A$_Q<L?7U]?R
MS1-X"MPZEW+QEZH]T7J'AXZ0 MIN])]F:3T%W/W;L-9NJ"U-\[4JE[K#8>GN
MN.MJ,.H6NP/;)7LB^&^C"Y9E7)2C;'D2/Z=OK^G^N5D$ [V>^AV _CLDGMKY
M?AK67S\<76<N\^O.YIZ1XR=FZ>F?PV;DB.IZTOD'6$%]>MZ7>;O=H*)V#TC
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M1;OV:^))H:U9>2K6JO'AHJ$<X,,L=>=U>5?=C98Q&^F\I[$VE#^S@ !&L/\
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M?^[^*WQ!Z1N74^EN>"'L6_-VSL[^M)W^I[]KFQZKHY:RC8OBW795TC32#J%
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M+:F]X?4:.;>LO;*.^L.T)LZT/Z?955:6C8M:?KVS@OL!LVT'$T"CC%M!*Q9
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M[\R5$TTI+*Q,I!_:,S+MF?J+DL6)ZFW>%;L/;&1)%!TIOF0/JX:$3ZSUA"$
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M4:E95ME=TT]+&U8B8'%NEK[^ID$F(WC0HTE 760]0**Z@!VZ"'*$ED[(S#H
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M8W>:6%HMOPW$%<2SGV;5Z*NIE>5J#XC+.&B)^X#RQ%H"\ICC-W^7Q^?P^?\
MIC)!]4[+K(,Q3ZWUACU2(]/(.QW<S:::8S[T/6UH8I2-'&<3\RRB*"\(!$3]
M;@'$*H0$*-;+,>^R68[)V?7Y;)[  >@[4JJIOI&NIF8_,LQV23\?D/D  .P
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M^LVI9:E:,U [>L#L%.4=FD1Y9Q4PC)"EAC+")K02453',Y1J+@6&1HY6F20
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-AQC#C&'&,.,8<8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g80783g50v97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g50v97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %A:^5E0X0DE-! 0      !L< 5H  QLE1QP"   "ZV < @4 !U-47S$P
M,V( .$))300E       08$)&_H*7?X:'_P-XYIEK^3A"24T$.@      Y0
M !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !)
M;G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O
M;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U
M<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T
M=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--
M64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO
M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              7$   *^
M      $                          0             "O@   7$
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7$
M4F=H=&QO;F<   *^    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   %Q     %)G:'1L;VYG   "O@
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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MO^=>)X97^:W_ -*K$+&*!K:DEW3]:L7M]J_S1_Z443]:L<\')'Q:/_2J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ =@#A P$1  (1 0,1 ?_$ !\   $#!0$! 0             $" D" P4&
M!PH!"__$ $<0  $# P,# @0#!04& 0T   $" P0%!A$ !R$2,4$($PD446$5
M(G$6,H&1H0HC)$*Q%Q@SP='A\!DT-41%4F)F@I*BL[3_Q  : 0$  P$! 0
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M-UVO'^[_ ".*ZE%XC'0KD_7O\!^UZO\ N.% ,"RLLV25C_Z^;P0P%?2?!O\
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MQG]W/ZX^^,ZT)_VI81!*AG=SG]<-7F*@(.8@3G[\^E?%.I'=9!)XR .KR<9
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MF Y/;=L*WVDLI9^8PXBY+\>#O1T*" E(4"HI('5WYR>1\2!^=9 /(0G0Z!P
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M)NVHP[Q_9V'&J%1K+< QJL%LSD(::4RVKV(\IUM<!]U$:6\I'*XRPOB+-]"
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MHZYD;KDICRH;D"HR_+\'^,6?C/ CC.'M7+5M5VY:Y;B$<PY&!8H4I*G<.RB
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M0:AZ<O5$Q(B/OLNB/LW.?C]:%.-*]B2AU276P4X2XG*71T+2LXUS_P#I?'*
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MQ+MDA@S4D<C$)/5R.#V/';&3Y...Q!U!!#.1DP""^<M@ZM^>DA0:'!;4.VI
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MKTHBTM1)2F-"6 Z%RYW<-D1I3];49$>W*.TE8< A-K"PE: KWLO9Z7$I6/\
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;/W^E  ';7.:6:BIHTI1I2C2E&E*-*4:4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g80783g58e87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g58e87.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &+ EX# 1$  A$! Q$!_\0
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M@M],?JCQW_+' LN:]?@?;Q:/X+?3'ZH\=_RQP++FO7X'V\6C^"WTQ^J/'?\
M+' LN:]?@?;Q:/X+?3'ZH\=_RQP++FO7X'V\6C^"WTQ^J/'?\L<"RYKU^!]O
M%H_@M],?JCQW_+' LN:]?@A"_/B#B/+\/&SZ]?,7I>"Q$O)6</'%^E_,\FTY
MD9 69--!WU"'>DY"31VL,CY=S];79),$_J?T*KKAPX:I+BJ-]&O7X-!\&1@#
M (H9T/2(ZP3MLL*?K%E:$H9.QTDL1K!(PA-CS$@T'L"+4O)TAG)DBB28"!#
MEP[>*Z(,0XEF\^G;"V"3<6[M:[LM%P/I5G4%44N$=QJH*T@56QU^2[,/@5>Q
M(##A+PKVS9C?ZBZ'Q]@/:KO.!@T:+2<*I=*(#!HX<CTFR8M$$1+MZNY^V]_I
M-:'^W<V_XT3P"*/%'W-/)/Y9*%_:N*8++5]7[EF\$& , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M>W#I(:[>M68YL/[;HJ.M/NG_ &LW11Y]'^G?Z2XKLSM:&W=N8S"8C&86%6.
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MB+02[M;A[=.5^/%GRI7Y*?!05T,0,FFEE578"MZRQ7RDY(PV'Q*82[T*T/\
M-FAC]B+ 5SSJ'FC$OF,J$ C*R[0!*),[)*N2K(/$Q$?"_GEGTTMW]_\ >\61
MOX:HYY35"PFPK=FBD]@5*W+ [9F<=_H+Q[9-B>BIE5UV6?:*!.1Q]VL.DPKT
M14\7LJ%NE!JHOZHV<QB11TH$?],FPKEF[9)M-+N2:2OKHR7@7AX5Q8SJY)U:
MTOGEJF5IAN12-4-%XX)>CY+5(ZH18,5&@P_EL&$Q@"/7---=/"1(C*3AU^1)
M*#' T.)$ODTED_/6_P +2V6E[D;S;X8-038=!$BDB>%BE85YY=@L(ZFL*@%B
M1));RW%_14(CYJ50&7 2$<EO,RB/INPQ$F&NTFFASA($?B#Z.R$2T*)"[S]6
M\KK6U\_!6];GV0'PXX%&5H=P$L$^+#QX=0W!N/!(36$4 R$]Y\];/_8<0.L0
MD+B,:!PY,A8$EG $X$C0MJ+=QJ2(=\)IGPZ9EX&\^YZZ]ZM[<^*3YWYU4'F\
MH!]@^DO3LB#\1YK.1T;A==Q[B2-SZ:BR0B+#+6MK35J.:(QA[;PBLJ BSZ-]
MNR3MNWHD89=KHN) JU1$;R2Y=>;MY7>?>7>P08 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'$I[.HG6$)EM
MC3PVTC<*@L=,2R5GW^U/J@@ !8+DBK];E'A5=7ELS;*J<H-TEG+CO7*#=%5=
M1-/KGPN&KXW$T,)A:4JV)Q-:G0H4H6WJE6K)0IP5VDG*32NVDM6TDV5)MV6;
M9CCY7^.QYB]2^BA?G\9#)Y7O4R?/A%:3:9K ]"I@;24^4.$=CQKITXCA*3-N
M%>@:3IR\2<$/JH959(B_:(J]\VU^F^V=C;+GM.I6PV)_IXQGC,-AU4=3#T[?
MZM12E%1JPHO_ .1Q4;0WJEMV,K=FVCV5Q^SMFT]I5*V&JTI1I2J0I3DYTU6M
MN-2<5"K%-J,G3D\WO14H*4EU3_<GJ[U//O5]F26S)S8<;F%=6?,!4-C3&1&@
M"-3-0DD?-Q06)-&"[/@*L+;M6J:A=GPD2,KH\E2#UX[<;<=_5NSVQMD4=D86
MCA*.&G1Q6$HSKU94X57BY5*47.=:4E+]Q2DY?Z<OXTU_IQBDDC](;$V-L+97
M9K!0PNRL'M&CC,!1JXC$NG1JO:+JTHU)3Q$JM.IO)N4DJ;_A3M^W&,$K+NR_
M"OMRU[T\%>?;/NQZ0+6)(@<E2*'BK=)L2D0P).9.!C1]ZFDW;<*N"L:&"7*C
M_:7SRO77]6446[?=+=_"NU^"P>SNT6TL'@%&.%HU*6Y"#WHTYU,/1J5:<6VV
ME"K.<=R_^G;<_P")^9>TV&PV$V[M&A@Z<:.'A63A0@W*-!SIPG.C%R;E:G.4
MH)-WBENO0T&SK9Z(\";ELJJJ@DX0460^32Z*:J?:J.^O_P .E4^>M]I_+_Z?
M/UKY?_3 /-KKG>]ZUUSO>O\ OK6];WK_ .NM?]L ;ZYY^3YW6M?+_P!OEWK7
MR_\ T^7_ +X ^=S_ /Q<_P#?Y/\ OK_O_P"W_P!< :ZYWOY-=:WO_P!M;UO>
M ?N ?F]ZUKY=[UK6O^^][^36O_Z[P!K>MZ^76];U_P!_EUO7R?)_[_+_ -L
M:ZYZ_P#P]:Z_^F];_P#]8!A]\?;[G=;?F6AW[77)@W#5]/RC<+!@8 P!@# (
M[M[_ $FM#_;N;?\ &B> 11XH^YIY)_+)0O[5Q3!9:OJ_<LW@@P#^-J<<[WK?
M?&MZU\[>M]:UO7/_ +[UO?RZU_\ GO\ RQ9\M=.\EU=JZNE=J^:7-KD>NS(,
M"#=)VP>M'S1?CE1!RS<HN6ZR?>M;X[261[[34X[UO6^>N.M\]:WK>M[UO#_B
M[/)JUT\FKZ9/GP$91DKQDI+G%IKS1[>"C & , 8 P!@# & , 8 P!@# & ,
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M8ZPB_$@Y>(.!,8<H.G[PHB)31)$G'#9)9_RQ149N?#Q..PF$E&.-K1H0J/\
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MY-@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MFGDG\LE"_M7%,%EJ^K]RS>"# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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ML3X5=['I8)!GFXR0 "8\]&C"@W0F2 WK4P">D!RZ;GH5JWV_L?6M[_2:T/\
M;N;?\:)X(11XH^YIY)_+)0O[5Q3!9:OJ_<LW@@P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MDUH?[=S;_C1/ (H\4?<T\D_EDH7]JXI@LM7U?N6;P08 P!@# & , 8 P!@#
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MU?5^Y9O!!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M<)U,#B:>(C3:C/<WHS@W?=WZ<XQJ14K/=;BE*SW6[.TKY[P\\8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8!ZZ#1HUZ7[;-F[?MRKM=ST@BFETX6WKY-K+])\\[55WK_+:B
MF^N]Z_[[S$:<(.3A"$'.6]-QBHN4GK*5DMZ3YN[(HQC?=BEO.[LDKMZMVU;Y
MO,]C-E& , 8 P!@# & , 8 P!@# & , 8!A[\?;[G=;?F6AW[77)@W#5]/RB
M//C!RCU?2LTK&Z$?</E_S_XV^N/HM)JZO>EY9:#B53@]##K%G'5*ZA7!LSZ
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M_EDH7]JXI@LM7U?N6;P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MMW-O^-$\$(H\4?<T\D_EDH7]JXI@LM7U?N6;P08 P!@# & , 8 P!@# & ,
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M, 8!'=O?Z36A_MW-O^-$\ BCQ1]S3R3^62A?VKBF"RU?5^Y9O!!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M2QSOO;60#5W7,FV5(]*K/&,E:)LW+D>W;*[$FDG9*V2X[R?>G9?4:<X,C &
M1W;W^DUH?[=S;_C1/ (H\4?<T\D_EDH7]JXI@LM7U?N6;P08 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@R, 8!'=O?Z36A_MW-O^-$\ BCQ1]S3R3^62A?VKBF"RU?5^Y9O!!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P##WX^WW.ZV_,M#OVNN3!N&KZ?E'(_C(1.82B,^9NI%7GIF
MX/' JV).Y]C57Y%<RCFY95&7%?&6E5N7 F"&8[.))6("PU&Y&PPL9--'G+?^
MD&NTEM!T^D AQ_VIVR<K63NKZY)VOF^BS9R7X.<9L6,TS=R3Z%^B:Q\X/[_-
M/?&U8^L71U>^(31O]DPAN^8GFTJ*&98$A[^RT)P2KN/RPDZD(^-N4EG:SAJ]
M8O'(3:;6CE;^35K7X6MW6N:]8,'ATY;]..VG*Z.W2:7"ZC;2O&W'"*G7?":W
M:.NOI.4E.TU..%.N=<=]<=\\[WOGK6@/U%P@YXVJW62<)Z[52VHBIPKQI1!3
MM%9/?:?77/ST5N.TE>/E^<FIQWQWK77.]: X!;W^DUH?[=S;_C1/ (H\4?<T
M\D_EDH7]JXI@LM7U?N6;P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!FQ\5ZVK.
MI[R$;,U:9+Q(E*9Y J^D<^C[E=@<@L3EQ;MB0)ARS??#@&5D9'@370P^S5;%
M03^;-BP)ZP/-!CYO8J[2?'[;Q#R3?%*ZXYY<.[5],\CK=>3[-L:E?25)GZJ.
M2)J7FUUU7!9E'&Q<HY&VE'K"GP")2EA-!B[I9K)2J80V4,B96<2>EHL99)23
M@@DV;%$W?+**L\DK+V^??/4XXR;EF[WO>[Y)Z-^W'3E;NV9PG(, 8 P#X_4A
M <[*<]' _/0,@R$&M=$V6MB"I)N->#AA36U];'D'[0T'=,F3OZ%RZ;EAJZ"2
MB3]KTJ![2!08Y?/Q;8BQ<$Q?#-4F.0=MU7PY,ARMVP4?M$U.G#3A]PW7[9]N
M$T^7/*"W2.^])=[Y ][ & , 8 P!@# & , 8!A[\?;[G=;?F6AW[77)@W#5]
M/RBU'O3WRP\(RGS$5F\2*GJ7MJ<3V'VO(XG#K GLX@#4/ W9^(2,'%X.#+)D
MA3N5HL0$FY?JI$&K$LW( AY;MF02;B)7OFDU:R;2OXMI9:D]^5O8-'>S89()
M_0Y68%HU&).I#RZ\SK*Q:N()G$A0PUVDU#63&(L6(,],"['O1-BS<#NE^UFO
M+K;ELX22$:MK;P:?LV6?P0Z]=^B(K:]O>HA7F2!R2J+ZKJ#^S$8A8*<"LQK=
MOJ#TQ,_.=APQ$&,M4M'E!@;SY7[XBU5A;$Y-MCY-9T!K?5<QF+P6L(>_GPVG
M:R;O>U^*BKYWX7R7@W?-Y7V\0A:]9VIZ),^>H$O7/F4I$?.0Z( &]>FJMCSB
MWP "PF]KDA$0-A(ZXT2:0EW1L2EI=(9_XDFBA"/$W:LAC!ILS&7WYO/C?+AQ
MZED/5^KAZHR=:I52M4Y%J/279S=HHRA<+N(_VC(OZKR)YB:[=]S(]N_Z9_3^
MWG70SEMI_IRGTKMOO0F7'[\=<^AZ7BC[FGDG\LE"_M7%,%EJ^K]RS>"# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# .'V#'8++H/+(U9PF-':[- ";&:")BV'NXL^
MC:K53^JI'T"NNAW0S332BCKMY\B**?&UNN^/H]=\\=6K2H4JE:O4IT:-*$JE
M6K5G&G2I4X1<IU*E2;4(0A%.4IR:C&*;;21F4XTXRJ3E&$(1<ISE)1C",5=R
ME)M*,8I-MMI)*[9G;Y+\]?#+B=KO)7YF:Q@_:X! GV-<F+.LVRBL79O$%1I9
M_ !]I2V2M0B:S)XY%/I#"VJ+G8@FN%7*?T9]IBIZ+9/:[LWM[$5<)LG;6"Q^
M)HQE*="C5_U7"+M*I3A-0=:G%M*56C^Y".]&\EO1OZ_![8V9CZDZ."QN'KU8
M)N5.FTIN*><HIJ+J03M>4-Z*NL\T:A9V$]D, 8 P#'7XG.S";3Y?,?R;]5*O
MJ1ZFR//#92M5*OXNF+ZA2WH?E19!+A7F9<K)T:HP5XL14[_=B(;753\7+VW&
MH]^EGUT>GAKW<G8OCY2YK75:O.X)U)U),I)R75V*V3IGS<_=SZ9C>9;JY>66
MM-$YHFUT'X'(A=<P1&"<PY.I>=5%S ]8(_\ %M+=WV][WSN69P08 P!@# &
M, 8 P!@&'OQ]ON=UM^9:'?M=<F#<-7T_*/=^.!+?4\2HJ!NJ")^GHY7[EU;'
M-PRKQT%[,WH(D#2I9&[\^M-K#F!641VIS%OI"&ML2>(LDS@\)PQ:)E138DX7
MZCOP^_?$02;S:[M[)///-Y7MI<E_X4%C>B;6K.\IU<[2]&M=2"\%2?G#7I6)
M_P!E7%JN7];U^\ES9V!7:LS*==,+?7L%G4KV4H]RA]"$F"I%PNUT.ZU2225D
MK72SL[J]WFG=\+7X7-5L&1@# ([M[_2:T/\ ;N;?\:)X!%'BC[FGDG\LE"_M
M7%,%EJ^K]RS>"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M 4:]3?$#I'R+,8O!;)#64<D,LC3F6L$()&A1ENU#-BG8?Z4@Y*R, FBLN^26
MX100^M=[X1[45^BYVG\^I-Z(C:2N\KY>7^3B?G;XFOGWTQ:PNG(/'[9!2XT$
M/GABDUB@46'=-8TBV<DT-/A,K.J).^6[KA9%-=JFDMSPISI?2FN..SBUJO8*
M2>C-$<A1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *E>Y*[GMI>8[(AU;
M<.'<G>(AGR8=HKI%U(!H<Z.*E0C7O?7'SW+QDT5[;M-=?*161X&_)UIYOG?1
MOU(V3M/;78[:^S]D*<\94CAZJP]-[L\72P^)I5Z^&@[J\ZE.G)PIK.M**HV?
M[ECT/:;"8K';%QF'P:E*O)4Y*G%VE5A3JPJ3IQ=U=RC%VC_S:4,]XZ[/PS14
MPN#U>Q7K\3)12%!V#RG9QHH.6$-!PEIT8%/DN5%.]*K,Y61#RN#C$54T79(@
M$D:B;+H0+<$,_/\ V&[ ]K]G]K.RV/JX#$8/#.%/;&(Q,H5*<<+@W.M2JX+%
MN<(?M8W%4H_M_P!'_*JJ6*A*:BHUOVOGFP>SVV,-M?96(G0G1I.,<95J-2BJ
M-&\XSP];>BG#$5())T+.2C5BW9*>YVV\_7)]A& , 8!4+U9Z4\]^0H9W,;6"
M[)D+&DS7^DP:'1@*:G5HRV/C1>TGR3$DZ"B%U8N& @M.)?,CH8''FXV-#%C[
M1ZO&Q[JI-Y(:9WLN?7WZ+/7(C3Q][_\ .WK:82N/0F*2ZKK>X!H2(O$K) Q
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M4P*@![8J='Q=NYZ#]2 L8Y,+<"3U7^V]L]VUF[OEDG:U_,V5P8& , CNWO\
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MWRL$/K P3I9VS,"2 8:4#/VB66FG9C)I-.Z?GT>N?X:?$N=D P!@# & , 8
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M.2:LL^-_/+-7XY\.I(PE"[:LWE;7C?73@K6;XWL=KC.,T, 8 P!@# & , 8
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M%6,;LJSY9&TRJD<D)T,F3V)Z?M6)8@BU<(Z=*[Z"[[O)+V18/!!@# & , 8
MP!@# & 8>_'V^YW6WYEH=^UUR8-PU?3\HD;XN=(2RYX?0O<-\_>K+Z-P*Q)#
M*1G'E'T_#?+\L@11Q%5P*,G*R>7/6.RW#H85, QR05=,@P2(EN5%-,R3A-42
M#2;NTLO^2<ETLK^JX'[\'H@]XJWT###\+]6UU-:VO]Q$9M"?87IQAZ>M(&:5
MK&N90SVQD31PNI&(@5CTC"F (?K6V1?A^O*1+EZ/-)..A9ZIJS37_&.ZM6M+
M+EJ:]X,# & 1W;W^DUH?[=S;_C1/ (H\4?<T\D_EDH7]JXI@LM7U?N6;P08
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M$)&7WWR."2;S=DVN[+C;6WD];(RIW:225T[\>#TXI=UWWMG<]SB-C & , 8
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MVC$5Y$"V+>(\Q6$'CXPKIN1:$"G!IPY;NMID^1OU;ENP04[&7;@K>-RT&"#
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MO'/+%M)FB 0]*8V= [?]I,'CV/24KV&>N1S<\@*4+A^7X-=Z?WOL:0X(, 8
MP#&3W=8WPPJ=MITI>_E.'>@_0,S&A9-+V<2IVKIA/$ 20]"+QH].Y78AN%Q]
MOM45'&X8 ,?RM>3.0P5!1B&[",DW2>DI/2_G8;UM967C^+EJ_!!?Q1,Z]DMA
M>-*O@U5-#)AA'+1C4?KP%7,Q$RB-,U2 R/6 *"HZ2<NQ0^4+D0+UL0-1]\-D
M"A6-%R \GT[6CO?.]^\7OG>ZX//\E\,@& , 8 P!@# & , ^')XQ&YM&I!#9
MD #2N(RP(5C4IB\C&,S4?D<=.,5QAH$<#D47 \J(+#G3E@2'/FZ[1ZS<+-G*
M*B*G?&P*I=?#L\"=\]<=^*?*G?'?.^>^.J"J[KGKGK6]=<]<[C&]=<]:WO6]
M;UO6];WK>ODRW?-^;+=\WYLMP($"H^)%@00U@&"!!S(0&#BVB# 8*%#6R3,<
M-',6J:39DP8M$46K-HW230;-TDT44^$^.>=0A]' & , 8 P!@# & , 8!7RT
M/)GER[I.C-;D\YT?:LP0#,HXA*K$JV%3*0I1\:\)$!X1,S( I AP)8OC)=XS
M'\N--&SHF0712X5>..E+=K1M%NUHVO$]^J/,'FZB"I8[25!TY41L^/0$G"]:
MUM$(23,"FKGIXV&DW\<$#G3Y@@[ZZ=(M'*JB";C>UN$]*;^=DNWJ[B[>K;)T
MP08 P!@# & , 8 P##WX^WW.ZV_,M#OVNN3!N&KZ?E&X6# P!@%/IU[6JNNK
M,N&O)4$L$6PHGSU-O1UAV ^AQ8;">8C > CV1BH<3*(,NI\7%!CC4D4=Q1,C
M'!SCOB/*G.Y.W-!PPMM.\YU2%^+VP;G<)E-9RRG[*KMC!C\@@LN)14V\_M&S
M!Q=]"9(S+PTT=#+HO7<;ET9*L>G:;L3*H=(F2>B ;D,?- UX^?Y2)#M[_2:T
M/]NYM_QHG@A%'BC[FGDG\LE"_M7%,%EJ^K]RS>"# & , 8 P!@# & , 8 P!
M@# & 9*>_O3D&;T3>'G.ZW8V@Y+9T;NBO6,EEDA[7B3BONZ7M^;Q&W8V[9AD
MW]BQTV^@H*MY_6X0>VF\9FDU;Q%1F5;'J[-6-5JK<RI<OAWY?F_)-\&CK!^,
M:*],>FJ]L,K4=&GB3BKSMA'[#&R!XXC'3-Z8F)B6#*YAQ0L&1#3NV"49.LSK
M..AG_$60'_5^S<Y"]R"(<R/EE-7TS;=UR^?#+O.-PN[IJV[%)\[))]%=/-^"
M>=NRA\#X<90\OVR;)1V41]A+/2\K,1W^ZXO(8B^*BQ=44Q"R3YL*DXT25TW8
M2Z)R>-.^U62?T!L 7&J?-=,'*:?')IMM?<C:5HQ3U2=\T_\ DWPRXFR^9 P!
M@%;/5_I^#^1Z?)6S-V)4]ULJ-BT0AX';3D[-IH;Y=*"8Z,5?K-V+/CEFP)G#
M91VK] &C(4V9Z1=[8<LW%2;=EJ-+M\#.+R_\8=M<5PQ6I[@H]C4"=BG&\7@D
MQB]H.++"<RTIUTE'XU,D"E<UP]![DCW2($ ;%IGFSZ3D18=\P#I/42'5<&E?
M5<>[@12C+)7OR:U7=9OAF_'D;89DHP!@# .JE_B</$=Q77 J;]45@AQ*(_0
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MY16&K<K,W#CGGI%7Z-7C4H)*Z;U2\T_@D9;U\K65]>]+EWG8CSC-# & , 8
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MM7U?N6;P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8!37XBNM;\#^T-;UK>M^7KQUO6_P#/6];K
MB1?+K>O_ %UO+'5=5[@Z<'U)G_\ RC;_ /L)?_HSG/'.Z/X>^Y7Y _*[0'[3
MQ+/'/(+18 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&'OQ]ON=UM^9:'
M?M=<F#<-7T_*-PL&!@# & , CNWO])K0_P!NYM_QHG@$4>*/N:>2?RR4+^U<
M4P66KZOW+-X(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , XY,(A%[ B<E@LW BY3#9D"*QB51HV
MT2?AS\>.,5QI@.49+\](NV!%@Y7:.VZG.^%45>^.M?)O *@__9J>!_PFTM^D
M6G_ZLMWS?FP7'C<< P^.@8E%A ^/QB+!1<<C@$2V29"P@$(Q0&"! UFCSRBT
M'C1[5NS9MDN>4D&Z*:2?.N>-:U ?:P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# ,/?C[?<[K;\RT._:ZY,&X:OI^4;A8,# & , 8!'=O?Z36A_MW-O\
MC1/ (H\4?<T\D_EDH7]JXI@LM7U?N6;P08 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!A[\?;[G=;?F6AW[77)@W#5]/
MRC<+!@8 P!@# ([M[_2:T/\ ;N;?\:)X!%'BC[FGDG\LE"_M7%,%EJ^K]RS>
M"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# ,/?C[?<[K;\RT._:ZY,&X:OI^4;A8,# & , 8!'=O?Z36A_MW-O^-$\
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M@M;\B@;]P3LJ(R@]+>U&7&YX@-JR/&8$$F K2M>S7+OY^">EOFV@&#(P!@#
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M@T[-O^2LW?CW]W>37!;(EM:0F'UQ!? WIB.0F 1:/PJ'1YG+_&BC0%%HJ):
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M10TLLHX5TBEPEI5PMU\Y9=37'//SUE>O^I17KY>^^O\ /KK>_P#/ /-@# &
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M(H:665<*Z12X2TJX6ZWVLNIKCGG7:RW>]]JJ]?+VIUO?7?6]_P"> >; & ,
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M ["ZE(J8O3@\@V-G0]?2.IVFY/'S9.-2L0M6DOE4WD\&*QJ2ARL:.Q@Y+3Y
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M(/\ L5*8J2<#EW"3,_'27'; R*7ZX>#W?/2#I)-36^<#[YZ'.< 8 P!@# &
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MLZ1-_--% 0&,!OJ@C@AP$!,A@$<W'@APYIUPX<)+O' X7Y="7\ 8 P!@# &
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M""CA72RZCY@JAVU=]KK<\JK=N$E.E%=:4[WUWK6\ ]GD2*XY&\<#!_/(?G7
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g80783g62v59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g62v59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1< 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %N2^6& X0DE-! 0      &$< 5H  QLE1QP"   "ZV < E  "')R,S<W
M,#$S' (% $!-:6-R;W-O9G0@5V]R9" M(#@P-S@S7U!R;VIE8W0@0WEC;&]N
M92 M($1R869T(%)E9VES=')A=&EO;B!3=&%T #A"24T$)0      $&$-4M4U
MEJU"%+'=42+'_F(X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              #A   #-0         !
M      $              S4   #A                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   #A     %)G:'1L;VYG   #-0    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    X0    !29VAT;&]N9P   S4    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     <X0DE-! P     #&,    !    H
M "P   '@  !2@   #$< &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MM_DMK9])O_&^J@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD2*AL=$(%",RP15"4N'Q,Q9B_]H # ,!  (1 Q$ /P!_CI2CI2CI2CI2H:Y
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M/K^FVU$I=H^X$3F3K$W(J+'4["6Z'!R*SD-OY?& DNIPI>'''/*<XGM[_/\
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M>?GGO<?]S"5J4KT^.O+<6D-Q;75J5\N.\AFAF:'$;D3QM$[AE (DY6/*^Y!
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MX==P3N;\'=/)TCICCZ6_34VB;MN'+EH'94W,YE9] 2#DY-$+B6?E<8 8]AG
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MO?[T=#G)(WSC?!VVZ;9.!].OH]!VX>X#CFQK9*+[K*Y:6WM5 !<7VC6JJ62
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M1)%1TVT2(0(\K#+PBQBGU"<#/OT^7YC:O.P><FOM76'CQ W.K6<)GD+3)RX
MV*.*KDU5Z*W&*I$?%A6^;C9AX3V;1:=A52G04W#*DX5V>F8Y!)HX1;9>%,_I
MG;X8S\^OU[5\$QS? 37N/\U2M+;'V-(<@=+6;>\%5X"3HD7.0M,J,519:9&.
M5:;1!Q!L_AF_Q+04:!*+08^.8A!*<8:RXI]/K[WS6S>O-JP&VM153<FN1C[#
M7;W2(^\5 !Y#$/*RH<O%(E(R.>1)/,BQLB1EQL)W!I*!12LJ]XC#*%.]*FM1
M([GX WH'?O(JYZ-V'1:5Q_FK36YT61L6N9F6L%@HMM*IETCH5JO6J2'81!3
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M]?T[G_-29KSFM5=QUS:LYJ&@W"\':KK>N;"?7LFU>MRDH[?(L^3D*\ARQ30
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M,S>VR4VI4)@=.(S-15*YJ:H;&(=4+F-Q@;I48]^_AMZUF]+X_:TU[L*[[-J
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DCI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g80783g63c42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g63c42.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_04&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     \0   /           $                          0
M   #P    \0                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   \0     4F=H=&QO;F<   /     !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   /$     %)G
M:'1L;VYG   #P     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M-W?;.GP1M]9\B-9]&_;!E74E-#]C8?\ I,K_ -B\G_WH2_8V'_I,K_V+R?\
MWH5]))30_8V'_I,K_P!B\G_WH2_8V'_I,K_V+R?_ 'H5]))30_8V'_I,K_V+
MR?\ WH2_8V'_ *3*_P#8O)_]Z%?224T/V-A_Z3*_]B\G_P!Z$OV-A_Z3*_\
M8O)_]Z%?224T/V-A_P"DRO\ V+R?_>A+]C8?^DRO_8O)_P#>A7TDE-#]C8?^
MDRO_ &+R?_>A+]C8?^DRO_8O)_\ >A7TDE-#]C8?^DRO_8O)_P#>A+]C8?\
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ML6;93ANJ+VBUS'[FE@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $U 3,# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
M  @$!08'"0H# @'_Q !&$  " @(" 0," @D!!@(&"P $!0(# 08 !P@1$Q0)
M$A4A%A@Q.%AWE[7701<B(U%A<3>X)"9"1:'8)S(S4F)X@9&8L<?_Q  > 0$
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M_5T\F?X_>X/Z->,O^)N,8_5T\F?X_>X/Z->,O^)N,8_5T\F?X_>X/Z->,O\
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M&.,9_,9C+U],XEZ9SC/IG&?24<^F<9]/V9QG]N/VXSP1_,?R/O\ Q!_W&/\
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M6PS1B;:,#XG[]S*'!L)XE*M)T\:F-2D@212!((L] '5CN[:=8ZZ=-%*'4]J
MNAIG:F@N1G$%8^CUVS>%[ ;K%B)%^$;3-Z,I%J:* [];P^85*2R;H?'!5<$Y
M6 5;7)0PRV+=253>XJ_ \1E:\5\"5X[0L3^:J(&F8Q2NMDP1M,B EI)=GA8L
MD3,JQNO[N:)^W4Q@@EBG0!7[!0"J]02$+?A1/T4R@S)4:<$8R&5,.[WQ"Q<9
MNKKJMEFC)5-."Z/MNAB)8N;A9SQ97"Z5E5L8:&R% FRI#H'7JZ/]I) [=&8H
MVU.T?JX&B5 ()R0.]_GT=>P1_AL#8_J-C^N57)<CCC&.,8XQCC&.,8XQCC&.
M,9!#Z8O[A'C#_+J']\<<@/\ <_ZG_7&81W%;W[KG97;>NZ6JU\^GMG:.J-AT
M0UAW<@TI\,)HP^KSV-,FU=A*32ZA_:F9+"I@RHJLK.NMNH+A*==G%/DA^7TN
M;^14^,KTYU^0W_CUWB99_E-+B[:1<4G'_6U:M"8FPRVWJV(':(JK+*Q9'!8'
MU#\*7]G/)_%OAO)<[;Y*N_PWB?F/&_(8*WP'D>>X^6;Y!)R_]EW;W+U@M2.3
MCDNU;<(L!V5H(TCDA90ZR:Z'5]I_C?;NW]HZB/HQ>[[6@8H];%V\/<J0EBC3
M$>OW3BQ!H%HJ^4<N()D/@4>6)6YGF-F99MGO'Q*#GOJOD7(\]QR<5)RG(5)J
ME&/DHN36*O6XVK49A-"D:+Y)87?H(U(+;.][/*_VA6_B/T'POA?B7-2?((>
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M53;W^/GE:4+7L+%/1#3"RT-HT_-<GK33%H&FBK&"B*J#]XL#X^E:DLSUT,I
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M&!(]4Y5YEFJZ,<U70LIG97*96*':Z!ZNOL ^G1D;T01LJS '\C>U((! C?\
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MD>O3@ CKF5N/$WF;SI/8W _T[G:M)Y"51T4AP%]1Q_JJG0=W^Y@!+UZ[4IY
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M_P .LRZ.8^_1.NO[+:;<YA95#$)8^V.,<KP)-,XBAC,SLK*J=0Y 8^R@/\+
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M$JJDBRNK8*A4K?!PGR[Y)$=I6FM.!9J2CHD\X$3UV!JU[1>"8S1@5HUAB1F
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M%L]\=E6A:CN'??7?7>GZ[JZ+2]TU@>PG7;65\6IS;1TK0JMS:P//QEVJG?\
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MKLLS>V8*A+-^I(4$Z&@"?67>2O5=?.V+<Q%M(S22V4MBM4URP6QK#A)A5)@
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MFG[V:DQNP".'M!BK:*8Y7>5'195>0SA"(W7Q_N^K!XP9(P1[53XY%\9[-M^
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M#4969NQ;C[[+[9I85*S,Q9^VG"^-).K1*#&40H>[HZB5 P8^0+KTJ@2H_M
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M<<#_ ._]?Z?\_G[QF_.S_'3J_MIR%LVR+W2O;5X/X4/MVF[*\TW99*/=G?\
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M'V$LHO"@UK(2@4=6IQ'#N&OWO[*16IEK!D+7\(6JZP@ZFD/,LW"&87WFD3H
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M D1DGC0B:#O)^ZL1)YD!," :.C&7,;,80[E1@#((R1%WC*L"C-M7ZC[D9NC
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MXQC.)2C/,L8]8_\ //.1_ME^=UOA?QPSR7%JS3^;[F(74*UK#;8B>%@I:/\
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MM,IAN'R]VW&@W8]AT!AHE.K[*4!LV:8YVP]9AGIRYJKT[;&.MZ_?LZY2V>V
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M;3-AU\^B$R#ES(,:5V,WYB02ND%5./W8JC&49$2SC/N1]/7/K+&,YSCZ'?\
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MQCC&.,8XQCC&.,9!#Z8O[A'C#_+J']\<<8R=_&,<8QQC'&,TUW9KO>&S:XN
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M'R5[/N^W5[F(??\ 9#U^W#']=_\ U_?F4_H!]1;^)_Q._P#X?=F__-]R'O\
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ML%J<X'2D+/9MDM-VJA7;JR:T!&G9L<".'()I0X=TQ![XPSG#&:'Z4\R_%_L
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M'=U^4/F%O/:W>06M/H1J"]?%?9]@W_7W956AP 7H:-:1364"$,%ZX-AAI10
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K@ =8^W4   #^(]M?Q:7>^HUOKF"RXQQC'&,<8QQC'&,<8QQC'&,<8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g80783g63h04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g63h04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>J^5A X0DE-! 0      &$< 5H  QLE1QP"   "J  < E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@0WEC;&]N92 M($1R
M869T(%)E9VES=')A=&EO;B!3=&%T96UE;G0@ #A"24T$)0      $,,<73S)
MVFF13QGH3K=82Z4X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q =84W4         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              .V   ($0         !
M      $             "!$   .V                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "VH    !    H
M $H   '@  "*P   "TX &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M$0 _ .0:Q]A?#H@]R?$J1HL'+_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5^<W'XU_73V:97^^*Y_[0/\ _-I]UM1_TRY_\4_"GSFX_&OZZ>S3*_WQ7/\
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MM5LX_G"Q--%$;QIQ"\;311,_ //L_P!MOW55_/K=#_E/I^J/6OH='_X)K_\
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M%=XQ$DDD>,]L#;?]UUGS[W1_Y3ZY_P"J76^[0/X+K_\ 66LG_1]JW^WGHO\
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M'_N-=K]25S_M2^33_E;Y3/\ V>GF'9G[?2/GE?\ _P!/6G4ZC_ING_P"X_\
M<:?J2N?]J7R:?\K?*9_[/62I\)VCR"T@T<'*#0IUM)'7PI9,COK08)DIW=12
M%KW;'T:2Q)(</O0^>*WJ&KN)8E]UK%/\_MH9;A[FQF2!&E>)+2XB:1$'$ZK(
M;V4(Q4'A8QN <97%:6I:#/I5A>:D_P HWR=:@EC;RW3V-MT?^46TN+M(%,CP
M07-SHDEO#-(JE8GG0Q!RO687+"LTQ2D5$7VQL+7E$7PB;@\>*<_#@2+\J:Z7
M /IIZ2?A7I3T7T7)_P#Z@]$.9'[#Z>]A(_\ @;R5Y]B=)]T7#/R3<#_@/3@'
MTT]9_HT_4OHW^T'HA_ ^GO\ 4:NG:XLV!5NN(&0T60P0SXM;,=3MO@E@RIT:
M;*@MD!OJ*D(1DL5;8*,L-LI@W1'LDJ!21^_@K@9R#O@XSMZ<8]N?)6GJ?1I;
M+36U:PU[1=?LH;ZVTZ[?25UR*2RNKV"\N;%+B+7-$T61UNXM.OS'):+=(C6D
MBW#0-);B6*\+ZE^1=5KS.#W'U&G"^I?D72F#W'U&O&E15K;$>_?LY^-3;SZ7
MTVJ2?>Y/J-^::LGC#T^XUB-U_?2W)^/N7_2"PU*>(OU5]PH_C'T>X5A\-"(^
M10!G$,PU;,<HRL:0:JR#)>Q58]'-56O:US>47AR(J>*)K(FS9[0K$><*2*)S
M_P"%O8I(]M7=YOK_ +7P/R*+_-:GK'^D:<;=_L'PIYOK_M? _(HO\UIUC_2-
M.-N_V#X5Y\W0..?-T'CP\?(8W'NDY;_YK_"1%5OK1%5.>%U/%( 3Q' \HJQZ
MP G? (!.!@%L\()\O"V/,:\>;Z_[7P/R*+_-:CK'^D:KQMW^P?"GF^O^U\#\
MBB_S6G6/](TXV[_8/A6TFWG8\S3<3#,%SVN%C\6ASK+;_%H@O,EM9W,,=-CF
M87\&Z6LJZ24MI"R:3MUN#C=#$J#S+4N18G+ASH4$%A42IU6N@A926)5%8G(
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M/9_L*Q_>=M_(K6'UEK8II2IQF_UV)_$G'?\ 8%U=^:_43W"O9=,O&Z,?]S=
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M(YC8WHYGYK/L"Q)_6V& .'<MR &Y[,UQ^D"RR:'JZ*K.QTZ\"JA9F+&!^'A
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M[(^<>]J@VIK%4\VU^RT7Q=SKZ!Y+H>1_X?SUK)'S;ZO_ *EJ$Q_[X!_EA?\
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MO1WI!T]U>70>A>C:CTJUBWFBMKJRT.VDO383SQ2W$$6J7"#YGI+W$,$\EO\
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M&GMB77[DJO\ 0S/Z?IQ_M1ZW_ITXE_%C\IOC3VQ+K]R57^AF?T_3C_:CUO\
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M(FE=/GCW,$TS!N*SB5$>3-\GW1C5>BVB3:?K$\$]W)?RW8E@U&?4T,<EM:Q
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M2'(]/Q-8+7T6L-=H$Z9%Y2/).%J^EC".1CD]3A\]#D7X4<U47U:C !R  ?I
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M=TU> 1<5IG&=:YGE-W,-(K3DN+6]L9%XZR&=0)YT0QAD8 Y0AEW)W&/I<6V
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M1/<6<0@Q]7HX\HC>51FM15^N(9B>/P+K[-;=+='F&'DGM&(Y7$+%<[?APB5
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MGD,XJQO),4V_55L_->=9H+J1E, XY^"XS(:J(CKJRAE<'-K>.1KWMJ*>2N'
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MH*ZURZ7?2(9[Z^@BN;18RP892C%8RU6PB+(?)*DDD.7'))8K!R'D8-C6_/\
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ME-*4TI32E7;LMVD-].SO96=GLMN?E& NO@QXV1U=9+%,Q?*HL0CBQ(F7X9<
MLL1R^%%*]Y8T+)J.VB (][Q!:Y[E6CQQR8XU#8.03D$'O!!!'/L/GJP8CERY
MX]=2C>+MA=I7?N@BXCNCNO=7.$PYX;:/@%%6XW@&W3;B.#R:/=/V[V[I<4P@
MUX"/R 5T:@?:L$Y[&S$:1Z.JD,49+(@#'FQ)9L=W$Q+8\F<4+$^3S5K5K+5:
M:4JUMB/?OV<_&IMY]+Z;5)/O<GU&_--63QAZ?<:Q&Z_OI;D_'W+_ *06&I3Q
M%^JON%'\8^CW"H!JU5II2FE*:4II2FE*:4II2FE*EF-8=:Y+Y5*&^)4T-6H5
MO,INBDAX_2#,J]VDR6,,B1*GG8PI(%%41+/(;9H)#:BHGD 5C1\$@'F>0&"3
M[0.[)) &1DBI SN=AWXV[-O/O62N[K%J^M-CN'U?E8S]#;7,\@AQUR"V41 F
M0%+7=Y,B8?3M.%O#(<B9D=DQ"I9WS*V:['8<#/,GS 9  Y[_ $CV;^",; G#
M58D <(WSS._L!^V*@.IJE-*4TI32E>XQD*1@A,>0I7M&(8VJ\A"/<C6#&QJ*
MY[WN5&L8U%<YRHUJ*JHFE*M!,8HL&1DK<)CK+(6])(^VD*46+*CJB,>QVX%O
M%<A<; Y7*TN+5A%S0R!DQ;,F#.)7VDJ >+..6/&[/^'O/<3X.>\;5< +XV<X
MSC'V]M0_(\KNLI/&):'$R)7 6)3T]?'%7T=%!5R/6%2U,9K(D !"(AY3QL63
M8S'%L;.1-LI$F6:0,<NWF>T^<\SY 3@=F !522?-V#L%6_M!L7<[R8=GDK$*
MV]O,XQ[+=J*.FIZH"2(#:G.Y>85]U>Y#W<.0:OIZ6;48^R3>ED0:JH%9%):&
MZ3QG#QO($9>+ 5@^2>>5 ( [R=]N9[*LJ@@]^?4/CSK>2H[#.RE]GBT^,9EE
M>4[?7.:;$MQW<B+DU W&$V[S'<*JVNW,=[+,8PO-L(G;E5^8)>KCN&6N08E)
M3&D@6L!F97469C9\!N) ,LJ@A9,J5(;C52ZX4L"$*XR0#X0(/",,,G O=Y,D
M_#;?U>7MK#TW9"V$EXQ$M;25NX++UW$O*J;MMCZY%<YS$P:NDU5+!R:5A5KL
M)CN9-QQ;RYJ5OKR#33L^K8MS6MJ=E[V$8E]&&>7B( CQP^,1X/%@DKD.PY X
M&=^UP10(O=MYSW^3WX]9V/SGW+Q,F![BYY@Y?)4+AV9Y/BY$@W3,CAHZANYU
M6J1L@'543+L">2H@[5*.D\O:B2G4]6XKH(-H'*J>]5/<=P#N.P[[C)QRR>=8
MF #8'D]9^PKEQK;Z[R,2RTZ*ZOZ7*.9,8]$D.1/!(XF_5"#1?KS^Y$U$=TO(
M]%'K8C@=QD^".PD'?S#;;RU'"1SR.?9GEV\_AWC-1FXJEJ)CHOET&P:B.5)-
M>5YH[E80@GL0CQCY>,@W-?T=;.4]R]WCQC=. XR&&^X\AP?;W$^NA '(Y]X\
MAYC;MWSY*Q6J5%>47A45/2GH_#\']4\?4J+XZ>H^0C(J0<'._H."#V$$;@CF
M*NL]SANY[ $RRR7#,]'%!#+E9(IYN,Y5Y*-D>+(R2/#82?37+@,&&1<0HTV%
M,[ORF;%CF5Y5XT0NM(1;9+:74=*B 2U%KU?W3TR 8"6IAFDBAU*QME\"U*30
MW]K;JEJD.HB.!$V98Q=237-M-%%=7$DEQ=65TW4VMS=2L7GN;"\X3'93WDTC
M33V5\L>G?.&FGBU+3X72S6.VVT>>5D9UA&IG9'3\_4[S$) ,IJ2L]/>+)I22
MWQDXY563@Q2MX5'C:OAK?MK^PO9.IM+R&:X'.S;CMM17ROIEXEOJ,:]SO:JC
M<U9EPQT[AFL@/G\4VGY(59+Q!%:RL>RUU!6?3KT';#V=W<1L#X+D[57) E"]
MPC#>(K%5KQD:K",<GI:YCN'-<GPHJ(J?"FMQE9"5=65AS5@5(\X(!%2I#J&4
MAE/)E(8$=X()!'E&WEKT1RM5%1>%:O**GI1?6B^E%^_Z=5J<G[?;[<N52BLS
M;*JCI2#>V#&-3A F-Y7'1J>AK02VG$U$_P#58GWN-=.TUG5;''S6_NH5!!X!
M*S1DCOC<M&?*"N]95FD7&';;L)R#V<B,<LYY\R:M&JM\@W,QW):O(I-538I
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M/8 2+?F1[.DX,-@]9/896OY0;;5I39G/"-SW6>/5]E88LQ@G!.P^@#D9[V.
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MMMNQCVL]X\9BYIM3V;-\MP<0GR4@UF4XMM;F5QCMO/1Y1%@TUU!J)%9;RPE
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M3=#U^'IO)J5WIMBFG2-?W(U.W: SL]W:V\0@F/6BZ:)6A' KP$!PSJ4#< U
M0@8S59#1R.<BM)*?PD@B*G#FL1JN;'$[ER*P3G$>U50IGL5!M]H"%&$R/VW(
MGX9\A![R>5?3C@<CD]^X]5;9[>8I*JMG+/,WUPH1U2Z)#ER.[%)L7PPF?'<,
M#U;(EPP$ YCR,:L83^6.(PI6-?[C2]*M)>C<][-:W(N<:F\%W'Q"$&RMXID6
M<%B.%F9E1A&59E>-I%;A!^=:QTEU&VZ96NDV>H:<UF4T=;S3IN W1&HWMS;-
M+;LJJQD0)&SQM,'5"LJP/&)674V2>TOY);*TF$*KG=)9LIRJUO'"H".Q$1'*
MU')T1H[4:-KD<Y!"ZB)X8AY6+.VQVR3MMV  ?Q5R<G/E'T0 GEV#RX]'EWY#
M?T5-<-Q!,I*0 I"0ZJ 43YAB+USI!#(_I:$?]P&JL$]$5?< :J=?E;U55RJ(
M<*K2+&O%@%R 78  XR0,8QL3E1]+<CMZ3T>UK6X[R71],N]22P$+7:V<77RH
M+CK1$>H0F9U;J9".KCDX> E^$8-2Z[SJCPZ*7'\*B@+*'U"E63VJ00CLY8YZ
MD<B/L93%ZN'N<D03N&L0HT4+<SW$<.4C SVG'@\L<QS(QYJXK9!*L,$$@KRX
M6R001C.5(QCR8SMBJA67/G^<;*RD'DGF":)),EZN><J2XI%8+J5.IHAB?RT3
M>Z B,8J,ZAM=J@NP=WR>(#A).=^($@>@$[; ;;<J@9\(GE@ $]ISN/5CS5/\
M5VXFVK&V5VYU13M;WRN*K!2I(6HKW/&TR=,6/TIRLJ0G'2JN&)[.7IGBMR?"
M?P5QRVXCZ^0\O/NJ<  9R23L >SR_P!GQKVRBWP@G%'CE)#.Z/'DM==-[X:-
M<",8K5CO81A9Q%(Q.N3+4@'-Y08C(YKVS(\.>!45O!;PM]N%20 >_;)\_;3B
MW (!V(&PVP"<9QD\N>3YS57IRJIPG*_ G'*_Q)Z_5_JUJU4#.PJQ*K$\\JHP
M\CJWS*0K.#,D M4IK((VJU[)"O61%*!%=PK%>89NI$5!\*QSESIT-] T-[:6
MUW X(>"\AAN(F4[$/#,CH<YW##<;$&MVSO;[3YEN-/O;JQN592LMG<RVLRE3
ME6$L$D;!E.,'B# [COK-$WQW%F] <ILX>> $WNE!GU57Y69S4X;TK:68"7C.
ME$Z4<*T&]J?6N1?'7&@T*SL4$6E2WNCQH.&.#3;R6*QB & L>DSFXT< =@.G
ML/)5)IXKF9IKZPL+N=V+2W/4&POIY&.6EN=3TA].U.ZD8[L]S>3%CN_%OGU;
MEFU]NY%OMNIF/2>4<MGM[D<F(QCT\4>VCR8=W&1&N7GH!8PT3CAJMYY3*4UJ
M(<*7.G:G'C!74+-[*Z<9.0;O3)%L$!4X.="ESV@\ZHL5F&+0W>IV,G$&4M\V
MU>UC(W"Q6\BZ5J(P1D23:W<.,#8XVMR<+9'=:($EMN0?%LX&$<<.2Y+C,N R
MY" 2L F8I4DMZJ18,:P879!"F0#R6JTDZ#)(-2/XBWVJZ($@/1_4K[28^!(H
MM/N;'4+C2H5'"L%C))+I]UJ5C"O"MO87&F6TUK&.JM]0>WB@LTVON<]Y*9K7
M4-&2[G9I)[>YGNM.M+J9R7DN6-Y;?-M&NKAS)).D.I:K87,[J_5:9F>YFKJU
M[.NYL;R<V-5D#<NOFN:V!8[76]?G;9+G_6"=64!I5[#DKRB.C3ZN,9'<HC7<
M:[5CKNCZE(L%K?QQW;GA73=2BN-&U8OS*1Z5J\5E?7&,C]>LX;FU<_>;B5?"
M.G=6M_I[.-2TZ\LD0A?GO!'?:-*Q&0+;I#I<E]H%V3]&VU.61>4D:,<"I+['
M<@Q:Q+3Y-17&.6P6L>:KOJR;3V(F$Y5CR0;$$:4-KT15:YXFH[CP776((.""
M#OL?(<$><'8CL.QWK$,$!@05(!# @@@C(((R,$;CO]%8;GX/@7_=_7Y?'X-1
MG'V^W]E*E%+FV78\K?,N1W%>UBHJ!!./Y,O'P.B/>^,Y/7U!7GX=:EU865\"
M+RSMKK.V;B"*5AYG=2R^=2#7.OM(TK4U*ZCIEC>Y&.*YM8I9 -O%D9>L0[ Y
M5@<[YJWZ/M*Y_7*UEF*HOQ-^N=+B+#E*U/@217N %%X\.I\4B^CE->8O.@?1
MZZR8H;BQ<]MK<$KZ8[D3KZ$,8[!BO#ZA\E712]RUO'>:7)C8V=R7C)[VBO!<
MC';B-H^X8&U1[M'"R#-J.ISJRB1L%G1:'R3'L:LGGM+_ "8DJR4Q)T*LB1F2
MJFG#%<\R6]X"/$.]@QPQS.^:YNAH&E-IK7<&E2/J5E),3+J;QB"TBEA5T:TM
M7#3'4[@2<*3/:)\UM")$N[B"=4MY?0]$^AL?0B+4-/EU%KV[O+N"=;-+41W-
MBBQE"VJM\X,-D67PHK9V^Z4RO%,-.6RE6[6KNS;)'#WIP0EC+BB>&+D+9D@I
M&1@M*[&K(74]3*-!(0SFL:C^CE[VM1J*YK=9^E,%Q<Z'=PP0RW$Y-N>JAC>2
M1@EQ"SE8T#,0JCB. <*,\MZUOE&MKF[Z'ZK!:6\]S,[616&WB>:5UCOK:1RL
M<2L[!$5G; /"H). *M+?R*DG=/()+BL'#>&H5ATX(IT2HA<I%&UR=^J*BHK^
MI@!KX%,QSF-=V>B4+KT<TQ9E:(K',&5U*L&%S."I0@-D9[0,=I%/D\B=.AVB
MI*KQ,D=VKJZLKJ?NA=@@HP# CM! QV\Q5/&(-R"&%BC$%BC8CGJ][D5[B*\C
MN&M5[G/55Z&#8B<(UB<*KO1$C8#D,XSN3GOY#S   #:O99&, ;9SOS]/]G*I
MIB. 6^5LDV*EBT>+UKVI=9;=/=%HZQ'(BH%#=#BV%D1%XC5-:.5827N8C0,$
MY3-Y]UJ"02BTMXI+_47CZR*PMB@E$1)7YS=RR%8+"R# J;N[>*)G_6H#-.R0
MOF6%$B6YNY1:VKN\<4A1I)KN:, O;:=:IB6^N5XD$BQE;>T$L4VHW-E:L;A<
M_>YACM)3V&(;<Q)"0+,3(F1YE;B:S(,HCA,TRPHL9KG"H,<)($*0E:-33YG<
M@6TED[M0:BWLI1.M[J,\=W?HLB0)"'73M.69&BE%BDJK-<7$D+M!/J=VJ320
MN\5I::=!-<13XIIGG"1K$+.SBD29+7B26ZN)HP>JN-3NE7@DDBXB\%C:<%A:
MN4=CJ%Y!%J%5-KH56FE*L"EPH7FV/DV9V#\6Q62CR5Q/)VR\BRM F< H</HG
MFCOL M.&1'E9'//78K7&BRX9K<UT.-238)[ ,G^*.6,]OH )Y'%7"@;ML/7G
MGW5PW^;/FU[\;QNN9BN'=Z$CZ:+)67/NS17H^+8YA=J"+(R2R"YJ& QT:!05
M<AQRX]C]&DF2,H#M)R>_&,>0#)QY=\GM[ (+=B[#VGSFH+J:K32E-.=2.8\X
MK-Y$1"W,XB<+U/'XI\/ 1MY^1/\ ?\.I[N?+;/=OZ_/5Y?'..6P&P'JQWG-8
M345CII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JUMB/?OV<_&IMY]+
MZ;5)/O<GU&_--63QAZ?<:Q&Z_OI;D_'W+_I!8:E/$7ZJ^X4?QCZ/<*@&K56F
ME*:4II2FE*:4II2FE*:4KF*[J8!.OKZ1*WCIZ4'R<[U8B^'6BJY2JY?0I%8G
M@Q$U)W[<_HW/]_II7#J*5G\=QBZRJ:2%2Q$,L8"S+&;)D1X%33U[2#$2SN[>
M<6/64]:(I1"?.L94:-WY@1F$?)D "6"0!D^;RY/( <SZ*D*3V;=]31+_ !W
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M7JBUU-))-%#;VX#2RR6[B.?GA(XX7*K--,T<43$)(RR,JFNK+.Z['(,G'MN
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MX0KT5K>IH<<=KJ6GW=Y,+:%;B-\O@.R[Y<!LA8\':5QP]P8^#6(Y(; +,5;
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ME-*4TI32E6ML1[]^SGXU-O/I?3:I)][D^HWYIJR>,/3[C6(W7]]+<GX^Y?\
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M_&\-L<ACRK4DB%1XS6%8&WRJ[>>-2P#D$XXJ\;P D2[:[D@80T+'J2+8W<P
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M7EQ8E3T*]NWM:)?!5Z45>EN,@@-V J<=^^#L.S\,@=O;3"$9#$;\COW>;O\
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M-<<K NY:P<@>Y5HYG"DEE>BN=K#C7GPN._Q6\_:I/Y ._*NL2K8R<'S>_O\
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(M^#]8?IK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g80783g63m25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g63m25.jpg
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MG^MCC3^ZR /,ZVZO,M=D+_$A!A?1,= B(_\ 'KG*K(DP?$;>A:/X=WUU_%E
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M6[<[?7L6IB 9)7]%5(HUCACBC24?+S-BS M5SVGTAD-\(0;F-H$.@U9M<\Z
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M41JG;RL?UW);GRY("@#CGN'>&\BO*D-FJ;'JF&M$C5(&G>4N%:0]D:A.T]Q
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MAK=A!<UZ22<23Q5H[) $ZYA^F+UJQ1GH;*4S;?0W)--LYRJH;<M>*&>GLBB
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M6!-??0 6%G=_TP5!-E*1]YFG6L1&A*CN3SD>,GLG( 7CAO+S/=SY*!W#R[@
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MD>1K+&I(N6P!JP/[$(=M5C+ ##(6*=-]I8+0J@8E258?'U )4'GX\_$#W^7
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M:U['M5KV.1'-<UR*CFN:J*CFN15145%14545/CQC,)I.8\US1X]KG.>X>@M
MVR,$LJ3)T%4>*R:%XTS!S :^ B!LH\D@\C8I&H^&1\3D6-[FJQF<>,8\8RJW
MNUZYG>VGJ[U?U\K-0)C+#H8.<A"TAU;-;!UQ.;VF;V$*% #E!SS0&OSR5\CX
MITD&:6I38YUA2"6(/!!^&0(Y!'QR(O13T@-]-K'V$++Z$+O(>T= IM=7-'S\
MU#+1@U--,'^(:DMI9L*+G,/,_O0.CA8,.-)]3I2)8AA/( ^'/\2< >OS//Y
M?TS8-Y#(X\8QXQD45Z_T_P!AOZYW^C"Z)DZ_5 1M_P"#+H\21!F-:1,[^$;,
M3GKCG XD?\OFAISY&_+1I/HLD_=7Y4]%M0+,H^,M<B&<GX$Q25 H]XC8^XYK
M<!^A=478#]6'>:R'90@>C7]0Z:_9R.?0/)1M:%(E]76K.PY$9XE?R]S9,>,8
M\8S&-KE@=OC]3CK-L#@-3G[>@*_)#AL(&16H$X2S2!$*D)7V%F29L,CFM>^-
MJ*]G_"1@^8(^.4S/]-]Q+85)-+[(;'*"YNIZKG<J-FZN]JI,_G.C#5JUE*(@
M?0H*E1,C950$@,7[*P?]LKJ@:B&RUW4 Z6.//]">3R"?G^OC\<AQ_+@<<CC\
M^/R^'P&6&X]S33<JK]'%K>LZ+I4%C-4%!EZJ2R5]!!548M8?]!EUH]$3(EL2
M-)<'._*$$A)GD2 2-OUO?#]?KXX'Z]?7\2?+Y>[)F%*&-'@,"(@+$)B9.,4+
M-&0.1#(U'QS03Q.?%+%(U4<R2-SF/:J*U51?GQD<TV]\%83[-4L<@49D,O1_
M86,F*;F+NC"3QL];.)RPPV-1#-#8:*%D[4G$SU0Z.<$QC=)8O=75[XW7"GB)
MQR?-(_24)SQ,WJA',G'NX/"?:(/EQG=0[+J.HU$DB!SJNY$VT5%9.V\A'?0=
M6?:=A^LAC*B@>;+\KY96*C%DDR.!DD!FEE_\"_NA:RS<I"MR4L(^I=PF@/6[
M'E:$EW#(:3.'TQ&?TS2SV)^JL1WC]=K6#5V/UF'<3_S49_\ E*WH" >>/,__
M +WHGDIYXS;K4\ANW";-@D]9Z>3D]859F++#*%F\<1\2R)P N]'[J@.V-T)1
MCGXU(CX\5TE\0,L4K/4/U>GCD&Y,%2D1F/UO"%G+@M3)GAUEM)^&.XW:%-=0
M67[<"36PM3DAZ$05CW(>YA_S$Q\[:KYD+R>>WR)Y\Y1Y2^:@ D9"G/*+FM(L
MV%*]5[YP1UC5KLK-!"&D%@Q%:LC\D/N"#'L@61$4R(<R+;U[8S^W0QU4<4,?
M<?5*" <?@BTX<0T^+ZFTL83)EE/L*:N)_.+99Y&PD?:ZS]SLZVFDB3LM2HTB
M$]L?#'_)L#@6%7CGOY!4CE ??&?\WU! YRRHS2"IJ0+%A0N@ZH4*O5-6J%#O
M=+(D#(6HK(>"^O<EML>)8RJLV93G@U3K67?^WHGT?J/:T=K_ .Q^*)6 1760
M*@%9:I,O[?2P$0QGAY*5%TN;/&'Z;8325>1('DB2>T_6;_XB#_Y*^G>OU>./
M-?\ _7^T/7GTQ)-(:DP^D6"/^"*,7!ZHK,.P;"$B'P0G+PK[NG>1/7\Y&<DC
M(BQH:QX_C;_P/LJ[G_NBA#_[(H<\KT"Y'JAZ]#K5DSD-;6PJH=$RJ1'\D$5<
M%J/R394F\B6),GUF/G5Y_P"8#\\ <<CC]Z![@/\ *.2[F61JO4P-B=P\'2_<
M'ZHKWA+V5!VB2)(P=P(_1$B*G3_9D+ 9Z/*K_DNM_P"H!_\ Z>/RS;U/WG^>
M:&OH/N'\LY_D,CD+=W^:O&@= B14GY)JJ'I,T[45[QLS3R3U?298843ZB"7\
MJN]R.&.Q4?,7/ QORJHUVQ],<3[&75-YKOJ-K3JI\@]VP%GTZLWHB#>5M8\C
MGR6-6)\@<U/K+FMJH=VOD_3.QI[]W\R8]?5+UM^RJ!S)(>F[>X2*,>;RN@'G
MY9-#7-<UKFN1S7(CFN:J*US53Y1S53Y145%145%^%3^4\UP@@D$<$>1!]0?@
M<VL$$ @@@CD$>8(/H0?>#G]\9''C&/&,>,8\8QXQCQC-45B>Z*YO8T551ES:
M,1%^/A%:=.U?_<O_ )__ &?/FP#S5#\47^/:#\?G[_\ SF);GN8^A[F_F<ZN
M0]55?[R_X_Y+\_S\?'^'^K__ +Y_GP>!Z\#[\BK<< ^7'/NYYY/Y?R_AG!><
MY%_A?\_\U5?E57_V?^;^/A?*;,.?+S\B/0?D?_8R?GGC@>[GS\OE\S^7'SS0
M_P#K<=PLN<A\%C'I)=%534_68;(.M!L3;%EO9"Y4"F%?)53L*%KSZ]V@C+<L
M) SY6!L*6!7P2+C[3NC)V<<E6Y#'R/!4CD=K'CGW_$#D9>5U5@_<2!ROF!R?
M,D'U/ \ONY!/GY<9I;Q?O]TOGDF.V>2]>\Q0ZG.029^GO&X;8FZ&& 0-PT-A
M826XM)4K^1$YS38X-$>V5IQR.#:V629^'>>=V)41@CMY5FYYY/)*E>\D<\]O
M<$/E[@?*_P#!B4?79RIY [5' X] >>#\.>TL?/R)(YSVF?IK_J+9_KECB^%]
M Z=C-?TW99(&^SXF>/ DLJVYK<I#<['+6%4%963AQ:U!CB!"F2*,-,.6#)/(
MLH:-N%=>$#2*9'')7GZQ('+'@$@ ? 'R^)RW[&7GZC!%/ )]..> .?C\/E[O
M+-V_E3(9!\"_TO[!GP/7[==UOG(5@$UO^C&CUW*;:8&[?,YWPV:VTF4WF9:%
M#&Y975?.[&58UB$D>S+M_P QI$/K)K+SHWO8U=C$'B X](X+-.P7)\O$O(.>
M6 RI]J('WHY!\O\ 2XY7\ RMZ^]ADX>8C*>/&,>,8\8QXQD!^P$.>FSE6FGG
MN6U+K0<0FMK/NH/H%MS:ZDK\\>J"$0L_=+VSIX1YF3UQH_Q//^X#TD=]]5W3
MV'[,F%D&))"8X(;,J2R&I+/-%%'8C2+N+2*6[ 'BF0)(Y\,L%9<+OHZLFO(O
M26%J&Q6BEKUP";[6IDIUZ,A"-(L=FU8@7OC>#L?L>6=(%EYQ&-D.$Q!Y$0>B
MT,=)47EZE:A%5?ZDY6B1W#Z6N9$.Q;2Q>]SJZJ&2620F7\:%Q4SGI,Z:Q,;U
MP,PJP&5HHBT2F"L.T)")BK$F-6"B20\*%Y8A$'"C):JB((JU)9Y>'E(\;83K
M(T)LS%R)[ '!C@,A!D/>1&O)>0@L:GY[V;VEQVOIF!L<A!#GAK;DSN?H _\
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M_P"W_#_%?]7DO8/7^?S^('EY?+@>[YY,&X'( Y\_+^1/ '/X<?B>>-/?ZCO
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MXA-IZLDT^7^;7CQC'C&5F]J.$)W/FMS75>@O\OLJ?-;5F3M<\VADG)-O<R8
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M=2EZNZ>-1)4@Z @]L1X=WXYF\PP [#_TKQY'[1]Y/O1;R&.6O(=)2D$&RN;
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M6MTL1*A4\TL5 N89(_HU[+]-'^'("X/Z7ZAS%51I9(E)5%+<J_6LWUHCD>'
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MTL+F+7V+ZA;<D/:KL9E54 (E>15^I&2@4F.,DH.)]!>#_P &].&NT#USK(O
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MYVV [3VW7= K*/0<6NL)E$VM_E#K:WI+\F2RJ<_F]R>S9Q'LB'J,W6WUU69
M2L"+GOA%;9D!@:*\(+AG!>7Q]WY\^G\//W8Y//IY?^/7^/ _CEN?(9''C&/&
M,>,8\8QXQD)Z+&Z7'W]ET'E0T!Q%S.PS?\R(+AKJK=2Q0Q#KH<X>2Y@.8Z7
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MOQQ^\_7;C[&P_P"FA?\ 8A_V3QRGP/Z_''[S]=N/L;#_ *:%_P!B'_9/'*?
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MZW8UY+6UAEBK:BC!<J;W5RZBU<:*6B^OUHDO/F"/S,U4%CFAG1&5T)0)XO\
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MF]TM/M4L;#604[\VN$H,];7V)3&[)S_I7F'N0,?!$M=G"+-&7M!^G_G]??\
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M!'D01Z',5-5?Z^S2?*_"X_<*J?Y*J77/?A?C_6GROQ_J^5_U^51]D_\ <O\
M)\CGZR__ !ES_P!?7_XI?#?Z?^T?URG'[_P_KF6^2Y4QXQD)'<9AJ+ V_P"2
M:4WE%W8%3V-G55H,%WS/1V1,KR"3-)S<N<.NB,.*DD+M[S"V>"V%X2K'6^H-
MBC;#YEDVIE1(=E738Q(JI'+([1;""-1VJD%]0SE$7A8H;D=VK"HXBKH3SE02
M<@!U#@#@$GAU'_2X\_+W!@ZCSX7/PW<==S'^AVG)7:P:/^ZFGX]?U5K%)!'_
M !+8V^*W)N0T%*^7X62*DRUCTXIB*D;3R9/Y\B:>LL>=39?1F/\ ^7VD$D9!
M/'"16Z:6H)0/1IK*:]?+GL QVQM]E^WY2 C[@&4,#\RP0>_R&9)F.N8[66T-
M$!%M*NY(BGE@K]?S3H^%DG:+&Z4E19]GE*(,UL+&N^J0$DF)_P!*_:DD145;
M>QK;5:(S.:DD2D O6V%"YVECPO<M6S,Z<\C[:J1SY@9 HRCD]I'O[71N/=Y]
MK'C\<ZOK6?\ WZ'/_9,L:H^N*-- M0RBH!(R(X8'Q VXU>:$?:5Q1$8YLM8V
M:$,A]6QQ)0Y$0/W<=X<3R0M-XS11RI(\<$YKM*JGDQF0+( &'^Z-P#P>T\<9
MC;](W8XPEF>M)!*L\3122K$TJ F,6HHI839@#\.T!E0,5!#J0"*2=6H-1R#E
MDEMA-SSW!0YC\B"OO.F:FWKLS2#$B2TU)8Z#6Z4R2K'D*"+H*.P(/S6C.;.B
MDCCZ YH<3*\(O2ZR+245G-AY8JL5B*!-E/!K8YQ/PE:58Y[,T"QDHIMA>QGC
M 4%I#FO9ITYT[0ZAUZ]0TMCM='KH+TM?1ZJQM'V&SL1I+!2B>U$\DK$Z]QX_
M[J%VGK1R2[,(.X9=Q'=MU1K,K=/Z!I--BLR0/=V6F.S80FB;=[F[ ^U8XO'3
MU^7J9+NLRU-IN>KJJ"HM'<ZUH21D#$%;,:.'[(FU]:G+8O&[-V/"T@+1J[2)
M7GE/@QPUJLOT>7NJ"2.)VKM#+$)"LQ>;:^K)Z\L^PL:S5Z73:?:[2O9JZVC%
M=N3TEH4I$A2'<[R;8[EU?]H6$WD-?:/0M[BLLLT!2IJO O+M'I%F+69:^6T6
M"*$B,.!!EG=- 5!-#-#^7-!"V465C"HWI*DS'PH\9'D)$QUO,[112R+&\S1Q
MNZPQ=OB2LBEA''WLB=[D=J=[JO<1W,HY(TV)!++%&TB0K)(B--+W>'$'8*9)
M.Q7?L0'N?L1V[0>U6/ -3JS14'1;^6LDIBZ4LS/ODT,5K,36:J2L&T8D8M"/
M:9NV<3"(#9OG)M88S"J^2"P%A1LD-Q+*FGZKK#_B2Y!I(X+NN@6A8VU_6[,I
M%<67Z3'0$==:.REA26&2,?3YAXZ&"2C&I,=Q77=;73$G2"-U+'-K=A>2_!JM
M;M*->*[1,1JS73+83;:KF6.2.9FUL3QQ/%;CN6 $L4N,PGMGJOSCO-KB;K56
MFGJ'8Z>SFD!R]C%7!:42VI+*C+#OF%4!\KI65C&UH5W6R5VBJ:B>UJ:BV #N
M;!A'2M=N+6LCGCKI"XF1%!E5V,)CD$B&+M=  ''<T3AX7<([QLT:<875=1W]
M1';C@6&8VPG[RR)9'A>.;QUDB*RH#S)S(\4@DAED"22QNT:$7HRH8065JP@J
MF$ $<!8(*L> . =86K(U/L00.:*R$U/DB)DGV7_00W\R(<A9XH\426)9B2Q)
M))))))Y))/F23YDGS)S LS,S,S%F8EF9B2S,3R68GDDDDDDGDGS.4-T,VCVW
M8**A!W9>#IL78T4E31TX]L;';W0AMA;7PMQ94UG6A1329)5J:S/V<=GFJR4:
MX.M:W6(;3"UO.1U&^RZPFT#3"BFOF2.K)6::VEZZD+WIX;$L ACJ3#6QS=M.
MTTD2-',TBV"T$>=JTT6HZ:]G]S9S=-1;^]U!4O1WK>QGJ56U>LF%>CJVUU*Y
M2O2O%#O2MNYM-<]79VT>A6UU_2)7OV+O>=RS%@3R/H$9%S<7%</S\P_2QLKU
MV&AUD&9QUE/8T]3B;F,;G+S=9! P,JL)H5SUO.:2,=3*L@9 /6=%)#4MPLYE
MFM2M%726:P:]='<Q1+:E:%/$@*<R2.:0JN'['60!&C?BZ5Y+G4=6S3^CZNO8
MW%*R(!<W!@HF.RYKPU))-A)+4KU6>NQL/):GEC@9K0LV"EA)>]2M9J=[RD3:
M;!E.197]C:S55U2D4-@/<9 6VL0\@:3<9R\NJBU/M:.$;5ESTS*JA@DU"!U]
M16E#V0 M+9P05KDL$ D"QA!(L@D4K.45IHU2:..5$BD9H5$O>Y$?<9'#!LR.
MYK5J>QFJU1*$A$2RB9949+)B1[$2QSQ0SQI!,SP*LPDD(B[S+('#&S_EAF+Q
MXQCQC(SO^74]E;DZG.65O@=F7]K\W39&40=]W]B-D,#-90V(EAF-<V(:-H0Q
M6@IC;BJ"=+#06M-+)]]LX<\=K<.H] WGQ_VGR9?/SX4@$_:!'EFU:[JV]5I1
M:C9U:74>B@[_ */J=TDTJT/$=I)&T^QK35MMI2\K&>6'6WJ]*Y.%?94[R+X9
MZMMYV',I]N_QM-TD)GPUMQSBQ$S-_.YW\HXG"[VY@IA!X&_"2E"=0M"BG?4^
M"E'16P>1XC;DABA_VN"P_!T')Y^<8X].3ZY>'7]$[;ZVMWE[I:=O,T>J:TVU
MUL8'//A=0].49;\\DA^Q#-TC4AA'"R;"3@R9EN7OZ_5SDVP];KJ8ROB2I,KM
M1F[W.?;?*]A:J,EH#!77/T*U&.LZ$ZUKF_+H$+5ZJWR5E*^]3SZ%6#?QX/(^
MX@'Y9K^VT\^GDA26YJ;T=A&E@GU.VU^TC>,-V]TR4[$EFB['S%?8P4[7;]8P
M!?/-3_ZB_P"JKZ-^H=_+RKK>+9WWK4-6-9E<RH\ME]%#GAK.+[M:W8WVI7]G
MS\UD+])D59!';7C:Z46P(IX@CZZ<O9]'T3L>H8A95*\%(NR"Q;7N\0KY/X,0
M1FD"GZI8]D?<&4.65@,#)U"^F?B"Y;@GX#=E.>2%QSY@LT;H%Y]1YD^_C@@F
MDVI_5B]=?=?UDKLMA,%I.0W5#MLX(;F=0/F(\]61UM0<K0<:?06R2V+6H>)
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M67H[.:[6663Q=C/XPEO6Y%B=NRM$WC2*[C=9YN6:=CQC*/\ L;UR_L]"?Q3
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M^EQ=@NW-O#KJNHV^KCV%EWM:\;W14WMPLXJ;#>?1;.P:8#?_ !_S/_J?N?\
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MB",)++"RR03202H>Z.:-F22)Q]F1&4AE93YA@001Y'/] WU^VVJXSFL/0XZ
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M*.PV%S:0_1OHL_TB.I&;,93PRTZQPB-W=.1)]148DLJ(>.V,-A^IO[\ROO\
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M'+''))!*J)&T<Z(W8Q*+SV%O*11R"O/D2!G^D@B_*(OPJ?*(OPO^*?/^2_\
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MI% K322NJ(S#J'1EFGKNC*5ZTZ5H56W/;D)+A9#=FB(/8I9W';'"@52SD(J
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M%VIS-0YPE4-37+R)#I8$2M;6G1W\=,0HL!,>#^/P]_KQ_;^(R'(_#GCGW?\
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M#+*C33&,AT63L9ECC9@ 4+-/(?W2Q*SAA]O5[F=[DJ+2;O:UTM/M>G&59DU
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MD$<@$YBMWKEVNJO43%7EDF@<U?I(_<QW4!>G.S".5HS!96*594C>2,H&12P
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MGUHE5-E\P%8$9'2B 2WEN"R<ZK_!56&V5-!9,<>7/N],AB#WY]3YZ_(6/]K
M(\6\S'-==DQ3:/2@6MQ3]8[ #P/(-BIS*>"TAM4ZY9U^*T=&4)!;Y"R*CDU
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M+'W$&@J]9>6F7*TQ]\X.RW.JIJW2[VP.2R,U-V-^X'SK-,0LK'/EQ^OUYG]
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M>R TKC;,O*L'D>_]<#^!XXY_GFP4[U8X+94ZT9F AD"1LJPSLT.L'N0C)!\
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:\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g80783g70q42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g70q42.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5XN:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,2TP-"TQ.50R,3HU,#HR,RTP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 T+3$Y5#(Q.C4P.C(S+3 W
M.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-"TQ.50R,3HU,#HR,RTP-SHP,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$S,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%H045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M574X>28C>$$[+W=$2T]A<B]!37=D>"]Y86)&5TIE66]V>3@X<654,#$S579,
M='!01$9(07!30WAG:V1N;&]O<5-O5E)5-W-X2#-K03(T<U)N3&A#628C>$$[
M:7I34F%-<W5R960W2T,R.&HV679K;2]S-'11:3%35%0T,6Q%53%Q<VEQ,&=9
M>&5P-C=C0V=5;6TO5#1S<VYI:$=*<RMS1W9T8VE73R8C>$$[07@S9G%:6DY9
M+VQJ1G$S-DE':E=-*V]+63%M9W1T3D9Z-D)M+W4O<D1147E,04='-$UP554S
M-EIJ3TUO5R\X07EQ931H9VMG,'%X:R8C>$$[831A-6II=&PP,G1Z>G-15&-O
M,70V4')Q,&9':$1)1%5Q0G5Y9W%O83-V.$$X;W)I,W5B;4Q2651$85-#0V1Z
M;VQW=$HR;5,S14E$5R8C>$$[;TQ3*W))<2MM=%<Y=75+<&ET:"M76'!X4U,V
M3EDR<7DR.7AE05AE;D,Q6F)E>EI%;FMK5V5'3F]W:&Q8-UE&46%I;S-X5C!U
M:2M83"8C>$$[6%4O3$8O<%=L,CEI.7AE=BLX:G16=%IV5&94<G!U3'%5:FM8
M;TMQ=S8Y4FER2DY5,5A4.4MS2G11,4-945=K04)K;$E*<'E92V]!528C>$$[
M1FU,35%!04MK-T1&571(;FYY945$5#9X83)B1FEN;S-K:3)K=UE&,31T1&-E
M;DEP+V1.4W$W,'(P>%9T+U!0:W%0:'HX=V%A;G%':28C>$$[8W)Y06-J>#55
M1E@S*TAF-5EQ<#(S;B]Y5F-M-3E05S=-9E4U<')A-$UK<7A!4S)Y:' Q0FM+
M:'9456=S5G%!3592369M-WEZ3&0R9"8C>$$[;F(V;&(S3GAQ1&-,4DQD>$U'
M67=.8VER4CAL6&Q$1WIQ5TE"2%1&53)X5E)V8GDQ<V)+-'9B=5%25W1R1S@P
M.'!Q47-C86QM63!Q9"8C>$$[9TU64VEY.#EE5')Y2T]33%=,5F9655-2>%13
M<D)+56%1>$MX:6TT4T)78V-62E@T=3)+=5AZ-S5)93=.;W5V-F5B:C!V<D%4
M-GI&=B8C>$$[14,T6C%02VI"5$4S2VXR86(P>%9#,R\U;"M3<D-->50V9U=1
M6$Q744U&=F-82$LT5S-7-TM,-DUC;DPY=S1C16)%9$1I<71&*UEN:R8C>$$[
M3U,P=')V.$%X1' P8TXT:5!B*W1C>%%S=VM66%5C2D=2=S-'4E1X27%+:D97
M46=G:6\S0GA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%9,
M=DUV+TM/87(O>D(S2"]*<'-666PU-&=K:#!J43EA=6)P:&]';4MV-F$P=U)I
M6F)U2V8P;S0P848O,V(X6"]M*WI8:R8C>$$[=GA!5G5H;6I#37)'+U$Y>FHU
M.&YH:FIV,&IM>5,T,74S;G9,2T=W;F576C5+=$1'1D--;$8U:59N4C)49VIL
M,4$T,4LX83$R>E9N6"8C>$$[-&IK1T]-<FYF269B9G<S*T)(3C)73%1K=TTU
M0V\Q>BLV=F5D=DLW<$PU3DPX=S9F-6<Q5%4Y3&Q-;&IF4S)S.3-P,'1T1$LX
M:VE2<"8C>$$[0DDQ<% Y871F5')$1VY)5$LQ0W!+,7)X>D]C5E5T=DPQ='!V
M;7)64$TQ=G P:S$U<3%T87AY<6=G16E.0WA2-E-35$PY=$=J3$MT1B8C>$$[
M+V0Q<7I5>%9,<FIY3F-N4DY6,%-+-&M",5A66#%H8CA2:%5H8C8T;#)S2D5D
M>D1-9C=R:4A2;$\Y9FA/2V]/.3AK-FAF,D=I3F-M.28C>$$[5%5.3U-624HT
M>7)T0F-81C%&8U)8378Q<2MU:DEL<3%O<&5.<$IE6$EC96Q&5EI,<7=U0F4K
M5FQU6%=3-$8K=VUK:E%X;WIJ5&)V:R8C>$$[>6]7:TMQ5#!"63 X5&EQ42ME
M9E!V;%<P,6(O0BMT-EAE6'=U-')385IO5FA-4U)89#),5T=6;4TP8W$X3&M+
M0WER5E-627A6:DM3+R8C>$$[.#0X*V(Y5T516G14,4ME0U=8,3(O4V=A4T9)
M2&=L8WIT>$16:&I+13AQ='A!,TMI:7%%,7E,.&AF,&9"-6<Q,WDO4%E16&QL
M3F1A8B8C>$$[8V-:,2MT,C%Z>FML.4TR:W)+1V8V,%1W;$M-03-10F9H5EA3
M3B]Z:DYC-F<X3&U'4S8Q0S1K3% O=5$T=%!Q-FU*=C-N,D4Y9$5Q=28C>$$[
M-$A(-'A11W5+<2]L<EA0*V-F3$155C%,4E=E3U=X64Q$9DEU;WEX57-B55=X
M8FMF551H1$)F96U79F(T=2]81EAR.6YD=UAL<$)D,B8C>$$[-T9R935J5U=&
M:7)+4VIQ1U5L5T%98DAO4EA&6%AL<D)E5VLY<&-!=$)C4G1&2V]::TI2,4MS
M07EK375X-F<Q>%8T+W$S:V(X<G)8>B8C>$$[6G%H=CE);C%',3!R5#=/4V5#
M0DI76%1O5VYU6C)M6GA/2C=J,3),339X>'511DYA.'%95F1987(O=T$T-W1.
M94Y!+T)R0W=M,&E6;28C>$$[82].9% Y23--:U-I<$I49U@T-V-Q23-$-%9W
M2W,O>$XO=T$T-#)E;7=M3UI:3&)3-6)F55DW96PK>E)-,%5&:D9C*VY*.%)#
M44Y&>"8C>$$[,D]W-4M/5TMS9SAQ*U,O>5@Q4T=A,#!44V\U5C Q;V97:6UJ
M=3!E1G=K9VE(*VLX6$159#)P-'1Z3S=62W(P:D9732MC9GI",%!Y;"8C>$$[
M4%E2-G1(8V5N<4%N.4\T9VI%:4E91E4X6D)Y1#%K6C%33VEM<D5$875+<%1P
M;C4T9FQV<49N1&-R<4QW4$Q':W(R<VQV33!S46M4;28C>$$[;VLY2EI50G T
M35)S9#EJ:7%9>2]M5C5F:$XU3DI$94QP=6Y4<&%8*W!M0G939VYK:E-2635)
M-B]75C)M449V4S1Q5'52=E)63$EV>B8C>$$[,2]+.31F56)71$8K.&YI-%!B
M6%!/='1Y36A+<D<Q07%*>DYF<W%6-54U1$96830O3W(X=&]48D)D5SEF-C%*
M8E))24E*-5=6<C)&<"8C>$$[<F)K:4E8+V5+;$%!0V%K5D%X5FLR9V59.4<X
M=U=B,VUK>FTT=&\U5V=D>DA*1E-204-Y.%I64G%R>6]D=&IT,4)X5C1U,VXW
M+VY)5B8C>$$[.4MT=%-S8E1Y+V9W,V1O;"]%:TM84TXV3')B=E9V<D1W<4]+
M6&%S>F-U26\Q5W%+67%H6F9Z12\U>6=I35-V-5<P,VY.24E5:D%6;B8C>$$[
M.55W;30T36=V0WET-E,X<4U08G)I;EIF0BM9=B]/4U9Z<'1T93)U:39*8W1D
M5$-"8D]*=6,V;')E3S9J3&=86$9E8TUO8TQY-6-D>28C>$$[;T9#5E5T9C@U
M9GHK:&MT1G5D2S!3,VIV2EEO5FQ9:5%2;6%$-C!P;5-'-FMK:D@Q9CDV87)8
M:CAX:7)&4"MH=&9Z3B\U6DY*+W=#4B8C>$$[12\X03%8>%=N9CA!43)V-6TO
M.$%,2G!0+TEI9B]Q=FET36HX:&9N+T%/95!/;7,S3V=A<$19=S)5*VXS,&IV
M87A32DI72S)D=T%:2B8C>$$[2D9O4TXY<U9)9E)U;5%Y9F\R,"]F4#A!,TUF
M6E U4B]K-&]6,71E3',V>4U(96Y.9W-93%5&0E4X9#AH2$A%17E!04UU6C<V
M-S!K;"8C>$$[9#9-;BLO,RLU4#A!;6Y*;V0V36XK+S,K-5 X06UN1EAE:DHO
M=CDO=50O;6Y&6&5J2B]V.2]U5"]!2G!X5DIT96EK+U-V;'HY.#5R<28C>$$[
M36Y:4"MR9&0O=T-4:7%-=69,;6M853AK.7IA=WIZ>D-*6EI:24E(9'AB=C9S
M25IM:DI0<'EF16QF<VYC8C1Q,5HK6$Y(<U1'8DLQ:"8C>$$[=%1#3TU2:&=G
M:C1!;&I294U9<'9),U1X4&II<4%N.&AE5W!P8F1J85%P8C(W>E,O53!T-U99
M6DI,:4IO2DAK55)666U+4C%)<E$Q,R8C>$$[0C)O<75F>40U3V4T:G58,&%W
M831I65!&33%N848Q6E=,:&Q9>%9"1'-7<C1M=4MQ9#,K6&YL4V5X=6)/2W=T
M-TYB<4M3,VUL=&)A,28C>$$[:FM-33166FM$96MA0U)50W0O54%H5E Q=#)6
M47%Z3W%Q2T%!24%!4#EJ:7)V4FLO,RLO,THO>E1I<4$Q1'DW<#DO2TQI9%9.
M.&MB4B8C>$$[45AX:'1P2C1L8T5(,#)L:6MP,39%53A2:7%#=&9)4&Q/,G,T
M-U)D371N:&IT,71+>3(Y=DEZ47)%:U!",F%-;'=9-&Q5,39G1$96<28C>$$[
M9FPQ-4A31U="3D,P-5E*,4-4>$-X=$%J<7!6;$1Q27%-0555:79G4$1&569P
M6&PV,#!Y4SEL=%I816UO5"]78FAU34LQ65)P0VEG2B8C>$$[1V\T<$A%<6HU
M8C%/2V\O,%I0.$%F-R]C;B].3TMO4SDP3%1B.30U3#9#3S9K:4)72C4T65I#
M<7-Y<U%P6D111F\Q4'I!.$U64S)(."8C>$$[=F9*55 Y>F]M;G@W0F9G<W)2
M9FA(46)29$U65F1A.&UA2G$X5C)T,T5O;'8T=G$Q-61,1&(K=DI!9&UI85)O
M;6)I>3=E23=%1VAX5B8C>$$[6F-E469*,7IZ*W,V3EE496]X:VLY4WIT6#5/
M>%EL:E=),4HY4G0O8RM/2W)X-4<X<'%S84QP3FM&:6%+4TI285=T1F4S2$=&
M;$AP8B8C>$$[1TY44D0K>C)X5D8V3F].=G!&;#E5=%IP3T13>EA%:G-)9WIY
M,T5R5%-U,T-.1G%Z=51S0FER-6=S+WET+TTO531T36DP2'IV8WE8328C>$$[
M=&IA6%4Q;&4S3C%A3F)16$UC57-!06IK=69H0E%R43A45TQ:9G,T<'1"-E K
M6"\U,V%T83(X=&HU>&ME>E=/-G5,4B\P:'%)049H228C>$$[3%=4:$@V9G%+
M,W@P46-25F9U>%<P6$0K568U,U<U=F)+4'IF-DXS04E*2DQA4%4W;TDP8DI,
M1T=::%-J271I<6=C9G,P<5%&>%<R028C>$$[*V4Y13@W95=59VDQ6%@R,4-+
M-FYU-V9J0F-88G%*8D92651H:$]K3F%**S5"1E%52$@W3TMS1WA3-T98;VXU
M168X<#(O=T0R>DY3+R8C>$$[-F<U35%G=G1Z5% K3V)A9CA962\K26I&0TIX
M5C)+<F97:3E5=VAG6E%V27!88TQ7;%1G=F5K6#!8655U>%9*9&8O-#9V;'8O
M04QA328C>$$[;B]D3W4X5E1R1EA9<7-L;F=I-"MR27-F33A5-45#<#A"6')G
M36=/8DM-0V51=&9H675X5C)+=7A6,DMR6EIO;U5,>75S841Q>FM+4"8C>$$[
M=D]!:T1M>6I%>4Y!5W4V-VI#>&1I<G-69&ER<U9D:7$R2U=/5TU34DU(:F(W
M3')U0U!%2$%$84%B6%E5=7A6.%DV5&]F-4)R671$<B8C>$$[;714>%A%.7!A
M=D9D5S1M:V5/47A7.'-P5T].2EDK8E-T8U)-<VA(0E97:6MN;59/-FLO;'HO
M;DAG85(V=S@Q86MD4RMQ22\Q8U%Y128C>$$[9E=Y:D8T.3=21D-+-%56-6UT
M9F%U2S=R,#!(+T%*>#)I=G(V3G9-96]81FU:64DW1V-P37)#1FI!6C5707-X
M.&%6;30Q1D119D0S2R8C>$$[=39(=$Y&+TE*:6E81W8V:$9(3W1U.&MN<'E3
M4U%.4V-Z>'%28GAO+U-!8VEN9&E-5C-14&U'>"]*;T<R:C!N54QO=WA75&EE
M-6I76B8C>$$[<#5,=C$S.4XR:&YI:FEA<UA$:W%Y4G%V6FU/-58S52]/2R]K
M-G9L:$(U5V4Y:S$W,3=B-#=H6%5'1#9O=G(K;T-745 Y6356-$=L9B8C>$$[
M<S%89D966#AI4#A!;$\S+T%/,EIQ6"]52$II1DPW8S!Z+VIM,FXO1T=0.$$T
M:4U526Y&6%EQ;U=L:F(R=G%M1E-$4$E:6D=9;&E78B8C>$$[,TYD:#)(8DEX
M9T)Y67AI0GE6.&MY9&EQ4S8O+T%-9%AY,R\R,%I0*S9D9#1Q;E=+=7A60U@K
M;%=';T<S3C-'6D1A>7)08C!D,31Y<B8C>$$[.6PO:$LW:DE4>'AL5CE'-T1Q
M2C0W-%1814M0=5)E5&%867$W1EA9<3=&54IQ;6Q71W$R8E=D+T8V,7-X5FUJ
M-4UL4W!Q<'%H53=(8R8C>$$[92M1>5EX355E5&1G,44X575+0G%8-#<P5T)1
M065(,#5.<&1I<G-69&ER<U953#)Y9W9B6G)A8T5X4%1K1EEQ5%$Q<%931%$Y
M.&I+228C>$$[:TM,1U5225568T%!04%503)!1U-:3WA6,DMV:FTP,6XX<'!D
M33 V1%9F2D]P>5AC8U9K;7!Z5W-!:#E6<F%Z94=5;U9K57%:2C)74B8C>$$[
M;5AJ>B]A1E8K2E,S-B\U1DA3>$=F2FUV1%5F<6E*-F]76&HY831-2&M*3C-1
M<GDT:T1G3R]J<W$W54Y4+TIY-W-)-&PX:S9R0DYB2B8C>$$[97A7+V]1=D9Y
M5U-E4C=/4V%1,U1V23AC8DM*3U9A;C=*0TM&6E9$4C9N*UA.<3DS939F-4YL
M3'=I9'),5'(R0S5K4UIZ95(O52MB3B8C>$$[3F,P0U=G;#EC8VQ$3W=O1%%&
M4W)Z5S8P>E9*<FU75U!46F]5:V1N4T99<$]+0FI52TMJ;T]M0DML*V@Y6"\U
M66)J+VM5+SA!5$9B6B8C>$$[+W=$:VA96#%T-3)E5S5T-5E):'!U;V=Y4TEY
M3%4R:V=!<5%"=6-19W9T1%1,<3(O4G1P*SE4*S5J+V%(.&]X46EF<E9R+W8U
M4"M#2"8C>$$[.6-69#EA=&8Y+THO=U$O<FER=G)6<B]V-5 X06=H+UA&6&97
M<E@O9GEF.$%"1"MU2W4K=%=V.$%V-5 K0T@Y8U938EAR;3)/<2M82R8C>$$[
M4W!T<4UL9FE(+U9U=3A65&XV,6$O=T,O:R\T268Q>%8S,7$Q+W="+THO=U$O
M<FER=G)6<B]V-5 K0T@Y8U9D.6%T9CDO2B]W42]R:28C>$$[<G9R5G(O=C50
M*T-(.6-69#EA=&8Y+THO=U$O<FER=G)6<B]V-5 X06=H+UA&6&97<E@O9GEF
M.$%"1"MU2W4K=%=V.$%V-5 K0T@Y8R8C>$$[5F0Y871F.$%F>68X15 V-'$W
M-C%A+S<K5"]G:"]81EAF5W)8+V9Y9CA%4#8T<3<V,6$O-RM4+V=H+UA&6&97
M<E@O9GEF.$50-C1Q-R8C>$$[-C%A+S<K5"]!24EF,7A6,S%Q,2\S.&XO04%1
M+W)I<G9R5G(O04PK5"]G:"]81EAF5W)8+T%(.&XO0D0K=4MV:75X,#,X:4QZ
M4V1++R8C>$$[4T=R6%=M86MS5G%U;W)A>#-%<74W=$=,;#-E5T]106]V37%S
M854Y,C)X5'5M96UA4B]Z:F1A>%1R938S9%@X=C$V3#9V27E8:40V;B8C>$$[
M.5I03W9P,C!8>&96+W1B5C5F6G!I=39$,'934'E+=6QV-U-+9E9,=2MM:W-L
M,&E&1FUA-6MA5G$S36-1:6=:2V]R0D4U<5-Z0W91-"8C>$$[<G5W1'IF<#)K
M86(U;3%,5'1);6MU9%!S-6UT-&)I57%Z4T=,-$AC1E918U=C358R*WI41DM4
M-'$W1EAO;C5%9CAP,B\O8DTQ3"]Q1"8C>$$[:WA#0RLS3DTO=T-/8F%F.%E9
M+RM):D9#2GA6,DMU>%8R2W5X5DID9B]W0T]R-6(O04\R:DHO,U1R=D95-GA6
M,DMU>%8R2W5X5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMV:F)3-VXX;%DW5%1J<2]L9E9.4E<X:FIH<UHW2T]737EZ4C(Y<6LP4$PQ
M-V1*<"8C>$$[0F1'9&U+2S)Z>&=';G=H4W)E5T(K42]M1'I"<&5I,EAL>E5F
M<DXW.5)G95-E9#0T4DI(2WHS,')C3&E29VIW.4MD2V1&-C1R=6QD;B8C>$$[
M<E U2U)8:TIT+TMM;S-D,49C5$Y*851-.'%'1F(U2E9&23=L0U=J<U9L43AG
M5C4X95A)5D]+;S!E9%!Y16$U;$TS;%<X83%U8E-+1R8C>$$[-5-.26\S.65*
M;T0V:TQ#8RMI<$559V)H.%1C:GE9.'9H5F]V26XT8S(T06A+;FE',TY/,6%5
M>%-T>%8V2BM22"]+9'8O=T)S>E5V*R8C>$$[;T]414E,-V,P>B]J;3)N+T%"
M:&HO=T-):D9#2GA6,DMO5S%S;FEN;6YM;6%E5U)J=TQ$:4DT-C%73E9',WI0
M53DK,E%J1VI:3G-)>"8C>$$[;S)484MY8DXR2W!,<B\X07@Q9DQF+V)2:R\W
M<#$S:7%D67$W1E5,93)5;# X24TW2F)+4UHT1D@Y-S!+9W1S=T%),T$V.41K
M2E)V<B8C>$$[<W=L1RMU>4MY8DXR2W5X5C)+=7A6039Z<# R;U=,5S!.,TQ9
M=7I+,S%I03!C8U179TY2<V%54'0Y*U8U64=1;T=N23 R65DU.%)I2B8C>$$[
M95(U23%146]"3E-!050T-5E'9W0T;V1I<G-69&EQ1S%/>F4Y<TIR5T]D-U8U
M;#1I-&DR:U1F-U-F-5AH6#AC:&MJ>$-R<'1W6D)#628C>$$[:U%*5C!027%L
M;D,X1G)$03AP;65*1E)P;7)Y67%+8VI5;F,O4$1!54%/8DA*25-K4T)6;FMQ
M-4IG-T98>&99+VYB-3ES=$QS9$]G="8C>$$[=$8Y1W=.=5E(6F]Y+W=$;W9O
M8T%0.4DT;T<K<7)Y15E51W!06&9&3DEH4'HU+TU'4%5B3R]J=$Y$:FQS<$1*
M2$A'-%-.>3!(,6-I4B8C>$$[5G5H>BM(9&$W<69S,%AB1F%D<'8U-2MC<E99
M64QJ5'1&;71);'-5.4]/4T]&>4Y.;$TP1DA%-TQU+S(V<6%J654V-')4>3)8
M5')Q4R8C>$$[5C5#,7-P9&DS1F)I,U9253%O04@R1TM6;C9+=78U-V8O<$IT
M+W=$;79&6&9O<38O;G0O*VMM,R]!3V$X5EHO*U-&;$YB*V1N:VMA2B8C>$$[
M;$=M-FE+4GEX4W1V85-$-TUB33,T66A"9F%';5A%9C9.=$YN+W59+SDQ=B]!
M0VHR>%%I9G)-9F<O=T1Y3&8X07!I<G9R369G+W=$>28C>$$[3&8X07!I<G9R
M369G+W=$>4QF.$%P:7)V<DUF9R]W1'E,9CA!<&ER=G)-9F<O=T1Y3&8X07!I
M<51A.6-2;E9F3&UZ-V%J2BMW+W=$,28C>$$[8G)V,GA63V9R369G+W=$>4QF
M.$%P:7)V<DUF9R]W1'E,9CA!<&ER=G)-9F<O=T1Y3&8X07!I<G9R369G+W=$
M>4QF.$%P:7)V<DUF9R8C>$$[+W=$>4QF.$%P:7)V<DUF9R]W1'E,9CA!<&ER
M=G)-9F<O=T1Y3&8X07!I<G9R369G+W=$>4QF.$%P:7)V<DUF9R]W1'E,9CA!
M<&ER=B8C>$$[<DUF9R]W1'E,9CA!<&ER=G)-9F<O=T1Y3&8X07!I<G9R369G
M+W=$>4QF.$%P:7)V<DUF9R]W1'E,9CA!<&ER=G)-9F<O=T1Y3&8X028C>$$[
M<&ER=G)-9F<O=T1Y3&8X07!I<G9R369G+W=$>4QF.$%P:7)V<DUF9R]W1'E,
M9CA!<&ER=G)-9F<O=T1Y3&8X07!I<C0T.'1E6F9)="8C>$$[,V]L;&]'<V55
M6C<O049#8E-(9VI/;C9B071Z3&1X,T1V0F12>E)01F-/=F]O<7E.6#1I<E9"
M0D]+5C!D,2M3,7-J,S)Q*U)T66<P-B8C>$$[5S1P8E1Q8FA9=G$X:WAE,T98
M=3%R2DQA>$5F8G!Y1'-/4S!#2W-T<V1#+TI#*S$R-#AR5T=I<G$X46IU9%)S
M<B]4<%IB:$E1,79%:R8C>$$[359Z8VE7,FQ,3E!%-%=),5AN2D=O87).:6@U
M,S5X,6XX;S502VI7,VQR>3-F85IQ.35*1$YB,W0U5U)F<3A1.4]12DDP.&QE
M8W%Y5B8C>$$[6EEW3G5.3G1L3'IF1DM+9E,Y5%14-#E293!M6%0U;DUC5C19
M,T5,=78R;%=1:FE72&-!-'%Z<CAI4#A!;$\S+T%/,EIQ6"]52$II128C>$$[
M1CEU85HO>'IB5"]J1$@O>$59;U)/2W5X5D,R;#0Y>DQ.>&EA3T-&:DAZ:T)6
M;F144G5+:V9:2#@S9DE2;%I94FQA2WEB3C)+<$QR+R8C>$$[05!X,69,9B]!
M1S!:4"LV9&0T<6Y72W5X5D18;#0X3'=W>%).3$Y/4TDY:458:E%S6&5H-#=F
M9FM*4W)99%=-<%9S:6-M>61I<G-69"8C>$$[:7)S5E$Q+V5',6E6;&EE85-2
M>$A&1V=*<3=!,#5%03A6,C-9.4UJ3U9-6GEP14IZ-$QZ;TAO3U%'-'(S<%A*
M0FLS:7)S5F1I<G-6428C>$$[,G!88VQN67I836-%;# X47%T=D5#6DA.86-6
M04(S*V4S:5%..&AK;'=I-G1T=UEX3UEI4TDS,5!)2VQP3S%X85%Z=$<P5%-O
M<G1%-"8C>$$[25I3=W%625E+86HS1T=*<T%S8VM/1U)&,U)68VMW9&ER-&Y8
M.'E03E5%;&TY;&)A5D8Y56AT5E9*8GE#6D)06G=2=U)Z4DPV-FE(-"8C>$$[
M649*4E!H8F9N>4<R1DY,<G(X,"]0,34U8VPP0SA':C-&<$Q:,C%H-G)814-Y
M<D9::"]324M82V]4*SA03&MP5G5H1DMG:%4Q:B]05"8C>$$[.'<T,S5R6F58
M*UAQ:6)K6F\K6$E44E1G8W9R;DQI1V=50F$P-"]$,$,X4W1-9CA!3$@U9V5C
M9DQS-U,R8U=J>DLP3FYB<D)C6$5,>"8C>$$[<DA9:'94-'%T>6TW33=/>DAF
M:V%R>'A63S1V>G0O35-):W!B-D-T66I#3TTP4VA635)H<6=7-T%J4$4Q2$-L
M1%=N,C,U2S!G9DYF-28C>$$[;BMA+TY/:#-U;&%N6C901CEA2CE+4S!U;TDQ
M:41Z47IY56IE95562G1504ML97(Q-49Q-$954'E4,#(T=&9/<VLP<G=-9S S
M55)32R8C>$$[-&=M8F4P:T@R26YD=G=X579S,U1,:5 Y1S)M>B]W0GI(+W5T
M+W=#564R2T54.5IJ.$@O-49V.$$P>%8S,6U0=V8O:U<O=T141EAF5R8C>$$[
M62]"+RM28B]!3DU69#E::CA(+S5&=CA!,'A6,S%M4'=F+VM7+W=$5$95;3$V
M-&I/<2M83FXR,4=4.6@O*W)D9"LR2W!Z.5IJ.$@O-28C>$$[1G8X03!X5C,Q
M;5!W9B]K5R]W1%1&6&9762]"+RM28B]!3DU69#E::CA(+S5&=CA!,'A6,S%M
M4'=F+VM7+W=$5$989E=9+T(O*U)B+R8C>$$[04Y-5F0Y6FHX2"\U1G8X03!X
M5C,Q;5!W9B]K5R]W1%1&6&9762]"+RM28B]!3DU69#E::CA(+S5&=CA!,'A6
M,S%M4'=F+VM7+W=$5"8C>$$[1EAF5UDO0B\K4F(O04Y-5F0Y6FHX2"\U1G8X
M03!X5C,Q;5!W9B]K5R]W1%1&6&9762]"+RM28B]!3DU69#E::CA(+S5&=CA!
M,'A6,R8C>$$[,6U0=V8O:U<O=T141EAF5UDO0B\K4F(O04Y-5F9(03AW9FQD
M<6EA5G!T,35.=C=Q-U=Y=&QH97=H:',U-W%C4DQ(8T]Q5S%#-G,X2"8C>$$[
M3EA9>6182$9A.&=P5"M4479Y=6TX='=8=SAI87A'.%8W<'1V1&%H2C!U-VE'
M-6YL=4IP56HY671*2$QB>"MN2'530U9!9CA!87A6:B8C>$$[='0U=R])9V%2
M04QJ>7!C+W!I1S%U;V95:E@Y>#9S<G0Y5UEQ,3)F545A3V%L=U=Q1C-O358S
M95@S3VPV;F$R='9D,TYP3D)A,V$X-R8C>$$[5S1K:F1)-59"2S%J9&=!=W%P
M1S)+54QI<G-696EF:U(O=T%P,B\X03)Z3E,O=T-O3U1%24PW8S!Z+VIM,FXO
M1T=0.$$T:4U526Y&6"8C>$$[67%H<E<Y3GI.37%237--3$=->75#<&%25'9X
M56ID4B]..3)1:DMY=VI+>6EC;7ID:7%3-B]W1#AD6'DS+W="=$=4+W5N6&5+
M<#%I<B8C>$$[<U91=#5E=$$X34UC5%,S1G=326Q!25%C849I-S!)54%B*R]B
M9DE3;%<S57-*4W)B<556:S)B<U9D:7)S5F1I<4,Q:E5N,#9X8393,"8C>$$[
M;7975FQ(,64R479)47AO4T%",C8U6&QN=VDV=C-.*VUW:DI0:$UH2'I02D=+
M87%$4VQ25VU70G!,94M(67$W1EA9<6AT4W9'<W)'828C>$$[-E=#4S5A2F51
M=#163'E/9C56560X:&ML=VDV='1W-"M/66I9:F95.&=Q5VQW8FDP:'5$1SA*
M;5)8355G2W5N258T<W S0DA1-%EM=R8C>$$[0WAY431:1TXS4C9+=5-93WA6
M.%)7,S5L*V%,3RMT3'%Z='1-45=I,D1#0C=I05)M8E1O66]%8RMH3&)U-DUS
M0VXP-5=D5DY3=$1I;28C>$$[:UI"*V-V;BM$-G5Q4F%1571:25I9,6MN16I(
M,$AJ:T%K;&4V85=4:S%V2'E:,TQF0T%#0G1I=$QT22]/:GHQ<%8Q93-&=&%A
M2S,Q*R8C>$$[-64X;6IE8SA056M-0F(W3C1R371B5F%">6%!<V]O<#0T<E-4
M95HO4%AM8GI*<$8O<"MO<%E5=F(U3#EF4W5,5EDW9FEB:#)31D,U9B8C>$$[
M-#5,>#):;FM9.4)S35996BMI3'8O9FQT+W="2E9T+S%5>%,W.4589BLO3&(O
M<$MT=BMQ;4MS*R]*1WAN='9/>GEY3D5Y:E1D4D9)<"8C>$$[;W!7,W1*0CEM
M3FUB.$U19W9S+U1,:5 Y1S)M>B]W0GI(+W5T+W=#564R2T54.5IJ.$@O-49V
M.$$P>%8S,6U0=V8O:U<O=T141EAF5R8C>$$[62]"+RM28B]!3DU69#E::CA(
M+S5&=CA!,'A6,S%M4'=F+VM7+W=$5$95;3$V-&I/<2M83FXR,4=4.6@O*W)D
M9"LR2W!Z.5IJ.$@O-28C>$$[1G8X03!X5C,Q;5!W9B]K5R]W1%1&6&9762]"
M+RM28B]!3DU69#E::CA(+S5&=CA!,'A6,S%M4'=F+VM7+W=$5$989E=9+T(O
M*U)B+R8C>$$[04Y-5F0Y6FHX2"\U1G8X03!X5C,Q;5!W9B]K5R]W1%1&6&97
M62]"+RM28B]!3DU69#E::CA(+S5&=CA!,'A6,S%M4'=F+VM7+W=$5"8C>$$[
M1EAF5UDO0B\K4F(O04Y-5F0Y6FHX2"\U1G8X03!X5C,Q;5!W9B]K5R]W1%1&
M6&9762]"+RM28B]!3DU69#E::CA(+S5&=CA!,'A6,R8C>$$[,6U0=V8O:U<O
M=T141EAF5UDO0B\K4F(O04Y-5F9&=6TO;&PK6#)Q869O.'8K3F)44TQM-F=H
M9E59-WE70U5X>7EH0SE&4C1H1W%&:28C>$$[2TTU878R9W%H;4-M,%%F>6TO
M3#8W,#AV<#-N:3%&-FM%:WE26$17,TME4F)E,VMJ9U-&2FDV3S@P,&ED6"MZ
M44$Y4W)A0S%J.'102R8C>$$[;FPS5F1:,'95=%IB54Y1,'%A,6IA,5(T9$MC
M=WI21U=79&9R=DU41U T5D5A8G1Y<E=M2S)J<G(X:V9,14,R8W8K4#E-*W%8
M=#=,6B8C>$$[43-J2VEW15$R;W5(;%=15'-P0WE/<U1E0DDS,W!I=&\W4R]Y
M<"]+0S1I85<U.#=1>"MP0G!K<TU0,7EZ:F5+4S592F5*25A(>"ML4B8C>$$[
M;2M%1&E#3U9A8G$R=S-Z,S5(.'1A1EE*<4=I*UE&,65#92MN<V]9;%)$.$YT
M.%1Y97)(239S0VMK3$0T4CEU;C=/-F]+3B]):B]L3R8C>$$[,R\W6FUP9CE1
M8VU)579T>E10.$%J;3)N+T='4"]I27A1:6-69&EQ1G1*-W5A85EY42MH0D=X
M:FI$-W4U52\S;7AO1E!B=FM):VMN=28C>$$[65)*2TMY8DXR2W!,<B\X07@Q
M9DQF+V)2:R\W<#$S:7%D67$W1E5,950S:5-1=S(P4$YP:655-V8S8U%7:$IC
M5D1';RMY0C,X36A);B8C>$$[:T%W:U1Y05)75%IU>%8R2W5X5C)+;TQ73&Y5
M-V5X85A48E%8=#)#;U,S3')'0T-F:5!*:4)S37)Y>6M"-E):8CE.1$A+9%I*
M8TUE*R8C>$$[<E)I:VQ14TM';30Y.'-$4U<X54]X5C)+=7A61#9J3F51,DTP
M=&Q".6%U:U=S3G570T(R.$]414)F;FM*:V=B0WDR-%EX;$U#6C19.28C>$$[
M4W9T2DQI4S!H:W5)=E%U2%)7;6AQ1S1/4E9L-4M31%$K1T=*2D%V;7AY04-2
M1519=EEQ=5-93WA6*V8Y,35#,5,R=$=U6EE,<W!(128C>$$[;'AC4E)X45-4
M=W=Y4BMQ:W,X161W,'-+1U T=55I<4M9<'15:3AI95EB92MT15-Y,5<S=C59
M<')Y>E0V<#9C+T,P-4Y*27%M64]/0B8C>$$[:DY/.65N8D9B4W)726%A;$].
M6G5D44=P:'%8479,9CDO=T%Q1"LX.5-B;E=N:FEL4VMU8E=3,&AS<$Y2=DAS
M-V1N93-T;6E":6IE5R8C>$$[;G%-:4=F:7!F9W9)9V(P1TMQ2'!A4B]Y,#-(
M+T%%:G O=T)6<U96-3=Q,G5)8F5#-#%'.&UG=$9-9')&2D5'4TI'67-6:E5Z
M:TM#>"8C>$$[2F]/*TMS-"]*0DQ&9D]Z;3)M;&ML+U)U;S!74TI9,7 Y56MR
M.%%K:U!4,GA#0RLP3DUA-2]2=' K-U0K-6HO8E X;R]Y8U5);FQD9B8C>$$[
M-S=4+T%)32\X,%EQ-VQD9C<W5"]!24TO.#!9<3=L9&8W-U0O04E-+S@P67$W
M;&1F-S=4+T%)32\X,%EQ-VQD9C<W5"]!24TO.#!9<28C>$$[:S)V3F,O<%AY
M-59%+W=#3VI*5#1Z+S%B<G8X07EC5E1N;&1F-S=4+T%)32\X,%EQ-VQD9C<W
M5"]!24TO.#!9<3=L9&8W-U0O04E-+R8C>$$[.#!9<3=L9&8W-U0O04E-+S@P
M67$W;&1F-S=4+T%)32\X,%EQ-VQD9C<W5"]!24TO.#!9<3=L9&8W-U0O04E-
M+S@P67$W;&1F-S=4+R8C>$$[04E-+S@P67$W;&1F-S=4+T%)32\X,%EQ-VQD
M9C<W5"]!24TO.#!9<3=L9&8W-U0O04E-+S@P67$W;&1F-S=4+T%)32\X,%EQ
M-VQD9B8C>$$[-S=4+T%)32\X,%EQ-VQD9C<W5"]!24TO.#!9<3=L9&8W-U0O
M04E-+S@P67$W;&1F-S=4+T%)32\X,%EQ-VQD9C<W5"]!24TO.#!9<28C>$$[
M-VQD9C<W5"]!24TO.#!9<2M2<E1Y>BME,%5&:F9A2&17*W%.<75N45%34S(P
M9'0V>',W;4M&;TDW=#=U1T9P45DR5E9::31!5FA50B8C>$$[5WA4<W%4,E@O
M3U)O=3=+-W1T4T9Z2EDR>C-#=&)45V-D=F%R3D%:2D]F35)7-TUK131B,44U
M2V=D44="86U+-TUE.'=F;#4K95AM1R8C>$$[2DY3,6DP;78W94LS1C-"5S9T
M5VEH='!%<4=I:&IL-%))>5$Y1556-"LR2S)%<&PO2E0X>DE:-VE'9E)J13EP
M>4YZ>6YT-DES8V%3>28C>$$[4'1)95-):W%&;5=O1E%/=3)+,FQN;6)Y1G%N
M;#8P3C%D6&QJ8WAI-F$P<%HS0WIS5T-E;TI+068S8D0W3%ER8D=S57924'E)
M+W=#528C>$$[-V8X03=:;7!F.5%C;4E16#(U<&XO2$YT4"M-368O15)I:$4T
M<3=&54QA=S-O;6UL=7!687)&64EO-FA&:D(R2G)U6%!F<T\S97-)9R8C>$$[
M,UI94D)U>6ES;7ID:7%3-B]W1#AD6'DS+W="=$=4+W5N6&5+<#%I<G-644]Q
M,BMR5&96=C!D8W)B96Y-<C-02E$S<5)$<D=+:'5.9B8C>$$[-78X04U66EEZ
M3F-*<'E.4%!(1RM-8U9J8GE096IS=&-D,DMU>%8R2W5X5D$V>D)Q<SEI,%=L
M,TLR;#)756ED,41G2T16:'A)22M)8B8C>$$[93-8,GEV2TI%96LP6$DP,#AC
M6C-K2$9(=5)Q.&=O-6)T4590=FQG84,S:6@R2W5X5C)+;V)5;V(R87AM:7-:
M:&)88G)31V1L-6A'+R8C>$$[;4LO=%4X3R]I36A-16IB671U0U5)>D)M3TM0
M560V*WI3-5,P:%,V8U,S2V]O;6M5541/0CA454%(52LR1T%.0RMB2$E9;5)-
M4E5B,B8C>$$[5G-K=V1I<C1T<R\P;#EC+S!,+TA8,3,V=F$O,U!0,69Q=DPO
M0450-U!X96QZ+W5U,69S-%5T3"MK3TUV2"](4$@P;#EA;DMN<&96>B8C>$$[
M=S5F-4@Q871+-V5N+VLT<6IX+VEZ.4A,5"]L668V3CE&94905SE$,$]0=U4O
M631C96YA;4MO5%5V,'AW=F8P;B]J>FA2=C!J.5HU,"8C>$$[<#9)-65T>B]!
M3TM+5C5F<V4R2W--+S5";B\R=78K;E1!=3=V*U%:+SER<B]!2V1-5C-:<BM5
M9BM$+SA!1F,S-D4O4U V42]2=6\K;B8C>$$[.6,Y1#!Q9E9*3U9F5"M+=$]M
M1E,K:F)(+VQB2#%+,SE,-FPV9G!P=W)3=DAI2U9X67$O+T%#1GHO;'@O1$98
M9CAH8R\U8V9W>%8S+R8C>$$[04-&>B]L>"]$1EAF.&AC+S5C9G=X5C,O04-&
M>B]L>"]$1E9!9C0K+WA";T@V82MQ+U9V<FMV;RML4W9Q+U5B;6Y+;3E/2$PV
M85EP6B8C>$$[=B]U5"]W0TMF*TAW2S<O8VXO>%0O=T%0:7)V.7EF.$%X5"]W
M*TMU+S-*+SA5+SA!1#1Q-R]C;B]!354O.%!I<G8Y>68O1E O04$K2R8C>$$[
M=2\S2B]W1$90+T0T<3<O8VXO>%0O=T%0:7)V.7EF.$%X5"]W*TMU+S-*+SA5
M+SA!1#1Q-R]C;B]!354O.%!I<G8Y>68O1E O04$K2R8C>$$[=2\S2B]W1$90
M+T0T<3<O8VXO>%0O=T%0:7)V.7EF.$%X5"]W*TMU+S-*+SA5+SA!1#1Q-R]C
M;B]!354O.%!I<G8Y>68O1E O04$K2R8C>$$[=B\O6CPO>&UP1TEM9SII;6%G
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&
M(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO
M<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @
M(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/F<W,'$T,CPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD
M8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z
M(" @(" @(" @(" @(" @4U1?,#DV+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @(')R,S<W,#$S)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q
M-RU!<'(M,C R,2 Q-SHP.3HR,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" Q-RU!<'(M,C R,2 P-SHS.3HR,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @
M(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C,F
M(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03OB
M@*(@,3<R($--64L@8FQA8VL@8VAA<F%C=&5R<R!C:&%N9V5D('1O(&=R87ES
M8V%L92XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97-.97=2;VUA
M;E!3+4)O;&1-5"8C>$$[(" @(" @(" @(%1I;65S3F5W4F]M86Y04RU";VQD
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @
M(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @
M(" @(" @4U1?,#DV+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R
M,S<W,#$S)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-RU!<'(M,C R
M,2 Q-SHQ,#HR."8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-RU!<'(M
M,C R,2 P-SHT,#HR."8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV
M)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C,F(WA!.T=R87!H
M:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E
M9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A
M;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97-.97=2;VUA;E!3+4)O;&0F(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @
M0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @
M("!G-S!Q-#(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(V,#8R
M,3,F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$Y+4%P<BTR,#(Q(#(Q
M.C4P.C$Q)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(P+4%P<BTR,#(Q
M(# P.C4P.C$Q)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!
M.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T
M>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG
M:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H
M96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4
M:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N
M=#HF(WA!.R @(" @(" @("!4:6UE<TYE=U)O;6%N4%,M0F]L9"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/G)R,3DU-C<V/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @
M(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!4
M4&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB
M;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @
M(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM
M.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I;65S3F5W4F]M86Y04RU";VQD
M/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86UI;'D^5&EM97,@3F5W(%)O;6%N(%!3/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^351"7U]?7U\N4$9".R!-5$)?7U]?7RY01DT\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @
M(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C
M:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#HV-C@U-3=%03DS03%%0C$Q049&-4,R,#DX-$9&1#-#0SPO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#HV-C@U-3=%03DS03%%0C$Q049&-4,R,#DX-$9&1#-#0SPO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7 N9&ED.D8R-SA&03%%-40Y1D5",3%"-3!&.4$Q,#(Q1$(U,4,R
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I2
M96YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#HV-3@U-3=%03DS03%%0C$Q049&-4,R,#DX-$9&1#-#0SPO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#HV-3@U-3=%03DS03%%0C$Q049&-4,R,#DX-$9&1#-#0SPO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.D8R-SA&03%%-40Y1D5",3%"-3!&.4$Q,#(Q1$(U,4,R/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D8R
M-SA&03%%-40Y1D5",3%"-3!&.4$Q,#(Q1$(U,4,R/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$W
M5#$V.C4S.C4S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV-C@U-3=%03DS03%%0C$Q
M049&-4,R,#DX-$9&1#-#0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TQ.50R,3HU,#HR,RTP-SHP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@!-P)= P$1  (1 0,1 ?_$ !\  0 " @(#
M 0$            ("08'!0L#! H" ?_$ $X0   & @$! @@*" 4$ 0(& P(#
M! 4&!P !" D65Q(3%!64EM;7$1<85'B5E[?4U1HX.E9YIKC2(2(Y6-@*&2,D
M,4%2)C(T-U%A<8&A_\0 '0$!  (# 0$! 0            $" P0%!@<("?_$
M $(1  (! @,& P0(!00#  ,  P ! @,1!"%1!1(QD:'1!A-!4F%QH@<B,F)R
M@;+P%$.2L=)"4\'A%2/Q)#/B%R7"_]H # ,!  (1 Q$ /P#[^, 8 P!@# &
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MJAI^1-%'A1*6!$L$3;D -"D62I0>DBZ14($@%HA3)%252F8"#=@->%"<\EN
MI,),"$39Z/D;UP0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@%(NOVCL7\%4/]<(\%_Y:_&_TQ)V\V^:T!X1UJU3J7LC
MK+WF4/8F"(0QE5I&]<]+4Z42YQ5*'%:$TEN:FI)HL2U8%,M.T>K0IRDAFU&Q
ME>K\)>$L?XNQU7"8.I3P]+#4?/Q6*JQE.%&$I;E.*A%ISJ5974([T5:,Y.24
M<]#%XVA@HP=:23J-QA&Z3DXJ\K7:R5U?XK4^>Z&](_B;U5+(D?-JL;>F]30B
M?60\J[NHD,=8'J0L-EB,2/<R0,,U)>_(6MOE.W9/(T9RJ..@D@'LPPE.GUX+
M4W_5MH>-_$7T?8:CX7VCL[#8_%87!4O_ !>U76K4J-? .,Z6&G5PLJ3E4GAW
M3="25:G=T;.4K^;/K;-VY1JX6]&%.M*FW34M^ZIR5GNSBEFXIK@XW3S9]5\2
MB<1K"!QN#QAO11R"U_%&J,L+;HS>D#)%XPU$-K<D$<I&,6TR!K1%%C/4FC&(
M!0C3S!"V,>_@F*Q5;%5\1C<55=2OB*M7$XBM-I.=6K.52K4D\DKRE*3M9+TL
MC"E5KUDHJ52M6J)1C!-SG4J2M&,(Q5W*4FE&,5Q:27 QNN;MJ*V&6,OU<6%%
M92U3% Z.D3&W.9!:F0-+&Z*F5U=&=L5^3.2UK0N:%2D,<$Z,:+8BO#+.&2,L
MP>C2Q>%Q"INCB*-7SH.K24:D7*I33:=2$;[TH736\DX^\Z6T-@[;V54QE/:6
MRL?A)X#$0PN.=?#58QPF*J1C4CA\34W73I5Y0G&2I3FJC37U;D!.M):]C4WT
MX>0<MJY4Y-<E7(HI#E+\TB-+7QZ-S:8,D8DSFG4D? :B-,9G)6UEKRAEFH37
M(M40:4>468'8.1)V3_\ O[_?$T#T1>)7%Q@X&4W:;+!*]GUAVPS.L@L>?O;$
MR2=^$_[?W9O60_2YR3KC6=!$P)2V$YF2;2%'*T:AQ6D&K5AIPA$4K+_E9Y9=
M_APX%KDUXW4A.Z8G''YVK>)M]2V$UO;9(H?&V-LCC48-_$(]<[(DC0D2ID+Z
M%QV6\)G=.2%:0\$)W()NU103,$V7]_?Q^-SXZS:-YJ1"S'7H%QV8 +JJ<6Z.
MX"+9-<-B6AXSK6\,A7-Q;;H10436)P:5;\^1Q.,L;E8)"YJ)$)D<E*U<,:O]
ME7RSX\_@L]'\'Z?8567&6D*JH^"\=X]7L97U37S0@:V2,25E;)$A.4(A&GG/
MCDG=4BE,N?W-Q4KG=R=#2/*%#FO6*?" (X6L&2R/FLJRK:Q4_P#4AWG E%<P
M11!D=5"4I(8=$(^;%$BGXD:R6>/31T;?MG(.\K4'JO&EHPF>4GG'>%XPP8A"
M+*ZRRO\ D_J^JO\ &UEZ$N_^H:B<5A732"Q0V,Q^),95^5PH*9HRS-K"U%*%
M*:5&*#RVYJ3)48#CQ_YSS DZ&:/_ ##$+?\ C@EY)Z9W5O3UMP,$X(V?R"<8
M=Q&B#GT<HH17JF*4FQJ>2BB0U.I4;BWF6.I/CD-:MP[SZ8><W:U+Q(A./G79
MAGBMJQ*O_-L57I]5>F?]O1^EO7XVSMJ?_J(W-_9.1?2_>8HP=JY0TV/.G.-Q
M?RPINW)'Y!-J*5-##IP/_P#"AV\.!2=O\K.^$I-Y1XXS6P WK"R:>A$[75]'
MIZ\WT^&9ZW2?-BG-SF[?O(/G2]#<N;U023S/67&R;MHF%GI>)M!RC1[Q"HD\
M'B/=G").I@F<01)!*XBMT&5O W&02AN>D(F.;N^*]/C=/+@EEEZOB^*/JNP7
M*1NE+^MEUHOI]@^[".X+2X0_"_UR+N<%3%YN5*#X7+R(.H2(YJ=%W\J(*W (
M!H$LH,:58(^H6@& P DA#L)(:I",L8!$A'H0!:WL.P*$^CP_40U].%MXS<I5
M$?:^2"Z?W@P\O*4M90 Z]9G<4RMV7KS'>30]48?/IT_3&-JXDOB,G9D3RH=6
MU.S[CKF><S!$D&2?V[QX9.-EE9)<%[O7WWND<?".:W,EXYG(*\?GE:E X=2'
ME=QVF=(B8HNB103A-6M$,$MJN_@GG,7:9HT<YJVJP"K*>G=3'98MG8H4$M2A
MW%F=F$-1M?/["=]9;UFOR5\EG9;Q&SIO<S>;W)Z4<=*\G7+V1JY1RCZ=W*J>
MJGM7 *(2CK"^JVY2/M:5;-HLPL=7M"0U<@@Z%0M>(M*4TA:9,D0KUQK8 E(G
M$@%IQC'>:S2E%*]\TXW=\^JMJGFK;C6\X^=4+Z<L'Y-6F*5PJ;Q2ZZ-XH\H5
M\BCL22((>BJ_D'(JOY=\I6I2P5R[!8FF9;1)XBD7 B[W'*_\WNLCCT,$>4D&
M<(W8N;7I9RC^:NEF_3AQ3O?,USR>Y@\S*\3TU&&7FU'5Y4DX.]2Z\MV)1;;4
MLLC%BN=$MSC,>+3TBEDYI\X#NX;8Q$QB4/,*;6>-64KC;TZQU.E-.&I2!%1=
M\N$H+._^JZDK)KU67K[S$W#D3<5@6;-+5L.[W]"HF/\ T[$>OV)0UR:JU7U7
M)KCET0EKG;C<U027P9]C+XBW(F*/OLQCY290<H5H&B,RDQ;#"T$1"^(LK*R_
MF-7]4LK*]\KY\N.3.);N?G-J*497IM?K4#1)H;PDZ0$IXOT_%8!7K'&.44[O
MF;0^%\HV5%$66)I"1I(PV&N,&'"ZN*BK73:- 6_(&N/CTD4DB7&-W\:EW=NR
M2^KS]_'A<VHZ\\.5;)S@71?7)-V<:Z:>LO .'A-5+8Q3@(S\GFPJ"?).^$+7
M)OK]#/%*R/V(D3M[%)SY=LYN<"!L[F<Y*QB+"&['=X9^7O7N^.];X>[_ +S-
M*+.HS;5TR7EI4C[?C;9-+SGI^=4WP"':(Q&N#C[-I&P9/$XBE9H&1ITE=>N+
M%6KJ*/%1>1SAWD4^BJ%IM231"..+ZC-.$;MK96:=-^O"46WIZV],GE=GT*],
MTTH[IR<!_%&%F^)X9\9$9WBQA'XI6AIB%HEJ4SP=[\!0C6$'I%1 O@-3J232
M#@@-+& ,+@O@BDN+^+_N3>R2!@# & 4N=3&&3]WO6@K*XU<MX1Q;Y>TQ5UON
M=?M-ZHFU9QWO>KIB]0(%DUG.%KF9X4;<P.T,A3NG>&4H^0!;"5:Y B-\Q#?H
MF+1MG=-Q;5[9--7S7P5[IY:VR96!.N?G(]B8( B#99_3_8%O16NCE5%*-CC+
M3PXXAY05K:0H[5K3"E%GP"629?$;!0%$*HO636]#->8JXM#*U!&K$<K5B^ZL
M\M[_ -B5\[M/W)K._P"=R5=1<W^;EH\N()3MDS*N^.DV2U5T\K;;*.L0HR,G
MWS&+6JM>]<RX_7\<,KJ226736+V,^&1-.>AF\;0U"=634[/"$R.+K*7'OW^9
M5I)75VKR5UZ>S\+^]9J]O=#*V^6')CD;T@N95U*N6DL37PV4T9#N0O$&+0",
MQV?\<;,:N5+E&;$TO=V9N*G4*@3[1#XBAQ41D3?M8]QF'+YX3-7!P.L(9ST_
M:_\ A91W9I633S3SLTUEZI>]^_W%GT6M2^[7ZFTYXYPOFQ,$W'VL^,'&/D6U
M^8HC0,G=;*>%%ENH9HS*I076'C#X99<"0-HG\42 WN"<M^CLBA;JRM"L]OD
MK9;E[)MRDLV](M9)K-9^[5/TJ)<>HI;W)6E>?%:R^^VVW*FGG1LY#6]&5R^)
MP^OG!XN%@NBW*85*66!M/G%ZK0]YB08REW4#M.)V])D)$3ESMN,RJ8/L5;19
M1LXNUO\ V)<;Y9/CZVSSMKF[960]2YP;A_\ 3FR(O2U&,;OQ!XMMS07I02,;
MHY"5TZ:4A;@:'L2U;L*50:%,FT:?X"8\S0/!(,$$5A??CKO+^^9K;J&1J4I>
MF:TV':\FK::2%_Y!<$F^JYO!F$451ZH\FQ..#^DB0TBR6S-8K,CTB8IV^.JQ
M3)%Y!ZGS_*6M#&&AX4,2 (K-V3^S.ZXY[LO=\/S,\AW,KFC+.9"2K%4@>$*J
M0]2'E1QHD%,ML>B!8H)PK@M!,4HJ3D.V:71E<^HE1CRO9[%;K%?UCI%I>Z3<
M,%,1.#:*-L35&M]<OA9:>_4G=CNM_=33UDWFM/[/U>AJVB^0_5?/M;CC +9E
M<X>8Y(;BY7]/>Y)<B@%1,XU5WUPY3>S:XYDQ)(DKX)!<-U2#&O;R(ZH.2Q%W
MD4'=QJ(NHVN1*5LAJ-G;C:,EF[*]DX\;Y-_'CP]?IX '8 !#L0A["$(=C'\'
MACWK6M>$+P=!#X0O@^$7@A#KX=[^#6M?X8,9^L 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!2+K]H[%_!5#_ %PCP7_EK\;_
M $Q))=3S@JHYSTDR1B-N;:T6)7TC,E$,.>AC)9W+2U")N>V%Q5%$*3D('%-I
M*I3+0$&A*7-R8L\&DYQII7T?Z,_&U'P5MNMB,;1JU]F[0PZPV,5!*5:DZ<_,
MH8BG"4HJIN2<H3IN46Z=23B]^*4O(>,-@8G;VSJ=/!5HT<=A*OGX?S).-*KO
M1W*E&I)*3AO1M*$]UI3A%-*,I-16Z7K#3W !%(>(5K6U$TW)"P["+E[K$VW;
MPHCC2>[L#(V1.* EIK4EC9LH<F]&4X[;M+RU)YKL@;4X#U7B GX_I2\=;,\8
M>(L+5P#J0PN#P-/!X=XF"I5J\W5JUZDW!.2@FZJC3A*6^U!RLE)17%\*XO!^
M'T]A[8VAAJ>VL3BHSE14JCHPG6C3AAL,L3*"HRQ%1;K4%).4JD*:3J-*5YXP
M ,"( PA& 81 & 8="", M;T((@[UO0@BUO>A!WK>MZWO6]?!GSQI---73R:?
M!K1GT=-Q:<6XM----IIK---6::>::=T\T57<A6F,1"^..5X\<*F8+6GS3*4M
M!OZ^(NBMPBU90?9RHAR;3XW$'9$RQ]]3MTDD1*!S>2#&Z/I +=K6E2+:82?Y
M'XEVM@]F^(O#.U?#VSI>(,7C-HKPOC*FRZ]3&X#9%*G)RG#%8? RJ4<'BXK$
M5TJV)5.E1ITZD:T4W"4?TKX#AC]M>"/'WA#Q[XCJ>%]D1V96\>;.I[8PM#![
M8\0[6J4Z?EUJ&TMJX6IC=H8"I6V?@)U\)@Y/$8ZK.DJ&)I_^Q3G_ ':RU3**
MJFD3O!*QK:LF#..)3%!(][TTKV^2G%,Q2$\P'P&DJ%2U:E(;U"892M.XC2'H
MSB599)H?KA^:':V?#\_^#Y\(YTT99Q9=)8JX%]6!PX_58[R2;Z=JTL)MC5@L
MC-(8(TG.\Z)+$N>T+,H<XA'4OECVL.B29[0L:)*J>'16064IV*VMPEQNE?C=
M7MIZ>OPMZ6N XAKE]35$1#;MYA,7**Q^U!SBXV8:0U,1BD$U=EZ&+1A S-KL
M[I]%$JF![2-)"(PH2@M"N-+0$$)3#-B4[9.5W?E_UZWR7J1V<./M9.?4B9.H
MF7R0@08_'*$55B=7 4A)JT].)]D$+%*@28+]HO3=J4.!C$ D#": YU2&(BEH
MCA?  3=:Y<%EZKCGZ_\ 3>I94]6S6<<&E"^SJ,-(5T?(E:-0N=DB=&JC:IS;
M69,^$+AF:1F-JAU>6E 2K"?LHU2YH"@"V)61X8-I<7QX?O\ ,JOB'":)QCJ7
MVWU-=\B(BNB+JTAK1WK\I@&6./R(Z#P2 DH5$RU(3DJMS.7MR$9#40Q!5'JG
MA(U%:$LUKQHCUO?)-Y:63]?@\^.>1L'J8T16W/R@=\9T7(>"59(A6JQ.I;DZ
M$IY&>>[PTUQ:G".I&,M]85*Q?IQ>0(#AI59WDC@E5MYA(E:944F$MKA>WH_[
MOXY<?1+-\"$%3<9.8]3(JY84'6DA9M55HVUTG)B9-1P4EJW7""4HZ[C[#I].
MD*H:5$]N;4; VMP/5G*3W<D]*48H7)S@A%<N&]P]$K::6XY\./I>Q(_J'\3Z
MYYFVUQ7MX/)F"U@BX@65)7J1-3NT;>S)(O;IM4"UW8RE87]EVT*FE>VL30L-
M\D=-%K)4U:V4$6P%J'[_ &PTF[W5TK?!WMGG^23X^]&.<W>"52\IN0%3<G>-
MO*B%\:>5-=RU+&E\^CA;5)!SM>F;7E4PQY_:D$D8C5TH0-D4D:$LM2>LT_0M
M*]L;PWN+4W( H@:4LT[._'EP]=,T_P"Y<E72I\70*&K9-((W+']9&F94ZRF'
MH5#9%I*L4("#3'Z/MJIQ>#T#2[^'IP0HS'9RVF(4 )"N5! $\8LN&I3QTI?U
MLNM%]/L'W81W!>7"'X7^N1=@L5IV](J7*S/$I4:<Y4I-\ 9GBB""Q&FF> 4$
M9@_ +"(7@@ (>_@^ (=[^#6"I&6,<W.(,U0,+K#^2M+2AJE2E_11=T8+!CCL
MVR1=%6UY>9*@8'!"N/2/*]A:HX_N#LB;3E*I D9'4Y226! JV4)::XIKXIHW
MA )[ +7B,=LNLY9&)_!Y8V!<8M-X@[-TACL@:##AEA6,SZV'*43@@&>08'1R
M10:0(TH6M"V(&_@$<.)F/@A\+8_!#X>PZ#L?P:\+80[WL(=B^#X=AUL0MZU\
M/P:V+>]:^'>\ #& L S#!A+++"(8QC%H(  #K8A#&(6]!"$(=;V(6]ZUK6M[
MWO6M8!'V+<K>,TY6M;7$;RJ^2&R.0*8E&!M,L:%C;-),E4*4KG'X0ZEJ-M,X
M=VQ2E6E/3?%%CRI:!I5FG4M)Y,?LL2TUQ37KFO34D'_E '_Z!"'7_P#00A"'
M7_\ K6M:UK_^M:UK!!XDRE.L3D*TAY*I(J)*4I528T!Z=2G/ $TD\@XH0BSB
M3BQ!,*-+$(!@!!& 6P[UO8'DV$.Q!%L(=B!\/@"WK6Q!\+7P"\'>]?"'X=?X
M;^#X/AU_AO\ PP#]8!ZP3D?E0D@#4OEI1&E0TH3"O*BTRHXP.E B=;\< A2H
M3FAT=L.BSCB#-:$(98O! ]G & , 8 P#\#++,UL)A8# [V'>PC"$6M[ +0P;
MWH6MZWL ]:&'_P"T6M"U\&_\< AS:-/\>ZVY"I^H/:]EF5S(8'1CAQ]6/4QE
M\3C54)*YDLZ;IF-$Z@?6DDX+\X3A$QG-BXJ1IUQZQ(@9T)!A2Q2B7";NVZN#
M=[>])]S>\$NBI+.='!F@D^B\EDC(UH7=ZC:)P*#+(\SO1IQ32X/\95:3R&/H
M7P:)0)G4.[<B)>2T9Y[<)42G,, (-DG*$B/01J#DR72E22G (XPHC2A6HV A
M.2$0Q!\:I/%H!))>MB-,WH!8 BWK6L ]G /SHL =ZV$  [UK>M;T'6MZT+?A
M"UK>M?X:$+_-O7_QO?\ CO\ QP#]8!X$ZI,K+$:D4$*B@'JDHS4YQ9Y85*%2
M<B6IQ#*$((3TBQ.>D5$[WHQ.I(.(-" TL8 @>7P0^%L?@A\/8=!V/X->%L(=
M[V$.Q?!\.PZV(6]:^'X-;%O>M?#O> ?WP0__ &Z_PWL6O\-?X"WK>MB__P [
MUO>M[_\ G>M[U_\ 7 /[@# & 8)95GUU3<,>+%M>;1JNH#'2RCI!,YB[HV",
M,2<\X"8E2\O;B:0W-:4Q0:4G"J7*"$^SSB2?&>-.+"(#!IER?XXUY4\;OB>7
MM4L/I69$QQ1$K8DD_C+/7LF(EZ';G%36&7+G(EC=@2)N")>RB0K3].*,(U"7
MQI0!#T)LWDDV]+&ZT2Q,X)$J]&9XY(M3DJDQV@C!HU.H+":29H!@0&!T,L01
M:", 1:^'X!!UOX=8(/9P#PJ5*=&G/5JSR4J1*2:I4J5)H"$Z9.0 1IQYYQH@
MEDDDEA$8::8(("P!$,8M!UO>@-#0KE5QML=SCC/!+OK25+YJO=6R"%LTK:E9
M-@K&) Y.CZ77:T!_D4_*9&YG=%KPJARA[2M:9 J.7G)P$CWH39YY/+C[L[9Z
M9Y?$WX::4048<<862226,TTTT82RBBBP[&8888/>@ + #6Q#&+>@A#K8A;UK
M6]X(!1I1Y19Q)A9Q)Q8#2C2AA,*-*,#H99A9@-[ ,L8-Z$ 8=["(.]"#O>MZ
MW@'[P!@'@"J3#4G(@*"!+$Y"=4>D"<6)20F5F*BDB@XC0MFED*C4*TI.<, 2
MSS$BH!0A"3FZ !Y\ 8 P!@# & , 8 P!@# & , 8 P!@# & , I%U^T=B_@J
MA_KA'@O_ "U^-_IB7=8*'SF<WNEAR!MKF<*YZB=D:B!S^01&4/!ZR2E-:BO9
M0Q(VMN<7(Q H&4I7(A:9DKTV#:?+E1:X]0ETD3;*)..\'XCV7M[$X^C+94:4
ML/7E356M*K&F\*XO_P!DYQD]^<;+>AY2E*3;@X\&?F[Q_P#1?XLVWXRI[3V-
MC'/9&-Q6"QE6%3&JC'9>,P\:5.K6="3BZL/_ $PQ-!TO-FJTYI4H249RM"M*
M:\@H[R$CC.R$.BJO7)7'$:5*G;BCVEX;51"<F0EGJ@(AGD.Q:D2X_9^U8#$!
M!"4X&@)AF>,_(_TT_2W]-O@GZ>O!_AG8.PML8_PCX@VOX<P6SX839CQ>R=M;
M.QO\-1V_AJF*IX*H\+M/"598VO4K3QE.>S\+0H8QP6#G4W_Z"^&=E?1WB_HY
MQN(Q\L,O$U"CM"I6KU<14IXS"XNE4J2V=.G1\Y4JF#G25"/EJC*->K.M3E>H
MH;N0\7.(J;C3*K.>T$K->VZ=&-A2%NVG.3B2I&M6YJDI[F(P\TI0Y%@<S$NC
MDX  $#QYHM_"HT43]Q^A3Z&=L?11M3QE6QGBF&W-E;<Q.'>QL'#"U</6PN&H
M5L55C5VE.I5J0K8_<Q$,.YX>U*4:<ZOU?,C1HZOTJ?2[_P#Y,V5X7P538M/9
MV*V%#%3Q.)C4A.-:OBZ.%I5886,*<)4L-*6%55PJ.4E+<BK[DIU)>O#*U2!O
M,:GI G<FXT]$I,1J@>,(&>W+D[DA-$#X=?"-*O2)E1._A_RG$EB_^F?H,^*F
MJUW':C',_P I<*KA:Q3ISECT4I4,R<U0F=IXE2(IJX(SA:V:A5RQ&A2I)"<C
M$0)W3%[(7;.*--",19?MOUX_#\CSM] TVT>;O--?L34)F*:B60;:!4@,8R61
MT=WEM+8S4BDDQF 0Y/[V>8%L$DTJ"Z+4ZOQZ4\9.PLO[=.!XP\?*8 G(3%U\
MQE!2MKDSI#B=+"5R)J=Y8BG2]N1.)2H"]$C-E[<AD!2=*I)+2.*8HU&$C0?!
MVOZ_O]_W%DNOJ_7^W_'H9(_556\G:D[%((5'79E2,::,I6E8VD&-I$>1N3([
MI64I%H.DX&U.Y1MA6$I-%Z* :U(_!#H)6@["RT7(_ *HKPIE?(Z3%T1+-(I$
M1+G9"0<M( ;)TJML<$K\D,*5 /:W1(XL[8Y)%C4:B.3.:,IQ($6M\(\0FUCB
MQT941KRGD)\ CZE[1R,4M0.:M,-6J;9&8\AD1CJUF*33?-9YK_HY[. WZ3$'
M.JYU<#2AJG=T-6"&D^/[_=CC-\<J+\WFM&JNB(6<^-M\//9P-N@-!\9:9,X3
M)L9SVL PH#DJ"4NSH^)/&)Q&D+G%:868'2HX(PLNEM,CG7NFJND1"M.\PIF6
M@7*718I'LLXA0)6].3 \.RHM6F.)5)U"]RBT>5J3DYQ1AAC2DUL7@!$ 063X
MF.AXUT&!X+?P5)!@O)+RVR-.X!8D@5":0LZY2X-3ZEWH.@I7AN4+5@4;FG"6
MM3HU:IN+/"WJ#4HU_P!_O]\-!9:=N7]M/0VK'(\SQ)B:HS'TFV]C8T1#:TH/
M*%2H"%O2@T6E1DFK3U*CR9*3H)"4D1P@)TY92<G0"2BRPB4K9(I@Z4OZV76B
M^GV#[L([@M+A#\+_ %R+L%JU&W(U3@X*TR! A3G*UJU8>4E2(TB<L1RA2J4G
MB 2G3D% &:<<:,!9181#&((0[WH5/F=Z)U76:V=.IK=+!?@)*]AL<YB[U3$F
MA1L:DT#L=RN9]E48L!Q5.9VG=:<[0HUV&S>6-+-YF9G80VXQT229:84+U+;S
MUM'X?97*WY_D0JIFVN=-/<(J"A5<[M* )8/TL6>5<9X_'&%U2KYYSE3\M$D9
M?:[?V$2'1TXE;7 38^@)IR2HG)L-B\IE,G,8E!J10ZQT7:BV[M9U)7];1U6B
MXYKAD3BYH.W5+K>S>4SA4;[9;O&8O3_&[GG"FUH>WARC;6*LW5]BW*;A7'O(
M=G+G;5J  LL2-DI2US@UM;0%D9U0#E[ 6V"JW,D[7=XM\,G]F7Y>O"_Y,L7Y
MZ5!R4M#I6<D:OJ!1)C>2%CTQ(5Z9C%(3UK^)RECR3+)W4L?>E2XT9A>XHMDE
M51 H;CX!B';2E,6[V,Q4(5BTI1;X77_U_P!V9'PTL?CA9'%?BM4#,@\@DD2J
MNJX^?36HZ_,EF4/,:^@R!"X$3:-E($<FIMUAKDV+VDF320N-I5SF8E1,3JZ'
MR)J)=0DFF_B\]4]'Z\?0JSF:#G-(.GOU/*ALJ1\@9/;G$)DY.TM!;+89#)2I
M3R>:IR&)7;5\[*:8B<B-.>XA2+]'H@J;F-L$A7IIB^M&P'+D"X.Q9;JG!Y6>
MZWHO1I^BSSS]+,Q*\;OYLUS%EC+QZ>+;T5$N%'"F1\%6(()6ZEW;>TJY$1V/
M7LQ21._DB666J;H@<FC3I#9/Y>U0.HUI<_9$4>1*"9B2)23>?M3WO<DDUZY>
MMN%WEG8\5YWCS(0\L;@11B\>04<B$>ZM'!^E(TPL!^EL.9>-%PUJ<'DBM1)W
M:+.B-XBC+)?.IBF3/FW9@K5Y9"PM@8\<G5D'B$DTKI?8D],TW:]O@OB8RP\J
MN;!=9<?X9,+3M>-5-(N874;H>=<B7QNG:R3PE&PH',C@VOG,MB#"MFBR**W*
M0JWUB>#]%L\Z616%M<K>E,-4NI"\+1XI*^[!V;RS7UK7?>V?"QF4]7\EZWM;
MJ[6"^V)>QUWM73,XIR'C_,F-LM"'1N66?'J:MI3,':MZ^4 4,K041=S@F4(J
M\4)U V"7S%7&5"!2]2)R3.())[GXVG\/J\6N*M?/XDE;(1\OZ/XJ\/\ F;!+
MRY,\C921:'&6Q>3-&N[['-DSVL[BAU=U98=>5U%F&.1$+,;#YXO:;!CK0^N2
MU4E=5$U!+G]>WK582!"W6VFDE9I/1J[3;S^#ME;T=B\:L(T]P^O(=&Y,^KY-
M)6I@0$R1_<G5P>E+K(3"=*'M6!R=1C<#T0W0Y5IL+5"\-*VA2(PA 60  11\
M7Z&=X P!@# *1NK5#;&'?O2TO(Z.268\6.//*UTF?)9GCC(Z2HN)KG=A:&BF
M[IDL894K@XGQ2I7_ %)G%YD)3>K+BA;T4YJ=$$",/+%XVM--I-QR].#O:[UZ
MDCN8GG?D=QEY!R/@I9ZIOY*1.LD+S6%PU2<8K:Y4[Q5<YS1GJ J=-Q1T6F2*
M5B0/<8>(ZC='-1"CYLC?5);$ZKVI6>(C:ZOPOGGKQ?[T]Q7M<SS:UTR7HZ<C
MI43R$@,"O3D:[6W8=?LDJLE4TU&U37BZYI*CC;R7&%*H]M6N;DD\XH27$L*Q
M+*I]+HT@ G*7C;L$KA-9.T5G\))^O'*_Q2,*JKD+S^=K0AR*;NMBIG]Z3=6D
M/,R('!=$D<HJ)U2K:@\)GN()0%%(X"-: ;6BK:01\Y&LN&,/<CF#@JFBAG\_
MM0FT<^#5X6SSNTMY+A?WY9>ZY X_D7U"0THX/0>0_*LR8./1IB7))3_B,#@'
MFRP\F5,&2Q9 D*AY9K3(AP%040_52SEH5TK1HDKS+VI].&L7+!:T;\%_^W=L
M^&YQOV;_ "]"U.!WSRSMOGV^5I+;2DE01]I%Q!L2GV0J$SY?#[[X]S:A5XN1
M+5&@1QI+A1DC#:\J<')WL21NQ;[5*N#1%*R$!CY4D"YBC22NK-.ZXYIINW2S
MRM>]B#W%]ZY-13B5TM:\:[<Y-U?95K<]^3$!Y=K7%5+%LP98U(+)Y!.SN>^I
MK,9I S,+@O<5<%?@R9>U*BB)A*VY\7"5+Y.H(=1;)N=TFE!-?EN\&OS3S]WI
ME:&&&\JZ;YZUWQV!:W("Y.-=^<;X,\-EFS"9B5R2H+&XG32"%W(ME#O&T<:(
MT7R5@S]&V]S7I428TRPI(X[CC4SQLIV)2"N3C?)-/FI++C>]FG^7K?A=+@H,
M 8 P"-/+=/#7"E53)8 &A1#)#8]&L4F;WW96VESCSA=M?%R% XEF[T UN,80
MN9KKH?\ XB6DE<J4B+2)U!I8F/'\G_9GR4<K.+_).H^D_P I>)UCQN0RJ'\0
M^6D8JSA0I3)G*1RJVZ?FET5'=:*:$LJ=&K5NJFM:W>S8JWOK#Y60RMKI9T2/
M-(2QM66 98R3J1EJKR]S49)\^-O>BR3F-S%Y!1;J#0.)4[/+D65['^7G3IB\
MU+20F3IJH;:(O9DFZ>V4,;51UJD,#MZ'2<EPCS]*+5FBJ.2BLIJD98;7OGM&
M%\7,0JDMU[UD]V36>=TU:ZUR:2^/NOK[5V]0)4T\Q*Z16ZWJ)M')A6]DTWR#
M=Y=/V:B+#@DJY S1_!QXMQL3:02?B%:ID-CBRHY,Z0ITC<?0P<,6EP%L52K1
M7)+G[_>73_Z$HNWPM))YII<5JO6R]ZX$H^7#3RGYD]!:;IZ?A=K1?D3;M$Q9
MZ/K.7/>GNUG%B*G["]V+ 02!*D:39:KEM:-TD98ZH"UH7"?,3JVHC6I*OD T
MI3]Z$1M&HK\$^/PX/G9O3W$]J#LGC->5,T- X :)&XL=>LR6-0R/L[NS6+QO
M<FZJ76&GDR9M*;BGBBI7&8\ZOL(;39:ECJH;BN$RM(%IBT))HJ[W?7WWS_[*
M7[03<Z)OTG^H7!+7=;Y?;[XOQ^Y>,Z>6QA[E*=YY+:1V8BGV[>11B.J1JUK.
MZT(_PAF(V@1I"5S>[60Q+D1S.4E;VU\?WU9D6[OQ>5G9V]%Z-9O6_%>BMDSG
MN0=Z<V8-)+%9Z >K65[B=2=.5=T_HP<*5.C9?KQ8=^)V3E<*7 ?4YJFR1-L)
M,/:I03*3%I-75>0T6,QABI3B1+5@JE'*[XN6]FLK)6M_QJ\EH85*[LY@CY//
M2%%?/(AHB7_>O9N.!,?;UF]Q9IX9S2DW%5,G),4XQI?H<62S\LIK:K%<U:])
M!7M*6FB;I'G@:HY0)25N"OY;?Y[_ !^-C#(%RKYUOU%<*(9/K>M6NX_9B_J'
M53(^2CS&)TZ22*W9%)VZM/#1PM11#XTL?71,AA:OM!#HU($R*,W>N2,R:6GO
M:( S%(-15WE=;CME9II.25O?;AFE?-YF5W,^\FJKF/76L-OF]^MUY-''_A,]
M<<'UD(L]K8WE7NEFA9,U-5Q-PTY,8F]!=+U+F]MAY>G(^.N;_*(YI*8H6/@3
M@CNMP3M:[OS]?R^"=B:]XM'+7CE >&O)^K;JY%<HTSQR#KPGD;3LFE3$2W36
M$<J(G$JA9$D011*,Q=/&X[4MQ.<9F,2:@!,/2;F,H/E<A=&%J0I6\0MU[R=E
MED\\FL_6[S5U;X97+JJ_C;A#H-$(J[R)UE[O'HVS-#O*WQ4J6N\E=D* @AS?
MG ]8H5*-J7=<!0O,*$>,M-M1Y,1X!!10 BAE^ ?']^F#<7O]HE]^MM>?BLG+
M5\EW,ODU/N?U2_P'Z8-Q>_VB7WZVUY^*QEJ^2[CR:GW/ZI?X#],&XO?[1+[]
M;:\_%8RU?)=QY-3[G]4O\!^F#<7O]HE]^MM>?BL9:ODNX\FI]S^J7^ _3!N+
MW^T2^_6VO/Q6,M7R7<>34^Y_5+_ ?I@W%[_:)??K;7GXK&6KY+N/)J?<_JE_
M@/TP;B]_M$OOUMKS\5C+5\EW'DU/N?U2_P !^F#<7O\ :)??K;7GXK&6KY+N
M/)J?<_JE_@/TP;B]_M$OOUMKS\5C+5\EW'DU/N?U2_P'Z8-Q>_VB7WZVUY^*
MQEJ^2[CR:GW/ZI?X#],&XO?[1+[];:\_%8RU?)=QY-3[G]4O\!^F#<7O]HE]
M^MM>?BL9:ODNX\FI]S^J7^ _3!N+W^T2^_6VO/Q6,M7R7<>34^Y_5+_ ?I@W
M%[_:)??K;7GXK&6KY+N/)J?<_JE_@/TP;B]_M$OOUMKS\5C+5\EW'DU/N?U2
M_P #;M ?]5%0'(J]::H"(<5;A9Y7=MI0*IXT[2290HB/-C]84H:XHTKWP]L*
M='(EH2+W4A0XFH&UP6%I"SA)D2H[0"1LM7R7<B5*<4V]RRTD_P# EKY?8WZ1
M+L[LK"?/W_9F"5YM[?OOFCS3\M@0_+?/?Q:^6><?+/A(\U^8/)O)O_;\\>-_
M]+3+5\O^RN?EK)?;?K]U>[X?M9W4>=+=_<>N/M4DWN<QEJ^2[E,]%S?8>=+=
M_<>N/M4DWN<QEJ^2[C/1<WV'G.W?W'KC[4Y-[G,6CQN\O<O7\QGHN;[#SI;O
M[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/7'V
MJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<Y
MC+5\EW&>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M7R7
M<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;
M[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN
M_N/7'VJ2;W.8RU?)=QGHN;[%*_2S7V,7RKZR(FV*PE6I-YX@&[$KI^^MY");
M\6<?UY.W*"*U<S'1+XOP1^6*4K0;X>Q%^0^"'1HF6KY?]EI7M#)?9?K]^7N+
MJ/.EN_N/7'VJ2;W.8RU?)=RN>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;[#SI;
MO[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/7'
MVJ2;W.8RU?)=QGHN;[''NWQHO;4YLKA!:_&WN[>M:UP4MP3)N4B1N"8Q(I"G
M<&ZI$K@A/$2:/1*Q"J3+$IFPGICR3P ,"RU?)=QGHN?_ /)@5/5M*J,KR-UC
M H'%-1N+MB!J1*I3?5C364+R&QO1M"$^02^5U:[R20KDK2W-S4G6O#FL4$-;
M<WMI RT*%(G)9:ODNX;D^*7-]C9OG2W?W'KC[5)-[G,9:ODNXST7-]AYTMW]
MQZX^U23>YS&6KY+N,]%S?8>=+=_<>N/M4DWN<QEJ^2[C/1<WV'G2W?W'KC[5
M)-[G,9:ODNXST7-]C44XJ)^L2PJRLZ40&-J)/4FI#J(E-_(:TV6-FADBZ*.R
MW4GB+16J*,S':)ZA$5>F,R3M3H:PNK04K:1I!*%H5++5\EW%Y:+/WY\]VZ]]
MN/J;=\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;[#
MSI;O[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N
M/7'VJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^QJFX:LD]YQMI
MBL[A+$!K9)A%YRWF0_D7:T =0/T1<0N37XYYA5;,3HK:S3-&)W-F5*CFMR2G
M#+5)1F 3FDLM7R7<)R7HN?\ _)L]*JM1$F3HT=?UBD1I""DJ1*FLZ1D)DR9.
M6$HA.G(*IL!1)!)0 %E%%A"666$( !T'6M:9:ODNXST7-]CS^=+=_<>N/M4D
MWN<QEJ^2[C/1<WV'G2W?W'KC[5)-[G,9:ODNXST7-]AYTMW]QZX^U23>YS&6
MKY+N,]%S?8>=+=_<>N/M4DWN<QEJ^2[C/1<WV-0Q"HGZ#V395L,<!C8YC:S@
MC<Y.<\\AK3D+,C5)8]%8P?V1C;Y6J]@A"=W:H1$]/R.*-[0E>EC"W+W D]61
MHW;+5\EW%Y:+G\>/U<^/%_#@;>\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/
M7'VJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)
MO<YC+5\EW&>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M
M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+5\EW&>BYOL/.EN_N/7'VJ2;W.8RU?)=QG
MHN;[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^QP$L;+&FL6DL-?X)!#6&6Q]YC+V4W
M7/.61P,:'YN4M3D6A>F6IT#PT+!HU9P4SHTKD3F@/V!6@5IE111P&6KY+N,]
M%S__ ). J^$32H('&ZYAD$AP8]%T $"$Z07E8$J?UN_"$8>O?)+(JJ<GQ[=%
M9PQG*E[DN4'C$+18!%D%DDELM7R7<7EHN;_Q,^\Z6[^X]<?:I)O<YC+5\EW&
M>BYOL/.EN_N/7'VJ2;W.8RU?)=QGHN;[#SI;O[CUQ]JDF]SF,M7R7<9Z+F^P
M\Z6[^X]<?:I)O<YC+5\EW&>BYOL:AE%1/TPM6"W(^P&-J)C7C _1N/IT_(:T
MD,//;9 \QJ1'#D,#1UJ1#9,XMC]$6!YCSJ_,B]Q8'-O3KFM2F4D)S"66KY+N
M+RX67//GNWM[N!M[SI;O[CUQ]JDF]SF,M7R7<9Z+F^P\Z6[^X]<?:I)O<YC+
M5\EW&>BYOL=9;T]N#%#\BN%CS=,QKYFD]FL_.RC>.>A22]2:4C*ZLK1;$Z^2
M'A>)%)F6/DSULV(X,2$FTXC7#V4CU#)2NT$@^#;G*2FHJ32<6\DGFM[W-^A[
M-X=+2/)W#EG7G%ROY[83S".H51_$^E)-:LJDE9VDWDVG&7Y4VQ24TU)*JC3.
M[MTC>C4AR6TG.3P_:=ACI$D[+M["\Z-7@JF:WFOL.322:R;];^[AKE<C-&ND
M-R;F-G5+6D7E=+.X+M4\FV>O[ #)YF@KUPEO$0;^.[X6XN3M7K>_,K\PM\?.
M>FI4Z1M-&9"TKFY0UR$\T:LA&+>9%)W35K765[2X/)O(\,KZ2U^1NLY!:S9:
M''^<1UHXE,G-QJ0Q*2V0%^F/'IREZ6"O$ICS?*:IBY2)QA\D6%(Y P3%7%'-
M86!0IB),H)2J1%!YD;VM)?6W<TN+X>M^F7K:Z,=D'2SY%1N!0*QUDFIQ=&IO
M>U,<=52IAF+Y(4\,L>^JZ9[/K\F1/3-$%L8>F8R-O)2>0N5;OT^%&7Y(M9'E
M,E7!3 5!YD;M9Y)O@LTN-KO^]B5E,=*1IC%D\U*8Y"S&L++M&B^%'.6U&.$4
M)9+_ "&7UQ>7&+4:1PTF>H 1IJ2'LLX5O^W%@CY>G1P>VTDU(Z%1A^;U[.$0
MYMJ+5TG**;:5FG>^O"V? B'5'3%Y"W3.+"@\#>( XF5+(*;@=FR$T-F@8H/:
M]X2;<0BM2OZ<BLE,I3S-ED".0(IVL)C1\'AFHE)E#S,2DZ DQ6+.I%)-WS3:
MX<%Z\?7T]7H<@?TM[Y9ZECUN36PN/U;H97+;SK..PVP+(7QR=O%OT!*6Z'R^
MHF]K-BIS.LFSL].&RHP:F?C8@J"D/ ]2IB4J&Q,X"/,5VK2=DF[)/)J]\GPS
M- <NN(=G<*[36TU<#A&C9\TG.J=\9V$F:I#F<YK=5+:4:H(G,,A*Y<T/Q!!3
M[$Y.R(W6*2J/+D;JPOJXH9P2!:,E-75[>^W_  WP]3A^3=;Q6GY57U;,B123
M+&"E*M>+>6*%JA3Y9:=C1\-JO#:%(>/9;,H@;!.8S5SNU)2R202""NZTT!BU
M:K4GA%MIO.S;MPX++TU]]R-^"PP!@# & 3MZ7/\ J5]/WZ:/&/[YX9@I4^Q+
MX'8HZ_:.Q?P50_UPCP:O\M?C?Z8EW6"@P!@# & , 8 P!@# & , 8 P!@%(W
M2E_6RZT7T^P?=A'<%I<(?A?ZY%W."HP!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!U 5*<]7>GN+,F
MXDJZ/JRS*VF%ZPSD'(E$V<K+1/2^90%$6V1YHTI@TYB $\2$@ 8G=6X@ '9=
MM6K-)?40]I/(QNR@I/>NTTK*UK6=[\5GQ?K\"2LGZX/,"826RK$>VRL-VI8W
M*&A>5O;IN87I!V3F?&]@21.LHA'8V&0FL1M?I8NG-9'MMD"=[?7\A28H<9&:
MM$>I4"OE1U?!QXK.]\^''/X9<.)P\5ZQ5VP>SJ8GL8JVJTL>HIPY:22&5JN,
MFZV,'S7FF"2)KGDSVX$RI%)'#:9JDIK! 6L+NG2Q=F:&CRT3^\#?WE_$^6FF
MFV[I*^7"/#T?YLX+_NRVH&LOBN*J&J -&N RSIV@<Q'3L;L&FEDT#/Q2C8NU
M@4(K(!) :."Z>1:C6T7PHQ178?\ R8'EJ][N]][TX\-.'NX^\R^P^L?9%@0"
M,5MKC?Q^AT7B%M<6[E86V&#MEK;&R4<68=N%QQO:(\JLI?&8W%Y4V[.'(8]%
M69B;]K7)]?BRS)B]+92(0J23OO2:LU9VX2O?/5^KXFI8?U0KB@G*;F%RXB\,
MA;+9O,JO;NK^7A:7*<M2.NP7XK0.4RE57.+=*DTC8Y8SNR MQA3DZO3V3'SQ
M:$<D<S"$YI0LZ::C&^47=<,[<+ZK597]QL27]76=62MY*[LOC9Q\F3!R]AE/
MMW(*,"+LV,-\ZMFBSE2J!\A2UL-L&/N\7M):J7+3)YJ(+V&)S;2Q8)?'$RM:
ML5J!7RDK6D_JWLLFL^*^&7!^_B17FW,Z23SCSQQXW/%:5T5"N-=J6E:D84I"
M9#I7)EEPOS*_3&,RA"J>U3(9&-&1UF;6=&U-K:K0M:=0G5+'$U68H"+*"3DT
MW>22^%E96]?CGF]#D.3/.:P^5R_CP&U8^V.\;XX10V#1-F<7^729Z>8>KG3G
M-U$7DE@2QZ?)R[L366YZA<.3N#VL61>$MC4WZ<'-X"Z/SJ$8;JE9N\O73*UT
MM?7WD9+9LF17+:5CVY+A)Q2FSYU*[ D.D9>R41;S+WU<_N)" @0A>3H$ZI>:
M0A3:%L"9(620#X %AUH62LDM$ER-?8)& , 8 P"=O2Y_U*^G[]-'C']\\,P4
MJ?8E\#L4=?M'8OX*H?ZX1X-7^6OQO],2[K!08 P!@# & , 8 P!@# & , 8
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ML$3/=P+87*GYJKF2*6G9+GQV6*6(E(Q#G$\6M[?(&>9O3_I!#4\I51M[:S9
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M."V3MNI3G5P&RH8G'U]ETZ;P..Q^)VA0Q;C(W.T?+A@# & , 8 P!@# & ,
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MP6EPA^%_KD7<X*C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI<_ZE?3]^FCQC^^>&8*5/L2^!V*.OVCL7\%4/]<(\&K_ "U^-_IB7=8*# &
M, 8 P!@# & , 8 P!@# & 4C=*7];+K1?3[!]V$=P6EPA^%_KD7<X*C & ,
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MWOB?3R7N9#+%H=$)/.Y%)I"[*?"\0W,[*U+E3@X*S-!&/1*8@P>BP&&"UHL
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MS6J<WAB943@0Z&/<$VF<&\MHL5F7(4#G!I*L$K2Q>1)4,B$W.1S82A4<O;&
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MV \+8'#PP^&V%LG%/%5ME8&G3V>L5B*6&IUJF^\ZQ\Y& , 8 P!@# & , 8
MP!@# (+1#BE-8KR/=N1P9A7RUUF+\^E2>&'P-S''HU%UJ!A:B7RK%8I3I;%[
M5E2"+-!5JRA64X-<Y+VW)ALZ$N*(3';RN&V!BL/MJIMK^)P<ZF)K557PSPE1
MT:&'E"C357 2_B-[#X_$0P]-;0KR4Z>+6XG2@L/!U/T+MOZ8]@[8^BW!?1:]
MB>)J&#V'L[9\]D[=I^(\)':>UMKT,3M'&3V?XPHK8[H;7\';&Q.V,;+P;L>A
M/"XSP]+^)JQQV)EMC$QP<Z<]4?GH8 P!@# & , Z8KCS7U_<@)8FXMT&A63"
M1W2ZMPT=8;?8PS-TMD<,1O#PS+TIDT=&B/I)2R-9TD3L[N2O0OP&EYDD?;U8
MV^2/#:XC>ENKZTLK>N>5\O3T^.5S0BM*>A5*42HO9*I&H.2J2M["+91Z<P11
MQ>Q $( M@, (.]@$(.]Z^$(MZ^#>"Q[[Y'WR,K@-DB:')C<3&QC>BT#JC/0*
MQM$E96^21YR"G4EEF[1/<?=FQZ:U/@^*6MC@C6IQ&)U!0Q G?@<1@$W$1W,J
M6<2+!H\#< '&#C;(X=R>G,5=X_5,8>HB_7FBC,&AMB$NKTWM%NRLN<,[W%$*
M- PNDA;@QY4TNQ[6D9BB%Y0I>&\GZRO%/-\'FM.*YD(\%S+H= Y=8*UV;(6R
M*9&Z,L;?9<M:6XQ,8[F1Z+H#7>2.+8U#/+<7O3 QIUTA>$K,F7K6V-M3U(E:
M8ED9'9>B$-I6OZNW!\7_ &_,Q'!(P!@# & , 8 P"=O2Y_U*^G[]-'C']\\,
MP4J?8E\#L4=?M'8OX*H?ZX1X-7^6OQO],2[K!08 P!@# & , 8 P!@# & ,
M8 P"D;I2_K9=:+Z?8/NPCN"TN$/PO]<B[G!48 P!@# & , 8 P!@# & , 8
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MO"5%$Y"XO>VQ.EF3VV15+M:]ENR-K$;RNHW6:OQUM;XW]W_*(QX+# & , 8
MP"=O2Y_U*^G[]-'C']\\,P4J?8E\#L4=?M'8OX*H?ZX1X-7^6OQO],2[K!08
M P!@# & , 8 P!@# & , 8 P"D;I2_K9=:+Z?8/NPCN"TN$/PO\ 7(NYP5&
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MES_J5]/WZ:/&/[YX9@I4^Q+X'8HZ_:.Q?P50_P!<(\&K_+7XW^F)=U@H, 8
MP!@# & , 8 P!@# & , 8!2-TI?ULNM%]/L'W81W!:7"'X7^N1=S@J, 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M\VKCTV3?@,9:ODNXST7-]AX=N_-JX]-DWX#&6KY+N,]%S?8>';OS:N/39-^
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M%(W2E_6RZT7T^P?=A'<%I<(?A?ZY%W."HP!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!T]M>\X)%7/
M">Q^%S+"$06JQ[LAE^*+/)DCDAF,=G5?)$R&*@CZ5,DTV$,Z9.G\:M)4A4NJ
MA><-6C>&T):=.0-UPO)2;X*UK>CO?.]_5_#0VAQGZH]S<8Z]IV'QF,QI]?\
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M%UL+AJ&'JX_$?Q>-J4J<82Q6)5&CA_/KN*3J5?(H4:>]*[W:<?6[?.YG-H8
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M & =..[<CD4WX20OBU+BUI#U0]V3>V:<?"2-*6]?&[F8XFR6E 7?P# '-JM
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M,.(C,)AT.B,393UFRESJ[AEKX8F1H79L0(@2>]*3R;LDN-DM?>^F69#[!88
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MR*N_/'DWRV!D>:/%=@?,7F[QO_N>,\R^=?*?\OG/R3X$NEU?@OAG;^YK6_\
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MLL?&'EJ.S,$Y4MGT(PW8J%6K#>VAM%PC&-3:>,Q7EMX:EA84]W9VSTXP!@#
M& , 8!2-TI?ULNM%]/L'W81W!:7"'X7^N1=S@J, 8 P!@# -$UY5\L8YI*)3
M/IAVW+0K75JJ0"D!HEL3A3VM$^NA3L>:  5\G4+U147V[!T<8*&1&,%[4><G
M"2#7<+9^R\70QN*Q6/QG\:H3JTMDJ2;GA,%7GY]55I-)5,5*I)85U?K/^"P>
M%6]YM3$N?E-C["VAA=IX_'[6VC_Y2-*K7P_AY34G5V?LS%57BZZQ$Y)*KCIU
MJD< \0MYO9NSL G/SZV-=7>V=T]6, 8 P!@# & , 8 P!@# & :=O:J3[MKA
MVJ\R1$1N.2XU*VS=3J/)WUX7P_9GC7=IBZE:O3(XI)ENRTX6J:&M[^IC)@!N
M+0U%OA;8[-?-VK@'M3!5, ZRH4<0XPQ4O)C6J3PU[U*="4IQCAZ\[)4\2X5I
M4'>=.FJJIU*?N/H\\8T_ /BC!>+H[,J;5VGL6%;%; I/:=79V!P^W%'<P.,V
MO2H8>K7VQLG#[U5XS8-/%;-I;6C*.%QN-EL^6+P6,\%!U.Y4A7C;6)LN(ET:
MB0_-$ -[)-45=&6$I""2F9BD(V-1YJDS\A\$_P OEB1GC8GOQA2A<S:<]+G)
MQC9&SY[+P<,"\1'$4,._+PC_ (>GAZE+"Q25.E6=*7EUZL,]_$1IT75NI3I^
M9O3GD^D?QEA?'_B?%>+8;$J;%VKMJ/\ &^)(?^:QFV,)C_$%>I4GC]H;,CM"
ME_&;)V;B+T_X;8M?';56S]V=+#X]X1X?"87=.=,\&, 8 P!@# & , 8 P!@#
M & 0TB?%)XB5_/O(Y'9Z R=SMR5H[(;M5BPD1E[@)"=I1QN-1@H+N9)8A)&I
M''V<+Y-S)1(3)J<3O4A83F]H@[;#/-X?8%3#[7J[:CCH/%XN<H8V'\#25"KA
M$J<:%"@E4=?#5Z<:5/S<4Z]9XEI^=1<*>%AAONFV?ICP.V?HWV=]%U?PEB(^
M'?#N%HXCPMBGXLVC4VML_P 25*F-K[5VKM:;P4=E;;V5C*VTL<]G^'X;(V9'
M8$*B>S-I0Q.-\0XK;TR\](?"Q@# & , 8 P#I!\'0& , 8!FT$L>;UDZ.#Q!
M9&OCRQX8W*+OA:;1"EMD48>-$Z=HS)69>2K9Y'''+:=,8N8GQ X-2HY*E./2
M#.2D#+$-*2LU=?O0]:8SN6S]<@<)<]J7<QH:B6%C2[+3(6B.L"=8N<"&",L3
M:0C9(VPDN+FYN)3*Q-[>V <7-R7A2Z5KU9QP))*R_?Y\3$L$G,1V0.\4?V24
M1]:)N?HX[-SZR.("B#S$#LTJR5[<M+)5%'IC#$JP@D\L)Y)I6QEA\,L0?AUL
M&DU9\&9+9]H3ZZ)[)K1M*3N$TL&9N(WB62QWTFV[R%W-+++/=78Y*0G"L<E6
MBPC6+C2Q*EAWA*%1IQYAA@A"22LE9+T,"P2, 8!LANN&T6BK9%239/),BJ26
MRAIFLDKQ.YG@BSQ*V-*)$UORUKT+Q W%*EV63XX.@^/"E0;4Z.$W(!)A&ZKJ
M5LTK)^XUO@D8!.WI<_ZE?3]^FCQC^^>&8*5/L2^!V*.OVCL7\%4/]<(\&K_+
M7XW^F)=U@H, 8 P!@# & , 8 P!@# & , 8!2-TI?ULNM%]/L'W81W!:7"'X
M7^N1=S@J, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & =*QVMK?NE(]>)-@W=V7^X_Z8]AVMK?NE(]>
M)-@;LO\ <?\ 3'L.UM;]TI'KQ)L#=E_N/^F/8=K:W[I2/7B38&[+_<?],>P[
M6UOW2D>O$FP-V7^X_P"F/8=K:W[I2/7B38&[+_<?],>P[6UOW2D>O$FP-V7^
MX_Z8]AVMK?NE(]>)-@;LO]Q_TQ[#M;6_=*1Z\2; W9?[C_ICV':VM^Z4CUXD
MV!NR_P!Q_P!,>P[6UOW2D>O$FP-V7^X_Z8]AVMK?NE(]>)-@;LO]Q_TQ[#M;
M6_=*1Z\2; W9?[C_ *8]AVMK?NE(]>)-@;LO]Q_TQ[#M;6_=*1Z\2; W9?[C
M_ICV)L]-610E?U$N":%FKLI@=UG+_CBE:WP$J?',3,X'V]$2D;H%N6_^FO$@
M4"+5:1JO_74[*\2=_P",8L%9QDH2O-M6>5HK^R/O?\PR[](EVC[=G^=/^S,%
M3YY[.,OA>0?+8&5YL\@\#R3P?*/_ &O*_P#]1\/_ (?A\5_ADW5[VRTN_?Z\
MN1K6?E)75]]YVS^RO?;H74]F)]WGJ/5"._V9-X^S\S,=I>U\J'9B?=YZCU0C
MO]F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._P!F+Q]G
MYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._V8O'V?F8M+VOE0
M[,3[O/4>J$=_LQ>/L_,Q:7M?*AV8GW>>H]4([_9B\?9^9BTO:^5#LQ/N\]1Z
MH1W^S%X^S\S%I>U\J'9B?=YZCU0CO]F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[
M/S,6E[7RH=F)]WGJ/5"._P!F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7
MRH=F)]WGJ/5"._V8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*BE?I9,,
MO/Y5]9(M'.SD!R;GD$I<H#&V53MR4?%G'Q:5B*.#LM)O0-Z+\0GUHK_+X7_Y
MM[R$UG=7TS>7<O).T+.WU7?)9_6ER+J.S$^[SU'JA'?[,F\?9^9E+2]KY4.S
M$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._V8O'V?F8M+VOE0[,3[O/4>J$
M=_LQ>/L_,Q:7M?*AV8GW>>H]4([_ &8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L
M_,Q:7M?*AV8GW>>H]4([_9B\?9^9BTO:^5#LQ/N\]1ZH1W^S%X^S\S%I>U\J
M'9B?=YZCU0CO]F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/
M5"._V8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*AV8GW>>H]4([_ &8O
M'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*AV8GW>>H]4([_9B\?9^9BTO:
M^5#LQ/N\]1ZH1W^S%X^S\S%I>U\J'9B?=YZCU0CO]F+Q]GYF+2]KY4.S$^[S
MU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._V8O'V?F8M+VOE0[,3[O/4>J$=_LQ
M>/L_,Q:7M?*AV8GW>>H]4([_ &8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:
M7M?*AV8GW>>H]4([_9B\?9^9BTO:^5#LQ/N\]1ZH1W^S%X^S\S%I>U\J'9B?
M=YZCU0CO]F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._
MV8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*AV8GW>>H]4([_ &8O'V?F
M8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*AV8GW>>H]4([_9B\?9^9BTO:^5#L
MQ/N\]1ZH1W^S%X^S\S%I>U\J'9B?=YZCU0CO]F+Q]GYF+2]KY4.S$^[SU'JA
M'?[,7C[/S,6E[7RH=F)]WGJ/5"._V8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_
M,Q:7M?*AV8GW>>H]4([_ &8O'V?F8M+VOE0[,3[O/4>J$=_LQ>/L_,Q:7M?*
MAV8GW>>H]4([_9B\?9^9BTO:^5#LQ/N\]1ZH1W^S%X^S\S%I>U\J'9B?=YZC
MU0CO]F+Q]GYF+2]KY4.S$^[SU'JA'?[,7C[/S,6E[7RH=F)]WGJ/5"._V8O'
MV?F8M+VOE1UE$(;6ZD^A>HY'<<5AC/R$L+G0"G>1UMQ0T:6T:TJ5!7#Z_06M
MFR2-X@/\ @LZ?$S2^OSHSJ&C4T=%2:*/+DZ-Z=,S%5_?[_?]C=>=5*7V=V\5
MG9M:^C:SY<]=\<*'2\SZBMGD1RF>9F]*N-_R,J4B$>C"ALALULYBY,<CI5$E
M-F2J4NT9DATD,B+2?)VUOD(6A2KDTJ.BQTF=W#3,\HI0$GNO=A9;V\V[974>
M'-9Z&Y;:Z5?'RL*VYJG1.TWJYKAX771<[;/Z\U-F&K9.JX\P:9P^(PZWX,S/
M$%DC19;:@=5,SB5WZ8Y.A7P"9[CX&YK6Z9C([83UY?\ )"J2;7HFE;*ZN^*=
MGZ^GNO>SS6.=3G@C1\3YT<M*SH^?T+QF@'&Q#6L8;8)=UO+VJ162-!2L5=]K
MJP;$%;JSG)Q<""$Z9^U('YV='F<.:A]7/XQ2$:5M$PF]U-IRO?[*5EF^.?\
MQPM\7O3DQT_.)H958CC#HE,(+$.+/2CH;E8NA;;/6E4\W//;*0UL$LQ>\*8$
M!<W)&5]L9U?;+?R=NRAZ+.C;#&D%>M.T@$8I&<N%\Y5&KM<$DO?Z^B^)!SG3
MTU89QAM[DE'(5RGH8R+4TJC2Z,UM:%BFMO(^2-$NJ>N[71,Z.)L<*[/2!Z:2
M[!['&.)*^.$/;Y&'I5YF80; @*&2,W)1;B\^+5K+-KU=_2_J5*X,@P!@# &
M, 8 P!@$[>ES_J5]/WZ:/&/[YX9@I4^Q+X'8HZ_:.Q?P50_UPCP:O\M?C?Z8
MEW6"@P!@# & , 8!ZBY>A;$IJYR6I&]$1X'CUBY02D2D^,, 47XU0>,LHOQA
MIA90/"'KPS!@ 'X1"#K=)U(4H.=2<*<(VWISDH0C=I*\I-)7;25WFVEQ9CJU
M:5"G*K7JTZ-*%MZI5G&G3C=J*WIS:C&\FHJ[5VTEFT>WES(, 8 P!@# & 4C
M=*7];+K1?3[!]V$=P6EPA^%_KD7<X*C & , 8 P!@# & , 8 P!@# & , 8
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3X'\J3;V;QN2TZKN-^.O1]C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g80783g70q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g70q94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1]84&AO=&]S:&]P(#,N,  X0DE-! 0
M    'SR^>98X0DE-! 0      &$< 5H  QLE1QP"   "ZV < E  "')R,3DU
M-C<V' (% $!-:6-R;W-O9G0@5V]R9" M(#@P-S@S7U!R;VIE8W0@0WEC;&]N
M92 M($1R869T(%)E9VES=')A=&EO;B!3=&%T #A"24T$)0      $((?'.3T
M2+Q@LIM#V;WS7MTX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              'L   !XP         !
M      $              >,   'L                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     @X0DE-! P     %+L    !    G0
M *    '8  $G    %)\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( *  G0,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M=NE/(%]=U![DM#VC^U27N_Z"IW?5SIEFK!92?Y#Y'^;<+%4M^JKP/T.4TR8
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M))3B_6BN<.JR"=E@!CP<"-?[6U<RY=GUFDW=,R&@20W>/[!W_P#?5QKPD@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ G0"; P$1  (1 0,1 ?_$ !X   $$ P$! 0
M   &!P@)! 4* @,!_\0 01   00" 0,# 08#!@0#"0   0(#! 4&$0< $B$(
M$S%!"10B46%Q%3*!%A<C0I&A);'!\$-2@C,T-41B<K31X?_$ !T!  $% 0$!
M 0             ! @,$!08'" G_Q  X$0 ! P,# @,&! 8# 0$!   ! @,1
M  0A$C%!!5$387$&(H&1H? 4,K'!!R-"T>'Q%3-2)!>"_]H # ,!  (1 Q$
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MPT+<MEJ_FJ_(VIQ/N:UR @:8*2)S-4'/8YZ[*387+SB@XEM*?""G"LDP"4D
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MB0#M73]-6B[=TOZVVQNH)&_Q/F./W-35PO[:K+(98C\C<)4%N#V^]/P_*)]
MZ$'0]Q-7<5]^VXOY(1_%&4GP.](VKJ:W_B0H*"+GIJ7=M3MJ\4IR3^5+J53Q
MC4#OQFNT9]E6KU(5:=02"HX0\T3P"/>0K'.Z?3F)A85]KSZ4,C]EG)_[PN.9
M2PGW3D6**M:]M1\'LF8C,R!];:?)]QV!'/9^)2$G:1T5M[=]"?(#JKBT)P?'
M9E(/;4TIPQV.D9QBH[OV)ZW;$Z$,721)'@.>\H#<A#B4>N":F=@WJG]./)(8
M3A7-G&]U)D@%FN&55=?<+WK0_@MH_"M4J_$!VJA@[.M;ZZ*VZOTN\(%MU"T>
M4=DI>1K/H@D+YC;?&^*P+CI74[4$W%A=- 3*E,KT")GWP"G@G?;.U/RVXVZA
M+C2T.MK2%(<;4E:%I4-A25I)2I)!!!!((.P>M $'(,CN-OG6><&#@C<'?Y5[
MZ6BCHHHZ**.BBCHHHZ**.BBD7G64RL4IQ-A4MQ=2I#_W1E%14V%Q]S4IEUW[
MY.CUK$F4F(W[?;WI9*%/+:;6MM*^\(?(3]\T5#6QRB)86;[]M;LHMI"RI]BS
M<5730K?;VB'8B'(3[8"4);2RD)2E*$I 2$B5 2)@DDS,[QVP.W;X4L_?E,_K
M0L**0O7X2"4+&E(*1_F"T[21\$D$@'7Z#J="4)"3_5'*B8)F8!)[P?2DK%4D
M'R2"3X^?/D;^/'T\^1]?R/4H(.QGTS16"XG0)&M?&OGSHG_4>/'ZG].EW2H1
MA0TJ]-0._!D1(.1CDRJ2 I*CL"2<3@@C;G>HZ4WITQN$+C^.)HLO<N[R]LK&
MYR[$X6391*I[_(VL@FX8;G(Y=LVUAW:VFK11-UXB(B);?C-1IS8E!';[K+CA
M ODLV31;4BU:8='B*0@03I>2UK,* <*#!.1,S-TQ;/3674-*O'KE9=<0^%);
M::65K6A83JF6I3( R0>28^IX\Y)JF;-N@RZ)"<<O*AS'518BQ2XIAT*TKY<W
M$X>#EZ#B\UE5-"D8]5S6Q4V<-F>N7(M94MM#[<!#KJ]2EJ*ISXFHDG@ JC;T
MQCUIBW7%K+JUE3BLJ4<E1[J[GS,UJ[;(N<*"S^YMXY59133;>OK6),Z$]7/5
M5&F T]:Y+DEM4*=KU.2I_P!YKZS%:*AM4QH[2;&VRILNMU[C%2H@J)('NQ *
M8 (/NE)$=AF>_9A,DF!GRD?(S6EQS#>,.=8EQ.R_T]U]$85C*KC8Y#24<.TL
MEM-1)3$^NL*4HM/8EQ);#RW/O:509@DU$M2+2!818N8]TCI]XK_Z+%APE,$E
MI*3 D[@#,DYY)]!2#&V/3'Z4W&5_9\\"7I<?IV<IP^00?;%+?/V$5"B?YE1<
MB;N5+2/D(1)9 ^ 4;\83GL)T1^2VA^W5P6CJ0?+0Y"8'<9&1L 1K]/ZY=].5
MJ06UI$>XYK (29P4"9/))&X F*CSEGV;>2!IUS#N2J6ST-L0LIH9U.L:)TE=
ME42+M*SX [DU321]4_GR_4_X;OEU*K'J*8!DH?:"=/8**"0>\IXD\&>A1[</
MNK*KI@A"2"4-N*+82 1[I5[R@(.^29!J,68>B+U$XJVMQ&#L9/%9))D8I;UU
ML%I2/E-<\[#NE:/CM35%1/PDDI'7,=1]@?:%@*<%F+TC"'+58*D@X"=*]*YR
M5  1$R0<CLNG>V'170AI=RW;I6 7$7#:PD*VW"2.0)W[3N4!1\D>IK@:ZH:.
MIM>;N/KFWG+B8]C3$[+,89N)#!27@S$FN0ZEV#$2 _9S93:X$""A<B<M+( <
MR;&S]LK5]MEEWJMH7,(27'TH!! _*H:% $0?=B2!))K6ZI=>Q[O3W+A]73+D
MH:42I*+=;A<_H3*%!Q*E J(3J22>#&.@C[(KU4<L>IGB;EE/-EXW=YWQURI,
MH&U>W"2_!QE^ U$K(,F1"@5QL7&[>CR)9L9482I"G%)64MM-,M>L^Q'6+WJE
MI?L]2<+M[TZ]_#.J4E"%$*:0X"4H2G916DDB24Y)BO"[Y=JX^7+-"6F%B4MA
M144P2,R202(,;01$U;7UVU4Z.BBCHHHZ**.BBCHHHZ**PYM=7V3)CV,&'/85
MX4Q-C,RF5#\BT^AQ!_JGHHIN['ACC&R*E'$H%8ZHE1?QYV9C+Y4>X]Q<Q^36
ME9VHJ_Q.\=VE$$@=(1/?YD?I13<9+Z?&&:NSDX;EN2U]JS F.U<&Y<@9'5/3
MFXSJH;$Q=C!5>*BN2 VE[V;EM[L*BA?=KI4%39*DJ43!P3/W]=Z/OM^V/E\*
MI<XT]>MODN(8WD65<;PVW+BM8E6+5!=/Q7*VR1W1K:"8EI#D>XJOLF9<0A<I
MA2C'_&EM1.K%O<(<MFW ,N&2F<ISDB<F,XP/2356VN1<,I>T%&J?=)!.(G.
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M?CYVOBK2D05*(P$R (VYC;_5 "P )&T$G>>_/W-2$QWUO\R4+85?Q<9S1A
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M \S7/+;0R H@*(*>X'Q^+7P/IKS^I^?&MCI2 9!')!!QD2"#Z9I5& 2,D *
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M#A;*9$R)3(4).2 4E,\@&)VKYVR6H[CNT]R__#1LE1*O@D:\ 'P=_E^6^HT
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M<X'I?[;6J5.1UYI>-O0<2BN!*A[M9#[FK*]6A?:4*<%=!6-J2^^@ *=X;A(
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MMFE)3J"4RJ=CB8B#@UWGLYT&TZ]T\-]<L+2^>L[=;J#=VR7%-J_%-:7T)49
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MJ(N+UE*BC$Q:LV1R(A2< FI_XBV_L+TKH#MO[*IZ:F_5?=)=;7:W:[EY*?\
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M2*Y-DV$!N%%0I]^39+:A,LLH&U./RRMJ*RE._P 2UMI"1H_HKJ0&@J$%.J2
M2=*3QN?0B,R?*17EA;>=44(:<6X=T-IU$&)43& D9*B< ;G<TH8LZI<6W'#D
M54E[N2RU'FQWW'>WO[PRVI33[Q1[3A7[;*BE*2H@)'F%227/"!3J5(&I02"0
M"2 3@D""8)P: P_*H96KPD%Q\H3XGA,H(2MU6G)2DP)F)(S,"MB[!B I"U):
M4H:T\%QP2?A +R4!1)\ )WL_&^H@V>#)'8;?(U&2!WR8&/OZ3GYTGLAC0:J
M].FOQH<1I)==?E.MLLH0-?C4\X4H2DGP"2-DI !)Z5*= 5J]V=\20?I)G!^-
M(4@F0<X.-L?XJA/U1_:;9)!G76'\$4[F/KK)<VNG9ODD&-)MA,@.NQY#-'0O
M*EUT9MM]EU'WRT,QUP *;AQR4DU'+DZOY9VF?/MC'UP?2I$A,^\F>QD#Y2/7
MXC$&I>V.39!D$.ON[]=S>2%UT%Z;/9KY<R+ ,F,VZ?=3 C.,5D=U25EM :9C
MGL4$G\"M6[)*W1I*L E4P?*,_'C]A6,^M,J00K>01!( D[$9[?[HI;JLG*4B
M#.AS5H'XD,2&W'&R#_XC25*<0H$E*DN)20?"@/CJY=6Q<0HZHA.J(F2D;:L0
M# F=N)S+67DH]R%*DD D3E1B#@[?IL*0G)/'&1Y5G_ .?X?9T]5D/#O+F/Y_
M[ULJ8VW)JX,N'-L*Z,N#'DK,N2]5URV4O(:CK2V\AQ]M*PKK)<&IN%)@HR#,
MYP)^GWFMSIUV+9%XA:=2;FW+.G4$@+).A>9G2<@;YW!BNO:)):FQ(LQA04S+
MCL265#X4T^TEUM0_0H6#U4IE0/\ 5SBU!GEM$Q?+:F/?T7\'A3!6S%R&VFY)
MDV+7OLO1)$64PZ4Z'<S(;)*4D[*01;M@DR2!()R1.(',8&_:D42 2-ZK$RST
M*<-W3RWZ9>4XA(4#V(@V@O*T*/U7!NDOSU@$$Z3>L'Z%12?#G$*4Z@@2 H3W
M &1],23R)SN-N9(4.!!,9[E,'><3ZQ395OHXY'X\R2KR#CG-J"=)JWG78DB3
M]]QNX:]R-(CA;3#[5Q3^ZVMY#H#EPCM]M2TH4M*0=&R>99=)N4J+:FRG()2,
MR1&3MR!Y=B+=FXPV^#< ^&0J5#\H,0-0 ))G P0.>2$KRSD'JGFY+QABW(U?
MR3<8E:9EBXR-K'</?O<3>@L7W)+MP]DV2X/52<<IJ^%7-<=3WI&16L!"XT>2
MU!5(F.V421MOW?26DD=-PXZZ@(44+2M"5I&HI5I2$@2L$2#D R-MEU?2S:W"
MK=*-8#A#JDD$)_"V@ !6 J/'#Q3@"=2HA22>:KU.^G.3SM]J/E'!U)E\CB;"
MN2LCIYEA,IVY\JI;9=P>LNK:UAXW&G08D^UNI2)2G4*=BQGK:4_*DN('OD^:
M6-U<7WM!?](3<*82;RX\)1<4A(:4QK3 "@"7$ #3 )$ @;5L]-Z4U==*L+A2
M$J=%J?$(0%J6ME;ASIDY,I)D $D@DDUT4Y#Q/Z1ZOT_<<<$6>:8]R]BM% XZ
MP^GPFWX\<:B6A5689%J[,A]J0FDL7Z_,Z>_>E!P3BQ>/!$EE29RSV;_L\MVV
M#-TV%-VZ/'#ZRG_N *0H$G7J3I(F#@P< 3SJ;?J2+AZY:0;9MQMY$H6E #*\
M!(2E6HIUMR4Q)4D&-B*8O5-ZTN/?2UR+G7IYO^(,C?M<)5"IZ.+B5Y3NXE:X
MK84?-2Z%MN;+99M*I9H><:V+)KG:BS<KY6++C(EV#<QE^)P;;OC+5;0/_B?=
M:4@J/YO"5I,  92^A8@X\CBO%^L?P:ZC<7ZNHVO5+9-OU"X7>*2MI8<;2ZYU
M(O)0EM)0X4..VX)64Z]1.XQ*+U,<<<P\Y?968S5X[@=Y9Y[E"\?Y&L,/H:ZP
MEE-3?9)?Y@,?AN2X$=ZSM\?:MX;$QII#,F3/JYS4>*5---.IU.WOA;=/<0%N
M%F\UN)0A14AI04E2E  P)4C8GW0.,5[%["=*9]GK1OHKUPT\FUZ=<V[2\(25
M.7"W4I@[%1B,Y)2#@5K/LQ,+Q#TT<3TC=YZ<H[?*V:M4]9R!>9'8Y;CV7I?M
M>3.+,2C5%M627%Q(4>K;Y+C6#%5&K:MTO4Z_O$AY^Q>D1KMHZAL-O*;\93B5
M)"_RK;"E-@H!4)*%3*A !T#BO%?:OV_Z[T?VIZ]TH(:N>GM75LCI[;X4P;=*
M4V-LXM/@XN4K=>N%%UP%862K4 J"M^=,]8@>D+FKU+89AV$8!RKA&88C?5BJ
MS%:JZDO)D,<:7S.+9=>6<%>1VU0J=F EJ+EE&F*LJBFE//*B1'8$G.ZM:V-Q
MT]RY2RVRIN]L@2VEL.H+JX4H$CWE$GWNZ9!F2#[#_!?VW]I6]?5&[A N'U7C
M:$+\9=L+==FATMPJ![JA ]Z!! /)CW]DEG_J6]57-D3D[*L?PBGXFXTJ[*GC
MC&I534S[C*TXIQ]AL.$_%RC(+C)95578_BV)N64JH;B@V577+?E.2K2PCV#>
MC=):M[Q*[-QU:DI2E]:RE.E);8M&$)$)"O$1;,S$P0"J <^A^VW\:>H=6;N/
M9?JS]HV^Y;HNELMMM)!:?O[V\"W'[ES5";J^NFVDLE12V$A0$HU75^KCF^DQ
MO@ODIT7C]1-XUG8E:9A;T%@U<.8;!>L''Z[()CN*2K:7&153X3=C(++;MK4"
M +1ZO0VTRZK1ZTIQ?3GDVJW%.MK:*5,JA:2'$D*"@1![9[D]ZYS^$7M+[..>
MV3;G4+AA^ULV;MF_:"F[EI0N[&Y0PVM"@I#B75)DA(4I&G40E0Q ;A[UXU'.
M_.W!O']'SP_RQ82^1<8R!.)TR;">D0*&\YOL+^RL1%I(<.)$I,;D\63Y;]K,
M;#<2$MN/[UA$LXKW/6%QUIWJ=F;];[]JT\@J2HE.F;F^4HG4KWOY*K0F,%"0
M@J44J2/?_:R^_AGT[H77U>RUM8LW_4.DWMHW<L-^,N7;/V>AM+3S2$-S<M=2
M3(_*ZEY84/%0I=UN;^H^CH67(&/1&LDN0@MDMNC^$1'$C1+\Q 5]Z6C0!8B%
MP=VTNO,K&CZ.FX2B2(,@;I)SO^_GF<5\HN.!$'>3QY#.>()&^*AYD^69/FDO
M[[D4]R0VA\/1ZR,@1:N,221[,)"NQ3B$D /2%/R#\!XI\=5%NDJ*E$PHF<XY
MWWS\X^5,+H5(28)'N@3,^O;CX\US;\E.D9=G > +B<UR]&]^ 1?6: % 'Y\:
M!4/Q>=$Z'5% .M1_I)'Q[GTC /E/<5*M92 =,P!SB1O\#VWY R:Z@N D 5\Y
M96G:J/%"-?Y@J',) )/RDD)*1]#^_6]T_P#,Z )(TD '9)TR/0^><"1M6?<>
M&2"D"2))]8B1_J.^].W>XCA=TT5WV+4=NX/Q!Z=5PGY3.OE3,Q;7WMA:=^'&
M'FUI'PL?'5U0<6" J$J!!.>9!X[R !O$"JZ%!1]S)F3L/.3MCUS)BJ^.9W,J
MR+FWBCTN^DYJP3S7G>0UDVT=G6MMD^+X3AT58EV%QD<*WDVCD"$B EVQGF*]
M&1#HXI#3"YUQ3I7QOM!?W%O<,='L0A5\["UJ)!\%F4^^L[:=))*9*L&4S JZ
MS"U[2!N#VX/;X$5UPX71S<8P_%L<LK-%U84&/4]--MVX9KV[.365\>&].1!,
MF88:)*V2\F,J7)4RE8;5(>*2XJRD*"4A1"E  %0$ GDQ)CYFKM16]0B>[,XH
M_+'X1_TFS^KMK_6/D-OK_;(WI%;'X?K][X[XI@"@[\#Y\^/C_4[_ "^O4ZMR
M>Q[\[XB"(_7<FH><9\H^FY/Q^5?%4=!5WE)!&_K^?R=']_IXZ0DD0<B/D.=O
M+OL-J4DG $<J]9^G%8RHZD#O:4M"D^06U*2L:^H4/(UX.A\]*D"1F(R#.9XB
M9S1.H$&2"(*1@$><=O0TA[WC/ \GLXU]D^$8CD%[!6VY!OKC&ZB9D,!3"DN-
MFOR!V$J\@*2I (5"L6%:VC?8I22@0AJY_$MMM(N-(07@VC61$25E)5,$B9P-
MHJVS=/6A!9=<1']*77 F,F-&K1!,SCG:,4P.6^CGB#))%3*J#EF!/U%WCMTR
MYB]S'GQ) QF)BE;"K'8685N2+:@OU6$X_6255LVMGH9B%^+.C3'%2.M%WJEX
M];FV<4-!TRH Z_=),3,9U0H1\CM8/5KHMELJ"DD:),R!*E<&!)61C@&!,U5=
MZE/L>LTY*]9&/>K+C_EK$79%=F?'^3V^(9E26]$^H8;'IXJOX7:5R,KKI,J2
MW3,2F$6*:R.F2XM+CZ&TI7UQS73+EOK#EVVME=K<7"7GF"%>,TH(0A2A$)+9
M" 1,J!.Y%;MA[06:;.WM[EAP/6REMAP$:"T5:@N"G5J*@ (Q!)D'W1++U"WG
MK/QOC^[K_:Y!M*K[DW'']W&.'.ITIB2YS:RB(M''E-<Y AF.V[PZIQ<AAAEA
M+!+SA0W=!7IB[SHC;#C^AM;@5 :(4%@Z&R-,$#0I>N1!B<F,!K3G175K>"&T
M.J4ZL:]60A"5 D2/ZBI)&9 V,9YSOM>*[+G_ %MX'3XK;W_&[G)V$\;4V0V5
M+(MZ=FSN;"\G4[UK>LU,F*;:=5,"%$DI=4N9]TKHL)12IAI*?,V4JOO:8=)0
MXAHW;_3FD!1]QE=_I1,"#X8<7&1P03(,LN+*Q'0E]059,/BU;O%)*[=EQP!C
M_P"A*/&6VI9 <:2H:U*5@&20(M4QOCWTG\?^AF7Z8[CDW-LH-OC5J[DT)WCA
M5?DF4Y3.SV7&E2IMK%N9=<Q8-YW"AXS$NAD<]$=B!7+=7+K>U?7K]S_![J*5
MNVEP6U]/#X6YU!-RA+WA,.)N4NAHLDZD6[B  4$$I)V-><=/]O[?2FXL[$VR
MU(2!;HMM-N-5LC7[R7$@ M$F0$D#W2DK$&$O)EWQ+]EZKAC'*#"\[SG N3G:
M[D^A?C9-1W69#)(.6<5WUW2S*YVCQYIJLLZ_$<?BTLF([,>5)L[14B,^N PQ
M+\?O;)/3NI/V27U+\%:E-K*D^\EF["X]U"00?P[8.,:U'RJO[6>P5S[:WMI[
M3MWUO8$6UE:O,>$\X@M,W)>)&EX+UEHO:I4I*B4A.C>I8>FSC[+N8O3QS9CG
M*>(9IP3CO+M#@&'TE'=LQE\J6-+BV(0,=L\BL<:>2W#PZ%?0H[;5="OI$NP(
M?G2UP;*N^Z??8;;IZEVEW;*=66W4,^^DD+E!3)0N2"D:0?RG$B>:=[$>SBO8
M9YQT75K?7#ZV75E+:"T%6X?T)6%?S 3^(65C6#(22 9!D=P-Z9.'/3G0O47$
M6"UF)-3&4,W-U^*SS')""%J_M)ELY*[:R8<6 Z:B,NOQR.\/<@4D4CK4MVVF
MT0F%J "2MP@JD 01 2,P-@/*NJN+JXN5J+IT@K4I+;0T(TDD@$ DD DQDXQB
M*?P0TMI2H#1.]C^78/G0_+]OG6NKB$ZE*$C !&P@YQ^_'Z53> *4X(&H[S.P
M\_+]"((K[!@*;4GMVI1)'D_76M?L/S^F_G?F):7-2DD?RR8D@S'?C'KQYFHF
MQ"AW$QSC,;_"?\"H?<?>C+ \>R>XS3.EISN]L\AN+Z%736 C&*4V-K+L&&TU
MBU+-U*CI?2A<FU4Y"]Q.V:MI24N],#8 ,&=R ,C';GM.3&U3.K4<8 (S&3))
M'.!MCRG-3IQ:];QVS+1<#;<UIE/:C\"?\!;G9H:UI/NK&AH#?@ >1J]/>4G6
M8G4D@\8$01W@;]H\ZJ. &)[@>F_QDSQ\(K']0_J;QO@SC"TR^U]B9</-KK<5
MI5.+]Z\R"4RM4&+[;9]\Q(X!E63C(*VX;+B&B9+K"%MZOU9OH]@N[,N/ E+%
MJ ?%=6J=+B=I;;7E8R2 0#4"-#(DDZEA24@Y3)P!$$G(G<'R[6$_9/>B6^X*
MP:[]1W.L-R7ZH/4(PW=Y*NU80+/CW"9KK=C38&TDC=?93.V+<Y=&8#*(T]%9
MC@0J+B\1QSC^DV#C:G^HWBE.7]\KQ'%.&5,M$E3;"<2 D*E0)5[V),2=1AO0
M@$_F4 5=AY#_ #)\ZN ZVZGJ'//H!S*-L;_X!"__ "[#_L_IU98V5ZC]*:K8
MXG[^S3%EHCSXU^1WX_<[W_WH]68]V9^'QC]_7>H="@H+V2(Q.=@#C;<;$CYX
MKPMO:"$C:M#P-_.QO7GXUOZ;_P"JI($S&?G^F?B:<8SWDQ$1O.XWYX^45\0T
MD>"CSH?(._IY\'_39Z8?E_FD0M), ';>/[*/Z5\BULE)'DI^N]:UK?Z_/^W1
M3E>\<9Q_>L93)2KM21\>!KQY\G6S^Y^GGIP23MQ^OEYTT"3'U_WY21S^V$]'
M '>ILE6_!V5#R=[UL> !]/CQO8'2$>GP/;'KG_6*4RDP..8'EO\ 'O6OD1CX
M4D:*!W)T2"""""//@^/'G?C>QKIA5! TJ,D9 D SSG8;[&B5'N?03 ,SC[/G
MDTA\RP7$,]C-1<XQ+%LSC1EH=B-9=CE+DJ(C[9"VWX?\:A351)#2PE;3\4L/
M-+2%-N)*=](EIH735V6TBX94EUJY!'BH6@^Z1(W!DB3O!V%(7'FF5VX>66'
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M3!C;_P!''K@CTYI8D9)G&Y.^#L<'M_FJY.8(I7RKER?('WJM/<1\C^#UWU^
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MIU.Y:2G9AX(N&%"("5!:0YI&X]\D'.:S_P#C5-A7X:Z>;DSI=/C-R#@$$I4
M-A"@1C<TU=QQYZ^>,6T.6G&_%?/E3'W[\SCG*IN%Y(8Z=*,AVJRF'(CSYA'=
MN'5PX[:U=J&5)'\TZ+GJ+0)?:9N<P/!46R4@#)"Q ,R(!B(BE2KJC(AQMBY
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M5]=$C0($)AJ-#A0F&HL2)&90&V8\:,PA#+##2$I0VTTA*$( 2E(  ZV0 !
K &P& /A6L      !  $ #L , 5D]+2T=%%'111T44=%%'111T44=%%?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g80783g74z75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g74z75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     GX   4R          $                          0
M   %,@   GX                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   GX     4F=H=&QO;F<   4R    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )^     %)G
M:'1L;VYG   %,@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M-0$  A$#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4V)X@Y*5LK2VP\88)55E<W9WAZ*CIJ>UPM+_Q  < 0$  @,! 0$
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M**BA?4553(V&G@CMORR.R:QMR!O..0!(N<EY>]L;'/>X-8P%SG.-@UHS))X
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M%I=Q7K!Z=E+58I3L)+624F9-W.<:>\CSS+GDN<>9MR4XHXJK] 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1:@W9A^ZJ[K,QW
MEM5&@3L>T##%RVA59DM^$ZMJX*A6Y4V$PFF/FI]Y*F'4J\X0T;;9FI)J(^1\
MXQ'9O$*OI-P7:+R:*7!Z/9BNPVHDD?$XMK)JN2:)@@==[@6O:=\-L+9G1=IP
M;;7",/Z#MI]C175-/M+B6W>%XW1P0QSL:[#:;#H:>>4U4=HV.ZQA;U3G!S@
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M9E>4)RKJL;V-P#8_%\ V;Q>JQ'$),7PS$H:N>CE@94OIZB"4"(.C:UD=(R
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M,9C'6AX+B2>L&1?<BV1LIDQR%7B B B B B B B B B B B B B B B B B
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M[50"'%I7  "9K9,A;/0_,/!9F&[6]P'@,AXVM[UMV-;7I 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M+6#W]8T<-U^??J#JI0-P#V>WBL_BG7U 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1>>7C-?=L<%/_?/9G_<PHXI=HON+B'^9']+&KC9_[M8;_I'*_P#<Y/CV
M)FY?;R=<7/<DIIB4\]R3M2H6Y%X<S/<NX]R'GHX9;"JAULW3M%[Y^:T^OO\
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M.'EF]\-1F>L8XZMEEIZBMI#3.D@C:P[XDZX,:/LA<";.=>Y!L1?/.Y61H !
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M5%<0+C)P8"2X:9^> <O:2%TC'2!7X#'RJ)3RUC \=,B<\]%O4.FJY0$497&
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M?_UDH/\ ^6B;?YO3[1[^/CN7D$YWSN#RM<BYS\!E_4?[)]L_S.6_]Y*5_P!
MC@HJTKU+\.+3#JTOV#DC,="NJHW33[>AVO'D42[:C0HOO3 ESIL9M<2*E32W
MDOU"2:GCV4I*D)/DA(V_ =N=H-FZ-]#A<]/'3R3NJ'-FIHYG=:]K&.(<_, M
M8W+2XOQ5A38E44L74QB(LWBX;[22"ZU\VN;EEQNM=_L(&@G]*>0_V1ZS_BQ>
M?7:VR_&J+^(0?0L_U:J_P(/WC_\ U$^P@:"?TIY#_9'K/^+#Z[6V7XU1?Q"#
MZ$^K57^!!^\?_P"HOP^"!H(/D=IY"/N_U1JSW_\ !CZ.EO;,:55%W>00VX?0
MO#\7J9!9S(/!CQ_^S@N,^!UH%/K:60_V1JQ_BAE'3#ML-*NA[O((>5N=U!DF
MZPDNC8;\M\:]N_?UDKY^P<: SZVCD,_7DBM?0V0]CIDVX&E70_R?#]/M41\$
M+]8QGK8OS];BOD^!KH!,]SM#(7[)%:^3\[_#U](]#IFVX%OUU09?_#X?I[>[
MDL+J&E=K$!VA\@_X_P!"^3X&>@#])^0R]62:V6_B9_ [Q]^O1MU^-4'\GP_2
ML9PRC)N8C^_?KS]*]_%?A<#+0!^E#(9^O)%:/_L_X>_<??KT[=<*K#QW8?$/
M^+^KA9>/J31'^YN_A'CW%?I\#+A_G_2?D+V9(K9?]F/GUZ-N?QJ@_D^+\Y/J
M30_X-W\(_P"E=N+P/M D-7::LV_S/K\/(]=/P_J23X?CW#Z]&W7XW0?R?#]*
MC3[/X;4#=D9+8BQW97#+QNKTIG![T14@TG#LV\D]GXI.7_7G"+U;N#Z.FG;H
M6M58?<6S^IT/"^N>>JUNNZ-=F<1:YM2RN<' @[E669&_$1]ISU60('#(TG4P
MD^9VQ=+?9+8C.\JNL^7CVU&1^TA[=TV[>N;N>64 ;V8;3W'<3<^U:17?)RZ,
ML1<75=#BLA=K;%IV7_>M%O!72QP^].$=/9:HUSI3MMM]5$T^7M;/T_**JHZ5
M-L*J_75=*Z^1M11"_J^,@HM/\F;HHI1:'#,4;QSQBK<2>9+B23]*^7.'UIQ<
M/=5(NC?Q*Z)A'\ODAK=9M1BM=?RET#][6T(;?7\%PMKPR5K%\G_HXAMU=#B0
ML;C]E)SR[.Q<"N'CIL7\:D74?3^FF9W?\"-8JX(*V_7Q-=>_HND;KEP?EV6T
M4]G0CL''Z-+B(_VC,?>WX"ZZN'1IH7\:D7:?]]<O_$C7ZC9+ ZJ_74KS?+*>
M86[O/\?<I3.A[8MGHT^(#._[?D_-777PWM,2SW51KM,SZ[79,+?Y&2_@%#4=
M%VQM3?KL/F=?6U94-_FO%OCBI3>BK9)FD5?PUK7G33[Q</V-C2__ .1KO_PN
MFE\S)" >AS84_P!X5@[L2J_GD/BLHZ,-E0;]56GOK'?F7]1"[K'#FTR1S(T4
M2ZSVZ=J[9YE\A((NO/Q/OY<A#EZ#NC^;TJ+$!^3B=2.?:>?NXYJ;#T?;-0$%
ME/4$BUMZJD-K>I5R+H'TZQ#(V:)<A;=.U<\]7T?EW"JG^3MT:5%^MHL6-^ Q
MBJ;X9<%;P;,X13VZJ"06TO-(?'7L5?C:+,$Q-O(4BO)V/<B.X9JOEW+<_:8I
MZCY+/1'4WZW#\:-P1ECE6->[XYJX@IH:>W5, L;BY)S'.Y5>8TH8=C&1MTRL
M\N9=JN3#+Z!3S?(\Z$JB_6X3CAOK;:"N'NY<%;18C4PVZLQBW-@/9Q/ :?2J
MRQIMQ;',C:I]53MXUB4?S\_D%<[Y$_0*\W=@N.W/'^V3$1_Q64]FT>*,MNR1
M9<X6'UKOIT_XY3R*'5"(^O\ XT?/YTCX[Y$W0(YCHS@N.ECA8C^V*OS&NM[Z
MYWNLK=JL7:;B2&XT/4MN/:NF_IPQ?(W\K3ZF>^^^U6DEU]73V;",SY#?R?H[
M[F!X^VYOEM+B.OBXJ=%MWM##]KG@%M/UNPGVWOXWRRT5+=TLXA>,S73*OS/<
MR*MS"+Y-]A*9\BGH&:&[N#8\,A_[Q5Q]5[D>'AQO.CZ2]JXO0JJ896_:<-_7
M:ZISND/"CV_;H]8/?KM79I>CQ\.[IZ!)9\C3H/9Z.%X^/_N&LX?ZME+CZ6=L
MXO0K*0:9^10\-.2ISFB_!#NY+HE;Y[]+AGEU_NOP=/0)+?D?]"S+6P['\K?]
MOU?#N:+^*F1]-&WD9NVNH_'#X#\WMU727H@P"X6RJ)7C+K_-)4?_ .AG;\D?
MH::;C#L<_EVJ_-4D=.72"W2OH!_LVG/O!]2ZB]">GA?QJ!7C]5RU(OF47X=Q
MF'R3NAYNE!CHX_=VJ/O;DL[>GOI&;I7X?_)=+]'QW+B/09IU/^@-P%Z"NBI[
M?\\>Q\E+HA']X8X>_'*H_P#"L@^4!TD#,5^&_P DTGJ]'WKB/0/IR4>YT"X?
M'E=%3+YE=_Y=X]#Y*G1$-*#&_P"7*KAWM7O]4'TE?NAAW\DTGYJIDKAWZ9)B
MC4_;EQJ-74TW954;_P#%66_M_$)47R8.BF$ ,HL;%N>-U)][?BY6=GRB^D^,
M6;B.&96M?"*0V(Y>;DK=E<,?2;+4:GK7N@S/KV;RK">OJ6+*+Y.W1K" &4N,
M #2^+SG33,LODI<?RF>E>/T<4PSQP>C/S?'>J'(X4VCJ49F]:=VJWZ[7O6D_
M,OU?(0GQ]!'1_';<IL5%B#]U9^&G!26_*CZ7&>CBF$C_ &+2'WA4=WA$Z*GC
M,UVC>6Y^%^5POP$O83&="VP[  V#$\N>)3'WA2!\JSIA&F*8/_(=&??\<-%3
M7>#IH?>W[=GWJ>^_3(%=[_[HQ)9T0;&1^C!B/CB,QY=G8LH^5ETR  ?53!LL
MQ? Z/XS_ *K+H+X,.A5S?M6=?&Q[\BR%72+GZ"/G[?Q"0WHIV0;:T%?EI^R$
MV2]CY6W3*+6Q3!1;3]@J/Z5U3X*N@Y76S+Y[^F0ZZ74MO$9!T7;)BWV&O-N!
MQ"<_';SXKU^JWZ9N.)X*>_ Z7\Y<!\$[089;'9M^>S(E<(>QT8[*#^X5I[Z^
M<_.OGZK?IE_=+!/Y"I/SE\?82M!7Z3K]_9&KH^_6RV5O^UZSN\NFM[_T)^JW
MZ9?W2P0_["I?F<%\GP2=!1];/O[]D:N>&W@/OUM-E?Q>K_CLR^_JM^F0ZXA@
M7\A4WY_Q<K\^PD:"OTH7_OX_7&KGXO8'UM-E?Q:K_CLWTKY^JVZ8_P!T,"_D
M*E_/5.F\#+A^5#M>=67D%?:VWVR7<*.GZDRV]@SQ='>S,/H4]5XUDQY]O:J^
MK^5'TLUI)GKL%).N[@E,WA;\(^-]>*M.7[G\X;,[?SG'N0W-^OYJ=T)_ ETB
M_%W<A-9L7@,=MVGFR%LZB4]]\^/%:]4]/G2-57ZVNPW/7=PNF;V<%17?<[G#
M$>YN8UR(9^/UV+L(_E*0)\>SN%Q6W(I&VM;[*_*WC[_!4%3TL;9U=Q-64A!O
M<-H8&WOGG8=I_K5/<]SD\+IWX^,\C'UZ9;NTNNY?[?W$9[> F,PND9HQ]^9>
M[G?WJDFVWQ^>_63P&Y)-J:,&Y[;7TRU765[F]X62]^UC'(Y[EL?YKEW<_P#Y
M_P#F] SBC@;HTC_6=]/O]RK)=H,3F].6,]T,8]PNN _<VO"N5OOB_)'/O++M
MW%\SY?EL,HBC&C0/$_3V*&_$JI_I.9X,:/CLY+X_T-CPK#/<\89)/_WO7?\
MX_<>@UHX?/[U'=4RNX@&][@9^V^2_#]S8<*H]_S+LD<^_P"N]=^__2!Z6/K'
M_A%=B'[FZX6$"9#GQL89'3(@RXTV.H\N7<I*7XCR'V5*2;^RDDXVDU(/DHB[
M/0]@3K'G(N)'(V(]JG;B16846-#CD:6(D=F*PE2C4I+,=M+39&H^:C)"$D:C
(YF?,P7A?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g80783g77t73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g77t73.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1DB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &0:^9 8X0DE-! 0      &$< 5H  QLE1QP"   "ZV < E  "')R,3DU
M-C<V' (% $!-:6-R;W-O9G0@5V]R9" M(#@P-S@S7U!R;VIE8W0@0WEC;&]N
M92 M($1R869T(%)E9VES=')A=&EO;B!3=&%T #A"24T$)0      $((?'.3T
M2+Q@LIM#V;WS7MTX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              $A   #C0         !
M      $              XT   $A                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     <X0DE-! P     #H4    !    H
M #,   '@  !?H   #FD &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MY?V/%%U5Q8;&-O:UFP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MG=P24\Y1HVX;#TS61<&]'(6F*N=<FP;"?@OJXB+B[.Q*L0G'/@F5"*" B'C
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M&8N;!8%D$D96ZW&0(FI8[?-&3#\-]+.R "*(G.2-BV\?$-1!G'MR%5<&WO\
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M?_X:]],0VX#<754S+A S6(H2?>I=QO!]+U^Y,6$:L<G($\PL[)*$*;@3"03
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M]2+8#&XVQ[&R&\K;:R?Q]'J;)\S<Y>I:+AH\:P+!!RV72/+@=)=!9,Z2J9@
MQ#D,4P (:5>) _'/@?#K]/&JX_7+^GM_?I[9_P#SBI'_ -QI4<P\_#/0]/I5
MW-+NU0R/5(&]4&RPEQIEHCD9:N6BMR+67@IR+<<^"0BY-DHLU>M%NTWC705.
MF?@>TP\:55UK!A\2+^+G+]O&,_Z/MVE4M]T^_&HM70__ !H^U/\ Z]R!_P"T
ME^TJVO4>_ _Q[WJ5OUD>DK![Y*,ZS'A^,CX;=31(4Q8Y0O@8-,O5V-3453I-
MA<&\:!; W3[R4V?=G(5!8Q(.4<)Q#A!U$*ND9! \?W_"H-N&<R9QV8YXB<C8
M^D)K'&7,76%VP?QLFT<M%2.&3D[&P4^W0;CP&=Q;X$EXN=A7Q"@H3O /"Y21
M725;!(/Q;9WSU./GN<9 V_3QV+'3BZB.*>H9A=O>*FHUKF3:PDRC<MXN6=E5
ME*?/+)B";]@"@E6DZ?.F26<UZ:(0Q3%*O&/A1EH]ZW(JX"#[]<?3UK(=I4UA
MIZNFP2:W4TF RKBR*+*Y>QDP<QJT"D)2/;K25EU7RD3'"80(K-PD@LXD(AJ8
MQ/7(OI1FF8[M1DB?<G9'QW;<,7UQI.KRF'1]4=9%N6WCL;Y5$8FEZD03QA8Y
M7 (C*1.0%#L-><?<,W&L6T6H:<ADU"Q1D:%3A[FV)+E(]\&6)BS1CJZO(BY9
ME%1!)O&<_&2[FOR,#*L9UL[,P<0KV-=MY9!Z504SLUF"J)'9'(*@*9FYT04[
M_P #M P#QUU'+;RPK<Q7$4ENRB19XY$:%HSOSK*K%"F-PX/+C)SC<:'6YECD
M,#HZS*_(\3(RRJX..4QD!P^<;8YL_"1S9J6?T5-C]LVU8VNN7\HPCJMY!S(6
M):15:D4C(2U>H4,*SMC]+M%4TUX^4GY)VH_6CEN5FT>RB3."(NU7#=#DGMDX
MRM.(-3M-(TN:.YT_1^]:6ZB(:*XOY@JR"%QE9(K>->[$BDJ\C2\A*!6._. M
M&NM/L9+Z^B:&YO@G=PN")([9<LID4@%'E9BW(V&50O, Q*C.%K2]9_32E-*4
MTI7QR$>PEF+N,E6322C7[=5J^8/VR+QD\;+%$BS=TU<$40<(*D$2J)+)G3.4
M1 Q1 >-6YH8;B)X)XHYX95*2PS(LD4B,,,CQN&1U8$@JP((V(J];W-Q9SQ75
MI/-:W-O(LL%Q;RO!/#*ARDD,T;))'(K8*NC*RG!!!J,AN>ZDF8<09\L./-K(
MXJQABO$%UD*XXH2M%K[:*R&_A'96]G<RSE!)F\BV<A)(O&<<XJJ\:Y19HI/7
M1W3Q0R2/-NK=JSZ-K]UH_#-EI%MHVCWDUE+9QV\=L;F>WD,5U(C18AC7O4DC
M1%CC+<JN\ZEB!^@_ O8#H/%'!EAQ'VEKQ1Q/Q%Q7HUOJ2Z\-;OYKS0H;V,RZ
M8ENLKSQ74D%J\,T\>HI-'))*T$7=1*',D+&-X9Y-QO0,CQS=1FPOM,K-Q9M%
M3E45:MK)#,IA%LHH7@JAT"/ 2,H4 *<2"8  !XUT787:7]E9WT0*QWEK!=1J
MV.8)<1)*H."1D*X!P2,]*X)X@TB;A_7=:T*X=9)]&U74-*FD4$+))I]W+:O(
MH))"NT18 DD @$U7.OKKR*\%4DUDU$5DR*HJD.DJDJ0JB:J:A1*=-0A@$IR'
M*(E.0P"4Q1$! 0$0TIUK 1O)^'IVC[CIJ6O>().5VS7Z666>2#6GQ;.:QC*/
MUA,=5VK0G"\<,&NLJ(&5"K34/&!^&I]#G74.L*J2H/I[_7UZ[UA-NWPR>]R%
M>KEI63]OUVC"G,#5RZL%QJLDJG_%,XCWE,D&C=0?XR:<LZ*'U*F^I5/(?F.F
MQQMGU'X_/Y9-+PWPTW4#D')4I.S;=X! 3 !G3N_VA\!2_68$8R@NU3<?V/!1
M'2G(<[G.W7/CY;^8\:DX=(GIZ9 Z=.$L@XUR'D.IW^6OF0T[V12GL)=K%0@_
M<W$0"[$'4TFU=2*BHQ22WG".8E(7@GC.(\E56!@8V^F/W-99-*FO!4HG24('
MS.F<H#\O<Q1 /?\ ..E*@QS?PSV^62FI>11R9MM(C(2C]ZD12VW\%").G:JY
M"G N-3% Y2* !N!$ , \"(>^E4%,^/A@9_GY]?3H!4R;:UC"?PIMLP+A^U.H
MM[9<7XBQ_0IYY"+.7,.ZEZK6(V%D%XQP\:L72S%5RS4.U5<,VJQT1(91!(PB
M0%5#H,^5=\Z5--*4TI40??KT#=WFZ'=_GC/M#OV!XJH9.N86&!C[-9;HTGFS
M((:*C_')MHZA2;)%QYF*INQN_=)^,Q!\O<(E*JDJ"2>OIT'\UG5Z4NT')&QW
M:% 8#RM,5&<MT5=KO8UY"D/Y21@3L;))IO6*:3F8AX-Z+E),IBN2&8%3(?CQ
MJJ /(*E1@8]_M62/2IJB<EUQ]<<<9 J,8HV1DK52;77(]5Z=1-FD^G()_&-%
M':B*2ZJ;8CATF9<Z2"RA4@.8B2A@ @J'H?"H07[&2WU#[CD[;5[^_P#7;D'_
M &::>7I5 3U.-QY['\-OE@_.G[&1WU?RG;:O\K<@_P"S32G(/$_MOGP_BG[&
M1WU?RG;:O\K<@_[--*<@\S4PW9'A.T[;]I> <$W=["R5MQ;CF%J,^^KCAV[@
MG4C&@J"RT6Y?L8UXLT-WAXSN6#54??N1+]:J@, #R&*MJZMFS#)V^_:@&#,2
MS5-@;6&3*?<1?7I_+1T']&0#6=0>(@XAH:=>>L4-)H"W3]#X3%*J)UDQ*4#J
M$9&//W[]FL,/3GZ$.[3:/O-PGN&R+>\&3%,QS)VAY-QU3L=R>V!PE-4:SUIJ
M$<UDZ+$L5CD?3+518J\@V K8BQR&.H4B2BJ0I!!ST)_3]3^WCX2V=*KJ/QU:
M^B9%[X;%'9PV_2=.QKN!5691M]/9C/XVFY(@VZ MFTQ,+P<1+OFETA44VK-"
M4)'KIS$0DFPDA(HP8.2*@C.>F_7;?T^E8XMJ?0ZZI.S?-%8SAA;-NVV'LT K
MZ>2C'%OR.I 7"N.%43RU2M4>ECE()*"EB(I@LD)R.&;I)K)QR[238LW:"H"\
MO3I^?AX^F^!CQJ857%Y]U 0SBU1T;$65:,9J3\9#22\S$,)<R!!D&L9*N8^*
M<R+!%UY"-'CB,8+KH FHLS;J&,D555<UI2N ?0E9([-8Y"'A!D&"*BPS;F-8
MG?M$$2&44.6040%RD1,A3"/:J  4!U>%S<+$T*W$RP-NT(ED$1\R8^;D/K\.
M_C5EXK<,9WBB#H"3*T:<ZJ 23SE>8 #<[U$!W(=3'<_FK*$Y,8[RG<,4XR9R
MKI&B5:BR:M;5&#;K')'RMDE(P492:F91L5)[((.WRL0S45])',DTT3+N<9NM
M4<,W=-R(NPV4L2,[G((\.@V QG.Y.@-5XOU;4[M[B#4+NQL^8FTM;*=[4+!G
M_P")II("DD\LB8=^]<Q*S%8XU5<F_GI[]5VUS^4JEMLW.33>>D;PDFRQ[E)9
MLQCY,+&JJ+>,JMT(Q29Q[HL\9,6D#.)-$7QI8$F4J+WZ03?-*+'6UDG6VN64
M-(P2*3IESL$<   L<!2!]X@'KD>SPMVD,FM67#>NS]^VH1\MCJ#A1*ER7Y(;
M2[**BL+D K;SE1(9@(Y3(95=)$FLCK=E-*52MWNE;QU4K!>+?))Q-;K,:XE9
M9^J4ZGA;-R\]J2*0&6<N7"@IMFC1 AW#MTLBV03.LJ0H^=J^K:?H6F7VL:M=
M1V6G:=;R75Y=2G"10QC))ZEF8X1$4%Y'940%F /IZ+HVH\0ZK8:)I%L]WJ6I
MW,=K:6Z%5+RR'JSL0D<4:AI)I9"L<42/+(RHC$8]L9]4_;[D*^,J/)PMYQZE
M,R*<5"6BX-(-.ONGKE8K=BA).(J:D5807RYR(H+NT3LDU%$P>/&H&$P:9X9_
MJ([/^)M9BT6&34=.ENI>XL[O48(8K2YE8XCCYX;B=X&F.1']H2-,X5G5F"G?
M7$G],?'N@:)-K%M>:+K[6D#7-YIND27S7\<,:EYWMTNK&WCO!#&ID>.)Q.Z*
MYAAD*X-IF?.D98<J;@[);H&QUB*QK>[2ZM,R\=+.QL<&,T\-(3[)G$ECU&DB
MMZQ9V>)4%\BB*2J!'IDSI'.KK?B+^G_BN^X_OM3TC6-.@X6UC4Y-2NFN)9_^
M1T_[9,)[Z""V6W:*X;O7E-H3.B<K(LS(58G<W _]6>@<.]F^F:/J>D:M=<6:
M!I$6D644"6__ !>H?881;Z;/<79N%FM4^SQP+>JMO(X=': .'0+G'JE:B*75
MZY3X!N#.#JL%$UV&:@/=Z:+A6"$:P0[N [A2:MDB"80 3" B(>^NM[2UBLK2
MVLX 5@M+>&VA4G)$4$:Q1@G;)"(,GQ.]<-:GJ-UJ^I:AJM])WM[J=[=:A=R8
MQWES>3O<3N!DX#2R,0,[ X\*Y_7T5\-6$Y.W#[DZGNYQMMWJ6*,,S=/RA6K7
M>8.Z3^4[C"V)I4\;N<>L;^,G7&&,IB.1GB.[X3[E6#:==,99O'G/*24*HJ5,
M%1O_ )Z_Q^ORSOCJ!QU%K(EOUD-G++&M/FF3#*->QPL[C;O-CE%"*FL),<OR
M&3U:8>F#60H-:5>)UR:<*79O+%<JMUF<<Z,IX14SOC'G_O\ UGJ#D=*[2R[O
MKCL6[P,4[:AI[>7JEK4J4%DG)_T^1J3&EYRR2Z)X5JSB%%HH$@M=W]%D&;I4
M[YH:*^FZNH*2P3" &4S^N/?O]LT1N5ZB"NW+.63<43&-FS^O5';'(9AJUX6L
M*S1M/Y7+!9?MM>Q#+,DXMP,,E::OA>XOHFQE7= H^C%8KT(O'+ CE0G'O_.P
MV/XU4>?-[MDP_:=M,&2FT2OUC.M<:STOE;+EOM-/QA7IATXJZ++&K"T5ZBVY
MB2_3S>?>R%?3MZU5@WS>'503DE':_A04)Z>OGM^OZ=?2J]R9N1RTIN*<;:MO
M>+Z3=[94L85_+F3+-DZ_R]"JE?KUOL4Y7*E7X(:]3+O,3EIFUZQ/OU!5CV$-
M%Q[)$SE^JY>)-RJ;^_?L_/:B,@[U;)5=\55VAQU<Q@W9R],QK<GMDN5WN$39
MI5*]6>YP<A#T:NP&.[-#RLK"-*@H^(%CLM68O%'Z" O42E45(IOGP\/GO^/G
MG_/0]5YBZFSC$.7]T&*)7$Z2AL*H8\^]K97%E.VBLI2TZTQ))WVLN@+%JJP%
M@J,+EZ$GXMFB$F%@AH^:=D,U"*>@DI_CU]^_#KV/N1WE9CQ#F#)E&QOA.G9,
MK&%-M=>W,Y&<2^29"EW!]59*U9$@YB'HT<%-GH"3FXJ,Q\\EFZ,].0+:05<D
M8E=H'[5!4)]^?IZ>SO@U?/4[HUR%CBMY#I*973.[4J(N531F#*QI'#>QP;>:
M@DI4Z*+Q=@55-XU(^,DW=JM0,J*:*YB 0ZIJR+ .ZC<-D1AN=G<G8DQ%4H/;
MA.9*H+LU)R?;;7)V+(F.J_ V=RW1:S6-ZNV:U)_%38$2F3.SRI'J'B-!@@8'
M&E1Y[8P?KZUP&U#J1TC==DK$F.*7'0ZSZY;5E<^Y!482$VHKCVXH3N/X5?'9
M4Y2 BT)INF:Y/E!GFKCL$T20@-A*Z[B*9WQZ9^G^Q7/;"-[-CWE,[K,RE=Q?
M5H^MKN6K>"J5WN%HNL8X:VNRUL"72/F\=U6NQ8/TJ\:1CQKUELPF37\3L&AR
M\"H,^(\_U/[8^M=N;BMP]VQQD'#&$,/X_@L@YDS@-XDX)&Z6QW2:#6*?C:,C
M9&WV6S3L9 6F;64(K-PD7#PT- /74@]D#*KKLFC154RA]-S[\:I;*FXK-]4M
MN L$TG&.-IK<9F&F72]6%I8<@6*-Q#1('&S6N)6]PG:H^D/+99%'5AMD'"UM
MNC4(Q5RDX<2<G]')-!064ST'B?VZXZ_0^?6NAKGU*9BL;5L7[B&6#)&=L\[N
M EL"Y/Q1&6('LO4IF@R>1(W*;BH2B,6"-T<1!,;R[^J,_2Q8V1!TQ;J&CWJA
MVY%,G!.-QY_GUQD8Z=*KJ2W]&# N?=P]:H\5:J%@7/$=1Y5W%61=<)["Y4,9
MS%CRU%*IQ9TCNX6IW]U:$X+N,T>1\$J4)5)1R'C4R?EOOGR\?'P_;Y5]=_WU
MOZQA;?#G.OT",GZ9M0LKZGT]XXL;IDCE*;JU7J<I>W"CA"'>%A(>"LUG7J3=
MTS)+JNGE?EE5$43%31TIG8D8.,_I\_X_>J;MV^W(=7V;1NY>$QICW+=PF\I5
M+'=?H>*;[:GL!8ONIO,92T48FR7/'M-EQL2;EXX23C7-818+2";=NG)J(KBL
M13.Q/7?;'CO@>._Y5V3C#=W9=Q--W!67;U5:-95L86G'\7CMS<+A-5^N7F N
M6&\59@=RL[(P]5L4E6I",C\A2,02+;Q$J8TE"HH/56)G+GT:F_ABNKZAOIRP
MYV/U+>'>\1T&(-D6RX01I-+JV09^=(-.S'D.BT(DE9):4I4$:.L,,K:W[X8B
M.:2L>Y+'-4_I=,7:HME 3@;>7KY;C'\]-_2N>SKO0RU4<A;AZOA+#M,R% ;1
M,:UC)6=Y*ZY!E*5+R06BO3%W;4O&$?'5&QLY*P-Z-#'FUI2R/H>$%\_80Q3^
M7U+I!3\/+\<^6_AX_P":^K(_4"B*+EK:?64:,O(8GW+8R6R+)9*<RGH7>-VT
MY*4"M8Y&;@O2KIKQEGN62:I5))^602^@Y":8N%4UF97*R2GT/O\ &N/N>_>;
M@-D6$]S,!B]A9<L;@&>/V6-L*EM1H]M-6ZYM5IM_#%M"T6=9-C7JI%6.PNY
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MG7[V0>WI'[J57T[;):3.]D+,ZGI"YV*6GU)!P962DWYG!U"$(1(%*^+$FR[
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&*4TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g80783g90d81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g90d81.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,:^8T(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'CP           *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             ",0
M!&L          0                         !              1K   "
M,0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M,0    !29VAT;&]N9P  !&L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   C$     4F=H=&QO;F<
M  1K     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M #DE(_VC@;/4^T5[")!W#B2W_JF[4AU+IY
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( (<!$ ,!$0 "$0$#$0'_Q  >   " @,! 0$!
M        !@4' P0( 0()"O_$ & 0  (" @$"! (#!PL+#1$   ,$ @4!!@<
M$0@2$Q05,18A(@D9,D%1EM87(S4V559787&!L1@D)3=&4G5WD[;1)B<S<I&2
ME*&BIM+5\#1%1U188W:"AH>7I[6WP=3A_\0 ' $!  (# 0$!
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MG6 \(WJEK5[)JZ+5=FP7L?>T#"$[S;+:I.YC64W<)UZTZ>ERN^PV:_LD0OU
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M4HZ4HZ4KD_:>7.;-9V+9U:[B\F[4=>W90J#U.M[O5><<;C7DJU65B:NLIVC
M*IR[M[=VLI)TK/L%A4%K9&.RDAM):94E)XS(HA,A2VSN5F.T1KE !(4-<PV$
M^$O<?X26=[>-M8(K$K5IQ\,+8L\28D"XM6V$<<IEXOK2PY</W#C-L;=?%(%H
M^\I2VVG#6N3.0-NUQF^2TP5/)#D2NH,KM)[!98N=3S9K5MU95_J)4+2[59(Y
MV"VBJ5]1Y%7LP3E83D2:=5--H5E+DRVI0(*1"P"4A6W141!*3)&HW[]EC>*X
MA9*NVL-%OQ6+,6I0XW=O\HL2^AFY>9'%VKB5L%2EJ>0W=6^5EP(XTR6^=+OQ
M&>*;7Z_<+:OX#-R"U3.[LS]#ZS2.4=+?H]?I.0M>U+22TVSVU7L%5S'8[OI.
MSQY;<2U2NUBUU>HU/9M,9I'=R*.OK,!$$CF)&X^D$@^(D<QKT[*U.,M.+3E4
MMIM:DPM(2I20I2<KJ&W1!,0XVVL;%H2J4A(:\9GBQ^+W.4/!)O$J.LV&^UM0
M%@EOX+.VE4V>C*+[,NZEHE@K#5'/I!=*)N#KVG[0*F-F11^$:[MJM?%9:M;D
M#G7Q4<?[=NZ2'A_3Y/U:NO[*IT1K50[I66FR++56J;0LR\85+ME36C)6;\77
MAV;QZZA<ON$N0<#LP7V_Z1I%.IUZ[*C[KQ">)N[T7<]KT[A".E_"^=:30-,S
MO&E\P;5=;/Q7-S)+?E6TXXUW4]?WJ@4?K&ZP5.B!*Z/464;7Z2A361-(*E5E
M>>.+Q+5]ALU+3^##:=@V76M*U/:W-90>WXEDN#;>2MJTM"T89CQ9*M8JC:UJ
MOT[7H*EFQY'BC?#J;'2JY_4MTS4*4V6OB7\9B!VSH>$->U3^&;==KI9V;<E6
M@+:_D$:&CPV+CIV%AL>W"(=F(,IUZU4< ZY>5U Q+)=2O?ZJ;Q:6$3'3\(=C
MKR2?)FLZ?8&V!K>[2Q5U:QV2^CL^Y!I:#0ISNJ[5M5UAO!&M8L+Y6WN=EU-V
MAS:IMXK6E*_1SI2CI2DOD.TV*ETV[M-4"L>_3$K- +=/?WX2>=]034,5&L+M
M7;A\I39]KA4$Q!:]%A[,*\31(W;"2L!7L3,ZI3N,:J@;=N\C0:D5SL7?N[;#
MKE^Q2A=TVE!:2NWNKH&76TK M[)#ERXOBROBPA!2ES*MV&4N$<R,^(;F.I.!
M&VX.L,';+9+5[<UML0%96 KB]%4U*Z:6O;*/W[]+5+,FRO;O  5F5B.9M?$:
MR!M"W95L?&@!.J#&B9,DI,23KE$ 0>ZT/B5\+N$-NI#5QP9=SN+?;:<*;UH/
M.IN+I+#"&V[2\3QKMNPA:LMPXE*UEU)7:I4ZB7Y=Y7Y]UY'DQ;B#C'&_[<EC
M4ZGC.BN-4VB@K'M@N"P^D#]MMKEDAIEKJ6N5S&+(]C/:=,*RY56M"KDS3="U
M9ZZD(#:5 C,9D!:3O $IT4DQ)B#I!)!D#U5K?WSN+WUHZPI-DR& PZY87UN2
MX6G'+@-W:DNV-VRDEAM#J7+=?&BX0&5H2TXY2;7C5YI0VC0D+3PK[O44&\<C
M-ZK'%A3<H?2RLUI);>M@L[B-4AQ<]476QT.@Z,#=G-7IKQKZ1CW)+6=#L]IV
M/2MX3K\5=VI#2/%%XKKK]3!K9?"%=TM7O?(.K:OL1BO[4O;\?T6S7&S9L+Z]
MI9Z24XZ[5*"OI,FMVII5C]J\<-Z73 $KBNJ5+,^(;Q2Z?MGPC;/#Q/;=9)OU
MW31V;0JCD')E>.=>LK2L=WXM0KKVWQ;LC*4@ME4TT5DK;7R>[ZW1Z%G=WM?V
MEX:E2,.8O%OM?$>B\CZ]PW2:%M-QMS\+SB?;*+;MIV>>G5^H7UL$+;I+'C3&
MAWMYM-*K0)6EE5;56()7]4\Y7%=R:M@I5=/>+_Q/+O;$_1^$7>=FUX[I9:LJ
MWKW)VIW-?4*;8CJJEE>@M>-9L,K[0"35\!"M48V[5DRXL;W5,ZFF38C*5VQP
MAOFV\D\=UNU[QHEEQOLK-ILU<]JMHM<K%7%2;':4R5@I'8JC7[PU5=)(KV]0
M[:4%&X_6NK.EJ*[W&%!*5;72E'2E'2E<^<H[_P JZEM:BVF:9C<J&=12L,)J
MZYM)GANL;0.OMY&V1?$->"/X.8$JQ%6%E9JLP>M;U1.@7@[G8:;:6DE:\BI,
M$J2!&4D=S[(]UM.@(T2<U>2QS%L<P^^;1AV'#$;55O;+6VBTO5.I<7>I9?*K
MM,6J0;=2>(;;2^\VX'7[IMNU2'*6M3YLY(VY;<%V.-V-1L->I'RQ:<J-YO8*
M;"-34WZ>KL*5?5JRS9)>);,=J*%1-^WIEZ8[S]>PB_5F=E;+:"B' L*(V%"9
M3*P2#F([DI DP%$P#((&I8<),7Q!.((5@Z[!VTMG5!Q;&)701=);L';=AVW3
M8L/*5=-7JW TP7G[=%LMUUI;3K"G:XV'GCQ/5UAHU1K_  >/8;6_>XVS?C8U
M?D2FUZCH-DK]UI-YM[#<9(6%74NZ3O0N/VV-=]O<7#.H.7SM:O;5&)[C1X7$
MI2M02<R0=#(,C=J-/D\ KTV$7-W=X=:7%^QR6\<90;E@-O-!M[*.,1Q=PD.)
M 7(@*=1IW#SR8<4D/>*;QACIA7$/!VTG!JMUFT A"YW:ZN4S/[Y=4%Y3758E
MQRN=>=;K&K-[&1ZJQ</#5W'4BBH&I"8"]2NE3ON7.OBIH:S5=OI^!$+"CN>-
M:C:=CTN:>^V>ZZ7OA=EKM>O= L6M7H;LET&N4OP7:U[K&HW)7OHE?14J6M6N
M ;MKRE9 >(KQ&;&/E-:E\-MSJ1=&X\YBMJBTV]+<;#-]R)I:E?#0]5U^A3UN
MC7WE#;7K*;,K+6-NPG9*U+2.KV-J9F;]:I58,^+;Q74U]2T.?"WMVYTJU/MV
MR['R37<9\F::C>4]3M6QU&G56K<>MXV_8:7<-WJAZNX.AVF^B[KDCV-GM*5)
M0GRY2J5W?PYN6S<A<8:7NFYZ19\<;3L-*)Z\TBY@V*RUY_U3!*FT%]-!X.9X
M%%H07$P,A"P,1X>K"4LJ59?2E'2E'2E?AYS3]T5\06@<P<C:%KZ'#\J;5MWV
MC7:B5W3WLK/-?26<DE2VC0]R11PP<>?P\"4]62[!,+!%Z.2_H7@_V+>#.*8)
MA>(W+N-IN+S#K2Z>XBXM@SQK[06M+*%6#B\H/\G.N,R1G)F/BN.=D+',-Q7$
M+-EK#BS;7S]LUGMWUNY&EE(4X4W0&H!)5E2"0>Y BJX^^>>)WS#C\/X&[D+(
M/?X?;XC"<8YGC,Y2Y"QB(28\N(,9_K?$YQ@4HY8GB'7[3W!/4E_A!&4*D/VQ
MT)C0>ILE0U[CV6F@.D\D=E'A#) M\-D&(Y+<:DG=Z[V#:I1@#<3K6NQ]U$\3
MBPIEG5<'DC#.,9BM2WS1)9R3T^T1@W^<I=OPY2CC,,#^WF7E[=2GL.\%"0.4
M8\)UUN;5.D3J3AT#3Z:MVT.$)T#.%D[O6UP)\9O/X]%1OWUCQ+?N#Q!^:NT_
MQ?DWK/\ '\OR=7[37!3W3CGGEG^[J=L[A'.MOA?F]QT_TL=&G31]]8\2W[@\
M08_]E=I_F_NZ_P#[CJ.TUP4]TXWYY9_N^A[)W",#VC"R=/T>XV^=\_3XQ1]]
M8\2W[@\0?FKM/Z==OR_C_)^7'4]IK@I[IQSSRS_=U.V=PCU];X7YN_K_ /5_
M1X8H^^L>);]P>(/R?M5VG^?^[K_<S\L_+IVFN"?NG'//+/\ =U.V=PC]SX7O
M_1W].;]+WU[]]7\2W[@\0?FKM'Z=?[O_ !=^H[37!3W5C?G=G^[Z=L[A'[GP
MO?\ H]QN_K>\[/&=FWS[ZQXEOW!X@_-7:>_^?7Y?]/?IVFN"GNG&_/+/]WT/
M9.X1[K?"S_5W_OG\>BC[ZOXE_P!P>(/S6VG].O\ M_2[37!3W5C?G=G^[Z=L
M[A'OM\+G39;7!V[^^_1KNKLKP0>-OEWQ&<M7&B[[6:*G4(:);;,$VLTMQ6O9
ML$+O7JX0R&L=DN!35DO;&E,<5X%]6$)8-B&,PSX;L@]C_ ^"V",8CAKV(KN'
M,18M%)N[AAULMNL73JB$M6C"@H*92 <Y !(*22"/7<#.&6+\(,5>LKYJR0RB
MR=N$FW9=0YQB'K= !4NX=3DAU<C*%$A)! !![8\4?(^]\3\*;3O'&E*ML6[5
MKNKIT=*U3VE^.P+=;33TS(8U%,VE9NGPD^R1<:K$)Q-"!)1(.$QR^?\  _"L
M.QK'[3#\6N%VN'NMWCEQ<(?9MBTFWLWWTJ+[Z'&FT\8VD*4M)&4D2"01[+A+
MB-YA>#W-[A[2'[MM=NAEI;3CP<4]<--%(::6AQ:LJR4A)F0-#LK\Q,>-OQV9
MQWQPY6YQY<YCC' /-F98S@GE[3_LOB$<^EG!.\)ECGOB/F[]\X^OGL?=C;9^
M$3@/.>$6!0=)D#B)V]SK'/7S <-^'9_W$CXIQ'3_ -;;/@FM"?CA^Z 1A"8^
M!$CYE^% /!?,OF'GRXSG$Y%MQ"EF,LYAG(B$QYHYSC.89C/,]KWL::@\)5")
MU_"#!-=>A@GP: \XG2I_#;AQK^0T^/",1@\QD/G0\^[?NG%_5R_=!/\ R>Q?
M_ SES_K_ *GM>=C37_:=6W_B#!=-NWUMZ=GEI^&W#GWC1/-ZE8CZ/QU>8\<W
MW0/..\?#X&7R^7!O+F?G]>/KQL'Y,]_Y/KQWZ=KWL:#;PF7MC\_X,-FT=Z[?
MDJ!PVX='_<:.G\E8B?\ [VWPZ:&C^KE^Z"?B\/8<_P#N-Y<_Z_ST/8\[&@F>
M$RN8?[08+H>8^M?JJ?PUX=:?D-.X_FG$3IS^W^+TB=E2*'C?\>I?<X>X$@MG
M"\\*9CP5R_F,F\_[%D^87)\X5AB,O6\D?6SF4,#Q^'*-5=CWL;RG)PE*AF&>
M>$&"B$;\OK=(*SIEG3:3S%^&W#D#7 A.L 83B&[G)?$#G\'2*R2\:_CZQ6+-
MXX)6]T5LX2+RX(YFP,8815]//J8MLQD:,BE*Q",YQPOD&0Y*:1 P@=C[L:E:
MD_A,K*$I,_A#@<DDKF06)"82 DQ)5FD90"1X;<.@ ?4$09U]2<0@P =#Q^IU
M,[M020)->L>-SQX1E8>VX*C.(B Q78GP/S%G+0IRS@TC2^,!]&8H]I>3T_+G
M/FA&9.T)D#L>]CCN)X2C4'C".$."@)( C*#;JD$S_*G88V@/PVX<Z_D*-X'J
M1B"C$D:D/CT [YC2?">-SQY8-"(^"Q2#E*<YDSP-S'YL/P5\V XC*Y%_6Y7<
M^F,O?,XK8R0L8$Q@<I'8^[&T:\)"#G@?[18)!05[3ZW5W01J1H"K0$C6H_#?
MAU!(P).X >I.(^ DDW V'6--T3-$_&[X\>V?2X'C^QZQ,8+P1S!C/Q*<1Y:7
MSY+F>/0%+!HP)YOM=P9S/ZR^2!V/>QO'=<)=<ZQW/"+!#W$]PK6W&I$2-QD:
M@ D>&_#B0!@:8T!)PG$!NU(BX,]ULV=R-0%:']2?#5OV[\G\*:7N_(].#7]W
MN/I&+8*5:ILJ(=:W3;;?40ELU%PRY9H&BI6+Y9 XQ,ON9%GY10E$4/CO"S#<
M/PC'[_#\+?5<X>QR15M<+>:N"ZA^RMK@KX]A"&G$E;RLBD)"<F422"H_4>#E
M_>8I@UG>W[26+QXW*7VD-.,AM;%V_;A/%.J6XA02TG,%JG-)A,Y1PMXS?&OS
M%P#S#'0]%7XSG3?0_6+S&-OI]A=MCO7=G>),Y U67]:C%),=<L0V&1@F&))3
M@5G,LC%]$X!=C_!.$V!G$L07BB7Q?75L>1/VS;*6F&K=:"I#MLZX5K4ZI(*"
MH$P"E($GQ/#'AGBV 8LFQLF[);)LV'_7#+SCA6XX\E8"FWVTY0EL$ I!F=3(
M Y2Q]T^\2\I1C%;@;/G[_:^![3".,8QG.<RR7=1YCVQC'U2QB4N^,#Q//?M[
M;M/<%!,OX_XKFT/R8>9_@?#7DAV4.$6I-MAJ8C;;/[_!>GKIMTK69^ZC^)98
M.#?#^#V.\HQ]);7MJ(;'?&,^;(Y;M#.,1[]I=\XSC.,]L9[=2GL.<%%&./QT
M1O5=68'@'K#K\H=E#A$3')L.&^56MP!Y>6'7HJ/^^K^)?Y_ >(/S5VG^;^[K
MJW::X*;[G&_/+/\ =QJ>V?PB]SX7YN_,Z3IRN:/OJ_B7_'0<08[?/_4KM/U?
MD_NZ_I[?Q=^G::X*>ZL;\\L_W?\ ZT/9/X0[F,+/-ZV?UC?I>'Z^BC[ZOXE_
MW!X@_)^U7:?G^3]O73M-<%/=.-^>6?[OIVS^$7_L,+U_H[_1J8N]G3Y8FC[Z
MMXE_Q4'$/X_[E=I^?Y/V]=3VFN"GNG&^CUY9_)ZGR?#I4=L_A%O8PO<>]W]G
M/WW'E/-1]]7\2_U?V X@_ESJNT_7V^><=MZ^O^/Y=1VFN"GNG&_.[/\ =]3V
MS^$4D<1A>G]'N/$#Z[TG2/)MTH^^K^)?]P.(/R_M5VGY?CS^WK\7_;MT[37!
M3W3C?GEG\GJ?]51VS^$4^T87S:VSXUW 'ED?+IJ*/OJ_B7[?L!Q#\OWJ[3^G
M6,?7_-U)[#7!3W3C<<W++,__ *_3QU/;/X13 8POS=_[WY8F*M+A#[I'X@.1
M>8>,M"OZ7B\%+N&[ZYKEL6LUO8UK$2%M9KILS289W%P 68A+/(2&48'&>,2D
M&>,9CGC\(>Q3P:PK \7Q*VN,74_8X?=73*7;JU6T7&65.(#B46*%*02 %!*T
M&)[H5T\%[(>.XCBV&V+S.'!B[O+=AU3;#Z7 AUQ*%9"JZ4 H Z$I4 =H.RK=
MVC[G]PUR;R'O_(NV\G[1KEIN^_<@W5@AVXQE5J91WO9Z5<*&-FJ+"[%$T*F3
M!"1"14TX'')C/I9$+S#'93Q7 ['#<'M\-L'FK'"L+;;>==OD.+#F'VKRBXEB
MY:02"XI*2 ,H@C62?0N\ K#%[J^Q)Z]NVG+K$,1SMM(8*4<5?7#2<I<0HZAL
M$S.I.Z(U*_[DUP7<X8=J.9=SLPR]%4Q:Y#C)]415P"S&,< U<RZS$Q2&8_I8
M&0_JQ,?!,SC+K8'9LQH #U'PR 3_ -OB,G,22%'E4J G3,3EV"!I6+M789OQ
M*]G34-VXB-!$(YH\,3M)G</]R X@8]/U.5N1XX'F4HX!3\>*XSF6,XSZGM=3
M#ZL>V<]H%\\(9[9A&.<8SB1V;<:$D8/ADF-2]B"CILC-<F.DB">>I[5^%Q'J
MC>CP(8&W:)RS'16H3[CGPR27FERQRCC/;&.PUM+#'ZOQ^0.N0AC/U_7G$<9S
MU;MWXYK^1L*UYUWI\IY1)'0?JBH[%N%B8Q&^U,ZH8/RH.G17Q]YOX7_A9Y5^
MKY?K>G_5_P W^G;PQS7\C83K_P ][Z?7&M3VKL+]\;W]G;_Y*\^\W\+_ ,+/
M*G^3T_\ '\_[G^I[>&.>\V$[OY=[N_K'DYJ=J[#/?&]_9V_^2O?O-_"_\+/*
MOR[?['I_R_)^U_Y=1V\,<]YL)VS[.]V\_M^WIIVKL,]\;W]G;_Y*/O-_#'\+
M/*OU_/\ 6]0^O_F_T[=^.>\V$Z;.[O=/!^/IVKL,]\;W]G;_ .2C[S?PO_"S
MRK_D]/\ T?ZGMX8Y[S83_P!=[]O3M787[XWO[.W_ ,E'WF_A?^%GE7_)Z?\
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M#I)T \M0(D^ 2--NNWIYZCMP-60H;XJ]+7"J<TDBI7(UJYE6S;L5;M=BOPC
MJQ8D0RJH8YFR 7SFQ!Z69E2:B/*ML(0G,N'2XXA;)2H*0E"4%"RH@)4',ZPD
M))*>+450%(*@,DZ:1[+3778(,Z>"-><$4AQV#2F]K@>O:J<RMLQLJ>$%HKMM
MJ4]5O.+$ZJQ0":[HG]ODT/2B49(0SB'<?>.+KUZ^&K5:%3:Z:NA0XNW:)*QV
MAZTC2AOS4RMO=LYL&32"L&<A_$'HB**3 T8E[9)'.(XC.&,X';FV96TV]<,M
M.7"E(8;==;;6^L1*&DJ4"XH2)2@*4 1(UK&MYII2$N.MMJ=.5M*UI25JD"$
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MHP'"QLI3R7T\EQ&6,5F<PQF.(YS.6/+'$X9S^%'O9*%*!(&@25$[H&\'?O\
M#!YJ@F!\@Y^O\*5.#Y>;CT,NW;S;ARAGM\^W?D_<?Q_5UTL7[Z8^"<!^8\.K
MGX7WL]\)XU\\7]+.WZAKFYVF_P!;LU17W*@++165PV(ERB Q.O(G)@>&JB\!
M@V%FF!0]2M)"6"RA(Z>)9<!CN9]3\,C^=>S^U161GOR^\%K_ ':Z7-9X/X6
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M;6_63I2CI2O,_+^>/]..E*\G^!+_ &LOZ,]*5]=*4=*4=*4=*4C6W]L'3?\
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7.E*.E*.E*.E*.E*.E*.E*.E*.E*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g80783g98d25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80783g98d25.jpg
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M 0$! 0$! 0$! 0$!_\  $0@! @)= P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M           )"@<( P8"!0L$ ?_$ &$0   & @$! 0H%#0L%# L   (#! 4&
M!P !" D1$A,4&2$W.%AWMA46F+72%Q@Q,C-R<Y:7L;*WUB(Y05%65V%T=M77
M)3:5N-0C)"="4E5B<7B!D? *-4938V1E=8*AM/_$ !X! 0 " @,! 0$
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M'N9M/876[*GD<]D[-$F%5(XA$4[N^K26] ;)9]*V:#0QE"H/$$OPZ1RZ0LC
MV%;WKOS@Y)BM["$6Q!"U]G&OP)=?D.VX P!@# & , 8 P!@# & , 8 P!@#
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M1(W0Q(G&XI$:X:<U:D3+1%[4D)59J1(8J3E&@*4#2IQF@&(DO80/W8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MQ-A^CJK:G6:=)Q&[8,69AK,;_P#Y=CG1UV;T-<\MIK,\]3+B(U&#*2SI\?\
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M$7+8MU3C2^W:O)MWL\R17!Q& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :B\^?0MY.>QN:_-1V;
MAH_W;86YZD?/-.AQ1N=K/-\Q\Q2B#E^"LHP!@# +2700\Q]Y^U9J]T&_*J]4
M!V]H/-,;ID0FK1?VMJ7?S.CL)YL@$DX8 P!@$:2KA=8)U2OW&@+[#=U&_P#,
M)?R9.L(QV??JEIXZ]\N]<U7B%:B?Q7&R*)&&P#EU;M,T,G0-HH<8@F)K2HD3
M;\ +!ROG??M;BR;JHOP;V>S?OE@B*=.BY8PTPM,S+:6B$D@$%X=P*)3B+ODE
M^&8T5Q^Y'7+8]G2AB2"K!N*0N%G599X8U\"!6[3+'%7(XS(7A1&U0W=R!53/
ME<OPIE\!EFG>$4Z8910DCLN.52+4"<'U_M1O:+6M>QVV9V$D@U?1N(6M'6J>
M0ME;&1\4/T!:9.X1PM,D%''IO22,4TGLF4FN:4+I94SWD3B2ZJJ+\/AX"3./
M,#1%&!DB\?1A;F&.-+<Q,C> T\\M TM*0E W(BSE1IZDPM*C3DD%C/.--V L
M.QF#%VBV.)[C & , T1Y,<_Z>X]F+HTA,W8UE)N[*,B,?6DEHF55K6]:+E<@
M[VJ3-!@=ZWWQL2IW)Z +O>E+<D(. JU)6#]%]?Q4D.;B)[4TA]G)/S4-RQ)A
MB[\E*W8^814M:,]T*77/4BO<U6$<XMTET+"ZQ)2&OMI5F719&5B-2'+OX)V9
ML]D!46]X+&Q9A,M>$QKD>0=W3SNY'76:K2N,U4PR+J-C""(P$Q3'&S:<6]Z[
MRXKR% WUZ",'<Z/*='10A&8'9A"%-H7>]6/P]HSPEAUK'PJ<RHSK;*L]5$9-
MQ4>GYT*$YB2TNJ+?5=!@MB(F3HCMI7BOZ1\55]SV1*@^GR;[HDC35?*PM1?S
M8L5KEF9A%2VLV-&=#54NV&V]C3H0A"$(0A;$(6]B$(6][$(6]]NQ"WOMWO>]
M[WO>][[=[\N\W]$1$1$1$1$LB)DB(FQ$3>1#1%55555;JN:JNU5X5/Y@&'^8
M'GH)]C_'+_5[K'.HPWVNF.?<3_\ 4E5)=B?[FG<R4#Z$IYJ_G?GY&5JJO.XJ
M/> OU1V5,*_<>^@-/W&WM8B0N&R^SN2WAHT8-H>D_DUVI'9"M2B[D/=DB[-=
MG556A4>N0?8]7ILG4(2(J-29@,B/AWVK!BV2+ =_C@O8_@<?;)5&?IT3KLC-
MQY5]T55@Q'-:^V]$9?4B-_PQ&N;Q$Z/%?KD.R90VQ/EG%B7%",12;ZK$!;@I
M7)+V]R#PN50@G>D2\KNA".5KXD)N-3D%Z CBK@<+(*Q5H,@O;$F\)32PHB:S
MO:FH15?"?M74E)YR+$AK:S60YSKJ.<MXDW#:2/1=(T1JL@5R"D1JV3V=+,1K
MV[$UH\LEF/3:KG0-141$1L!ZK<L.U]8L%M:)M,ZK>5LDTB+X3W]L?F!<4N0J
M-!\AI Q%[[XE6I3.TA<WJRR%Z!2$Q,M3$*"QE!KM4:;/TF;C2%2E(\E.0':L
M67F&*Q[;[')?)\-Z>ZAQ&*Z'$:J.8YS515E25FY:=@0YF4CPYB!$2[(L)R.:
MO"BVS:YJY/8Y$>QR*US4<BH=TSXCZ#\JY64WHE:\\!YA*)*H5F@2ICUBH928
MH9Q@$R1,6:I5'B"#>B4Z<HPXXS82R@#&((=@=(JBTH3=E95]<%;NJAZKZTX?
M'I]!'I8T/,>4/D1EC4F?(X\Z9)$@:GUN*=F=8E<4Z9U;4*X"906(]*2/>P:&
M514547:BV7E0Z/5W).J+B?E<=@SH]K%I$"AMJ(5CE%)(R,4CK2PRU)T'G$4D
M3JVI6.3,$C)1*Q)SF=>K5-QR52@?$K4YISD18*BIMXT^#:9?D3#'94R.T8EC
M,RR2./K>J;7R/2)N0O#(\-2HO9*U [-+D2H0.#>I)'LI4E6)SDQQ8]@-+$$6
M];&#JT=JBJ(8]ER2)UM7D4D9,=!$BGZ.PZ-L3V5$B' 3J7&2W1M;DJX$=)=#
MQ.0&4)^FPMP.$L"F"I,V8(#M[L^,K"G+6/;LVM"4YR9&8I2YK4R$@UWDKPBC
MT=:RS5)A8!N#Z_.3<RLZ,(MJ')U7)$"0LY4H**&!QLCVF?40ER=*ZH"PNKZT
M:3OC2X,2XP^/O3DQJ5)*!U3I59K:N.:SW!D<@%;1/;&>@?&PY2V+TBDT#V^A
M!WO>M"UO8=]@M:WK>P[[.WLWK7V-]F];[-_P8!_< 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -1>?/H
M6\G/8W-?FH[-PT?[ML+<]2/GFG0XHW.UGF^8^8I1!R_!648 P!@%I+H(>8^\
M_:LU>Z#?E5>J [>T'FF-TR(35HO[6U+OYG1V$\V0"2<, 8!IIR4E%Y0NR:%D
MD5<5R:B-6) H5;*&%2&#I9ZM>[6LB)U]"%+M&)]2T^)D-8(GIW2(YEN#674,
M^:65Y?)"TN3^:PI&S!E+67AWMN]R+_!4X>+DKJ1VA"7SD5(IK9SM=%71B*,4
MC@VU\=@+%)RIM%T<Y4W7'(4F@D>CP'6LD02:Z:H8?*!2:7H)I]4!D>9@_)43
M2:4"VRLEES\*;WAVWV)LR3,ZBCDMXRQ/Q/GK'<O@#C-DM>3&T:N(CM>;K157
MTO85KU-5SL]N<:4V*A/;W)W:8I4!\:E[*H7O22/IY2V3!(*:/10+9%5."_+Q
M<7_=>(P\T6+S'94UFQV?/ZE+*8)/6Z:V7+&)_J*8P"+T)):RM>2Q1?2J]71U
M4.Z DFRHK'(S/XA:,9N*S(S!@JET;D<[6O['+ !E\GP+QYYY<%L]Y#O\;Y3R
M<-#OMHG@F;L[PJSHZ6^)I4R0AK32&)R"^WFDWZ)1M+%MZ<E2N%B8I,WM3ZK;
MV#4QG<<;W]E6OE<R!*4K!$2]KIO^3*^6_P##R*2+X,'\$(( B&,00 "'8A"%
MO00A"'7:(0A;[-:#K6M[WO>]:UK7;OR81%5;(EU7)$3:J\ 541%55LB9JJ[$
M3A4@LYO=1E<O5/%1\>7H2-J($>VRNT6L[85CH:'8B5;3"%A>]"2-I>^Z*4RA
M.+2MP,T+X"-3("RW-TLGHYT30X;)>NXJETB1G(V+(T6,V\."U;.9'J4-<HD5
M<G,DG)UN$VRS*/B.6#!KII"TJ1(CX]$PO,+#@M5T*=K$%UGQ7)=KX%/>GX$)
M,VOG&KKQ%O[&5L-$C1871C&8,9A@Q&&&"$,8QBV(8QBWL0AC$+>Q"$(6][$+
M>][WO>][WO>\L(B(B(B(B(B(B(B61$3)$1$R1$3)$380&JJJJJJJJJJJJJW5
M57-555S557-57:>.9,# & 8?Y@>>@GV/\<O]7NL<ZC#?:Z8Y]Q/_ -254EV)
M_N:=S)0/H2GFK^=^?D, 8!MEQ,YE7)P^FY<FKEW&MC3BI3[F==.R@\<3F"(O
M>@"TK2AV+X->B">Z"UR-  #DWC["C-K&PU:V+-3Q;@RC8QD5E:E!1DS#:[V%
M48+6^RY)[L[L<MNN07.LL66B+UJ(F::D1&16=W1*_4*#,)&E(FM"<J>R)2(J
M]8F&IO.;GJ1$3\",Q-=BY>Z8KF.N;<6^4M7<M:P0656C@+7<B+02J*+S"=2*
M%R#O6C#V9Z3%"WK81:[HYL<R=;0NZ+N524>AA4)T],,585JF$:I$IE3AHMT6
M)*3<-%]CSLOK6;&@N78J?@Q83O[2"_W+D5%8YT_46M25=DVS<FY45+-CP'JG
M79:+:ZPXB)EGM8]/<Q&^Z3.Z)L&Y!5C;EX$!2<Y<-$J C)6*#4B0U6(@S2<M
M4J)2KCDR<9VP!.4%(E9A)>Q& 2GB#HH>M';D0M.=..=UL7QG4O2RH7][H*F>
M$E/JG8 7GPQZ1\8:[OVN;#<&Q:KAXU3:DM=EMIA1&LI@C2MM#$K9WQ8XI0HN
MZ')77O\ XE<JIMVJB_"EMMCWL*X$VE!(32L0:U=*+$==<<.)M%2UM6)WP+7*
M%=!320R"92-J!J)&D-2F7%OI;PUKES6ZN"9X2JT9G@2]>CFC*,*M_A5>2]O)
M;B_@=+BO3.FI## TL],I69OT<50?4G>'4AW>3Y<SQ;IY/W#US9EZQYA1JQ2A
M?;.41BX3TKAM6E[8\A$H)42%N;EY8SK;;99*FWA=?_0XU_3(F;ZRR<B2JZ;?
MY)*D\J2N4C=DKJZ+U"=\X 5'Q12I5JU=$#5R]-JW:RW="HH\W191ZEO6%%J)
M,C\.P-;)$XK?_+6O\O$=FEO F[II+?C-(GJEG8LF2U_)5*$XV3E$3$5:\C^)
M=\,".6E'P]Q\(<5+/0\]KUPE*\Z2+@?'8M_0MR=B7&U_'P142]\]MO"U4\JH
MO@.TH. U@;3R=N<YM$0-\LDED/#6-!IW&OI55)>;]I\L8],ZA/-:4X44T''K
M-1062:[&-()UK&O7HE<XM3>:Q!PB6^7Y55?XB_KPY(F?R\.VW&9;X=\2)!QI
ME$N>G V!:12^IZTA;BGAA:Y,:KED#MGDG-U,D<0'L322OVY1>ZXM&REQXA.9
M 83I(;HUN^#=)<A5O9,\N%>)$M\B\M]B&_&#B, 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&HO/GT+>3G
ML;FOS4=FX:/]VV%N>I'SS3H<4;G:SS?,?,4H@Y?@K*, 8 P"TET$/,?>?M6:
MO=!ORJO5 =O:#S3&Z9$)JT7]K:EW\SH[">;(!).& , ZFH@,%5R]/82J%Q)3
M/DC20P))PHCC.=+TK$E4.2M,RIY*8C$]$-*96\NZHAN*6A1DJ'5R.+)"8N5"
M- Z]7U*4U4AS\HJJI:RK)1*AI#).?7T#BL,.D9C>-<8@,?C8XU-HW@:(;FY#
M2#<!*!)AN"X1.P;5G[, ZV5QGX^:<(B\KJ6JU\D%?MJ!C@<GD4!B;]*(7'F9
M2K4QZ.Q>2.C0I>F1CC6EAR>.MJ!<20T)=Z)2:!^Z$(#OT=KBO(?&TD.B4#AD
M7B" YM4(8K'8NQLD;1*&<: QH/2,;8A2MB8YJ,:FL;::2E -"-M0"2B*$C3[
M+ X%M:05<G)1"C+.D;PS-#82MN;4"1M0/$S;'@$D;I$^)D)) '=S1R@A%*2E
M:WOIPI&W-SN<,U6D*,T!WK (8.IAS$4,):[CC6CH(AT7(P:M-_0'=R<@;EQ
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MNI4;Z8::H/5$:FP6G8MH6IO&8%LD7C5/@M_/Y#8G!@8 P!@# & , 8 P!@#
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M2H&](0D0H2=E(TA83!$$ -4*3#@/>X P!@# & , 8 P!@# & , 8 P!@# &
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M4EV)_N:=S)0/H2GFK^=^?D, 8 P!@'?*NL-_J2R(+9T6.V1((%*F.5M6^[$
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M.Y5X5X2PF")I9G#<AK+=\OU^5<M[V2%&?UI.*T%T)+<7!8D=R-S;!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & <1_W [\$9^@+,MVIRIY3#MB\B^0^<</[<7WPOS[STF;L3D3R%2#QS(&
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M&SL1BK[72[LT<J3L9O68<*'-6.2224Y)2=.460G(+ 20026$HDDDH.@%%%%
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MV1 6Q1M=)01-FVE9F1O+WM,XR56QL*884Q&A."U*WEG&[[DKOH]C!E3 & ,
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M<+ 1%'IK+;FV514P"C;HQ(E*08Y/7R;V2Y<AO)@P, 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"AMSL],SD_[;[$]Y%V7[P%N*PMS%3>B
MPRL>)MT-:YRF_//-4,VTZ,8 P"2CI$_O@=&?U6T_U/3W(RTP_D\KO[=)^F9
MV_ >ZJF<D]]'S9=0RDA8DXC_ +@=^",_0%F6[4Y4\IAVQ>1?(?..']N+[X7Y
M]YZ3-V)R)Y"I!XYD# & 3O=!+S]W9[(4GOFR9 ?5 =H*'SP_H4<DW1AVTJ7>
M#>D0RTUE4R:S47GSZ%O)SV-S7YJ.S<-'^[;"W/4CYYIT.*-SM9YOF/F*40<O
MP5E& , 8!:2Z"'F/O/VK-7N@WY57J@.WM!YIC=,B$U:+^UM2[^9T=A/-D DG
M# & , 8!KM<$FIFL'V!.DSKM&_2NW["9Z]BBQG@S&_2!\G35&91.(^C6N"D*
M=0G&W1^%R9S:71P5EHFTUL\%)5IEZUN3JP_A_/\ FIZB 2/C79C<[M4,@L76
MQ]4FF,/L%(XUDCC:"-+JK=(^0[5S:$?DC*T.3$ZHQRQ,^,$>D#-I&X,05<H:
MA&,REN<7(96Z;>7;P[Z?!M,Q&1BK7%8H,-CT 7.#W"1QY4,QICJI8[UQH?>Q
ML:@0DXSU\)T-3W VPS9K%H:CN=D=IO8(8.)'%ZG&6U$M\=KP9*]S'+F0I&T1
ML1:UY1I2TQDG:BR$^PJ7-*B&2G&])-#5$)1%E"4A*$$.P/ $5J1R4'+@1NN7
M!7-#SW ]8!GC*I1+%*,QJ.4KCE&DYAK\>E-8V0T]2,:HP@QG:C#!A$WI-D@9
M!(()3$DIDQ)2=.G*+(3IR"P%$D$E T642247H)9110 A 66 (0  '00ZUK6M
M8!TN?UK!;18S(]/8RV21K%W8B0+B=Z5(3AA[@2EK<"!%+VM7W/[GPI I3G[!
MV@$/98A!WE'*U;HJIZ[Z;%\)A41=J$9MI=-(WOJERI^9E=Y%W1A<8FVAA&7O
MRCV4CDC:F,T8'?;WM,0O:"Q UH/A+H9L0C0_NV/O.3PI_+B^4_-6+O9\2[?7
MX#1J8\6>0,&,,"]59*5)!?=;VOCJ+4J;^]Z^P<-7&QNA:<L6O+KPOP<P/;V&
M  +6PZ_5(C%V.3D7+RG%6JFU%,&KFQR:SMIW-O7-QX=[T(A<D/2':WKR;ULM
M066/6];\F];#VZ_ASG=%V*BF#O50 \(LV%-N]=H']]31<W6_)K9,KT.-GZ%O
M_D;*=1Z'V^3N.WM\F=77)-*C1:O3U362>ID_**U=CDF96+!LO+KV\)VE#G?:
MVM4>HWU?8%4I\[K)M3V+-P8]_!UNYA**4?<DY,+!$*MGT@";O6M*6Z*/1R '
M;]@1[EM&%O3%_P#Q%"DHO^,6>2E*P1C&MN:VDX6K\^CU1$BR]*G72Z7V*^96
M"DO#;_BB16MXSV J^/,%4%KG5C%>'J>K455A3%6DFS#K7R9+)&68B.R7W,.$
MYW$;JUATOK[EYJ=3/ED=JUH'L(CPKUA,GDG>A=F]#3,S"I,;-B[G[8I?(FX\
MH6]!&3W6A!#,^&>ICQY5W0XM>C4_"\HJHKVQXS*G4M5<T6')R,1TK>VUL>H2
M[VK9%9>Z)!^*>JIT?T=L2%AZ!4L5SC45(;H$%]+IFNF5HDY/PFS5K['2].F&
M.1%5'HBHJRNT/P>HNAS$CRVLADQFR;N# 3*8Z3N*U$H#V"[ZQ-@"2VEB$ ?=
M;(5)4HW<LL6R3790#M[;58%T)8'P*Z#.2TDZL5J%9S:S6$AS$>#$2WNI&61C
M9215%OUN)"A.FVM56/FXB;:D8_TZX]Q^R-)34\VC4.+K-=1:-UR6EX\-;IJ3
M\RKW3<^BMMUR%&C))N<B/;*0W6MN'DO$-# & , ?_O\ \_TX!&ZQ\R;2U6UH
M2F:UJ@A=C0"[:.KMUIF5M;Q'))"XK=-H0F$M;XZR5O?)E#[)":S2Y2OC\KKI
MVU#'IUCKPU'JFUU;G=F:1RLF]P+GR)Z_#O[5W#G-H&1VP*^JM@:TSS.+ C]B
MS1 D<%HVUN30^K2HJFDBXY86G5#VI52BP:\BR4L)(O P2E5(AEKR8^8S.@QZ
M^ORFH<TY@V?4=7\B'FQ(M7#O.ZHE4F;*Z61MU>H_!K)B\9KR!S>4R4:=^.<W
MI "NGR9+*QDH6MQ>D#Q/&=O:"G",N3XY-$2&41%5.!?#;;EX;<![.8<BM-=L
M*B)!64(8TJVP"Z=89/,&-[52YZA054#&Y/Z Y QJCI*T6$LECW$Z[@\7V[A6
MR0^N53TY[4V<FC+(,6R^7+PV_BO(;1P.T8^_3^85.VIT9*B%0&JK*8SV@KO+
M*X5C;"B?L<(4)T^PE^ KTKQ5$W;5;:2 :0MK1L#H2:0)Y,:&H8]?7X3,N ,
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M+^%[W7X51;<'&2C8.(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M!!2G2!D/(5LSJN2EB G<E;0O1H'1L$X%J@H'=K:'=*$IR:&U4E ]]@# & ,
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MQ/>1=E^\!;BL+<Q4WHL,K'B;=#6N<IOSSS5#-M.C& , DHZ1/[X'1G]5M/\
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M48 P!@%I+H(>8^\_:LU>Z#?E5>J [>T'FF-TR(35HO[6U+OYG1V$\V0"2<,
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MF36:B\^?0MY.>QN:_-1V;AH_W;86YZD?/-.AQ1N=K/-\Q\Q2B#E^"LHP!@#
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M4^<)WI,4M;(?B,EWI+>98=^SKSZRG5UI?3CD/LZKSYL49<S0EN$E^<JCYUI
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M/-QEFVP6Q$F7P7(U(*Q%;J=:@P;7ZZ[6UM:]DM:RWWG^N!Y0>H39OY<N-/\
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<T7[HPX\TPP8O*(6]X"[5Y5\IG?!@8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
